<SEC-DOCUMENT>0000906709-23-000004.txt : 20230228
<SEC-HEADER>0000906709-23-000004.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228164843
ACCESSION NUMBER:		0000906709-23-000004
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		23686584

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nktr-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:c6319d4c-7e41-446e-a208-11c24c30fce3,g:5a9b6e6c-7a94-44cb-81e7-2ed70e787342,d:58bfbcf8a2404a36aa337c3511f6d52d--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nktr="http://www.nektar.com/20221231" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nktr-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF80L2ZyYWc6MDM1YTc3YmZkOTY0NDdiNjg2YTI1Y2IyZTFmMzRiNGEvdGFibGU6YjVkNTI3ZDUyZGEwNDE2ZmFkNWJjNDk4ZmJmZDkwNzAvdGFibGVyYW5nZTpiNWQ1MjdkNTJkYTA0MTZmYWQ1YmM0OThmYmZkOTA3MF8yLTEtMS0xLTM5ODM2_00bf7fb3-8fbf-4e85-bb75-6ceff41e4cca">false</ix:nonNumeric><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF80L2ZyYWc6MDM1YTc3YmZkOTY0NDdiNjg2YTI1Y2IyZTFmMzRiNGEvdGFibGU6YjVkNTI3ZDUyZGEwNDE2ZmFkNWJjNDk4ZmJmZDkwNzAvdGFibGVyYW5nZTpiNWQ1MjdkNTJkYTA0MTZmYWQ1YmM0OThmYmZkOTA3MF8zLTEtMS0xLTM5ODM2_d808af98-870e-4a0c-a4a1-41cd99c4b0bc">2022</ix:nonNumeric><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF80L2ZyYWc6MDM1YTc3YmZkOTY0NDdiNjg2YTI1Y2IyZTFmMzRiNGEvdGFibGU6YjVkNTI3ZDUyZGEwNDE2ZmFkNWJjNDk4ZmJmZDkwNzAvdGFibGVyYW5nZTpiNWQ1MjdkNTJkYTA0MTZmYWQ1YmM0OThmYmZkOTA3MF80LTEtMS0xLTM5ODM2_dba9f2fa-25a5-4f67-b92f-15e375533776">FY</ix:nonNumeric><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF80L2ZyYWc6MDM1YTc3YmZkOTY0NDdiNjg2YTI1Y2IyZTFmMzRiNGEvdGFibGU6YjVkNTI3ZDUyZGEwNDE2ZmFkNWJjNDk4ZmJmZDkwNzAvdGFibGVyYW5nZTpiNWQ1MjdkNTJkYTA0MTZmYWQ1YmM0OThmYmZkOTA3MF81LTEtMS0xLTM5ODM2_45fefbe0-c8d6-47db-a3f8-02e96a766aa2">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="iaa285e8d668f45b28f17028c2066a303_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTMwOTA_777cbe6f-53e1-4ebb-939f-b2bf951dd6a7">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ic9e50785bed64ddaac9dcc4ee38f8d0b_D20210101-20211231" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTUz_cabe071a-9291-4113-98c3-9850259068b6">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i7f516ae040844d74a523bf6793681072_D20220101-20221231" name="nktr:LeaseExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMS0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmZDFjZGUwODRhMjM0MjRiODM0ZTUxNjRlODJmZWYwMl8xOQ_2b0e6231-2800-4ca2-b334-9e61b9740c93">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i48c8e42537d84cce85b95bb5c5b6d70c_D20220101-20221231" name="nktr:LeaseExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMy0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmNWM1YzY0MzkwN2Q0MjkzODY0ODc2YzY1NzI1Y2VjN183_28da30aa-6692-46e9-9d13-2ccc8f191594">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nktr-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b49844a173491ea91b890806242f5c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0b2a1c9a44244244898eecdde8576b9e_I20230221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i36ac95832e534e18a6137ad8de7f1444_D20220531-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i809049297a1d4491a7387259a291ce70_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffeba43c66e94db7b8603276d878e2a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iba9224c1c3bd45fd8d3b954982ffff11_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if399252e1f284f4aadda7ec3f6d82e87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b547e794cef44a7b04668aed100c659_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee714b03e314804b75754b42ac2d14e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b02b8a4045435d96c81a09160eff2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff94ac8dace24c4e96ac5e215d7b240c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2592f70effb34a4d89f653e896ef7a34_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce1c72e26324dd38e6bc70f0d447453_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3503693dbb724782841e65e8f113c6fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife468d8852de4a56a284ece7b19844fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b34672efed424da1803ccc001fd4f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3787df08c6d74cf98da1829469ef1b09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d92114cae74251becb89962c58cc74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c9d9fd3ecfa4c9086a8279fc8984311_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08cf5e99f4c4729b75cd9f892d3dd95_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac079dca38e543e29cee54f4bb8d8c85_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8982bed90c24581aca18ab4ef0fbd1b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f208c2b206d4f43af4e746f193bb362_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i987ef113f8824c15b8f15d8db5465d6d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44c951d25d843329584f5aa34d0f5ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e6cce64ebb4bf1829c2e2305936cf8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i998d6d8b90244039983cd9cc2d9e138d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1950a10af3724176843a6dc1e9e84e54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04a5ee614c94e08a816a4c6381aec19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ebfebc03d28484bb3537335575f477e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a8e3652a3d447ea7e5a6799fd339b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i448f61765d3a4f728112443592038e8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic10a28643df74c40af9cdf7c813b5a44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a4fdda5691415fa69f3baedf60a37e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ad8acf8f34426eb3f1aeef9273f29b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id748358d445d433fb8c8c90c82d6f1a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ef15d4863f04c8db682812ea8b05dc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746ebde8a5a14d7fab51bbdd9974e2fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id726a6530b544c1ea713e5fd50d15fea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49140130df5b432e8dbcb7033e45422d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i935ae0dae4f141c8bb7ac64103e6fe70_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6bae5374b2b41c484f1e8a2efee68bf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab357fe657f4da88592a410901a0389_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c3d2d7dc6d4a638d0a5df9eb67618a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0edd83c86ce440bd97d489289b92afbc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9c9a3627d54feea3a17351378935e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e18c528c36849c0a6d2470e6cf2054f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2410d2e734464c24a881fc5993536b43_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7395e5dc92e34456b97e26b144017d8e_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33ecf05d707f40b5927205653bd6a5c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa285e8d668f45b28f17028c2066a303_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfdbb2c2768a43c9b3cbce49b01157c7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i714c46f612124cfcade9ea69f3665fc3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>nktr:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i82b4b2a5e5094624ba910d5a452b36cf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6021c4787edd4734a14b823201617271_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i889f3563e17448ed9a713f77242ff320_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic66d4e5d50724998a83872fccfd73607_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e6c9c34e274b01a7184f32edcfcc5c_D20200114-20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:ProgramTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-14</xbrli:startDate><xbrli:endDate>2020-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id12f39942a7f4712bbddc41b4ff72c32_D20200114-20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:ProgramTerminationAdvancePaymntToContractManyfacturersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-14</xbrli:startDate><xbrli:endDate>2020-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieee6e806d4bd4db3ac3280df3387e625_D20200114-20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:ProgramTerminationNoncancellableCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-14</xbrli:startDate><xbrli:endDate>2020-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4204e31ff284f828fdbd3d7d5d1e925_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799848d20d124621af203b62f338ec15_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2827b996b8d84b178c45819a76165160_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e50785bed64ddaac9dcc4ee38f8d0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ee4e8815e44e2eaf7870c781941a30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f814cb3446b46a5b7c97104c33668a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e9c0aab9a347229701114a13ba3b14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70cb12d6ed274cb3bc4aae55062cef33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24cdb13ced474b1e9afa182b37799a5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b3e1815f004636b2e747e17d73a6f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id00bc4b3a9074f93bce79a9e4c8911e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52837a82692c4071bbd19aa6f8dfc744_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ddb90dcdc5b4e7aa2740103176d7a92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedbeaf00736c4ec5b4e73d8f63d31829_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a690bee3fdb41e69aa7a67bfdee3e57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8386997073541c38bb72fe0270ebcf7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b488f3b36c44ef2a771d6736c3a2bbd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie418bae4d52d43e884dd28a74b932d6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a44796e8144efd8952281ed5f82527_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3264cdda22e4ccb9b495d63ecf07335_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida76ac790e3346c9abae40c1d17bbf09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i229a4d508cf44e958dcc2e374b94852b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5bf9ea7884421aab5dcf25a470d1db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89433d88568a4bbd9019d46526e1fb80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4700d3b1885a4b0d8c4f82c6feb9dcfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i6c4d7fb18f6d46d8988b427878e0c23f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f516ae040844d74a523bf6793681072_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="term"><xbrli:measure>nktr:term</xbrli:measure></xbrli:unit><xbrli:context id="i48c8e42537d84cce85b95bb5c5b6d70c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i428577ef84824447b2265e91b8e6ca13_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefb7645eeeaf42b793851c3bab72abca_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf73feefa4248f9bc901c6de5114e62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i296d2b099c6744c69a9b940e65fc438f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cd1c1703c6a49d18229ba501627fd87_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b11067296644fba18e31a4fd031969_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7c3411cc864b8fa20d76eb1a6c16ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie67fe37584df4144b73e3e9eab99c4d3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96e50a20c84741bf96617a4a3059d745_D20120224-20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-24</xbrli:startDate><xbrli:endDate>2012-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee1e09ac15b43f982a08e4065ea0c1c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputInceptionDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic27548c7b9c047ce81417f7851d5a13b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb7eac326dd4bd1860d0018b43342d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8f403286c134e56995c7fac6aabe42c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d861344a14b4ed19a94c299e3f1bd9c_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a46e523740a48e4bc313c9c8f371a46_D20201230-20201230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-30</xbrli:startDate><xbrli:endDate>2020-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e6083883184909bf4a11a730aefa63_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee97d6bd60ef4aa78a34aa3a4e187ea1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib56808f00dc44ceea4a81c7aadbb5013_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58214773cc764c89b77413cc27cba0d6_I20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50db82185e724189a23e8bcbadd1f46d_I20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e27ff45c6344a70a6715b2e56bebc4a_I20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2012-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-25</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-17</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0211a1334ced40e2833626cd80c87266_D20120225-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-25</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f4ba6c9266400796c445c6f33d98d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb1ef455fc644610936464822e51b81e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfb29fc19c9d46639cf8c5115010c1ec_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ff6330b45e466abdfd7de31f51f2d6_D20130301-20130331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-03-01</xbrli:startDate><xbrli:endDate>2013-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01976cfee21a4bc1ac8121bef4c3c1f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07893b3959254f9ebfe26a0ff8ffc37b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78314c12234445bbd7f0667b5fef4fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:MergerAndAcquisitionRelatedClaimsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie58f9f4376a2484a87512c90b4835ff7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:SecuritiesRelatedClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c5fd482c6864667b05d8be19b108140_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:NonSecuritiesRelatedClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3995f200366f48ddae334a6ff1b42719_D20180403-20180403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-03</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5004dfaad50e4a37b683b94437e9c3fe_D20180403-20180403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-03</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dee2bf1b1104b36a37ca5af4f6c6e08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:ShareBasedPaymentArrangementOptionRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a12065b592f45eb91672b4c2ecfc993_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a09c769b2cf4b7d96bd94af49863ae2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a2b75f3c2c497e821c32654dcf273d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b2e426dae1d4dcb82e953621113a971_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41101ca7c6074352b2c8edbbded90a47_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6f6ddc21ca64160889eff82cd22dac0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb79cd1e8a9d4e9b956b054364d945b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b00cf7a680342eabe29c33d1f30ca48_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4d0375d0754d04bfbcb3001a3a73ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1acc968e13bf49b2af89cb89994d8c21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a0cc81cd3464c5b93834a7c5444f287_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i518ea15aaef14db7aa415c20c69633ba_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2e2d3e9e2a7461daef194bc19d22bb4_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f5d9b4d79b4feca3f3a4d2b14a9583_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i034999d286934f979052476fb5f2c14a_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6238407fbe54f7f8ccc426559162694_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c808ebe93bd410caafb0853708fc73f_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcde63790f2b4c09a640ee1fb4bcaf0e_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cbcedb2872f472f8169616cf817be26_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia59bf42370df4deeb31e0accd2bdaf1a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d8701f92c324d04925cd7cef5dec02f_D20220401-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f996738350426c90cc53b744993a58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i398cab648ac141a89899e3e28583c043_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if58625a341de4335a5fee3c3a3737dae_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb537ce80dc447d8acffa6a5eb73666_I20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0f6b7f71328485db76064f93dc003eb_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d02ce2e1364896bbbc49fa46ce2648_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22df0cf6959c4db1b5ac09a71e43c84c_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a7eeedf4d74cc9a9917ed4c99c02c8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79208888512146d7bc75e741ef3f64e2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81256841f310427f8d19dc50d08b735c_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc20cfb1c4a48679a78206fc2ea8b1d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ac9a278cf47443e98c7cfa38fb872b4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb69ada362dc437e9819aaa096864a94_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c9b0c23b6004aa1922ed92ae6e42a1c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie391f9f234c444d2ae0b217cc409af4b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i761caeec68a54ac890af6ea722b34752_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3cbdfb27cfb4debb4992b2d68d5cf26_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab6c152af63d4a498aafc8fa69bf4bca_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i948d3d10847d41cbaa8d5e99b9e0ca18_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nktr:ThirdStFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i678b972618854ccfa5f8b75959d9a207_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44bbfe0cc7fd4079a8fc3d2aa0c332c7_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c9135dab8146c78e84573062004417_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e18421949d4c96bbefcd9f889dee65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21602aeba0af4306b9db2ff5a747c939_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cf06f89dab34bc49d9056719d6cf796_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic43d66fd88c34d01b4ff0cd1a46695cd_D20220601-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idedb361025fe4dc4be9515a9ddc5cd78_D20220601-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4cee9d0d7e4f278ad6b604a58efaa1_D20220601-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0ef1164091d46e7b57ab43df8707987_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac8a6dd98aab4d3dbbc732084af7018f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e4effa18ad3427aa1e582fbe34e43d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b03bb908cf46a1975c75a41487f342_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c718ae96904cc5b999aca6b38e6acc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14542c4fb8594026a9f1f2689a366572_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:RSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c9ec41962e341438be60878bcaa9e09_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa5c4f56ceb45109dc0bac18906c879_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e80ebc90964b95852b0af70c1a0bed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e36b8afe0164eeca7a3f8aee4dc3069_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided66bf243294649aa10f28f877a38bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1da4578eb344c37a4ac66d8094312cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833b94c48c5d400b9f223dd465244748_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cb540e2259a4eb5ba670a48eb66248a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c7e882eb974894b44df7c39cfa9ea3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if13a72164f93445d97d6df5a196ca7b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6627c3421cb942dfafa0a03fa35c32f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f55b5dda92449f87631aec26801a47_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b60fd0890f4d5ea688cd88f60c0fdc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3928dcd65fad4307afa1ad19230facf4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76c5c0679b2b4b999749ec226dd1c85a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3119b6ee8f3b4dde9cd9450833493c0f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05810fa0da244bacbdcde63b4b7a095b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1708b7bc3884af6be169aa6e4bd9ee9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f2ce65d9b74f5ab00210112601e860_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief64bc46a28844f3b364287244422030_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ca801a96804d5caed8be9bb6955df9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec82e56d740a40949cb39ff40fc8cd9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5277dcb595b47198bdeb0c40ae34d2c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa7a7c1e8844691b326d42966bf4551_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0beac0b0ae64d58915ff881a46e62b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0201532ad324c8c9dbec3f1607c4d7b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72308160e9054ecaaaa7ec0beb1ff284_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nktr:segment</xbrli:measure></xbrli:unit><xbrli:context id="i7bf92b2d15d544d6937956567cbd8076_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc6254636f546a2a43ce040c6c6085e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa8e4e763a2449e0a04e0609515b8c63_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00a63dfc4ab4080a7c7be10c52a4120_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b3e0f8c46714fc9be46c65f8de72fe0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd42991fff149128d3dc16bf7316b6f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id07a9952dc4c450b824484980ebe8928_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7daa5860832a47c08be4e2bbcc929c50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56fc82462fb045c19add828b177099e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib462fc56afce4ed7b4b6728742f20fd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4868926af54225af1a855f5d4d34d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14494e5a12494d72a7acb39246fa450e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06754ac5c8fe4627adbc24980fd082b4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86844cf0f9cb4932bc6509504c7a663f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaecd4f6f9c444958b8f0e06d42b1c2aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e1f0e358824a6bbe3fb5fb2404dc19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057ece2c908047309cf984bb11af2ec4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78596537cc1e4bba8d4c10682953227a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i836074eda2e7444d9c8ad2e1bd97d05c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54faac177aa94cc8a0cc84d3f8d86a9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ1_4b77c832-7634-4dec-83fd-0c02cadc6cc0">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6YjVhNDk2MTI4ZjIyNGRjODlmZDI0ZGI0MmU5ZGRhOWYvdGFibGVyYW5nZTpiNWE0OTYxMjhmMjI0ZGM4OWZkMjRkYjQyZTlkZGE5Zl8wLTAtMS0xLTM5ODM2_f754f679-407b-41bb-8551-186cc6d282d0">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8yNjk_7535c695-8a41-49fd-af38-72e04b8d3264"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8yNjk_1fe5cb20-1d37-4a9f-8304-0f5bf4e03da9">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6NWNmMDdlYjU0ZDFmNGUzZWI0NjJiZTVkNTU5NDI0MWMvdGFibGVyYW5nZTo1Y2YwN2ViNTRkMWY0ZTNlYjQ2MmJlNWQ1NTk0MjQxY18wLTAtMS0xLTM5ODM2_e863f63e-a68a-4ac2-a85c-c96468083b1f">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODM5_a089ec18-d243-435a-8d4b-812bb5111625">0-24006</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQw_9dea91f6-6848-416d-b85a-fbcd2b249f6d">NEKTAR THERAPEUTICS</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ODUzNzhiNzRiYmExNGRhMWI3ZGE0MGFhY2EyYTI5MTQvdGFibGVyYW5nZTo4NTM3OGI3NGJiYTE0ZGExYjdkYTQwYWFjYTJhMjkxNF8wLTAtMS0xLTM5ODM2_a92c9662-3d36-47d5-a245-396b160c9a58">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ODUzNzhiNzRiYmExNGRhMWI3ZGE0MGFhY2EyYTI5MTQvdGFibGVyYW5nZTo4NTM3OGI3NGJiYTE0ZGExYjdkYTQwYWFjYTJhMjkxNF8wLTItMS0xLTM5ODM2_bd849490-fdac-44d3-b546-c4d95b152950">94-3134940</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ2_ee176120-e290-4b43-8af6-52501083ba93">455 Mission Bay Boulevard South</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODM1_cb61fc57-fef2-44bb-a5fd-61679be1124c">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODMz_01dbcebe-cca4-44ba-a3f0-a0b38f00b491">California</ix:nonNumeric> <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQx_a7f67411-e029-414d-9941-43b685c71b8c">94158</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODM2_2e1dfe1d-946b-4d00-a3f5-f5b0d366d6ba">415</ix:nonNumeric>-<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODM3_b5924a08-d6fe-4882-92c7-dcb63f01cf81">482-5300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:43.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of Each Class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ZjkzYTUxNDdjZjg2NDdhMjg2ZWRlNzU0ZGQ0YmNhZmUvdGFibGVyYW5nZTpmOTNhNTE0N2NmODY0N2EyODZlZGU3NTRkZDRiY2FmZV8xLTAtMS0xLTM5ODM2_b2ec5fb7-b7ac-410b-bd73-1e289d366fb9">Common Stock, $0.0001 par value</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ZjkzYTUxNDdjZjg2NDdhMjg2ZWRlNzU0ZGQ0YmNhZmUvdGFibGVyYW5nZTpmOTNhNTE0N2NmODY0N2EyODZlZGU3NTRkZDRiY2FmZV8xLTEtMS0xLTM5ODM2_a258a48e-5433-462c-9d2c-954a2af5d779">NKTR</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ZjkzYTUxNDdjZjg2NDdhMjg2ZWRlNzU0ZGQ0YmNhZmUvdGFibGVyYW5nZTpmOTNhNTE0N2NmODY0N2EyODZlZGU3NTRkZDRiY2FmZV8xLTItMS0xLTM5ODM2_9c85cddc-e479-4339-aea1-5f13c657f219">NASDAQ Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8xMDk5NTExNjMzMDcz_ec8ddf18-f5ff-4757-a9dc-34eb22bd01e7">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQy_e9aef6e9-7bf8-441a-a7d3-b150c1fe6555">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ3_f0c1d330-f6f1-4a68-a91d-9b1a04f49a59">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ4_876474bf-ea21-41a0-921e-32fa43b0b18b">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. :</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:20.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6Y2M3OTRhM2U0YjczNDVlZWJkMWIxNGNkNWU2OTBhYmQvdGFibGVyYW5nZTpjYzc5NGEzZTRiNzM0NWVlYmQxYjE0Y2Q1ZTY5MGFiZF8wLTAtMS0xLTM5ODM2_7f556159-9761-4569-9be0-2e7143af2a8d">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6Y2M3OTRhM2U0YjczNDVlZWJkMWIxNGNkNWU2OTBhYmQvdGFibGVyYW5nZTpjYzc5NGEzZTRiNzM0NWVlYmQxYjE0Y2Q1ZTY5MGFiZF8xLTQtMS0xLTM5ODM2_309f37b4-7371-420e-bbae-530a3177876f">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6Y2M3OTRhM2U0YjczNDVlZWJkMWIxNGNkNWU2OTBhYmQvdGFibGVyYW5nZTpjYzc5NGEzZTRiNzM0NWVlYmQxYjE0Y2Q1ZTY5MGFiZF8yLTEtMS0xLTM5ODM2_7c2c687e-4203-4d89-ad60-424bd66456b4">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQz_7791308e-99a3-49ce-a793-5b9557a62267">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  &#9744;&#160;</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8xODE0MTk0MTg2MzYwOA_154be084-fb3b-4c82-b045-8b9bea7041dc">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The approximate aggregate market value of voting stock held by non-affiliates of the registrant, based upon the last sale price of the registrant&#8217;s common stock on the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June&#160;30, 2022, as reported on The NASDAQ Global Select Market, was approximately $<ix:nonFraction unitRef="usd" contextRef="i16b49844a173491ea91b890806242f5c_I20220630" decimals="-6" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zMzc3_6af691df-389d-468a-808d-0bb0e044aba1">704</ix:nonFraction> million.</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;21, 2023, the number of outstanding shares of the registrant&#8217;s common stock was <ix:nonFraction unitRef="shares" contextRef="i0b2a1c9a44244244898eecdde8576b9e_I20230221" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zNDYx_c6c67642-042b-416f-bb48-22a2101ad17d">189,235,139</ix:nonFraction>. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ0_fbf03d37-0368-40be-a33b-1e7b1264d897" escape="true">Portions of registrant&#8217;s definitive Proxy Statement to be filed for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_13">Summary of Risks</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_13">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_22">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_22">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_25">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_25">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_28">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_28">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_31">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_31">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_34">39</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_37">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_40">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_40">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_43">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_43">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_46">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_61">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_61">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_61">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_64">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_64">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_64">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_136">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_136">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_136">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_139">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_139">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_139">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_142">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_142">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_142">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_145">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_145">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_148">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_151">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_151">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_151">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_154">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_154">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_154">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_157">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_157">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_157">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_160">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_160">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_160">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_163">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_163">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_163">95</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_166">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_169">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_169">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_169">96</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_172">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_172">101</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this annual report on Form 10-K, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements related to our strategic reorganization and cost restructuring plans, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates and our future research and development plans, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of our collaboration arrangements, commercialization activities and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part I, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this annual report on Form 10-K. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this annual report on Form 10-K, the &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nektar brand and product names, including but not limited to Nektar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:63pt"><span><br/></span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks to our business are more fully described below in Item IA in this Form 10-K, which risks include, among others:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Research and Development Efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical drug development is a lengthy and uncertain process and we may not be able to generate and develop successful drug candidates for commercial use;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on the success of rezpegaldesleukin (previously referred to as NKTR-358) and NKTR-255 and our business will be significantly harmed if either rezpegaldesleukin or NKTR-255 do not continue to advance in clinical studies;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcomes from competitive immunotherapy clinical trials, and the discovery and development of new potential immunotherapy could have a material and adverse impact on the value of our pipeline;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significant competition for our polymer conjugate chemistry technology platforms and our products and drug candidates could make our technologies, drug products or drug candidates obsolete or uncompetitive;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">preliminary and interim data from our clinical studies are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical trials for any of our drug candidates could be delayed for a variety of reasons. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Financial Condition and Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">we have implemented a 2022 strategic reorganization plan and cost restructuring plan to focus on prioritizing key research and development efforts and our business will be significantly harmed if either of these plans is unsuccessful;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">we may undertake additional restructuring and cost-saving activities in the future, which could further harm our market valuation, prospects, financial condition and results of operations; </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our revenue is exclusively derived from our collaboration agreements. If we are unable to establish and maintain collaboration partnerships with attractive commercial terms, including significant development milestones and research and development cost-sharing, our business, results of operations and financial condition could suffer; and </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we expect to continue to incur substantial net losses from operations and may not achieve or sustain profitability in the future. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Collaboration Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on Eli Lilly and Company, our collaboration partner for rezpegaldesleukin to initiate, properly conduct and prioritize clinical trials for rezpegaldesleukin and to perform important additional development and commercialization activities, and our business will be significantly harmed if our partner deprioritizes or discontinues clinical trials in or otherwise harm the prospects of rezpegaldesleukin; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may rely on academic and private non-academic institutions to conduct investigator-sponsored clinical studies or trials of our product candidates and any failure by the investigator-sponsor to meet its obligations with respect to the clinical development of our product candidates may delay or impair our ability to obtain regulatory approval or commercialize for other product candidates. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Supply and Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, our business, financial condition and results of operations could be harmed; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause delays, loss of revenue and contract liability.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we or our partners may not obtain regulatory approval for our drug candidates on a timely basis, or at all;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required, which may not be available to us on commercially reasonable terms; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">from time to time, we are involved in legal proceedings and may incur substantial litigation costs and liabilities that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above-mentioned risks, our business is subject to a number of additional risks faced by businesses generally. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_19"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nektar Therapeutics is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy.  Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> apply our deep understanding of immunology and unparalleled expertise in polymer chemistry to create innovative drug candidates and use our drug development expertise to advance these molecules through preclinical and clinical development. Our pipeline of clinical-stage immunomodulatory agents targets the treatment of autoimmune diseases and cancer. We continue to make significant investments in building and advancing our pipeline of drug candidates as we believe that this is the best strategy to build long-term shareholder value. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Drug Candidates and Pipeline</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By modulating the immune system, our drug candidates target pathways that play critical roles in a wide range of serious diseases. In autoimmune diseases, our focus is on addressing imbalances in the immune system to restore the body&#8217;s self-tolerance mechanisms and to achieve immune homeostasis. In oncology, we are focused on activating the immune system&#8217;s natural tumor-fighting mechanisms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Autoimmune diseases (rezpegaldesleukin, formerly NKTR-358)</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that many autoimmune diseases are caused by an imbalance in the body&#8217;s immune system. A failure of the body's self-tolerance mechanisms enables the formation of pathogenic T cells that cause the immune system to mistakenly attack and damage healthy cells in a person&#8217;s body.</span><span style="background-color:#ffffff;color:#333333;font-family:'Open Sans',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current systemic treatments for autoimmune diseases, including corticosteroids and anti-TNF agents, suppress the immune system broadly and come with severe side effects. Pharmaceutical agents designed to rebalance the immune system by increasing the function of regulatory T cells (Treg cells), powerful inhibitory immune cells, could be used to treat patients suffering from autoimmune disorders and inflammatory diseases. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rezpegaldesleukin has advanced to Phase 2 development, which our collaboration partner, Lilly, has carried out in various indications. On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study). The primary endpoint of the Phase 2 Lupus Study, a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4-points reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, was not met and Lilly has notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. Although the Phase 2 Lupus Study did not meet its primary endpoint, patients within the modified intent-to-treat population, defined as all patients who were randomized and received at least one dose of study medication, that were treated with rezpegaldesleukin demonstrated improvement in SLEDAI-2K score as compared to placebo. Additionally, clinically meaningful improvements were  observed in the British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) response and Lupus Low Disease Activity State (LLDAS) as compared to placebo, and exploratory biomarker data also showed that rezpegaldesleukin led to dose-dependent proliferation of Treg cells, which was consistent with prior studies. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lilly has also completed a Phase 1b study in patients with atopic dermatitis. We and Lilly are working together to determine next steps for the planned Phase 2b study in atopic dermatitis as well as a potential third Phase 2 study in a yet-to-be-announced autoimmune indication. We previously announced that Lilly would be discontinuing further development of rezpegaldesleukin in ulcerative colitis and psoriasis in order to prioritize other indications.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology (NKTR-255)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we focus on developing medicines based on targeting biological pathways that stimulate and sustain the body&#8217;s immune response in order to fight cancer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of natural killer (NK) cells and induces survival of both effector and CD8+ memory T cells. Recombinant human IL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and the formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Our development strategy for NKTR-255 is focused on three therapeutic areas: to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enhance response to antibody-dependent cellular cytotoxicity (ADCC) mediated therapies by restoring NK cells, to improve CAR-T cell persistency in cellular therapies and to augment response to checkpoint inhibitors. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are studying NKTR-255 in ADCC combinations in both liquid and solid tumors. We have initiated a Phase 1 dose escalation and expansion study of NKTR-255 in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma where patients are treated with NKTR-255 as a monotherapy or NKTR-255 in combination with daratumumab. We have also initiated a Phase 1/2 study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer where patients are treated with NKTR-255 in combination with cetuximab. We expect to receive data from the expansion stage of both studies in the second half of 2023.  We are evaluating NKTR-255 following treatment with CAR-T cell therapy and initiated a Nektar-sponsored Phase 2/3 study (currently in the Phase 2 portion) to evaluate NKTR-255 following Yescarta&#174; or Breyanzi&#174; CD19 CAR-T cell therapy in patients with large B-cell lymphoma. We expect initial data from the study to be available in the second half of 2024.  Two ongoing investigator sponsored trials are also studying NKTR-255 in combination with CAR-T cell therapy. These studies include a Phase 1 study evaluating NKTR-255 in combination with CD19 CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphoma and a Phase 1 study evaluating NKTR-255 in combination with CD19/22 CAR-T cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. A third investigator sponsored study is evaluating NKTR-255 in combination with darvulumab in patients with unresectable Stage 3 non-small cell lung cancer who have received chemoradiation. We are </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continuing our oncology clinical collaboration with Merck KGaA and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255 in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study. We expect to receive topline data from the study in the second half of 2024. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Development Programs and Our Advanced Polymer Conjugate Technology Platform</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe it is important to maintain a diverse pipeline of new drug candidates to build on the value of our business. Our discovery research organization is continuing to identify new drug candidates by applying our technology platform to a wide range of molecule classes, including small molecules and proteins, peptides and antibodies. We aim to advance our most promising research drug candidates into preclinical development with the objective of advancing these early-stage research programs to human clinical studies over the next several years. One of our research programs is focused on developing a tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist antibody. TNFR2 signaling drives immunoregulatory function and can provide a direct protective effect for tissue cells. Our focus is on TNFR2 antibody candidates that show selective Treg cell binding and signaling profiles that may be developed for treatment of autoimmune diseases. In connection with this program, we are targeting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IND </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">readiness for a lead TNFR2 agonist antibody candidate by the end of 2023 in order to submit an Investigational New Drug (IND) filing for the first clinical study in 2024. We also plan to continue our preclinical stage NKTR-288 development program. NKTR-288 is an investigational PEG conjugate of the protein interferon gamma that is designed utilizing a site-specific conjugation approach to modify binding of interferon gamma with one of its substrates and to optimize the pharmacodynamic duration of interferon gamma signaling. We believe this program has applications in a number of therapeutic indications including oncology as well as in other infectious diseases.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advanced and proven polymer conjugate technology platform is focused on conjugating polyethylene glycol to a pharmaceutically active agent, a process often referred to as &#8220;PEGylation.&#8221; PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Amgen&#8217;s Neulasta (pegfilgrastim) and UCB&#8217;s CIMZIA (certolizumab pegol). In addition to inventing new PEGylated drug candidates, our expertise extends to developing robust manufacturing processes for generating the PEGylation reagents that allow us to utilize the full potential of this important technology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improve efficacy or safety of a drug as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improve targeting or binding affinity of a drug to its target receptors with the potential to improve efficacy and reduce toxicity or drug resistance;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improve solubility of a drug;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">enable oral administration of parenterally-administered drugs, or drugs that must be administered intravenously or subcutaneously, and increase oral bioavailability of small molecules;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">prevent drugs from crossing the blood-brain barrier, or reduce their rate of passage into the brain, thereby limiting undesirable central nervous system effects;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduce first-pass metabolism effects of certain drug classes with the potential to improve efficacy, which could reduce the need for other medicines and reduce toxicity;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduce the rates of drug absorption and of elimination or metabolism by improving stability of the drug in the body and providing it with more time to act on its target;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">differentially alter binding affinity of a drug for multiple receptors, improving its selectivity for one receptor over another; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduce immune response to certain macromolecules with the potential to prolong their effectiveness with repeated doses.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our substantial investment in research and development has the potential to create significant value if one or more of our current drug candidates demonstrates positive clinical results, receives regulatory approval in one or more major markets and achieves commercial success.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Collaboration Partner Programs</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We decide on a drug-candidate-by-drug-candidate basis, how far to advance clinical development (e.g., Phase 1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches. When we determine to seek a partner, our strategy is to selectively access a partner&#8217;s development, regulatory, or commercial capabilities with the structure of the collaboration depending on factors such as economic risk sharing, the cost and complexity of development, marketing and commercialization needs, therapeutic areas, potential for combination of drug programs, and geographic capabilities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we announced on February 14, 2018, that we and Bristol-Myers Squibb Company (BMS) executed a global strategic development and commercialization collaboration to develop Nektar&#8217;s Phase 2 drug candidate, bempegaldesleukin, in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab). Under the collaboration, BMS made an upfront payment of $1.0 billion and an equity investment of $850 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin in combination of Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we and BMS announced on April 14, 2022, that the companies jointly decided to end the global clinical development program for the combination.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also discontinued all studies of bempegaldesleukin in combination with other drugs or drug candidates. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration partners have advanced drug candidates we invented into commercial drug products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, through our collaborations and licensing partnerships with a number of well-known biotechnology and pharmaceutical companies, more than ten products using our PEGylation technology have received regulatory approval in the U.S. or Europe.  The following table outlines our collaborations and licensing partnerships. These collaborations generally contain one or more elements including a license to our intellectual property rights and manufacturing and supply agreements under which we may receive manufacturing revenue, milestone payments, and/or royalties on commercial sales of drug products.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:32.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary or Target<br/>Indications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug<br/>Marketer/Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Status(1)</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2015*</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxegol tablets) and&#160;&#160;MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid-induced constipation in adult patients with chronic non-cancer pain (US); Opioid-induced constipation in adult patients who have and inadequate response to laxatives (EU).</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca AB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2014*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certolizumab pegol)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn&#8217;s disease, Rheumatoid arthritis, and Psoriasis/ Ankylosing Spondylitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2008**</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (C.E.R.A.) (Continuous Erythropoietin Receptor Activator)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F. Hoffmann-La Roche&#160;Ltd</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2007**</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macugen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegaptanib sodium injection)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Age-related macular degeneration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved 2004</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Somavert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegvisomant)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved 2003</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dapirolizumab Pegol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic Lupus Erythematosus</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma (Biogen)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Status definitions are:</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; regulatory approval to market and sell product obtained in one or more of the U.S., EU or other countries. Year indicates first regulatory approval.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; drug candidate in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results).</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  *&#160;&#160;&#160;&#160;In December 2020, pursuant to a purchase and sale agreement (the &#8220;2020 Purchase and Sale Agreement&#8221;) we sold our rights to receive royalties on future worldwide new sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MOVANTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (as well as REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and specified licensed products under a Right to Sublicense Agreement, dated October 27, 2017) from and after October 1, 2020 until the purchaser of these rights has received payments equal to $210.0 million (the &#8220;2025 Threshold&#8221;), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0 million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). All rights to receive royalties will return to Nektar once the 2020 Purchase and Sale Agreement expires.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** &#160;&#160;&#160;&#160;In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective as of January&#160;1, 2012.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Development and Approval Process</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The research and development, clinical testing, manufacture and marketing of our drug candidates and products using our technologies are subject to regulation by the FDA and by comparable regulatory agencies in other countries. These national agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing (in&#160;vitro, in animals, and in human clinical trials), manufacture, labeling, storage, recordkeeping, approval, marketing, advertising and promotion of our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S.&#160;depends on whether the chemical composition of the product has previously been approved for use in other dosage forms. If the product is a new chemical entity that has not been previously approved, the process includes the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">extensive preclinical laboratory and animal testing;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission of an Investigational New Drug (IND) prior to commencing clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for the intended indication;&#160;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">extensive pharmaceutical development for the characterization of the chemistry, manufacturing process and controls for the active ingredient and drug product; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission to the FDA of a New Drug Application (NDA) for approval of a drug or a Biological License Application (BLA) for approval of a biological product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests, including those relating to systemic toxicity normally required for the IND and NDA or BLA, and clinical trials, may not be necessary if the company has a right of reference to existing preclinical or clinical data under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) or is eligible for approval under Section&#160;505(b)(2) of the FDCA or the biosimilars provisions of the Public Health Services Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Preclinical tests include laboratory evaluation of product chemistry and animal studies to assess the safety and efficacy of the product and its chosen formulation. Preclinical safety tests must be conducted by laboratories that comply with FDA good laboratory practices (GLP) regulations. The results of the preclinical tests for drugs, biological products and combination products subject to the primary jurisdiction of the FDA&#8217;s Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) are submitted to the FDA as part of the IND and are reviewed by the FDA before clinical trials can begin. Clinical trials may begin 30&#160;days after receipt of the IND by the FDA, unless the FDA raises objections or requires clarification within that period. Clinical trials involve the administration of the drug to healthy volunteers or patients under the supervision of a qualified, identified medical investigator according to a protocol submitted in the IND for FDA review. Drug products to be used in clinical trials must be manufactured according to current good manufacturing practices (cGMP). Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be evaluated in the study. Each protocol is submitted to the FDA in the IND.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Apart from the IND process described above, each clinical study must be reviewed by an independent Institutional Review Board (IRB), and the IRB must be kept current with respect to the status of the clinical study. The IRB considers, among other things, ethical factors, the potential risks to subjects participating in the trial and the possible liability to the institution where the trial is conducted. The IRB also reviews and approves the informed consent form to be signed by the trial participants and any significant changes in the clinical trial.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Clinical trials are typically conducted in three sequential phases. Phase 1 involves the initial introduction of the drug into healthy human subjects (in most cases) and the product generally is tested for tolerability, pharmacokinetics, absorption, metabolism and excretion. Phase 2 involves studies in a limited patient population to:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">determine the preliminary efficacy of the product for specific targeted indications;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">determine dosage and regimen of administration;&#160;and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identify possible adverse effects and safety risks.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If Phase 2 trials demonstrate that a product appears to be effective and to have an acceptable safety profile, Phase 3 trials are typically undertaken to evaluate the further clinical efficacy and safety of the drug and formulation within an expanded patient population at geographically dispersed clinical study sites and in large enough trials to provide statistical proof of </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efficacy and tolerability. The FDA, the clinical trial sponsor, the investigators or the IRB may suspend clinical trials at any time if, amongst other reasons, any one of them believes that study participants are being subjected to an unacceptable health risk. In some cases, the FDA and the drug sponsor may determine that Phase 2 trials are not needed prior to entering Phase 3 trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Following a series of formal meetings and communications between the drug sponsor and the regulatory agencies, the results of product development, preclinical studies and clinical studies are submitted to the FDA as an NDA or BLA for approval of the marketing and commercial shipment of the drug product. The FDA may deny approval if applicable regulatory criteria are not satisfied or may require additional clinical or pharmaceutical testing or requirements. Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy all of the criteria for approval. Additionally, the approved labeling may narrowly limit the conditions of use of the product, including the intended uses, or impose warnings, precautions or contraindications which could significantly limit the potential market for the product. Further, as a condition of approval, the FDA may impose post-market surveillance, or Phase 4, studies or risk evaluation and mitigation strategies. Product approvals, once obtained, may be withdrawn if compliance with regulatory standards is not maintained or if safety concerns arise after the product reaches the market. The FDA may require additional post-marketing clinical testing and pharmacovigilance programs to monitor the effect of drug products that have been commercialized and has the power to prevent or limit future marketing of the product based on the results of such programs. After approval, there are ongoing reporting obligations concerning adverse reactions associated with the product, including expedited reports for serious and unexpected adverse events.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Each manufacturing establishment producing the active pharmaceutical ingredient and finished drug product for the U.S.&#160;market must be registered with the FDA and typically is inspected by the FDA prior to NDA or BLA approval of a drug product manufactured by such establishment. Such inspections are also held periodically after commercialization. Manufacturing establishments of U.S.&#160;marketed products are subject to inspections by the FDA for compliance with cGMP and other U.S.&#160;regulatory requirements. They are also subject to U.S.&#160;federal, state, and local regulations regarding workplace safety, environmental protection and hazardous controls, among others.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In situations where our partners are responsible for clinical and regulatory approval procedures, we may still participate in this process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for polymer conjugation materials or drug product. For those products for which we have development responsibility, we prepare and submit an IND and are responsible for additional clinical and regulatory procedures for drug candidates being developed under an IND. The clinical and manufacturing, development and regulatory review and approval process generally takes a number of years and requires the expenditure of substantial resources. Our ability to manufacture and market products, whether developed by us or under collaboration agreements, ultimately depends upon the completion of satisfactory clinical trials and success in obtaining marketing approvals from the FDA and equivalent foreign health authorities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sales of our products outside the U.S.&#160;are subject to local regulatory requirements governing clinical trials and marketing approval for drugs. Such requirements vary widely from country to country.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA may grant Fast Track or Breakthrough Therapy designation to a drug candidate, which allows the FDA to expedite the review of new drugs that are intended for serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Important features of Fast Track or Breakthrough Therapy designation include a potentially expedited clinical review and close, early communication between the FDA and the sponsor company to improve the efficiency of product development.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S.&#160;The company that obtains the first FDA approval for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. In addition, the Orphan Drug Act provides for protocol assistance, tax credits, research grants, and exclusions from user fees for sponsors of orphan products. Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication generally may be approved during the exclusivity period only if the second product is shown to be &#8220;clinically superior&#8221; to the original orphan drug in that it is more effective, safer or otherwise makes a &#8220;major contribution to patient care&#8221; or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Similar incentives also are available for orphan drugs in the EU.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage, Reimbursement, and Pricing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sales of any products for which we may obtain regulatory approval depend, in part, on the coverage and reimbursement status of those products. In the U.S., sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payers. Third-party payers include government programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care providers, private health insurers and other organizations. Other countries and jurisdictions will also have their own unique mechanisms for approval and reimbursement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The process for determining whether a payer will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payer will pay for the product. Third-party payers may limit coverage to specific products on an approved list or formulary which might not include all of the FDA-approved products for a particular indication. Third-party payers may also refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. Further, private payers often follow the coverage and payment policies established by certain government programs, such as Medicare and Medicaid, which require manufacturers to comply with certain rebate, price reporting, and other obligations. For example, the Medicaid Drug Rebate Program, which is part of the Medicaid program (a program for financially needy patients, among others), requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services under which the manufacturer agrees to report certain prices to the government and pay rebates to state Medicaid programs on outpatient drugs furnished to Medicaid patients, as a condition for receiving federal reimbursement for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Further, in order for a pharmaceutical product to receive federal reimbursement under Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the Public Health Service&#8217;s 340B drug pricing program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Third-party payers are increasingly challenging the prices charged for medical products and services, and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the price of therapeutics have been a focus in this effort. The U.S. government and state legislatures have shown significant interest in implementing cost-containment programs, including price controls and restrictions on reimbursement, among other controls. Adoption of price controls or other cost-containment measures could limit coverage for or the amounts that federal and state governments or private payers will pay for health care products and services, which could also result in reduced demand for our drug candidates or additional pricing pressures and affect our ultimate profitability, if approved. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover an approved product or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Healthcare Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. On December 2, 2020, the Office of Inspector General, or OIG, published further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. This rule (with exceptions) became effective January 19, 2021. Implementation of this change and new safe harbors for point-of-sale reductions in price for prescription </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. We continue to evaluate what effect, if any, the rule will have on our business;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payers if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">provisions of the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes, referred to as the &#8220;HIPAA All-payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other licensed health care practitioners and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information, and also includes the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; </span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">additionally, state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts. These state-equivalent laws may also apply to our business practices, including, but not limited to, research, distribution, and sales or marketing arrangements. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If our drug candidates become commercialized, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid, integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.  Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.  Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act (collectively, the Affordable Care Act), enacted in 2010, expanded the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal fraud statutes contained within 42 U.S.C. &#167;&#160;1320a-7b. Pursuant to the Affordable Care Act, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act or the civil monetary penalties statute. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The federal False Claims Act prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent. Although we would not submit claims directly to payers, manufacturers can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been prosecuted under the federal False Claims Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $11,463 and $23,331 for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. In addition, private individuals have the ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the federal False Claims Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In each country or jurisdiction outside of the U.S. in which we seek and receive regulatory approval to commercialize our products, we will be subject to additional laws and regulations specific to those locations. These regulations and laws will also impact, among other things, our proposed sales and marketing programs in those jurisdictions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legislative and Regulatory Landscape</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing, marketing, coverage and reimbursement of products regulated by the FDA or other government agencies. In addition to new legislation, FDA and healthcare fraud and abuse and coverage and reimbursement regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. For example, in 2010, the United States Congress enacted the Affordable Care Act, which, among other things, included changes to the coverage and payment for drug products under government health care programs. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the provisions of the Affordable Care Act of importance to potential product candidates are: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expansion of eligibility criteria for Medicaid programs, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expanded the types of entities eligible for the 340B drug discount program; </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 70% point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year. Subsequent legislation extended the 2% which remains in effect through 2030. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022, or IRA, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation, and delay the rebate rule that would limit the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one rare disease designation and for which the only approved indication is for that disease or condition. If a product receives multiple rare disease designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, federal agencies, Congress, state legislatures, and the private sector have shown significant interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. Any proposed or actual changes could limit coverage for or the amounts that federal and state governments will pay for health care products and services, which could also result in reduced demand for our products or additional pricing pressures and affect our ultimate profitability. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We own more than 300 U.S. and 1,500 foreign patents and a number of pending patent applications that cover various aspects of our technologies. We have filed patent applications, and plan to file additional patent applications, covering various aspects of our advanced polymer conjugate technologies and our drug candidates. More specifically, our patents and patent applications cover polymer architecture, drug conjugates, formulations, methods of making polymers and polymer conjugates, methods of administering polymer conjugates, and methods of manufacturing polymers and polymer conjugates. Our patent portfolio contains patents and patent applications that encompass our advanced polymer conjugate technology platforms. Our patent strategy is to file patent applications on innovations and improvements to cover a significant majority of the major pharmaceutical markets in the world. Generally, patents have a term of twenty years from the earliest non-provisional patent application filing priority date (assuming all maintenance fees are paid). In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully protect our trade secrets. Others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to, or disclose, our trade secrets. Please refer to Item&#160;1A. Risk Factors, including but not limited to &#8220;We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.&#8221; In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies may be affected by limitations in our access to these proprietary drugs. Even if we believe we are free to work with a proprietary drug, we cannot guarantee that we will not be accused of, or determined to be, infringing a third party&#8217;s rights and be prohibited from working with the drug or found liable for damages. Any such restriction on access or liability for damages would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, opposition, reexamination or other proceedings that can result in the revocation of the patent or maintenance of the patent but in an amended form (and potentially in a form that renders the patent without commercially relevant or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of protection, if any, following the commercialization of products encompassed by our patent.&#160;We may have to participate in post-grant proceedings before the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us. Please refer to Item&#160;1A. Risk Factors, including without limitation, &#8220;If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;U.S.&#160;and foreign patent rights and other proprietary rights exist that are owned by third parties and relate to pharmaceutical compositions and reagents, and equipment and methods for preparation, packaging and delivery of pharmaceutical compositions. We cannot predict with any certainty which, if any, of these rights will be considered relevant to our technology by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. We could incur substantial costs in defending ourselves and our partners against any such claims. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S.&#160;and abroad and could result in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from third parties. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternative technology. The failure to obtain licenses if needed may have a material adverse effect on our business, results of operations and financial condition. Please refer to Item&#160;1A. Risk Factors, including without limitation, &#8220;We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. The agreements provide that all inventions conceived by an employee shall be our property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer Concentrations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;Our revenue is derived from our collaboration agreements with partners, under which we may receive a combination of revenue elements including up-front payments for licensing agreements, clinical research reimbursement or co-funding, milestone payments based on clinical progress, regulatory progress or net sales achievements, royalties and/or product sales revenue. Our revenues are concentrated among a limited number of collaboration partners under long-term arrangements. We derive the substantial majority of our PEGylation reagent product sales from UCB and Pfizer. Following the 2020 Purchase and Sale Agreement (wherein under a capped return sale arrangement we sold our rights to receive royalties on future worldwide new sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/MOVANTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, as well as REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and specified licensed products), other than our product sales, substantially all of our revenues are non-cash royalty revenues. However, our collaboration with Lilly for the development of rezpegaldesleukin provides for the most significant portion of our potential future development and regulatory milestone payments, as well as royalties from net sales of rezpegaldesleukin, if approved. Additionally, these collaboration partners can provide significant financial support for the development and commercialization </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of these programs. For example, Lilly bears 75% of the Phase 2 development costs of rezpegaldesleukin, will bear 100% of the  Phase 3 development costs, subject to our right to contribute up to 25% of Phase 3 development costs on an indication-by-indication basis, which we have announced our intention to exercise our option to fully fund Nektar's 25%  share of the Phase 3 development costs, in exchange for higher royalties, if approved. Lilly will also be responsible for all costs of global commercialization, subject to our option to co-promote in the U.S. under certain conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Competition in the pharmaceutical and biotechnology industry is intense and characterized by aggressive research and development and rapidly-evolving science, technology, and standards of medical care throughout the world. We frequently compete with pharmaceutical companies and other institutions with greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Science and Technology Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We face intense science and technology competition from a multitude of technologies seeking to enhance the efficacy, safety and ease of use of approved drugs and new drug molecule candidates. A number of the drug candidates in our pipeline have direct and indirect competition from large pharmaceutical and biopharmaceutical companies. With our advanced polymer conjugate technologies, we believe we have competitive advantages relating to factors such as efficacy, safety, ease of use and cost for certain applications and molecules. We constantly monitor scientific and medical developments in order to improve our current technologies, seek licensing opportunities where appropriate, and determine the best applications for our technology platforms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the fields of advanced polymer conjugate technologies, our competitors include Biogen Idec Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories, Ltd., Mountain View Pharmaceuticals, Inc., SunBio Corporation, NOF Corporation, and Novo Nordisk A/S (assets formerly held by Neose Technologies, Inc.). Several other chemical, biotechnology and pharmaceutical companies may also be developing advanced polymer conjugate technology or technologies intended to deliver similar scientific and medical benefits. Some of these companies license intellectual property or PEGylation materials to other companies, while others apply the technology to create their own drug candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product and Program Specific Competition</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rezpegaldesleukin</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based, microbiome-based, or toleragenic-based therapies (Symbiotix, LLC, Janssen Pharmaceuticals, AstraZeneca and Tizona Therapeutics), regulatory T cell therapies (Sangamo Therapeutics, Inc., Quell Therapeutics, Ltd., TxCell, Inc., Sonoma Biotherapeutics, Inc. GentiBio, Inc., Kyvema Therapeutics, Inc. and Tract Therapeutics, Inc.), or IL-2 based therapies (Amgen, Inc., BMS (through its acquisition of Delnia, Inc.), Novartis, Inc., ILTOO Pharma, Xencor, inc., Merck &amp; Co (through its acquisition of Pandion Therapeutics), and Sanofi SA (through its acquisition of Synthorx, Inc.)).</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-255</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous companies engaged in developing immunotherapies with different approaches to enhancing NK cell populations which are a key component of the innate immune system. The approaches include engineered biologics targeting the IL-15 pathway as well as autologous and allogenic cell therapy approaches. For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include SOTIO Biotech, Inc., Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., nkarta therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.).</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our total research and development expenditures can be disaggregated into the following significant types of expenses (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third party and direct materials costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel, overhead and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation and depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a manufacturing facility located in Huntsville, Alabama that manufactures our proprietary PEG reagents for subsequent conjugation to active pharmaceutical ingredients (APIs). The facility is also used to produce APIs themselves, as well as PEG conjugates of those APIs, to support the early phases of clinical development of our drug candidates. The facility and associated equipment are designed and operated to be consistent with all applicable laws and regulations. As we do not maintain the capability to manufacture biologics nor finished drug products for our development programs, we primarily utilize contract manufacturers to manufacture biologics and finished drug product for us. We also utilize the services of contract manufacturers to manufacture APIs and finished drug products required for later phases of clinical development and eventual commercialization.  Our contract manufacturers have contractual obligations to comply with all applicable laws and regulations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We source drug starting materials for our manufacturing activities from one or more suppliers. For the drug starting materials necessary for our drug candidate development, we have agreements for the supply of such drug components with drug manufacturers or suppliers that we believe have sufficient capacity to meet our demands. However, from time to time, we source critical raw materials and services from one or a limited number of suppliers and there is a risk that if such supply or services were interrupted, it could materially harm our business. In addition, we typically order raw materials and services on a purchase order basis for early phase clinical development products and enter into long-term supply arrangements only for late-stage products nearing regulatory approval for marketing authorization.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As a manufacturer of PEG reagents for the U.S.&#160;market, we are subject to inspections by the FDA and the U.S. Environmental Protection Agency for compliance with cGMP and other U.S.&#160;regulatory requirements, including U.S.&#160;federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. To our knowledge, we comply with all material governmental regulations applicable to our business.  We would be subject to significant penalties for failure to comply with these laws and regulations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2022, we had 216 employees, of which 140 employees were engaged in research and development, manufacturing, and quality activities. Of the 216 employees, 213 were located in the U.S. We have a number of employees who hold advanced degrees, such as a Ph.D. None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages. We are committed to attracting, developing, advancing and retaining a diverse and talented workforce. As part of our measures to attract and retain personnel, we offer a total rewards package to our full-time employees consisting of base salary, cash bonuses based on individual and company performance, equity compensation and comprehensive benefits, including health insurance, life insurance, retirement plans, and paid holiday and vacation time. We support our employee&#8217;s further development by providing professional development opportunities. We believe that we maintain good relations with our employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To complement our own expert professional staff, we utilize specialists in clinical development, regulatory affairs, pharmacovigilance, process engineering, manufacturing and quality assurance. These individuals include scientific advisors as well as independent consultants.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.nektar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information in, or that can be accessed through, our website is not part of this annual report on Form&#160;10-K. Our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q and current reports on Form&#160;8-K and amendments to those reports are available, free of charge, on or through our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities Exchange Commission (SEC). The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding our filings at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov.</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION ABOUT OUR EXECUTIVE OFFICERS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table sets forth the names, ages and positions of our executive officers as of February&#160;28, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Age</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Position</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Howard W. Robin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, President and Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jillian B. Thomsen</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Financial Officer and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark A. Wilson, J.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Legal Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan Zalevsky, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Research and Development Officer</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Howard W. Robin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our President and Chief Executive Officer since January 2007 and has served as a member of our board of directors since February 2007. Mr.&#160;Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr.&#160;Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (Berlex), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer of Berlex. From 1984 to 1987, Mr.&#160;Robin was Director of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen&#160;&amp; Co. prior to joining Berlex. Mr.&#160;Robin serves as a director of the Biotechnology Industry Organization, the world&#8217;s largest biotechnology industry trade organization, and also serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jillian B. Thomsen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Senior Vice President, Chief Financial Officer and Chief Accounting Officer since July 2022. From February 2010 to July 2022, Ms. Thomsen served as our Senior Vice President, Finance and Chief Accounting Officer. From April 2008 through January 2010 she served as our Vice President Finance and Chief Accounting Officer and from March 2006 through March 2008, Ms. Thomsen served as our Vice President Finance and Corporate Controller. Before joining Nektar, Ms. Thomsen was Vice President Finance and Deputy Corporate Controller of Calpine Corporation from September 2002 to February 2006. Ms. Thomsen began her career as a certified public accountant at Arthur Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies. Ms. Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mark A. Wilson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Senior Vice President and Chief Legal Officer since July 2022. Previously, Mr. Wilson served as our General Counsel since June 2016. Mr. Wilson joined Nektar in May 2002 and initially served as Patent Counsel and then as Senior Patent Counsel to the company prior to 2008 when he was promoted to Vice President, Intellectual Property. Before joining Nektar in 2002, Mr. Wilson was an associate at Reed &amp; Associates, a patent law firm in Menlo Park, California, where he represented both start-up and Fortune 500 companies. Mr. Wilson received his J.D. from Seton Hall University, School of Law, and his B.S. in Pharmacy from Rutgers University, College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the California Bar.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jonathan Zalevsky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Chief Research &amp; Development Officer since October 2019. Dr. Zalevsky served as our Senior Vice President, Biology and Preclinical Development from April 2017 through November 2017 and served as our Senior Vice President, Research and Chief Science Officer from November 2017 to October 2019. From July 2015 through April 2017, Dr. Zalevsky served as our Vice President, Biology and Preclinical Development. Prior to joining Nektar, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. Prior to working at Takeda, Dr. Zalevsky held a number of research and development positions at Xencor, Inc. Dr. Zalevsky received his Ph.D. in Biochemistry from the Tetrad Program at the University of California, San Francisco. He received dual bachelor degrees in Biochemistry and Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the success of drug candidates, including rezpegaldesleukin (previously referred to as NKTR-358) and NKTR-255.&#160;If these drug candidates fail in clinical development our business will be significantly harmed.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is highly dependent on the clinical success of our drug candidates, including rezpegaldesleukin and NKTR-255. In general, most investigational drugs, including drug candidates designed to treat patients suffering from autoimmune disorders and cancers, such as rezpegaldesleukin and NKTR-255, respectively, do not become approved drugs. Accordingly, there is a very meaningful risk that our drug candidates will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals. Further, if Lilly, our collaboration partner for rezpegaldesleukin, delays the initiation or completion of one or more clinical trials for reasons outside of our control, or discontinues development of rezpegaldesleukin for scientific or other reasons, or is not successful, it would materially harm our market valuation, prospects, financial condition and results of operations. Under our collaboration agreement with Lilly, we are eligible for up to $250.0 million in additional development and regulatory milestones, and a royalty rate up to the low twenties percent based upon our Phase 3 development cost contribution and the level of annual global product sales. In February 2023, we announced that the Phase 2 Lupus Study of rezpegaldesleukin in SLE conducted by Lilly did not meet the study's primary endpoint and that Lilly does not intend to advance rezpegaldesleukin to Phase 3 development in SLE. One or more clinical failures of our drug candidates would jeopardize and could result in reduced, delayed or eliminated revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, promising results from earlier trials may not predict similarly favorable outcomes in subsequent trials. For example, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our drug candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="margin-top:9pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may experience delays in conducting clinical trials of our drug candidates. Clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our drug candidates could be delayed for a variety of reasons, including:</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in obtaining regulatory authorization to commence a clinical study;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">for drug candidates (such as rezpegaldesleukin) partnered with other companies, delays caused by our partner; </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by the COVID-19 pandemic (see also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in recruiting suitable patients to participate in a trial;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites dropping out of a trial due to the detriment of enrollment rates;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory authorities policies or guidance applicable to our drug candidates; and</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by changing standards of care or new treatment options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, results for the studies would be delayed, and consequently the regulatory approval process would be delayed which would also delay the ability to commercialize these drug candidates, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely on academic and private non-academic institutions to conduct investigator-sponsored clinical studies or trials of our product candidates. Any failure by the investigator-sponsor to meet its obligations with respect to the clinical development of our product candidates may delay or impair our ability to obtain regulatory approval or commercialize for other product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on academic and private non-academic institutions to conduct and sponsor clinical studies or trials relating to our product candidates. We do not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored studies or trials as providing adequate support for future clinical trials, whether controlled by us or independent investigators, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such arrangements will likely provide us certain information concerning our drug candidates with respect to the investigator-sponsored studies or trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored studies or trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored studies or trials. If we are unable to confirm or replicate the results from the investigator-sponsored studies or trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored studies or trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA or non-U.S. regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored studies or trials or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored studies or trials. If so, the FDA or other non-U.S. regulatory authorities may require us to obtain and submit additional preclinical, manufacturing or clinical data before we may initiate our planned clinical trials and/or may not accept such additional data as adequate to initiate our planned clinical trials. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcomes from the clinical trials of drug candidates from others, and the discovery and development of new potential therapies in immunology and oncology, could have a material and adverse impact on the value of the drug candidates in our research and development pipeline.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development of immune-modulatory agents is a very competitive global segment in the biopharmaceutical industry attracting tens of billions of dollars of investment each year.  Our clinical trial plans for rezpegaldesleukin, NKTR-255 and other immunomodulatory agents drug candidates face substantial competition from other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regimens already approved, and many more that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As immunotherapy represent a relatively new approach to treatment of autoimmune disorders and cancer and few have successfully completed late stage development, drug development in this area entails substantial risks and uncertainties that include rapidly changing standards of care, identifying contribution of components when therapeutic combinations are employed, patient enrollment competition, evolving regulatory frameworks to evaluate regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of our drug candidates. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The risk of clinical failure for any drug candidate remains high prior to regulatory approval and there can be no assurance that our product candidates will obtain regulatory approval for any particular indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a drug candidate may not predict the results that will be obtained in later phase clinical trials of the drug candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary drugs and drug candidates could make our technologies, drugs or drug candidates obsolete or noncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and drug candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Laysan Bio, Inc., Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.),  NOF Corporation and Aurigene Pharmaceutical Services. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many competitors for our drug candidates currently in development. For rezpegaldesleukin, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based, microbiome-based, or toleragenic-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Sangamo Therapeutics, Inc., Quell Therapeutics, Ltd, TxCell, Inc., Sonoma Biotherapeutics, Inc., GentiBio, Inc. Kyvema Therapeutics, Inc. and and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., BMS, Novartis, Inc., ILTOO Pharma, Xencor, Inc. Merck &amp; Co, through its acquisition of Pandion Therapeutics, and Sanofi SA, through its acquisition of Synthorx, Inc.). For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., Nkarta Therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.). There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies noncompetitive or obsolete.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Collaboration Partners</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our collaboration partner to initiate, properly conduct and prioritize clinical trials for rezpegaldesleukin and to perform important additional development and commercialization activities, and our business will be significantly harmed if they deprioritize or discontinue clinical trials or otherwise harm the prospects of our drug candidates. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on Lilly (through the Lilly Agreement) to initiate, properly conduct, and prioritize clinical trials and other development-related activities for rezpegaldesleukin.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we will rely on Lilly to perform specified commercialization activities for rezpegaldesleukin, pursuant to our collaboration agreement. In the event Lilly fails to initiate, properly conduct and prioritize their obligations under their applicable agreement with us, our business will be significantly harmed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our agreement with Lilly provides us with enforcement or other curative rights to address the harm caused by Lilly&#8217;s action (or failure to act), our efforts in pursuing a remedy would be costly and time-consuming, and there is no guarantee that these efforts would succeed or be sufficient to fully address the harm.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirement</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our 2022 strategic reorganization plan and cost restructuring plan may not be successful and we may undertake additional restructuring activities in the future. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan) to prioritize key research and development efforts that will impact the Company&#8217;s future business activities, including activities involving rezpegaldesleukin, NKTR-255 and several core research programs.  In connection with the 2022 Restructuring Plan, we also announced cost restructuring measures aimed at ensuring we will have significant capital to fund key programs over a multi-year time horizon. There is no guarantee that the 2022 Restructuring Plan will achieve its intended benefits or that our post-restructuring focus will be sufficient for us to achieve success. In addition, in view of the outcome of the Phase 2 Lupus Study and Lilly&#8217;s decision not to initiate Phase 3 clinical testing of rezpegaldesleukin in SLE, we may undertake additional restructuring and cost-saving activities in 2023 to further prioritize our key research and development efforts. There is no guarantee these new efforts will be successful and may further harm our business. For example, our cost restructuring efforts may not result in the anticipated savings or other economic benefits, may prioritize the wrong drug candidates or wrong indications to study for those drug candidates, or could result in total costs and expenses that are greater than expected, which would require us to seek potentially dilutive financing alternatives, disrupt or restrain the scope of our business activities, and would make it more difficult to attract and retain qualified personnel, each of which could have a material adverse effect on our business, financial condition and prospects</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreements with various pharmaceutical or biotechnology companies, our collaboration partner is generally solely responsible for:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">designing and conducting large scale clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">marketing and selling the drugs when and if they are approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaboration partners with commercial rights may choose to devote fewer resources to the development or marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of drug candidates or to litigation or arbitration proceedings;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may be unable to pay us as expected;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may respond to natural disasters or health epidemics, such as the COVID-19 pandemic, by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial future capital requirements and there is a risk that we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash and investments in marketable securities valued at approximately $505.0 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates, particularly rezpegaldesleukin;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, cost and results of our clinical development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our general and administrative expenses, capital expenditures and other uses of cash; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes concerning patents, proprietary rights, or license and collaboration agreements that could negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue to advance our drug candidates to later stage research and development, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is very difficult to estimate the commercial potential of drug candidates due to important factors such as safety and efficacy compared to other available treatments, including changing standards of care, third party payer reimbursement standards, patient and physician preferences, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic and biosimilar versions of our drug candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We may also depend on our relationships with other companies for sales and marketing performance and the commercialization of drug candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If government and private insurance programs do not provide payment or reimbursement for our partnered drug or proprietary drugs, those drugs will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States and markets in other countries, patients generally rely on third-party payers to reimburse all or part of the costs associated with their treatment. In both domestic and foreign markets, sales of our partnered and proprietary products that receive regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid in the U.S., managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a biologic candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. For more information, see &#8220;Business &#8211; Government Regulation &#8211; Coverage, Reimbursement, and Pricing.&#8221; </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payers tend to follow CMS to a substantial degree. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors payers consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any of our drug product candidates that are commercialized and, if reimbursement is available, the level of reimbursement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future biologic candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is exclusively derived from our collaboration agreements (whether based on our drug candidates or polymeric reagents), from which we receive upfront fees, research and development reimbursement and funding, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture or ultimately commercialize any biologic candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, we reported a net loss of $368.2 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestones and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary biologic candidates and the regulatory approval and market success of our biologic candidates. We may not be able to achieve and sustain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for rezpegaldesleukin and NKTR-255;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive necessary regulatory and marketing approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain or expand manufacturing at necessary levels;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieve market acceptance of our partnered products;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive revenue or royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain sufficient funds to finance our activities.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Supply and Manufacturing</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our contract manufacturers are not able to manufacture biologic substance or substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our contract manufacturing organizations (CMOs) are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on CMOs to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of biologics involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party CMOs required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our CMOs to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or biologic candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop biologic candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our biologic candidate that such CMO owns independently. This would increase our reliance on such a CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our products or biologic candidates. In addition, in the case of the CMOs that supply our biologic candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We purchase some of the starting material for biologics and biologic candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CMOs are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our CMOs for compliance with applicable regulatory requirements. Any failure to follow and document our or our CMOs&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our CMOs, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Business Operations</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to conduct the clinical trials for our biologic candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our biologic candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our biologic candidates to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy requires us to manage our business to provide for the continued development of our proprietary and partnered biologic candidates. Our strategy also calls for us to manage the capital necessary to fund key programs through value-enhancing data and other milestones. If we are unable to manage effectively our current operations, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other dilutive financing arrangements on unfavorable terms.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must attract and retain experts in the areas of research, development (including clinical testing), manufacturing, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel.  Furthermore, as a result of our 2022 Restructuring Plan, our employees may experience distractions or decreases in employee morale and we may experience increased levels of employee attrition and turnover, which would adversely affect our business. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rising inflation rates have increased our operating costs and could negatively impact our operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inflation rates, particularly in the United States, have increased recently to levels not seen in decades. Increased inflation has resulted in increased operating costs. In addition, the United States Federal Reserve has raised, and is expected to continue to raise, interest rates in response to concerns about inflation.  Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business could be adversely affected, directly or indirectly, by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, including both our own manufacturing operations as well as the manufacturing operations of third parties upon whom we rely.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, the ongoing COVID-19 pandemic has not had a significant, long-term impact on our business. However, any prolonged or worsening effects in the progression of the COVID-19 pandemic could cause a negative impact on our clinical trial timelines, operations, financial condition and prospects. Our clinical trials and those run by our collaborators or other third parties may be affected by delays in investigator recruitment, clinical site initiation, patient screening, or patient enrollment due to challenges associated with the COVID-19 pandemic. Supply chain disruptions or shortages in raw materials and equipment caused by the COVID-19 pandemic may affect our ability to manufacture our products and to supply drug candidates for clinical trials. Throughout the pandemic we have modified our policies to allow our employees to safely work, including remotely when possible, and we may experience unpredictability in our expenses, employee productivity and availability and employee work culture. The COVID-19 pandemic has had a broad impact on global financial markets and could reduce our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from a health epidemic, including the COVID-19 pandemic, could materially affect our business and the value of our common stock.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to actively monitor the ongoing COVID-19 pandemic and applicable government recommendations in light of new developments, including the recently announced intention to end the national emergency and public health emergency declarations in May 2023. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain regulatory approval for our biologic candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may not obtain regulatory approval for biologic candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Biologic candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a biologic candidate. In addition, undesirable side effects caused by our biologic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of drug candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue to fund our research and development efforts from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered biologic candidate development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, we could be subject to substantial liabilities, which would harm our financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property licenses related to the development of our biologic candidates on a commercially reasonable basis, if at all.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partners&#8217; technology or biologic candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the biologic, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 300 U.S. and 1,500 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, re-examinations or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire prior to the commercialization of the biologic. Moreover, even if a patent encompassing a biologic has not expired prior to the biologic's commercialization, the patent may only provide a short period of protection following the commercialization of the covered product.&#160; In addition, our patents may be subject to post grant proceedings, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examinations, before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our biologic candidates.&#160;There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our biologic candidates, if approved, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any biologic candidates for which we obtain marketing approval. Our current and future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. For more information, see &#8220;Business &#8211; Government Regulation - Other Healthcare Laws and Regulations.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government- paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Governmental policy can also change the commercial potential of our product candidates, including efforts to increase patient access to lower-cost generic and biosimilar drugs. For example, on July 9, 2021, President Biden issued an executive order directing the FDA to, among other things, continue to clarify and improve the approval framework for generic drugs and biosimilars, including the standards for interchangeability of biological products, facilitate the development and approval of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">biosimilar and interchangeable products, clarify existing requirements and procedures related to the review and submission of BLAs, and identify and address any efforts to impede generic drug and biosimilar competition. Additional changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the Affordable Care Act and the passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback program. For more information regarding the risks related to recently enacted and future legislation please see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business &#8211; Government Regulation &#8211; Legislative and Regulatory Landscape</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business. </span></div><div style="margin-top:9pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In the past, average review times at the agency have fluctuated, and this may continue in the future. In addition, government funding of other agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government shutdowns, if prolonged,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could significantly impact the ability of government agencies upon which rely (such as the FDA and SEC) to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Disruptions at the FDA and other agencies may slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since March 2020, when foreign and domestic inspections were largely placed on hold due to the COVID-19 pandemic, the FDA has been working to resume pre-pandemic levels of inspection activities, including routine surveillance, bioresearch monitoring and pre-approval inspections. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the ongoing COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proprietary rights through one or more potential legal remedies. Third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or biologic candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. For example, we are involved in ongoing litigation with Aether Therapeutics Inc., who in March 2020 filed a complaint against AstraZeneca, Nektar and Daiichi-Sanko, Inc. alleging that MOVANTIK&#174; infringes U.S. Patent Nos. 6,713,488, 8,748,448, 8,883,817 and 9,061,024. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. We are also regularly involved in opposition proceedings at the European Patent Office and in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examination proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our biologic candidates and platform technologies.  If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain biologics or biologic candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may also be involved in legal proceedings other than those related to intellectual property, including securities actions or derivative actions or other complaints.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from any litigation or the settlement would be sufficient and could result in substantial financial risk to the Company.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of lawsuits and complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses for any of the legal proceedings we may be involved in. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages.We have recorded no liability for any litigation matters in our Consolidated Balance Sheets at December&#160;31, 2022.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to many laws and regulations intended to protect the privacy and data of individuals participating in our clinical trials and our employees, among others. For example, with regard to individuals participating in our clinical trials, these laws and regulations govern the safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. In addition to federal laws and regulations in the United States, such as the HIPAA requirements relating to the privacy, security and transmission of individually identifiable health information, many state and foreign laws also govern the privacy and security of health information. These laws often differ from each other in significant ways, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation. If passed, these proposals could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), and the implementing legislation of EU Member States, which became effective on May 25, 2018, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. The GDPR is wide-ranging in scope and imposes strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to, for example, (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the individuals about how their personal information is used, and (iii) ensuring the security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20 million or 4% of annual global revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are found liable for the inappropriate collection, storage, use or disclosure of protected information of individuals (such as employees and/or clinical patients protected by any privacy or data protection law), we could be subject to reputational harm, monetary fines (such as those imposed by the GDPR and CCPA), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and the development of our biologic candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations (including, but not limited to, the handling and disposal of both our hazardous and non-hazardous waste) is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Investment and Securities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial                                losses for investors and securities class action and shareholder derivative litigation. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. During the year ended December&#160;31, 2022, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from $2.03 to $13.72 per share. In response to volatility in the price of our common stock in the past, plaintiffs&#8217; securities litigation firms have sought information from us and/or shareholders as part of their investigation into alleged securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, plaintiffs&#8217; securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by plaintiffs&#8217; securities litigation firms following share price fluctuations. A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of our 2022 Restructuring Plan; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, the results from clinical studies of bempegaldesleukin has had a significant impact on our stock price;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of outcomes from our clinical trials which can be difficult to predict particularly for clinical studies that have event-driven end points such as progression-free survival and overall survival;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by collaboration partners as to their plans or expectations related to biologic candidates and approved biologics in which we have a substantial economic interest;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding terminations or disputes under our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products that may compete with our approved partnered products or products under development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of changes in governmental regulation affecting us or our competitors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation brought against us or third parties to whom we have indemnification obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of drug formulations developed by us or others;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financing needs and activities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions, including the impacts of rising inflation and interest rates and global geopolitical tensions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years. In addition, as a result of our lower stock price, we are no longer a well-known seasoned issuer, which otherwise would allow us to, among other things, file automatically effective shelf registration statements. As a result, any attempt to access the public capital markets will be more expensive and subject to delays.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on who may call a special meeting of stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We significantly rely on information technology systems, and any failure, inadequacy, interruption, breach, or security lapse of that technology within our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to loss, damage, denial-of-service, unauthorized access, or misappropriation. Such cybersecurity breaches may be the result of unauthorized activity by our employees and contractors, as well as by third parties who use cyberattack techniques involving malware, hacking and phishing, among others. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of an increase in the number of employees who adopted a remote working environment during the COVID-19 pandemic, which may be less secure and more susceptible to hacking attacks. Our information technology systems, and those of our partners, vendors, CROs, CMOs or other contractors or consultants are also vulnerable to natural disasters, terrorism, war and telecommunication and electrical failures. Any such compromise or disruption, no matter the origin, may cause an interruption of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our biologic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, the loss, corruption or unauthorized disclosure of our trade </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secrets, personal data or other proprietary or sensitive information could compromise the commercial viability of one or more of our programs, which would negatively affect our business. Also, the costs to us to investigate and mitigate cybersecurity incidents could be significant.  </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 31, 2020, the U.K. ceased to be a member state of the EU, a process known as Brexit, and began a transition period, which expired on December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the U.K. and the EU agreed on a trade and cooperation agreement, under which the EU and the U.K. will now form two separate markets governed by two distinct regulatory and legal regimes. The trade and cooperation agreement covers the general objectives and framework of the relationship between the U.K. and the EU, including as it relates to trade, transport and visas. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the EU. Depending on the application of the terms of the trade and cooperation agreement, we, our collaboration partners and others could face new regulatory costs and challenges.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic and political conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions, including, for example, adverse global economic conditions resulting from the COVID-19 pandemic. See also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; In addition, our operations and performance may be affected by political or civil unrest or military action, terrorist activity, and unstable governments and legal systems. For example, in late February 2022, Russia commenced a military invasion of Ukraine, and the sustained conflict in Ukraine, including the potential effects of sanctions and retaliatory cyber-attacks on the world economy and markets, has contributed to increased market volatility and uncertainty.  In particular, sanctions imposed by the U.S., EU and other countries in response to the conflict between Russia and Ukraine and the potential response to such sanctions may have an adverse impact on our business, including our clinical trials, the financial markets and the global economy.  As the conflict in Ukraine continues, there can be no certainty regarding whether the U.S., EU or other governments will impose additional sanctions, or other economic or military measures relating to Russia.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of global economic and political conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. Our ability to conduct clinical trials in regions experiencing political or civil unrest could negatively affect clinical trial enrollment or the timely completion of a clinical trial. We believe the aforementioned economic conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with rising international trade tensions or sanctions, our business may be adversely affected following new or increased tariffs that result in increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by corporate citizenship and&#160;sustainability&#160;matters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and&#160;sustainability&#160;matters, which include environmental concerns and social investments. We could fail to meet, or be perceived to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, civil unrest, or terrorist event in any of these locations, our ability to manufacture and supply materials for biologic candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_25"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.  Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_28"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.  Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">California</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We lease a 155,215 square foot facility in the Mission Bay Area of San&#160;Francisco, California (Mission Bay Facility), under an operating lease which expires in January 2030. The Mission Bay Facility is our corporate headquarters and also includes our research and development operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also lease 135,936 square feet of office space in San Francisco (the Third Street Facility), under an operating lease which expires in January 2030, which previously provided additional space to support our research and development activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2022 Restructuring Plan, we have consolidated our San Francisco operations in our Mission Bay Facility, and we have vacated our Third Street Facility and certain laboratory and office spaces at our Mission Bay Facility. We are seeking to sublease the vacated spaces, while still maintaining sufficient office and laboratory space to allow our team to develop our proprietary programs. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alabama</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We currently own facilities consisting of approximately 124,000 square feet in Huntsville, Alabama, which houses laboratories as well as administrative, clinical and commercial manufacturing facilities for our PEGylation and advanced polymer conjugate technology operations as well as manufacturing of APIs for early clinical studies.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_31"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.  Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, we are subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. </span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_34"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.  Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_40"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.  Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our common stock trades on The NASDAQ Global Select Market under the symbol &#8220;NKTR.&#8221; </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of February&#160;21, 2023, there were approximately 148 holders of record of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have never declared or paid any cash dividends on our common stock. We currently expect to retain any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There were no sales of unregistered securities and there were no common stock repurchases made during the year ended December&#160;31, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding our equity compensation plans as of December&#160;31, 2022 is disclosed in Item&#160;12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; of this Annual Report on Form&#160;10-K and is incorporated herein by reference from our proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC pursuant to Regulation&#160;14A not later than 120&#160;days after the end of the fiscal year covered by this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Measurement Comparison</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The material in this section is being furnished and shall not be deemed &#8220;filed&#8221; with the SEC for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liability of that section, nor shall the material in this section be deemed to be incorporated by reference in any registration statement or other document filed with the SEC under the Securities Act or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following graph compares, for the five year period ended December&#160;31, 2022, the cumulative total stockholder return (change in stock price plus reinvested dividends) of our common stock with (i)&#160;the NASDAQ Composite Index, (ii)&#160;the NASDAQ Biotechnology Index and (iii)&#160;the RDG SmallCap Biotechnology Index. Measurement points are the last trading day of each of our fiscal years ended December&#160;31, 2018, December&#160;31, 2019, December&#160;31, 2020, December&#160;31, 2021 and December&#160;31, 2022. The graph assumes that $100 was invested on December&#160;31, 2017 in the common stock of the Company, the NASDAQ Composite Index, the Nasdaq Pharmaceutical Index, the RDG SmallCap Pharmaceutical Index, the NASDAQ Biotechnology Index and the RDG SmallCap Biotechnology Index and assumes reinvestment of any dividends. The stock price performance in the graph is not intended to forecast or indicate future stock price performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><img src="nktr-20221231_g1.jpg" alt="nktr-20221231_g1.jpg" style="height:568px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_43"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.  Reserved</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_46"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8.8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section as well as factors described in &#8220;Part&#160;I, Item&#160;1A&#160;&#8212; Risk Factors.&#8221;</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Direction of Our Business</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nektar Therapeutics is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy.  Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> apply our deep understanding of immunology and unparalleled expertise in polymer chemistry to create innovative drug candidates and use our drug development expertise to advance these molecules through preclinical and clinical development . Our pipeline of clinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin) and cancer (e.g. NKTR-255). We continue to make significant investments in building and advancing our pipeline of drug candidates as we believe that this is the best strategy to build long-term shareholder value. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we announced new strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan) focused on prioritizing key research and development efforts that will be most impactful to the Company&#8217;s future, including our rezpegaldesleukin (previously referred to as NKTR-358) and NKTR-255 programs and several core research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person's body. A failure of the body's self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. Our drug candidate rezpegaldesleukin is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases. It is designed to target the interleukin-2 (IL-2) receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells (Treg cells). By activating these cells, rezpegaldesleukin may act to bring the immune system back into balance. Rezpegaldesleukin is being developed as a once or twice monthly self-administered injection for a number of autoimmune disorders and inflammatory diseases. In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to develop and commercialize rezpegaldesleukin, pursuant to which we received an initial payment of $150.0 million and are eligible for up to an additional $250.0 million for development and regulatory milestones. We have completed our responsibilities for Phase 1 clinical development and certain drug product development and supply activities. We also share Phase 2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to 25% of the costs of Phase 3 development on an indication-by-indication basis in order for us to achieve the maximum royalty level under the Lilly </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement, and further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, we will have the opportunity to receive a royalty rate up to the low twenties percent based upon our Phase 3 development cost contribution and the level of annual global product sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have announced our intention to exercise our option to fully fund Nektar&#8217;s 25% share of the Phase 3 development costs for rezpegaldesleukin.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rezpegaldesleukin has advanced to Phase 2 development, which our collaboration partner, Lilly, has carried out in various indications. On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study). The primary endpoint of the Phase 2 Lupus Study, a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4-points reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, was not met and Lilly has notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. Although the Phase 2 Lupus Study did not meet its primary endpoint, patients within the modified intent-to-treat population, defined as all patients who were randomized and received at least one dose of study medication, that were treated with rezpegaldesleukin demonstrated improvement in SLEDAI-2K score as compared to placebo. Additionally, clinically meaningful improvements were  observed in the British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) response and Lupus Low Disease Activity State (LLDAS) as compared to placebo, and exploratory biomarker data also showed that rezpegaldesleukin led to dose-dependent proliferation of Treg cells, which was consistent with prior studies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we focus on developing medicines that target biological pathways that stimulate and sustain the body&#8217;s immune response in order to fight cancer. Our drug candidate NKTR-255 is an investigational biologic that is designed to target the IL-15 pathway in order to activate the body's innate and adaptive immunity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules as well as to enhance CAR-T therapies. Our development strategy for NKTR-255 is focused on three therapeutic areas: to enhance response to antibody-dependent cellular cytotoxicity (ADCC) mediated therapies by restoring NK cells, to improve CAR-T cell persistency in cellular therapies and to augment response to checkpoint inhibitors. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are studying NKTR-255 in ADCC combinations in both liquid and solid tumors. We have initiated a Phase 1 dose escalation and expansion study of NKTR-255 in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma where patients are treated with NKTR-255 as a monotherapy or NKTR-255 in combination with daratumumab. We have also initiated a Phase 1/2 study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer where patients are treated with NKTR-255 in combination with cetuximab. In addition, we initiated a Nektar-sponsored Phase 2/3 study to evaluate NKTR-255 following Yescarta&#174; or Breyanzi&#174;  CD19 CAR-T cell therapy in patients with large B-cell lymphoma.  Two ongoing investigator sponsored trials are evaluating NKTR-255 following treatment with a CAR-T cell therapy. These studies include a Phase 1 study evaluating NKTR-255 in combination with CD19 CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphoma and a Phase 1 study evaluating NKTR-255 in combination with CD19/22 CAR-T cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. A third investigator sponsored study is evaluating NKTR-255 in combination with darvulamab in patients with unresectable Stage 3 non-small lung cancer who have received chemoradiation.  We are continuing our oncology clinical collaboration with Merck KGaA and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255 in combination with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to advance our most promising research drug candidates into preclinical development with the objective of advancing these early-stage research programs to human clinical studies over the next several years. Our lead research program is focused on developing a tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist antibody. TNFR2 signaling drives immunoregulatory function and can provide a direct protective effect for tissue cells. Our focus is on TNFR2 antibody candidates that show selective Treg cell binding and signaling profiles that may be developed for treatment of autoimmune diseases. In connection with this program, we are targeting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IND </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">readiness for a lead TNFR2 agonist antibody candidate by the end of 2023 in order to submit an Investigational New Drug (IND) filing for the first clinical study in 2024. We also plan to continue our preclinical stage NKTR-288 development program. NKTR-288 is an investigational PEG conjugate of the protein interferon gamma that is designed utilizing a site-specific conjugation approach to modify binding of interferon gamma with one of its substrates and to optimize the pharmacodynamic duration of interferon gamma signaling. We believe this program has applications in a number of therapeutic indications including oncology as well as in other infectious diseases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically derived all of our revenue and substantial amounts of research and development operating capital from our collaboration agreements. In addition to our collaboration with  Lilly, we have received upfront and milestone payments under a number of other previous collaboration agreements, several of which have resulted in approved drugs, for which we may continue to manufacture the polymer reagents used in the production of the drug products and may be entitled to royalties for net sales of these approved drugs. However, we have sold the majority of our rights to receive royalties under these arrangements, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2012 Purchase and Sale Agreement: In 2012, we sold all of our rights to receive royalties from CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of Crohn&#8217;s disease and other autoimmune indications) and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of anemia associated with chronic kidney disease) under our collaborations with UCB Pharma and F. Hoffmann-La Roche Ltd, respectively, to RPI Finance Trust (RPI), an affiliate of Royalty Pharma for $124.0 million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2020 Purchase and Sale Agreement: In December 2020, we sold our rights, subject to a cap, to receive royalties from MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of opioid-induced constipation), ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a half-life extension product of Factor VIII) and other hemophilia products, under our arrangements with AstraZeneca AB, Baxalta, Inc. (a wholly owned-subsidiary of Takeda Pharmaceutical Company Ltd.), and Novo Nordisk A/S, respectively, for $150.0 million to entities managed by HealthCare Royalty Management (HCR) under a capped sale arrangement, such that all future royalties return to Nektar if HCR receives $210.0 million in royalties by December 31, 2025 (the 2025 Threshold) or $240.0 million if the 2025 Threshold is not met.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market opportunities. We continue to actively monitor the ongoing COVID-19 pandemic and applicable government recommendations in light of new developments. If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our prospects for growth. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A &#8220;Risk Factors.&#8221; </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to financing our near-term business needs, as set forth below in &#8220;Key Developments and Trends in Liquidity and Capital Resources,&#8221; we estimate we have working capital to fund our current business plans through at least the next twelve months. At December&#160;31, 2022, we had approximately $505.0 million in cash and investments in marketable securities. </span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_52"></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the years ended December&#160;31, 2022 and 2021 is presented below. Additional information required by Item 7 for the year ended December 31, 2020 can be found in Item 7 in our Annual Report on Form 10-K for the year December 31, 2021, filed with the SEC on March 1, 2022 and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue (in thousands, except percentages)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Decrease)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Decrease)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,377)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,907&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,852)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as development or manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required to make these estimates.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales decreased for the year ended December&#160;31, 2022, as compared to the year ended December&#160;31, 2021, due to decreased demand from our collaboration partners. We expect product sales for 2023 to be consistent with 2022.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash Royalty Revenue Related to Sales of Future Royalties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For a discussion of our Non-cash royalty revenue, please see our discussion below &#8220;Non-Cash Royalty Revenue and Non-Cash Interest Expense.&#8221;</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements and certain research and development activities. The level of license, collaboration and other revenue depends in part upon the estimated recognition period of the upfront payments allocated to continuing performance obligations, the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of research and development work, and entering into new collaboration agreements, if any. During the year ended December&#160;31, 2022, we recognized $1.5 million for a license agreement, under which we are entitled to no further consideration. As a result of the recognition of this revenue, revenue increased for the year ended December&#160;31, 2022 as compared to year ended December&#160;31, 2021. We do not expect significant license, collaboration and other revenue for 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties. See Item&#160;1A.&#160;Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by geography (in thousands)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,114&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,055&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,907&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of goods sold (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,635&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,897&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,262)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit (loss) (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,287)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Percentage change represents a worsening since the negative gross margin has increased.</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our strategy is to manufacture and supply polymer reagents to our third-party collaborators where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. Typically, we have elected to enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate. We have a predominantly fixed cost base associated with our manufacturing activities. As a result, our product gross profit and margin are significantly impacted by the mix and volume of products sold in each period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product gross margin was negative for the years ended December&#160;31, 2022 and December&#160;31, 2021. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the polymer reagent, and we expect this arrangement to continue in future years. We also receive royalty revenue from this collaboration. In each of the years ended December&#160;31, 2022 and 2021, the royalty revenue from this collaboration exceeded the related negative gross margin.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our customers. We expect product gross profit to be negative in 2023 as a result of the collaborative arrangement described above.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expense (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,323&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,269&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,946)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the expense reimbursement from our partners as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense. Under the BMS Collaboration Agreement, BMS generally bears 67.5% of development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 35% of costs for manufacturing bempegaldesleukin. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 1 to our Consolidated Financial Statements, in April 2022, BMS and we decided to discontinue development of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will wind down the various clinical trials under the BMS Collaboration Agreement, and we also decided to discontinue all other development of bempegaldesleukin. The cost sharing under the BMS Collaboration Agreement remained unchanged through December 31, 2022. Additionally, we have implemented the 2022 Restructuring Plan to reduce our workforce by approximately 70%. As a result of our termination of the development program, research and development expense includes development expenses for bempegaldesleukin only for the first quarter of 2022. For the remaining three quarters of 2022, we reported clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS, within restructuring, impairment and other costs of terminated program in our Consolidated Statement of Operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize our employee and infrastructure resources across multiple development and research programs. The following table presents expenses incurred for clinical and regulatory services, clinical supplies, and preclinical study support provided by third parties as well as contract manufacturing costs for each of our drug candidates. The table also presents other costs and overhead consisting of personnel, facilities and other indirect costs (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Clinical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Study</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (CD122-preferential IL-2 pathway agonist)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terminated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-255 (IL-15 receptor agonist)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rezpegaldesleukin (cytokine Treg stimulant)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery research, manufacturing and other costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total clinical development, contract manufacturing and other third party costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel, overhead and other costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation and depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Clinical Study Status definitions are provided in Part&#160;I, Item&#160;1. Business.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In April 2022, BMS and we terminated the development of the bempegaldesleukin program. Accordingly, development expenses for bempegaldesleukin are reported in research and development expense for the first quarter of 2022 and for the full year of 2021. For the remaining three quarters of 2022, we reported third party costs for the wind down of the bempegaldesleukin program in restructuring, impairment and other costs of terminated program. The amounts for the quarter ended March 31, 2022 and the year ended December, 31, 2021 include net reductions of $15.1 million and $64.3 million, respectively, of development cost reimbursements from BMS under our collaboration, net of our share of BMS&#8217;s costs. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The amounts includes our 25% share of costs incurred by Lilly for the Phase 1B and Phase 2 development of rezpegaldesleukin. Lilly is responsible for 75% of costs.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The amounts include reductions of $9.8 million and $37.2 million of employee cost reimbursements from BMS under our collaboration for the quarter ended March 31, 2022 and the year ended December 31, 2021, respectively. For the remaining three quarters of 2022, we reported direct employee costs supporting the wind down of the bempegaldesleukin program in restructuring, impairment and other costs of terminated program.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we reported development expenses for bempegaldesleukin in research and development expense for only the quarter ended March 31, 2022, research and development expense decreased significantly for the year ended December&#160;31, 2022 as compared to the year ended December&#160;31, 2021. During the quarter ended March 31, 2022, we recorded $24.9&#160;million as a reduction of research and development expense for the net reimbursement from BMS. Please see our discussion below in Restructuring, impairment and other costs of terminated program for additional information for the remaining three quarters of 2022. For the year ended December&#160;31, 2021, we recorded $101.5&#160;million as a reduction of research and development expense for the net reimbursement from BMS. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and amount of our future clinical trial expenses will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of additional clinical development programs and potential clinical collaboration partnerships (if any) for these programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our drug candidates that we plan to evaluate in clinical development during 2023 and beyond, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates across a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies. We also plan from time to time to evaluate opportunities to in-license potential drug candidates from third parties to add to our drug discovery and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development pipeline. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for a given clinical study design;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll clinical study participants;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and location of sites included in the clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes);</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential for changing standards of care for the target patient population;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety and efficacy profile of the drug candidate;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of clinical research organizations to assist with the management of the trials;&#160;and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of, and the ability to secure, approvals from government health authorities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as the collaboration that we have already completed for rezpegaldesleukin, or clinical collaborations where we would share costs and operational responsibility with a partner. In certain situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expense (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,333&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,844&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,511)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;General and administrative expense includes the cost of administrative staffing, pre-commercial (before the termination of the bempegaldesleukin program), finance and legal activities. As discussed in Note 11 to our Consolidated Financial Statements, we have implemented our 2022 Restructuring Plan to reduce our workforce by approximately 70%. As a result of our 2022 Restructuring Plan, the commercial organization was eliminated and all other bempegaldesleukin-related pre-commercialization activities ceased. We report severance and benefit costs for the terminated employees in restructuring, impairment and other costs of terminated program in our Consolidated Statements of Operations. Accordingly, general and administrative expense decreased for the year ended December&#160;31, 2022 compared with the year ended December&#160;31, 2021. We expect general and administrative expense to decrease in 2023 as compared to 2022 due to the termination of the bempegaldesleukin commercial program and reduction in force.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Other Costs of Terminated Program (in thousands, except percentages)</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,930&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 11 to our Consolidated Financial Statements, following the announcements in March and April 2022 that our registrational trials in bempegaldesleukin failed to meet their primary endpoints, on April 25, 2022, we announced strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan) to prioritize key Phase 2 development programs, to advance our early stage research pipeline and to reduce our workforce by approximately 70% from approximately 735 to approximately 225 employees. The following table presents the components of restructuring, impairment and other costs of terminated program, as further described and disclosed in Note 11 to our Consolidated Financial Statements (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss (gain) on sale or disposal of other property, plant and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For nine-month period ended December&#160;31, 2022, we recorded a reduction of expense of $20.8&#160;million for the net reimbursement from BMS, primarily for clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program. We will continue to recognize expenses in future periods for the wind down of the bempegaldesleukin program, but we expect these expenses to be significantly lower in 2023 as compared to 2022. For the impairment of right-of-use assets, we will continue to update our estimates based on changes in market conditions, whether or not we are able to enter into subleases and, if we do enter into subleases, the economic terms of those subleases, and we may record impairment charges in future periods as these estimates change. We do not expect to recognize any further severance and benefit expense in connection with the 2022 Restructuring Plan, and we do not expect to recognize significant contract termination and other restructuring costs in 2023.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Development Derivative Liability (in thousands except percentages)</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of development derivative liability (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,023)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Percentage change represents a gain on the termination of the derivative.</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 6 to our Consolidated Financial Statements, we remeasured the development derivative liability under our co-development agreement with SFJ to fair value at each reporting date. As of March 31, 2022, due to the results of the bempegaldesleukin trial in metastatic melanoma, we concluded that it was remote that SFJ and we would continue the clinical trial in head and neck cancer. Accordingly, we reduced the liability to zero as of March 31, 2022 and recognized a corresponding gain in the change in fair value of development derivative liability. The agreement was subsequently terminated in May 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense recorded for the change in fair value for the year ended December 31, 2021 primarily reflected the accretion of our obligation to potentially pay Success Payments to SFJ using our imputed borrowing rate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Cash Royalty Revenue, Non-Cash Interest Expense and Loss on Revaluation of Liability (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to the sales of future royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Increase)/<br/>Decrease<br/>2022 vs.<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 7 to our Consolidated Financial Statements, we recognize non-cash royalty revenue and non-cash interest expense for the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue decreased for the year ended December&#160;31, 2022 as compared to the year ended December&#160;31, 2021 primarily due to lower net sales of the drug products for which we are entitled to royalties. Non-cash interest expense decreased significantly for the&#160;year ended December&#160;31, 2022 as compared to the year ended December&#160;31, 2021 primarily due to the decrease in the effective interest rate for the 2012 Purchase and Sale Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2012 Purchase and Sale Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue for the 2012 Purchase and Sale Agreement resulting from net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022 decreased as compared to the year ended December&#160;31, 2021 due to a decrease in the net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Non-cash interest expense for the 2012 Purchase and Sales Agreement decreased significantly for the&#160;year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021&#160;due to the lower effective interest rate as a result of the revaluation of the liability. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 7 to our Consolidated Financial Statements, to resolve UCB's challenges to our patents and their resulting obligation to pay us the royalties on net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;which we had sold to RPI, RPI and UCB negotiated a reduction in the royalty term and decreased royalty rates over the remaining term, which was implemented through the Settlement Agreement between UCB and us in October 2021. As a result of accounting for the Settlement Agreement as a debt modification, we remeasured the liability to fair value based on the present value of the royalty payments to RPI after the modification, discounted at a rate of 16%. The recognition of the loss on the revaluation has no effect on our cash flows, and the net income statement effect over the term of 2012 Purchase and Sale Agreement remains unchanged. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the term of this arrangement, the net proceeds of the transaction of $114.0 million, consisting of the original proceeds of $124.0 million, net of $10.0 million in payments from us to RPI, is amortized as the difference between the non-cash royalty revenue and the sum of the non-cash interest expense and the loss on the revaluation of the liability. To date, we have amortized $58.8 million of the net proceeds. There are a number of factors that could materially affect our estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  After the modification, we continue to periodically assess future non-cash royalty revenues, and we will adjust any such change in our estimated interest rate prospectively based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $55.2 million of the net proceeds, since all changes in the royalties are absorbed by RPI. As of December 31, 2022, our prospective estimated interest rate is 10%.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before the modification, we had increased our forecasts of future non-cash royalties at various intervals, primarily due to sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> exceeding previous expectations. Due to these increases in estimated future royalties, we increased the prospective effective interest rate from 17% at inception to 48% as of the modification date. In connection with the modification and the reduction in the royalty rate and the royalty term, the net present value of the modified royalty stream, discounted at the fair market value discount rate of 16%, is higher than the prior liability balance. The difference of $23.5 million was reported as a loss on the revaluation of the liability. We also wrote off the remaining $0.9&#160;million of unamortized transaction costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Purchase and Sale Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue and non-cash interest expense for the 2020 Purchase and Sale Agreement decreased for the year ended December&#160;31, 2022 as compared to the year ended December&#160;31, 2021. The decrease in non-cash royalty revenue reflects net decreases in the net sales of the underlying drug products, and the decrease in non-cash interest expense reflects the lower liability balance as it is amortized over the remaining life of the arrangement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement provides for a capped return sale arrangement under which the 2020 Purchase and Sale Agreement will automatically expire, and HCR&#8217;s right to receive the sold royalties will cease when HCR has received payments equaling $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025. Our estimate of the imputed interest rate reflects our best estimates of future royalties to achieve the respective cap. As of December 31, 2022, our prospective estimated interest rate is 20%.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other Income (Expense), net (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net increased for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021, primarily due to increases in market interest rates, which was partially offset by lower investment balances as we have utilized our cash to fund our operations. We expect that our interest income and other income (expense), net will increase for 2023 compared to 2022 due to the anticipated continued higher interest rates.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense (in thousands, except percentages)</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs.<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022 and 2021, our income tax expense primarily results from our foreign operations. For the year ended December&#160;31, 2022, our expense primarily represents taxes associated with our decision to close our research and development operations in India, including income taxes on the gain on the sale of the facility and estimated withholding taxes on the repatriation of the funds from India. Due to our expected net loss in 2023, we expect income tax expense to be lower for 2023 as compared to 2022.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have financed our operations primarily through revenue from upfront and milestone payments under our strategic collaboration agreements, royalties and product sales, as well as public and private placements of debt and equity securities. As of December&#160;31, 2022, we had approximately $505.0&#160;million in cash and investments in marketable securities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the clinical development of our drug candidates, including rezpegaldesleukin and NKTR-255, will continue to require significant investment to continue to advance in clinical development with the objective of obtaining regulatory approval or entering into one or more collaboration partnerships. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Lilly for our collaboration agreement for rezpegaldesleukin. In the future, we have the opportunity to receive up to $250.0 million in milestone payments under our collaboration agreement with Lilly.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current business is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for rezpegaldesleukin and NKTR-255; the sales levels for those products (for both wholly owned products such as NKTR-255 and for licensed products such as rezpegaldesleukin for which we are entitled to royalties), if and when they are approved; whether, when and on what terms we are able to enter into new collaboration transactions; expenses being higher than anticipated; unplanned expenses and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations; and cash receipts, including sublease income, being lower than anticipated.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no credit facility or any other sources of committed capital. The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our 2022 Restructuring Plan, we have executed subleases for a portion of our excess laboratory spaces and are seeking to sublease additional laboratory and office space. For our vacant office space on Third St., however, there is significant uncertainty as to whether or when we will be able to enter into a sublease as well as the economic terms of such subleases, if any. The San Francisco Bay Area office lease market has been negatively impacted by economic uncertainties, particularly impacting the technology industry, and the change in work habits due to the COVID-19 pandemic, as employees continue to work remotely. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of various conditions on the financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the filing of this Annual Report on Form 10-K, we had an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the Securities and Exchange Commission. The 2021 Shelf Registration Statement permitted the offering, issuance and sale by us of up to an aggregate offering price of $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which could be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities were sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are no longer a well-known seasoned issuer, the 2021 Shelf Registration Statement will no longer be available for us to offer and sell securities pursuant to the 2021 Shelf Registration Statement following the filing of this Annual Report on Form 10-K.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash flows used in operating activities for the years ended December&#160;31, 2022 and 2021 totaled $304.0 million and $412.7 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, if any, will decrease for 2023 as compared to 2022 because we do not expect any further costs for the wind down of the bempegaldesleukin program and the various cost restructuring activities described above to be significant.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from invest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ng activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the maturities and sales of our investments, net of purchases, totaled $358.3&#160;million and $217.8&#160;million, respectively, which we used to fund our operations. Our maturities and sales of investments, net of purchases were lower during the year ended December&#160;31, 2021 as compared to the year ended December&#160;31, 2022, because we purchased securities in early 2021, utilizing the $150.0 million in proceeds from the 2020 Purchase and Sale Agreement that were included in cash equivalents at December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $5.7&#160;million and $15.0&#160;million for the purchase or construction of property, plant and equipment in the years ended December&#160;31, 2022 and 2021, respectively. We also received $13.2&#160;million from the sales of property, plant and equipment, primarily from the sale of our research and development facility in India.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received proceeds from issuance of common stock related to our employee option and stock purchase plans of $0.8 million and $33.2 million in the years ended December&#160;31, 2022 and 2021, respectively. Additionally, during the years ended December&#160;31, 2022 and 2021, we received $0.8&#160;million and $3.0&#160;million, respectively, from SFJ pursuant to our co-development agreement.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation and presentation of financial statements in conformity with U.S.&#160;generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. We have determined that, for the periods in this report, the following accounting policies and estimates are critical in understanding our financial condition and the results of our operations.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 11, in connection with our 2022 Restructuring Plan, we have consolidated our San Francisco operations in our Mission Bay Facility, and we have vacated our Third St. Facility and certain laboratory and office spaces at our Mission Bay Facility. We are seeking to sublease the vacated spaces, while still maintaining sufficient office and laboratory space to allow our team to develop our proprietary programs. As a result, we reviewed each of our vacated spaces for impairment as of May 31, 2022, when management had determined which spaces we would seek to sublease, and subsequently at each reporting date or as facts and circumstances changed. As part of our impairment evaluation of each vacated space, we separately compared the estimated undiscounted income to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily leasehold improvements (collectively, sublease assets). We estimated sublease income using market participant assumptions, including the length of time to enter into a sublease and sublease payments, which we evaluated using sublease negotiations or agreements when applicable, current real estate trends and market conditions. If such income exceeded the net book value of the related assets, we did not record an impairment charge. Otherwise, we recorded an impairment charge by reducing the net book value of the assets to their estimated fair value, which we determined by discounting the estimated sublease cash flows using the estimated borrowing rate of a market participant subtenant, which we estimated to be <ix:nonFraction unitRef="number" contextRef="i36ac95832e534e18a6137ad8de7f1444_D20220531-20220531" decimals="3" name="nktr:OperatingLeaseMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF81OC9mcmFnOjE0ZTQzZjUzZjE0ODRjNWZiMjg1ZDZlYjNlYWRlYzFhL3RleHRyZWdpb246MTRlNDNmNTNmMTQ4NGM1ZmIyODVkNmViM2VhZGVjMWFfMTA5OTUxMTYzMzYwNTE_4ce5c355-8571-49b9-a6c2-9650b68ddc20">6.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i809049297a1d4491a7387259a291ce70_D20221231-20221231" decimals="3" name="nktr:OperatingLeaseMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF81OC9mcmFnOjE0ZTQzZjUzZjE0ODRjNWZiMjg1ZDZlYjNlYWRlYzFhL3RleHRyZWdpb246MTRlNDNmNTNmMTQ4NGM1ZmIyODVkNmViM2VhZGVjMWFfMTA5OTUxMTYzMzYwNTk_c4d2abb8-451c-478f-8d3a-f51a150cb575">7.9</ix:nonFraction>% as of May 31, 2022 and December 31, 2022, respectively. Determination of these key assumptions is complex and highly judgmental.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain impairment charges, we used the terms of active sublease negotiations or agreements to estimate sublease income. However, for our facility at 360 Third. St., which represents the substantial majority of our impairment charges for the year ended December 31, 2022, we developed our estimates of the time to enter into a sublease and sublease payments, including estimated free rent periods, based on current real estate trends and market conditions. Accordingly, if our estimates for the time to enter the sublease and estimated free rent periods were longer (shorter), the impairment charge would be higher (lower), and if our estimates for the rental rates were lower (higher), the impairment charge would be higher (lower). Given the current office lease market rental conditions in San Francisco and the larger Bay Area, our estimates are subject to significant uncertainty. The ultimate amount of sublease income may be significantly lower or higher than the amounts used to record our impairment charges, and we may record additional impairment charges in future periods as our estimates change or when we enter into sublease negotiations or execute a sublease agreement.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements with pharmaceutical and biotechnology partners, we assess whether the arrangements fall within the scope of Accounting Standards Codification (ASC) 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we record such payments as a reduction of research and development expense or general and administrative expense, based on where we record the underlying expense.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that our collaboration agreements with BMS and Lilly fall within the scope of ASC 808. We concluded that the upfront and milestone payments under these arrangements fall within the scope of ASC 606 and therefore recognize these payments as revenue in license, collaboration and other revenue. However, due to the collaborative nature of our joint development and commercialization of bempegaldesleukin, we recognize the reimbursements we receive from BMS for their share of the costs that we incur for the development, manufacturing and commercialization of bempegaldesleukin as a reduction of research and development expense; general and administrative expense; or restructuring, impairment and other costs of terminated program, as applicable.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We recognize license, collaboration and other research revenue, including the upfront fees and milestone payments based on the facts and circumstances of each contractual agreement. At the inception of each agreement, we determine which promises represent distinct performance obligations, for which management must use significant judgment. Additionally, at inception and at each reporting date thereafter, we must determine and update, as appropriate, the transaction price, which includes variable consideration such as development and commercial launch milestones. We must use judgment to determine when to include the variable consideration for these milestones in the transaction price such that inclusion of such variable consideration will not result in a significant reversal of revenue recognized when the contingency surrounding the variable consideration is resolved. To date, we have not included the milestones from Lilly in the transaction price due to the significant uncertainties involved with clinical development and regulatory approval. We generally do not believe that we would update the transaction price before events that are outside of our control occur, such as the release of clinical trial results, regulatory acceptance of a BLA or similar filing or regulatory approval. However, if these results are positive, we may conclude that certain milestones meet the recognition requirements for inclusion in the transaction price and therefore we would recognize them as revenue before the milestone event occurs and the payment becomes due to us, provided that the achievement of the milestone is within our control.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties and significant delays between these expenses being incurred and the timing of vendor submission of invoices to us. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratably over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Modification</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 7 to our Consolidated Financial Statements, to resolve UCB&#8217;s challenges to our patents and their resulting obligation to pay us the royalties on net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;which we had sold to RPI, RPI and UCB negotiated a reduction in the royalty term and decreased royalty rates over the remaining term. This negotiation was implemented through the Letter Agreement between RPI and us, which permitted us to enter into the Settlement Agreement with UCB in October </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. When we initially sold our rights to receive royalties to RPI, we concluded that we should account for the transaction as debt under ASC 450-10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 450) due to our continuing involvement in the generation of the royalties due to our obligation to manufacture the polymer reagent purchased by UCB for the production of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since this obligation remained unchanged as a result of the Settlement Agreement, we concluded that we should account for the Letter Agreement within the scope of ASC 450. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our assessment, we concluded that the Letter Agreement represented a modification of the 2012 Purchase and Sale Agreement, since RPI had agreed to reduced royalty payments. Since our estimates of the present value of the reduction in the future royalties exceeded 10% of our estimates of the present value of the royalties before the modification (including the royalties from MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which remain unchanged as a result of these agreements), we concluded that we should treat the modification as an extinguishment of the prior liability and recognize a new liability based on the revised royalty payments and term, discounted to fair value. The estimation of the fair value required us to develop estimates of the future sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over the remaining royalty terms, as well as to estimate an appropriate discount rate. Since no active, traded markets exist for arrangements of this nature, we concluded that the 2020 Purchase and Sale Arrangement was economically similar enough to the modified 2012 Purchase and Sale Agreement to use as a basis for the discount rate because the products under both arrangements are well established drugs and the duration of the arrangements are similar. Accordingly, we utilized our estimated imputed interest rate of 16% from the inception of the 2020 Purchase and Sale Agreement as the discount rate to estimate the fair value of the modified 2012 Purchase and Sale Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our estimates of the future royalties to be received by RPI under the modified 2012 Purchase and Sale Agreement had been higher or lower, our estimated fair value of the new liability would have been higher or lower as well, resulting in a larger or smaller loss on the revaluation. Similarly, if our estimated discount rate had been lower or higher, the estimated fair value of the liability would have been higher or lower, resulting in a larger or smaller loss on revaluation.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_61"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of inflation, which has increased significantly during 2022 and may result in increases to our operating expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A hypothetical 50&#160;basis point increase in interest rates would result in an approximate $0.6 million decrease, less than 1%, in the fair value of our available-for-sale securities at December&#160;31, 2022. This potential change is based on sensitivity analyses performed on our investment securities at December&#160;31, 2022. Actual results may differ materially. The same hypothetical 50&#160;basis point increase in interest rates would have resulted in an approximate $1.8 million decrease, less than 1%, in the fair value of our available-for-sale securities at December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, we held $427.7&#160;million of available-for-sale investments, excluding money market funds, with an average time to maturity of four months. To date we have not experienced any liquidity issues with respect to these securities, but should such issues arise, we may be required to hold some, or all, of these securities until maturity. We believe that, even allowing for potential liquidity issues with respect to these securities, our remaining cash, cash equivalents, and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months. Based on our available cash, the timing of the maturities of our investments and our expected operating cash requirements, we currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the sale of our research and development facility in India, we have significant cash and investment balances in India that we intend to repatriate as part of our closure of this entity. We are subject to foreign currency exchange risk until we can repatriate these funds.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our revenue, expense, and capital purchasing activities are transacted in U.S.&#160;dollars. However, we have contracts with contract manufacturing organizations in Europe and incur costs from sites in a variety of international locations which are paid in their respective local currencies. Additionally, until the closure and sale of our research and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development facility in India, a portion of our operations consisted of research and development activities outside the United States, with transactions in the Indian Rupee. Accordingly, we are subject to foreign currency exchange risk for these transactions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our international operations are subject to risks typical of international operations, including, but not limited to, differing economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. We do not utilize derivative financial instruments to manage our exchange rate risks. We do not believe that inflation has had a material adverse impact on our revenues or operations in any of the past three years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.  Financial Statements and Supplementary Data</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_67">Reports of Independent Registered Public Accounting Firm (PCAOB ID:</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_67"> </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF82NC9mcmFnOjA0NDMzMjQ0MWJkMjQxZDg4OThhNTRhMDhmOGFkNjc2L3RhYmxlOmI2ZjAzNjM5ZDA1MTQyMDE5NGI1MTlhOGU0OTJhODRiL3RhYmxlcmFuZ2U6YjZmMDM2MzlkMDUxNDIwMTk0YjUxOWE4ZTQ5MmE4NGJfMS0wLTEtMS0zOTgzNi90ZXh0cmVnaW9uOjNlNGU5MDQ0YmIxMjRhYTI5OGU4NDBjNTAxODRhNmY3Xzcy_78909f2d-2b7f-463a-94de-b13ee5b34f22">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_67">)</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_67">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_70">Consolidated Balance Sheets at December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_70">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_70"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_70">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_70">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_73">Consolidated Statements of Operations for each of the three years in the period ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_73">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_73">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_76">Consolidated Statements of Comprehensive Loss for each of the three years in the period ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_76">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_76">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_79">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_79">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_79">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_82">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_82">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_82">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_85">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_85">67</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Nektar Therapeutics</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Nektar Therapeutics (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:13pt"><span><br/></span></div><div style="margin-bottom:13pt"><span><br/></span></div><div style="margin-bottom:13pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accounting for cost-sharing under the Bristol-Myers Squibb (BMS) Collaboration Agreement</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">The Company and Bristol-Myers Squibb Company (BMS) both conduct research and development activities under a Strategic Collaboration Agreement for bempegaldesleukin (NKTR-214). As more fully explained in Note 10 to the consolidated financial statements, the Company and BMS share certain internal and external development costs under the collaboration agreement. As discussed in Note 10 to the consolidated financial statements, subsequent to the receipt of the unsuccessful results from the clinical trials studying bempegaldesleukin, Nektar and BMS decided to discontinue bempegaldesleukin. The decision to terminate the program did not modify the cost-sharing provisions under the Strategic Collaboration Agreement. The Company&#8217;s research and development costs include external actual and estimated Clinical Research Organizations (&#8220;CRO&#8221;) and Contract Manufacturing Organization (&#8220;CMO&#8221;) costs in addition to internal employee costs. BMS provides reports to support their research and development activities performed and costs incurred in the relevant period under the terms of the agreement. Estimates included in each party&#8217;s research and development costs are trued-up to actuals by each party when known. Eligible costs incurred by each party during the reporting period are offset and the net amount is owed to the party with the higher net costs. The Company has a net receivable of $4.2 million from BMS under the collaboration as of December 31, 2022. During the three-month period ended March 31, 2022, the net amount of BMS&#8217; reimbursement of collaboration expense is recorded as a reduction of research and development expense. As discussed in Note 11 to the consolidated financial statements, beginning in the three-month period ending June 30, 2022, Nektar began reporting the external actual and estimated third-party and internal employee costs incurred in connection with the wind down of the bempegaldesleukin program within restructuring, impairment and other costs of terminated program. During the first quarter of 2022, the Company recorded $24.9 million as a reduction of research and development expenses for BMS&#8217; share of the Company&#8217;s research and development expenses, net of the Company&#8217;s share of BMS&#8217; research and development expenses. For the remaining nine-month period ended December 31, 2022, the Company recorded $20.8 million as a reduction of restructuring, impairment and other costs of terminated program for BMS&#8217; share of the external actual and estimated third party and internal employee costs for the wind down of bempegaldesleukin, net of the Company&#8217;s share of BMS&#8217; wind down costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the cost-sharing under the collaboration agreement was especially challenging because of the complexity of the data used by the Company for determining the actual and estimated research and development and bempegaldesleukin program wind down costs that are eligible for reimbursement under the collaboration agreement. These costs include management&#8217;s judgment regarding the estimated third-party contract service costs for clinical research and contract manufacturing incurred during the reporting period. Additionally, the Company evaluates the costs incurred and activities performed by BMS to assess their eligibility for reimbursement under the agreement.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We evaluated the design and tested the operating effectiveness of controls over the accounting for the cost-sharing conducted under the collaboration agreement, including the Company&#8217;s assessment and measurement of its and BMS&#8217;s activities performed and costs incurred that are eligible for reimbursement. This includes conducting meetings with program management and clinical operations personnel to determine the activity incurred to date under the collaboration and substantiating the calculation of eligible costs and activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit procedures included, among others, testing the eligibility of the Company&#8217;s cost billed to BMS against the terms of the agreement. We met with Company personnel and reviewed meeting minutes to understand discussions held with BMS during various committee meetings to corroborate our knowledge of the collaboration and wind down related activities that have occurred to date. We tested the activities reported by the Company and BMS for appropriate classification and disclosure under the collaboration agreement. We obtained an external confirmation from BMS for the net amount owed to the Company.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Impairment of Long-Lived Assets</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">As discussed in Note 11 to the consolidated financial statements, during the current year the Company announced the unsuccessful results from the clinical trials studying bempegaldesleukin in combination with Opdivo under their Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). As a result, the Company decided to discontinue all of their ongoing clinical trials of bempegaldesleukin. Subsequently, the Company announced a strategic reorganization and cost restructuring plan whereby the Company implemented certain strategic, operational and organizational steps to advance their ongoing early-stage research and a plan to significantly reduce their workforce and consolidate office spaces. For the year ended December 31, 2022, the Company recorded an impairment charge of $65.8 million related to the right-of-use assets and property, plant and equipment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We identified the impairment of right-of-use assets as a critical audit matter. Auditing the Company&#8217;s impairment model of right-of-use assets was complex due to the subjectivity of certain unobservable assumptions utilized to estimate the fair value of the right-of-use assets. In particular, determining the length of time to enter into a sublease and market rental rates of a market subtenant utilized in the computation of the fair value of the right-of-use-assets involve complexity due to difficulty in obtaining estimated current market rental rates and forecasting future real estate trends.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over management&#8217;s long-lived assets impairment evaluation, including controls over the length of time to enter into a sublease and market rental rates of a market subtenant.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit procedures related to management&#8217;s computation of the estimated fair value of the right-of-use assets included, among others, evaluating the appropriateness of the methodology utilized by management to estimate the fair value of the right-of-use assets. We evaluated the accuracy and consistency of the application of the Company&#8217;s model to estimate the fair value of the right-of-use assets including the estimated length of time to enter into a sublease and the estimated market rental rates. For vacated Company office spaces that were not sublet as of the end of the year, we involved a specialist to assist in evaluating the appropriateness of the estimated rental market rates and estimated length of time to enter into a sublease utilized by the Company in their impairment assessment. </span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accounting for accrued research and development expenses</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As more fully described in Note 1 to the consolidated financial statements, the Company records expenses and accruals for estimated costs of research and development activities, including third party contract services costs for clinical research and contract manufacturing. Clinical trial and contract manufacturing activities performed by third parties are expensed based upon estimates of work completed in accordance with agreements with the respective Clinical Research Organization (&#8220;CRO&#8221;) or Contract Manufacturing Organization (&#8220;CMO&#8221;). Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations including cost incurred in connection with the wind down of the bempegaldesleukin program are appropriate as of period end. Monitoring the cost incurred by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements. Additionally, beginning in the second quarter of 2022, following the Company&#8217;s decision to terminate the bempegaldesleukin development program, the Company recorded costs related to winding down the bempegaldesleukin program in restructuring, impairment and other costs of terminated program in the Consolidated Statements of Operations. During 2022, the Company incurred $31.7 million in clinical trial expense, other third-party and employee cost for the wind down of the bempegaldesleukin program. The Company recorded an accrued liability of $12.3 million for accrued clinical trial expenses as of December 31, 2022. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing the accounting for accrued clinical trial expense is complex because of the high volume of data used in management&#8217;s estimates to develop their estimates and verifying the cost and extent of unbilled work performed during the reporting period. In particular, testing the completeness and presentation of bempegaldesleukin wind down expense required an increased extent of effort that included procedures to verify the cost of unbilled work performed during the reporting period and evaluate the appropriateness of the classification of wind down cost.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the accounting for accrued research and development expenses and accounting for bempegaldesleukin clinical trial wind down expense including controls over the presentation of cost incurred in connection with clinical trial wind down activities. This assessment was done with the Company&#8217;s financial and operational personnel to determine the appropriate status of wind down activities and estimated accrual of costs.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the Company&#8217;s accounting for bempegaldesleukin clinical trial wind down expenses, our audit procedures included, among others, obtaining supporting evidence from third parties of the research and development activities performed for significant clinical trials. We agreed, on a sample basis, the Company schedules to evidence received from third parties and invoices in order to evaluate the accuracy of the data included in the company schedules and to verify proper classification of bempegaldesleukin clinical trial wind down expense. We met with clinical personnel to understand the status of significant bempegaldesleukin clinical trials. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements. <br/></span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF82Ny9mcmFnOmRhMmRlMzFiNjcyMjQ0YjlhOWUzNmU0YTBkMWE0NDM2L3RleHRyZWdpb246ZGEyZGUzMWI2NzIyNDRiOWE5ZTM2ZTRhMGQxYTQ0MzZfNzcxMA_2d29b15d-ec13-4488-b375-1f559016b08f">Ernst &amp; Young LLP</ix:nonNumeric>  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1993.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF82Ny9mcmFnOmRhMmRlMzFiNjcyMjQ0YjlhOWUzNmU0YTBkMWE0NDM2L3RleHRyZWdpb246ZGEyZGUzMWI2NzIyNDRiOWE5ZTM2ZTRhMGQxYTQ0MzZfNzcxMQ_5c67fc2c-232a-4f15-919d-05bde6fcf560">San Mateo, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2023</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the Stockholders and the Board of Directors of Nektar Therapeutics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have audited Nektar Therapeutics&#8217; internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Nektar Therapeutics (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February 28, 2023 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernst &amp; Young LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Mateo, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except par&#160;value&#160;information)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNC0xLTEtMS0zOTgzNg_bfbc7a31-4dac-4308-8560-8ba5e2fcbb05">88,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNC0zLTEtMS0zOTgzNg_dac7a712-6d78-4c90-bbae-ac8644c8ca7d">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNS0xLTEtMS0zOTgzNg_14fb2016-8145-436d-a7ed-e2ce5a5ea973">416,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNS0zLTEtMS0zOTgzNg_d7716f55-3e15-4718-af6b-688e24894454">708,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNi0xLTEtMS0zOTgzNg_e05d73e9-c771-47a2-b35c-3c99d7333ad1">5,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNi0zLTEtMS0zOTgzNg_fb86b52d-5850-48f2-8b19-1a85e18c7cc3">22,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNy0xLTEtMS0zOTgzNg_7a132462-7766-44bf-90ca-fa58cf8bdf5a">19,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNy0zLTEtMS0zOTgzNg_42957f17-d25b-42d6-92d4-18bd272d1198">15,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfOC0xLTEtMS0zOTgzNg_38b7dd37-ff0c-4743-805e-14c763655bef">15,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfOC0zLTEtMS0zOTgzNg_da6af886-467f-4476-91bb-754d8300a41a">23,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfOS0xLTEtMS0zOTgzNg_4e5037bc-423c-481e-a462-7f2337e1972e">545,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfOS0zLTEtMS0zOTgzNg_0d35978c-4217-4dfb-95c5-904b47aebb3d">795,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTAtMS0xLTEtMzk4MzY_415c2a15-643a-48ee-90f5-e0ff4cb9ab81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTAtMy0xLTEtMzk4MzY_fc9d325d-6e2b-48d7-8815-5c56b5e14c42">64,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTEtMS0xLTEtMzk4MzY_085e932f-f95f-49e4-adc0-c4cfa8103ff5">32,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTEtMy0xLTEtMzk4MzY_9e7bd0a6-64ab-4026-ad8f-64ed3141dbed">60,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTItMS0xLTEtMzk4MzY_dc896d1c-7deb-4282-9fdc-d0e22c961a1c">53,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTItMy0xLTEtMzk4MzY_46fe935f-0de6-4193-ac77-e8d95c291780">117,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTMtMS0xLTEtMzk4MzY_7bde027f-09d3-4751-a2bd-fd1acd406df2">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTMtMy0xLTEtMzk4MzY_77c0e68c-0f9a-4cc8-885f-d33587e20d5a">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTQtMS0xLTEtMzk4MzY_bd4d022b-c1e8-4405-91a0-9d19a9bd7a76">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTQtMy0xLTEtMzk4MzY_2d7c6b00-7d0a-43b4-bc95-c9ab90abd763">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTUtMS0xLTEtMzk4MzY_05fc4191-96dd-4830-bd83-f203a68ba355">710,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTUtMy0xLTEtMzk4MzY_4e6d26c3-6a65-488b-aed3-5d0adf09fdb7">1,117,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTgtMS0xLTEtMzk4MzY_a96981ec-1904-41e6-b0c3-8647b9ca4002">12,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTgtMy0xLTEtMzk4MzY_2822bb91-5fc6-474e-ae3f-e69a7a18628c">9,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTktMS0xLTEtMzk4MzY_226c86cc-2146-4d27-b90f-9e63c6b53f7b">9,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTktMy0xLTEtMzk4MzY_1f3434fb-ea57-40d5-866e-eab5e76e23ba">15,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjAtMS0xLTEtMzk4MzY_4cfcbc95-e0f8-4382-92fb-70671b706445">12,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjAtMy0xLTEtMzk4MzY_24efe366-13be-45d6-9c8d-a4f9ec76f5ca">26,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjEtMS0xLTEtMzk4MzY_37fe0859-7cbf-4dcb-9b03-4aef6e3d7188">14,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjEtMy0xLTEtMzk4MzY_d26a36e4-e65e-4264-a50f-378e54a18207">15,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjItMS0xLTEtMzk4MzY_b597e1a9-11ae-431f-85ff-cf1b8c569452">18,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjItMy0xLTEtMzk4MzY_baac18d7-f0b4-4c39-aab1-497ee66c1887">17,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjMtMS0xLTEtMzk4MzY_0c34e6c6-98b2-4deb-8824-1f2d82b35f8a">68,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjMtMy0xLTEtMzk4MzY_745f687c-5035-49cd-bf66-47b8b8a2cc74">85,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjQtMS0xLTEtMzk4MzY_4a048ad3-2229-4298-9872-4cb5205c870d">112,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjQtMy0xLTEtMzk4MzY_5062280e-a4df-416e-9a46-45779513a921">125,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjUtMS0xLTEtMzk4MzY_1d64cb82-e0f3-4111-b050-bcb58e83fa9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjUtMy0xLTEtMzk4MzY_e52219bf-57e8-425a-9c7c-758f276fbf63">27,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjYtMS0xLTEtMzk4MzY_b4650791-b6c4-4071-aefe-fc6011bf41fa">155,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjYtMy0xLTEtMzk4MzY_542bb35d-4b9d-47c4-8b27-7c279f0356f1">195,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjctMS0xLTEtMzk4MzY_c4533197-6f9b-45e3-a006-6b358e001ca0">7,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjctMy0xLTEtMzk4MzY_d425882f-85d2-41ad-8492-b161eb5f747e">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjgtMS0xLTEtMzk4MzY_c66e8ab4-e4d3-4978-9819-90c1995fe488">343,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjgtMy0xLTEtMzk4MzY_061f086a-f5ba-42e9-9ea0-d9bd774694a0">437,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjktMS0xLTEtMzk4MzY_6246198d-264c-4cd8-8ada-6a2e2e2870a6"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjktMy0xLTEtMzk4MzY_e1430153-aa43-4694-ac0e-20b7215fdc79"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF8yMQ_4dad132a-411a-44bd-8e56-783a5ca8ad1a"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF8yMQ_d056c25a-bde2-469f-a720-3e00f4cc777b">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF8zNQ_b4f5e184-56d9-4e37-91c3-c2950fc1f409"><ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF8zNQ_df7b547a-9c29-4268-a1fe-3730e96e973b">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_2a6f5f8f-9ef9-4264-b8d9-64cee7ba8c86"><ix:nonFraction unitRef="shares" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_4c6908a5-44e7-4d46-b1b2-4a1aecc8b0b3"><ix:nonFraction unitRef="shares" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_a3cb3cbd-a9d1-474f-8080-c1f4bea17e0b"><ix:nonFraction unitRef="shares" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_b90eb74a-ef23-4f49-99a2-5bc10d9dd1b1"><ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_bb020b7e-a4e4-4675-9f42-c71fa7ae0b99"><ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_ef74d774-8e7e-4e91-8869-154c21c16db6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares designated, issued or outstanding at December 31, 2022 or 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMS0xLTEtMzk4MzY_3b2fd877-806b-4e34-8174-c6ecdff658eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMy0xLTEtMzk4MzY_e9744415-d750-4266-b662-ae138c803502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl8xOA_93f4cfbe-cda7-4607-a629-1f9ffc1a3780"><ix:nonFraction unitRef="usdPerShare" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl8xOA_e153b34f-13b3-4cc6-9569-71f8d6a113da">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl8zMg_1050baa7-d526-487e-96b4-c41398c97142"><ix:nonFraction unitRef="shares" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl8zMg_73b0b8b1-1a4e-495e-8ad0-c13a9c21cbd0">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl81NA_2b1c069a-f1c9-4fbf-bfe8-1f417e2747cb"><ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl81NA_b9d5af2e-46f5-48e6-933f-575b5fa337a5">188,560</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl82OA_c4034a33-3ada-4ca4-bf3f-f981273c41a8"><ix:nonFraction unitRef="shares" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl82OA_ef50b3e7-f98d-49bd-8955-fd1eae594e9c">185,468</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMS0xLTEtMzk4MzY_1f8358e0-67ce-4f31-898d-42216a5be986">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMy0xLTEtMzk4MzY_8a49c1ab-3842-4b93-a6ea-675bbec32040">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in excess of par value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzMtMS0xLTEtMzk4MzY_95690f8a-4116-433a-8ac2-365955aa0606">3,574,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzMtMy0xLTEtMzk4MzY_3857e2ae-e812-44c2-b784-03071374da5e">3,516,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzQtMS0xLTEtMzk4MzY_694a3c0e-1ae1-4e66-83c7-364b2f44c83d">6,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzQtMy0xLTEtMzk4MzY_78d0b8ba-33b5-42b5-8be2-6e3c9e3ae666">4,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzUtMS0xLTEtMzk4MzY_189ce3bb-fc2b-4b19-ba27-fece5a62a3ff">3,201,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzUtMy0xLTEtMzk4MzY_f690fe4c-396c-45e0-ac7d-ad4125cb739f">2,832,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzYtMS0xLTEtMzk4MzY_2bb3e832-60e5-4280-b8fe-406e9556b600">366,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzYtMy0xLTEtMzk4MzY_544ffa2c-d462-4583-9baa-b190a706f697">679,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzctMS0xLTEtMzk4MzY_ffbf2bc6-7eff-4c09-8c03-d8917f3c8618">710,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzctMy0xLTEtMzk4MzY_e21647d7-fce9-42cc-be8e-1a173be6fe85">1,117,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;per&#160;share&#160;information)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9224c1c3bd45fd8d3b954982ffff11_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMy0xLTEtMS0zOTgzNg_25de8fb9-d24e-438e-9762-8f6a71c5c92b">20,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if399252e1f284f4aadda7ec3f6d82e87_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMy0zLTEtMS0zOTgzNg_968e57e5-f115-4688-8466-843336d9aa77">23,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b547e794cef44a7b04668aed100c659_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMy01LTEtMS0zOTgzNg_72a39aa0-0bd1-426d-84b9-84adc96d8838">17,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee714b03e314804b75754b42ac2d14e_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNC0xLTEtMS0zOTgzNg_2d2f2433-d5b1-4396-b711-2e1de51cfc25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b02b8a4045435d96c81a09160eff2d_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNC0zLTEtMS0zOTgzNg_a562fba8-2f6c-467d-ae0a-94b2c9318f73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff94ac8dace24c4e96ac5e215d7b240c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNC01LTEtMS0zOTgzNg_0996982a-a038-4430-a9f8-ed1448d2c3e3">30,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2592f70effb34a4d89f653e896ef7a34_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNS0xLTEtMS0zOTgzNg_c9b0b3be-5071-48ca-afcf-c2eb5b4e3c34">69,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce1c72e26324dd38e6bc70f0d447453_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNS0zLTEtMS0zOTgzNg_500a7ba1-4df7-425d-9e05-2c31c8f26453">77,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3503693dbb724782841e65e8f113c6fd_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNS01LTEtMS0zOTgzNg_5497b635-c85d-4ad0-bd11-a912effa770d">48,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife468d8852de4a56a284ece7b19844fb_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNi0xLTEtMS0zOTgzNg_5eacbfcc-6edc-42ff-a164-80fac4886790">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b34672efed424da1803ccc001fd4f1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNi0zLTEtMS0zOTgzNg_67ef0889-1a63-4ecd-a243-b09ffbb4a12b">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3787df08c6d74cf98da1829469ef1b09_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNi01LTEtMS0zOTgzNg_86cf4d70-cd5a-4bc0-b8a4-fcc7b1dba661">55,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNy0xLTEtMS0zOTgzNg_aff95734-eef2-4019-a9a7-aec8bee7fd42">92,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNy0zLTEtMS0zOTgzNg_95ab96cf-5707-4c3b-9f08-6d2f9cd04ee7">101,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNy01LTEtMS0zOTgzNg_2acdafd8-e7c6-4674-9656-126ab75d6fce">152,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating costs and expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfOS0xLTEtMS0zOTgzNg_a372cf33-3cd0-4448-ab27-62748946100d">21,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfOS0zLTEtMS0zOTgzNg_2810fb2f-ff67-4b74-9fcf-a4df47f4dd16">24,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfOS01LTEtMS0zOTgzNg_eabebc0f-266c-4a6d-aee2-0b296ecea53d">19,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTAtMS0xLTEtMzk4MzY_91eb53fd-9dd9-4e02-8b1f-baedec4bb7be">218,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTAtMy0xLTEtMzk4MzY_a0d47773-624a-4166-8a42-c860b067af61">400,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTAtNS0xLTEtMzk4MzY_aedc1b9d-51ab-4ccf-88f1-e6e6bbd1dd83">408,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTEtMS0xLTEtMzk4MzY_af228767-cc90-4357-987c-d1e3066b8097">92,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTEtMy0xLTEtMzk4MzY_47830201-b98d-4cd9-b250-69f9b0d596a8">122,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTEtNS0xLTEtMzk4MzY_5a785520-a505-425c-a96f-d6ad9c15cab2">104,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTItMS0xLTEtMzk4MzY_b3fb388e-f853-460b-a587-8e538a999cc4">135,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTItMy0xLTEtMzk4MzY_e75cad05-12e6-412a-bee3-1865ae5eef3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTItNS0xLTEtMzk4MzY_edfa4a38-f9f1-4cdb-b905-21fcaeaf3fc9">45,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTMtMS0xLTEtMzk4MzY_63f8184b-b1c9-4d80-a087-8f42d475dca7">468,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTMtMy0xLTEtMzk4MzY_b49c392d-1092-44cf-bf3a-4a32c88a1a5d">548,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTMtNS0xLTEtMzk4MzY_b6a1b6b9-6543-44d7-b3fb-b480881fd303">578,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTQtMS0xLTEtMzk4MzY_68bbb4af-c13a-4e5e-9817-c8be0990e614">376,166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTQtMy0xLTEtMzk4MzY_bca23fd0-d536-4689-b310-dbe85c0d3678">446,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTQtNS0xLTEtMzk4MzY_990b5f9e-ab2b-4235-99c1-f522b0e3b392">425,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTYtMS0xLTEtMzk4MzY_58a88887-7627-4a70-877e-b953140ae3c0">33,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTYtMy0xLTEtMzk4MzY_be4365d1-ff06-487d-923a-b9a484f21038">8,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTYtNS0xLTEtMzk4MzY_41ed74b9-d88f-4f62-9b7f-9195b1bf253c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTctMS0xLTEtMzk4MzY_f3a86c66-2155-422d-b895-a7f91e2ec67f">28,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTctMy0xLTEtMzk4MzY_876ec188-c721-420f-8ab4-2f77417ed774">47,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTctNS0xLTEtMzk4MzY_589858f8-09a4-4ee6-bf76-eb67b404b685">30,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTgtMS0xLTEtMzk4MzY_f81500de-ce42-40b4-9bb9-eb3e7eb0b540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTgtMy0xLTEtMzk4MzY_569feedc-b14d-4df5-b02f-ce6b58bcdfcb">24,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTgtNS0xLTEtMzk4MzY_1b695837-2cca-419f-82a7-9723d39cbb69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTktMS0xLTEtMzk4MzY_b9567ef4-c62b-4c54-815f-8017fa1d6da8">6,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTktMy0xLTEtMzk4MzY_dc92c129-4031-4f96-9e3a-68863ebf5475">2,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTktNS0xLTEtMzk4MzY_7ca91f46-cbe0-4e50-ae51-ec4d8f463c28">18,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjAtMS0xLTEtMzk4MzY_c3e37a49-9656-4a2c-8c1a-d3b2894471a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjAtMy0xLTEtMzk4MzY_e6383483-fac3-4937-a7c2-6f6f8cfbeed4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjAtNS0xLTEtMzk4MzY_d68b5762-f65c-415b-8eaf-c7914a9f3ff5">6,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-operating income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjEtMS0xLTEtMzk4MzY_3351bf2e-05ce-468c-8ccd-f833af82c8c1">11,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjEtMy0xLTEtMzk4MzY_6299681b-894d-4275-bd7e-b6755ed8ae2f">77,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjEtNS0xLTEtMzk4MzY_33c9db5c-c86b-4e58-add8-9bdd6769a1ee">18,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjItMS0xLTEtMzk4MzY_5cc2fa48-dc7a-440f-90ea-500109d6ffae">364,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjItMy0xLTEtMzk4MzY_80ec3a97-05d0-48a8-97c7-028edc6db529">523,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjItNS0xLTEtMzk4MzY_a3d0764e-3a9e-4476-886e-eecc2bf65c36">443,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjMtMS0xLTEtMzk4MzY_79301b55-3911-4825-86b5-6415a642e222">3,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjMtMy0xLTEtMzk4MzY_abff24fe-afe3-4876-9b34-8eb7d3842199">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjMtNS0xLTEtMzk4MzY_44282e5d-0a98-414b-8536-c731183cb900">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjQtMS0xLTEtMzk4MzY_c143059e-cf65-451b-88d5-007ca363627a">368,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjQtMy0xLTEtMzk4MzY_512566d5-cd98-4400-97d9-c7a922b2c098">523,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjQtNS0xLTEtMzk4MzY_aa4445fc-decf-4671-9b19-4a2341954f5e">444,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtMS0xLTEtMzk4MzY_1f98abe9-7964-4e23-b1ea-e3c6bff2b72e"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtMS0xLTEtMzk4MzY_cfde8a50-078c-4f04-9bb2-599f3d2956b4">1.97</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtMy0xLTEtMzk4MzY_4daee685-792e-4a66-a8bc-e53beedd89e2"><ix:nonFraction unitRef="usdPerShare" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtMy0xLTEtMzk4MzY_bcad4ce8-abf8-46bd-9a21-02f312119943">2.86</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtNS0xLTEtMzk4MzY_3e55e465-fd0f-4604-8d6e-e9ac69cf54af"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtNS0xLTEtMzk4MzY_f23a9563-8e58-4687-9a59-e3d85668b004">2.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in computing basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctMS0xLTEtMzk4MzY_07900a56-14df-4922-9f8f-55554219f95c"><ix:nonFraction unitRef="shares" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctMS0xLTEtMzk4MzY_91f320d9-7c08-4eab-8365-00faceec3d14">187,138</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctMy0xLTEtMzk4MzY_6baa3a49-6188-4fd0-82df-076f8ec084d0"><ix:nonFraction unitRef="shares" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctMy0xLTEtMzk4MzY_e844fbd7-14e7-4a9e-8bc9-14eea8847714">183,298</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctNS0xLTEtMzk4MzY_9454361c-59f5-40fc-a78e-39c9c5d3ffd7"><ix:nonFraction unitRef="shares" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctNS0xLTEtMzk4MzY_a1a48de2-75c2-42bb-9f57-b4a247214d49">178,581</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfMi0xLTEtMS0zOTgzNg_d1d61a2b-9b8b-4e64-898d-7f673f7c31a4">368,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfMi0zLTEtMS0zOTgzNg_cab0ac39-5199-4ca3-8bde-ac1e2b998afa">523,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfMi01LTEtMS0zOTgzNg_536fd8cf-09fc-4fa0-a75b-4474163eab5c">444,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNC0xLTEtMS0zOTgzNg_cc460fec-91b6-455a-a75b-14c69d8f3d61">1,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNC0zLTEtMS0zOTgzNg_85262271-ba0d-4596-a4f8-409812886f49">1,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNC01LTEtMS0zOTgzNg_8f73fd78-5320-477b-83a1-0fde4f59587a">927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNS0xLTEtMS0zOTgzNg_afa60f65-d643-45ff-8f6f-48290f6a5202">1,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNS0zLTEtMS0zOTgzNg_7b474484-2ef9-4b68-836b-121ef25f6893">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNS01LTEtMS0zOTgzNg_ee455292-dfd5-4bcc-8c37-b42d88dc030d">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNi0xLTEtMS0zOTgzNg_446fff84-42ba-4f53-a3fc-01b584ec994b">2,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNi0zLTEtMS0zOTgzNg_95e7755e-e306-4ba5-9afe-9cc36ae9d8e2">1,862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNi01LTEtMS0zOTgzNg_c8eb8f46-5cf6-43f9-953f-891c548f7955">1,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNy0xLTEtMS0zOTgzNg_cc7ad452-c690-4c91-af1d-c740897ce693">370,948</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNy0zLTEtMS0zOTgzNg_1ac3d8bc-d815-4c15-9fc0-01161664a244">525,699</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNy01LTEtMS0zOTgzNg_1ef04744-8189-43fd-a4c3-5e5e960323b7">445,730</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Excess of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c9d9fd3ecfa4c9086a8279fc8984311_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS0xLTEtMS0zOTgzNg_bd2ecb29-9916-4a92-ba8e-2427b1fa20c7">176,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c9d9fd3ecfa4c9086a8279fc8984311_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS0zLTEtMS0zOTgzNg_4430aeeb-d687-4810-8206-a289ebb96841">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08cf5e99f4c4729b75cd9f892d3dd95_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS01LTEtMS0zOTgzNg_791422e0-b327-4eb4-9b0c-e6c52c050a69">3,271,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac079dca38e543e29cee54f4bb8d8c85_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS03LTEtMS0zOTgzNg_de2187e1-f1c5-4827-bc35-73b17652dafc">1,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8982bed90c24581aca18ab4ef0fbd1b_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS05LTEtMS0zOTgzNg_d4b2f976-2c91-4151-a94d-aaafe17ff76a">1,864,718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f208c2b206d4f43af4e746f193bb362_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS0xMS0xLTEtMzk4MzY_4bc2b064-6392-4232-96f9-10c19bfb7957">1,405,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i987ef113f8824c15b8f15d8db5465d6d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMi0xLTEtMS0zOTgzNg_2826b5e3-d377-4bd7-8114-615681d6701b">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987ef113f8824c15b8f15d8db5465d6d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMi0zLTEtMS0zOTgzNg_76592146-e518-4f5e-b5b2-daa64c10d42a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44c951d25d843329584f5aa34d0f5ca_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMi01LTEtMS0zOTgzNg_cc04165f-c669-4087-befa-2ff3c2c1771f">23,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMi0xMS0xLTEtMzk4MzY_cdefc23a-90da-4f54-8cf5-0da6465caea4">23,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44c951d25d843329584f5aa34d0f5ca_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMy01LTEtMS0zOTgzNg_f794d839-4234-490d-8fad-3d3e0cf44c7e">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMy0xMS0xLTEtMzk4MzY_4c1636f3-5c39-41bf-a1ce-c14587c96b1b">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38e6cce64ebb4bf1829c2e2305936cf8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNC03LTEtMS0zOTgzNg_78d5206d-8ca9-41f1-9d9b-202dcbdb769b">1,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i998d6d8b90244039983cd9cc2d9e138d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNC05LTEtMS0zOTgzNg_5b7a5a84-6ade-4ee6-b323-50819dfae0d7">444,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNC0xMS0xLTEtMzk4MzY_000a61ed-0cc6-4cd3-a36f-79ee77fea98d">445,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1950a10af3724176843a6dc1e9e84e54_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS0xLTEtMS0zOTgzNg_8dbb49e6-c778-4a5a-a299-dd0eb9514358">180,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1950a10af3724176843a6dc1e9e84e54_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS0zLTEtMS0zOTgzNg_f0361874-dccd-4a1d-9074-0c9f1d6994e1">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04a5ee614c94e08a816a4c6381aec19_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS01LTEtMS0zOTgzNg_abb59d16-5693-482a-8edb-6642eb2fcd06">3,388,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ebfebc03d28484bb3537335575f477e_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS03LTEtMS0zOTgzNg_76e76130-cee5-495e-9edf-a202d4a7a31c">2,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96a8e3652a3d447ea7e5a6799fd339b8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS05LTEtMS0zOTgzNg_5dcd9e02-79f2-4a41-907c-e6c7497b4c43">2,309,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448f61765d3a4f728112443592038e8d_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS0xMS0xLTEtMzk4MzY_805c9ef0-9909-412b-acdf-66fb7891d0f3">1,077,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic10a28643df74c40af9cdf7c813b5a44_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNi0xLTEtMS0zOTgzNg_9924bcf8-4d2b-45e4-bb04-77181ff52092">5,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10a28643df74c40af9cdf7c813b5a44_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNi0zLTEtMS0zOTgzNg_ff335dad-b5fd-4c00-b86f-aef8fc4b27d5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a4fdda5691415fa69f3baedf60a37e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNi01LTEtMS0zOTgzNg_cae330f5-f942-4170-ae32-bbe74f699ba6">33,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNi0xMS0xLTEtMzk4MzY_30121272-550e-45a5-ac78-5ef1d085a42c">33,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a4fdda5691415fa69f3baedf60a37e_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNy01LTEtMS0zOTgzNg_7fbe2e76-fae9-4be5-bb84-c76ba842e529">94,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNy0xMS0xLTEtMzk4MzY_f6be11c9-4b73-4b6d-9ff3-6cc15be7be1c">94,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73ad8acf8f34426eb3f1aeef9273f29b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOC03LTEtMS0zOTgzNg_de9a4026-92d5-48fb-a247-15bc8e75539a">1,862</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id748358d445d433fb8c8c90c82d6f1a0_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOC05LTEtMS0zOTgzNg_ca21d3a0-df12-4b16-84cd-67630cb1b55a">523,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOC0xMS0xLTEtMzk4MzY_adb0908b-7fa0-4adb-81db-7467cc59bd52">525,699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ef15d4863f04c8db682812ea8b05dc0_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS0xLTEtMS0zOTgzNg_db58377e-54c2-4324-b057-d2744c36a0db">185,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef15d4863f04c8db682812ea8b05dc0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS0zLTEtMS0zOTgzNg_88cf5368-4913-405f-b7ec-aff933e837a3">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746ebde8a5a14d7fab51bbdd9974e2fa_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS01LTEtMS0zOTgzNg_f9045f30-148a-4384-9483-a9080eb43c60">3,516,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id726a6530b544c1ea713e5fd50d15fea_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS03LTEtMS0zOTgzNg_67d1a16d-03a0-4fe2-a0b4-cac18e19bf31">4,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49140130df5b432e8dbcb7033e45422d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS05LTEtMS0zOTgzNg_abe650d2-fabb-4aac-a20e-118b5d211fde">2,832,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS0xMS0xLTEtMzk4MzY_4d6f73b7-2dc6-4e55-a087-a1d1f3708c5a">679,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i935ae0dae4f141c8bb7ac64103e6fe70_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTAtMS0xLTEtMzk4MzY_c3aa94d0-29b2-4cb9-9732-efffbba65b7e">3,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i935ae0dae4f141c8bb7ac64103e6fe70_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTAtMy0xLTEtMzk4MzY_5fee223f-f51f-4f86-b5a9-370440d35dc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6bae5374b2b41c484f1e8a2efee68bf_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTAtNS0xLTEtMzk4MzY_f5c3a3f5-f9ce-4465-89c5-94a748ac9458">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTAtMTEtMS0xLTM5ODM2_da95b386-13e6-4bdf-a0f0-bd499565e8fa">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6bae5374b2b41c484f1e8a2efee68bf_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTEtNS0xLTEtMzk4MzY_b7d3f0e0-38b5-4460-8eb8-1d3054041be2">57,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTEtMTEtMS0xLTM5ODM2_52b1d323-8a26-4c45-85cd-df933b2dd98d">57,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idab357fe657f4da88592a410901a0389_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTItNy0xLTEtMzk4MzY_2cacdc23-e492-4408-8fb0-dafd930c94b7">2,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6c3d2d7dc6d4a638d0a5df9eb67618a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTItOS0xLTEtMzk4MzY_1a8e656c-7eee-4fa7-927b-b4a40cbe22c4">368,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTItMTEtMS0xLTM5ODM2_7a6d9869-0608-4576-920d-977356e55b4c">370,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0edd83c86ce440bd97d489289b92afbc_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtMS0xLTEtMzk4MzY_485ff588-59bc-4864-a8b8-6fe67f099c77">188,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0edd83c86ce440bd97d489289b92afbc_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtMy0xLTEtMzk4MzY_2d611687-fe99-4d8b-9b4c-a7e340a99eef">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9c9a3627d54feea3a17351378935e7_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtNS0xLTEtMzk4MzY_f2ba3db0-96e3-4a2a-899a-f829294f529b">3,574,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e18c528c36849c0a6d2470e6cf2054f_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtNy0xLTEtMzk4MzY_56e8cd89-df0d-448d-a97a-6afd38d7ea15">6,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2410d2e734464c24a881fc5993536b43_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtOS0xLTEtMzk4MzY_be54a041-3514-4ba3-9404-d490a4671e40">3,201,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtMTEtMS0xLTM5ODM2_bf0a029b-209f-44e9-92d7-4f1197c8efc0">366,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMy0xLTEtMS0zOTgzNg_89aca290-857c-4be2-a97d-d54de58f17c9">368,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMy0zLTEtMS0zOTgzNg_dfc8e128-f3b9-40b0-8f06-1dcb2f801523">523,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMy01LTEtMS0zOTgzNg_92031950-489b-463a-b80f-0a17aea871ca">444,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNS0xLTEtMS0zOTgzNg_5e0f485b-7bff-44d3-8bfd-39606c462254">69,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNS0zLTEtMS0zOTgzNg_585bc252-bf1d-41d5-87ff-69960175f503">77,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNS01LTEtMS0zOTgzNg_05425f08-5dd5-4ce3-bccd-1ba275353033">48,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense on liabilities related to sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNi0xLTEtMS0zOTgzNg_556d0fd1-4d2d-4149-921d-410c3ed1d90c">28,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNi0zLTEtMS0zOTgzNg_5027a7f8-13c5-4e3a-9940-aa11250873a2">47,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNi01LTEtMS0zOTgzNg_b591d68c-b586-434b-b2e1-e91c6f390790">30,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNy0xLTEtMS0zOTgzNg_330d56d2-5fc2-47d0-a161-9565d296694a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNy0zLTEtMS0zOTgzNg_8eb440f7-ffe2-40a0-a314-98deea232e13">24,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNy01LTEtMS0zOTgzNg_9f000ee9-2fd8-4d54-aad5-cfb6229b6d1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOC0xLTEtMS0zOTgzNg_2ffd238d-1bb6-482f-8e3c-85ab35dd359a">33,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOC0zLTEtMS0zOTgzNg_5814e028-86bd-47a5-a538-339797dd6e9f">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOC01LTEtMS0zOTgzNg_67094220-617d-4dce-a18e-ce557658ab53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOS0xLTEtMS0zOTgzNg_b41d419e-bc5b-45ff-b385-788a9fb16254">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOS0zLTEtMS0zOTgzNg_48095aea-75a8-43d0-94e7-a564bb916420">16,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOS01LTEtMS0zOTgzNg_02413bbe-e453-4395-b8c3-3d0892229a2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTAtMS0xLTEtMzk4MzY_f40e13d6-5dc1-4291-b24d-68650ec241d1">57,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTAtMy0xLTEtMzk4MzY_8968c2f7-2441-45a8-a9d5-942c5c207e4c">94,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTAtNS0xLTEtMzk4MzY_a4836701-3a6b-4a9c-9c71-b55184952f78">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTEtMS0xLTEtMzk4MzY_a3a35f22-78ce-4015-93d2-ec653c1beb5c">13,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTEtMy0xLTEtMzk4MzY_3d2897b0-34af-4321-a1fe-46ba9277bccd">14,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTEtNS0xLTEtMzk4MzY_0a49635f-32f8-4534-9440-6d2e0d7ab64b">14,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItMS0xLTEtNDUzOTA_5b79eb41-3a67-4b2e-9401-ea2354341779">2,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItMy0xLTEtNDUzOTg_652d71da-7774-4b71-9f88-02b5304b21f5">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItNS0xLTEtNDU0MDY_a7d3ca25-f1e3-46d8-a18e-1965949dd939">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of right-of-use asset and property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtMS0xLTEtNDYxMjY_f1a5db67-8fee-4358-8edd-47eb2d686d38">65,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtMy0xLTEtNDYwODk_2080f0b1-d6ac-4397-ab19-f6b8982206cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtNS0xLTEtNDYwOTc_c74820fc-1903-4d64-a632-cad281284c40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on sale or disposal of property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTQtMS0xLTEtNDYxNDI_007da6de-8e96-4108-9839-e3a0d5de906e">3,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTQtMy0xLTEtNDYxMDU_c20cad8f-8034-4f8b-b8f9-d27c988af2fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTQtNS0xLTEtNDYxMTM_713275ad-ab74-4333-9eb8-bda9731aadaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of advance payments to contract manufacturers and equipment for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItMS0xLTEtMzk4MzY_4bf9d008-96b0-4857-9777-96a2d8682354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItMy0xLTEtMzk4MzY_e93e22ee-d8a1-45c7-b5d8-f63a34e2c839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItNS0xLTEtMzk4MzY_b09b0a40-b5a4-420e-8d25-62fc3ae181fb">20,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of premiums (discounts), net and other non-cash transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtMS0xLTEtMzk4MzY_65d16810-d50e-44d1-ae62-3c46a3a0f86a">2,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtMy0xLTEtMzk4MzY_88fbf253-04c1-4958-a060-dfd626cafb5a">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtNS0xLTEtMzk4MzY_eb432a5f-8829-41c7-bd39-8b4615a4f081">3,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTUtMS0xLTEtMzk4MzY_97ff6a71-c937-4226-b96b-0c8cd48d65c2">16,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTUtMy0xLTEtMzk4MzY_107c6fb0-5602-4363-8735-dfd538a81d54">12,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTUtNS0xLTEtMzk4MzY_2cb8165e-a87b-4715-8ae2-272a0851d7c0">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTYtMS0xLTEtMzk4MzY_4dff00af-c1ae-4391-b2de-c51847bfd06f">3,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTYtMy0xLTEtMzk4MzY_ae076cf0-5a47-4031-b5ad-6a3afb88b072">509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTYtNS0xLTEtMzk4MzY_7a375c16-9147-402d-b77a-25654ac8121f">2,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTctMS0xLTEtMzk4MzY_ab953907-b5fb-4f9d-b408-8392661a6326">2,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTctMy0xLTEtMzk4MzY_7969c031-1713-4c2b-b9ad-652e345bc751">2,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTctNS0xLTEtMzk4MzY_50ed07d7-c691-49d2-863c-8cf8f1d7f8c1">2,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTgtMS0xLTEtMzk4MzY_fc28f501-b6aa-4a29-b286-41039559c29e">6,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTgtMy0xLTEtMzk4MzY_5a5e21a5-5928-457b-b2d5-da54b74b8497">2,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTgtNS0xLTEtMzk4MzY_e382a129-ecfd-4396-bb64-3b758bea65c0">4,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTktMS0xLTEtMzk4MzY_1f5a06ff-796a-4509-a442-0077fc8c3d6a">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTktMy0xLTEtMzk4MzY_57004979-521a-4578-9cfd-0e6ca3d0ebb9">11,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTktNS0xLTEtMzk4MzY_014a0968-fde4-41fb-934d-ef693fab1f5b">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjAtMS0xLTEtMzk4MzY_b8fd6624-e3fa-44d1-8f32-34dcceb1e6ce">6,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjAtMy0xLTEtMzk4MzY_aa74b952-20e3-4681-aaf2-fc5954680533">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjAtNS0xLTEtMzk4MzY_e91237de-9b2a-4c17-b1a5-bd3bc725af18">4,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjEtMS0xLTEtMzk4MzY_8a4c1179-a4ea-4631-a6b8-35f69005acf9">12,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjEtMy0xLTEtMzk4MzY_2de36933-1e80-454f-afb6-f4bd41b221a8">23,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjEtNS0xLTEtMzk4MzY_7281809a-7758-443a-920f-1c0f7537da46">8,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjItMS0xLTEtMzk4MzY_c897f084-d076-41e2-8b48-dd325d4ca04d">1,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjItMy0xLTEtMzk4MzY_713ccb97-a9fa-4efb-add8-8d1d0b882a7d">605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjItNS0xLTEtMzk4MzY_7277537a-3b67-4289-abf6-4457ce846538">5,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjMtMS0xLTEtMzk4MzY_3387fa2b-44f8-469e-9bce-042af7e8f22a">304,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjMtMy0xLTEtMzk4MzY_47a44dd1-5b86-43a3-ab5a-642600d710bc">412,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjMtNS0xLTEtMzk4MzY_05cab722-1c33-4f60-b4fb-846ae945922c">313,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjUtMS0xLTEtMzk4MzY_713932f5-a19a-4f22-8452-b564bdc9fadd">467,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjUtMy0xLTEtMzk4MzY_f73338a6-13fd-41bd-8044-6fce899649a9">960,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjUtNS0xLTEtMzk4MzY_a471f0ee-5d4e-4ffa-8f3b-0528e72ad597">987,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjYtMS0xLTEtMzk4MzY_c5891816-2398-4862-8d0d-7c752aef401e">826,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjYtMy0xLTEtMzk4MzY_3930685b-0889-4b57-953f-9285a5c19915">1,166,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjYtNS0xLTEtMzk4MzY_28aa8c10-839c-4469-b3a9-391412fda273">1,449,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjctMS0xLTEtMzk4MzY_71491b18-14af-4436-9e30-ad2366198af9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjctMy0xLTEtMzk4MzY_e843cb2d-c92d-4fe7-b2a1-d31e5907c733">11,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjctNS0xLTEtMzk4MzY_b45789d5-6a35-4d72-8c42-2418e7ff61c3">41,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjgtMS0xLTEtMzk4MzY_f9f2afa8-a59d-4ee7-8153-2e6108bba054">5,676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjgtMy0xLTEtMzk4MzY_0c0de79a-2114-4dfe-ba79-58bea7f7e511">14,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjgtNS0xLTEtMzk4MzY_f4e00a11-6ee2-4b2b-a9d7-53b9e0ecceb4">7,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktMS0xLTEtNDM2NTE_1a57d4a2-b1ce-459f-b97e-eedefbcbd9dc">13,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktMy0xLTEtNDQwOTc_c637eff4-f968-4609-b293-3ddda2f6ca5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktNS0xLTEtNDQwOTc_93b0e106-4e25-4093-afb0-75b7c19e08fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktMS0xLTEtMzk4MzY_d2df0086-a182-4666-a8a2-eff60a4351a6">365,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktMy0xLTEtMzk4MzY_4b27b6f8-838a-447f-a59b-ab2585c55c80">202,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktNS0xLTEtMzk4MzY_e37afd75-6a9e-438c-bf55-a843fc015f9c">496,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties, net of $<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-5" name="nktr:SaleOfFutureRoyaltiesTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4ZThiNjAyNTQyYWI0NTA0YTkyZjc1MzkzMTk3MWMzMV81MQ_99c885bd-991b-46f8-845c-6b1aa92bf639">3.8</ix:nonFraction> million of transaction costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:ProceedsFromSaleOfFutureRoyaltiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzEtMS0xLTEtMzk4MzY_e89e7c06-8f2b-452c-aa63-6202f12806e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:ProceedsFromSaleOfFutureRoyaltiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzEtMy0xLTEtMzk4MzY_f75316c3-7404-46f9-a020-a2a889f05442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:ProceedsFromSaleOfFutureRoyaltiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzEtNS0xLTEtMzk4MzY_2f7721aa-7be8-485f-8e90-6559f1efaf2c">146,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzItMS0xLTEtMzk4MzY_557435f1-4710-4fa9-af52-42dc5963af35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzItMy0xLTEtMzk4MzY_106041e8-9461-4e27-9e92-4186411a858d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzItNS0xLTEtMzk4MzY_9c5b54ec-65f4-4168-bd0b-7f5ca939d3c3">250,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash receipts from development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzMtMS0xLTEtMzk4MzY_cf642b99-0656-4c92-a61f-7b9b7aa258d1">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzMtMy0xLTEtMzk4MzY_eccc7f3b-8d84-44d8-ae20-f0b6bd2005dd">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzMtNS0xLTEtMzk4MzY_93818e74-89bd-4bed-9adc-8dd8b4e10e76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzQtMS0xLTEtMzk4MzY_bc1330b2-eefb-417e-aa82-406035ba21a3">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzQtMy0xLTEtMzk4MzY_a78786dc-b9ac-4db3-bae6-dd1fd7fdb326">33,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzQtNS0xLTEtMzk4MzY_54d9c1f8-e99f-4cf0-a6e1-2397d3275fe3">23,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzUtMS0xLTEtMzk4MzY_7638858d-f6e4-4689-9b91-7a5defcedb27">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzUtMy0xLTEtMzk4MzY_40460a7e-9ad5-4989-963a-febb802c4798">36,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzUtNS0xLTEtMzk4MzY_d3a95325-f508-4555-b8f2-8eaa290b660b">80,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzYtMS0xLTEtMzk4MzY_09852104-0992-4ed4-83d8-01f09c2a55e1">327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzYtMy0xLTEtMzk4MzY_9a99693e-9e7c-43ee-a41f-97c621ee826c">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzYtNS0xLTEtMzk4MzY_311ca09a-714e-461a-81ba-aa188995a05a">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzctMS0xLTEtMzk4MzY_c67443ee-a24e-48ed-8276-b920f2f83322">63,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzctMy0xLTEtMzk4MzY_11589d53-5cff-4432-992a-0cc4c256924a">173,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzctNS0xLTEtMzk4MzY_49ad795a-84f3-47aa-be17-68ac2603fcf8">102,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzgtMS0xLTEtMzk4MzY_c3dfef52-950a-425b-9d57-febf6b85c0fd">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448f61765d3a4f728112443592038e8d_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzgtMy0xLTEtMzk4MzY_d39fa184-15e6-472e-ad7a-c74616959362">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f208c2b206d4f43af4e746f193bb362_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzgtNS0xLTEtMzk4MzY_1fc36739-b3f4-426e-89ab-cd8b4fe42e9a">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzktMS0xLTEtMzk4MzY_e88b15bd-4764-4b31-9647-af64cb15ac1f">88,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzktMy0xLTEtMzk4MzY_1f8c34d0-be2a-4dd9-be37-c79be30e3067">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448f61765d3a4f728112443592038e8d_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzktNS0xLTEtMzk4MzY_3652bbb3-02d0-4da9-b417-a8965c8b9483">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDEtMS0xLTEtMzk4MzY_69460b9e-2e42-48f4-bfb3-6a9be3188798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDEtMy0xLTEtMzk4MzY_acd4657a-c61d-4893-86fd-2c7c3f7ac740">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDEtNS0xLTEtMzk4MzY_4f94b09f-245a-4c01-9639-52a8db8f5dfd">9,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDItMS0xLTEtMzk4MzY_69d43b44-6ab3-47b0-b0b0-b1877a206ae5">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDItMy0xLTEtMzk4MzY_7cc11b56-5a10-4f49-bd03-10df765d7193">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDItNS0xLTEtMzk4MzY_728989fa-7a1b-420e-94d5-254d7b454c21">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets recognized in exchange for lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDMtMS0xLTEtMzk4MzY_0dce54e4-be83-4dc8-a7df-74b476d6011a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDMtMy0xLTEtMzk4MzY_1c68cfe8-9e6a-431c-a00b-262f494fb534">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDMtNS0xLTEtMzk4MzY_7080a249-ea29-4b48-8889-35d213726ec4">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable recognized in exchange for long-term liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDQtMS0xLTEtMzk4MzY_dd269379-af86-4063-8994-8243456777e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDQtMy0xLTEtMzk4MzY_4ca7d054-c705-4f8d-ba67-c47ce0214ab7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDQtNS0xLTEtMzk4MzY_947f0eb0-1982-43c4-a8d0-fb9c77b7b937">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1&#160;&#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzODk_bd861817-dd1a-4c6a-8a99-4312778a1985" continuedAt="i1196ad0cc405487bbd27d55588796da0" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i1196ad0cc405487bbd27d55588796da0" continuedAt="i73d5d15d16b0417f8c07f64e17cbf6c7"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:OrganizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDc_6e5dd984-beed-4980-95c4-0d1612c6a883" continuedAt="i963406a6b6c24d318f745f1909614fef" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes innovative medicines in the field of immunotherapy.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i963406a6b6c24d318f745f1909614fef">&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> At December&#160;31, 2022, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-5" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTA0OA_502b6faf-06d7-4fa7-9949-64bace823955">505.0</ix:nonFraction> million in cash and investments in marketable securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Bempegaldesleukin Program and the 2022 Restructuring Plan</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan) for the Company&#8217;s future:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 14, 2022, BMS and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 10 for additional information on our BMS Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we decided to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 6 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, subject to activities required for an orderly wind down of the studies, there will be no ongoing clinical development activities of bempegaldesleukin.    </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 25, 2022, we announced our 2022 Restructuring Plan, which was reviewed and approved by our Board of Directors on April 14, 2022. Pursuant to the 2022 Restructuring Plan, on April 26, 2022, our duly authorized officers implemented certain strategic, operational and organizational steps, including the prioritization of key Phase 2 development programs to advance our early stage research pipeline. In addition, we announced our plan to reduce our workforce by approximately <ix:nonFraction unitRef="number" contextRef="i7395e5dc92e34456b97e26b144017d8e_D20220401-20220430" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfOTM0NTg0ODg3OTY0Mg_45af498b-1285-4878-a402-6b5d4055887e">70</ix:nonFraction>% and to close our research facility in India.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant costs resulting from these decisions and plans. See Note 11 for additional information on the effect of the 2022 Restructuring Plan on our Consolidated Financial Statements.</span></div><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDU_66f72636-decb-48e3-aa3f-e2bc9aff5ed8" continuedAt="if788f6f4497d402e9279eba6b9c63e31" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation, Principles of Consolidation and Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i73d5d15d16b0417f8c07f64e17cbf6c7" continuedAt="i58daf3fd83be43f8891db81e79ac0f36"><ix:continuation id="if788f6f4497d402e9279eba6b9c63e31"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the fair value and impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; income taxes; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></div></ix:continuation><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDg_a5da7dbc-5896-4e3a-b177-8d693deac68e" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. We record available-for-sale investments and cash equivalents at their estimated fair values, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. As further described in Note 11, we estimated the fair value of our lease assets for recognizing impairment charges based on management&#8217;s estimates of several unobservable inputs, including estimated time to enter a sublease, sublease rental rates and free rent periods. As further described in Note 6, we recorded the development derivative liability at its estimated fair value based on management&#8217;s estimates of several unobservable inputs, including the probabilities of success of clinical trials and various other inputs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTk_ca4a547d-472c-4039-97ab-69b4a1bc01be" continuedAt="i71f763a29f6043e29b1d1b9a96b71aa9" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments in Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i58daf3fd83be43f8891db81e79ac0f36" continuedAt="i1e5c7b7e20494c16aade38162f994681"><ix:continuation id="i71f763a29f6043e29b1d1b9a96b71aa9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a variety of factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#8217; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDk_cf992dfe-a118-4f29-979a-647f13cbc51b" continuedAt="if598a3b6dd55420296d45fc9bf2169d9" escape="true">Accounts Receivable and Significant Customer Concentrations</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if598a3b6dd55420296d45fc9bf2169d9" continuedAt="i2479eb8d58f3474ebb6f4725c45ee978">&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements.</ix:continuation> Our accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="i33ecf05d707f40b5927205653bd6a5c7_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTAzNDI_61dc957f-4fbc-463c-bcac-235eddec9c6c">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-5" name="nktr:NetExpenseReimbursementsFromCollaborationPartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTAzNDk_2ff83262-72cd-44ca-9f0a-f741469a9362">21.4</ix:nonFraction> million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) as of December&#160;31, 2022 and December&#160;31, 2021, respectively. The remaining accounts receivable related primarily to product sales. <ix:continuation id="i2479eb8d58f3474ebb6f4725c45ee978">We perform a regular review of our partners&#8217; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.</ix:continuation></span></div><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MTE_6520da53-33ee-4ad2-85a1-0867722f0d84" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Significant Supplier Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTA5OTUxMTY3MDMxOQ_076de0a1-22b2-4200-b740-54f2c9e310c4" continuedAt="i52308d020171473f95fdb7c7ddd83a48" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i1e5c7b7e20494c16aade38162f994681" continuedAt="i7da9a0079955444ba455b0de9e86c374"><ix:continuation id="i52308d020171473f95fdb7c7ddd83a48"><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract termination costs when we cancel the contract in accordance with its terms; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for additional information on the severance expense that we recognized for employees terminated in connection with our 2022 Restructuring Plan.</span></div><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDA_ea8bcd07-1f43-4786-aef7-a5951aa5cddb" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We report property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTMwOTA_777cbe6f-53e1-4ebb-939f-b2bf951dd6a7">three</span> to <ix:nonNumeric contextRef="idfdbb2c2768a43c9b3cbce49b01157c7_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MTc_c7844777-5395-4f8c-8113-2bd8ec97cffc">ten years</ix:nonNumeric>, depreciate buildings over the estimated useful life of generally <ix:nonNumeric contextRef="i714c46f612124cfcade9ea69f3665fc3_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTMxNzE_cc5eb7ef-5967-4948-a85a-8404a26e3f9c">twenty years</ix:nonNumeric> and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in <ix:nonFraction unitRef="reporting_unit" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="INF" name="nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTM0ODQ_a8085299-794a-4324-b42e-70f8052e7bcb">one</ix:nonFraction> reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting unit equals its fair value.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for additional information on the long-lived asset impairment expense that we recognized in connection with our 2022 Restructuring Plan.</span></div><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTM_ab1b3beb-cc05-4f47-b29e-62bb1c4b1592" continuedAt="i6e1cc5b6b3f64c2c81298fe8aa3fde27" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, under which we do not recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i7da9a0079955444ba455b0de9e86c374" continuedAt="i6db59ec4f3e94cd097a6d3612dcc85bb"><ix:continuation id="i6e1cc5b6b3f64c2c81298fe8aa3fde27"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 5 for additional information regarding our leases.</span></div></ix:continuation><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTA_a215127c-4cc9-4347-a0e0-ba15770d4d41" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTQ_8c9b5c15-07bd-45da-8c97-05a4febe02d1" continuedAt="iccffedf50b8e4176931e52619f018cbf" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of an invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue, including Non-cash royalty revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. We have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i6db59ec4f3e94cd097a6d3612dcc85bb" continuedAt="id29e0464f538416bb98b2a87d625ac43"><ix:continuation id="iccffedf50b8e4176931e52619f018cbf"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="i82b4b2a5e5094624ba910d5a452b36cf_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjE3OTk_d73bd985-47fb-43be-baac-397733c189a8">69.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i6021c4787edd4734a14b823201617271_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjE4MDM_e869556c-c66c-4a6f-8985-739c71054b65">77.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i889f3563e17448ed9a713f77242ff320_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjE4MTA_d7924372-52b6-4013-86ff-58e716359ad8">79.6</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 10, we recognized $<ix:nonFraction unitRef="usd" contextRef="ic66d4e5d50724998a83872fccfd73607_D20210101-20211231" decimals="INF" name="nktr:SalesMilestoneRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjM5NjM_6f11ab2f-7dfc-481a-8c2c-278928957092">50.0</ix:nonFraction>&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div></ix:continuation><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzODM_450325b1-d1e4-448b-a0e1-2e47904d3928" continuedAt="ia1e2e3b753a5482d9cb37743150e61ac" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratably over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="id29e0464f538416bb98b2a87d625ac43" continuedAt="i2b8a473a76884a94a7506db8a95e635b"><ix:continuation id="ia1e2e3b753a5482d9cb37743150e61ac"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div></ix:continuation><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTI_ebf7d9ba-5a48-4029-b937-aa8d4cd2b444" continuedAt="i7cbd51dda8244232b908a6052c06a586" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2022 relate to the termination of the bempegaldesleukin program and the 2022 Restructuring Plan. See Note 11 for additional information.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7cbd51dda8244232b908a6052c06a586">Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2020 relate to the termination of the NKTR-181 program. On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and wound down Inheris and the NKTR-181 program.</ix:continuation> As a result, we wrote off $<ix:nonFraction unitRef="usd" contextRef="ib2e6c9c34e274b01a7184f32edcfcc5c_D20200114-20200114" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzI5ODUzNDkyNzU0OQ_f5976cfd-e802-4980-8c54-4bf819bb0844">45.2</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="id12f39942a7f4712bbddc41b4ff72c32_D20200114-20200114" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjk2MjU_02a33864-9753-47df-92df-894fce78f77f">19.7</ix:nonFraction>&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181 and $<ix:nonFraction unitRef="usd" contextRef="ieee6e806d4bd4db3ac3280df3387e625_D20200114-20200114" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjk3Mjc_aef8b528-259d-4e35-a02b-3263478dc40e">25.5</ix:nonFraction>&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. </span></div><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MTM_6d9296cc-31f2-4fa5-814e-4f970613fe67" continuedAt="i86908a0315384c09b8388507038e5aa5" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i2b8a473a76884a94a7506db8a95e635b"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i86908a0315384c09b8388507038e5aa5" continuedAt="i8c5186fd0fc54aed8e9b88150374e6d0">volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#8217; stock to the index. </ix:continuation></span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c5186fd0fc54aed8e9b88150374e6d0" continuedAt="i89ddfda77b014a46b818a0055ff6e5e8">&#8226;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:continuation id="i89ddfda77b014a46b818a0055ff6e5e8">The fair value of an RSU is equal to the closing price of our common stock on the grant date.</ix:continuation> </span></div><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTU_aff0549c-7be7-40a3-90c5-d33fe9abd283" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, our income tax provision primarily relates to our Nektar India subsidiary. As a result of the 2022 Restructuring Plan and our intent to wind down our foreign subsidiaries, we have recorded a provision for the repatriation of accumulated earnings and profits from India. See Note 13 for additional information.</span></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzODQ_cdfd80f7-aae8-46d3-89e1-7a4102e88d21" continuedAt="i437f3f5d0d6f4a1d8a77b4793bfc49c1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i437f3f5d0d6f4a1d8a77b4793bfc49c1">&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented.</ix:continuation> For the years ended December 31, 2022,  2021 and 2020, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, RSUs and PSUs, which totaled <ix:nonFraction unitRef="shares" contextRef="if4204e31ff284f828fdbd3d7d5d1e925_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzQ2MDE_2bc206c5-5101-4669-b5c8-6e6011a7c1eb">21.2</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i799848d20d124621af203b62f338ec15_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzQ2MDU_77dcc9b3-8494-428b-9b81-8fbd969172fa">18.4</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i2827b996b8d84b178c45819a76165160_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzQ2MTI_b7ae9120-4432-4dde-8813-b542c482ab7e">17.4</ix:nonFraction> million for the years ended December 31, 2022,  2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTY_aca44250-d013-40a1-9462-d48df92378b3" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzODg_08d81608-cd7f-42f9-b942-7cf82e9d937b" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTMzNw_9b43c8f5-7eee-4b52-aac4-6ceba888f91f" continuedAt="ib0ca1af4d22844d49f66a38e064e1fbd" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="ib0ca1af4d22844d49f66a38e064e1fbd" continuedAt="i3ba0feb9891f43969e14896ea587a2aa"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTMzOQ_d6a1109c-884c-45bf-8e13-e6bd4de0d50c" continuedAt="iddb59ae7eda94351a62324a1f2468eab" escape="true">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="iddb59ae7eda94351a62324a1f2468eab"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfMi0xLTEtMS0zOTgzNg_f0975ae6-da67-4545-9c7e-98822d14c4b7">88,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfMi0zLTEtMS0zOTgzNg_81cdad59-8ad1-4997-80d8-81822e7c223a">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfMy0xLTEtMS0zOTgzNg_44c850c2-2759-48be-b763-f8a7bba04630">416,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfMy0zLTEtMS0zOTgzNg_ac32cf25-706e-4594-aabc-8410ee955def">708,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfNC0xLTEtMS0zOTgzNg_e1f0d837-6104-4270-b612-1d4848dcef58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfNC0zLTEtMS0zOTgzNg_ff02a372-b402-43ce-90af-a9136f8ba00a">64,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfNS0xLTEtMS0zOTgzNg_cc6471ea-048c-43ca-8d2c-f024ef6f2692">504,977</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfNS0zLTEtMS0zOTgzNg_d06ca723-3335-4b8a-851a-a3ca516c5177">798,783</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i3ba0feb9891f43969e14896ea587a2aa"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of <ix:nonNumeric contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" name="nktr:InvestmnetsTargetMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTQ5NzU1ODE2NTMz_66fb2c61-5e6a-447c-9841-f6989bf849cd">two years</ix:nonNumeric> or less and maintain a weighted average maturity of <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:InvestmentsWeightedAverageMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTQ5NzU1ODE2NTU5_e10f9478-eae5-4dfc-a80d-0c25aea74280">one year</ix:nonNumeric> or less. All of our long-term investments as of December&#160;31, 2021 had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTUz_cabe071a-9291-4113-98c3-9850259068b6">one</span> and <ix:nonNumeric contextRef="i81ee4e8815e44e2eaf7870c781941a30_D20210101-20211231" name="nktr:LongTermInvestmentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTYw_e07c56b2-391f-4367-b399-d6256612ba08">two years</ix:nonNumeric>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2022 we sold <ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTA5OTUxMTYyNzkzNDY_2fa027d9-8890-448a-8150-a372e265d9f7">no</ix:nonFraction> available-for-sale securities. During the years ended December 31, 2021 and 2020, we sold available-for-sale securities totaling $<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNjU0_9a79f73b-fac4-4dfc-abd1-391f1a91c9f8">11.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTA0NDUzNjA0NjUyNTg_79f9d0de-593b-4132-b691-89cf6e29c91b">41.7</ix:nonFraction>&#160;million, respectively. Gross realized gains and losses on those sales were not significant. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our accrued interest receivable, which totaled $<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfODg2_c8efa32c-a3d7-401f-9e1b-1f06d9bd52da">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfODkz_3d3f170d-9bd0-4d7d-9b8b-92d45a3d010e">1.4</ix:nonFraction>&#160;million at December&#160;31, 2022 and December&#160;31, 2021, respectively, in other current assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTM0MQ_3d6b94b9-d180-4cde-97cb-0fad924e8c0a" continuedAt="i7a56363a474c49e9bff842f3c2439c72" escape="true">Our portfolio of cash and investments in marketable securities includes (in thousands):</ix:nonNumeric></span><ix:continuation id="i7a56363a474c49e9bff842f3c2439c72"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi0zLTEtMS0zOTgzNg_e8c6c333-25ef-480b-bee2-983898b7b842">84,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi01LTEtMS0zOTgzNg_6c5ca89c-58b8-44e6-bf73-60d40cad2da0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi03LTEtMS0zOTgzNg_b11f67e2-4971-4c80-979f-840680b9c3ef">855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi05LTEtMS0zOTgzNg_126388ab-a3e6-4bed-8236-f286957e6fc5">83,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f814cb3446b46a5b7c97104c33668a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi0xMS0xLTEtMzk4MzY_c3d11e19-6e38-4c45-9a84-9cee10775a1d">278,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e9c0aab9a347229701114a13ba3b14_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy0zLTEtMS0zOTgzNg_558f806a-cda9-4f8f-837a-27ec75f2a5ce">345,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e9c0aab9a347229701114a13ba3b14_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy01LTEtMS0zOTgzNg_a9fb5ec5-ab28-4d25-9839-74e5853f6bd0">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71e9c0aab9a347229701114a13ba3b14_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy03LTEtMS0zOTgzNg_e33fe8de-c2e5-4bc9-8688-0ed763da3492">946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e9c0aab9a347229701114a13ba3b14_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy05LTEtMS0zOTgzNg_e4b8e64b-967f-4b1a-93b5-14cee9704d5d">344,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cb12d6ed274cb3bc4aae55062cef33_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy0xMS0xLTEtMzk4MzY_73a5f605-aada-4b32-86e5-e9beb0221093">478,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24cdb13ced474b1e9afa182b37799a5d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC0zLTEtMS0zOTgzNg_256b39c5-c524-45aa-bd1a-8f1129fb49cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24cdb13ced474b1e9afa182b37799a5d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC01LTEtMS0zOTgzNg_3ce40483-95e6-446e-9089-47863fca6a1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24cdb13ced474b1e9afa182b37799a5d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC03LTEtMS0zOTgzNg_42ce7662-cb59-4044-9760-3a34212a91aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24cdb13ced474b1e9afa182b37799a5d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC05LTEtMS0zOTgzNg_51ddbd92-c74a-4993-8b47-8f8a1404f4fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b3e1815f004636b2e747e17d73a6f8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC0xMS0xLTEtMzk4MzY_fcacaab6-fa8f-4aab-b321-7e9d043db9a6">5,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS0zLTEtMS0zOTgzNg_51f896ab-8571-41ab-9a8b-9246dc9ab656">429,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS01LTEtMS0zOTgzNg_9a167f4b-e3bf-433f-bdb1-92a105127a0a">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS03LTEtMS0zOTgzNg_a3a03a79-94e0-419c-b44f-d13ef03589ea">1,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS05LTEtMS0zOTgzNg_05041978-e3cf-4959-87e2-37b395b28e7d">427,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS0xMS0xLTEtMzk4MzY_b7e23e83-a87d-4ae4-a2cd-7de5a5e7a23e">762,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00bc4b3a9074f93bce79a9e4c8911e8_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNi05LTEtMS0zOTgzNg_59d855df-a9bb-418e-b6dc-9e36c37330b7">47,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52837a82692c4071bbd19aa6f8dfc744_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNi0xMS0xLTEtMzk4MzY_3a93a116-b0c6-4943-af41-c34527837827">23,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddb90dcdc5b4e7aa2740103176d7a92_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNy05LTEtMS0zOTgzNg_f8c64ca2-3039-4878-be9e-5be855eb8662">21,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedbeaf00736c4ec5b4e73d8f63d31829_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNy0xMS0xLTEtMzk4MzY_3a66a95d-9df3-4f4c-8f05-d3c567a0b60a">10,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfOC05LTEtMS0zOTgzNg_c5b6bf8e-65bf-4a7b-80fe-728ae64610c2">8,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfOC0xMS0xLTEtMzk4MzY_55043cb8-9aee-4064-9d0b-80d52e076e11">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfOS05LTEtMS0zOTgzNg_8d3168fd-2b14-4747-9b49-434a4f191715">504,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfOS0xMS0xLTEtMzk4MzY_ca710523-cb33-4e68-8431-9db22d64ca94">798,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2021, our gross unrealized losses totaled $<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTEzNQ_adfbf114-6096-4d2e-90be-076bae8b01b6">0.7</ix:nonFraction>&#160;million. Our gross unrealized gains were not significant. As of December 31, 2022 and 2021, we assessed our marketable securities with unrealized losses and concluded that the losses were not attributable to credit. Accordingly, we have not recorded an allowance for credit losses for these securities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both December&#160;31, 2022 and 2021, we had letter of credit arrangements in favor of our landlords and certain vendors totaling $<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTA5OTUxMTYyOTI1MQ_fa52c2cd-8797-4204-a677-6550681d1b8c">7.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTI2NA_e6ca08d2-61e9-4115-8074-081b28faf630">8.1</ix:nonFraction> million, respectively. These letters of credit are secured by investments of similar amounts.</span></div></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RleHRyZWdpb246YTQ1ZmRkNmViM2Y3NGRmNWE0NDU4MGQzNDFkM2EwMTVfNzc_c0178b3a-923d-4552-beca-4729af16c1bc" continuedAt="i11912f71c7794819b6c68c2a467619d9" escape="true">Inventory</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i11912f71c7794819b6c68c2a467619d9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RleHRyZWdpb246YTQ1ZmRkNmViM2Y3NGRmNWE0NDU4MGQzNDFkM2EwMTVfNzk_da04819c-db7a-45a3-b186-d72667bd6ecb" continuedAt="ib30a311adf8841e3b290a1c3af998ffe" escape="true">Inventory consists of the following (in thousands):</ix:nonNumeric></span><ix:continuation id="ib30a311adf8841e3b290a1c3af998ffe"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfMi0xLTEtMS0zOTgzNg_7a13b9cf-3a28-4f12-99f1-f2be0327e51c">2,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfMi0zLTEtMS0zOTgzNg_f520b06b-3d57-44f8-9736-508457b4acd8">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfMy0xLTEtMS0zOTgzNg_a31bd5a4-d16a-4af0-8c36-0f959fa275f6">10,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfMy0zLTEtMS0zOTgzNg_27bfe92f-f258-4822-84a5-204402fe6884">9,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfNC0xLTEtMS0zOTgzNg_22a465ad-5f27-4901-ba7c-ba38d1753c96">5,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfNC0zLTEtMS0zOTgzNg_6b68b216-cc96-4e8d-8c57-9c7479964f71">3,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfNS0xLTEtMS0zOTgzNg_f5bb49a2-a824-41a0-a49f-5b985e972548">19,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfNS0zLTEtMS0zOTgzNg_058d6c73-e230-4a4f-8bda-0728d93233e9">15,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4&#160;&#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjc3_e78c0aed-cb21-419c-8c44-b1dbb899f184" continuedAt="i8c6a0ee7495545f69b6eddafbe38e5d6" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="i8c6a0ee7495545f69b6eddafbe38e5d6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjc1_f85fe4eb-c6ad-47c8-bd02-c662a82f9bbf" continuedAt="icc045e4f86ef4295a2945b65e348503b" escape="true">Property, plant and equipment consists of the following (in thousands):</ix:nonNumeric></span><ix:continuation id="icc045e4f86ef4295a2945b65e348503b" continuedAt="ie46e9cd2272043ce86aef6762f70f40d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a690bee3fdb41e69aa7a67bfdee3e57_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMi0xLTEtMS0zOTgzNg_f6bc1189-2537-4f6b-ad32-d6ad3e23cfb9">74,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8386997073541c38bb72fe0270ebcf7_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMi0zLTEtMS0zOTgzNg_651d674b-7c77-4841-bb08-de0a8655fb76">97,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b488f3b36c44ef2a771d6736c3a2bbd_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMy0xLTEtMS0zOTgzNg_e3a17102-de60-451b-96bb-faf746b8d5c8">24,243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie418bae4d52d43e884dd28a74b932d6c_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMy0zLTEtMS0zOTgzNg_9bd1a8bc-5dda-4f05-a028-fc11b637bc52">42,704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a44796e8144efd8952281ed5f82527_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNC0xLTEtMS0zOTgzNg_977dc6e2-360c-4a4b-8d12-51573d1fc1be">26,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3264cdda22e4ccb9b495d63ecf07335_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNC0zLTEtMS0zOTgzNg_76805b3d-e29e-4acf-a05c-873616f35c55">28,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida76ac790e3346c9abae40c1d17bbf09_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNS0xLTEtMS0zOTgzNg_1ce49280-b3b1-49a6-9270-6fb6d3295b43">25,052</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229a4d508cf44e958dcc2e374b94852b_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNS0zLTEtMS0zOTgzNg_369ac31f-195e-4900-a676-2de20bb18965">22,374</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5bf9ea7884421aab5dcf25a470d1db_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNi0xLTEtMS0zOTgzNg_837ea8e1-36f7-472b-bd66-a7172a586692">4,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89433d88568a4bbd9019d46526e1fb80_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNi0zLTEtMS0zOTgzNg_a4d2dad4-0f3d-476b-888c-5e1577327589">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNy0xLTEtMS0zOTgzNg_7e363020-3bd7-4f2f-a43f-b703bb4a1cd2">154,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNy0zLTEtMS0zOTgzNg_93ac6543-fbdb-4070-8f74-ebf6fbe66119">201,386</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfOC0xLTEtMS0zOTgzNg_5e1399b2-4065-42d7-9d1b-e2f2ec908527">124,731</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfOC0zLTEtMS0zOTgzNg_44bf8012-5f59-477c-976f-45f4b9d9c982">148,039</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfOS0xLTEtMS0zOTgzNg_caf713dd-08da-40f9-9a8f-347b48ea80f7">29,921</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfOS0zLTEtMS0zOTgzNg_70bddf00-9587-4433-a4b8-58c0696f0478">53,347</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMTAtMS0xLTEtMzk4MzY_15e80b91-cf50-4bf4-8023-da1244b1fbf2">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMTAtMy0xLTEtMzk4MzY_32411506-c960-4287-817c-bf6ea33ec279">7,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMTEtMS0xLTEtMzk4MzY_976b8224-7401-4b50-837e-ef8375edbf7a">32,451</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMTEtMy0xLTEtMzk4MzY_913ed6e3-e7eb-45fc-8096-0c7e596e3cf9">60,510</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Laboratory and manufacturing equipment, including construction-in-process, include assets that support both our manufacturing and research and development activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment decreased significantly for the year ended December 31, 2022 as a result of our 2022 Restructuring Plan. As further disclosed in Note 11, we sold our research and development facility in India, we sold or disposed of laboratory equipment and certain computer software, and we recognized impairment charges for leasehold improvements and certain furniture and fixtures for spaces we seek to sublease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense for property, plant and equipment for the years ended December&#160;31, 2022, 2021, and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjQ3_7b6d5c39-6d51-4777-ac0a-08c13da6ab7d">12.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjUx_336669d9-cd26-46b3-83fe-cd5c2c731e2c">13.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjU5_c9a33116-317b-47e0-9ae3-0cbead220414">12.5</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5&#160;&#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxMzc_c06c9e1c-80c9-47ec-b211-26893af29038" continuedAt="i92822355bba445e0bde344bf1c91a2a9" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:continuation id="i92822355bba445e0bde344bf1c91a2a9" continuedAt="i4596ff21c0aa452fb3b16900c3d2de57"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our leases consist of a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. 19, LLC (ARE) for our <ix:nonFraction unitRef="sqft" contextRef="i4700d3b1885a4b0d8c4f82c6feb9dcfe_I20221231" decimals="0" name="nktr:AreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzE0NQ_9d602d9b-8db3-4c4b-8807-3025c6ca74ee">155,215</ix:nonFraction> square foot corporate office and R&amp;D facility located at 455 Mission Bay Boulevard South, San Francisco, California (the Mission Bay Facility) and a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) for an additional <ix:nonFraction unitRef="sqft" contextRef="i6c4d7fb18f6d46d8988b427878e0c23f_I20221231" decimals="0" name="nktr:AreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzQwNA_61359db6-c44b-4a37-a6fc-12c7da45e8db">135,936</ix:nonFraction> square foot of office space at 360 Third Street, San Francisco, California (the Third Street Facility). <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:LesseeOperatingLeaseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxMzg_8d212108-2a20-48e9-8879-f8ad13370a02" continuedAt="ic52733bc66de42da9fc9dd94dc9792be" escape="true">The following table presents key information regarding these leases (dollars in thousands):</ix:nonNumeric></span><ix:continuation id="ic52733bc66de42da9fc9dd94dc9792be"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mission Bay Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Street Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commencement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewal terms</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="term" contextRef="i7f516ae040844d74a523bf6793681072_D20220101-20221231" decimals="INF" name="nktr:NumberOfConsecutiveTermsToExtendLease" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMS0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmZDFjZGUwODRhMjM0MjRiODM0ZTUxNjRlODJmZWYwMl80_9dd7be27-1e6a-4073-8fc1-c4f0e8901896">Two</ix:nonFraction> consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMS0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmZDFjZGUwODRhMjM0MjRiODM0ZTUxNjRlODJmZWYwMl8xOQ_2b0e6231-2800-4ca2-b334-9e61b9740c93">five</span>-year terms</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="term" contextRef="i48c8e42537d84cce85b95bb5c5b6d70c_D20220101-20221231" decimals="INF" name="nktr:NumberOfConsecutiveTermsToExtendLease" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMy0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmNWM1YzY0MzkwN2Q0MjkzODY0ODc2YzY1NzI1Y2VjN180_b65851e6-bca7-4da4-9c37-8c61e4e90e7c">One</ix:nonFraction> <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMy0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmNWM1YzY0MzkwN2Q0MjkzODY0ODc2YzY1NzI1Y2VjN183_28da30aa-6692-46e9-9d13-2ccc8f191594">five</span>-year term</span></div></td></tr></table></ix:continuation></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The monthly base rent for both facilities will escalate over the term of the lease at various intervals. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Both leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance costs and taxes. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the Third Street Lease, our fixed annual base rent on an&#160;industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our 2022 Restructuring Plan, during the year ended December 31, 2022, we recorded impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i428577ef84824447b2265e91b8e6ca13_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzkzNDU4NDg4NDA2OTQ_eb64d0eb-a267-4f61-afbf-1ee1c7e8a30c">54.6</ix:nonFraction>&#160;million for our right-of-use assets which we are seeking to sublease. See Note 11 for additional information.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i4596ff21c0aa452fb3b16900c3d2de57"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally recognize lease expense for our operating leases on a straight-line basis over the lease term, and we continue to recognize lease expense on a straight-line basis for spaces for which we did not recognize an impairment. For spaces where we did recognize an impairment charge, the aggregate lease expense recognized over the remaining term is reduced by the amount of the impairment charge, but we recognize the remaining lease expense on an accelerated basis. <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxNDA_15ac3f26-b480-4c6a-b5ea-5eea9d42818b" continuedAt="ice07ffc5a92546f9a3e0c9ac4054062d" escape="true">The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="ice07ffc5a92546f9a3e0c9ac4054062d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzItMS0xLTEtMzk4MzY_a291c071-45a6-45c3-8196-e48224618070">17,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzItMy0xLTEtMzk4MzY_adf22d26-8cf4-41e1-aa3c-5b5dbef04c13">19,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzItNS0xLTEtMzk4MzY_b564f6cd-3a67-45dc-9d1e-51db817a7f0f">18,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzMtMS0xLTEtMzk4MzY_4a026638-5ae0-4dd1-9da9-35675cc7fb1e">10,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzMtMy0xLTEtMzk4MzY_b10afda5-dcf8-43d2-acec-577887c9075b">8,974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzMtNS0xLTEtMzk4MzY_b856d014-f985-4625-8973-a0266d1bc7d4">8,179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzQtMS0xLTEtMzk4MzY_55084149-c3f3-4aa1-8770-7ff3474edf5e">27,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzQtMy0xLTEtMzk4MzY_5d360a5c-2976-448b-9ed5-a62d66394019">28,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzQtNS0xLTEtMzk4MzY_aef9166c-648e-46ca-9b5c-80b64ca8df26">27,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the years ended December&#160;31, 2022, 2021 and 2010, we paid $<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzE2OTU_87c6d989-9e3d-45e1-be95-d8bb6dd43fe3">20.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzE2OTk_0aec7228-88c9-4937-8920-6fd689ab2a82">16.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzE3MDY_c7ab1d58-35c7-436b-9b60-5fb6ba006ddd">16.2</ix:nonFraction>&#160;million, respectively, of operating lease payments related to our lease liabilities, which we include in net cash used in operating activities in our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxMzU_c2f7eec2-0f76-4c1c-b4da-6a6c5240a75d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzEtMS0xLTEtMzk4MzY_79aeeea4-babe-4d26-ad28-7b13982a2478">19,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzItMS0xLTEtMzk4MzY_3834bf99-3ebf-4897-94ec-7a2b89acaeab">21,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzMtMS0xLTEtMzk4MzY_0ff4d580-35b5-42fc-8911-f9882581b7e5">22,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzQtMS0xLTEtMzk4MzY_6b2f5c96-fef6-4809-b07f-0f985d9b4149">22,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzUtMS0xLTEtMzk4MzY_a3b7188a-3fb5-4741-acdf-fbc0f5002b72">23,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzYtMS0xLTEtMzk4MzY_69acc5b8-a2e0-4319-87a9-81ce2ce2836e">51,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzctMS0xLTEtMzk4MzY_121ba350-fbca-48b0-807b-4fae0187abaf">161,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: portion representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzgtMS0xLTEtMzk4MzY_00b48a1f-067a-45c8-8ca3-fe8dcf01184e">29,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzEwLTEtMS0xLTM5ODM2_f13c30c1-cc5e-41f3-b1b3-e9c92b5b5d5f">131,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzExLTEtMS0xLTM5ODM2_07fee6a8-5960-4368-944a-739c221c0d59">18,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzEyLTEtMS0xLTM5ODM2_af178b0f-c831-49b6-924d-7492f95a99a3">112,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, the weighted-average remaining lease term is <ix:nonNumeric contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIwMzk_9e317ea4-593a-4f4a-8bfb-5ff61cafba7a">7.1</ix:nonNumeric> years and the weighted-average discount rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxMzM_0d2387f5-a020-4aaa-ba42-df4a19ede204">5.8</ix:nonFraction>%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into subleases for certain spaces that provide recovery of $<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-5" name="nktr:SubleasesIncomeToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzEwOTk1MTE2MzIyNzg_558e1477-1838-4df8-bf48-359025210559">10.5</ix:nonFraction>&#160;million in aggregate lease payments, as well as the subtenants' share of operating expenses. The reduction to lease expense for the year ended December 31, 2022, was not significant but will increase in future periods.</span></div></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:DevelopmentDerivativeLiabilityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzY0NjY_7b336583-8273-4151-9fd1-744cb5a49fd2" continuedAt="i42ead57f04ad4d03b8cb4b29820bceb5" escape="true">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ix:nonNumeric></span></div><ix:continuation id="i42ead57f04ad4d03b8cb4b29820bceb5" continuedAt="ic506baeaee6e4fb5872aa391173caa39"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $<ix:nonFraction unitRef="usd" contextRef="iefb7645eeeaf42b793851c3bab72abca_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementCommittedFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzMwMg_bcadd77c-59fa-4fa9-ac60-d8056a12ae84">150.0</ix:nonFraction>&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ has primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we are the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $<ix:nonFraction unitRef="usd" contextRef="iefb7645eeeaf42b793851c3bab72abca_D20210212-20210212" decimals="-5" name="nktr:CollaborativeArrangementSuccessBasedPaymentsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzkzNDU4NDg4NDQ0MTE_ef3162ba-22d4-46c6-af89-f7e163c26838">637.5</ix:nonFraction>&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin for the metastatic melanoma, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented the SFJ Agreement as a Development derivative liability in our Consolidated Balance Sheets, which we remeasured to fair value at each reporting date. As SFJ conducted the SCCHN Clinical Trial, we recorded non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remitted funding to us to support our internal costs of conducting the trial, we also recorded a corresponding increase to the development derivative liability. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Consolidated Statements of Operations. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="ic506baeaee6e4fb5872aa391173caa39"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzEwOTk1MTE2NDU4NDE_8274781a-7627-4d00-b9a5-23108becf777" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the development derivative liability:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf73feefa4248f9bc901c6de5114e62_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzItNC0xLTEtNDQxMzY_354b6a91-1bd1-4ba2-b388-65dbcfa98e2c">27,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296d2b099c6744c69a9b940e65fc438f_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzItNi0xLTEtNDQxMzQ_a9335c74-15b3-4572-9e05-753ce39fbb14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd1c1703c6a49d18229ba501627fd87_D20220101-20221231" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzMtNC0xLTEtNDQxMzY_1e8226b2-4bc3-4511-91ad-695ab8d4d16b">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b11067296644fba18e31a4fd031969_D20210101-20211231" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzMtNi0xLTEtNDQxMzQ_fce2999a-575b-46b5-bbed-d78eca3499fa">16,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd1c1703c6a49d18229ba501627fd87_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzQtNC0xLTEtNDQxMzY_7d8d91c7-391e-42f4-a383-674bb8e78c4f">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b11067296644fba18e31a4fd031969_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzQtNi0xLTEtNDQxMzQ_6f4c73ee-de2d-49cc-905a-45993767ef38">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cd1c1703c6a49d18229ba501627fd87_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzUtNC0xLTEtNDQxMzY_c4f84286-087c-4b57-8e0c-523b2d8a875a">33,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b11067296644fba18e31a4fd031969_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzUtNi0xLTEtNDQxMzQ_7ee8f9de-c4e4-41c6-938e-73dc4beaaabf">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b7c3411cc864b8fa20d76eb1a6c16ee_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzYtNC0xLTEtNDQxMzY_a0f55ae8-2464-4d27-8d84-514adc48a1e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf73feefa4248f9bc901c6de5114e62_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzYtNi0xLTEtNDQxMzQ_fe7b7dc1-3fed-4a72-9fe7-cb2f87614b01">27,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we valued the derivative using a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and we discount such cash flows to present value using a risk-adjusted rate. The key inputs to the valuation included our estimates of the following: (i) the probability of the  bempegaldesleukin trials meeting their primary endpoints, and if successful, the probability and timing of achieving FDA approval, (ii) the timing and the amount of costs incurred by SFJ for the SCCHN Clinical Trial, including the probability of early termination of the study based on an interim futility analysis, and (iii) each party&#8217;s cost of borrowing.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to <ix:nonFraction unitRef="usd" contextRef="ie67fe37584df4144b73e3e9eab99c4d3_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzkzNDU4NDg4NTYxNDI_0b0f8995-3014-4151-a374-0ce57436c1db">zero</ix:nonFraction> as of March 31, 2022, and we recognized a corresponding gain in the Change in fair value of development derivative liability. As discussed in Note 1, on April 14, 2022, BMS and we decided to end the development for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and that all other ongoing studies in the bempegaldesleukin program would be discontinued. We also announced that SFJ and we agreed to discontinue the SCCHN Clinical Trial. Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.</span></div></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzg4ODU_b3aea71a-6fb5-4ea6-a3b1-8a3d33c12b5c" continuedAt="i2aba905d5f0442d7ba198515c2e8c982" escape="true">Liabilities Related to the Sales of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="i2aba905d5f0442d7ba198515c2e8c982" continuedAt="i25614f1f6a614b6dae42e38855bfb2b8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i96e50a20c84741bf96617a4a3059d745_D20120224-20120224" decimals="-5" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzcxOA_95ee6352-93de-4458-9081-e2a8b71546c4">124.0</ix:nonFraction> million for the 2012 Transaction Royalties.&#160;Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $<ix:nonFraction unitRef="usd" contextRef="i96e50a20c84741bf96617a4a3059d745_D20120224-20120224" decimals="-5" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzEwMzQ_0a9c9464-5350-469b-9d22-c94e825e6857">124.0</ix:nonFraction> million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the effective interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. As of December 31, 2022, our prospective effective interest rate used to amortize the liability is <ix:nonFraction unitRef="number" contextRef="i0ee1e09ac15b43f982a08e4065ea0c1c_I20221231" decimals="2" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzkxMjY_110e2f3a-fae5-4b74-afca-165ca07815db">10</ix:nonFraction>%.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2020, UCB served notice of a Declaratory Judgment of Patent Invalidity, filed in the United States District Court for the District of Delaware, seeking a declaration of invalidity of certain of our patents that we had licensed to UCB and pursued similar actions in other jurisdictions. On October 14, 2021, RPI and we entered into a Letter Agreement which permitted us to enter into a Settlement Agreement, effective October 13, 2021, with UCB to effect the negotiation between RPI and UCB in which UCB and RPI agreed to a reduction in the royalty term and annual decreases in the royalty rate over the remaining royalty term in exchange for UCB&#8217;s withdrawal of all of UCB&#8217;s litigation and challenges. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded that we should account for the decrease in royalty payments to RPI as a result of these agreements as a modification of our liability. Due to the significance of the change in the estimated royalty payments, we concluded that we should treat the modification as an extinguishment of the prior liability and recognize a new liability based on the revised royalty payments and term, discounted to fair value. Accordingly, we estimated the fair value to be approximately $<ix:nonFraction unitRef="usd" contextRef="ic27548c7b9c047ce81417f7851d5a13b_I20221231" decimals="-5" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzI1MTI_ddab91db-bc47-439c-aa7f-89131c502565">84.7</ix:nonFraction>&#160;million, reflecting a discount rate of <ix:nonFraction unitRef="number" contextRef="i1bb7eac326dd4bd1860d0018b43342d6_I20221231" decimals="3" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzI1NDY_a04551b2-31cf-4b93-8a61-c7fc7dac0b5b">16.0</ix:nonFraction>%. As a result, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="ia8f403286c134e56995c7fac6aabe42c_D20211001-20211231" decimals="-5" sign="-" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzI3MDg_2c8e67ad-5d32-46d1-b66c-65d8c801c242">23.5</ix:nonFraction>&#160;million on the revaluation of the prior liability in the three months ended December 31, 2021, and we wrote off the remaining $<ix:nonFraction unitRef="usd" contextRef="ia8f403286c134e56995c7fac6aabe42c_D20211001-20211231" decimals="-5" name="nktr:TransactionCostsRelatedToRevisedRoyaltyPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzI4MzI_4776f17b-9a4d-4fb1-88f3-cec9ee07971a">0.9</ix:nonFraction>&#160;million of unamortized </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i25614f1f6a614b6dae42e38855bfb2b8" continuedAt="i5387388dc2e94e0cb4fae314b0eb7dd9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction costs. We present these charges in Loss on revaluation of liability related to the sale of future royalties line in our Consolidated Statement of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time that certain return thresholds are met as described below, of (a) MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB, as amended, (b) ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH, as amended, (c) REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $<ix:nonFraction unitRef="usd" contextRef="i6d861344a14b4ed19a94c299e3f1bd9c_D20201216-20201216" decimals="-5" name="nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzQ0MDY_715c9b98-ace5-4158-a560-c55ae23e6b28">210.0</ix:nonFraction>&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $<ix:nonFraction unitRef="usd" contextRef="i6d861344a14b4ed19a94c299e3f1bd9c_D20201216-20201216" decimals="-5" name="nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzQ1MDI_23b1545f-b90b-499c-a146-721055e14df1">240.0</ix:nonFraction>&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $<ix:nonFraction unitRef="usd" contextRef="i6d861344a14b4ed19a94c299e3f1bd9c_D20201216-20201216" decimals="-5" name="nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzQ3NjY_8e331393-6b26-4476-9e51-2c8a16e65969">208.0</ix:nonFraction>&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2020, we received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0a46e523740a48e4bc313c9c8f371a46_D20201230-20201230" decimals="-5" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzUxODI_ed553d70-ba26-42f3-96ea-4cfdba5b7211">150.0</ix:nonFraction>&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i0a46e523740a48e4bc313c9c8f371a46_D20201230-20201230" decimals="-5" name="nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzUyNjg_d1357dd2-9472-43e6-ac85-70508278b67b">3.8</ix:nonFraction>&#160;million in transaction costs, which will be amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these products up to the cap, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, to be received by HCR in the first quarter of 2021. We recorded the $<ix:nonFraction unitRef="usd" contextRef="i0a46e523740a48e4bc313c9c8f371a46_D20201230-20201230" decimals="-5" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzU4Njk_19be6b13-3e5b-4bd7-ab00-06d82524327d">150.0</ix:nonFraction>&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. As of December 31, 2022, our prospective effective interest rate used to amortize the liability is <ix:nonFraction unitRef="number" contextRef="ib9e6083883184909bf4a11a730aefa63_I20221231" decimals="2" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzEwOTk1MTE2Mjg2OTE2_02a3a9d0-36fe-465b-bfd6-72ebecd022e1">20</ix:nonFraction>%.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzg4ODY_3648877e-9fce-4ede-95f0-edce2c3f8909" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account of each arrangement (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties&#8212;beginning<br/>balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee97d6bd60ef4aa78a34aa3a4e187ea1_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItMS0xLTEtMzk4MzY_436a7eef-877e-42ad-b3e6-6c76bf32e847">78,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56808f00dc44ceea4a81c7aadbb5013_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItMy0xLTEtMzk4MzY_700e1402-f777-455b-b771-cc279ab40cc7">120,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItNS0xLTEtMzk4MzY_826be46b-d0a7-4821-98dc-0057653894c2">198,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58214773cc764c89b77413cc27cba0d6_I20120224" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItNy0xLTEtMzk4MzY_9d9082e3-0f55-41f1-935d-f8651360b9a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50db82185e724189a23e8bcbadd1f46d_I20201216" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItOS0xLTEtMzk4MzY_ae4e9137-8134-42d6-b2b2-cf998e192e6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e27ff45c6344a70a6715b2e56bebc4a_I20120224" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItMTEtMS0xLTM5ODM2_5e8423ec-5250-408f-b334-a07424463de5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtMS0xLTEtMzk4MzY_acc70f8c-c8eb-4885-9c4d-25e365b0962e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtMy0xLTEtMzk4MzY_929a334a-f8b2-46a9-9b8d-12732db2014f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtNS0xLTEtMzk4MzY_d278cccc-b101-4d0a-b201-3efccf6da02f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtNy0xLTEtMzk4MzY_a2f18c4b-0a3f-41cb-b7d5-46442fd777bd">124,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtOS0xLTEtMzk4MzY_684dae20-a784-4e16-9f72-dbc3b4d9430b">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtMTEtMS0xLTM5ODM2_f1bcc1d7-7132-4812-8715-86b9df5ff745">274,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtMS0xLTEtMzk4MzY_65e7ffd2-63d6-4231-a2f4-3667d79cd679">33,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtMy0xLTEtMzk4MzY_8f082c5c-a568-48fc-8950-4a6bb38e6b6b">35,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtNS0xLTEtMzk4MzY_98bdca44-f6f5-4732-a2ca-64563759c94a">69,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtNy0xLTEtMzk4MzY_9aae32da-12d4-489f-ba79-da193e193af9">316,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtOS0xLTEtMzk4MzY_38a43833-98be-473c-9112-3163408aed2c">86,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtMTEtMS0xLTM5ODM2_1f4d2436-3de0-4c7d-a282-e6f55e936662">403,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtMS0xLTEtMzk4MzY_e05acdbb-c422-4172-812b-b53465ef8389">10,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtMy0xLTEtMzk4MzY_7cfb3655-dd3f-4dee-8634-4dded9f8bebc">18,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtNS0xLTEtMzk4MzY_ec95f999-0b06-4703-9d9a-594c2b4c3e28">28,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtNy0xLTEtMzk4MzY_f6293760-203b-48d8-8ad1-bdd184b710f9">234,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtOS0xLTEtMzk4MzY_c85611ec-a611-4ded-ada6-06a54ed82c4f">39,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtMTEtMS0xLTM5ODM2_b2722b41-f3d8-48c5-9f49-6d37e3fc3cb8">273,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtMS0xLTEtMzk4MzY_12217ec7-04d2-46d1-b92f-5f7070e17a2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtMy0xLTEtMzk4MzY_3f18a5df-dc30-4309-8579-587f33ea2317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtNS0xLTEtMzk4MzY_d3bf0b2a-0739-48d2-9c64-95a081451931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtNy0xLTEtMzk4MzY_646be4e6-fc31-46ec-b52f-0fabe94bb306">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtOS0xLTEtMzk4MzY_aba03b13-b2a5-4143-a33b-2b70f72ea149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtMTEtMS0xLTM5ODM2_20955ee2-15d3-4c1d-b49d-8700c3597157">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctMS0xLTEtMzk4MzY_3c21b978-91da-43cb-8e3b-09cda6bc47ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231" sign="-" xsi:nil="true" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctMy0xLTEtMzk4MzY_5ede970a-02f6-4738-a960-b7c480c6ab21"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctNS0xLTEtMzk4MzY_6fc602f4-5155-4ec1-a4b6-e5775e32c199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231" decimals="-3" sign="-" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctNy0xLTEtMzk4MzY_0af39998-20e3-4db7-b313-30b03b93ec8e">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctOS0xLTEtMzk4MzY_794a7416-8ed7-4059-8fa5-4070051a6669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231" decimals="-3" sign="-" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctMTEtMS0xLTM5ODM2_e6d907ce-7921-483b-bd84-3acc038bb04e">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtMS0xLTEtMzk4MzY_f63a77c1-c224-45d1-a1d7-d995517b03f0">55,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1ef455fc644610936464822e51b81e_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtMy0xLTEtMzk4MzY_b7a3fbd1-35a8-4688-9cf3-c24becbcf33f">102,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtNS0xLTEtMzk4MzY_b998cf8f-c352-4104-80a4-d49c0d32da65">157,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtNy0xLTEtMzk4MzY_3bd5ac41-505b-45c3-8ff3-f6c341d9ae17">55,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1ef455fc644610936464822e51b81e_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtOS0xLTEtMzk4MzY_8d5c1a5d-4ee3-4a76-9946-1a1f1a38e0e9">102,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtMTEtMS0xLTM5ODM2_7973c040-a839-4b09-b572-ed6ed01e496d">157,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktMS0xLTEtMzk4MzY_86bb0ea3-1578-49d8-98d7-eaca0adaf0d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb1ef455fc644610936464822e51b81e_I20221231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktMy0xLTEtMzk4MzY_7b5e09bb-3d18-4896-912f-9b5cc526bd18">2,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktNS0xLTEtMzk4MzY_69849de3-3aba-4bc9-860e-96efd6fb7753">2,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktNy0xLTEtMzk4MzY_7fddc1ca-a7c6-412b-9616-b73a50b2650c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb1ef455fc644610936464822e51b81e_I20221231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktOS0xLTEtMzk4MzY_f5dabcdf-330f-4ac8-819f-2e1dd603ae82">2,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktMTEtMS0xLTM5ODM2_d441204a-0c1c-43ed-9c32-82e8ff6dedab">2,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTEtMS0xLTM5ODM2_8ef50d37-99e1-4354-a821-255c2870b086">55,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1ef455fc644610936464822e51b81e_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTMtMS0xLTM5ODM2_73b91ced-6fbe-431c-9442-73d845d471b9">100,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTUtMS0xLTM5ODM2_56da65f3-42b7-4547-93d8-3d24c7013c95">155,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTctMS0xLTM5ODM2_f75a154e-cdb6-4be7-8be6-c2adfb2354c3">55,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1ef455fc644610936464822e51b81e_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTktMS0xLTM5ODM2_947e271b-9c9c-40bd-8f46-97be9f699ea1">100,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTExLTEtMS0zOTgzNg_04eb3587-22b3-4bf5-aaf8-385f17547fa8">155,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the 2012 Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $<ix:nonFraction unitRef="usd" contextRef="icfb29fc19c9d46639cf8c5115010c1ec_D20140301-20140331" decimals="-5" name="nktr:PaymentMadeForMilestoneNotAchievedYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzYzOTI_faa45281-8a06-428b-a9db-dd5ea45cdcdb">7.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i11ff6330b45e466abdfd7de31f51f2d6_D20130301-20130331" decimals="-5" name="nktr:PaymentMadeForMilestoneNotAchievedYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzYzOTk_7b370a4e-0337-4593-a053-df87cc370a89">3.0</ix:nonFraction> million, respectively, as a result of worldwide net sales of MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the 12 month periods ended </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i5387388dc2e94e0cb4fae314b0eb7dd9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2013 and 2012 not reaching certain minimum thresholds. The 2012 Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense, as well as the loss on the revaluation described above, over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the appropriate Royalty Obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are a number of factors that could materially affect the amount and timing of royalty payments from our licensees, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI or HCR are made in U.S. dollars (USD) while significant portions of the underlying sales of the products of our licensees are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from our licensees, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the respective Royalty Obligation. Conversely, for the 2012 Purchase and Sale Agreement, if sales of these products are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the 2012 Royalty Obligation.</span></div></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8&#160;&#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzk5MTM_5e3e5513-9b11-4d63-acf1-a374cd5d0d0c" continuedAt="i647a93670d624b4dad413d5228a1799a" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i647a93670d624b4dad413d5228a1799a" continuedAt="ic04b1dd78a2445e6981d030cf0a3c803"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the normal course of business, we enter into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&#160;31, 2022, these commitments were not significant.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have recorded no liability for any litigation matters in our Consolidated Balance Sheets at either December&#160;31, 2022 or December&#160;31, 2021. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have operated in a number of foreign countries, but we are in the process of winding down our foreign subsidiaries. As of December 31, 2022, we no longer have any foreign properties and only a few remaining employees in foreign locations. We are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any of these potential indemnification obligations is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded <ix:nonFraction unitRef="usd" contextRef="i01976cfee21a4bc1ac8121bef4c3c1f7_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzYwNjk_119bac4a-49bb-4c55-82b6-06e9cfb6f4f6"><ix:nonFraction unitRef="usd" contextRef="i07893b3959254f9ebfe26a0ff8ffc37b_I20221231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzYwNjk_aae53d1c-3266-4d1f-a627-625accd24011">no</ix:nonFraction></ix:nonFraction> liabilities for these obligations in our Consolidated Balance Sheets at either December&#160;31, 2022 or December 31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="ic04b1dd78a2445e6981d030cf0a3c803"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification of Underwriters and Initial Purchasers of our Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with our sale of equity we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director and Officer Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification would not be material, other than retention of up to $<ix:nonFraction unitRef="usd" contextRef="id78314c12234445bbd7f0667b5fef4fb_I20221231" decimals="INF" name="nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzk0MzM_280f5da4-8b5f-4c46-b29f-c3e5acf8860b">10.0</ix:nonFraction> million per incident for merger and acquisition related claims, $<ix:nonFraction unitRef="usd" contextRef="ie58f9f4376a2484a87512c90b4835ff7_I20221231" decimals="INF" name="nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzk0OTI_a24e04d9-22f3-4067-9bab-150c99f1aa2c">10.0</ix:nonFraction> million per incident for securities related claims and $<ix:nonFraction unitRef="usd" contextRef="i9c5fd482c6864667b05d8be19b108140_I20221231" decimals="INF" name="nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzk1NDI_fdaab462-4f4d-4c4e-b601-7fc4942ffc92">10.0</ix:nonFraction> million per incident for non-securities related claims per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.</span></div></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9&#160;&#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzExMTY_f34f05b2-3430-456d-b7f5-802965d750d1" continuedAt="ie6ef4b6adab3454286df8b89c5dd7c9f" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="ie6ef4b6adab3454286df8b89c5dd7c9f" continuedAt="i54609e5c39354cb3a74a8e490bc5f59d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 10, on April 3, 2018, we completed the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="i3995f200366f48ddae334a6ff1b42719_D20180403-20180403" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzExOQ_e5188534-44bd-439f-bc69-0d956675e348">8,284,600</ix:nonFraction> shares of our common stock under a Share Purchase Agreement with BMS. These shares are unregistered and subject to certain lock-up and stand-still provisions for a <ix:nonNumeric contextRef="i5004dfaad50e4a37b683b94437e9c3fe_D20180403-20180403" name="nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzExMTM_0968f389-c31a-428d-9234-50b0b933eb3e">five-year</ix:nonNumeric> period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the filing of this Annual Report on Form 10-K, we had an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the SEC. The 2021 Shelf Registration Statement permitted the offering, issuance and sale by us of up to an aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="INF" name="nktr:SaleOfStockValueAuthorizedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzU5OQ_96516748-4c2e-4124-8f43-478a01bbc093">300.0</ix:nonFraction>&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which could be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities were sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement. As a result of the recent decline in our market capitalization, we are no longer a well-known seasoned issuer. Accordingly, the 2021 Shelf Registration Statement will no longer be available for us to offer and sell securities pursuant to the 2021 Shelf Registration Statement following the filing of this Annual Report on Form 10-K.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i54609e5c39354cb3a74a8e490bc5f59d"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzExMTQ_55fc0e92-a195-4ff7-93be-69453874b441" continuedAt="ie1f6e646269d4d6aba985eef78a8449e" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, shares of common stock reserved for future issuance are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and PSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dee2bf1b1104b36a37ca5af4f6c6e08_I20221231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90YWJsZTo2ODI5NWQwZTMyZjM0YmZiOGQ1M2Q0OTUzN2U0NzMyOC90YWJsZXJhbmdlOjY4Mjk1ZDBlMzJmMzRiZmI4ZDUzZDQ5NTM3ZTQ3MzI4XzAtMS0xLTEtMzk4MzY_dc934727-e520-40b7-a0df-6bb5adb2eca8">23,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2017 Performance Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a12065b592f45eb91672b4c2ecfc993_I20221231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90YWJsZTo2ODI5NWQwZTMyZjM0YmZiOGQ1M2Q0OTUzN2U0NzMyOC90YWJsZXJhbmdlOjY4Mjk1ZDBlMzJmMzRiZmI4ZDUzZDQ5NTM3ZTQ3MzI4XzEtMS0xLTEtMzk4MzY_0edecadb-c46a-4812-a4c0-a824ad4ca92b">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a09c769b2cf4b7d96bd94af49863ae2_I20221231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90YWJsZTo2ODI5NWQwZTMyZjM0YmZiOGQ1M2Q0OTUzN2U0NzMyOC90YWJsZXJhbmdlOjY4Mjk1ZDBlMzJmMzRiZmI4ZDUzZDQ5NTM3ZTQ3MzI4XzItMS0xLTEtMzk4MzY_183ab0d0-bcb0-454e-857a-b16c2a163ab9">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90YWJsZTo2ODI5NWQwZTMyZjM0YmZiOGQ1M2Q0OTUzN2U0NzMyOC90YWJsZXJhbmdlOjY4Mjk1ZDBlMzJmMzRiZmI4ZDUzZDQ5NTM3ZTQ3MzI4XzMtMS0xLTEtMzk4MzY_984134c1-8446-4743-8530-8aa800cf8d16">27,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated other comprehensive loss as of December 31, 2022, includes $<ix:nonFraction unitRef="usd" contextRef="ib0a2b75f3c2c497e821c32654dcf273d_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzEwOTk1MTE2Mjk3MDI_fb0afa30-6f58-491d-a80d-bede109dab85">1.8</ix:nonFraction>&#160;million for net unrealized losses on our available for sale securities and $<ix:nonFraction unitRef="usd" contextRef="i9b2e426dae1d4dcb82e953621113a971_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzEwOTk1MTE2Mjk3MTY_4b4754d2-3b45-427d-9d74-b811223ef713">5.1</ix:nonFraction>&#160;million for accumulated net translation losses primarily from our subsidiary in India.</span></div></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_121"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10&#160;&#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzE2NjA0_eb667dc2-0fec-4cfa-9b48-be229c30ee2e" continuedAt="ie6a33e20093b4003bc741d1b9522c6cc" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="ie6a33e20093b4003bc741d1b9522c6cc" continuedAt="ib86d54d6c8994099a036b876732a5b00"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzE2NjA2_e894ef4c-cbe6-40d7-98d9-9a9bd8087459" continuedAt="i08d31d1788ec49afb840d149eb4544f8" escape="true">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i08d31d1788ec49afb840d149eb4544f8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:32.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41101ca7c6074352b2c8edbbded90a47_D20220101-20221231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzItNC0xLTEtMzk4MzY_4f557415-dc12-49e6-83d3-ea783ff206ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f6ddc21ca64160889eff82cd22dac0_D20210101-20211231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzItNi0xLTEtMzk4MzY_3dacdc2b-c99e-4b16-80eb-6dc20ad8ea23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb79cd1e8a9d4e9b956b054364d945b9_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzItOC0xLTEtMzk4MzY_ccadcc4f-7b5d-4afc-a41c-a27f6392131d">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b00cf7a680342eabe29c33d1f30ca48_D20220101-20221231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzUtNC0xLTEtMzk4MzY_f15efc1f-7f3d-49b2-88c2-1d335e311743">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4d0375d0754d04bfbcb3001a3a73ab_D20210101-20211231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzUtNi0xLTEtMzk4MzY_6a68d40a-94cc-4b52-b6eb-b9f4d7de20cd">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1acc968e13bf49b2af89cb89994d8c21_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzUtOC0xLTEtMzk4MzY_7d247824-166e-4f80-95cf-a4e43c0a3a53">5,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzYtNC0xLTEtMzk4MzY_00171857-c266-4700-9878-6e01f88bacc9">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzYtNi0xLTEtMzk4MzY_838b9083-4db1-4cce-b88f-233032474aee">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzYtOC0xLTEtMzk4MzY_226b904c-62f7-4439-aad1-299c2c07942b">55,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb (BMS): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (previously referred to as NKTR-214)</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="number" contextRef="i5a0cc81cd3464c5b93834a7c5444f287_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE5OTYw_b1e79dc8-a071-4edb-ae5c-ccfec546c43e">67.5</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="i518ea15aaef14db7aa415c20c69633ba_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDA0_70847ab3-79ec-406a-92b0-334c0a57f301">32.5</ix:nonFraction>% to Nektar. The parties share costs for the manufacturing and commercialization of bempegaldesleukin, <ix:nonFraction unitRef="number" contextRef="if2e2d3e9e2a7461daef194bc19d22bb4_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDE1_d0f97a61-4cbe-41a5-8988-bd1697eee40d">35</ix:nonFraction>% of the costs to BMS and <ix:nonFraction unitRef="number" contextRef="i93f5d9b4d79b4feca3f3a4d2b14a9583_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDI0_c100ad95-c0a4-4cfd-8e29-1bf2184e5389">65</ix:nonFraction>% to Nektar. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i034999d286934f979052476fb5f2c14a_D20180401-20180430" decimals="-8" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDQy_e9e3c4ff-e0e4-433e-915e-96a6d55a9786">1.0</ix:nonFraction>&#160;billion and purchased <ix:nonFraction unitRef="shares" contextRef="if6238407fbe54f7f8ccc426559162694_I20180430" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDY2_cd596268-ac24-4ee0-a388-8a1bda14e976">8,284,600</ix:nonFraction> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i3c808ebe93bd410caafb0853708fc73f_D20180401-20180430" decimals="-5" name="nktr:SaleOfStockConsiderationReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE5OTgy_5bf2ed09-0ddb-4981-81e7-d362c059b7e7">850.0</ix:nonFraction>&#160;million. In 2020, we received non-refundable milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ibcde63790f2b4c09a640ee1fb4bcaf0e_I20180430" decimals="-5" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDkx_24b1665f-0f24-44d4-8ce6-f2e7b48370f5">50.0</ix:nonFraction>&#160;million in aggregate for the first patient, first visit in the registrational trials in muscle-invasive bladder cancer and adjuvant melanoma.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, on March 14, 2022, we announced our registrational trial in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the trials in metastatic melanoma and adjuvant melanoma. On April 14, 2022, we announced that our registrational trials in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided that these studies and all other ongoing studies in the program will be discontinued. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. However, without further development of bempegaldesleukin, we will no longer be eligible for the development, regulatory and sales milestones under the arrangement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="ib86d54d6c8994099a036b876732a5b00" continuedAt="i84949dbfde0744b5a641051d7aa895c7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proportionately with the performance of the underlying services. We recognized BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. As discussed in Note 11, we terminated the development of bempegaldesleukin, and therefore, in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the bempegaldesleukin program in restructuring, impairment and other costs of program. Accordingly, during the year ended December&#160;31, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i4cbcedb2872f472f8169616cf817be26_D20220101-20221231" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4NzEy_661c9c3c-9d93-44a8-aa31-c2187a5a1ad1">45.7</ix:nonFraction>&#160;million for the net reimbursement from BMS, of which we recorded $<ix:nonFraction unitRef="usd" contextRef="ia59bf42370df4deeb31e0accd2bdaf1a_D20220101-20220331" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE3OTk4_90edaae4-c715-49d7-b89f-d821ac6e07c0">24.9</ix:nonFraction>&#160;million as a reduction of research and development expense for the first quarter of 2022, and $<ix:nonFraction unitRef="usd" contextRef="i2d8701f92c324d04925cd7cef5dec02f_D20220401-20221231" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4MTQy_884c26af-39c8-4eca-b0c1-3df73005e9d9">20.8</ix:nonFraction>&#160;million as a reduction of restructuring, impairment and other costs of terminated program for the remaining three quarters of 2022. During the years ended December&#160;31, 2021 and 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i28f996738350426c90cc53b744993a58_D20210101-20211231" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4MDgy_5fe518d6-6c71-462b-ae58-22d37c2cf502">101.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i398cab648ac141a89899e3e28583c043_D20200101-20201231" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4MDk4_6532ad19-609a-4d3d-b992-ccde8664cfae">128.2</ix:nonFraction>&#160;million, respectively, as a reduction of research and development expense for the net reimbursement from BMS. As of December&#160;31, 2022, we have recorded an unbilled receivable of $<ix:nonFraction unitRef="usd" contextRef="i33ecf05d707f40b5927205653bd6a5c7_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4MTYy_61dc957f-4fbc-463c-bcac-235eddec9c6c">4.2</ix:nonFraction> million from BMS in accounts receivable in our Consolidated Balance Sheet, which we received in February 2023.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NKTR-358 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop rezpegaldesleukin, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="if58625a341de4335a5fee3c3a3737dae_D20170723-20170723" decimals="-6" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMTIx_60365ed3-fc71-4140-a977-4f30ab614bfe">150.0</ix:nonFraction>&#160;million and are eligible for up to $<ix:nonFraction unitRef="usd" contextRef="iebb537ce80dc447d8acffa6a5eb73666_I20170723" decimals="-6" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMTUy_5b6232d7-fca1-4bba-b953-4210ea03214e">250.0</ix:nonFraction>&#160;million in additional development and regulatory milestones. Although we are entitled to significant development milestones under this arrangement if Lilly decides to proceed to Phase 3 development, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in Phase 1B and Phase 2 development, where we share costs with <ix:nonFraction unitRef="number" contextRef="ib0f6b7f71328485db76064f93dc003eb_D20170723-20170723" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMTcy_8e35b04f-f09e-410e-9b22-fc3968027b8d">75</ix:nonFraction>% of the costs borne by Lilly and <ix:nonFraction unitRef="number" contextRef="if58625a341de4335a5fee3c3a3737dae_D20170723-20170723" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzkzNDU4NDg4Nzg1NTU_0412a7e1-200b-4ee3-86cd-23d6d58f72eb">25</ix:nonFraction>% of the costs borne by us. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to <ix:nonFraction unitRef="number" contextRef="i45d02ce2e1364896bbbc49fa46ce2648_D20170723-20170723" decimals="INF" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzkzNDU4NDg4Nzg1NjQ_14670f9f-473a-4bd6-9f18-cb94f425b8dc">25</ix:nonFraction>% of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the costs of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 development on an indication-by-indication basis in order for us to achieve the maximum royalty level under the Lilly Agreement, and further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, we will have the opportunity to receive a royalty rate up to the low twenties percent based upon our Phase 3 development cost contribution and the level of annual global product sales.  Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by <ix:nonFraction unitRef="number" contextRef="i22df0cf6959c4db1b5ac09a71e43c84c_D20170723-20170723" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMTgx_d1979894-97b1-4eec-b1fc-658774789648">50</ix:nonFraction>% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by <ix:nonFraction unitRef="number" contextRef="i22df0cf6959c4db1b5ac09a71e43c84c_D20170723-20170723" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzkzNDU4NDg4Nzg1NzM_2f4e4e3b-dabb-4a28-8ee2-1c174adaf5bf">75</ix:nonFraction>% if both conditions occur. The Lilly Agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The Lilly Agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study). The primary endpoint of the Phase 2 Lupus Study was not met, and Lilly has notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baxalta Inc. / Takeda Pharmaceutical Ltd.: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology, resulting in the approval of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by the FDA in  2015, which is now marketed in the U.S., the European Union, and many other countries. We are entitled to royalties based on worldwide net sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a sales milestone upon achievement of an annual worldwide net sales target. We are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, we are entitled to single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement. As described in Note 7, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i84949dbfde0744b5a641051d7aa895c7"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (naloxegol oxalate)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Through various sublicense arrangements to RedHill Biopharma, Kyowa Hakko Kirin Co. Ltd. and Knight Therapeutics, as of April 2020, AstraZeneca has sub-licensed all of its global commercialization rights. Our rights, including the royalty rate, royalty term and future potential sales milestones, remain unchanged as a result of these sublicenses. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally entitled to escalating double-digit royalty payments and sales milestones for net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As described in Note 7, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $<ix:nonFraction unitRef="usd" contextRef="if7a7eeedf4d74cc9a9917ed4c99c02c8_I20221231" decimals="-5" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMjAw_5dfd80de-3c01-4ac6-84b5-09be974367e7">40.0</ix:nonFraction>&#160;million of regulatory milestones, as well as royalties based on net sales, if approved, and sales milestones upon achievement of an annual net sales targets. However, given the current phase of development of the product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.</span></div></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_1664"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11 &#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTU2_5080f635-00fa-428a-b8b1-f81e2ce8e33c" continuedAt="idead6213dd244d35892ccedd7e8a424e" escape="true">Restructuring, Impairment and Other Costs of Terminated Program</ix:nonNumeric></span></div><ix:continuation id="idead6213dd244d35892ccedd7e8a424e" continuedAt="i2273370f3cb34446a6fc5810fff724c9"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, because our registrational trials in bempegaldesleukin did not meet their primary endpoints, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors, and, during April 2022, we announced the 2022 Restructuring Plan to prioritize key Phase 2 development programs, to advance our early stage research pipeline and to reduce our workforce by approximately <ix:nonFraction unitRef="number" contextRef="i7395e5dc92e34456b97e26b144017d8e_D20220401-20220430" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjI5NDYxOQ_c74c6312-80cd-4523-a887-07effc4bf3ea">70</ix:nonFraction>% from approximately <ix:nonFraction unitRef="number" contextRef="i79208888512146d7bc75e741ef3f64e2_I20220630" decimals="0" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjI5NDYyOA_e5617644-abde-4f8f-ad24-3740d678ac51">735</ix:nonFraction> to approximately <ix:nonFraction unitRef="number" contextRef="i81256841f310427f8d19dc50d08b735c_I20220430" decimals="0" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjI5NDYzNw_4a3e1da9-e21c-4f95-8e59-ccffd8ce8b93">225</ix:nonFraction> employees. In connection with these events, we reported the following costs in restructuring, impairment and other costs of terminated program for the year ended December&#160;31, 2022:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Severance and related benefit costs pursuant to the 2022 Restructuring Plan;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impairment of sublease assets, including right-of-use assets and property, plant and equipment resulting from the 2022 Restructuring Plan, reflecting excess office and laboratory leased spaces in San Francisco, CA; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">(Gain) loss on sale or disposal of property, plant and equipment; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract termination and other costs associated with the wind down of the bempegaldesleukin program.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In prior periods through March 31, 2022, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin program primarily in research and development expense. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTU3_c8eb5cac-bb6d-41ae-ac1b-a657710899fc" continuedAt="ia3565d53f85c4d609edd2793efbb9f88" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF8xLTItMS0xLTQxODY1_eca30f90-1c5e-4a56-9c15-d18b7f9fb233">31,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF8yLTItMS0xLTQxODY1_58b81dd8-0f28-4462-bd86-10ee51c1e1d4">30,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF8zLTItMS0xLTQxODY1_929cf2e3-1b8f-4e7a-8d98-23d91cc56812">65,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Gain) loss on sale or disposal of property, plant and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF80LTItMS0xLTQxODY1_ceb405df-6939-4ba6-866f-22adbc8b8bfb">3,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:LossOnContractTermination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF81LTItMS0xLTQxODY1_4d684817-5ea1-4b4b-a58a-223c8dd8e8b0">10,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF82LTItMS0xLTQxODY1_d9b5131d-df6b-427e-a907-3f36b2e2594d">135,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i2273370f3cb34446a6fc5810fff724c9" continuedAt="i5c8a5c0a50da4d27a916e70da66031c2"><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical costs associated with winding down the bempegaldesleukin program primarily include clinical trial and other development expenses to transition patients from our sponsor-led trials to standard of care or our post-trial access program, as well as direct employee costs supporting these efforts. We recorded a reduction of expense of $<ix:nonFraction unitRef="usd" contextRef="i2d8701f92c324d04925cd7cef5dec02f_D20220401-20221231" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjI5MTU2Mg_884c26af-39c8-4eca-b0c1-3df73005e9d9">20.8</ix:nonFraction>&#160;million for the net reimbursement from BMS primarily for such costs. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and Benefit Expense</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under our 2022 Restructuring Plan were entitled to receive severance payments and certain Company funded benefits. We recognized severance and benefit expense in full for employees who were notified of their termination in April 2022 and had no requirements for future service, and we recognized expense for employees who were required to render services to receive their severance ratably over the service period. This service period began in April 2022 with all affected employees terminated on or before December&#160;31, 2022, and therefore we will recognize no further expense. <ix:continuation id="ia3565d53f85c4d609edd2793efbb9f88" continuedAt="iaffedacc96b44b66b92742959e9719da">The following table provides details regarding the severance and other termination benefit expense. We present the liability, which we paid in January 2023, in accrued compensation on our Consolidated Balance Sheet (in thousands):</ix:continuation></span></div><div style="margin-top:18pt"><ix:continuation id="iaffedacc96b44b66b92742959e9719da" continuedAt="ia42efbad7b414d329b85f34ed18fa3ae"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No service period</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service period required</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc20cfb1c4a48679a78206fc2ea8b1d_I20220630" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV80LTItMS0xLTQ0MTc4_4013ac2e-2d7f-4b0b-a93e-59bf6518117a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac9a278cf47443e98c7cfa38fb872b4_I20220630" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV80LTQtMS0xLTQ0MTc4_bbf331e0-5fb2-4c7f-9827-b2eca60bf406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79208888512146d7bc75e741ef3f64e2_I20220630" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV80LTYtMS0xLTQ0MTc4_64b2b4b0-f6c6-440b-a205-c0dfa16e11f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb69ada362dc437e9819aaa096864a94_D20220701-20220930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV81LTItMS0xLTQ0MTc4_c3a827bc-5a4a-4e0a-b828-b733e1f357d9">22,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9b0c23b6004aa1922ed92ae6e42a1c_D20220701-20220930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV81LTQtMS0xLTQ0MTc4_afa3b51d-54f7-4785-a83a-39ce2d1dffab">7,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie391f9f234c444d2ae0b217cc409af4b_D20220701-20220930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV81LTYtMS0xLTQ0MTc4_80ace0c7-d076-4f77-9182-40a810807350">30,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb69ada362dc437e9819aaa096864a94_D20220701-20220930" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV82LTItMS0xLTQ0MTc4_adcc836a-b8c0-41cd-8231-d93b526d43b2">22,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c9b0c23b6004aa1922ed92ae6e42a1c_D20220701-20220930" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV82LTQtMS0xLTQ0MTc4_c9dc243b-39d2-45f1-b846-d0005c8798a7">4,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie391f9f234c444d2ae0b217cc409af4b_D20220701-20220930" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV82LTYtMS0xLTQ0MTc4_4295eccd-d7e4-4a59-8e21-3a07c90d6950">27,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i761caeec68a54ac890af6ea722b34752_I20220930" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV83LTItMS0xLTQ0MTc4_6756fdd3-e1e6-4ae8-aada-ab750e3a7b06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3cbdfb27cfb4debb4992b2d68d5cf26_I20220930" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV83LTQtMS0xLTQ0MTc4_24593e34-4d39-4c6c-b2c7-818954255a3c">3,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6c152af63d4a498aafc8fa69bf4bca_I20220930" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV83LTYtMS0xLTQ0MTc4_cd5caf08-447a-4f8a-be2d-3717b5bd4058">3,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Right-of-Use Assets and Property, Plant and Equipment</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2022 Restructuring Plan, we have consolidated our San Francisco operations in our Mission Bay Facility, and we have vacated our Third St. Facility and certain laboratory and office spaces at our Mission Bay Facility. We are seeking to sublease the vacated spaces, while still maintaining sufficient office and laboratory space to allow our team to develop our proprietary programs. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these plans, we reviewed each of our vacated spaces for impairment as of May 31, 2022, when management had determined which spaces we would seek to sublease, and subsequently at each reporting date or as facts and circumstances changed. As part of our impairment evaluation of each vacated space, we separately compared the estimated undiscounted income to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily leasehold improvements (collectively, sublease assets). We estimated sublease income using market participant assumptions, including the length of time to enter into a sublease and sublease payments, which we evaluated using sublease negotiations or agreements when applicable, current real estate trends and market conditions. If such income exceeded the net book value of the related assets, we did not record an impairment charge. Otherwise, we recorded an impairment charge by reducing the net book value of the assets to their estimated fair value, which we determined by discounting the estimated sublease cash flows using the estimated borrowing rate of a market participant subtenant, which we estimated to be <ix:nonFraction unitRef="number" contextRef="i36ac95832e534e18a6137ad8de7f1444_D20220531-20220531" decimals="3" name="nktr:OperatingLeaseMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTc2_4ce5c355-8571-49b9-a6c2-9650b68ddc20">6.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i809049297a1d4491a7387259a291ce70_D20221231-20221231" decimals="3" name="nktr:OperatingLeaseMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTgy_c4d2abb8-451c-478f-8d3a-f51a150cb575">7.9</ix:nonFraction>% as of May 31, 2022 and December 31, 2022, respectively. We recorded the substantial majority of our impairment charges as of May 31, 2022, primarily reflecting decreased rental recovery rates for our office lease space on Third St. However, as the office lease market in San Francisco deteriorated after May 31, 2022 in the fourth quarter of 2022, we recorded an additional impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i948d3d10847d41cbaa8d5e99b9e0ca18_D20221001-20221231" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTg4_8fc851d8-71f4-4cfb-a00c-ea56abcce5a3">12.0</ix:nonFraction>&#160;million in the three months ended December 31, 2022, for the Third St. Facility, reflecting an increase in our estimated time to enter into a sublease. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i5c8a5c0a50da4d27a916e70da66031c2"><ix:continuation id="ia42efbad7b414d329b85f34ed18fa3ae"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded impairment charges as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of impaired sublease assets as of May 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678b972618854ccfa5f8b75959d9a207_I20220531" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8yLTEtMS0xLTQ0MjIw_49e11a1e-2661-45e4-adc8-48c3cf06b9fc">72,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44bbfe0cc7fd4079a8fc3d2aa0c332c7_I20220531" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8yLTMtMS0xLTQ0MjIw_2752b62a-59ab-4bcc-b0d9-deb84defd994">16,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c9135dab8146c78e84573062004417_I20220531" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8yLTUtMS0xLTQ0MjIw_0f0973db-9d42-4ff6-a2c9-6e0c6c2bbb2b">88,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Fair value of impaired sublease assets &#8212; Level 3 of Fair Value Hierarchy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97e18421949d4c96bbefcd9f889dee65_I20221231" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8zLTEtMS0xLTQ0MjIw_d540414d-55d2-4aa0-8db9-2a170ae35e3b">16,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21602aeba0af4306b9db2ff5a747c939_I20221231" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8zLTMtMS0xLTQ0MjIw_57c827aa-603d-4890-9cf1-02b6fbc8887a">4,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cf06f89dab34bc49d9056719d6cf796_I20221231" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8zLTUtMS0xLTQ0MjIw_912c9cd1-0121-49b7-9aa4-eea2706dfe1c">20,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Book value in excess of fair value</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43d66fd88c34d01b4ff0cd1a46695cd_D20220601-20221231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl80LTEtMS0xLTQ0MjIw_d60480e3-8f72-4266-83da-b1b75b4aa801">56,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedb361025fe4dc4be9515a9ddc5cd78_D20220601-20221231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl80LTMtMS0xLTQ0MjIw_3963fa9b-b3c0-465c-b961-cd0e231c0477">11,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4cee9d0d7e4f278ad6b604a58efaa1_D20220601-20221231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl80LTUtMS0xLTQ0MjIw_aec45a3e-f812-48fc-a7c7-5a33db2a3e3c">67,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43d66fd88c34d01b4ff0cd1a46695cd_D20220601-20221231" decimals="-3" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl81LTEtMS0xLTQ0MjIw_1fe08e95-29f9-4534-adf4-f38c67733075">1,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedb361025fe4dc4be9515a9ddc5cd78_D20220601-20221231" decimals="-3" name="us-gaap:AdjustmentForAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl81LTMtMS0xLTQ0MjIw_76fea340-bd15-4cd8-84da-d95b2a56ff3d">397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4cee9d0d7e4f278ad6b604a58efaa1_D20220601-20221231" decimals="-3" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl81LTUtMS0xLTQ0MjIw_f6382c41-79e8-4797-bc0d-64ab329fbd24">2,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total impairment of sublease assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428577ef84824447b2265e91b8e6ca13_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl82LTEtMS0xLTQ0MjIw_946fce7e-92f3-49de-abcd-5fdaa48633ee">54,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ef1164091d46e7b57ab43df8707987_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl82LTMtMS0xLTQ0MjIw_07fae03f-7ac6-49ad-98d7-aeea732d0c78">11,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl82LTUtMS0xLTQ0MjIw_51b1560b-032a-4778-9adc-c6bcdfb502e5">65,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may record adjustments to impairment expense in future periods as we enter into sublease agreements or update our estimates as additional information becomes available to us. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Sale or Disposal of Property, Plant and Equipment, Net</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2022 Restructuring Plan, we terminated all research and development activities at our owned facility in India, which we sold in December 2022. We also recognized losses including excess equipment, net of sale proceeds, and the disposal of software to support the commercialization of bempegaldesleukin. <ix:continuation id="ie46e9cd2272043ce86aef6762f70f40d" continuedAt="ie3fe0b96ec0a4a66a1259ca89ffb888b">We recorded the gains and losses as follows (in thousands):</ix:continuation></span></div><div style="margin-top:9pt"><ix:continuation id="ie3fe0b96ec0a4a66a1259ca89ffb888b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8a6dd98aab4d3dbbc732084af7018f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6OGE1OTI5N2YyMmE1NGE0MWFiNTllYzVhMWZiMWVhMzMvdGFibGVyYW5nZTo4YTU5Mjk3ZjIyYTU0YTQxYWI1OWVjNWExZmIxZWEzM18yLTYtMS0xLTQ0MjM2_3f0a66da-5a7a-4fd3-9f5f-2daebdb87d66">13,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4effa18ad3427aa1e582fbe34e43d1_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6OGE1OTI5N2YyMmE1NGE0MWFiNTllYzVhMWZiMWVhMzMvdGFibGVyYW5nZTo4YTU5Mjk3ZjIyYTU0YTQxYWI1OWVjNWExZmIxZWEzM18zLTYtMS0xLTQ0MjM2_e2d5c411-ed2f-49ff-984a-63fa95125ecb">9,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total (gain) loss on sale or disposal of property, plan and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac8a6dd98aab4d3dbbc732084af7018f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6OGE1OTI5N2YyMmE1NGE0MWFiNTllYzVhMWZiMWVhMzMvdGFibGVyYW5nZTo4YTU5Mjk3ZjIyYTU0YTQxYWI1OWVjNWExZmIxZWEzM180LTYtMS0xLTQ0MjM2_19b1521d-3e61-4167-a0d8-9983e0965758">3,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i58bfbcf8a2404a36aa337c3511f6d52d_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12 &#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwODI_5080252d-25b9-4992-b633-0196498387e9" continuedAt="i417f2d84aa4542a8a93599d7c84b2f14" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i417f2d84aa4542a8a93599d7c84b2f14" continuedAt="i2ece277033da4cfc81052fd768808aff"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> 2017 Performance Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our 2017 Performance Incentive Plan (2017 Plan) provides for the issuance of our common stock to members of the Board of Directors, officers or employees, certain consultants and advisors and our subsidiaries. Our 2017 Plan has been amended and restated such that an aggregate <ix:nonFraction unitRef="shares" contextRef="i7a12065b592f45eb91672b4c2ecfc993_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzM1MQ_37c24788-3fed-47db-9516-fe4eb93e841f">39,200,000</ix:nonFraction> shares have been authorized for issuance as of December&#160;31, 2022, including <ix:nonFraction unitRef="shares" contextRef="if6b03bb908cf46a1975c75a41487f342_I20220608" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzQxNQ_828d130d-570b-48b2-ad57-778e430ffe13">5,000,000</ix:nonFraction> shares that were approved on June 8, 2022. Under the 2017 Plan, we may issue stock options, restricted stock, performance stock, stock units, stock appreciation rights and other similar types of awards. When the 2017 Plan was approved on June&#160;14, 2017, any shares of our common stock that were available for issuance under our 2012 Performance Incentive Plan (the 2012 Plan) ceased to be available for future grants. However, options and RSUs granted under the 2012 Plan remained outstanding, and any options or RSUs that were cancelled or forfeited became available for issuance under the 2017 Plan. Shares issued for RSUs, PSUs or any other &#8220;full-value award&#8221; are counted against the share limit as <ix:nonFraction unitRef="number" contextRef="i7a12065b592f45eb91672b4c2ecfc993_I20221231" decimals="INF" name="nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzExMjQ_da4c5cf3-9548-4e13-9bb4-b88c23f663a2">1.5</ix:nonFraction> shares for every one share granted in connection with the award. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted non-qualified stock options, RSUs and PSUs to employees, officers, and non-employee directors. For our employees, the requisite service period is generally <ix:nonNumeric contextRef="i63c718ae96904cc5b999aca6b38e6acc_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEzODM_5c3094a5-4246-48f0-a0a7-62b13a51948c">four years</ix:nonNumeric> for stock options, and <ix:nonNumeric contextRef="i14542c4fb8594026a9f1f2689a366572_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzE0MDk_57621f1f-d226-467f-b672-68f0cc2f95a5">three years</ix:nonNumeric> for RSUs and PSUs. For our directors, the requisite service is generally <ix:nonNumeric contextRef="i2c9ec41962e341438be60878bcaa9e09_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzE0ODU_08b522b1-8809-4af9-ac96-02370d889027">one year</ix:nonNumeric> for stock options and RSUs. The maximum term of a stock option is <ix:nonNumeric contextRef="i6fa5c4f56ceb45109dc0bac18906c879_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzE1ODI_ffcbb713-ab5e-4362-9b14-19e1de83b5e8">eight years</ix:nonNumeric> from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of our common stock on the NASDAQ Stock Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Change in Control Plan (the CIC Plan), in the event of a change of control of Nektar and a subsequent termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) within <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:ChangeInControlSeverancePaymentPeriodForExecutives" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzIwMTg_cfffe240-2b21-41b8-bfec-ec055407cf2c">twelve months</ix:nonNumeric> following a change of control, our employees are entitled to full acceleration of their unvested equity awards. Our Chief Executive Officer, Senior Vice Presidents and Vice Presidents (including Principal Fellows) are also entitled to full acceleration of unvested equity awards if the termination is initiated by the employee for a Good Reason Resignation (as </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i2ece277033da4cfc81052fd768808aff" continuedAt="i41bb9aa8e0f64c9bbb9f2d32a3d0eafc"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defined in the CIC Plan) within <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:ChangeInControlSeverancePaymentPeriodForExecutives" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzI0MTQ_cfffe240-2b21-41b8-bfec-ec055407cf2c">twelve months</ix:nonNumeric> following a change of control. Additionally, non-employee directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the terms of our Employee Stock Purchase Plan (ESPP), employees may purchase shares of our common stock based on a percentage of their compensation subject to certain limits. Shares are purchased at <ix:nonFraction unitRef="number" contextRef="i20e80ebc90964b95852b0af70c1a0bed_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzI4NjA_0908f056-1f53-4ab1-9fd8-9f432e84e9e4">85</ix:nonFraction>% of the lower of the closing price on either the first day or last day of each <ix:nonNumeric contextRef="i2e36b8afe0164eeca7a3f8aee4dc3069_D20220101-20221231" name="nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU0OTc1NTgyMDk2NQ_3eeb3da2-c770-4439-9de6-5a0048a52df4">six-month</ix:nonNumeric> offering period. An aggregate <ix:nonFraction unitRef="shares" contextRef="ided66bf243294649aa10f28f877a38bd_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzI5ODE_ddac291f-b4f0-4faa-a2c7-409ab2f67dd4">3,500,000</ix:nonFraction> shares have been authorized for issuance under our ESPP.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwODQ_96951b49-a585-4725-9f7b-4eccd1f58f95" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1da4578eb344c37a4ac66d8094312cb_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzItMS0xLTEtMzk4MzY_95d43f3a-265b-41f1-9c3f-7fed0e5455fc">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833b94c48c5d400b9f223dd465244748_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzItMy0xLTEtMzk4MzY_b7ae35c6-ec4c-47ec-9542-df214dbce0b2">2,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb540e2259a4eb5ba670a48eb66248a_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzItNS0xLTEtMzk4MzY_0aab2c14-7c60-4fad-85cc-1811a340c7da">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c7e882eb974894b44df7c39cfa9ea3_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzMtMS0xLTEtMzk4MzY_2b8186a8-cc1c-48a3-a001-70e670fa0ddb">27,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13a72164f93445d97d6df5a196ca7b5_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzMtMy0xLTEtMzk4MzY_f99250b3-41ac-4116-b2cd-1f0709a412bf">54,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6627c3421cb942dfafa0a03fa35c32f8_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzMtNS0xLTEtMzk4MzY_64f338ee-94c4-4f45-b26a-155675295399">57,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f55b5dda92449f87631aec26801a47_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzQtMS0xLTEtMzk4MzY_3c56876d-7d4e-4af5-ae21-8575e2f9c04e">24,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b60fd0890f4d5ea688cd88f60c0fdc_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzQtMy0xLTEtMzk4MzY_d5c2b97e-4d1b-4bd2-b78b-d8c97b87ca4b">37,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3928dcd65fad4307afa1ad19230facf4_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzQtNS0xLTEtMzk4MzY_7741fb08-fb58-420b-86ec-5a8f9d240757">33,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c5c0679b2b4b999749ec226dd1c85a_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzUtMS0xLTEtMzk4MzY_5750c5ab-63bb-451b-bb0d-f0d650d89004">2,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3119b6ee8f3b4dde9cd9450833493c0f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzUtMy0xLTEtMzk4MzY_ea7b0077-cdda-41e2-8e64-82290cdd6d1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05810fa0da244bacbdcde63b4b7a095b_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzUtNS0xLTEtMzk4MzY_a4de06b3-1e86-402b-82e0-28af41462013">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzYtMS0xLTEtMzk4MzY_a8a5c88f-e6f3-4b25-ad37-e1db6d71b2a9">57,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzYtMy0xLTEtMzk4MzY_1971ffe7-0751-4307-9b1f-6fc3ca49aaba">94,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzYtNS0xLTEtMzk4MzY_b9e2d3d9-a090-4489-bbf5-37fe0e4b9718">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation expense resulting from PSUs and our ESPP was not significant in the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation costs of $<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzM1NjI_fca465e2-8104-4dee-a2b3-b83599c6a3bb">83.1</ix:nonFraction> million related to unvested stock-based compensation awards are expected to be recognized as expense over a weighted-average period of <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwNzY_713d6f38-6dc7-4dbf-80f6-e7343d3ad141">2.3</ix:nonNumeric> years.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Black-Scholes Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:continuation id="ie1f6e646269d4d6aba985eef78a8449e" continuedAt="ie71a6e50071b49c59754366f810db588">The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:</ix:continuation></span><ix:continuation id="ie71a6e50071b49c59754366f810db588"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzItMS0xLTEtMzk4MzY_73f86674-c239-45fd-88c5-27d6cd65c3a8">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzItMy0xLTEtMzk4MzY_80c56b98-8cf3-48f2-9927-6649028cbdef">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzItNS0xLTEtMzk4MzY_5c26cdd3-4044-45b8-82db-9b7dbf60a0bd">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzMtMS0xLTEtMzk4MzY_78c02e04-971a-4df9-882c-97a0e3ae1701">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzMtMy0xLTEtMzk4MzY_86534731-c8df-4204-814e-f13044e98003">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzMtNS0xLTEtMzk4MzY_dab75ed8-cc87-405c-a77c-bb6d16fd436c">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzQtMS0xLTEtMzk4MzY_c5289d14-8e73-41fd-b13d-431c172d3384">77.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzQtMy0xLTEtMzk4MzY_21a1057f-b7bc-446b-b60a-5d5dc049dd51">63.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzQtNS0xLTEtMzk4MzY_598a8a69-d9df-4973-b1d4-a4e7bbbbc790">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzUtMS0xLTEtMzk4MzY_46697d35-efa9-47cf-be15-b4990f6e9b49">5.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzUtMy0xLTEtMzk4MzY_b6d236a8-6c03-47d0-ae0d-8622ec4564a8">5.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzUtNS0xLTEtMzk4MzY_ee8147ba-a084-4fc6-b576-aa53f5724069">5.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzYtMS0xLTEtMzk4MzY_f36737bd-08e7-4346-b0ed-195cf2efdfb4">3.18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzYtMy0xLTEtMzk4MzY_b56aae3c-77ce-47f6-9c53-6a4f185cf177">8.07</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzYtNS0xLTEtMzk4MzY_72114415-9074-4b04-9a90-0117618a6ea3">10.70</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The average risk-free interest rate is based on the U.S.&#160;treasury yield curve in effect at the time of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of <ix:nonFraction unitRef="number" contextRef="if1708b7bc3884af6be169aa6e4bd9ee9_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzQyNDg_e271b62a-ff77-419e-a8f2-05e2676628a3">zero</ix:nonFraction>. Our estimate of expected volatility is based on the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. We estimated the weighted-average expected life based on the contractual and vesting terms of the stock options, as well as historical cancellation and exercise data.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i41bb9aa8e0f64c9bbb9f2d32a3d0eafc"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwODY_67b1a059-ff79-449a-8c11-8daaa47e2852" continuedAt="i607e6d196e6740509ae5dcb0bbc0e611" escape="true">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):</ix:nonNumeric></span><ix:continuation id="i607e6d196e6740509ae5dcb0bbc0e611" continuedAt="i828f501ec3534e75bbcef00a398bac30"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:51.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzEtMS0xLTEtMzk4MzY_f2bcb004-682b-4bda-94d3-6e32053b1030">13,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzEtMy0xLTEtMzk4MzY_9e0877b6-99de-4129-9951-57cf3e84e01a">23.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzItMS0xLTEtMzk4MzY_b16c096f-ee04-47e8-b07d-1e578fbb67e4">6,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzItMy0xLTEtMzk4MzY_e18763c9-f4bd-47f5-addc-f02174ffba11">4.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzMtMS0xLTEtMzk4MzY_a4722488-5722-4205-a91b-2315b657c632">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzMtMy0xLTEtMzk4MzY_eb256807-e001-4280-b546-7b2cff427514">12.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited &amp; canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzQtMS0xLTEtMzk4MzY_45c70ef6-961d-4651-a545-bd034b52550d">5,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzQtMy0xLTEtMzk4MzY_37cb1f61-441d-4831-a750-ed790450c8ca">20.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzUtMS0xLTEtMzk4MzY_765656f6-86a7-41ec-aeaa-feeb1ab04fbe">14,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzUtMy0xLTEtMzk4MzY_a00ee7f0-b824-413b-af56-08962d9f4f54">16.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzUtNS0xLTEtMzk4MzY_20696c2b-803f-4f74-8d6d-edf2f3de2c00">5.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzUtNy0xLTEtMzk4MzY_2e7f9a7e-75ad-4ca6-ad0f-8d2f9cc99ee6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzctMS0xLTEtMzk4MzY_53adc36a-2f94-4d51-a06f-f7d73b69d0cd">6,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzctMy0xLTEtMzk4MzY_eedeb8ac-7b75-4237-837a-100060c7983d">27.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzctNS0xLTEtMzk4MzY_16c6ed4d-ad8e-4c11-aac9-27629649919e">3.60</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzctNy0xLTEtMzk4MzY_43f6aec3-d3cf-4285-8362-c565c6a0078c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="i828f501ec3534e75bbcef00a398bac30" continuedAt="i381acf92b7644a0cbce88510e3a1f943">_______________________________________________________________</ix:continuation></span></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i381acf92b7644a0cbce88510e3a1f943" continuedAt="ibaf2f4b544b54ac4b46494568ca3a8db">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"><ix:continuation id="ibaf2f4b544b54ac4b46494568ca3a8db">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2022.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The intrinsic value of options exercised during the year ended December&#160;31, 2022 was not significant and totaled $<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0NTE1_368efa62-66b3-44f1-8122-b2a9ab05bfeb">17.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0NTIz_af1ddc08-17b2-48db-8632-1049e3589983">15.9</ix:nonFraction> million during the years ended December 31, 2021 and 2020, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of RSU Activity</span></div><div style="margin-top:12pt;text-indent:36pt"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwODA_6745fb06-c8f9-4135-8b7b-ed9e0ba40952" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU award activity is as follows (in thousands except for per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5f2ce65d9b74f5ab00210112601e860_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzEtMS0xLTEtMzk4MzY_4e111c5d-75ba-41dc-a48c-fe4e9d30e025">9,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5f2ce65d9b74f5ab00210112601e860_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzEtMy0xLTEtMzk4MzY_3540a835-b041-4234-97e7-032f7e7be60c">16.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzItMS0xLTEtMzk4MzY_f5f63aa3-f083-420d-a9bd-ec37c941d89c">7,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzItMy0xLTEtMzk4MzY_a09ac6f5-1a88-4c6a-a1e8-40c098f36ca2">4.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzMtMS0xLTEtMzk4MzY_82535a8a-b1e1-4529-a651-e2d6926be361">2,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzMtMy0xLTEtMzk4MzY_465f3e6d-9b69-486a-966f-4beda3c31982">17.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzQtMS0xLTEtMzk4MzY_193627c3-2712-41b8-8ffd-4968017c039f">5,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzQtMy0xLTEtMzk4MzY_d99d25be-7bb6-4f23-81df-0c18f7bad833">15.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61ca801a96804d5caed8be9bb6955df9_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzUtMS0xLTEtMzk4MzY_027dba58-1374-4328-9739-416f8e3a3350">9,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61ca801a96804d5caed8be9bb6955df9_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzUtMy0xLTEtMzk4MzY_1d5b7fbe-4023-4855-9e8a-b9e2b9cdf899">6.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair values of RSUs granted during the years ended December&#160;31, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzUzOTI_2c9d1b3b-090d-4126-817a-5e42a229b9f2">4.14</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="iec82e56d740a40949cb39ff40fc8cd9a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzUzOTY_3c4b32ba-2818-48a7-998f-da2dc1696e2a">14.68</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="id5277dcb595b47198bdeb0c40ae34d2c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU0MDM_fb39001f-1772-4972-8714-cbec259d54de">19.24</ix:nonFraction>, respectively. The fair value of RSU's that vested in the years ended December&#160;31, 2022, 2021 and 2020 totaled $<ix:nonFraction unitRef="usd" contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU1MDk_58b6110e-9e59-41f1-a81b-c87b55a008bd">17.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iec82e56d740a40949cb39ff40fc8cd9a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU1MTM_52644e40-9f09-40ef-b51a-efbd50233857">45.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id5277dcb595b47198bdeb0c40ae34d2c_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU1MjA_027815d0-149f-4ffc-8ae2-01cc79ab8c4b">33.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Retirement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of <ix:nonFraction unitRef="number" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU2Njk_4071d0f6-df48-4a54-8aac-91ff918a1f04">60</ix:nonFraction>% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2MzQ4MzM_e00375cf-7570-4d4f-8bca-e7d3fa2099b5">12,000</ix:nonFraction> per participant for the year ended December 31, 2022, and up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU5MDY_68a0ebd7-4f7c-4722-9bf4-09660feb68c0"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU5MDY_f8a2815a-42b3-4df3-b034-fd59ebc6468b">6,000</ix:nonFraction></ix:nonFraction> per participant for the years ended December 31, 2021 and 2020. For the years ended December&#160;31, 2022, 2021, and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0NzUz_1f56d7ad-18da-4ae1-9b68-a8fd67de33f6">2.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0NzY3_0b132a6f-a5e7-452a-80c1-4cce01fcdd74">3.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0Nzgx_a3edaca8-5929-44dc-ac52-8acca628c917">3.5</ix:nonFraction>&#160;million, respectively, of compensation expense in connection with our 401(k) retirement plan.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13&#160;&#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MzA_db3de166-2e57-46d4-9b99-9b2f9d4c701c" continuedAt="i853d2d2d67c3470dac30756271717729" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i853d2d2d67c3470dac30756271717729" continuedAt="id8cb7f20fe334f4c82c58e0e4d7cf091"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MjY_f26540b4-753e-4767-86a2-fcf208bc9d85" continuedAt="i40c19b8eb1f344edbedf6ea6bdfe5a9f" escape="true">Loss before provision for income taxes includes the following components (in thousands):</ix:nonNumeric></span><ix:continuation id="i40c19b8eb1f344edbedf6ea6bdfe5a9f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzItMS0xLTEtMzk4MzY_7154afc9-66be-4fac-a116-ad96b95052da">371,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzItMy0xLTEtMzk4MzY_c3a34e5c-3c1c-4c32-b5f8-a14dd8aeee45">524,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzItNS0xLTEtMzk4MzY_6b25227c-04b3-46f1-8695-77a8a4bf9eb5">445,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzMtMS0xLTEtMzk4MzY_18731e0d-1b7d-493e-863b-6aee6f236e6c">6,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzMtMy0xLTEtMzk4MzY_c5f9ea85-0283-4874-b498-ac1eff8abff7">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzMtNS0xLTEtMzk4MzY_3d52b9f5-fdfb-41e0-ba08-af7ac395412a">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzQtMS0xLTEtMzk4MzY_d254c984-7c8a-4ea3-bb80-48e40d37b7c7">364,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzQtMy0xLTEtMzk4MzY_d9284205-0b0f-48e8-ba4f-4faa58cfbd35">523,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzQtNS0xLTEtMzk4MzY_e4c07542-65d2-45f7-81aa-a798495697e5">443,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MzE_fc5b1633-9ecb-42fc-be83-c4a0e864b894" continuedAt="idd49055a5e0d4401b0b94ffa76ed333d" escape="true">The provision for income taxes consists of the following (in thousands):</ix:nonNumeric></span><ix:continuation id="idd49055a5e0d4401b0b94ffa76ed333d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzMtMS0xLTEtMzk4MzY_a4995c27-beaf-4115-b9d5-f61e0f3d77db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzMtMy0xLTEtMzk4MzY_71450a8a-3a5c-4c4a-898a-135040ac294e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzMtNS0xLTEtMzk4MzY_d6bd38ad-9075-44d6-900a-9c39c19f0e2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzQtMS0xLTEtMzk4MzY_0423f71e-40d5-4296-9c71-6bda3a1400c9">608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzQtMy0xLTEtMzk4MzY_a32074d1-d23e-4ad8-97d7-e59f7c57a01c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzQtNS0xLTEtMzk4MzY_9bd08e43-fc7f-430d-b305-d7d7b9b8f6bf">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzUtMS0xLTEtMzk4MzY_fdb026a9-f669-4aa1-9f00-f0d4bad76d54">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzUtMy0xLTEtMzk4MzY_922428a6-15fb-4fc7-bd33-cf58abb3b254">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzUtNS0xLTEtMzk4MzY_577401fd-9104-4efc-8ae9-ba4d1f4d4a35">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzYtMS0xLTEtMzk4MzY_7c00ef14-1321-4813-af9a-024548e7549a">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzYtMy0xLTEtMzk4MzY_8ed7c2a2-9bfb-409d-8977-ad910049e25f">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzYtNS0xLTEtMzk4MzY_0d5869be-6ecc-4fef-be2d-d12679b9f886">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzgtMS0xLTEtMzk4MzY_340a7a6f-a341-4896-bb46-467f64a48253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzgtMy0xLTEtMzk4MzY_278391a4-33c2-4146-8d6a-1d47420fc2ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzgtNS0xLTEtMzk4MzY_78b6d51c-86e3-4966-a47d-5abfdaf6d78b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzktMS0xLTEtMzk4MzY_95e0d70e-3907-4df7-8d39-1a7291bee3fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzktMy0xLTEtMzk4MzY_ee98e130-4ac0-4014-b24d-e1d4cb81a884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzktNS0xLTEtMzk4MzY_7c892447-bc69-4f74-94c1-afa80f04de04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEwLTEtMS0xLTM5ODM2_1fddc00c-bc88-4755-8352-7429f8d686a0">2,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEwLTMtMS0xLTM5ODM2_2f415dc9-6942-4f79-904d-c6bd9ba80098">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEwLTUtMS0xLTM5ODM2_6e3e64cd-52ac-4237-abee-627f729330c8">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzExLTEtMS0xLTM5ODM2_579f0f0b-a33c-49a6-8d97-8e6a57706eaf">2,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzExLTMtMS0xLTM5ODM2_3ad597de-8c2f-4bd0-9835-f0b0606c0804">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzExLTUtMS0xLTM5ODM2_fd7ab200-7275-4d50-a848-c3385ca28310">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEyLTEtMS0xLTM5ODM2_8f79ecb3-c793-48de-8080-11d68f9bcf04">3,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEyLTMtMS0xLTM5ODM2_4418d0b4-db1e-46f2-bbc2-0d6eca7757df">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEyLTUtMS0xLTM5ODM2_5223660d-1a35-46f4-aada-3ebae2ba54ba">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5Mjc_e668577b-0780-4d2b-b049-812f91f699b2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzItMS0xLTEtMzk4MzY_39a1950e-b946-4bf9-8e63-02e02dcd24ef">76,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzItMy0xLTEtMzk4MzY_3897d24d-36b5-46b0-92ee-564db3a96074">109,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzItNS0xLTEtMzk4MzY_4160ab57-f059-43c8-a438-6e02f94bcdeb">93,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzMtMS0xLTEtMzk4MzY_83aa14e7-8aa8-47ee-90a8-016c646442f6">987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzMtMy0xLTEtMzk4MzY_84d50bcb-75a8-4f53-9847-dc657ec649fb">4,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzMtNS0xLTEtMzk4MzY_6314140e-3a28-4418-9cad-2207b103750d">3,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzQtMS0xLTEtMzk4MzY_f81649a1-5c9d-40ef-8761-0a9ec07d6ee9">51,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzQtMy0xLTEtMzk4MzY_638fd3d5-e0b0-4461-beff-5905db2734b8">97,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzQtNS0xLTEtMzk4MzY_7a2815a5-b820-4716-9711-754c72fc090b">87,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtMS0xLTEtNDcxNTg_46385de5-1950-40b3-acc7-a47ddb309e5c">12,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtMy0xLTEtNDcxNTg_6554162d-3a19-4569-bba2-342ed4d7bb74">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtNS0xLTEtNDcxNTg_9c5db167-8d4d-474f-9af1-e1498f17bab7">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtMS0xLTEtNDcxNTg_f505ac67-181b-4632-ba9a-9d46bed79b4c">15,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtMy0xLTEtNDcxNTg_57943893-c8a4-4d85-ae63-0821e863a68f">6,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtNS0xLTEtNDcxNTg_2e2ff5fa-d86b-472d-a9c6-3562ad82641a">7,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtMS0xLTEtMzk4MzY_b5cba60e-6759-4910-91a4-3cc5bd5f1b31">6,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtMy0xLTEtMzk4MzY_690b7d34-ed69-442a-b471-246204488f23">9,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtNS0xLTEtMzk4MzY_42fcce2f-ff1a-4677-b61c-f73cd9cc15c1">6,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" sign="-" name="nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtMS0xLTEtMzk4MzY_e5d15e61-d50a-48ce-9b4c-6c24e7b662ad">7,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" sign="-" name="nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtMy0xLTEtMzk4MzY_d25eeb95-7d99-4165-94a3-c7abe4639165">7,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" sign="-" name="nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtNS0xLTEtMzk4MzY_d213db69-08c8-4b72-ac1c-582a643967e8">7,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzctMS0xLTEtMzk4MzY_88ce5f6b-9ff2-498e-9319-5f28405860b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzctMy0xLTEtMzk4MzY_a87f052f-1942-4a80-b99c-fb30ccc5777c">4,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzctNS0xLTEtMzk4MzY_a148dee1-8fa2-4ebf-bfb1-f6e9c96402db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzktMS0xLTEtMzk4MzY_675ee62b-94f1-4746-b7d7-24e5cfd1b9df">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzktMy0xLTEtMzk4MzY_cb90619c-efdf-4e94-9a3f-493412d187dd">3,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzktNS0xLTEtMzk4MzY_5d78a2bf-21f6-4d89-8230-bdea2cd6c79e">3,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzEwLTEtMS0xLTM5ODM2_fc7f2b22-a691-49e0-8e23-73fc1e899dc8">3,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzEwLTMtMS0xLTM5ODM2_442b0cea-c2ae-4bde-b9ed-6841df10c6a5">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzEwLTUtMS0xLTM5ODM2_972f737e-b5e5-4763-823c-d3ec69d67302">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="id8cb7f20fe334f4c82c58e0e4d7cf091" continuedAt="i01146d50f6d74af0b65b2e81a066ba01"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets and Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MzQ_709c506b-8e96-474d-bf6a-44bf700a37d0" continuedAt="i6b33cc80a8b04a508f7d34f3bebbcdc8" escape="true">We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i6b33cc80a8b04a508f7d34f3bebbcdc8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzMtMS0xLTEtMzk4MzY_e81afa93-8aa2-442b-b685-696057896154">545,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzMtMy0xLTEtMzk4MzY_7c64b2a8-0f86-4b6d-975e-c44d6718b2eb">564,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzQtMS0xLTEtMzk4MzY_2a318e66-9b15-403c-8d77-482112b6d004">142,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzQtMy0xLTEtMzk4MzY_754b835a-cb25-4f58-a15b-c487223372d6">139,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzUtMS0xLTEtNDgxNTE_e536914b-df4a-439b-96dd-5298d51d8faf">38,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzUtMy0xLTEtNDgxNTE_877a525d-d57f-456a-85c4-50a42beafd4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzUtMS0xLTEtMzk4MzY_00d171eb-0462-468e-8182-a37c4d6c0255">28,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="nktr:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzUtMy0xLTEtMzk4MzY_d529d670-9ba8-4728-a0ed-ff4789a29ef9">34,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzYtMS0xLTEtMzk4MzY_1b182b78-8a1d-488d-b2d7-616cfc09ca4d">22,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzYtMy0xLTEtMzk4MzY_95599523-45d1-443b-9a8d-51eb08eb0171">33,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzctMS0xLTEtNDcxNjM_f41348e7-2aab-48b2-802d-97d241e51d17">24,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzctMy0xLTEtNDcxNjM_737cf12f-0b44-489a-86a6-c9bc0e923b24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzctMS0xLTEtMzk4MzY_5e6c35b5-cf90-4dd1-9e57-16bb91288ac7">13,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzctMy0xLTEtMzk4MzY_16f52b4a-9d29-4623-befa-a6a6944943eb">23,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzktMS0xLTEtMzk4MzY_75879d48-e355-41ce-b945-d700e61c8e09">13,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzktMy0xLTEtMzk4MzY_5a73c2d0-21d8-4e94-a29e-3f4178927f4b">17,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzEwLTEtMS0xLTM5ODM2_ccc25559-836a-4e19-93d9-210862505021">828,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzEwLTMtMS0xLTM5ODM2_c5d15fc4-1274-469b-8bb3-c8cb4a3fcf25">813,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzExLTEtMS0xLTM5ODM2_119da61c-fe5d-4de2-a84a-5e959d62971b">816,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzExLTMtMS0xLTM5ODM2_be0d9c36-a691-4718-a048-fc2c926cbd3e">785,748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzEyLTEtMS0xLTM5ODM2_c982452b-0e1d-4000-ace2-345dfd165eea">11,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzEyLTMtMS0xLTM5ODM2_228f24e8-fa60-4c08-9df9-5b9ba4a9f2b6">28,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE0LTEtMS0xLTM5ODM2_397a3463-920d-424f-982e-1b92e52bbc44">11,335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE0LTMtMS0xLTM5ODM2_0b28db18-fba1-45cf-9425-2a4711aa9cf7">27,204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in foreign subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE1LTEtMS0xLTQ3MTYz_15c380a4-1e42-4517-81ca-e5f07796deea">2,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE1LTMtMS0xLTQ3MTYz_2380fe92-399b-4239-a69c-cbac8d77f136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE1LTEtMS0xLTM5ODM2_1b369dbf-8ff8-4c73-8088-76d234bce1a9">392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE1LTMtMS0xLTM5ODM2_2f2b75a0-698b-443c-9d88-2761c2862851">564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE2LTEtMS0xLTM5ODM2_dedf42b7-9ba7-4901-984c-97d6ff1a4da0">14,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE2LTMtMS0xLTM5ODM2_7a1cf679-bdfc-4f1a-8fb9-48499e2260dc">27,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE3LTEtMS0xLTM5ODM2_2db2d1c0-486b-4a81-939c-3fbdf8fa6430">2,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE3LTMtMS0xLTM5ODM2_1e3e3a01-9020-40c0-b50f-1cb69c494b52">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S.&#160;earnings history, other than income resulting from revenue recognized from the BMS Collaboration Agreement, and projected future losses, we have fully reserved our net U.S.&#160;deferred tax assets with a valuation allowance. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MjgxNzU2_1bf83982-fe7f-4134-b0df-a270404e7dcd">30.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MjgxNzIy_0baceffa-07db-4dc9-a20a-06d5d29260e9">115.6</ix:nonFraction>&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net deferred tax liability position reflects the provision for the withholding taxes associated with the repatriation of accumulated earnings and profits from India.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Operating Loss and Tax Credit Carryforwards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, we had a net operating loss carryforward for federal income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="i1aa7a7c1e8844691b326d42966bf4551_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MjgxNzg4_11661ff3-28f6-4532-8a45-62c3fbf089c3">2.4</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-8" name="nktr:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MzIyMzk_5ae7e4a8-ad9d-46f7-9584-80a153323d45">1.3</ix:nonFraction>&#160;billion is subject to expiration beginning in 2023 and a total state net operating loss carryforward of approximately $<ix:nonFraction unitRef="usd" contextRef="ia0beac0b0ae64d58915ff881a46e62b6_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MjgxODE3_12dbc96e-e298-4f62-a912-f98acb5aa29a">0.7</ix:nonFraction>&#160;billion, portions of which will begin to expire in 2027. We have federal tax credits of approximately $<ix:nonFraction unitRef="usd" contextRef="ie0201532ad324c8c9dbec3f1607c4d7b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzE5MTE_34f74fdb-662a-45f8-9001-7f43272cb159">123.8</ix:nonFraction>&#160;million, which will begin to expire in 2023 and state research credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i72308160e9054ecaaaa7ec0beb1ff284_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzE5OTQ_981a2bd4-2d8c-4bc7-940d-6270cb57af06">48.8</ix:nonFraction>&#160;million which have no expiration date. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><ix:continuation id="i01146d50f6d74af0b65b2e81a066ba01" continuedAt="i4c51efd985f44e069edcf501946df466"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized tax benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MzY_7ecc4201-877e-442c-879b-46d25d4f7d8a" continuedAt="ia44039f92d8c47cd9fbdf398c228c072" escape="true">We have the following activity relating to unrecognized tax benefits (in thousands):</ix:nonNumeric></span><ix:continuation id="ia44039f92d8c47cd9fbdf398c228c072"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzItMS0xLTEtMzk4MzY_5df4d4ea-bf50-4729-8ff1-214eba8275f0">80,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448f61765d3a4f728112443592038e8d_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzItMy0xLTEtMzk4MzY_c4abb8bb-d8c4-4dea-840e-cf085e41bf22">78,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f208c2b206d4f43af4e746f193bb362_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzItNS0xLTEtMzk4MzY_46ba8115-c091-4ccd-9b1e-7816795d4f46">77,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzQtMS0xLTEtMzk4MzY_739342f1-4fc4-4bb5-89b5-fc7f598f80e7">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzQtMy0xLTEtMzk4MzY_a54f2282-39ac-4304-a52d-0a825b4af67c">2,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzQtNS0xLTEtMzk4MzY_a0c9446d-8d83-4a5d-b37b-9e623203cd38">2,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzUtMS0xLTEtMzk4MzY_05753b09-afc2-4ef0-8489-6646c435d452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzUtMy0xLTEtMzk4MzY_9ed66aaa-4f09-440e-8386-99b60fb6e3cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzUtNS0xLTEtMzk4MzY_af0d9d0c-01c0-4db5-9612-fa992768d96d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzctMS0xLTEtMzk4MzY_c9a0cbed-d7b0-4b6c-a2a4-16642f119510">5,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzctMy0xLTEtMzk4MzY_5b644482-9270-461e-ae59-2f18a4a42a50">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzctNS0xLTEtMzk4MzY_14110b76-dda3-4d51-88e9-b14072548290">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzgtMS0xLTEtMzk4MzY_b1eeaf97-c29f-4d0f-b224-97f004a1f346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzgtMy0xLTEtMzk4MzY_8e6b7bc4-2ec7-4a51-b358-a87f881b012e">490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzgtNS0xLTEtMzk4MzY_7c605cee-b1cd-49fb-99b3-d4be0a5c3fd1">1,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzktMS0xLTEtMzk4MzY_951264a0-4068-465d-a55a-a992f891a358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzktMy0xLTEtMzk4MzY_34fea6dd-85d6-4c6e-a4b4-5239dbe7e85b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzktNS0xLTEtMzk4MzY_6d508038-3311-4cb4-b45d-7fa545dd16e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzEwLTEtMS0xLTM5ODM2_4f812ee1-fc2a-4349-b278-ff619e0f7535">409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzEwLTMtMS0xLTM5ODM2_c5b8778b-a2e4-41ca-98e6-b88a58a6dc87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzEwLTUtMS0xLTM5ODM2_9bea6827-bbab-4abf-8003-87b644dbaf5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzExLTEtMS0xLTM5ODM2_6fda73f4-249b-4482-9d44-c64f41513583">85,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzExLTMtMS0xLTM5ODM2_49b7ce90-fac7-430c-b668-89e6cc0d8821">80,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448f61765d3a4f728112443592038e8d_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzExLTUtMS0xLTM5ODM2_b19a74ee-d54c-4a3b-8a99-1db762b27a9d">78,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we are eventually able to recognize our uncertain tax positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Adjustments to the substantial majority of our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carryforwards rather than resulting in a cash outlay.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We file income tax returns in the U.S., California, Alabama, certain other states and India. As a result of our net operating loss and research credit carryforwards, substantially all of our domestic tax years remain open and subject to examination. We may be subject to examination in India from time to time, but we do not believe that any liability resulting from such an examination would have a material effect on our financial position or results of operations.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c51efd985f44e069edcf501946df466">Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. During the years ended December&#160;31, 2022, 2021 and 2020, <ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_1a444d3a-4d7f-4388-9f2a-98fb066379bf"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_365e6d47-8eed-4c86-b9a1-f353d05cd908"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_53e9cd54-6452-46c3-b8a1-8961c89662fd"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_658cfc3b-62e7-42c6-81bd-0596bee109e0"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_9e20fcbf-efab-4bfd-a23d-596042aeb4ee"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_a5db90be-ab8c-4e93-aa0f-dd9c716d6795">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> significant interest or penalties were recognized relating to unrecognized tax benefits. Although it is reasonably possible that certain unrecognized tax benefits could change in the future, we do not anticipate any significant changes over the next <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MjM_dfee5e05-b89e-4c45-966a-7bac21f7c827">twelve months</ix:nonNumeric>.</ix:continuation> </span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14&#160;&#8212; <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzE0ODY_4aa209d1-67eb-40e8-b433-3283711ed399" continuedAt="ie9c6bdecace8410988b552fc2e104847" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="ie9c6bdecace8410988b552fc2e104847" continuedAt="i57a7161254234a728ebc1d1943ee15b2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in <ix:nonFraction unitRef="segment" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="INF" name="nktr:NumberOfOperatingBusinessSegment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzQ4_f68fc394-238d-4660-90c3-47a192ce8ded">one</ix:nonFraction> business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as <ix:nonFraction unitRef="segment" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="INF" name="nktr:NumberOfOperatingBusinessSegment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzM5MQ_f68fc394-238d-4660-90c3-47a192ce8ded">one</ix:nonFraction> business segment by our Chief Executive Officer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from UCB Pharma, Baxalta / Takeda, AstraZeneca and Pfizer represented <ix:nonFraction unitRef="number" contextRef="i7bf92b2d15d544d6937956567cbd8076_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzkzNDU4NDg4MzgzNzg_2b521e93-343c-4536-9537-74a5ac2c92c7">37</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ifdc6254636f546a2a43ce040c6c6085e_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzkzNDU4NDg4MzgzODM_6b0a3509-ac03-42a8-b660-cae1f11094bd">25</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="iaa8e4e763a2449e0a04e0609515b8c63_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzkzNDU4NDg4MzgzODg_762d83e7-1c5c-480a-aaf6-df898e7c8c4d">14</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if00a63dfc4ab4080a7c7be10c52a4120_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzkzNDU4NDg4MzgzOTM_f7b0401a-7bd3-4e09-bd21-bd78837f808f">11</ix:nonFraction>% of our revenue, respectively, for the year ended December&#160;31, 2022. Revenue from UCB Pharma, Baxalta / Takeda, AstraZeneca and Pfizer represented <ix:nonFraction unitRef="number" contextRef="i5b3e0f8c46714fc9be46c65f8de72fe0_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzYyMw_9563c590-2d90-4ed8-82e0-811cc66f6828">36</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i8bd42991fff149128d3dc16bf7316b6f_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzYyNw_cbadd349-115d-43cb-bd3a-9a73ed1a224f">23</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="id07a9952dc4c450b824484980ebe8928_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzYzMQ_f2a8f376-d8b3-42d3-aae4-132b039cf046">16</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7daa5860832a47c08be4e2bbcc929c50_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzYzOA_3d92dbe1-d7a2-4791-83a7-5dc7c0287a36">13</ix:nonFraction>% of our revenue, respectively, for the year ended December&#160;31, 2021. Revenue from BMS, UCB Pharma, Baxalta / Takeda, and AstraZeneca represented <ix:nonFraction unitRef="number" contextRef="i56fc82462fb045c19add828b177099e9_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzc3MA_398eb9a2-c58c-4ffb-a86c-e7efbfb5289f">33</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ib462fc56afce4ed7b4b6728742f20fd7_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzc3NA_42c9e9d8-5d63-4050-8e80-6fc426618596">23</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i9d4868926af54225af1a855f5d4d34d9_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzc3OA_e880002d-c62b-4530-ac15-de4acf9a9b9a">14</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i14494e5a12494d72a7acb39246fa450e_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzc4NQ_f29970e8-f748-4945-8cbb-ebea79fb817a">13</ix:nonFraction>% of our revenue for the year-ended December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. <ix:nonNumeric contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzE0ODg_6ed9b451-bdf5-4bf7-a196-5f82f980ec7a" continuedAt="idc7210a656bb4cdc8591cbee2ec14d20" escape="true">The following table sets forth revenue by geographic area (in thousands):</ix:nonNumeric></span><ix:continuation id="idc7210a656bb4cdc8591cbee2ec14d20"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06754ac5c8fe4627adbc24980fd082b4_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzItMS0xLTEtMzk4MzY_dcb093ba-d943-40af-8b06-c579d7c914ff">9,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86844cf0f9cb4932bc6509504c7a663f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzItMy0xLTEtMzk4MzY_0e40a269-144d-4fab-916e-f5519e019032">10,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaecd4f6f9c444958b8f0e06d42b1c2aa_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzItNS0xLTEtMzk4MzY_3d95dcce-629b-42e9-90df-656b89de0f93">64,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of World</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e1f0e358824a6bbe3fb5fb2404dc19_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzMtMS0xLTEtMzk4MzY_11aca244-2193-4fa9-ba1d-0dd90a908efe">82,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057ece2c908047309cf984bb11af2ec4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzMtMy0xLTEtMzk4MzY_4affae16-37ca-4e85-8d0d-9e3533cb8304">91,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78596537cc1e4bba8d4c10682953227a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzMtNS0xLTEtMzk4MzY_ff2c6ccf-83b3-4da5-bed8-22f456f4d5a2">87,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzQtMS0xLTEtMzk4MzY_ca08d789-0c8c-4f9a-82f9-8a98e2376566">92,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzQtMy0xLTEtMzk4MzY_415c8f47-03b4-4746-a607-e46939aaafe2">101,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzQtNS0xLTEtMzk4MzY_2addc928-35bb-469f-8a68-1274a0c9da9e">152,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i57a7161254234a728ebc1d1943ee15b2">&#160;&#160;&#160;&#160;At December&#160;31, 2022, all of our property, plant and equipment was located in the United States. At December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i836074eda2e7444d9c8ad2e1bd97d05c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzEwOTk1MTE2MzAyMDg_addea9a3-4b4b-4623-b780-d9a4980c57fd">56.1</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="i54faac177aa94cc8a0cc84d3f8d86a9b_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzEwOTk1MTE2MzAyMjM_9f10be2d-1a2c-48c9-b0b6-6563ea8c044d">93</ix:nonFraction>%, of the net book value of our property, plant and equipment was located in the United States with the remainder in India.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_139"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule&#160;13a-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management has assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2022. In making its assessment of internal control over financial reporting, management used the criteria described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212; Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Based on our evaluation under the framework described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212; Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The effectiveness of our internal control over financial reporting as of December&#160;31, 2022 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report, which is included herein.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. There was no change in our internal control over financial reporting during the quarter ended December&#160;31, 2022, which was identified in connection with our management&#8217;s evaluation required by Exchange Act Rules&#160;13a-15(f) and 15d-15(f) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on the Effectiveness of Controls</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_151"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Officers and Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information relating to our executive officers required by this item is set forth in Part&#160;I&#160;&#8212; Item&#160;1 of this report under the caption &#8220;Information about our Executive Officers&#8221; and is incorporated herein by reference. The other information required by this Item is incorporated by reference from the definitive proxy statement for our 2020 Annual Meeting of Stockholders to be filed with the SEC pursuant to Regulation&#160;14A (Proxy Statement) not later than 120&#160;days after the end of the fiscal year covered by this Form&#160;10-K under the captions &#8220;Corporate Governance and Board of Directors,&#8221; &#8220;Proposal&#160;1&#160;&#8212; Election of Directors&#8221; and &#8220;Section&#160;16(a) Beneficial Ownership Reporting Compliance.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding our audit committee financial expert will be set forth in the Proxy Statement under the caption &#8220;Audit Committee,&#8221; which information is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a Code of Business Conduct and Ethics applicable to all employees, including the principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Business Conduct and Ethics is posted on our website at www.nektar.com. Amendments to, and waivers from, the Code of Business Conduct and Ethics that apply to any of these officers, or persons performing similar functions, and that relate to any element of the code of ethics definition enumerated in Item&#160;406(b) of Regulation&#160;S-K will be disclosed at the website address provided above and, to the extent required by applicable regulations, on a current report on Form&#160;8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As permitted by SEC Rule&#160;10b5-1, certain of our executive officers, directors and other employees have or may set up a predefined, structured stock trading program with their broker to sell our stock. The stock trading program allows a broker acting on behalf of the executive officer, director or other employee to trade our stock during blackout periods or while such executive officer, director or other employee may be aware of material, nonpublic information, if the trade is performed according to a pre-existing contract, instruction or plan that was established with the broker when such executive officer, director or employee was not aware of any material, nonpublic information.  Executive officers and directors can only sell our stock in accordance with our securities trading policy and pursuant to a stock trading program set up under Rule 10b5-1 (wherein &#8220;exercise and hold&#8221; and stock purchases are exempted, and sales outside such a program can proceed upon approval of the Nominating and Corporate Governance Committee of our Board of Directors.  Employees who are not executive officers may trade our stock outside of the stock trading programs set up under Rule&#160;10b5-1 subject to our securities trading policy.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_154"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_157"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_160"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions and Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_163"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principal Accountant Fees and Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_169"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;15.  Exhibits and Financial Statement Schedules</span></div><div style="padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.91pt">The following documents are filed as part of this report:</span></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Consolidated Financial Statements:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following financial statements are filed as part of this Annual Report on Form&#160;10-K under Item&#160;8 &#8220;Financial Statements and Supplementary Data.&#8221;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reports of Independent Registered Public Accounting Firm (PCAOB ID: 42)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_67">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets at December 31, 2022 and 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_70">62</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations for each of the three years in the period ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_73">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income (Loss) for each of the three years in the period ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_76">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_79">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_82">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i58bfbcf8a2404a36aa337c3511f6d52d_85">67</a></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:51.34pt">Financial Statement Schedules:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;All financial statement schedules have been omitted because they are not applicable, or the information required is presented in our consolidated financial statements and notes thereto under Item&#160;8 of this Annual Report on Form&#160;10-K.</span></div><div style="padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:51.34pt">Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Except as so indicated in Exhibit&#160;32.1, the following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form&#160;10-K.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">Certificate of Ownership and Merger of Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000121390022080498/ea170222ex3-1_nektartherap.htm">Amended and Restated Bylaws of Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to Exhibits&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">3.4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000121390020043821/ea132008ex3-1_nektartherap.htm">3.5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-4_1.htm">Specimen Common Stock certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415002842/s101972_ex10-2.htm">Indenture dated October 5, 2015 by and between Nektar Therapeutics and Wilmington Trust, National Association, and TC Lending, LLC including the form of 7.75% Senior Secured Note due 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4(28)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex44.htm">Description of Securities. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1(8)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex107.htm">Discretionary Incentive Compensation Policy++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2(8)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex108.htm">Amended and Restated Change of Control Severance Benefit Plan.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3(9)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415001516/s101346_ex10-1.htm">2012 Performance Incentive Plan.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4(10)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415003667/s102370_ex10-1.htm">Forms of Stock Option Agreement, Performance Stock Option Agreement, Restricted Stock Unit Agreement and Performance Restricted Stock Unit Agreement under the 2012 Performance Incentive Plan.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5(11)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670922000014/nktr2022-06x30xexx101ar201.htm#i7b0c4c07e114409f9b9c3f6a9592b777_1">Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670922000014/nktr2022-06x30xexx101ar201.htm#i7b0c4c07e114409f9b9c3f6a9592b777_1">, as amended</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670922000014/nktr2022-06x30xexx101ar201.htm#i7b0c4c07e114409f9b9c3f6a9592b777_1">.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6(12)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459019005639/nktr-ex109_7.htm">Forms of Stock Option Agreement, Performance Stock Option Agreement, Non-Employee Director Stock Option Agreement, Restricted Stock Unit Agreement, Performance Restricted Stock Unit Agreement, and Non-Employee Director Restricted Stock Unit Agreement under the Amended and Restated 2017 Performance Incentive Plan.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7(13)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000014/nktr-2020x06x30xexx102.htm">Employee Stock Purchase Plan, as amended and restated.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8(14)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000906709/000090670920000009/nktr2020-03x31ex101.htm">Amended and Restated Compensation Plan for Non-Employee Directors.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9(15)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000110465904022735/a04-8706_1ex10d4.htm">401(k) Retirement Plan.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10(16)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312507240872/dex104.htm">Form of Severance Letter for executive officers of the company.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w26.htm">Amended and Restated Letter Agreement, executed effective on December&#160;1, 2008, with Howard W. Robin.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w27.htm">Amended and Restated Letter Agreement, executed effective on December&#160;1, 2008, with John Nicholson.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13(17)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000095012311020657/f57959exv10w22.htm">Letter Agreement, executed effective on December&#160;10, 2009, with Stephen K. Doberstein,&#160;Ph.D.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14(28)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex1017.htm">Transition, Separation and General Release Agreement, dated as of January 9, 2020, by and between Stephen K. Doberstein and Nektar Therapeutics.  ++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15(19)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000090670919000010/nktr2019-09x30xexx101.htm">Separation, Consulting and General Release Agreement effective as of October 15, 2019, by and between Nektar Therapeutics and John Nicholson.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16(28)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex1019.htm">Employment Agreement effective as of December 4, 2019, by and between Nektar Therapeutics and John Northcott.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17(16)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312507240872/dex108.htm">Amended and Restated Built-to-Suit&#160;Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August&#160;17, 2004, as amended on January&#160;11, 2005 and July&#160;19, 2007.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18(18)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459017022445/nktr-ex102_237.htm">Lease Agreement dated August 4, 2017, as amended by the First Amendment to Lease dated as of August 29, 2017, by and between ARE-San Francisco No. 19, LLC and Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.19(20)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312506167850/dex102.htm">Settlement Agreement and General Release, dated June&#160;30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville, Nektar Therapeutics AL, Corporation (a wholly-owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w34.htm">Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated September&#160;26, 2005, as amended.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w35.htm">Exclusive License Agreement, dated December&#160;31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22(17)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000095012311020657/f57959exv10w31.htm">Supply, Dedicated Suite and Manufacturing Guarantee Agreement, dated October&#160;29, 2010, by and among Nektar Therapeutics, Amgen Inc. and Amgen Manufacturing, Limited.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.23(21)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420409056637/v164533_ex10-1.htm">License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September&#160;20, 2009.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24(22)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459016022647/nktr-ex101_193.htm">Collaboration and License Agreement dated as of May 30, 2016, by and between Daiichi Sankyo Europe GmbH and Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.25(18)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459017022445/nktr-ex101_179.htm">License Agreement effective as of August 23, 2017, by and between Eli Lilly and Company and Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.26(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415002842/s101972_ex10-1.htm">Purchase Agreement dated September 30, 2015 by and among Nektar Therapeutics and TC Lending, LLC and TAO Fund, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415002842/s101972_ex10-3.htm">Pledge and Security Agreement dated October 5, 2015 by and among Nektar Therapeutics and TC Lending, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.28(23)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512209441/d311622dex101.htm">Purchase and Sale Agreement, dated as of February 24, 2012, between Nektar Therapeutics and RPI Finance Trust.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29(24)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312513433110/d594595dex101.htm">Amendment No. 1 to License Agreement dated effective as of August 8, 2013, by and between Nektar Therapeutics and AstraZeneca AB.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.30(25)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459018012975/nktr-ex41_103.htm">Investor Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.31(25)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459018012975/nktr-ex101_104.htm">Strategic Collaboration Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000906709/000090670921000005/nktr20201231-exx1035.htm">Co-Development Agreement, dated as of February 12, 2021, by and between SFJ Pharmaceuticals XII, L.P. and Nektar Therapeutics.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.33(28)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191213ex1035.htm">Amendment No. 1 to Strategic Collaboration Agreement dated as of January 9, 2020, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.34(26)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312518044320/d499642dex101.htm">Share Purchase Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.35(27)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459018020709/nktr-ex101_86.htm">Office Lease, effective as of May 31, 2018, by and between Kilroy Realty Finance Partnership, L.P., and Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670921000005/nktr20201231-exx1039.htm">Purchase and Sale Agreement, dated December 16, 2020, by and between entities managed by Healthcare Royalty Management, LLC and Nektar Therapeutics.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37(30)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670922000005/nktr20211231-exx1040.htm">Amendment No. 2 to Strategic Collaboration Agreement dated as of January 12, 2022, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38(31)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670922000014/nktr2022-06x30xexx102north.htm">Employment Transition, Separation and Consultation Agreement, dated as of June 29, 2022, by and between Nektar Therapeutics and John Northcott.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1(32)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr20221231-exx211.htm">Subsidiaries of Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1(32)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr20221231-exx231.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_175">Power of Attorney (reference is made to the signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1(32)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr-20221231xexx311.htm">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2(32)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr-20221231xexx312.htm">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr-20221231xexx321.htm">Section&#160;1350 Certifications.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document. </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document. </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document. </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Label Linkbase Document. </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document. </span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101). </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Exhibit&#160;32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Inline XBRL information is filed herewith.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2008.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 1998.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2000.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on January&#160;23, 2003.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2009.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on December 16, 2022.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on October&#160;6, 2015.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2011.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form 8-K, filed on June&#160;17, 2015.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form 8-K filed on December&#160;17, 2015.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form 10-K for the year ended December 31, 2018.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2020.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the Quarter ended March 31, 2020.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30, 2007.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December 31, 2010.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2006.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2009.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2012.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form 8-K filed on February 14, 2018.&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2019.  </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(29)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2020. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(30)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2021. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(31)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(32)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:46.34pt">Filed herewith.</span></div><div style="padding-left:27pt;text-indent:-45pt"><span><br/></span></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;16. Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;28, 2023</span></div><div style="margin-top:12pt;text-align:right;text-indent:63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.233%"><tr><td style="width:1.0%"></td><td style="width:10.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEKTAR THERAPEUTICS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILLIAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HOMSEN</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Senior Vice President, Chief Financial Officer and Chief Accounting Officer</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i58bfbcf8a2404a36aa337c3511f6d52d_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i58bfbcf8a2404a36aa337c3511f6d52d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;KNOW ALL PERSON BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Howard W. Robin and Jillian B. Thomsen and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratify and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer, President and Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Howard W. Robin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ILLIAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> B. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">HOMSEN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Chief Financial Officer and Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jillian B. Thomsen</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OBERT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> B. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">HESS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, Chairman of the Board of Directors</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Robert B. Chess</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EFFREY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">JER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jeffrey R. Ajer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> M. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RAINARD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diana M. Brainard </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">YRIAM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> J. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">URET</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Myriam J. Curet</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ARIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ASTHAM</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Karin Eastham</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  R. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">REER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R. Scott Greer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A. W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">HITFIELD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Roy A. Whitfield</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>nktr20221231-exx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1d76f0318a254c06823d00e7509d34f2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 21.1</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Subsidiaries of Nektar Therapeutics</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">None. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>nktr20221231-exx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i209d871a5639404cb8124c33c9f0ead4_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.05pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Consent of Independent Registered Public Accounting Firm </font></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Registration Statement (Form S-8 No. 333-145259) pertaining to the 401(k) Retirement Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Registration Statement (Form S-8 No. 333-170371) pertaining to the Employee Stock Purchase Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Registration Statement (Form S-8 No. 333-183193) pertaining to the 2012 Performance Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4) Registration Statement (Form S-8 No. 333-197781) pertaining to the Employee Stock Purchase Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5) Registration Statement (Form S-8 No. 333-206136) pertaining to the 2012 Performance Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6) Registration Statement (Form S-8 No. 333-218777) pertaining to the 2017 Performance Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7) Registration Statement (Form S-8 No. 333-226004) pertaining to the Amended and Restated 2017 Performance Incentive Plan of Nektar Therapeutics, </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8) Registration Statement (Form S-8 No. 333-242327) pertaining to the Amended and Restated 2017 Performance Incentive Plan and Amended and Restated Employee Stock Purchase Plan of Nektar Therapeutics, </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9) Registration Statement (Form S-3 No. 333-254237) of Nektar Therapeutics, </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10) Registration Statement (Form S-8 No. 333-258900) pertaining to the Amended and Restated 2017 Performance Incentive Plan of Nektar Therapeutics, and</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11) Registration Statement (Form S-8 No. 333-266580) pertaining to the Amended and Restated 2017 Performance Incentive Plan of Nektar Therapeutics&#59; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of our reports dated February 28, 2023, with respect to the consolidated financial statements of Nektar Therapeutics and the effectiveness of internal control over financial reporting of Nektar Therapeutics included in this Annual Report (Form 10-K) of Nektar Therapeutics for the year ended December 31, 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">San Mateo, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">February 28, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>nktr-20221231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4841de96a6c14cdc9b287f55174a6145_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Howard W. Robin, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December&#160;31, 2022&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;28, 2023</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td></tr></table></div><div style="margin-top:6pt;text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>nktr-20221231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5dc570dbc4e04767945be7b3c165941f_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I, Jillian B. Thomsen, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December&#160;31, 2022&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;28, 2023</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILLIAN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HOMSEN</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Chief Financial Officer and Chief Accounting Officer</font></td></tr></table></div><div style="margin-top:6pt;text-align:right;text-indent:45pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>nktr-20221231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8c0ba36afa2b48a684b0db82d7517208_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS*</font></div><div style="margin-top:12pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Jillian B. Thomsen, Senior Vice President, Chief Financial Officer and Chief Accounting Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:10pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Annual Report on Form 10-K, for the year ended December&#160;31, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Annual Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;28, 2023</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILLIAN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HOMSEN</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Chief Financial Officer and Chief Accounting Officer</font></td></tr></table></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification accompanies the Annual Report on Form 10-K, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nktr-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6319d4c-7e41-446e-a208-11c24c30fce3,g:5a9b6e6c-7a94-44cb-81e7-2ed70e787342-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.nektar.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.nektar.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical">
        <link:definition>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecurities" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities">
        <link:definition>0000011 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.nektar.com/role/Inventory">
        <link:definition>0000012 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.nektar.com/role/PropertyPlantandEquipment">
        <link:definition>0000013 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.nektar.com/role/OperatingLeases">
        <link:definition>0000014 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability">
        <link:definition>0000015 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyalties" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties">
        <link:definition>0000016 - Disclosure - Liabilities Related to the Sales of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.nektar.com/role/CommitmentsandContingencies">
        <link:definition>0000017 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.nektar.com/role/StockholdersEquity">
        <link:definition>0000018 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements">
        <link:definition>0000019 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgram" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram">
        <link:definition>0000020 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>0000021 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.nektar.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.nektar.com/role/SegmentReporting">
        <link:definition>0000023 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000024 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables">
        <link:definition>0000025 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.nektar.com/role/InventoryTables">
        <link:definition>0000026 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentTables">
        <link:definition>0000027 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.nektar.com/role/OperatingLeasesTables">
        <link:definition>0000028 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables">
        <link:definition>0000029 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables">
        <link:definition>0000030 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.nektar.com/role/StockholdersEquityTables">
        <link:definition>0000031 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsTables" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables">
        <link:definition>0000032 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramTables" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables">
        <link:definition>0000033 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>0000034 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.nektar.com/role/IncomeTaxesTables">
        <link:definition>0000035 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.nektar.com/role/SegmentReportingTables">
        <link:definition>0000036 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000037 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails">
        <link:definition>0000038 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>0000039 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails">
        <link:definition>0000040 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoriesDetails" roleURI="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails">
        <link:definition>0000041 - Disclosure - Inventory - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000042 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentAdditionalInformationDetails" roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails">
        <link:definition>0000043 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails">
        <link:definition>0000044 - Disclosure - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofOperatingLeaseInformationDetails" roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails">
        <link:definition>0000045 - Disclosure - Operating Leases - Schedule of Operating Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofLeaseExpenseDetails" roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails">
        <link:definition>0000046 - Disclosure - Operating Leases - Schedule of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails">
        <link:definition>0000047 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1">
        <link:definition>0000047 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails">
        <link:definition>0000048 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails">
        <link:definition>0000049 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails">
        <link:definition>0000050 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail">
        <link:definition>0000051 - Disclosure - Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000052 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>0000053 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" roleURI="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>0000054 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails">
        <link:definition>0000055 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetails" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>0000056 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails">
        <link:definition>0000057 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails">
        <link:definition>0000058 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails">
        <link:definition>0000059 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails">
        <link:definition>0000060 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000061 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>0000062 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>0000063 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails">
        <link:definition>0000064 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails">
        <link:definition>0000065 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails">
        <link:definition>0000066 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails">
        <link:definition>0000067 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails">
        <link:definition>0000068 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails">
        <link:definition>0000069 - Disclosure - Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000070 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000071 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>0000072 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>0000073 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuebyGeographicAreaDetail" roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail">
        <link:definition>0000074 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nktr_PurchaseAndSaleAgreement2012Member" abstract="true" name="PurchaseAndSaleAgreement2012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SaleOfFutureRoyaltiesTransactionCosts" abstract="false" name="SaleOfFutureRoyaltiesTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_RSUsAndPSUsMember" abstract="true" name="RSUsAndPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LeaseExtensionTerm" abstract="false" name="LeaseExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" abstract="false" name="TransactionCostsRelatedToRevisedRoyaltyPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ReimbursementOfExpenses" abstract="false" name="ReimbursementOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MissionBayLeaseMember" abstract="true" name="MissionBayLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NonSecuritiesRelatedClaimsMember" abstract="true" name="NonSecuritiesRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" abstract="false" name="StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_FutureRoyaltiesMember" abstract="true" name="FutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LicenseCollaborationOtherRevenue" abstract="false" name="LicenseCollaborationOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ProceedsFromSaleOfFutureRoyaltiesNet" abstract="false" name="ProceedsFromSaleOfFutureRoyaltiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EmployeeSeveranceWithNoServicePeriodMember" abstract="true" name="EmployeeSeveranceWithNoServicePeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock" abstract="false" name="RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" abstract="false" name="AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LongTermInvestmentMaturityPeriod" abstract="false" name="LongTermInvestmentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_PercentageOfSharingInProductionCosts" abstract="false" name="PercentageOfSharingInProductionCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_ProgramTerminationNoncancellableCommitmentsMember" abstract="true" name="ProgramTerminationNoncancellableCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_InvestmnetsTargetMaturityPeriod" abstract="false" name="InvestmnetsTargetMaturityPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" abstract="false" name="NumberOfReportingUnitsToEvaluateGoodwillForImpairment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nktr_AccruedClinicalTrialExpensesCurrent" abstract="false" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EmployeeSeveranceWithServicePeriodRequirementMember" abstract="true" name="EmployeeSeveranceWithServicePeriodRequirementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MergerAndAcquisitionRelatedClaimsMember" abstract="true" name="MergerAndAcquisitionRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" abstract="true" name="SubleaseOperatingLeaseRightOfUseAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInDevelopmentCosts" abstract="false" name="PercentageOfSharingInDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" abstract="false" name="MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" abstract="false" name="ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_IncomeTaxesDisclosureTable" abstract="true" name="IncomeTaxesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ThirdStreetLeaseMember" abstract="true" name="ThirdStreetLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NetExpenseReimbursementsFromCollaborationPartner" abstract="false" name="NetExpenseReimbursementsFromCollaborationPartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" abstract="false" name="GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LesseeOperatingLeaseTableTextBlock" abstract="false" name="LesseeOperatingLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_RoyaltyMonetizationProceeds" abstract="false" name="RoyaltyMonetizationProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SubleasePropertyPlantAndEquipmentMember" abstract="true" name="SubleasePropertyPlantAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" abstract="false" name="PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SalesMilestoneRevenue" abstract="false" name="SalesMilestoneRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PartialRepaymentOfRoyaltySaleProceeds" abstract="false" name="PartialRepaymentOfRoyaltySaleProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2020Member" abstract="true" name="PurchaseAndSaleAgreement2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" abstract="false" name="TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" abstract="true" name="TwoThousandSeventeenPerformanceIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_TaxPositionsRelatedToCurrentYearAbstract" abstract="true" name="TaxPositionsRelatedToCurrentYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" abstract="false" name="ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_Nektar214Member" abstract="true" name="Nektar214Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ScheduleOfLeasesTable" abstract="true" name="ScheduleOfLeasesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" abstract="false" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ProgramTerminationMember" abstract="true" name="ProgramTerminationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_CashAndNonCashRoyaltiesMember" abstract="true" name="CashAndNonCashRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" abstract="false" name="NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCollaborationAgreementMember" abstract="true" name="BristolMyersSquibbCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember" abstract="true" name="ProgramTerminationAdvancePaymntToContractManyfacturersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" abstract="true" name="MeasurementInputMarketParticipantSubtenantBorrowingRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OrganizationPolicyTextBlock" abstract="false" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsLineItems" abstract="true" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" abstract="false" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_TaxPositionsRelatedToPriorYearsAbstract" abstract="true" name="TaxPositionsRelatedToPriorYearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PotentialDevelopmentMilestones" abstract="false" name="PotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_Nektar358Member" abstract="true" name="Nektar358Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" abstract="false" name="ProceedsFromSaleOfPotentialFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DepreciablePropertyPlantAndEquipmentNet" abstract="false" name="DepreciablePropertyPlantAndEquipmentNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" abstract="false" name="UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" abstract="false" name="DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OpdivoMember" abstract="true" name="OpdivoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfEquipmentFromTerminatedProgram" abstract="false" name="ImpairmentOfEquipmentFromTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementCommittedFunding" abstract="false" name="CollaborativeArrangementCommittedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreementMember" abstract="true" name="PurchaseAndSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" abstract="false" name="LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SecuritiesRelatedClaimsMember" abstract="true" name="SecuritiesRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" abstract="false" name="GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NumberOfConsecutiveTermsToExtendLease" abstract="false" name="NumberOfConsecutiveTermsToExtendLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nktr_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" abstract="false" name="AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_InvestmentsWeightedAverageMaturityPeriod" abstract="false" name="InvestmentsWeightedAverageMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_BempegaldesleukinMember" abstract="true" name="BempegaldesleukinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DevelopmentDerivativeLiabilityTextBlock" abstract="false" name="DevelopmentDerivativeLiabilityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" abstract="false" name="PaymentMadeForMilestoneNotAchievedYearTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SubleasesIncomeToBeReceived" abstract="false" name="SubleasesIncomeToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_RoyaltiesLiabilityMeasurementInput" abstract="false" name="RoyaltiesLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nktr_UCBPharmaMember" abstract="true" name="UCBPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SaleOfStockValueAuthorizedInTransaction" abstract="false" name="SaleOfStockValueAuthorizedInTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NumberOfOperatingBusinessSegment" abstract="false" name="NumberOfOperatingBusinessSegment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nktr_BaxaltaIncorporatedOrTakedaPLCMember" abstract="true" name="BaxaltaIncorporatedOrTakedaPLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" abstract="true" name="ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsTable" abstract="true" name="LicenseAndCollaborationAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" abstract="false" name="ShareBasedCompensationPlansShareLimitForEveryOneShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="nktr_ChangeInControlSeverancePaymentPeriodForExecutives" abstract="false" name="ChangeInControlSeverancePaymentPeriodForExecutives" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_BMSCollaborationAgreementMember" abstract="true" name="BMSCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" abstract="false" name="InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_AstraZenecaAbMember" abstract="true" name="AstraZenecaAbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OperatingLeaseMeasurementInput" abstract="false" name="OperatingLeaseMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_ComputerFurnitureAndOtherMember" abstract="true" name="ComputerFurnitureAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" abstract="false" name="PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" abstract="false" name="PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ThirdStFacilityMember" abstract="true" name="ThirdStFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_AreaOfLeasedSpace" abstract="false" name="AreaOfLeasedSpace" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="nktr_SFJPharmaceuticalsMember" abstract="true" name="SFJPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ManufacturingLaboratoryAndOtherEquipmentMember" abstract="true" name="ManufacturingLaboratoryAndOtherEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_StockOptionsRSUsAndPSUsMember" abstract="true" name="StockOptionsRSUsAndPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DepreciablePropertyPlantAndEquipmentGross" abstract="false" name="DepreciablePropertyPlantAndEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OtherPartnerMember" abstract="true" name="OtherPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LeasesLineItems" abstract="true" name="LeasesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_IncomeTaxesDisclosureLineItems" abstract="true" name="IncomeTaxesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" abstract="true" name="RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PaymentMadeForMilestoneNotAchievedYearOne" abstract="false" name="PaymentMadeForMilestoneNotAchievedYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SaleOfStockConsiderationReceived" abstract="false" name="SaleOfStockConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" abstract="true" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" abstract="false" name="PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BuildingAndLeaseholdImprovementsMember" abstract="true" name="BuildingAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NKTR181Member" abstract="true" name="NKTR181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>nktr-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6319d4c-7e41-446e-a208-11c24c30fce3,g:5a9b6e6c-7a94-44cb-81e7-2ed70e787342-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c7a883e3-adcc-4ae3-a3dc-9a4418aa692f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_a3c6f2ff-878c-445c-9a43-ab414ec3dbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c7a883e3-adcc-4ae3-a3dc-9a4418aa692f" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_a3c6f2ff-878c-445c-9a43-ab414ec3dbe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_37f66098-df30-4c24-ba77-538f51e1290c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c7a883e3-adcc-4ae3-a3dc-9a4418aa692f" xlink:to="loc_us-gaap_LiabilitiesCurrent_37f66098-df30-4c24-ba77-538f51e1290c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_70b1711c-6d88-4d47-95ce-adca2eff260a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c7a883e3-adcc-4ae3-a3dc-9a4418aa692f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_70b1711c-6d88-4d47-95ce-adca2eff260a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22d154a2-0a1d-4c06-8916-90c00a99fd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c7a883e3-adcc-4ae3-a3dc-9a4418aa692f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22d154a2-0a1d-4c06-8916-90c00a99fd6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_fbfed388-9db0-4945-b491-550579c68c16" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c7a883e3-adcc-4ae3-a3dc-9a4418aa692f" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_fbfed388-9db0-4945-b491-550579c68c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_66b7d000-62ac-422a-858c-cb17e6dcee9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a81bb105-d7d3-499c-b39f-c38e88eacaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_66b7d000-62ac-422a-858c-cb17e6dcee9d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a81bb105-d7d3-499c-b39f-c38e88eacaef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_76780407-711a-4ccc-8c5f-6a9875cf3fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_66b7d000-62ac-422a-858c-cb17e6dcee9d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_76780407-711a-4ccc-8c5f-6a9875cf3fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0954ea79-eb70-41ed-9c7c-3997917e6c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_66b7d000-62ac-422a-858c-cb17e6dcee9d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0954ea79-eb70-41ed-9c7c-3997917e6c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9356c561-f0c4-429a-9b2d-e70ff26b72ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_66b7d000-62ac-422a-858c-cb17e6dcee9d" xlink:to="loc_us-gaap_InventoryNet_9356c561-f0c4-429a-9b2d-e70ff26b72ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_477d01b8-3c99-4437-bf2f-11e9fcaaa053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_66b7d000-62ac-422a-858c-cb17e6dcee9d" xlink:to="loc_us-gaap_OtherAssetsCurrent_477d01b8-3c99-4437-bf2f-11e9fcaaa053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f949c9cd-0094-4107-9535-340899a7d360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_919c99df-c7e1-4b75-a531-b38e9537b295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f949c9cd-0094-4107-9535-340899a7d360" xlink:to="loc_us-gaap_PreferredStockValue_919c99df-c7e1-4b75-a531-b38e9537b295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7d63fc02-0c32-484e-99b0-7b315364c074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f949c9cd-0094-4107-9535-340899a7d360" xlink:to="loc_us-gaap_CommonStockValue_7d63fc02-0c32-484e-99b0-7b315364c074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1f60ba8e-d766-4fbe-93c7-174aaf08fdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f949c9cd-0094-4107-9535-340899a7d360" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1f60ba8e-d766-4fbe-93c7-174aaf08fdf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41fabb9b-690c-4743-acf6-ed854c8d8e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f949c9cd-0094-4107-9535-340899a7d360" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41fabb9b-690c-4743-acf6-ed854c8d8e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_193c21c7-ffad-4161-9026-3ddff01c1573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f949c9cd-0094-4107-9535-340899a7d360" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_193c21c7-ffad-4161-9026-3ddff01c1573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c542fef-75be-470d-a32d-138b42672c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_aa6e7a3b-19f1-421b-a760-22ef3c498b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c542fef-75be-470d-a32d-138b42672c65" xlink:to="loc_us-gaap_Liabilities_aa6e7a3b-19f1-421b-a760-22ef3c498b7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e442e227-188c-4ba6-8388-ffc60fd5ffcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c542fef-75be-470d-a32d-138b42672c65" xlink:to="loc_us-gaap_StockholdersEquity_e442e227-188c-4ba6-8388-ffc60fd5ffcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_539bb83a-1ee4-4467-a71a-897bb68cff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c542fef-75be-470d-a32d-138b42672c65" xlink:to="loc_us-gaap_CommitmentsAndContingencies_539bb83a-1ee4-4467-a71a-897bb68cff73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1da32083-0621-47fa-a8ae-94bb0a09f937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e87af010-4d6e-446e-904f-2ac0a1a49bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1da32083-0621-47fa-a8ae-94bb0a09f937" xlink:to="loc_us-gaap_AssetsCurrent_e87af010-4d6e-446e-904f-2ac0a1a49bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_45700643-a257-436d-b94c-daff5478ff44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1da32083-0621-47fa-a8ae-94bb0a09f937" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_45700643-a257-436d-b94c-daff5478ff44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8724244f-670d-4233-97bb-75ed171926d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1da32083-0621-47fa-a8ae-94bb0a09f937" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8724244f-670d-4233-97bb-75ed171926d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5e4bd5b1-a7a4-4c15-afd3-607ae2b764f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1da32083-0621-47fa-a8ae-94bb0a09f937" xlink:to="loc_us-gaap_Goodwill_5e4bd5b1-a7a4-4c15-afd3-607ae2b764f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1002d144-6a51-457e-ad65-c3fb8e6b5694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1da32083-0621-47fa-a8ae-94bb0a09f937" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1002d144-6a51-457e-ad65-c3fb8e6b5694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_88ba8cb0-7054-44e6-9fd9-4a721b13504f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1da32083-0621-47fa-a8ae-94bb0a09f937" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_88ba8cb0-7054-44e6-9fd9-4a721b13504f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5c8e6058-a48f-4467-a0bd-6e5feac0ecf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2d134ecb-3f22-47c2-857b-b470956b7ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c8e6058-a48f-4467-a0bd-6e5feac0ecf7" xlink:to="loc_us-gaap_AccountsPayableCurrent_2d134ecb-3f22-47c2-857b-b470956b7ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c59f8235-1875-4690-9d59-4d93340f72fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c8e6058-a48f-4467-a0bd-6e5feac0ecf7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c59f8235-1875-4690-9d59-4d93340f72fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_f95e641d-a9dc-4289-867b-c96b55b885b6" xlink:href="nktr-20221231.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c8e6058-a48f-4467-a0bd-6e5feac0ecf7" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_f95e641d-a9dc-4289-867b-c96b55b885b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_364461e0-e1f7-4745-81ed-d8c96c6c56f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c8e6058-a48f-4467-a0bd-6e5feac0ecf7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_364461e0-e1f7-4745-81ed-d8c96c6c56f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_df9448ce-3f78-4c71-94cd-01eb9df15015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c8e6058-a48f-4467-a0bd-6e5feac0ecf7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_df9448ce-3f78-4c71-94cd-01eb9df15015" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3b86ccfc-693e-4a7a-9e04-ec9d69cf8570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8d403c80-5b1e-4fd8-81ce-a1f3a8c32f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3b86ccfc-693e-4a7a-9e04-ec9d69cf8570" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8d403c80-5b1e-4fd8-81ce-a1f3a8c32f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0cb960e3-41ef-4ef0-9143-0f6af18b62f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3b86ccfc-693e-4a7a-9e04-ec9d69cf8570" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0cb960e3-41ef-4ef0-9143-0f6af18b62f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_25dc446b-ffef-4321-af16-d911fb556e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3b86ccfc-693e-4a7a-9e04-ec9d69cf8570" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_25dc446b-ffef-4321-af16-d911fb556e0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_8680aa09-4053-4912-84bd-dc2d3cef30c4" xlink:href="nktr-20221231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3b86ccfc-693e-4a7a-9e04-ec9d69cf8570" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_8680aa09-4053-4912-84bd-dc2d3cef30c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_661aa07d-0d1f-4329-a9c3-6dbd931eb54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_3a787015-805d-4dbe-b947-09bcccc0bcd1" xlink:href="nktr-20221231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_661aa07d-0d1f-4329-a9c3-6dbd931eb54e" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_3a787015-805d-4dbe-b947-09bcccc0bcd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_49ef0c0c-f6e4-4acc-9749-eb814509017f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_661aa07d-0d1f-4329-a9c3-6dbd931eb54e" xlink:to="loc_us-gaap_InterestExpense_49ef0c0c-f6e4-4acc-9749-eb814509017f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a11a0ba8-06ee-4785-98da-5bb4d2130805" xlink:href="nktr-20221231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_661aa07d-0d1f-4329-a9c3-6dbd931eb54e" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a11a0ba8-06ee-4785-98da-5bb4d2130805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_06c33d60-fe04-49b3-9c1e-32dec2d8e4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_661aa07d-0d1f-4329-a9c3-6dbd931eb54e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_06c33d60-fe04-49b3-9c1e-32dec2d8e4f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_041d3864-3e21-4c56-961f-3012508787e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_661aa07d-0d1f-4329-a9c3-6dbd931eb54e" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_041d3864-3e21-4c56-961f-3012508787e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d4e04540-1622-452c-b062-1d829326c2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9570998b-e90a-4f7a-bb1c-d458f2c5402c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d4e04540-1622-452c-b062-1d829326c2c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9570998b-e90a-4f7a-bb1c-d458f2c5402c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f645d13a-4c23-40fb-899b-f68ae7b61cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d4e04540-1622-452c-b062-1d829326c2c7" xlink:to="loc_us-gaap_CostsAndExpenses_f645d13a-4c23-40fb-899b-f68ae7b61cf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_43da1e9d-35b1-4317-a381-848cd8bc4cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_99f4aaf0-cd54-4ddb-9a07-81145080c074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_43da1e9d-35b1-4317-a381-848cd8bc4cd7" xlink:to="loc_us-gaap_OperatingIncomeLoss_99f4aaf0-cd54-4ddb-9a07-81145080c074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1fa26b76-fa87-4e1c-b512-f499dd1f81fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_43da1e9d-35b1-4317-a381-848cd8bc4cd7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1fa26b76-fa87-4e1c-b512-f499dd1f81fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab456efb-ff45-46e4-a852-50106209358f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c28eef9a-babc-4b32-aa11-be65fb503841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ab456efb-ff45-46e4-a852-50106209358f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c28eef9a-babc-4b32-aa11-be65fb503841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_693b254d-323f-4cf2-af2e-105f59882314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ab456efb-ff45-46e4-a852-50106209358f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_693b254d-323f-4cf2-af2e-105f59882314" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_166fb21c-9afc-455f-8180-e259ff8c494c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c30c6b45-b659-4ceb-a3d0-a6cd2253786a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_166fb21c-9afc-455f-8180-e259ff8c494c" xlink:to="loc_us-gaap_NetIncomeLoss_c30c6b45-b659-4ceb-a3d0-a6cd2253786a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dc35587e-d048-4b2e-8475-39172c9ef60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_166fb21c-9afc-455f-8180-e259ff8c494c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dc35587e-d048-4b2e-8475-39172c9ef60f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_75ad1a24-ec39-4e2b-a473-502f2c50ff93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d95345da-c2ad-470c-9031-efba317fca80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_75ad1a24-ec39-4e2b-a473-502f2c50ff93" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d95345da-c2ad-470c-9031-efba317fca80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d98e9c7a-f0cd-4c0c-90d0-e7f2c1b1357f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_75ad1a24-ec39-4e2b-a473-502f2c50ff93" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d98e9c7a-f0cd-4c0c-90d0-e7f2c1b1357f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf399bb-99d6-4ed9-ab4f-c3c48b0d4c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4727d279-d750-4fac-917b-41b3a046a8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf399bb-99d6-4ed9-ab4f-c3c48b0d4c17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4727d279-d750-4fac-917b-41b3a046a8c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_828f930c-26fb-44e2-92d2-953ac58e150b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf399bb-99d6-4ed9-ab4f-c3c48b0d4c17" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_828f930c-26fb-44e2-92d2-953ac58e150b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_08cf9073-f740-401e-bb22-634a1ecddb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf399bb-99d6-4ed9-ab4f-c3c48b0d4c17" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_08cf9073-f740-401e-bb22-634a1ecddb96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_776f5437-63bd-41b6-a6fe-2e4a2e0476a9" xlink:href="nktr-20221231.xsd#nktr_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_daf399bb-99d6-4ed9-ab4f-c3c48b0d4c17" xlink:to="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_776f5437-63bd-41b6-a6fe-2e4a2e0476a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_caae10e1-2667-48d8-ac1d-2508227c46dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_ProfitLoss_caae10e1-2667-48d8-ac1d-2508227c46dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_d0b67c87-2d9e-4518-8b18-3faf7a6ec686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_d0b67c87-2d9e-4518-8b18-3faf7a6ec686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_fa675990-dd4e-42b7-9ca8-d41bb1220345" xlink:href="nktr-20221231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_fa675990-dd4e-42b7-9ca8-d41bb1220345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_18905594-a3d1-4264-887d-47d559411472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_18905594-a3d1-4264-887d-47d559411472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_14d6c810-9001-4501-bf82-3f7e480c4ebb" xlink:href="nktr-20221231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_14d6c810-9001-4501-bf82-3f7e480c4ebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6a1cc5f8-ad5a-48c6-873b-5a3a328857af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6a1cc5f8-ad5a-48c6-873b-5a3a328857af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_d1c03a1b-aa94-4f64-9dd9-066af1af608a" xlink:href="nktr-20221231.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_d1c03a1b-aa94-4f64-9dd9-066af1af608a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_0974285c-852e-442e-a82e-8b50575a44c7" xlink:href="nktr-20221231.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_0974285c-852e-442e-a82e-8b50575a44c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_58e15fc0-4104-43bc-b260-344f85f37445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_58e15fc0-4104-43bc-b260-344f85f37445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_6d63f535-cfae-4df6-a242-850b77c6fc52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_6d63f535-cfae-4df6-a242-850b77c6fc52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5b70b955-0f39-4056-918b-f9c88d313324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5b70b955-0f39-4056-918b-f9c88d313324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2e151ea7-f5ce-46dc-8aeb-56f4a7d189a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2e151ea7-f5ce-46dc-8aeb-56f4a7d189a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_94c295e2-542c-4b4e-b9bb-07c59f3db74a" xlink:href="nktr-20221231.xsd#nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_94c295e2-542c-4b4e-b9bb-07c59f3db74a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2babdc72-be65-4402-84fc-fc61b6f9275d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_DepreciationAndAmortization_2babdc72-be65-4402-84fc-fc61b6f9275d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_209d41c2-b221-4a72-a647-1a9e140f09be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_209d41c2-b221-4a72-a647-1a9e140f09be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_4e7ecfc7-284e-4293-9845-d1a77f85ee36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_4e7ecfc7-284e-4293-9845-d1a77f85ee36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_a4f3fe2d-b6de-4b44-aab7-a5f2624facb5" xlink:href="nktr-20221231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_a4f3fe2d-b6de-4b44-aab7-a5f2624facb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c820aed0-8b64-434b-a944-9f194353beca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c820aed0-8b64-434b-a944-9f194353beca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9636e8f6-4bf9-4c04-950d-0b0cf202a615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9636e8f6-4bf9-4c04-950d-0b0cf202a615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4746d1db-c507-474a-a7ef-0fa27169f484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_AssetImpairmentCharges_4746d1db-c507-474a-a7ef-0fa27169f484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4bfc2f2c-c0ac-4e99-9ac1-f7538192519a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1c8d2a6-01dd-4061-8753-210a19005032" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4bfc2f2c-c0ac-4e99-9ac1-f7538192519a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59614a43-788d-41d1-8cd7-b827458fc6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_205f9eba-eec9-4482-9764-b98a372b0beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59614a43-788d-41d1-8cd7-b827458fc6f1" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_205f9eba-eec9-4482-9764-b98a372b0beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_bb10c79d-ad23-4781-860e-1e00bca2d157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59614a43-788d-41d1-8cd7-b827458fc6f1" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_bb10c79d-ad23-4781-860e-1e00bca2d157" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_545bb057-b15f-4fa4-a46c-e2f631fc5dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59614a43-788d-41d1-8cd7-b827458fc6f1" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_545bb057-b15f-4fa4-a46c-e2f631fc5dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a0038d5c-ce52-402e-897e-7238fa8295d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59614a43-788d-41d1-8cd7-b827458fc6f1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a0038d5c-ce52-402e-897e-7238fa8295d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_17354f1d-868b-4680-a8ca-76556526aff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59614a43-788d-41d1-8cd7-b827458fc6f1" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_17354f1d-868b-4680-a8ca-76556526aff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b319dc8-3522-4ce6-a13c-746b3a999459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1eda8aa2-961d-4d0f-94a1-3409409d6b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b319dc8-3522-4ce6-a13c-746b3a999459" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1eda8aa2-961d-4d0f-94a1-3409409d6b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca648aeb-491b-4a93-9620-93015138e668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b319dc8-3522-4ce6-a13c-746b3a999459" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca648aeb-491b-4a93-9620-93015138e668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1cf7a916-d8ef-4b33-87b8-1e9862a7f583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b319dc8-3522-4ce6-a13c-746b3a999459" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1cf7a916-d8ef-4b33-87b8-1e9862a7f583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf54b9a2-d16f-4fe7-8c33-b5f443583e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b319dc8-3522-4ce6-a13c-746b3a999459" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf54b9a2-d16f-4fe7-8c33-b5f443583e09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_61286cb2-5018-465d-9dfa-685c1013dfdf" xlink:href="nktr-20221231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b95d993-8578-4a9b-a7b2-14fbc48fd444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_61286cb2-5018-465d-9dfa-685c1013dfdf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b95d993-8578-4a9b-a7b2-14fbc48fd444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1ff2e358-da4f-4460-9388-42a5ea3d4e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_61286cb2-5018-465d-9dfa-685c1013dfdf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1ff2e358-da4f-4460-9388-42a5ea3d4e8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_96e805fb-5142-49dd-a7d7-e807e4999230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_61286cb2-5018-465d-9dfa-685c1013dfdf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_96e805fb-5142-49dd-a7d7-e807e4999230" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_574d9670-a91d-4c18-815d-584888285e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6355ffa-751a-4e1c-9fb9-344de549fe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_574d9670-a91d-4c18-815d-584888285e21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6355ffa-751a-4e1c-9fb9-344de549fe2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8da9c6e1-cc94-48d7-a99d-c6efabf02e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_574d9670-a91d-4c18-815d-584888285e21" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8da9c6e1-cc94-48d7-a99d-c6efabf02e21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_635ab2f0-b2d2-4d83-88f7-fc59e4e7044b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_574d9670-a91d-4c18-815d-584888285e21" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_635ab2f0-b2d2-4d83-88f7-fc59e4e7044b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_9c0309c1-1761-4c84-b1ba-9b5a0584defe" xlink:href="nktr-20221231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ba84ce6-a074-4881-91a4-8111232eddc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_9c0309c1-1761-4c84-b1ba-9b5a0584defe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ba84ce6-a074-4881-91a4-8111232eddc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_062348f5-2915-4a93-9f64-dcf939922896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_9c0309c1-1761-4c84-b1ba-9b5a0584defe" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_062348f5-2915-4a93-9f64-dcf939922896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_cdd79bc6-1eab-4f4c-995a-4fdc6e87bfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_9c0309c1-1761-4c84-b1ba-9b5a0584defe" xlink:to="loc_us-gaap_Cash_cdd79bc6-1eab-4f4c-995a-4fdc6e87bfb2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#InventoryScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bc231788-ef13-4755-b218-ec91ffea7e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3e224272-12c0-45d3-8a4c-b0839b6d6d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bc231788-ef13-4755-b218-ec91ffea7e65" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3e224272-12c0-45d3-8a4c-b0839b6d6d64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b803ae8b-d023-47df-b3ed-5217ddc6064d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bc231788-ef13-4755-b218-ec91ffea7e65" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b803ae8b-d023-47df-b3ed-5217ddc6064d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ac777007-10e6-467b-9873-154c88d68750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bc231788-ef13-4755-b218-ec91ffea7e65" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ac777007-10e6-467b-9873-154c88d68750" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_109cd1b9-34ac-4b3e-b4e3-9fa902fd3b09" xlink:href="nktr-20221231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_cb3b7b70-49ee-4d74-91fc-9c94b7ae091d" xlink:href="nktr-20221231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_109cd1b9-34ac-4b3e-b4e3-9fa902fd3b09" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_cb3b7b70-49ee-4d74-91fc-9c94b7ae091d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e5ce29fa-fc7a-4ed0-af67-d9daadb0c02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_109cd1b9-34ac-4b3e-b4e3-9fa902fd3b09" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e5ce29fa-fc7a-4ed0-af67-d9daadb0c02d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6a83c5c9-4483-4e5b-9f7e-20008bd14eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_47074aaf-6666-4cb9-a185-15ae397d7ede" xlink:href="nktr-20221231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6a83c5c9-4483-4e5b-9f7e-20008bd14eac" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_47074aaf-6666-4cb9-a185-15ae397d7ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_17f9f864-66d3-4586-927f-7652ec561dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6a83c5c9-4483-4e5b-9f7e-20008bd14eac" xlink:to="loc_us-gaap_ConstructionInProgressGross_17f9f864-66d3-4586-927f-7652ec561dfc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesScheduleofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_aa3db8f8-b534-4a27-8c28-1372dbdd4122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f8191c89-f063-4bd4-a3d7-a989470131d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_aa3db8f8-b534-4a27-8c28-1372dbdd4122" xlink:to="loc_us-gaap_OperatingLeaseCost_f8191c89-f063-4bd4-a3d7-a989470131d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_6b545cab-bc3f-47b7-acfb-601bf880145e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_aa3db8f8-b534-4a27-8c28-1372dbdd4122" xlink:to="loc_us-gaap_VariableLeaseCost_6b545cab-bc3f-47b7-acfb-601bf880145e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8e0f4910-0298-4c0e-b2bf-4a77ac127446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5622fc83-4e33-4976-ac4b-12d28ebe6ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8e0f4910-0298-4c0e-b2bf-4a77ac127446" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5622fc83-4e33-4976-ac4b-12d28ebe6ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4bbb7616-bb49-4b17-a21a-db1b29bbb1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8e0f4910-0298-4c0e-b2bf-4a77ac127446" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4bbb7616-bb49-4b17-a21a-db1b29bbb1f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf536748-66b3-4c4f-8e9b-fa4a5fcb84e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bb6f0f61-3d13-4fe2-85fc-c8e228b73528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf536748-66b3-4c4f-8e9b-fa4a5fcb84e3" xlink:to="loc_us-gaap_OperatingLeaseLiability_bb6f0f61-3d13-4fe2-85fc-c8e228b73528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b3b011b0-ecf0-47ca-85ac-787264d6acea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf536748-66b3-4c4f-8e9b-fa4a5fcb84e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b3b011b0-ecf0-47ca-85ac-787264d6acea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db0e3b0e-aec1-4036-9c2e-4332ac980071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_699c4ebb-c620-4251-8972-458e95d1dd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db0e3b0e-aec1-4036-9c2e-4332ac980071" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_699c4ebb-c620-4251-8972-458e95d1dd2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a642826d-dd9d-453a-b6ae-3428ca8ea728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db0e3b0e-aec1-4036-9c2e-4332ac980071" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a642826d-dd9d-453a-b6ae-3428ca8ea728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5f98de9c-9818-44af-9b53-d320842b0172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db0e3b0e-aec1-4036-9c2e-4332ac980071" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5f98de9c-9818-44af-9b53-d320842b0172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09674649-8144-43a7-9e5d-80c914950843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db0e3b0e-aec1-4036-9c2e-4332ac980071" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09674649-8144-43a7-9e5d-80c914950843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_27b26cc9-8829-4f19-b3d7-0f0b5577ed91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db0e3b0e-aec1-4036-9c2e-4332ac980071" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_27b26cc9-8829-4f19-b3d7-0f0b5577ed91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_76ceeff0-3894-4bb2-8c73-11c1b764ce5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db0e3b0e-aec1-4036-9c2e-4332ac980071" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_76ceeff0-3894-4bb2-8c73-11c1b764ce5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20221231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_e82b4c83-6a64-4729-ae4d-2af8cb4d601b" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_b2fd1dd8-f3cb-41b4-9682-8369e6d3fd7d" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_e82b4c83-6a64-4729-ae4d-2af8cb4d601b" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_b2fd1dd8-f3cb-41b4-9682-8369e6d3fd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_8a8645c6-f7ea-4aba-8915-f4142f9f0140" xlink:href="nktr-20221231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_e82b4c83-6a64-4729-ae4d-2af8cb4d601b" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_8a8645c6-f7ea-4aba-8915-f4142f9f0140" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_96aea705-b8f1-4d16-8eea-61265c761105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c65445a0-c491-47a1-bbee-3f515f5aa801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_96aea705-b8f1-4d16-8eea-61265c761105" xlink:to="loc_us-gaap_SeveranceCosts1_c65445a0-c491-47a1-bbee-3f515f5aa801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3706583c-fb51-410a-99c9-73ee15a55a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_96aea705-b8f1-4d16-8eea-61265c761105" xlink:to="loc_us-gaap_AssetImpairmentCharges_3706583c-fb51-410a-99c9-73ee15a55a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_dc28c6ff-fda8-425f-94cf-ee5d9b5169c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_96aea705-b8f1-4d16-8eea-61265c761105" xlink:to="loc_us-gaap_BusinessExitCosts1_dc28c6ff-fda8-425f-94cf-ee5d9b5169c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_df331a42-7503-4053-b482-efa8dac5bef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_96aea705-b8f1-4d16-8eea-61265c761105" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_df331a42-7503-4053-b482-efa8dac5bef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_5987e0fd-0fa0-40be-b894-19478cbfafaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_96aea705-b8f1-4d16-8eea-61265c761105" xlink:to="loc_us-gaap_LossOnContractTermination_5987e0fd-0fa0-40be-b894-19478cbfafaa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cac0802a-6fd5-485b-b677-a604dc0890f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_dccae868-813c-40e6-922d-a32e8c474dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetImpairmentCharges_cac0802a-6fd5-485b-b677-a604dc0890f5" xlink:to="loc_us-gaap_AdjustmentForAmortization_dccae868-813c-40e6-922d-a32e8c474dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_01fee17c-3bb4-4802-8a35-a7ea259d687a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetImpairmentCharges_cac0802a-6fd5-485b-b677-a604dc0890f5" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_01fee17c-3bb4-4802-8a35-a7ea259d687a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_35fc875f-6bd1-4949-842d-dcbd2712084c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_af694e11-cace-4b39-89f4-94994a6e60c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_35fc875f-6bd1-4949-842d-dcbd2712084c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_af694e11-cace-4b39-89f4-94994a6e60c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6aaca308-37f4-4a9b-b3c6-f5f9a34bea59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_35fc875f-6bd1-4949-842d-dcbd2712084c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6aaca308-37f4-4a9b-b3c6-f5f9a34bea59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a71729c8-5fb3-4b55-892b-3e4ed141a89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b464374e-6faa-456b-a8cc-8d06c01f0537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a71729c8-5fb3-4b55-892b-3e4ed141a89c" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b464374e-6faa-456b-a8cc-8d06c01f0537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_531b8d8f-dda2-41c3-95c5-8ed65dcf1c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a71729c8-5fb3-4b55-892b-3e4ed141a89c" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_531b8d8f-dda2-41c3-95c5-8ed65dcf1c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_69407b9a-88d8-471e-bf67-b2180d1aa411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a71729c8-5fb3-4b55-892b-3e4ed141a89c" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_69407b9a-88d8-471e-bf67-b2180d1aa411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2930dc1-9a31-4163-9f4b-d7408ab7fa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_572f5d1c-69fe-4b06-8710-77344875d00e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2930dc1-9a31-4163-9f4b-d7408ab7fa09" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_572f5d1c-69fe-4b06-8710-77344875d00e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c6466b87-e3a6-4b6a-b9f4-cc3f77153ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2930dc1-9a31-4163-9f4b-d7408ab7fa09" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c6466b87-e3a6-4b6a-b9f4-cc3f77153ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_23466211-46cf-45cd-b174-a08ca0621761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2930dc1-9a31-4163-9f4b-d7408ab7fa09" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_23466211-46cf-45cd-b174-a08ca0621761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2e3194ea-130f-4245-96eb-2ed6bc106540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1dea333e-8fc8-4120-bcef-849a375d9709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2e3194ea-130f-4245-96eb-2ed6bc106540" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1dea333e-8fc8-4120-bcef-849a375d9709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c94cc287-44a2-4e8f-80ce-4b7e35927374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2e3194ea-130f-4245-96eb-2ed6bc106540" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c94cc287-44a2-4e8f-80ce-4b7e35927374" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_cb3f8b82-8501-4046-aede-de2999700c87" xlink:href="nktr-20221231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_cb3f8b82-8501-4046-aede-de2999700c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4884c507-fabd-4ed0-9cbc-6ed5d9ba337f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4884c507-fabd-4ed0-9cbc-6ed5d9ba337f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_39d28a94-39d9-4498-bcb3-d38e12723ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_39d28a94-39d9-4498-bcb3-d38e12723ab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_e7a16328-99d8-4cc3-94aa-82d079c0d9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_e7a16328-99d8-4cc3-94aa-82d079c0d9be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_d36fc649-dea2-4636-8071-6c99e5001624" xlink:href="nktr-20221231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_d36fc649-dea2-4636-8071-6c99e5001624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_200f07df-1e48-409c-b942-9a077598f99e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_200f07df-1e48-409c-b942-9a077598f99e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_961404cf-a145-4856-9036-4b3116e6217f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_961404cf-a145-4856-9036-4b3116e6217f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_fd5c3cdd-bf85-4aee-94d8-bbd25c075fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_fd5c3cdd-bf85-4aee-94d8-bbd25c075fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards_4aed5f57-fe99-4b52-8621-55b2792af7e3" xlink:href="nktr-20221231.xsd#nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_05e03c51-76c4-4cac-9cf1-7e034c273c01" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards_4aed5f57-fe99-4b52-8621-55b2792af7e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_58d82ccd-473e-4129-b3d4-9143ba22f65e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f485fadd-728f-4bc9-8e68-2759fa54ee12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_58d82ccd-473e-4129-b3d4-9143ba22f65e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f485fadd-728f-4bc9-8e68-2759fa54ee12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_52b79b7e-461b-4e28-94e7-becf35f2d2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_58d82ccd-473e-4129-b3d4-9143ba22f65e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_52b79b7e-461b-4e28-94e7-becf35f2d2e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_13be6636-9c01-4116-aa1f-81d32f8d9e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_58d82ccd-473e-4129-b3d4-9143ba22f65e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_13be6636-9c01-4116-aa1f-81d32f8d9e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_caeb2007-25bc-4760-a27c-12430bf86334" xlink:href="nktr-20221231.xsd#nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_58d82ccd-473e-4129-b3d4-9143ba22f65e" xlink:to="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_caeb2007-25bc-4760-a27c-12430bf86334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLeaseLiability_60b25ddb-3d77-4e6b-94a0-d88ad4d0afbd" xlink:href="nktr-20221231.xsd#nktr_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_58d82ccd-473e-4129-b3d4-9143ba22f65e" xlink:to="loc_nktr_DeferredTaxAssetsLeaseLiability_60b25ddb-3d77-4e6b-94a0-d88ad4d0afbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b0b5a3ca-9e6f-45cc-8bb5-67c9353fd254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_58d82ccd-473e-4129-b3d4-9143ba22f65e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b0b5a3ca-9e6f-45cc-8bb5-67c9353fd254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_06136703-9618-4bb1-974c-a675bbc80109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_58d82ccd-473e-4129-b3d4-9143ba22f65e" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_06136703-9618-4bb1-974c-a675bbc80109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_740cfab3-6555-4ebf-804b-1d6d5827517a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_58d82ccd-473e-4129-b3d4-9143ba22f65e" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_740cfab3-6555-4ebf-804b-1d6d5827517a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8092cb30-3a33-4dfb-aea1-fc38c1038587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8917eabb-8cad-4e8a-a9ce-0c238ca5c0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8092cb30-3a33-4dfb-aea1-fc38c1038587" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8917eabb-8cad-4e8a-a9ce-0c238ca5c0d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_af65e5d6-6db3-4eaa-9738-a020b8666617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8092cb30-3a33-4dfb-aea1-fc38c1038587" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_af65e5d6-6db3-4eaa-9738-a020b8666617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e205d186-f630-478a-9afd-71de7eb27df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c8749f16-169b-48c2-bcca-a2733f63caa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e205d186-f630-478a-9afd-71de7eb27df3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c8749f16-169b-48c2-bcca-a2733f63caa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_13ff0f12-fc94-44b4-90fe-a6ac37505daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e205d186-f630-478a-9afd-71de7eb27df3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_13ff0f12-fc94-44b4-90fe-a6ac37505daa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_220c79dd-e84c-4898-823a-5aa17da39752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e205d186-f630-478a-9afd-71de7eb27df3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_220c79dd-e84c-4898-823a-5aa17da39752" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_424ebed2-5d9d-4cb8-96d6-7b564998a41a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c83daecb-b227-47f0-ac91-cddc55094041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_424ebed2-5d9d-4cb8-96d6-7b564998a41a" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c83daecb-b227-47f0-ac91-cddc55094041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_389d4fe9-191b-43df-a2c1-180d293b1ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_424ebed2-5d9d-4cb8-96d6-7b564998a41a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_389d4fe9-191b-43df-a2c1-180d293b1ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_b5b3025b-f5ba-468a-b1f0-b407ee0498d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ca69c9e0-55a0-490d-b992-5b43d67f9fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_b5b3025b-f5ba-468a-b1f0-b407ee0498d1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ca69c9e0-55a0-490d-b992-5b43d67f9fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_17d61c21-06d2-4a19-86d3-60f8272cf196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_b5b3025b-f5ba-468a-b1f0-b407ee0498d1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_17d61c21-06d2-4a19-86d3-60f8272cf196" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>nktr-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6319d4c-7e41-446e-a208-11c24c30fce3,g:5a9b6e6c-7a94-44cb-81e7-2ed70e787342-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i1f4405faeaaa454da7d3393177f113c2_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d38e2246-655f-4a1b-86dd-f07197ba6773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_RevenuesAbstract_d38e2246-655f-4a1b-86dd-f07197ba6773" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29d8972c-abb7-4e8d-a85a-2d4b0bab86c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d38e2246-655f-4a1b-86dd-f07197ba6773" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29d8972c-abb7-4e8d-a85a-2d4b0bab86c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d810dbbd-183b-4aba-9023-190f2b9e7e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d810dbbd-183b-4aba-9023-190f2b9e7e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_186cd0bb-6606-4e0c-b8cd-d9147b703522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_186cd0bb-6606-4e0c-b8cd-d9147b703522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_853d2618-4228-41ff-a2bb-12090332d425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_853d2618-4228-41ff-a2bb-12090332d425" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_d0f52b9e-f912-49af-86f5-690c3bd37bde" xlink:href="nktr-20221231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_d0f52b9e-f912-49af-86f5-690c3bd37bde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ba04673d-04c5-4f36-8c5c-1d3c2f51af1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_us-gaap_CostsAndExpenses_ba04673d-04c5-4f36-8c5c-1d3c2f51af1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_69e561a8-f305-4945-b159-d686597233f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_OperatingIncomeLoss_69e561a8-f305-4945-b159-d686597233f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_57fa1ead-af20-4e8f-833d-6e42f99fbe6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_57fa1ead-af20-4e8f-833d-6e42f99fbe6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1d554f96-1e6b-41a0-a9ee-89b2fc80387e" xlink:href="nktr-20221231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1d554f96-1e6b-41a0-a9ee-89b2fc80387e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_33f1bbd9-766c-4500-8838-9a251d399b15" xlink:href="nktr-20221231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_33f1bbd9-766c-4500-8838-9a251d399b15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1f078254-1a34-46da-a142-79bc7f1b835f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1f078254-1a34-46da-a142-79bc7f1b835f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3ee80b6f-90c3-4198-958a-bc76cc61cf14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_us-gaap_InterestExpense_3ee80b6f-90c3-4198-958a-bc76cc61cf14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3f0915bf-4d42-418b-b0e7-8552d04c7d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3f0915bf-4d42-418b-b0e7-8552d04c7d23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12b4be3b-2156-43bd-97a0-0d3ecbbb5f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12b4be3b-2156-43bd-97a0-0d3ecbbb5f76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_810c61c9-4304-4dde-8f83-2c48f0b99998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_810c61c9-4304-4dde-8f83-2c48f0b99998" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_493ed87a-1732-4d1f-bb6c-ba11cdd8c688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_NetIncomeLoss_493ed87a-1732-4d1f-bb6c-ba11cdd8c688" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b4f78dfa-4b0b-4868-b17e-75a2abb275d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_EarningsPerShareBasic_b4f78dfa-4b0b-4868-b17e-75a2abb275d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_98b082b0-c833-4535-a479-e6d3421ff2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_98b082b0-c833-4535-a479-e6d3421ff2f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_512175d3-a550-400f-bad6-c7154b876912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_512175d3-a550-400f-bad6-c7154b876912" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32c616e7-5f17-48b6-9d57-bebed31c636c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32c616e7-5f17-48b6-9d57-bebed31c636c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_057a11ce-9815-4e11-b713-4434866d889f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_StatementTable_057a11ce-9815-4e11-b713-4434866d889f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d54d39ee-b5de-46b6-92af-6fedb10f8ed8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_057a11ce-9815-4e11-b713-4434866d889f" xlink:to="loc_srt_ProductOrServiceAxis_d54d39ee-b5de-46b6-92af-6fedb10f8ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d54d39ee-b5de-46b6-92af-6fedb10f8ed8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d54d39ee-b5de-46b6-92af-6fedb10f8ed8" xlink:to="loc_srt_ProductsAndServicesDomain_d54d39ee-b5de-46b6-92af-6fedb10f8ed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d54d39ee-b5de-46b6-92af-6fedb10f8ed8" xlink:to="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_90f0777b-e86f-4a34-a3b6-5b6262f9f88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:to="loc_us-gaap_ProductMember_90f0777b-e86f-4a34-a3b6-5b6262f9f88a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_75aa332a-c9e8-4180-87d8-f39cf11d3ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:to="loc_us-gaap_RoyaltyMember_75aa332a-c9e8-4180-87d8-f39cf11d3ccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_2f0a91ec-1ae7-457d-9c76-9df00012cb24" xlink:href="nktr-20221231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_2f0a91ec-1ae7-457d-9c76-9df00012cb24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_2299a5c0-210a-4d6b-8053-cde25d490d1d" xlink:href="nktr-20221231.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_2299a5c0-210a-4d6b-8053-cde25d490d1d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="icad2ecab0f0e43f9ac9424cb8096c8c4_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0978b387-13d7-4b0e-864f-db77cd130eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0978b387-13d7-4b0e-864f-db77cd130eea" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c65c4113-a4bc-4a85-98ed-be2af841b7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c65c4113-a4bc-4a85-98ed-be2af841b7e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_68d1c164-4bcd-4871-9e0c-887e3b3aeb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_StockholdersEquity_68d1c164-4bcd-4871-9e0c-887e3b3aeb99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_67faed7a-1056-423d-9088-8d2c8f6d22ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_67faed7a-1056-423d-9088-8d2c8f6d22ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c2932614-8458-48af-9df2-cbf0b23e4f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c2932614-8458-48af-9df2-cbf0b23e4f94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7589d248-d6af-4184-95fc-55c7af25ee61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7589d248-d6af-4184-95fc-55c7af25ee61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ada000c-e20c-4363-bc66-d2279429f6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ada000c-e20c-4363-bc66-d2279429f6d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3d53af14-8488-4ca3-8ff3-7ad57480e311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_152a11f1-3fa5-4154-90f3-6e94ed922f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e645f6fe-7d3b-4644-923d-df14a00e1ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffb911b0-5640-4ec7-9486-0120bf0d5861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0978b387-13d7-4b0e-864f-db77cd130eea" xlink:to="loc_us-gaap_StatementTable_ffb911b0-5640-4ec7-9486-0120bf0d5861" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_123410e0-1cd4-46f3-923f-05bb3438c184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffb911b0-5640-4ec7-9486-0120bf0d5861" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_123410e0-1cd4-46f3-923f-05bb3438c184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_123410e0-1cd4-46f3-923f-05bb3438c184_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_123410e0-1cd4-46f3-923f-05bb3438c184" xlink:to="loc_us-gaap_EquityComponentDomain_123410e0-1cd4-46f3-923f-05bb3438c184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_123410e0-1cd4-46f3-923f-05bb3438c184" xlink:to="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_de462e73-5207-42fc-91af-9a52e6bc605e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:to="loc_us-gaap_CommonStockMember_de462e73-5207-42fc-91af-9a52e6bc605e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_48336abc-531f-44c5-a015-04a3f6e2a888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_48336abc-531f-44c5-a015-04a3f6e2a888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e205be80-77a2-4654-a92f-8a1a0aef49f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e205be80-77a2-4654-a92f-8a1a0aef49f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_43cad262-f5dc-46ae-9440-f3edd9f38c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:to="loc_us-gaap_RetainedEarningsMember_43cad262-f5dc-46ae-9440-f3edd9f38c3e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i0567f90575da41c68ebc6a7f13150a74_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:href="nktr-20221231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f6a9d524-0a08-4f14-b7e4-a34eafdd4b96" xlink:href="nktr-20221231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f6a9d524-0a08-4f14-b7e4-a34eafdd4b96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_57bdc59a-332a-49b9-8c53-2ddb86038c79" xlink:href="nktr-20221231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_57bdc59a-332a-49b9-8c53-2ddb86038c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17e6cbeb-bf64-4129-bfe2-89558e0d54db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17e6cbeb-bf64-4129-bfe2-89558e0d54db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_f9f8492f-5a02-48ca-965f-074d9a54a23f" xlink:href="nktr-20221231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_f9f8492f-5a02-48ca-965f-074d9a54a23f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e35423ca-8eb0-4c1e-bfce-b888aab45295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e35423ca-8eb0-4c1e-bfce-b888aab45295" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_c394650b-077e-41a3-a1ae-274d828b39c4" xlink:href="nktr-20221231.xsd#nktr_SalesMilestoneRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_SalesMilestoneRevenue_c394650b-077e-41a3-a1ae-274d828b39c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f2ef7deb-175d-41fd-a40f-078ec8038e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f2ef7deb-175d-41fd-a40f-078ec8038e4b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_fb973bdb-78e1-4376-a06c-e1623e90c40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_fb973bdb-78e1-4376-a06c-e1623e90c40f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_bf29fe00-1e6c-4203-9971-d124696fa1ab" xlink:href="nktr-20221231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_bf29fe00-1e6c-4203-9971-d124696fa1ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_de34bcb1-fcd5-484d-b1c0-5411e62ba149" xlink:href="nktr-20221231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_de34bcb1-fcd5-484d-b1c0-5411e62ba149" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_31cfb057-509e-4ab9-ba9b-e5e1f9ca6387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_31cfb057-509e-4ab9-ba9b-e5e1f9ca6387" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_442b5f05-5b0c-44ee-b839-4aefa2f68bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_RestructuringCharges_442b5f05-5b0c-44ee-b839-4aefa2f68bfd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:href="nktr-20221231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c60ad38e-d70f-4c75-9a76-aced2e2f949e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_srt_RangeAxis_c60ad38e-d70f-4c75-9a76-aced2e2f949e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c60ad38e-d70f-4c75-9a76-aced2e2f949e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c60ad38e-d70f-4c75-9a76-aced2e2f949e" xlink:to="loc_srt_RangeMember_c60ad38e-d70f-4c75-9a76-aced2e2f949e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f4d886d-a1b4-4bb5-be16-a9063818a45b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c60ad38e-d70f-4c75-9a76-aced2e2f949e" xlink:to="loc_srt_RangeMember_9f4d886d-a1b4-4bb5-be16-a9063818a45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_30cc0cc6-253e-4b66-baa4-23af56570b25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f4d886d-a1b4-4bb5-be16-a9063818a45b" xlink:to="loc_srt_MinimumMember_30cc0cc6-253e-4b66-baa4-23af56570b25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1dd703a-911f-4960-a290-503ac7bcab44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f4d886d-a1b4-4bb5-be16-a9063818a45b" xlink:to="loc_srt_MaximumMember_b1dd703a-911f-4960-a290-503ac7bcab44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_722c30a8-392b-4bb2-832a-c5629166eebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_722c30a8-392b-4bb2-832a-c5629166eebc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_722c30a8-392b-4bb2-832a-c5629166eebc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_722c30a8-392b-4bb2-832a-c5629166eebc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_722c30a8-392b-4bb2-832a-c5629166eebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1d08600-3760-4707-a60a-8bccb007ca10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_722c30a8-392b-4bb2-832a-c5629166eebc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1d08600-3760-4707-a60a-8bccb007ca10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_9ed74e5d-7dbb-4a37-862b-dd0577bda0b3" xlink:href="nktr-20221231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1d08600-3760-4707-a60a-8bccb007ca10" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_9ed74e5d-7dbb-4a37-862b-dd0577bda0b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_5ef60188-64d1-4645-aa40-22a7a1efa709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1d08600-3760-4707-a60a-8bccb007ca10" xlink:to="loc_us-gaap_BuildingMember_5ef60188-64d1-4645-aa40-22a7a1efa709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f749659f-5715-4381-a8dd-bfc5a39c5c90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_srt_ProductOrServiceAxis_f749659f-5715-4381-a8dd-bfc5a39c5c90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f749659f-5715-4381-a8dd-bfc5a39c5c90_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f749659f-5715-4381-a8dd-bfc5a39c5c90" xlink:to="loc_srt_ProductsAndServicesDomain_f749659f-5715-4381-a8dd-bfc5a39c5c90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e746001-404b-4d50-82b2-e4ebd343b5e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f749659f-5715-4381-a8dd-bfc5a39c5c90" xlink:to="loc_srt_ProductsAndServicesDomain_1e746001-404b-4d50-82b2-e4ebd343b5e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndNonCashRoyaltiesMember_1b41c1cf-4592-4b0a-9b6a-2b3bf490a719" xlink:href="nktr-20221231.xsd#nktr_CashAndNonCashRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1e746001-404b-4d50-82b2-e4ebd343b5e5" xlink:to="loc_nktr_CashAndNonCashRoyaltiesMember_1b41c1cf-4592-4b0a-9b6a-2b3bf490a719" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_0f082eb8-5972-458e-be45-15c027750d81" xlink:href="nktr-20221231.xsd#nktr_NKTR181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1e746001-404b-4d50-82b2-e4ebd343b5e5" xlink:to="loc_nktr_NKTR181Member_0f082eb8-5972-458e-be45-15c027750d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_61b3df13-b93d-4aae-9fa1-0ce3756a5661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_TypeOfArrangementAxis_61b3df13-b93d-4aae-9fa1-0ce3756a5661" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_61b3df13-b93d-4aae-9fa1-0ce3756a5661_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_61b3df13-b93d-4aae-9fa1-0ce3756a5661" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_61b3df13-b93d-4aae-9fa1-0ce3756a5661_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe0b2bd-aa5e-42a4-adf4-9a15cb491897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_61b3df13-b93d-4aae-9fa1-0ce3756a5661" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe0b2bd-aa5e-42a4-adf4-9a15cb491897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_a363a420-ea3d-41e9-b6a3-2a9261e16952" xlink:href="nktr-20221231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe0b2bd-aa5e-42a4-adf4-9a15cb491897" xlink:to="loc_nktr_BMSCollaborationAgreementMember_a363a420-ea3d-41e9-b6a3-2a9261e16952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_52e8b453-597f-486f-a502-974bc91ea0b1" xlink:href="nktr-20221231.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe0b2bd-aa5e-42a4-adf4-9a15cb491897" xlink:to="loc_nktr_Nektar358Member_52e8b453-597f-486f-a502-974bc91ea0b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_71e99251-5f28-4104-a75b-7e67e3e27beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_71e99251-5f28-4104-a75b-7e67e3e27beb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_71e99251-5f28-4104-a75b-7e67e3e27beb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_71e99251-5f28-4104-a75b-7e67e3e27beb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_71e99251-5f28-4104-a75b-7e67e3e27beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1e6197e-a269-4f0f-8b62-2614fb823a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_71e99251-5f28-4104-a75b-7e67e3e27beb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1e6197e-a269-4f0f-8b62-2614fb823a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsRSUsAndPSUsMember_64ee5d51-456a-4ac9-9e80-5fec697808fb" xlink:href="nktr-20221231.xsd#nktr_StockOptionsRSUsAndPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1e6197e-a269-4f0f-8b62-2614fb823a3a" xlink:to="loc_nktr_StockOptionsRSUsAndPSUsMember_64ee5d51-456a-4ac9-9e80-5fec697808fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_bcb6e5ee-14c5-4a97-b6df-feb653b767b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_bcb6e5ee-14c5-4a97-b6df-feb653b767b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bcb6e5ee-14c5-4a97-b6df-feb653b767b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_bcb6e5ee-14c5-4a97-b6df-feb653b767b3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bcb6e5ee-14c5-4a97-b6df-feb653b767b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_dd13113d-3dbe-4a1e-8beb-9279ac837f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_bcb6e5ee-14c5-4a97-b6df-feb653b767b3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_dd13113d-3dbe-4a1e-8beb-9279ac837f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_22f91c66-e771-4972-98ad-6feb1c99f7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_dd13113d-3dbe-4a1e-8beb-9279ac837f6b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_22f91c66-e771-4972-98ad-6feb1c99f7cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProgramTerminationMember_a4aa56ac-6908-4a0e-865d-903c29330f04" xlink:href="nktr-20221231.xsd#nktr_ProgramTerminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_dd13113d-3dbe-4a1e-8beb-9279ac837f6b" xlink:to="loc_nktr_ProgramTerminationMember_a4aa56ac-6908-4a0e-865d-903c29330f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember_ac225a09-63dd-459c-a959-e4eb93f33bfd" xlink:href="nktr-20221231.xsd#nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_ProgramTerminationMember_a4aa56ac-6908-4a0e-865d-903c29330f04" xlink:to="loc_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember_ac225a09-63dd-459c-a959-e4eb93f33bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProgramTerminationNoncancellableCommitmentsMember_b15c8b71-dced-464e-9374-2b582b8c6429" xlink:href="nktr-20221231.xsd#nktr_ProgramTerminationNoncancellableCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_ProgramTerminationMember_a4aa56ac-6908-4a0e-865d-903c29330f04" xlink:to="loc_nktr_ProgramTerminationNoncancellableCommitmentsMember_b15c8b71-dced-464e-9374-2b582b8c6429" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d69ca878-4146-4c97-bcde-31ddbf0d2c54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d69ca878-4146-4c97-bcde-31ddbf0d2c54" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d69ca878-4146-4c97-bcde-31ddbf0d2c54_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d69ca878-4146-4c97-bcde-31ddbf0d2c54" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d69ca878-4146-4c97-bcde-31ddbf0d2c54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ab85db1f-100d-420d-9fdd-c2112c7b9a7a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d69ca878-4146-4c97-bcde-31ddbf0d2c54" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ab85db1f-100d-420d-9fdd-c2112c7b9a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_322e49b5-748e-48ce-8b46-4a96f665c0e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ab85db1f-100d-420d-9fdd-c2112c7b9a7a" xlink:to="loc_srt_ParentCompanyMember_322e49b5-748e-48ce-8b46-4a96f665c0e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7c0a5071-d877-4d13-b316-3202a4273827" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_dei_LegalEntityAxis_7c0a5071-d877-4d13-b316-3202a4273827" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7c0a5071-d877-4d13-b316-3202a4273827_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7c0a5071-d877-4d13-b316-3202a4273827" xlink:to="loc_dei_EntityDomain_7c0a5071-d877-4d13-b316-3202a4273827_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f17d4751-eb1e-4e5b-9bd9-c9655b39f355" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7c0a5071-d877-4d13-b316-3202a4273827" xlink:to="loc_dei_EntityDomain_f17d4751-eb1e-4e5b-9bd9-c9655b39f355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_67d75544-f089-4df4-97c2-a55176f5589e" xlink:href="nktr-20221231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f17d4751-eb1e-4e5b-9bd9-c9655b39f355" xlink:to="loc_nktr_EliLillyAndCompanyMember_67d75544-f089-4df4-97c2-a55176f5589e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cc30a27-7061-42f4-aed9-754e7d65daa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cc30a27-7061-42f4-aed9-754e7d65daa6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cc30a27-7061-42f4-aed9-754e7d65daa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cc30a27-7061-42f4-aed9-754e7d65daa6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cc30a27-7061-42f4-aed9-754e7d65daa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c017f4a-71d6-4dc1-8483-83302a040bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cc30a27-7061-42f4-aed9-754e7d65daa6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c017f4a-71d6-4dc1-8483-83302a040bdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_24acf6ad-5c43-4198-bfe5-2a52e02bef8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c017f4a-71d6-4dc1-8483-83302a040bdf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_24acf6ad-5c43-4198-bfe5-2a52e02bef8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_285a237c-6fcb-437b-88e6-f42630de1aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_285a237c-6fcb-437b-88e6-f42630de1aa9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_285a237c-6fcb-437b-88e6-f42630de1aa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_285a237c-6fcb-437b-88e6-f42630de1aa9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_285a237c-6fcb-437b-88e6-f42630de1aa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3f1b297c-f230-408c-a66f-8c24dfdefc40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_285a237c-6fcb-437b-88e6-f42630de1aa9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3f1b297c-f230-408c-a66f-8c24dfdefc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_18c49bca-cb5b-4520-bd60-22744b1eb108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3f1b297c-f230-408c-a66f-8c24dfdefc40" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_18c49bca-cb5b-4520-bd60-22744b1eb108" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" xlink:type="extended" id="ia24e16fb546140c0b711d008db07911c_CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:href="nktr-20221231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InvestmnetsTargetMaturityPeriod_eb8066bf-30f4-4649-9550-0baed76eeea5" xlink:href="nktr-20221231.xsd#nktr_InvestmnetsTargetMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_nktr_InvestmnetsTargetMaturityPeriod_eb8066bf-30f4-4649-9550-0baed76eeea5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InvestmentsWeightedAverageMaturityPeriod_11fd82f5-5e93-48ef-a448-c5e8944b3737" xlink:href="nktr-20221231.xsd#nktr_InvestmentsWeightedAverageMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_nktr_InvestmentsWeightedAverageMaturityPeriod_11fd82f5-5e93-48ef-a448-c5e8944b3737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_76037234-0c86-4620-a3de-dc6a98cb8047" xlink:href="nktr-20221231.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_76037234-0c86-4620-a3de-dc6a98cb8047" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c7593ae0-1a25-41c9-b6fb-bd11d97de2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c7593ae0-1a25-41c9-b6fb-bd11d97de2d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_deac17e7-9fce-4b1b-b7c9-5de90cca101d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_InterestReceivableCurrent_deac17e7-9fce-4b1b-b7c9-5de90cca101d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b6297493-3e7d-47cc-8bf1-00aea1566aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b6297493-3e7d-47cc-8bf1-00aea1566aa2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_053e2926-4563-4f2c-8ac8-6505b5f9308a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_053e2926-4563-4f2c-8ac8-6505b5f9308a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_72058ae6-de77-4dbe-b4ef-2803b63e9a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_72058ae6-de77-4dbe-b4ef-2803b63e9a05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_309d374a-a884-4bd6-8069-c7527648a6e5" xlink:href="nktr-20221231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_309d374a-a884-4bd6-8069-c7527648a6e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9df30d5d-21ed-43a0-b999-61b3b08634f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_309d374a-a884-4bd6-8069-c7527648a6e5" xlink:to="loc_srt_RangeAxis_9df30d5d-21ed-43a0-b999-61b3b08634f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9df30d5d-21ed-43a0-b999-61b3b08634f0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9df30d5d-21ed-43a0-b999-61b3b08634f0" xlink:to="loc_srt_RangeMember_9df30d5d-21ed-43a0-b999-61b3b08634f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7f44a1e-a512-40b1-911d-875f44a70649" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9df30d5d-21ed-43a0-b999-61b3b08634f0" xlink:to="loc_srt_RangeMember_d7f44a1e-a512-40b1-911d-875f44a70649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4661951b-bc3d-48b6-874d-f70bf27f7c03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d7f44a1e-a512-40b1-911d-875f44a70649" xlink:to="loc_srt_MinimumMember_4661951b-bc3d-48b6-874d-f70bf27f7c03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_36ed9bca-7c30-493b-84b9-ef295f018bd5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d7f44a1e-a512-40b1-911d-875f44a70649" xlink:to="loc_srt_MaximumMember_36ed9bca-7c30-493b-84b9-ef295f018bd5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="extended" id="i8484b0f0a80f4c31a61e9865ef887a36_CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab057737-178a-4671-8582-7a48f2dc94de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab057737-178a-4671-8582-7a48f2dc94de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6b9a47ea-62de-4444-abea-ae8f6cb55ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6b9a47ea-62de-4444-abea-ae8f6cb55ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dc2f0c3d-1a21-4d68-bca0-c34648a6004d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dc2f0c3d-1a21-4d68-bca0-c34648a6004d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9ae2f7b0-0a02-4bd1-82df-d2dae086b166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9ae2f7b0-0a02-4bd1-82df-d2dae086b166" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_92c13978-df8d-44bf-9df5-8fbc53570fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_92c13978-df8d-44bf-9df5-8fbc53570fea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_5f86d6c2-eaf0-4e48-b061-3f7a7e05df79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_Cash_5f86d6c2-eaf0-4e48-b061-3f7a7e05df79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c743e03f-1b34-43c0-9f1f-655c95f3b7ce" xlink:href="nktr-20221231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c743e03f-1b34-43c0-9f1f-655c95f3b7ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1923763f-fd40-477f-92a2-015454d8ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1923763f-fd40-477f-92a2-015454d8ee3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5e55f1c5-e6ea-4006-94ef-b3de7deb4896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1923763f-fd40-477f-92a2-015454d8ee3f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5e55f1c5-e6ea-4006-94ef-b3de7deb4896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5e55f1c5-e6ea-4006-94ef-b3de7deb4896_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5e55f1c5-e6ea-4006-94ef-b3de7deb4896" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5e55f1c5-e6ea-4006-94ef-b3de7deb4896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5e55f1c5-e6ea-4006-94ef-b3de7deb4896" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6514d337-e154-4641-aa09-e98b705040f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6514d337-e154-4641-aa09-e98b705040f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2d620c50-0372-45f1-aaa7-ac018b6dba23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_CommercialPaperMember_2d620c50-0372-45f1-aaa7-ac018b6dba23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_dfd59140-610f-4598-8a6c-bea6ad2de09f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_dfd59140-610f-4598-8a6c-bea6ad2de09f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ba891623-7a30-4937-bc6e-10a56d660ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ba891623-7a30-4937-bc6e-10a56d660ca8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e60f12b0-ef2b-434b-b8d9-115c83993593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e60f12b0-ef2b-434b-b8d9-115c83993593" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d8bb376-80cc-482c-b515-1cdd4317b615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1923763f-fd40-477f-92a2-015454d8ee3f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d8bb376-80cc-482c-b515-1cdd4317b615" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d8bb376-80cc-482c-b515-1cdd4317b615_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d8bb376-80cc-482c-b515-1cdd4317b615" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d8bb376-80cc-482c-b515-1cdd4317b615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d2d60bc-6de0-4067-bb44-344b8b2e12b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d8bb376-80cc-482c-b515-1cdd4317b615" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d2d60bc-6de0-4067-bb44-344b8b2e12b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_98a67aee-da03-41ed-abe3-f1ee4a135054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d2d60bc-6de0-4067-bb44-344b8b2e12b0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_98a67aee-da03-41ed-abe3-f1ee4a135054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8aff77a7-bb87-4b94-afc0-ae842732fb16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d2d60bc-6de0-4067-bb44-344b8b2e12b0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8aff77a7-bb87-4b94-afc0-ae842732fb16" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i121d395ee1ee4b92af206abdf5b64380_PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_128632c7-b63f-49d5-acd1-3529b818a98c" xlink:href="nktr-20221231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_128632c7-b63f-49d5-acd1-3529b818a98c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_40f839e6-75f7-4607-ad6e-9ae841dfb82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_40f839e6-75f7-4607-ad6e-9ae841dfb82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_0c0b5e26-3939-423f-8e63-519ae2daefc9" xlink:href="nktr-20221231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_0c0b5e26-3939-423f-8e63-519ae2daefc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_dc759b93-e13a-4a73-8c1a-de771e865a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_us-gaap_ConstructionInProgressGross_dc759b93-e13a-4a73-8c1a-de771e865a56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_abb0ee83-9fc8-491a-be6f-374f459995cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_abb0ee83-9fc8-491a-be6f-374f459995cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82bcb834-6bf2-463f-8528-a54264453590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82bcb834-6bf2-463f-8528-a54264453590" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_060f9e70-7cea-4d97-acad-3ab2620494eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82bcb834-6bf2-463f-8528-a54264453590" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_060f9e70-7cea-4d97-acad-3ab2620494eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_060f9e70-7cea-4d97-acad-3ab2620494eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_060f9e70-7cea-4d97-acad-3ab2620494eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_060f9e70-7cea-4d97-acad-3ab2620494eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_060f9e70-7cea-4d97-acad-3ab2620494eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_c26aa939-ce69-463e-a8cd-23bcb795bfc8" xlink:href="nktr-20221231.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_c26aa939-ce69-463e-a8cd-23bcb795bfc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_ddf8f32f-4409-4b0d-88c3-968a04bbcbda" xlink:href="nktr-20221231.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_nktr_LaboratoryEquipmentMember_ddf8f32f-4409-4b0d-88c3-968a04bbcbda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember_2eba4752-1844-445f-967b-2e301d3a1908" xlink:href="nktr-20221231.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_nktr_ComputerFurnitureAndOtherMember_2eba4752-1844-445f-967b-2e301d3a1908" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_75c1a0fe-3a6e-421d-8445-467da2c67401" xlink:href="nktr-20221231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_75c1a0fe-3a6e-421d-8445-467da2c67401" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c2163073-924d-484f-b95a-e98abe7405dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c2163073-924d-484f-b95a-e98abe7405dc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="extended" id="i5736e902a3204ce0a913fe9f90dddbd0_OperatingLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:href="nktr-20221231.xsd#nktr_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpace_b013e56c-ee38-40f1-8de7-b29374238d52" xlink:href="nktr-20221231.xsd#nktr_AreaOfLeasedSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_nktr_AreaOfLeasedSpace_b013e56c-ee38-40f1-8de7-b29374238d52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1bf7fcd6-9aeb-4d6a-92cf-211adc130304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_us-gaap_AssetImpairmentCharges_1bf7fcd6-9aeb-4d6a-92cf-211adc130304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_94ceab3a-5017-4e37-9125-37ffd0a362e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_us-gaap_OperatingLeasePayments_94ceab3a-5017-4e37-9125-37ffd0a362e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab5f37f5-2168-4cf3-a2bf-5fa3afb3c33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab5f37f5-2168-4cf3-a2bf-5fa3afb3c33a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_69ed6ba5-4609-444b-b973-a22e7d14f5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_69ed6ba5-4609-444b-b973-a22e7d14f5cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasesIncomeToBeReceived_ca7074b2-fd00-4b33-a9b8-7300345fa6ce" xlink:href="nktr-20221231.xsd#nktr_SubleasesIncomeToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_nktr_SubleasesIncomeToBeReceived_ca7074b2-fd00-4b33-a9b8-7300345fa6ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_f00a0e18-66a6-427b-96ac-63fe76847432" xlink:href="nktr-20221231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_nktr_ScheduleOfLeasesTable_f00a0e18-66a6-427b-96ac-63fe76847432" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_fdc69b57-0dba-459c-8b11-e53e5c15a4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_ScheduleOfLeasesTable_f00a0e18-66a6-427b-96ac-63fe76847432" xlink:to="loc_us-gaap_LeaseContractualTermAxis_fdc69b57-0dba-459c-8b11-e53e5c15a4a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_fdc69b57-0dba-459c-8b11-e53e5c15a4a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_fdc69b57-0dba-459c-8b11-e53e5c15a4a7" xlink:to="loc_us-gaap_LeaseContractualTermDomain_fdc69b57-0dba-459c-8b11-e53e5c15a4a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_87de3485-bf96-433c-8ae3-b32071392fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_fdc69b57-0dba-459c-8b11-e53e5c15a4a7" xlink:to="loc_us-gaap_LeaseContractualTermDomain_87de3485-bf96-433c-8ae3-b32071392fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_933f7ad9-1126-42e9-8e87-626bfc75dc01" xlink:href="nktr-20221231.xsd#nktr_MissionBayLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_87de3485-bf96-433c-8ae3-b32071392fd9" xlink:to="loc_nktr_MissionBayLeaseMember_933f7ad9-1126-42e9-8e87-626bfc75dc01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_4a4b3ce1-d4ab-454d-b4e3-b196243c3d94" xlink:href="nktr-20221231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_87de3485-bf96-433c-8ae3-b32071392fd9" xlink:to="loc_nktr_ThirdStreetLeaseMember_4a4b3ce1-d4ab-454d-b4e3-b196243c3d94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4d1f5554-9c81-404e-a5d4-f8a65fb567d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_ScheduleOfLeasesTable_f00a0e18-66a6-427b-96ac-63fe76847432" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4d1f5554-9c81-404e-a5d4-f8a65fb567d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4d1f5554-9c81-404e-a5d4-f8a65fb567d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4d1f5554-9c81-404e-a5d4-f8a65fb567d8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4d1f5554-9c81-404e-a5d4-f8a65fb567d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94e11655-f80d-4e9d-b1b7-ba933d36159f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4d1f5554-9c81-404e-a5d4-f8a65fb567d8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94e11655-f80d-4e9d-b1b7-ba933d36159f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_5b57857a-d4d3-4e00-8ce1-af0b5f761148" xlink:href="nktr-20221231.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94e11655-f80d-4e9d-b1b7-ba933d36159f" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_5b57857a-d4d3-4e00-8ce1-af0b5f761148" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesScheduleofOperatingLeaseInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails" xlink:type="extended" id="i3c70d9f8831a4c82ab0c216685c2dcd7_OperatingLeasesScheduleofOperatingLeaseInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_ed484d86-4a82-48bc-a7fc-a6add6ae1a6d" xlink:href="nktr-20221231.xsd#nktr_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfConsecutiveTermsToExtendLease_c2f02514-1502-4afd-8221-8dfe53224c9d" xlink:href="nktr-20221231.xsd#nktr_NumberOfConsecutiveTermsToExtendLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_ed484d86-4a82-48bc-a7fc-a6add6ae1a6d" xlink:to="loc_nktr_NumberOfConsecutiveTermsToExtendLease_c2f02514-1502-4afd-8221-8dfe53224c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeaseExtensionTerm_73606246-739b-40ed-959c-5549156cec07" xlink:href="nktr-20221231.xsd#nktr_LeaseExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_ed484d86-4a82-48bc-a7fc-a6add6ae1a6d" xlink:to="loc_nktr_LeaseExtensionTerm_73606246-739b-40ed-959c-5549156cec07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_78e25900-7420-4745-8c6e-69e92a112523" xlink:href="nktr-20221231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LeasesLineItems_ed484d86-4a82-48bc-a7fc-a6add6ae1a6d" xlink:to="loc_nktr_ScheduleOfLeasesTable_78e25900-7420-4745-8c6e-69e92a112523" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ee57d817-94d0-4c29-8df9-aa69cde7d827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_ScheduleOfLeasesTable_78e25900-7420-4745-8c6e-69e92a112523" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ee57d817-94d0-4c29-8df9-aa69cde7d827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ee57d817-94d0-4c29-8df9-aa69cde7d827_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ee57d817-94d0-4c29-8df9-aa69cde7d827" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ee57d817-94d0-4c29-8df9-aa69cde7d827_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_1a78a1ed-b88a-4c48-b0b7-791df8a3263f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ee57d817-94d0-4c29-8df9-aa69cde7d827" xlink:to="loc_us-gaap_LeaseContractualTermDomain_1a78a1ed-b88a-4c48-b0b7-791df8a3263f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_99bc68f7-e638-4eb5-b271-e9e83a1bad64" xlink:href="nktr-20221231.xsd#nktr_MissionBayLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_1a78a1ed-b88a-4c48-b0b7-791df8a3263f" xlink:to="loc_nktr_MissionBayLeaseMember_99bc68f7-e638-4eb5-b271-e9e83a1bad64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_df182449-3e5f-4d45-8d8c-73f9d0083d60" xlink:href="nktr-20221231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_1a78a1ed-b88a-4c48-b0b7-791df8a3263f" xlink:to="loc_nktr_ThirdStreetLeaseMember_df182449-3e5f-4d45-8d8c-73f9d0083d60" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="extended" id="i6b232e7f160c4bae95834eef13dbcc47_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e217ea66-41fc-4b26-ae0d-dc43501cd864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_f57ff1c6-7783-4179-95c4-304c19b59e00" xlink:href="nktr-20221231.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e217ea66-41fc-4b26-ae0d-dc43501cd864" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_f57ff1c6-7783-4179-95c4-304c19b59e00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_d6523d2e-6f34-4a48-b58d-780e92349226" xlink:href="nktr-20221231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e217ea66-41fc-4b26-ae0d-dc43501cd864" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_d6523d2e-6f34-4a48-b58d-780e92349226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_814d68bd-a234-4cfa-ac26-9c9c2611441f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e217ea66-41fc-4b26-ae0d-dc43501cd864" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_814d68bd-a234-4cfa-ac26-9c9c2611441f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27cd6afe-7064-4d81-8c65-46bb16b32106" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_814d68bd-a234-4cfa-ac26-9c9c2611441f" xlink:to="loc_srt_CounterpartyNameAxis_27cd6afe-7064-4d81-8c65-46bb16b32106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27cd6afe-7064-4d81-8c65-46bb16b32106_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_27cd6afe-7064-4d81-8c65-46bb16b32106" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27cd6afe-7064-4d81-8c65-46bb16b32106_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4bdd03ad-3112-43c1-807e-2f37558ec4cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_27cd6afe-7064-4d81-8c65-46bb16b32106" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4bdd03ad-3112-43c1-807e-2f37558ec4cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_21661015-8cc5-4238-833a-2cf9b8bc8457" xlink:href="nktr-20221231.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4bdd03ad-3112-43c1-807e-2f37558ec4cb" xlink:to="loc_nktr_SFJPharmaceuticalsMember_21661015-8cc5-4238-833a-2cf9b8bc8457" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" xlink:type="extended" id="i0b36a6cb885545a3a30218c5b3520dcc_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ea6610e4-b23c-4bba-92e3-a9b3cce21277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ea6610e4-b23c-4bba-92e3-a9b3cce21277" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_80e49566-b554-4d19-9380-af81fc1cb1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_80e49566-b554-4d19-9380-af81fc1cb1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_16bf562e-12ca-472e-8373-e2ec293bcdda" xlink:href="nktr-20221231.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_16bf562e-12ca-472e-8373-e2ec293bcdda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b3cf0db9-e3b7-4d5f-a54e-01eec03d6117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b3cf0db9-e3b7-4d5f-a54e-01eec03d6117" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_cb6a3578-9d2f-43b4-ae9f-666d7e9f0fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_cb6a3578-9d2f-43b4-ae9f-666d7e9f0fcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b3c9b046-c6da-4bbb-bb05-c501c195adb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff57519a-4321-4711-85f4-0f7ab5c3b1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ea6610e4-b23c-4bba-92e3-a9b3cce21277" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff57519a-4321-4711-85f4-0f7ab5c3b1bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_079fb43f-ff8c-4bb5-8ee8-016d70124518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff57519a-4321-4711-85f4-0f7ab5c3b1bd" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_079fb43f-ff8c-4bb5-8ee8-016d70124518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_079fb43f-ff8c-4bb5-8ee8-016d70124518_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_079fb43f-ff8c-4bb5-8ee8-016d70124518" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_079fb43f-ff8c-4bb5-8ee8-016d70124518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ea068d3b-a4ea-43df-966c-c202a444b644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_079fb43f-ff8c-4bb5-8ee8-016d70124518" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ea068d3b-a4ea-43df-966c-c202a444b644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_af3a204d-1591-4e98-b945-5738bd0fcea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ea068d3b-a4ea-43df-966c-c202a444b644" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_af3a204d-1591-4e98-b945-5738bd0fcea6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c580168f-ea45-46c9-8e8f-bf98f614cc10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff57519a-4321-4711-85f4-0f7ab5c3b1bd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c580168f-ea45-46c9-8e8f-bf98f614cc10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c580168f-ea45-46c9-8e8f-bf98f614cc10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c580168f-ea45-46c9-8e8f-bf98f614cc10" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c580168f-ea45-46c9-8e8f-bf98f614cc10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78daa9ea-cea4-4a50-a1ef-2f0671f5f424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c580168f-ea45-46c9-8e8f-bf98f614cc10" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78daa9ea-cea4-4a50-a1ef-2f0671f5f424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1e8328a9-86fb-4173-ad16-8a992ae6b2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78daa9ea-cea4-4a50-a1ef-2f0671f5f424" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1e8328a9-86fb-4173-ad16-8a992ae6b2ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="extended" id="idcfa8df1b90048b4b2f421087d188ee8_LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_db2ee59b-9609-4a96-8777-bdbe895a9fd9" xlink:href="nktr-20221231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_db2ee59b-9609-4a96-8777-bdbe895a9fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_381aa3ab-4e2e-40ae-81da-e8a73c9fb729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_381aa3ab-4e2e-40ae-81da-e8a73c9fb729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_6a247666-7dd0-4e1e-8e80-59f22e1496a2" xlink:href="nktr-20221231.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_6a247666-7dd0-4e1e-8e80-59f22e1496a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_ca2380e5-2bbb-4b1f-8f6d-66174b5012a7" xlink:href="nktr-20221231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_ca2380e5-2bbb-4b1f-8f6d-66174b5012a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_6250178a-90e2-4a66-98a7-7402dfd5310b" xlink:href="nktr-20221231.xsd#nktr_TransactionCostsRelatedToRevisedRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_6250178a-90e2-4a66-98a7-7402dfd5310b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_48f47591-e552-4492-ba5a-04e4f5b5dcbc" xlink:href="nktr-20221231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_48f47591-e552-4492-ba5a-04e4f5b5dcbc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_6d0c8ecc-32c0-48e1-9997-7a030c30eb06" xlink:href="nktr-20221231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_6d0c8ecc-32c0-48e1-9997-7a030c30eb06" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_7fae5a5d-a53b-48b7-ab01-fc90cb2dafe7" xlink:href="nktr-20221231.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_7fae5a5d-a53b-48b7-ab01-fc90cb2dafe7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_e2307690-92f9-4b04-a955-32370b1463a6" xlink:href="nktr-20221231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_e2307690-92f9-4b04-a955-32370b1463a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_b515b043-6668-4180-bbf9-1c119507a040" xlink:href="nktr-20221231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_b515b043-6668-4180-bbf9-1c119507a040" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_0443d9d6-6e7f-45a8-ab21-c8c7e8d1f89e" xlink:href="nktr-20221231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_0443d9d6-6e7f-45a8-ab21-c8c7e8d1f89e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_50fdb780-3ba4-4ce1-baca-23cd1f088536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:to="loc_us-gaap_TypeOfArrangementAxis_50fdb780-3ba4-4ce1-baca-23cd1f088536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50fdb780-3ba4-4ce1-baca-23cd1f088536_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50fdb780-3ba4-4ce1-baca-23cd1f088536" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50fdb780-3ba4-4ce1-baca-23cd1f088536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50fdb780-3ba4-4ce1-baca-23cd1f088536" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_095fb2a6-8a47-4af9-98ac-c27970cd1ba7" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_095fb2a6-8a47-4af9-98ac-c27970cd1ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_a4e2d576-db25-42cc-9fd8-3a9a18b54cc7" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_a4e2d576-db25-42cc-9fd8-3a9a18b54cc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_cfe42540-5b7e-4613-a0bd-1a2a27cd2b4b" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_cfe42540-5b7e-4613-a0bd-1a2a27cd2b4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5dd64ec2-c3ff-46f5-949c-2c3b664e9d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5dd64ec2-c3ff-46f5-949c-2c3b664e9d28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5dd64ec2-c3ff-46f5-949c-2c3b664e9d28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5dd64ec2-c3ff-46f5-949c-2c3b664e9d28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5dd64ec2-c3ff-46f5-949c-2c3b664e9d28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b677e9e0-7d16-47a0-97a0-8e0a05a94c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5dd64ec2-c3ff-46f5-949c-2c3b664e9d28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b677e9e0-7d16-47a0-97a0-8e0a05a94c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FutureRoyaltiesMember_c3081f3b-b88f-4349-b44b-62121be269c4" xlink:href="nktr-20221231.xsd#nktr_FutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b677e9e0-7d16-47a0-97a0-8e0a05a94c82" xlink:to="loc_nktr_FutureRoyaltiesMember_c3081f3b-b88f-4349-b44b-62121be269c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_147efa77-c53f-41f6-a568-d757fe3020b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_147efa77-c53f-41f6-a568-d757fe3020b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_147efa77-c53f-41f6-a568-d757fe3020b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_147efa77-c53f-41f6-a568-d757fe3020b2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_147efa77-c53f-41f6-a568-d757fe3020b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_007f7d28-d7bd-43cb-bdb0-2f31bb201d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_147efa77-c53f-41f6-a568-d757fe3020b2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_007f7d28-d7bd-43cb-bdb0-2f31bb201d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_78f68f4f-532d-4391-9d4e-ea6d6b145e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_007f7d28-d7bd-43cb-bdb0-2f31bb201d04" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_78f68f4f-532d-4391-9d4e-ea6d6b145e2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputInceptionDiscountRateMember_6d16c85e-f52d-4543-b16a-e54f7adc62dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputInceptionDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_007f7d28-d7bd-43cb-bdb0-2f31bb201d04" xlink:to="loc_us-gaap_MeasurementInputInceptionDiscountRateMember_6d16c85e-f52d-4543-b16a-e54f7adc62dc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20221231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="extended" id="i95d28f2777c54df78fc602d7c8f9a046_LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_f3238c98-02fd-45fe-878e-acb5fca6cf0d" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_f3238c98-02fd-45fe-878e-acb5fca6cf0d" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_94ca88c9-0dea-40db-b7d4-dda8ec9851c7" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_94ca88c9-0dea-40db-b7d4-dda8ec9851c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_a979cf62-7828-4a4e-8015-5c45fd0c1f67" xlink:href="nktr-20221231.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_a979cf62-7828-4a4e-8015-5c45fd0c1f67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_fcee4e80-a614-4526-8fa9-e5aab9af18f8" xlink:href="nktr-20221231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_fcee4e80-a614-4526-8fa9-e5aab9af18f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b0ccb828-c8bc-4776-99ba-bcf96b8a985e" xlink:href="nktr-20221231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b0ccb828-c8bc-4776-99ba-bcf96b8a985e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_1b4c491a-2629-43d6-bf9a-1b4ed3e1256a" xlink:href="nktr-20221231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_1b4c491a-2629-43d6-bf9a-1b4ed3e1256a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_3ec00082-59b0-4ba8-8674-b0b740fb1d75" xlink:href="nktr-20221231.xsd#nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_3ec00082-59b0-4ba8-8674-b0b740fb1d75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_27d81000-7000-4db8-b613-07993a9f3c20" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_cd8347cd-d2be-422f-994c-feae4de9c55c" xlink:href="nktr-20221231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_cd8347cd-d2be-422f-994c-feae4de9c55c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_8f5a74d3-5de0-4fee-afc7-00fa6d7e9dc3" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_8f5a74d3-5de0-4fee-afc7-00fa6d7e9dc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_5d2fbfa6-3c5a-4ae4-a126-713b707163e0" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_f3238c98-02fd-45fe-878e-acb5fca6cf0d" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_5d2fbfa6-3c5a-4ae4-a126-713b707163e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c2e87a69-e05b-4089-903c-d0483622eb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_5d2fbfa6-3c5a-4ae4-a126-713b707163e0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c2e87a69-e05b-4089-903c-d0483622eb7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2e87a69-e05b-4089-903c-d0483622eb7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c2e87a69-e05b-4089-903c-d0483622eb7c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2e87a69-e05b-4089-903c-d0483622eb7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38788017-4891-4aba-984a-e0b3a790e57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c2e87a69-e05b-4089-903c-d0483622eb7c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38788017-4891-4aba-984a-e0b3a790e57c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_a019f463-668d-4500-aa14-15b677a30f0f" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38788017-4891-4aba-984a-e0b3a790e57c" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_a019f463-668d-4500-aa14-15b677a30f0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_8e595b24-79fd-4b13-8106-707d5b8ff8d4" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38788017-4891-4aba-984a-e0b3a790e57c" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_8e595b24-79fd-4b13-8106-707d5b8ff8d4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="id707c59a05ed43adad568b0678935610_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_08176748-508c-434d-8dc0-24ec7ea16ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_198096ec-d8bc-4910-a516-eb4ff2ab0c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_08176748-508c-434d-8dc0-24ec7ea16ee1" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_198096ec-d8bc-4910-a516-eb4ff2ab0c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_e753fd0c-20cc-44a6-a59d-abe97196b8be" xlink:href="nktr-20221231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_08176748-508c-434d-8dc0-24ec7ea16ee1" xlink:to="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_e753fd0c-20cc-44a6-a59d-abe97196b8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ae5f4e2b-91fc-43c6-aede-a7d4c34381c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_08176748-508c-434d-8dc0-24ec7ea16ee1" xlink:to="loc_us-gaap_LossContingenciesTable_ae5f4e2b-91fc-43c6-aede-a7d4c34381c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_af66958a-64fe-424e-9f94-20d914e6f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ae5f4e2b-91fc-43c6-aede-a7d4c34381c1" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_af66958a-64fe-424e-9f94-20d914e6f99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_af66958a-64fe-424e-9f94-20d914e6f99b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_af66958a-64fe-424e-9f94-20d914e6f99b" xlink:to="loc_us-gaap_LossContingencyNatureDomain_af66958a-64fe-424e-9f94-20d914e6f99b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_af66958a-64fe-424e-9f94-20d914e6f99b" xlink:to="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_ec9f3299-0c1b-4bb1-b2fb-07340e018fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_ec9f3299-0c1b-4bb1-b2fb-07340e018fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_ea33ee76-4032-4fba-8370-61787a56e4c6" xlink:href="nktr-20221231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:to="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_ea33ee76-4032-4fba-8370-61787a56e4c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuritiesRelatedClaimsMember_660ac26e-9f7e-4b70-9ddb-7d0a48a8c6ed" xlink:href="nktr-20221231.xsd#nktr_SecuritiesRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:to="loc_nktr_SecuritiesRelatedClaimsMember_660ac26e-9f7e-4b70-9ddb-7d0a48a8c6ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonSecuritiesRelatedClaimsMember_4cb6090e-8afe-4f70-835e-336d80785e7f" xlink:href="nktr-20221231.xsd#nktr_NonSecuritiesRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:to="loc_nktr_NonSecuritiesRelatedClaimsMember_4cb6090e-8afe-4f70-835e-336d80785e7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f1ca8ebe-7555-47ed-b0c2-af4b8b6649d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ae5f4e2b-91fc-43c6-aede-a7d4c34381c1" xlink:to="loc_srt_RangeAxis_f1ca8ebe-7555-47ed-b0c2-af4b8b6649d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f1ca8ebe-7555-47ed-b0c2-af4b8b6649d9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f1ca8ebe-7555-47ed-b0c2-af4b8b6649d9" xlink:to="loc_srt_RangeMember_f1ca8ebe-7555-47ed-b0c2-af4b8b6649d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9fb92912-230e-41e5-9450-32897b43ddde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f1ca8ebe-7555-47ed-b0c2-af4b8b6649d9" xlink:to="loc_srt_RangeMember_9fb92912-230e-41e5-9450-32897b43ddde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_691de37f-656b-4f89-8620-fbcfc01814d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9fb92912-230e-41e5-9450-32897b43ddde" xlink:to="loc_srt_MaximumMember_691de37f-656b-4f89-8620-fbcfc01814d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i5f87d062aa424e4985ccd4fb4cc2f02f_StockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15eeb4d2-05c0-4dd1-b605-457908548623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15eeb4d2-05c0-4dd1-b605-457908548623" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_45d9e1b4-9bad-456c-b053-5cad1ab5527e" xlink:href="nktr-20221231.xsd#nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:to="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_45d9e1b4-9bad-456c-b053-5cad1ab5527e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockValueAuthorizedInTransaction_29f8b277-5d75-493a-b360-1d878bf83007" xlink:href="nktr-20221231.xsd#nktr_SaleOfStockValueAuthorizedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:to="loc_nktr_SaleOfStockValueAuthorizedInTransaction_29f8b277-5d75-493a-b360-1d878bf83007" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e6f981a6-9c14-4ab0-8cef-a6da9f210181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:to="loc_us-gaap_StockholdersEquity_e6f981a6-9c14-4ab0-8cef-a6da9f210181" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9fab8c39-d356-4e9c-a41a-9aece9c955b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9fab8c39-d356-4e9c-a41a-9aece9c955b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4c2836fe-93c9-448b-964c-1acd106c892c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9fab8c39-d356-4e9c-a41a-9aece9c955b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4c2836fe-93c9-448b-964c-1acd106c892c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4c2836fe-93c9-448b-964c-1acd106c892c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c2836fe-93c9-448b-964c-1acd106c892c" xlink:to="loc_us-gaap_EquityComponentDomain_4c2836fe-93c9-448b-964c-1acd106c892c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c2836fe-93c9-448b-964c-1acd106c892c" xlink:to="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9fd09881-a31c-4464-87e2-d9f051e3ebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:to="loc_us-gaap_CommonStockMember_9fd09881-a31c-4464-87e2-d9f051e3ebb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e387d7dc-0c13-4eae-b9e7-00e7ea1e2485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e387d7dc-0c13-4eae-b9e7-00e7ea1e2485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7c1f6ed9-d364-4045-9642-6a831cbbf46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7c1f6ed9-d364-4045-9642-6a831cbbf46e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended" id="if07081da27f9431e9aafc6310d5a2b5b_StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_767a3036-2162-46d9-bf63-9ad2e1c60937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a165476-9792-47b3-b43c-0be1a95c816a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_767a3036-2162-46d9-bf63-9ad2e1c60937" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a165476-9792-47b3-b43c-0be1a95c816a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d78a0707-cfbd-45e9-a184-69954ebc1dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_767a3036-2162-46d9-bf63-9ad2e1c60937" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d78a0707-cfbd-45e9-a184-69954ebc1dc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5d5ae51-013b-43f5-9398-409ef2f9abfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a0707-cfbd-45e9-a184-69954ebc1dc5" xlink:to="loc_us-gaap_AwardTypeAxis_f5d5ae51-013b-43f5-9398-409ef2f9abfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5d5ae51-013b-43f5-9398-409ef2f9abfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f5d5ae51-013b-43f5-9398-409ef2f9abfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5d5ae51-013b-43f5-9398-409ef2f9abfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36c4e3ed-cb33-4753-a50c-fb5c49b1c729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f5d5ae51-013b-43f5-9398-409ef2f9abfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36c4e3ed-cb33-4753-a50c-fb5c49b1c729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_d0849a5f-992b-474b-86f4-d0baf6f3012b" xlink:href="nktr-20221231.xsd#nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36c4e3ed-cb33-4753-a50c-fb5c49b1c729" xlink:to="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_d0849a5f-992b-474b-86f4-d0baf6f3012b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6332c2b7-c35c-4c10-bcc6-fe12fab5e4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a0707-cfbd-45e9-a184-69954ebc1dc5" xlink:to="loc_us-gaap_PlanNameAxis_6332c2b7-c35c-4c10-bcc6-fe12fab5e4cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6332c2b7-c35c-4c10-bcc6-fe12fab5e4cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6332c2b7-c35c-4c10-bcc6-fe12fab5e4cd" xlink:to="loc_us-gaap_PlanNameDomain_6332c2b7-c35c-4c10-bcc6-fe12fab5e4cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_475285c9-237d-4dc6-8f77-dd17e98952b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6332c2b7-c35c-4c10-bcc6-fe12fab5e4cd" xlink:to="loc_us-gaap_PlanNameDomain_475285c9-237d-4dc6-8f77-dd17e98952b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_d837ab17-0117-4911-892e-09602bd596ae" xlink:href="nktr-20221231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_475285c9-237d-4dc6-8f77-dd17e98952b6" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_d837ab17-0117-4911-892e-09602bd596ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_8da7e3d2-ab34-443e-b380-123c8fa22d6c" xlink:href="nktr-20221231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_475285c9-237d-4dc6-8f77-dd17e98952b6" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_8da7e3d2-ab34-443e-b380-123c8fa22d6c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" xlink:type="extended" id="i1595ec48fd714e8fa2e133ee3907c91e_LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_ebc55657-90e4-4b49-ba9d-21e634c1557b" xlink:href="nktr-20221231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_e7765eef-8a09-4c79-b234-3029bfbb8ca9" xlink:href="nktr-20221231.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_ebc55657-90e4-4b49-ba9d-21e634c1557b" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_e7765eef-8a09-4c79-b234-3029bfbb8ca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_f37a7948-66a1-496f-b9a6-c61ac4aa8a34" xlink:href="nktr-20221231.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_ebc55657-90e4-4b49-ba9d-21e634c1557b" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_f37a7948-66a1-496f-b9a6-c61ac4aa8a34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e0d0e796-105c-4e5c-afe5-dadec6be089e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_f37a7948-66a1-496f-b9a6-c61ac4aa8a34" xlink:to="loc_dei_LegalEntityAxis_e0d0e796-105c-4e5c-afe5-dadec6be089e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e0d0e796-105c-4e5c-afe5-dadec6be089e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e0d0e796-105c-4e5c-afe5-dadec6be089e" xlink:to="loc_dei_EntityDomain_e0d0e796-105c-4e5c-afe5-dadec6be089e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ceb4848a-71e7-4f78-bdbb-ba90e46a6dc7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e0d0e796-105c-4e5c-afe5-dadec6be089e" xlink:to="loc_dei_EntityDomain_ceb4848a-71e7-4f78-bdbb-ba90e46a6dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_189600e3-19eb-4a7b-b5c9-4d9baca60e34" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ceb4848a-71e7-4f78-bdbb-ba90e46a6dc7" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_189600e3-19eb-4a7b-b5c9-4d9baca60e34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_8dd80f3d-5f96-4ce6-8a33-f6a54b1d3ac1" xlink:href="nktr-20221231.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ceb4848a-71e7-4f78-bdbb-ba90e46a6dc7" xlink:to="loc_nktr_OtherPartnerMember_8dd80f3d-5f96-4ce6-8a33-f6a54b1d3ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f55feca2-3248-4b6d-8a1d-28df67958e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_f37a7948-66a1-496f-b9a6-c61ac4aa8a34" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f55feca2-3248-4b6d-8a1d-28df67958e8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f55feca2-3248-4b6d-8a1d-28df67958e8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f55feca2-3248-4b6d-8a1d-28df67958e8d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f55feca2-3248-4b6d-8a1d-28df67958e8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1cd6619b-9dc5-4e61-af7b-74bb669c9201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f55feca2-3248-4b6d-8a1d-28df67958e8d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1cd6619b-9dc5-4e61-af7b-74bb669c9201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BempegaldesleukinMember_07d190ba-76be-4850-aecd-7fcdf8dbad1d" xlink:href="nktr-20221231.xsd#nktr_BempegaldesleukinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1cd6619b-9dc5-4e61-af7b-74bb669c9201" xlink:to="loc_nktr_BempegaldesleukinMember_07d190ba-76be-4850-aecd-7fcdf8dbad1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended" id="ia0423fb73b6c4052b0bfb3c1927b710f_LicenseandCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_9706ee03-a423-4377-b812-6aacb41ad2ac" xlink:href="nktr-20221231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_9706ee03-a423-4377-b812-6aacb41ad2ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_05ef0393-d05d-4d6a-baab-f4296bfb67de" xlink:href="nktr-20221231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_05ef0393-d05d-4d6a-baab-f4296bfb67de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_fb183793-3da0-49e7-8bac-557f078f9b7f" xlink:href="nktr-20221231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_fb183793-3da0-49e7-8bac-557f078f9b7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_09eb0955-32c3-4423-979d-c284d3a007c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_us-gaap_SharesIssued_09eb0955-32c3-4423-979d-c284d3a007c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_e905bcec-16f8-47a7-9ea7-7dd80e7d1138" xlink:href="nktr-20221231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_e905bcec-16f8-47a7-9ea7-7dd80e7d1138" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_55e3344a-3aa7-45e7-a62d-f5f28d4f58ef" xlink:href="nktr-20221231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PotentialDevelopmentMilestones_55e3344a-3aa7-45e7-a62d-f5f28d4f58ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_d0a88a5b-54a7-40c5-a509-50a87c4fac95" xlink:href="nktr-20221231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_ReimbursementOfExpenses_d0a88a5b-54a7-40c5-a509-50a87c4fac95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_32b97497-443d-496c-98ab-e18169dbb1a4" xlink:href="nktr-20221231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_32b97497-443d-496c-98ab-e18169dbb1a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_5f85c461-4968-40fd-b464-381e8ddf856c" xlink:href="nktr-20221231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_5f85c461-4968-40fd-b464-381e8ddf856c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_28946935-39ae-4c9f-93ab-0758af7c8aa5" xlink:href="nktr-20221231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_28946935-39ae-4c9f-93ab-0758af7c8aa5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_b1e5f4d4-15dd-4549-ab70-287d8bfd6c2c" xlink:href="nktr-20221231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_b1e5f4d4-15dd-4549-ab70-287d8bfd6c2c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_ca15c8d9-a0a5-441a-a287-5da6d88eaa6a" xlink:href="nktr-20221231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_ca15c8d9-a0a5-441a-a287-5da6d88eaa6a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_14f51dfa-e2d3-4f8c-a0b7-57d91dc13781" xlink:href="nktr-20221231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_14f51dfa-e2d3-4f8c-a0b7-57d91dc13781" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_0063faa0-c7e5-4da0-b480-d3526d079183" xlink:href="nktr-20221231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_0063faa0-c7e5-4da0-b480-d3526d079183" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b03eefe3-2cef-4e0f-bdea-ba9094551a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b03eefe3-2cef-4e0f-bdea-ba9094551a7a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b2ff2d85-7f81-4823-b164-8b00eaefa39e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b2ff2d85-7f81-4823-b164-8b00eaefa39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b2ff2d85-7f81-4823-b164-8b00eaefa39e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b2ff2d85-7f81-4823-b164-8b00eaefa39e" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b2ff2d85-7f81-4823-b164-8b00eaefa39e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8a0b565e-42f6-41c8-9abe-8cc1b35c1bb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b2ff2d85-7f81-4823-b164-8b00eaefa39e" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8a0b565e-42f6-41c8-9abe-8cc1b35c1bb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_29ecda9c-1fc7-4b2a-9372-34cdb1b6bd52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8a0b565e-42f6-41c8-9abe-8cc1b35c1bb2" xlink:to="loc_srt_ParentCompanyMember_29ecda9c-1fc7-4b2a-9372-34cdb1b6bd52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a9bface7-2704-4f9e-84ab-767830c68a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a9bface7-2704-4f9e-84ab-767830c68a58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9bface7-2704-4f9e-84ab-767830c68a58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a9bface7-2704-4f9e-84ab-767830c68a58" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9bface7-2704-4f9e-84ab-767830c68a58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a4175b8-a18f-4b02-a517-d79bd6620b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a9bface7-2704-4f9e-84ab-767830c68a58" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a4175b8-a18f-4b02-a517-d79bd6620b35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_5c2c76e7-8fa5-4b64-b755-d292db290404" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a4175b8-a18f-4b02-a517-d79bd6620b35" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_5c2c76e7-8fa5-4b64-b755-d292db290404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_15f8231b-c88f-4145-98f6-7c65d7c21822" xlink:href="nktr-20221231.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a4175b8-a18f-4b02-a517-d79bd6620b35" xlink:to="loc_nktr_Nektar358Member_15f8231b-c88f-4145-98f6-7c65d7c21822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d1328f3a-0093-4e7a-9bff-608ce9326ed1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_srt_ProductOrServiceAxis_d1328f3a-0093-4e7a-9bff-608ce9326ed1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d1328f3a-0093-4e7a-9bff-608ce9326ed1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d1328f3a-0093-4e7a-9bff-608ce9326ed1" xlink:to="loc_srt_ProductsAndServicesDomain_d1328f3a-0093-4e7a-9bff-608ce9326ed1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4363a8c4-7f20-4a52-ac12-4f3c41a66b18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d1328f3a-0093-4e7a-9bff-608ce9326ed1" xlink:to="loc_srt_ProductsAndServicesDomain_4363a8c4-7f20-4a52-ac12-4f3c41a66b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_59ff004e-ad72-480a-8a80-67ab8ea7812e" xlink:href="nktr-20221231.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4363a8c4-7f20-4a52-ac12-4f3c41a66b18" xlink:to="loc_nktr_Nektar214Member_59ff004e-ad72-480a-8a80-67ab8ea7812e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_edd937ab-8237-4f00-a80f-f7272593e7eb" xlink:href="nktr-20221231.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4363a8c4-7f20-4a52-ac12-4f3c41a66b18" xlink:to="loc_nktr_Nektar358Member_edd937ab-8237-4f00-a80f-f7272593e7eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a9eee41c-dfa0-4af0-becc-28e2e091a6e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_dei_LegalEntityAxis_a9eee41c-dfa0-4af0-becc-28e2e091a6e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a9eee41c-dfa0-4af0-becc-28e2e091a6e7_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a9eee41c-dfa0-4af0-becc-28e2e091a6e7" xlink:to="loc_dei_EntityDomain_a9eee41c-dfa0-4af0-becc-28e2e091a6e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a9eee41c-dfa0-4af0-becc-28e2e091a6e7" xlink:to="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_db05ec8c-3d48-481f-9ae8-d5975aa623c7" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_db05ec8c-3d48-481f-9ae8-d5975aa623c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_b59b5ecd-9a06-4248-99c8-9597670b6eac" xlink:href="nktr-20221231.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:to="loc_nktr_EliLillyMember_b59b5ecd-9a06-4248-99c8-9597670b6eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_bf9aa363-824f-43f9-9361-b7239e83d3a5" xlink:href="nktr-20221231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:to="loc_nktr_EliLillyAndCompanyMember_bf9aa363-824f-43f9-9361-b7239e83d3a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_e6ee9403-2b00-47a7-81de-6e75399ef2a3" xlink:href="nktr-20221231.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:to="loc_nktr_OtherPartnerMember_e6ee9403-2b00-47a7-81de-6e75399ef2a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_19e83573-5aff-46ce-b005-bfb6d7ba55da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_19e83573-5aff-46ce-b005-bfb6d7ba55da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19e83573-5aff-46ce-b005-bfb6d7ba55da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_19e83573-5aff-46ce-b005-bfb6d7ba55da" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19e83573-5aff-46ce-b005-bfb6d7ba55da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0696b614-73ff-45d7-a550-58cb96839bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_19e83573-5aff-46ce-b005-bfb6d7ba55da" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0696b614-73ff-45d7-a550-58cb96839bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_651d2f74-aef4-4d76-86ee-61a478b7489c" xlink:href="nktr-20221231.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0696b614-73ff-45d7-a550-58cb96839bcf" xlink:to="loc_nktr_OpdivoMember_651d2f74-aef4-4d76-86ee-61a478b7489c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_58da2e04-f5a7-4352-bba6-5eaf3b316654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_58da2e04-f5a7-4352-bba6-5eaf3b316654" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58da2e04-f5a7-4352-bba6-5eaf3b316654_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_58da2e04-f5a7-4352-bba6-5eaf3b316654" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58da2e04-f5a7-4352-bba6-5eaf3b316654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf1293be-d9a2-4cb0-b790-3d7be8b53bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_58da2e04-f5a7-4352-bba6-5eaf3b316654" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf1293be-d9a2-4cb0-b790-3d7be8b53bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_0a87d282-2e15-4946-b890-6f6f38e55651" xlink:href="nktr-20221231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf1293be-d9a2-4cb0-b790-3d7be8b53bbb" xlink:to="loc_nktr_SharePurchaseAgreementMember_0a87d282-2e15-4946-b890-6f6f38e55651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_5d3ccd9b-ba58-45d7-80d9-219ad9f9a380" xlink:href="nktr-20221231.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_nktr_MilestoneAxis_5d3ccd9b-ba58-45d7-80d9-219ad9f9a380" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_5d3ccd9b-ba58-45d7-80d9-219ad9f9a380_default" xlink:href="nktr-20221231.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_5d3ccd9b-ba58-45d7-80d9-219ad9f9a380" xlink:to="loc_nktr_MilestoneDomain_5d3ccd9b-ba58-45d7-80d9-219ad9f9a380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_799b4b1b-8671-403b-af3f-7fca316d7abe" xlink:href="nktr-20221231.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_5d3ccd9b-ba58-45d7-80d9-219ad9f9a380" xlink:to="loc_nktr_MilestoneDomain_799b4b1b-8671-403b-af3f-7fca316d7abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_22b6924a-bf91-42ca-926c-67d4fcb75cc6" xlink:href="nktr-20221231.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_799b4b1b-8671-403b-af3f-7fca316d7abe" xlink:to="loc_nktr_MilestoneOneMember_22b6924a-bf91-42ca-926c-67d4fcb75cc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea28372a-2a5e-4db9-8ad0-45afbac7883e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_srt_RangeAxis_ea28372a-2a5e-4db9-8ad0-45afbac7883e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea28372a-2a5e-4db9-8ad0-45afbac7883e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ea28372a-2a5e-4db9-8ad0-45afbac7883e" xlink:to="loc_srt_RangeMember_ea28372a-2a5e-4db9-8ad0-45afbac7883e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a76c1c0a-bf6e-4dee-9d8f-1e95f4861e9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ea28372a-2a5e-4db9-8ad0-45afbac7883e" xlink:to="loc_srt_RangeMember_a76c1c0a-bf6e-4dee-9d8f-1e95f4861e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6d476037-7971-45c6-aa6f-33fb8bc79fa7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a76c1c0a-bf6e-4dee-9d8f-1e95f4861e9b" xlink:to="loc_srt_MaximumMember_6d476037-7971-45c6-aa6f-33fb8bc79fa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b9f96040-b298-4870-a868-074245d4e3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b9f96040-b298-4870-a868-074245d4e3c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b9f96040-b298-4870-a868-074245d4e3c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b9f96040-b298-4870-a868-074245d4e3c9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b9f96040-b298-4870-a868-074245d4e3c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_72ee96e8-9fb4-4643-9c6f-0f8b0635b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b9f96040-b298-4870-a868-074245d4e3c9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_72ee96e8-9fb4-4643-9c6f-0f8b0635b5c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17182af9-c308-41d9-be61-74d2c47286d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_72ee96e8-9fb4-4643-9c6f-0f8b0635b5c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17182af9-c308-41d9-be61-74d2c47286d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e7b9b6af-294d-405b-9f64-caeeb9430faa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_srt_CounterpartyNameAxis_e7b9b6af-294d-405b-9f64-caeeb9430faa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7b9b6af-294d-405b-9f64-caeeb9430faa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e7b9b6af-294d-405b-9f64-caeeb9430faa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7b9b6af-294d-405b-9f64-caeeb9430faa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d5421d7-de17-420d-b333-99eacd4b70fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e7b9b6af-294d-405b-9f64-caeeb9430faa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d5421d7-de17-420d-b333-99eacd4b70fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_69bd1240-415f-4693-8561-dd9087a81ee6" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d5421d7-de17-420d-b333-99eacd4b70fa" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_69bd1240-415f-4693-8561-dd9087a81ee6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" xlink:type="extended" id="i55c8f99a16d642a6afe574d4708a1143_RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d95bb6bb-4f10-4a72-9b4f-caf9672ddc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d95bb6bb-4f10-4a72-9b4f-caf9672ddc46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_6d1ec03c-0058-4938-8314-cf10d2d3b9fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_dei_EntityNumberOfEmployees_6d1ec03c-0058-4938-8314-cf10d2d3b9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_1c0c5e78-ba84-4bc4-a660-d2d865b8bf90" xlink:href="nktr-20221231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_nktr_ReimbursementOfExpenses_1c0c5e78-ba84-4bc4-a660-d2d865b8bf90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OperatingLeaseMeasurementInput_b78b8799-8edb-4e4d-bca8-05544a15b583" xlink:href="nktr-20221231.xsd#nktr_OperatingLeaseMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_nktr_OperatingLeaseMeasurementInput_b78b8799-8edb-4e4d-bca8-05544a15b583" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_066f1b1f-f284-4fae-a2e7-9da1daa08918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_us-gaap_AssetImpairmentCharges_066f1b1f-f284-4fae-a2e7-9da1daa08918" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_95708993-baa9-486b-8cd9-853bebd67998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_95708993-baa9-486b-8cd9-853bebd67998" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_4ee9122f-06ba-4af0-a20f-67202346bfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_4ee9122f-06ba-4af0-a20f-67202346bfa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4ee9122f-06ba-4af0-a20f-67202346bfa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_4ee9122f-06ba-4af0-a20f-67202346bfa9" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4ee9122f-06ba-4af0-a20f-67202346bfa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0b33f7bd-47b6-4fbc-9146-cf925cd6821c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_4ee9122f-06ba-4af0-a20f-67202346bfa9" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0b33f7bd-47b6-4fbc-9146-cf925cd6821c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_daa06dbe-ab79-44d6-afae-388293a9a8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0b33f7bd-47b6-4fbc-9146-cf925cd6821c" xlink:to="loc_us-gaap_EmployeeSeveranceMember_daa06dbe-ab79-44d6-afae-388293a9a8d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_697673ee-42cd-4dbf-99b9-0ae878268133" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_srt_ProductOrServiceAxis_697673ee-42cd-4dbf-99b9-0ae878268133" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_697673ee-42cd-4dbf-99b9-0ae878268133_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_697673ee-42cd-4dbf-99b9-0ae878268133" xlink:to="loc_srt_ProductsAndServicesDomain_697673ee-42cd-4dbf-99b9-0ae878268133_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e0372062-7e4b-4a06-963f-f81efd608b48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_697673ee-42cd-4dbf-99b9-0ae878268133" xlink:to="loc_srt_ProductsAndServicesDomain_e0372062-7e4b-4a06-963f-f81efd608b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_8c62655a-84da-4654-97fb-3917993772ef" xlink:href="nktr-20221231.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e0372062-7e4b-4a06-963f-f81efd608b48" xlink:to="loc_nktr_Nektar214Member_8c62655a-84da-4654-97fb-3917993772ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8bfc7906-92ee-43f8-b1f7-28f5cf2c5948" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_dei_LegalEntityAxis_8bfc7906-92ee-43f8-b1f7-28f5cf2c5948" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8bfc7906-92ee-43f8-b1f7-28f5cf2c5948_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8bfc7906-92ee-43f8-b1f7-28f5cf2c5948" xlink:to="loc_dei_EntityDomain_8bfc7906-92ee-43f8-b1f7-28f5cf2c5948_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_545ea326-b834-4c70-99e8-785cc46bef2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8bfc7906-92ee-43f8-b1f7-28f5cf2c5948" xlink:to="loc_dei_EntityDomain_545ea326-b834-4c70-99e8-785cc46bef2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_bd270444-4307-4dc0-a3df-520f15a001c7" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_545ea326-b834-4c70-99e8-785cc46bef2b" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_bd270444-4307-4dc0-a3df-520f15a001c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_db16d1fa-bff9-471b-8e20-d9c117881869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_db16d1fa-bff9-471b-8e20-d9c117881869" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_db16d1fa-bff9-471b-8e20-d9c117881869_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_db16d1fa-bff9-471b-8e20-d9c117881869" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_db16d1fa-bff9-471b-8e20-d9c117881869_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_eeac9738-c03b-44a7-947a-f7ddc904424e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_db16d1fa-bff9-471b-8e20-d9c117881869" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_eeac9738-c03b-44a7-947a-f7ddc904424e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_48708260-b702-4e7b-897c-c6ea489e380b" xlink:href="nktr-20221231.xsd#nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eeac9738-c03b-44a7-947a-f7ddc904424e" xlink:to="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_48708260-b702-4e7b-897c-c6ea489e380b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b2d581c-aeb3-475c-8397-57a136d5779e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b2d581c-aeb3-475c-8397-57a136d5779e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5b2d581c-aeb3-475c-8397-57a136d5779e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b2d581c-aeb3-475c-8397-57a136d5779e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5b2d581c-aeb3-475c-8397-57a136d5779e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0bb85978-2ceb-4993-a2d3-c5ad384d9854" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b2d581c-aeb3-475c-8397-57a136d5779e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0bb85978-2ceb-4993-a2d3-c5ad384d9854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStFacilityMember_74bb382f-f160-48a8-8ba4-1cab641a5656" xlink:href="nktr-20221231.xsd#nktr_ThirdStFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0bb85978-2ceb-4993-a2d3-c5ad384d9854" xlink:to="loc_nktr_ThirdStFacilityMember_74bb382f-f160-48a8-8ba4-1cab641a5656" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" xlink:type="extended" id="ic45b42a0e3ac4289a60fb78812b57c58_RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a836d388-893b-4325-ae3b-cab68787b7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a836d388-893b-4325-ae3b-cab68787b7f4" xlink:to="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_af7bc208-652c-4ec7-8adb-ef6da23b9964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:to="loc_us-gaap_RestructuringReserve_af7bc208-652c-4ec7-8adb-ef6da23b9964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_507f0636-5ead-4d64-9221-4b875876aefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:to="loc_us-gaap_RestructuringCharges_507f0636-5ead-4d64-9221-4b875876aefd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_a0d21630-995e-47f1-8b19-9fef534b0b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:to="loc_us-gaap_PaymentsForRestructuring_a0d21630-995e-47f1-8b19-9fef534b0b1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_53b791e5-c8ea-4e39-b1f5-4d3c0a83cb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1eef9b-7fb8-401a-bca8-3cbd828d33f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a836d388-893b-4325-ae3b-cab68787b7f4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1eef9b-7fb8-401a-bca8-3cbd828d33f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_624d2d03-78a7-45ad-9d89-24a24f3c1e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1eef9b-7fb8-401a-bca8-3cbd828d33f2" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_624d2d03-78a7-45ad-9d89-24a24f3c1e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_624d2d03-78a7-45ad-9d89-24a24f3c1e93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_624d2d03-78a7-45ad-9d89-24a24f3c1e93" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_624d2d03-78a7-45ad-9d89-24a24f3c1e93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6e8d20b0-6539-4539-89fc-bb746180484d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_624d2d03-78a7-45ad-9d89-24a24f3c1e93" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6e8d20b0-6539-4539-89fc-bb746180484d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_bbeb8a7e-76a9-4b38-ad92-f348d909e87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6e8d20b0-6539-4539-89fc-bb746180484d" xlink:to="loc_us-gaap_EmployeeSeveranceMember_bbeb8a7e-76a9-4b38-ad92-f348d909e87f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember_f57b5151-bf11-42bb-9a64-6e9c97b0b846" xlink:href="nktr-20221231.xsd#nktr_EmployeeSeveranceWithNoServicePeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeSeveranceMember_bbeb8a7e-76a9-4b38-ad92-f348d909e87f" xlink:to="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember_f57b5151-bf11-42bb-9a64-6e9c97b0b846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_b958bddd-9bd3-4076-b95d-7ccc77d1cffa" xlink:href="nktr-20221231.xsd#nktr_EmployeeSeveranceWithServicePeriodRequirementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeSeveranceMember_bbeb8a7e-76a9-4b38-ad92-f348d909e87f" xlink:to="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_b958bddd-9bd3-4076-b95d-7ccc77d1cffa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="extended" id="i34a42e68e1a2438bb89addc5d6eae32f_RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_3ebd92e7-315d-4e63-b6bd-be9b74a954cd" xlink:href="nktr-20221231.xsd#nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:to="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_3ebd92e7-315d-4e63-b6bd-be9b74a954cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_78dde971-3e10-4a5f-8596-d6eb6cbb5c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_78dde971-3e10-4a5f-8596-d6eb6cbb5c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_0d5060fd-cac7-4a61-af32-9d0d50fdb063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:to="loc_us-gaap_AdjustmentForAmortization_0d5060fd-cac7-4a61-af32-9d0d50fdb063" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_66f24fbf-03de-43d7-ae60-7eb054f4ef69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:to="loc_us-gaap_AssetImpairmentCharges_66f24fbf-03de-43d7-ae60-7eb054f4ef69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9468ff50-e260-432f-a9ac-cc11fe220769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9468ff50-e260-432f-a9ac-cc11fe220769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9468ff50-e260-432f-a9ac-cc11fe220769_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9468ff50-e260-432f-a9ac-cc11fe220769" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9468ff50-e260-432f-a9ac-cc11fe220769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ef78888a-c2ac-4736-8691-8e636aa10352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9468ff50-e260-432f-a9ac-cc11fe220769" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ef78888a-c2ac-4736-8691-8e636aa10352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_50cdc20f-1d1a-43ea-85fa-995976c67001" xlink:href="nktr-20221231.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ef78888a-c2ac-4736-8691-8e636aa10352" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_50cdc20f-1d1a-43ea-85fa-995976c67001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_c82da3b7-7e35-4c80-9d0b-82d5be0fafee" xlink:href="nktr-20221231.xsd#nktr_SubleaseOperatingLeaseRightOfUseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ef78888a-c2ac-4736-8691-8e636aa10352" xlink:to="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_c82da3b7-7e35-4c80-9d0b-82d5be0fafee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a5f68345-c192-405f-b294-25cd1df3d85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a5f68345-c192-405f-b294-25cd1df3d85e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5f68345-c192-405f-b294-25cd1df3d85e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a5f68345-c192-405f-b294-25cd1df3d85e" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5f68345-c192-405f-b294-25cd1df3d85e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3c790cc6-6bbc-420e-84c6-7f4ed9863336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a5f68345-c192-405f-b294-25cd1df3d85e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3c790cc6-6bbc-420e-84c6-7f4ed9863336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5b0561c8-6061-444d-976f-1a0e37ecae08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3c790cc6-6bbc-420e-84c6-7f4ed9863336" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5b0561c8-6061-444d-976f-1a0e37ecae08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a90fefe8-0075-4b5e-90bd-2a142f564c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5b0561c8-6061-444d-976f-1a0e37ecae08" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a90fefe8-0075-4b5e-90bd-2a142f564c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_66d967bc-108c-4b0e-ac62-e10c17105f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5b0561c8-6061-444d-976f-1a0e37ecae08" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_66d967bc-108c-4b0e-ac62-e10c17105f21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4492261-494a-4f83-b5fe-00207dc3f35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4492261-494a-4f83-b5fe-00207dc3f35d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4492261-494a-4f83-b5fe-00207dc3f35d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4492261-494a-4f83-b5fe-00207dc3f35d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4492261-494a-4f83-b5fe-00207dc3f35d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b1014b6-b23d-428e-bd5d-fface91c70df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4492261-494a-4f83-b5fe-00207dc3f35d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b1014b6-b23d-428e-bd5d-fface91c70df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_16ada25a-322e-4f93-adf0-fddf6c6b6708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b1014b6-b23d-428e-bd5d-fface91c70df" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_16ada25a-322e-4f93-adf0-fddf6c6b6708" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i07ea9dffb9eb4f348679cc2e54b6ba6f_RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2be18577-0400-42cf-a4fd-521fdb8acbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2be18577-0400-42cf-a4fd-521fdb8acbdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d567d54c-1ac9-43dc-830d-2c2c550ae383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d567d54c-1ac9-43dc-830d-2c2c550ae383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_b6fb9ebf-254c-4450-8836-0e6fa3fc3f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_b6fb9ebf-254c-4450-8836-0e6fa3fc3f27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af0e0934-5146-4d8b-b8ca-e55c41063d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af0e0934-5146-4d8b-b8ca-e55c41063d94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_7e8ee746-9916-4713-8ccd-8831d6205e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af0e0934-5146-4d8b-b8ca-e55c41063d94" xlink:to="loc_us-gaap_RestructuringPlanAxis_7e8ee746-9916-4713-8ccd-8831d6205e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_7e8ee746-9916-4713-8ccd-8831d6205e52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_7e8ee746-9916-4713-8ccd-8831d6205e52" xlink:to="loc_us-gaap_RestructuringPlanDomain_7e8ee746-9916-4713-8ccd-8831d6205e52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_226aad73-fc7f-429e-80ed-6fcb5e6e806c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_7e8ee746-9916-4713-8ccd-8831d6205e52" xlink:to="loc_us-gaap_RestructuringPlanDomain_226aad73-fc7f-429e-80ed-6fcb5e6e806c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_52364acf-c509-49dd-9971-b012a56cdac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_226aad73-fc7f-429e-80ed-6fcb5e6e806c" xlink:to="loc_us-gaap_FacilityClosingMember_52364acf-c509-49dd-9971-b012a56cdac9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="idcf497c0efc54b3a88330d6efb1dea1f_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cb106843-bad8-4ffa-b027-3cecbb0b7daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cb106843-bad8-4ffa-b027-3cecbb0b7daf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_d10574d1-88c1-41ce-bcb3-7bb1f20edc62" xlink:href="nktr-20221231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_d10574d1-88c1-41ce-bcb3-7bb1f20edc62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fa4684d2-77bb-4c9b-a0ce-bf9cb1006a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fa4684d2-77bb-4c9b-a0ce-bf9cb1006a69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_85b394f8-51c7-4465-a888-204f638c4114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_85b394f8-51c7-4465-a888-204f638c4114" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_599bacf3-819e-4843-88fb-da2366b1d851" xlink:href="nktr-20221231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForExecutives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_599bacf3-819e-4843-88fb-da2366b1d851" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_69f089d0-69b7-4678-861d-34d26a9677f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_69f089d0-69b7-4678-861d-34d26a9677f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_576d123c-ff48-4ad0-b945-5d186f728eaa" xlink:href="nktr-20221231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_576d123c-ff48-4ad0-b945-5d186f728eaa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7f4b251d-f346-466d-bcbf-1e7d7d8cc811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7f4b251d-f346-466d-bcbf-1e7d7d8cc811" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c6700546-b6df-448c-83df-4e9bf92e8a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c6700546-b6df-448c-83df-4e9bf92e8a95" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2e992d48-0f45-4aba-968d-8c48df83c618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2e992d48-0f45-4aba-968d-8c48df83c618" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_012556ad-f3b1-4a07-8fa8-9e83f69256fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_012556ad-f3b1-4a07-8fa8-9e83f69256fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ee6977df-6b17-4750-bde2-3f5a28deb04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ee6977df-6b17-4750-bde2-3f5a28deb04b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cc3bcc9f-5d98-4ef9-b7e0-f31bed279ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cc3bcc9f-5d98-4ef9-b7e0-f31bed279ec2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4926f69f-a401-4b75-848f-409c96e6093d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4926f69f-a401-4b75-848f-409c96e6093d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2632e90d-c0e2-4cb6-bca0-5e5ef1558e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2632e90d-c0e2-4cb6-bca0-5e5ef1558e6a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_23116c5b-66d2-4702-a2ae-25b6f60b664c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_23116c5b-66d2-4702-a2ae-25b6f60b664c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_be73edd6-ca1f-461c-8bfa-094f57d8d9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_be73edd6-ca1f-461c-8bfa-094f57d8d9bf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_abffaefa-607f-44d7-837f-96d500fb46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:to="loc_us-gaap_AwardTypeAxis_abffaefa-607f-44d7-837f-96d500fb46d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abffaefa-607f-44d7-837f-96d500fb46d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_abffaefa-607f-44d7-837f-96d500fb46d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abffaefa-607f-44d7-837f-96d500fb46d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_abffaefa-607f-44d7-837f-96d500fb46d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a81b7ab9-d081-4d1e-9b74-ab648bcd50fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a81b7ab9-d081-4d1e-9b74-ab648bcd50fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RSUsAndPSUsMember_ce74e84c-94f5-4aad-9083-a6cb58b58d5c" xlink:href="nktr-20221231.xsd#nktr_RSUsAndPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:to="loc_nktr_RSUsAndPSUsMember_ce74e84c-94f5-4aad-9083-a6cb58b58d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9e9d7f3a-c722-4ab0-9a1d-416789177d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:to="loc_us-gaap_EmployeeStockMember_9e9d7f3a-c722-4ab0-9a1d-416789177d05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_58215507-0cfb-4d7d-a926-100e75a9a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_58215507-0cfb-4d7d-a926-100e75a9a1e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0146db76-6cd4-4e08-9ad3-f004478f3bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:to="loc_us-gaap_PlanNameAxis_0146db76-6cd4-4e08-9ad3-f004478f3bca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0146db76-6cd4-4e08-9ad3-f004478f3bca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0146db76-6cd4-4e08-9ad3-f004478f3bca" xlink:to="loc_us-gaap_PlanNameDomain_0146db76-6cd4-4e08-9ad3-f004478f3bca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ea21383f-e696-44d6-b9a8-4eab1569e876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0146db76-6cd4-4e08-9ad3-f004478f3bca" xlink:to="loc_us-gaap_PlanNameDomain_ea21383f-e696-44d6-b9a8-4eab1569e876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_9520a822-8f5b-4947-aec8-a34b59018c45" xlink:href="nktr-20221231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ea21383f-e696-44d6-b9a8-4eab1569e876" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_9520a822-8f5b-4947-aec8-a34b59018c45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_443dbc6d-a957-4ca5-aa49-6452c1e85724" xlink:href="nktr-20221231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ea21383f-e696-44d6-b9a8-4eab1569e876" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_443dbc6d-a957-4ca5-aa49-6452c1e85724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fbdb5ae2-3243-4cc2-8e45-9c05f8b62811" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:to="loc_srt_TitleOfIndividualAxis_fbdb5ae2-3243-4cc2-8e45-9c05f8b62811" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdb5ae2-3243-4cc2-8e45-9c05f8b62811_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_fbdb5ae2-3243-4cc2-8e45-9c05f8b62811" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fbdb5ae2-3243-4cc2-8e45-9c05f8b62811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76e8a2ab-0a9e-49ea-a601-b20fa2262cde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_fbdb5ae2-3243-4cc2-8e45-9c05f8b62811" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76e8a2ab-0a9e-49ea-a601-b20fa2262cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeMember_4e3c6bc6-064c-46e8-91fe-4bed67de489d" xlink:href="nktr-20221231.xsd#nktr_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76e8a2ab-0a9e-49ea-a601-b20fa2262cde" xlink:to="loc_nktr_EmployeeMember_4e3c6bc6-064c-46e8-91fe-4bed67de489d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_de9a0526-9a87-4cfd-ba3c-e7108cb50afd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76e8a2ab-0a9e-49ea-a601-b20fa2262cde" xlink:to="loc_srt_DirectorMember_de9a0526-9a87-4cfd-ba3c-e7108cb50afd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended" id="i678536646ba540059e98f74b4b6c39fd_StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_41eaa7f4-858c-4573-a25d-ad2d0757c9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_33280e02-afe8-4e70-820e-334ac2bbd9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_41eaa7f4-858c-4573-a25d-ad2d0757c9db" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_33280e02-afe8-4e70-820e-334ac2bbd9c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e72e238-97ae-423e-ac11-213af1d0dc77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_41eaa7f4-858c-4573-a25d-ad2d0757c9db" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e72e238-97ae-423e-ac11-213af1d0dc77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6e1b01f8-37e8-4fa9-b1c9-17c0442291a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e72e238-97ae-423e-ac11-213af1d0dc77" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6e1b01f8-37e8-4fa9-b1c9-17c0442291a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e1b01f8-37e8-4fa9-b1c9-17c0442291a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6e1b01f8-37e8-4fa9-b1c9-17c0442291a8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e1b01f8-37e8-4fa9-b1c9-17c0442291a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6e1b01f8-37e8-4fa9-b1c9-17c0442291a8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_647f42b6-1ba4-47fc-b9e0-cf325336eb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:to="loc_us-gaap_CostOfSalesMember_647f42b6-1ba4-47fc-b9e0-cf325336eb6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16d0c4c6-be6a-44b0-b757-9dbf34c807d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16d0c4c6-be6a-44b0-b757-9dbf34c807d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2e695a82-87f9-4b9e-951f-1c3f29e28de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2e695a82-87f9-4b9e-951f-1c3f29e28de7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_e5b556d1-2e28-4609-9503-b1e1f19b6654" xlink:href="nktr-20221231.xsd#nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:to="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_e5b556d1-2e28-4609-9503-b1e1f19b6654" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" xlink:type="extended" id="id8315d9bdfa24e098338af2ee342d22a_StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b0f683c-d60c-492c-b8c7-494f5e541ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b0f683c-d60c-492c-b8c7-494f5e541ee9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8242697f-e884-4a4b-9616-75cf56ef74bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8242697f-e884-4a4b-9616-75cf56ef74bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3359ac47-b523-4551-a0a8-1b3444a20f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3359ac47-b523-4551-a0a8-1b3444a20f2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f17d09b7-ec3c-4e5e-b3c8-b598059478ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f17d09b7-ec3c-4e5e-b3c8-b598059478ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_09d8b9e1-6823-47fe-8693-44c2c918228b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_09d8b9e1-6823-47fe-8693-44c2c918228b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65b7eb02-5e9e-4625-9ad3-0e04e26280d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b0f683c-d60c-492c-b8c7-494f5e541ee9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d3f1bfc7-2e00-488f-aafa-023b3167759a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d3f1bfc7-2e00-488f-aafa-023b3167759a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e81fcee-4152-48a8-9cc6-16e9ae65a4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e81fcee-4152-48a8-9cc6-16e9ae65a4c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bed80d57-73a8-46fb-91b5-bd042574c25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bed80d57-73a8-46fb-91b5-bd042574c25f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2473e392-5403-4580-a579-1cd6180d3420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2473e392-5403-4580-a579-1cd6180d3420" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5bb1e254-9e6a-49bc-ab04-0acf4537f3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa238795-1646-4b86-8ac7-103b22f085b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b0f683c-d60c-492c-b8c7-494f5e541ee9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa238795-1646-4b86-8ac7-103b22f085b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8ea5c8a-b01a-4e30-a7dd-eda9047cca58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa238795-1646-4b86-8ac7-103b22f085b2" xlink:to="loc_us-gaap_AwardTypeAxis_b8ea5c8a-b01a-4e30-a7dd-eda9047cca58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8ea5c8a-b01a-4e30-a7dd-eda9047cca58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b8ea5c8a-b01a-4e30-a7dd-eda9047cca58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8ea5c8a-b01a-4e30-a7dd-eda9047cca58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9ff64b5-5241-4029-9b75-984fef39e000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b8ea5c8a-b01a-4e30-a7dd-eda9047cca58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9ff64b5-5241-4029-9b75-984fef39e000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f4c9e396-cce5-45b4-b271-52c62d925da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9ff64b5-5241-4029-9b75-984fef39e000" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f4c9e396-cce5-45b4-b271-52c62d925da1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i12edf011211040e5871cb5f3ac21f964_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:href="nktr-20221231.xsd#nktr_IncomeTaxesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1d91a69e-6808-439f-9716-c0b53c28f3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1d91a69e-6808-439f-9716-c0b53c28f3ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ee3b524b-7bbd-4169-81b4-e861c349d8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ee3b524b-7bbd-4169-81b4-e861c349d8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OperatingLossCarryforwardsSubjectToExpiration_95319bbc-f52e-48dd-94ca-9e3a328f2475" xlink:href="nktr-20221231.xsd#nktr_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_nktr_OperatingLossCarryforwardsSubjectToExpiration_95319bbc-f52e-48dd-94ca-9e3a328f2475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7c7c246d-89e4-4988-9de9-df5748087c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7c7c246d-89e4-4988-9de9-df5748087c4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_4c1e87a5-72b7-4d34-aa4f-3cedeb66b829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_4c1e87a5-72b7-4d34-aa4f-3cedeb66b829" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_57f5adc2-77aa-4a4c-93e5-f8aa953a1b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_57f5adc2-77aa-4a4c-93e5-f8aa953a1b39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_8cf0823d-e9b8-4f36-81b8-71033ecad327" xlink:href="nktr-20221231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_8cf0823d-e9b8-4f36-81b8-71033ecad327" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureTable_cb0fa5cc-93f1-4f10-bd31-61a441f85e2f" xlink:href="nktr-20221231.xsd#nktr_IncomeTaxesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_nktr_IncomeTaxesDisclosureTable_cb0fa5cc-93f1-4f10-bd31-61a441f85e2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b6b843a4-0a0f-46c2-bd73-7fcac964b7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_IncomeTaxesDisclosureTable_cb0fa5cc-93f1-4f10-bd31-61a441f85e2f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b6b843a4-0a0f-46c2-bd73-7fcac964b7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b6b843a4-0a0f-46c2-bd73-7fcac964b7dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b6b843a4-0a0f-46c2-bd73-7fcac964b7dc" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b6b843a4-0a0f-46c2-bd73-7fcac964b7dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bce76e04-5186-48c5-bdec-2f45546a877e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b6b843a4-0a0f-46c2-bd73-7fcac964b7dc" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bce76e04-5186-48c5-bdec-2f45546a877e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6a089b5d-857a-430b-abaf-d73f4a67ca4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bce76e04-5186-48c5-bdec-2f45546a877e" xlink:to="loc_us-gaap_DomesticCountryMember_6a089b5d-857a-430b-abaf-d73f4a67ca4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_7fe6aaee-8422-45d5-8641-594506195600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bce76e04-5186-48c5-bdec-2f45546a877e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_7fe6aaee-8422-45d5-8641-594506195600" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended" id="i90930ace062142a48d9ea191032b842f_SegmentReportingAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfOperatingBusinessSegment_0029422d-6fdf-4dbb-aa3c-8acb0aa235b4" xlink:href="nktr-20221231.xsd#nktr_NumberOfOperatingBusinessSegment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:to="loc_nktr_NumberOfOperatingBusinessSegment_0029422d-6fdf-4dbb-aa3c-8acb0aa235b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e0829c03-95ec-4690-b9d3-76fdb39f0348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e0829c03-95ec-4690-b9d3-76fdb39f0348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_36210071-3bfd-42a0-8ea1-fef262005266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_36210071-3bfd-42a0-8ea1-fef262005266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_54069b3a-3aa4-4ab6-a2c1-15b6721e238b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_54069b3a-3aa4-4ab6-a2c1-15b6721e238b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_54069b3a-3aa4-4ab6-a2c1-15b6721e238b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_54069b3a-3aa4-4ab6-a2c1-15b6721e238b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_54069b3a-3aa4-4ab6-a2c1-15b6721e238b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07efec40-a304-4603-84c7-5a4732fa5321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_54069b3a-3aa4-4ab6-a2c1-15b6721e238b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07efec40-a304-4603-84c7-5a4732fa5321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a40603e9-421f-41d0-b12c-e16480df383b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07efec40-a304-4603-84c7-5a4732fa5321" xlink:to="loc_us-gaap_SalesRevenueNetMember_a40603e9-421f-41d0-b12c-e16480df383b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_7855013d-65a6-4a33-b6de-fd0ba250e7df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07efec40-a304-4603-84c7-5a4732fa5321" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_7855013d-65a6-4a33-b6de-fd0ba250e7df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7af07ff8-f396-41d4-8cd8-2b70d04a0ae8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:to="loc_srt_MajorCustomersAxis_7af07ff8-f396-41d4-8cd8-2b70d04a0ae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7af07ff8-f396-41d4-8cd8-2b70d04a0ae8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7af07ff8-f396-41d4-8cd8-2b70d04a0ae8" xlink:to="loc_srt_NameOfMajorCustomerDomain_7af07ff8-f396-41d4-8cd8-2b70d04a0ae8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7af07ff8-f396-41d4-8cd8-2b70d04a0ae8" xlink:to="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UCBPharmaMember_bf3cf7ca-20f0-4db7-b490-ac9b9eb6fcc4" xlink:href="nktr-20221231.xsd#nktr_UCBPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_UCBPharmaMember_bf3cf7ca-20f0-4db7-b490-ac9b9eb6fcc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_51aaf3cb-e32d-4f0b-b423-3a41ed912f70" xlink:href="nktr-20221231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_51aaf3cb-e32d-4f0b-b423-3a41ed912f70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_52300469-5c4e-4622-aeda-b236b78f813c" xlink:href="nktr-20221231.xsd#nktr_AstraZenecaAbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_AstraZenecaAbMember_52300469-5c4e-4622-aeda-b236b78f813c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PfizerMember_18aab4b0-20ea-4229-9586-0ebfa5f24595" xlink:href="nktr-20221231.xsd#nktr_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_PfizerMember_18aab4b0-20ea-4229-9586-0ebfa5f24595" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_2d3bf5a9-7a33-4f59-9ee5-f85359774e15" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_2d3bf5a9-7a33-4f59-9ee5-f85359774e15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_418027ea-0f0a-4696-b382-08248f57213d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_418027ea-0f0a-4696-b382-08248f57213d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_418027ea-0f0a-4696-b382-08248f57213d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_418027ea-0f0a-4696-b382-08248f57213d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_418027ea-0f0a-4696-b382-08248f57213d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e2f927c4-ff03-4f7c-85c4-cc824264b96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_418027ea-0f0a-4696-b382-08248f57213d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e2f927c4-ff03-4f7c-85c4-cc824264b96f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_63d51ac5-1771-4b10-98ab-20bd6624b840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e2f927c4-ff03-4f7c-85c4-cc824264b96f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_63d51ac5-1771-4b10-98ab-20bd6624b840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_bda79080-c6d8-4f25-a4e6-ca0f42e671cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e2f927c4-ff03-4f7c-85c4-cc824264b96f" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_bda79080-c6d8-4f25-a4e6-ca0f42e671cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a2555d73-4ba8-4e13-ad6a-f0d7edf1fd8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:to="loc_srt_StatementGeographicalAxis_a2555d73-4ba8-4e13-ad6a-f0d7edf1fd8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a2555d73-4ba8-4e13-ad6a-f0d7edf1fd8f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a2555d73-4ba8-4e13-ad6a-f0d7edf1fd8f" xlink:to="loc_srt_SegmentGeographicalDomain_a2555d73-4ba8-4e13-ad6a-f0d7edf1fd8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c524e8d1-bce7-437e-885b-097a518c1907" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a2555d73-4ba8-4e13-ad6a-f0d7edf1fd8f" xlink:to="loc_srt_SegmentGeographicalDomain_c524e8d1-bce7-437e-885b-097a518c1907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_53a42eaa-55d4-40d3-92fb-1befa2fd4f93" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c524e8d1-bce7-437e-885b-097a518c1907" xlink:to="loc_country_US_53a42eaa-55d4-40d3-92fb-1befa2fd4f93" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="simple" xlink:href="nktr-20221231.xsd#SegmentReportingRevenuebyGeographicAreaDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="extended" id="i42510beb72aa4d76aa2074211d6807ba_SegmentReportingRevenuebyGeographicAreaDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_49aa6714-81bc-41e9-ac04-cf92f028c186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_a6a6125b-6084-490f-ad38-68915695b214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_49aa6714-81bc-41e9-ac04-cf92f028c186" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_a6a6125b-6084-490f-ad38-68915695b214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb3854bf-98fd-4492-8a60-e015889a2129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_a6a6125b-6084-490f-ad38-68915695b214" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb3854bf-98fd-4492-8a60-e015889a2129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9c25d3bd-d7df-4c5d-ae77-70e445684ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_49aa6714-81bc-41e9-ac04-cf92f028c186" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9c25d3bd-d7df-4c5d-ae77-70e445684ba4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_96e86926-39e5-494d-8b5c-dec09c5075f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9c25d3bd-d7df-4c5d-ae77-70e445684ba4" xlink:to="loc_srt_StatementGeographicalAxis_96e86926-39e5-494d-8b5c-dec09c5075f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_96e86926-39e5-494d-8b5c-dec09c5075f3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_96e86926-39e5-494d-8b5c-dec09c5075f3" xlink:to="loc_srt_SegmentGeographicalDomain_96e86926-39e5-494d-8b5c-dec09c5075f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5436af3f-5899-47b5-8e8b-500573a47908" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_96e86926-39e5-494d-8b5c-dec09c5075f3" xlink:to="loc_srt_SegmentGeographicalDomain_5436af3f-5899-47b5-8e8b-500573a47908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_787e8d65-af13-4827-9d81-9f01e0c900f2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5436af3f-5899-47b5-8e8b-500573a47908" xlink:to="loc_country_US_787e8d65-af13-4827-9d81-9f01e0c900f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_80640532-2918-4583-b6ac-46713b6001e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5436af3f-5899-47b5-8e8b-500573a47908" xlink:to="loc_us-gaap_NonUsMember_80640532-2918-4583-b6ac-46713b6001e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_405ade8b-d571-4016-b128-b06476b53123" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9c25d3bd-d7df-4c5d-ae77-70e445684ba4" xlink:to="loc_srt_ConsolidationItemsAxis_405ade8b-d571-4016-b128-b06476b53123" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_405ade8b-d571-4016-b128-b06476b53123_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_405ade8b-d571-4016-b128-b06476b53123" xlink:to="loc_srt_ConsolidationItemsDomain_405ade8b-d571-4016-b128-b06476b53123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c9f96ecc-1c76-42d0-a71a-4fb70e2c6a68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_405ade8b-d571-4016-b128-b06476b53123" xlink:to="loc_srt_ConsolidationItemsDomain_c9f96ecc-1c76-42d0-a71a-4fb70e2c6a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_aa7b0641-0996-46e4-955e-d8fb7c5505a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c9f96ecc-1c76-42d0-a71a-4fb70e2c6a68" xlink:to="loc_srt_ReportableGeographicalComponentsMember_aa7b0641-0996-46e4-955e-d8fb7c5505a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>nktr-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6319d4c-7e41-446e-a208-11c24c30fce3,g:5a9b6e6c-7a94-44cb-81e7-2ed70e787342-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_075a667a-b44c-45b4-b00c-2041932240db_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SecuritiesRelatedClaimsMember_c80c5d36-e580-474e-93ac-849ed7dbab7a_terseLabel_en-US" xlink:label="lab_nktr_SecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Related Claims</link:label>
    <link:label id="lab_nktr_SecuritiesRelatedClaimsMember_label_en-US" xlink:label="lab_nktr_SecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Related Claims [Member]</link:label>
    <link:label id="lab_nktr_SecuritiesRelatedClaimsMember_documentation_en-US" xlink:label="lab_nktr_SecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities related claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuritiesRelatedClaimsMember" xlink:href="nktr-20221231.xsd#nktr_SecuritiesRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SecuritiesRelatedClaimsMember" xlink:to="lab_nktr_SecuritiesRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_3be63bbc-dbfb-4f7f-95ca-e50d0f3d782e_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Obligation</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2faada49-3b8b-40cf-9b0e-5912725f3d33_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_80f621a3-887f-48df-9b6d-895897b68fa7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bc9002d9-d225-478f-baf2-e84446340ec8_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_0affad6a-9a19-429d-8a1d-b046ad38cbca_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_32a72c55-2913-426a-82b8-6e4531292778_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PfizerMember_dfddd3aa-9337-45fe-b980-ba485381704e_terseLabel_en-US" xlink:label="lab_nktr_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_nktr_PfizerMember_label_en-US" xlink:label="lab_nktr_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_nktr_PfizerMember_documentation_en-US" xlink:label="lab_nktr_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PfizerMember" xlink:href="nktr-20221231.xsd#nktr_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PfizerMember" xlink:to="lab_nktr_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MissionBayLeaseMember_ac133783-a10b-4364-aeb7-ba36303c9e62_terseLabel_en-US" xlink:label="lab_nktr_MissionBayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mission Bay Facility</link:label>
    <link:label id="lab_nktr_MissionBayLeaseMember_label_en-US" xlink:label="lab_nktr_MissionBayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mission Bay Lease [Member]</link:label>
    <link:label id="lab_nktr_MissionBayLeaseMember_documentation_en-US" xlink:label="lab_nktr_MissionBayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mission bay lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember" xlink:href="nktr-20221231.xsd#nktr_MissionBayLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MissionBayLeaseMember" xlink:to="lab_nktr_MissionBayLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_7b559b32-5a47-4f79-8de4-13e15121489c_terseLabel_en-US" xlink:label="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Operating Lease Right of Use Assets</link:label>
    <link:label id="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_label_en-US" xlink:label="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Operating Lease Right of Use Assets [Member]</link:label>
    <link:label id="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_documentation_en-US" xlink:label="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Operating Lease Right of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:href="nktr-20221231.xsd#nktr_SubleaseOperatingLeaseRightOfUseAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:to="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0171baee-15af-45f6-907e-ccd1af972005_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_68598eed-0442-46fd-a57d-8263741dfedc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_61bfaedf-fcfa-4404-9991-0b82a5c09a6f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a3623b29-45b1-4653-be91-817860ea019c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ea186a26-3c5f-48c6-9811-88db689af788_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_2c731858-99c6-4207-bfe7-7ea488afaed5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_efe20d5f-9dd2-4796-8c19-a6afd2071797_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_cf5e684b-75a9-407c-9061-066243c3fac4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from development derivative liability</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_c40a068c-58e3-4f0d-b07e-4b769c8b9e41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_73b1e695-fa3d-4cd7-a67b-d6d3cd0ae05e_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability balance as of March 31, 2022</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_7456feda-ab1d-4d0d-b618-918315f62672_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability balance as of December 31, 2022</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_da7cb7e0-1abb-4a91-883a-d2125f26f600_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_fe62f380-d277-4768-8302-34620ec43aac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c10454a5-330c-4997-90d8-f35653f3c082_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_ebc87c7a-39d3-4d52-ba86-79c1f2b45612_terseLabel_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period required</link:label>
    <link:label id="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_label_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance With Service Period Requirement [Member]</link:label>
    <link:label id="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_documentation_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance With Service Period Requirement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:href="nktr-20221231.xsd#nktr_EmployeeSeveranceWithServicePeriodRequirementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:to="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9354d711-b0d8-4ee9-868b-9d659afc182a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8131ca35-d327-4f36-89af-081066305823_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_dcab13e7-62d2-4f6c-91b1-cf8fbd4b072b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_88b9c25e-1b64-4d8f-89a4-65728f32dd4c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da5a2445-7e75-4541-865f-00b9402df7d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_5d66f9f4-0c71-4975-a0b3-958ed117430b_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapses in statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoMember_3e1599a2-76f2-4a0b-8019-865bc2a93756_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_label_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_documentation_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember" xlink:href="nktr-20221231.xsd#nktr_OpdivoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember" xlink:to="lab_nktr_OpdivoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_InvestmnetsTargetMaturityPeriod_7d6e7aa8-2ce9-4020-844e-637c5c0ec80a_terseLabel_en-US" xlink:label="lab_nktr_InvestmnetsTargetMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target maturity period</link:label>
    <link:label id="lab_nktr_InvestmnetsTargetMaturityPeriod_label_en-US" xlink:label="lab_nktr_InvestmnetsTargetMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investmnets, Target Maturity Period</link:label>
    <link:label id="lab_nktr_InvestmnetsTargetMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_InvestmnetsTargetMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investmnets, Target Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InvestmnetsTargetMaturityPeriod" xlink:href="nktr-20221231.xsd#nktr_InvestmnetsTargetMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_InvestmnetsTargetMaturityPeriod" xlink:to="lab_nktr_InvestmnetsTargetMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SubleasePropertyPlantAndEquipmentMember_848d47b5-f32e-42cb-a323-6d89e614ab08_terseLabel_en-US" xlink:label="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Property, Plant And Equipment</link:label>
    <link:label id="lab_nktr_SubleasePropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Property, Plant And Equipment [Member]</link:label>
    <link:label id="lab_nktr_SubleasePropertyPlantAndEquipmentMember_documentation_en-US" xlink:label="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Property, Plant And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:href="nktr-20221231.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:to="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9526e337-8831-484b-ba28-1906614a26f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_58360071-e823-449f-8c7c-2e788ee2f214_terseLabel_en-US" xlink:label="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, RSUs And PSUs</link:label>
    <link:label id="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_label_en-US" xlink:label="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, RSUs And PSUs [Member]</link:label>
    <link:label id="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_documentation_en-US" xlink:label="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, RSUs And PSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:href="nktr-20221231.xsd#nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:to="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_a11d2014-bc11-43c5-8cc0-a74ec7727229_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UCBPharmaMember_360c52b9-6362-43e0-9b09-00d05647197e_terseLabel_en-US" xlink:label="lab_nktr_UCBPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB</link:label>
    <link:label id="lab_nktr_UCBPharmaMember_label_en-US" xlink:label="lab_nktr_UCBPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U C B Pharma [Member]</link:label>
    <link:label id="lab_nktr_UCBPharmaMember_documentation_en-US" xlink:label="lab_nktr_UCBPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UCBPharmaMember" xlink:href="nktr-20221231.xsd#nktr_UCBPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UCBPharmaMember" xlink:to="lab_nktr_UCBPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeStockPurchasePlanMember_5fac1287-9573-43bd-896e-df5fdb4ab140_terseLabel_en-US" xlink:label="lab_nktr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nktr_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_nktr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_nktr_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_nktr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember" xlink:href="nktr-20221231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeStockPurchasePlanMember" xlink:to="lab_nktr_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_683f6530-6287-4c1f-9a92-4b10bfe26ebb_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AuditorInformationAbstract_label_en-US" xlink:label="lab_nktr_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_nktr_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_nktr_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AuditorInformationAbstract" xlink:href="nktr-20221231.xsd#nktr_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AuditorInformationAbstract" xlink:to="lab_nktr_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_eed7acac-ff25-4d90-975b-37703afe2618_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_278084dc-989f-46ca-926b-f82a1b01b1d5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_0cd156f8-0683-405f-9ece-6921c3c09ba8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ca50525a-e820-4289-9944-483e0156dc91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average volatility factor</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_f47e09f2-99fb-4dd9-afb2-417b96f37c8e_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:href="nktr-20221231.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8973e213-5499-4ee9-a211-b91ad47d3db4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_40174d1f-e60b-4557-91b5-4e110cd025d5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ff76b93a-72f4-4a0a-a9ee-59be5b5a89b4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_5e9f525d-0f9c-4cfb-b91d-4921259e1edd_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:href="nktr-20221231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_90cb0a25-5fbb-41f5-9f05-82b04b8825a5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7bb22512-8e1d-4646-927f-afb3d953d066_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_f30200d7-f733-4fdf-83b4-cca6c4eab5c2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_6225e7c3-94ea-4ae9-a680-c3c4bb4dbf02_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:href="nktr-20221231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b0257d19-0345-4c63-84b4-c67f1f3f11e6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_fcf4155c-88c7-40dd-ba3c-91a24d54964c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_021c0b2d-059e-4db3-bf2f-941dd891ec25_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7944a86c-2df8-4627-917d-6d3a8ca7783b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_429a1fa8-f2fb-44f8-9c7f-fcd58c90c456_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dc0ba5a2-7ad7-4c1b-bcb9-f048cf4120a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited and canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_InvestmentsWeightedAverageMaturityPeriod_5d31b2f3-be1a-477f-8f2a-341ce459269e_terseLabel_en-US" xlink:label="lab_nktr_InvestmentsWeightedAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average maturity period</link:label>
    <link:label id="lab_nktr_InvestmentsWeightedAverageMaturityPeriod_label_en-US" xlink:label="lab_nktr_InvestmentsWeightedAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Weighted Average Maturity Period</link:label>
    <link:label id="lab_nktr_InvestmentsWeightedAverageMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_InvestmentsWeightedAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Weighted Average Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InvestmentsWeightedAverageMaturityPeriod" xlink:href="nktr-20221231.xsd#nktr_InvestmentsWeightedAverageMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_InvestmentsWeightedAverageMaturityPeriod" xlink:to="lab_nktr_InvestmentsWeightedAverageMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_1c60547b-18e6-4950-8047-fd6deb4714f3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_dc1f580f-1f42-42b2-9b54-bcd1d3e1e4f7_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts" xlink:href="nktr-20221231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_850db45f-05ca-44df-908b-2e24edae2d5f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_fb8cb89e-c421-4ec7-9099-08bffbc0ceb5_negatedLabel_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized transaction costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_label_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities On Sale Of Future Royalties Unamortized Transaction Costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_documentation_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities on sale of future royalties, unamortized transaction costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:href="nktr-20221231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:to="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_44ae7ae7-fbc4-49ee-acb5-8d5d6d57ab04_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_f53db9dc-8504-45fa-b3b8-8a0821718b2c_terseLabel_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B M S Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember" xlink:href="nktr-20221231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BMSCollaborationAgreementMember" xlink:to="lab_nktr_BMSCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_13ce6e08-8a9d-44f1-8e7f-8a586456bd30_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncomeTaxesDisclosureTable_5d159d15-da44-4a47-a72e-db679a8b4930_terseLabel_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureTable_label_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureTable_documentation_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureTable" xlink:href="nktr-20221231.xsd#nktr_IncomeTaxesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncomeTaxesDisclosureTable" xlink:to="lab_nktr_IncomeTaxesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e6a4c027-afb9-4ef4-b573-9574731bb04f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OtherPartnerMember_1267e901-93bf-4a33-881d-1c2462b8e7ff_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_label_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember" xlink:href="nktr-20221231.xsd#nktr_OtherPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember" xlink:to="lab_nktr_OtherPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_708656fa-774c-46b3-b7f6-61843741559a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_203b9ba9-74e8-439e-a879-8be7ad908394_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_d2dd3e9f-c139-4f0f-a984-fb29dcb2d876_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_93505dea-6c76-4464-ab64-beef5701c8f2_negatedTerseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20221231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ea73b780-9f24-49ff-83bd-8e8500e4b3c0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1cdeb9d1-ac01-4eee-9d64-6fc9489ef537_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1ca05991-e222-4cf7-bf5b-3fa2dc808511_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f197eff7-0857-46ee-9fc4-556b95c48e76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_3d86ac97-e406-4086-8a66-34a8367387b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c5ef9ca-620b-4622-ae7c-7be3a91386b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_8991f95a-ccf4-4b70-bf18-94605c2b2f12_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_c8c7018e-33ce-4823-bfb4-f548b40b246c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockValueAuthorizedInTransaction_3eaf0ec9-54dc-4647-9b90-2703370bee8d_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_nktr_SaleOfStockValueAuthorizedInTransaction_label_en-US" xlink:label="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Value Authorized In Transaction</link:label>
    <link:label id="lab_nktr_SaleOfStockValueAuthorizedInTransaction_documentation_en-US" xlink:label="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Value Authorized In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:href="nktr-20221231.xsd#nktr_SaleOfStockValueAuthorizedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:to="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_c0253cc1-8177-4039-9ca4-96f6a12cd7e1_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_6203149a-c9a1-41fc-a8cf-6cff1383366c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum 401(k) per employee, percentage of annual salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7b8cc96b-8c53-41e1-8a06-900de600eb04_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited and canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f6ebc422-0e87-42ed-b47b-5e1c21004384_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_67aa4088-1ec8-4277-a28e-e21c2fea7cb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_579690c8-5a33-41bc-bd19-683ce8f103a5_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_de4994a3-b70b-4f4d-b406-66e294526400_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:href="nktr-20221231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_6efdcd52-f07a-4c43-9aca-ae79c5f9fbcf_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:to="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_743242a7-ced3-4ed7-89cd-ae29d658027e_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_127ab6e5-1f19-49c3-8544-7013f7e84e5c_negatedLabel_en-US" xlink:label="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</link:label>
    <link:label id="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:href="nktr-20221231.xsd#nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:to="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_6754d478-8a12-4884-8127-b806e9ae17a3_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liabilities related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_bf364408-a23e-409b-82f8-77c9c6479491_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liabilities related to sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_cb453661-12ff-4069-8afb-2c83ab730bfc_verboseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:href="nktr-20221231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_92c552ca-136d-447c-96d3-2f6fb0f287bd_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_8001b072-b5bf-474c-84a1-1d3028746454_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional payments for development milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones" xlink:href="nktr-20221231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones" xlink:to="lab_nktr_PotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fc8801b4-961f-4d36-a3ca-fbf80a9b3a14_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_4ebf2c8c-4c06-4e1a-a54c-6df9521e72a2_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e488acc-2be1-4194-bed8-ee59f96fb1a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_068e992f-0849-4efc-b75c-2f8ab0ec5416_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner_80d739a0-41af-492f-a225-e281b69c93e8_terseLabel_en-US" xlink:label="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net expense reimbursements from collaboration partner</link:label>
    <link:label id="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner_label_en-US" xlink:label="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Expense Reimbursements From Collaboration Partner</link:label>
    <link:label id="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner_documentation_en-US" xlink:label="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net expense reimbursements from collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:href="nktr-20221231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:to="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_968bfcfc-2dcb-42d9-baf1-60bcdba1dcf7_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_3e064c8d-c451-4215-9116-e861f2c95e47_totalLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d8047329-a843-47c3-9707-2a42a8919c88_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1dac6228-82ec-4ab8-b01d-be018581bcd8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28caf444-8261-429e-b896-cbe46a5f297c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of License, Collaboration and Other Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_10fa4e97-f607-4073-aeec-09e5e5cb069f_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment and other costs of terminated program</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_6fb9039d-00f9-48a7-9135-4e53f3b92d50_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:href="nktr-20221231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ec2d1be1-4262-4cf9-9e31-6620c5d10845_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6b464ec4-713f-4fda-9f6c-0ecb26df3acf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bff5a2a9-9df0-47ca-9fd5-8ee991ba4093_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d64f6774-4543-4763-9e91-703040e80956_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_943c7bab-b144-4d57-be9d-98a58810072c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0e822692-1746-43ec-aa44-5d7fe977761f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c1df32e2-e88e-43a2-afab-78204b1b5456_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a2241806-daf7-4d7b-8518-b206d4f35453_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_47302b0b-4412-4954-8630-30b6a7e749bf_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:href="nktr-20221231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2371e9b5-e3a7-4c78-92ad-637822cc47b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SubleasesIncomeToBeReceived_9b2e2820-5691-4fa9-bf45-9a90e8afb42c_terseLabel_en-US" xlink:label="lab_nktr_SubleasesIncomeToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subleases aggregate lease payments</link:label>
    <link:label id="lab_nktr_SubleasesIncomeToBeReceived_label_en-US" xlink:label="lab_nktr_SubleasesIncomeToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subleases Income, To Be Received</link:label>
    <link:label id="lab_nktr_SubleasesIncomeToBeReceived_documentation_en-US" xlink:label="lab_nktr_SubleasesIncomeToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subleases Income, To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasesIncomeToBeReceived" xlink:href="nktr-20221231.xsd#nktr_SubleasesIncomeToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SubleasesIncomeToBeReceived" xlink:to="lab_nktr_SubleasesIncomeToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_0f3472ee-18ef-477b-ae48-dc479e93817a_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:href="nktr-20221231.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_2182dd2a-507e-46bc-b68f-1d945d51b1de_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_eaa4dc6c-bfb8-43b3-b76e-55da15ef038e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55d57205-e895-4e37-af7f-c19178675f75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units Issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets_5ebf436d-b054-41f0-9f44-7eb0cdf4ac32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfOperatingBusinessSegment_44a0a4dd-1358-49b1-b490-6f41f7510580_terseLabel_en-US" xlink:label="lab_nktr_NumberOfOperatingBusinessSegment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating business segment</link:label>
    <link:label id="lab_nktr_NumberOfOperatingBusinessSegment_label_en-US" xlink:label="lab_nktr_NumberOfOperatingBusinessSegment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Business Segment</link:label>
    <link:label id="lab_nktr_NumberOfOperatingBusinessSegment_documentation_en-US" xlink:label="lab_nktr_NumberOfOperatingBusinessSegment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating business segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfOperatingBusinessSegment" xlink:href="nktr-20221231.xsd#nktr_NumberOfOperatingBusinessSegment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfOperatingBusinessSegment" xlink:to="lab_nktr_NumberOfOperatingBusinessSegment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_fb8a4555-3b4e-47e0-aac4-0904826cf34f_terseLabel_en-US" xlink:label="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment and other costs of terminated program</link:label>
    <link:label id="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_label_en-US" xlink:label="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Costs of Terminated Program [Member]</link:label>
    <link:label id="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_documentation_en-US" xlink:label="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Costs of Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:href="nktr-20221231.xsd#nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:to="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_ab5ecce9-44e3-497f-8199-72ede7196943_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_404794a1-0542-4792-ba22-a0634f385467_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and benefit expense</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1883cc74-585f-4f0b-ac66-4cb0f78836aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7ca417fa-e62a-46ec-a41f-a82dbcb60a74_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_6f5faea1-fd4a-4eb6-ba2d-e085393bc365_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in foreign subsidiary</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9d634ea5-f0ad-4498-b5f6-a384090d2678_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_f0585d68-2b18-4927-9116-3f0b2c92bd3b_terseLabel_en-US" xlink:label="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting unit evaluated for goodwill</link:label>
    <link:label id="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_label_en-US" xlink:label="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reporting Units To Evaluate Goodwill For Impairment</link:label>
    <link:label id="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_documentation_en-US" xlink:label="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units to evaluate goodwill for impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:href="nktr-20221231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:to="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3e5a5e25-d4dd-4f90-ab9b-d9e5b8c8e3e2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_264d3ffb-bd96-4a2e-9124-2825b847d2e4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2e67c793-396f-4cbe-ad24-a7266d250802_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_f99c1926-ee60-4373-a9b6-a9ab833132b5_negatedTerseLabel_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to RPI</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_label_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial Repayment Of Royalty Sale Proceeds</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_documentation_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial repayment of royalty sale proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:href="nktr-20221231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:to="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a60adb06-0667-484a-af06-c50711cd35e7_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_74a034c5-51a4-457a-9d59-f986f2baed37_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_label_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization [Policy Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock" xlink:href="nktr-20221231.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyTextBlock" xlink:to="lab_nktr_OrganizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_720b3aae-f84e-461b-8b70-3971cebb8eff_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Related to the Sales of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_18f2434f-fb66-4ce9-9dd9-d4c94cbd5b21_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pursuant to the 2012 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase And Sale Agreement [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and sale agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreementMember" xlink:to="lab_nktr_PurchaseAndSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_734594ce-c67b-4591-bbb8-a1f631e888ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_48818b37-0ae8-4c56-b596-70dabd0f41c9_terseLabel_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember" xlink:href="nktr-20221231.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LaboratoryEquipmentMember" xlink:to="lab_nktr_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_eb649a27-d894-434e-ba5f-3b421e62f008_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment and other costs of terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Assets And Other Costs For Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equipment and other costs for terminated program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:href="nktr-20221231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputInceptionDiscountRateMember_508691f7-c545-4c48-8842-25098b38b879_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputInceptionDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Inception Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputInceptionDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1474aa70-2401-4fd4-ae37-60c1ffcc4823_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AstraZenecaAbMember_c051b948-d5c8-4b60-9570-e1712761dbd9_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Ab</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_label_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Ab [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca AB.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember" xlink:href="nktr-20221231.xsd#nktr_AstraZenecaAbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAbMember" xlink:to="lab_nktr_AstraZenecaAbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_23e2fcd2-baa7-4bac-b7a7-5a11b1021d87_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_fc9c64a7-e8bf-4160-944d-a06e312bce6c_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_fb242aeb-4a1b-4426-8140-7f9f4fc5a812_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_396f7fe8-441d-438f-b77d-b3300e5f30a6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_1b60faca-8bd2-4ce2-a22a-a128754b2c41_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_396d6d7e-741a-47eb-89de-16c55852f89c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Costs of Terminated Program</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ThirdStFacilityMember_da784e00-78d8-4d48-ae5d-2717f9e2d6bc_terseLabel_en-US" xlink:label="lab_nktr_ThirdStFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third St. Facility</link:label>
    <link:label id="lab_nktr_ThirdStFacilityMember_label_en-US" xlink:label="lab_nktr_ThirdStFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third St. Facility [Member]</link:label>
    <link:label id="lab_nktr_ThirdStFacilityMember_documentation_en-US" xlink:label="lab_nktr_ThirdStFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third St. Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStFacilityMember" xlink:href="nktr-20221231.xsd#nktr_ThirdStFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ThirdStFacilityMember" xlink:to="lab_nktr_ThirdStFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OperatingLeaseMeasurementInput_f2239050-e20e-497f-be7e-29b017f5c445_terseLabel_en-US" xlink:label="lab_nktr_OperatingLeaseMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, measurement input</link:label>
    <link:label id="lab_nktr_OperatingLeaseMeasurementInput_label_en-US" xlink:label="lab_nktr_OperatingLeaseMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Measurement Input</link:label>
    <link:label id="lab_nktr_OperatingLeaseMeasurementInput_documentation_en-US" xlink:label="lab_nktr_OperatingLeaseMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OperatingLeaseMeasurementInput" xlink:href="nktr-20221231.xsd#nktr_OperatingLeaseMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OperatingLeaseMeasurementInput" xlink:to="lab_nktr_OperatingLeaseMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bb9a0724-3d86-468d-8259-f6f006eb0241_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_8f9fc700-d7d4-4b88-940c-14bd0a981aa8_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="nktr-20221231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_7793f2dc-7106-456e-9d09-f8a4f24ce0a2_terseLabel_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to revised royalty payments</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_label_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Revised Royalty Payments</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_documentation_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Revised Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:href="nktr-20221231.xsd#nktr_TransactionCostsRelatedToRevisedRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:to="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5ca4d317-e130-425f-be37-f50ef370259d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_0ae718fb-5e61-4cd1-8dd8-46da5c2cda78_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:href="nktr-20221231.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_88ac76ab-268d-47f1-a2a9-c9b69f286cd0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_537c924b-eb2b-4532-9bad-427abcfb00c3_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_94b31912-357c-4588-b75e-9a132183c232_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_d4816caa-5396-46b6-a8db-0143df9bbfd7_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Abstract]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Abstract]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b7375e29-6315-44d7-82f2-a87fa5091ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_82d50825-4948-43aa-a7be-82b4f453724b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d84d93f-0923-4dbe-84d6-a76f8843d7c5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_24aec6f7-0ab0-4afa-8b40-e7128749c6bb_terseLabel_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_4abb28e4-cb4e-4a0f-8a05-2c5688300062_negatedTerseLabel_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</link:label>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:href="nktr-20221231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:to="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4cf607d4-7f3f-4da6-9279-80e9958e23ea_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_30db8999-a644-4bf2-b1a8-a87253cb4dd1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ca60642f-5cb2-468a-ac5a-83cfe0b2d15a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_09713023-559e-4bb2-8468-591a3ab23732_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_3e47c45b-8880-49f1-9777-e4e1066adfd9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_2a3c30e7-46ba-4b8a-b563-c846df068773_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_14bc6d81-3d15-4121-9917-a5e38bc98a9b_terseLabel_en-US" xlink:label="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations under Director and Officer Indemnifications per incident</link:label>
    <link:label id="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_label_en-US" xlink:label="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations Under Director And Officer Indemnifications Per Incident</link:label>
    <link:label id="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_documentation_en-US" xlink:label="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations under director and officer indemnifications per incident.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:href="nktr-20221231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:to="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_758959eb-dde8-4218-8c2d-e6ac68151523_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_bfa9b42d-2d1c-4125-9d9b-653f7784e4d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract_7877f7ab-337a-456f-9c30-4f39bc7a192d_terseLabel_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to prior years:</link:label>
    <link:label id="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract_label_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related To Prior Years [Abstract]</link:label>
    <link:label id="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract_documentation_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related To Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:href="nktr-20221231.xsd#nktr_TaxPositionsRelatedToPriorYearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:to="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_879acfef-9112-47a8-89b4-49d92564c9ae_terseLabel_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_label_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Furniture And Other [Member]</link:label>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_documentation_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture computer and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember" xlink:href="nktr-20221231.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ComputerFurnitureAndOtherMember" xlink:to="lab_nktr_ComputerFurnitureAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_00fb98d2-8deb-4c59-847c-36f5268e538f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fad40628-c066-40f7-9507-99021f8fcaa0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39a5372a-03d5-4ea7-8beb-36f3a7cf83db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e3c87dcd-0b91-4ff4-b94c-c59e4e7c5dfc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized over a weighted-average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6063ddca-95ca-4243-afef-13c922c86d90_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_8dd08ac5-3024-4962-894e-0b0158b57568_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_63903bcc-4fd6-494a-944b-6e90f5bbc672_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26ccd78f-1fa1-4ed0-a008-24df7f148c34_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock to Bristol-Myers Squibb (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_076402d6-07a7-442b-8f66-0a640576137c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLeasesTable_15b8f3d1-0a8f-4c6b-b656-6c68b2959981_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLeasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Leases [Table]</link:label>
    <link:label id="lab_nktr_ScheduleOfLeasesTable_label_en-US" xlink:label="lab_nktr_ScheduleOfLeasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Leases [Table]</link:label>
    <link:label id="lab_nktr_ScheduleOfLeasesTable_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLeasesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Leases [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable" xlink:href="nktr-20221231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLeasesTable" xlink:to="lab_nktr_ScheduleOfLeasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_77be51c1-858f-41a9-90b4-5e123545f29d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_3f121d99-8bca-4770-b146-834827c5e644_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination and other restructuring costs</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_342cbb3d-b6a4-45f7-92d0-fde2012bd551_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts_71f7afd7-83ff-43d8-8a98-1a6ff347f191_terseLabel_en-US" xlink:label="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of future royalties transaction costs</link:label>
    <link:label id="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts_label_en-US" xlink:label="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Royalties Transaction Costs</link:label>
    <link:label id="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts_documentation_en-US" xlink:label="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Royalties Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:href="nktr-20221231.xsd#nktr_SaleOfFutureRoyaltiesTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:to="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_86f98b63-e72c-41e7-9940-8c89d8818ef3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_53ccc712-f9b1-4834-b835-d8de5be8edca_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_35c405c0-baf3-4a02-98ad-7212e122d51a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_2f51b7b9-cd98-482a-a4c9-f8f22f860f2e_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_af81493d-34d9-42d5-9824-865a28713ff3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_239299f2-413e-45b0-b07c-99c49e08e36a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Principles of Consolidation and Use of Estimates</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94e5ce17-d95c-4ad7-842a-986f3ab0eea5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_897809a2-9467-4fdd-9a01-028eb5a7175f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5441d3c4-199e-4904-ac30-ee4bba362c3c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_72b3e5df-642a-4254-902f-8b7ae83e5f09_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_b2e4e161-a52a-4db1-b158-ee0ef8edd3e0_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_118d9e45-c876-4878-921c-9d86bad57f34_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_a3c73a21-8c8f-4da0-b184-481c28f4b2de_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe633a56-3d8e-4b98-ad90-8e0a590e2e7b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6cf81df1-9bd8-4c30-b795-21c171b775fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_fda46ea6-631e-451c-82d3-d5682c561e73_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_a2de266f-91e9-460c-aa15-2e9606abf9b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6aee8a78-9418-462a-91f9-30e00152fd3d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3259cd6e-a307-475f-ba32-dd0da6a66de2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_51b27117-20dc-41b0-a0c5-114589ebd9d0_negatedLabel_en-US" xlink:label="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (discounts), net and other non-cash transactions</link:label>
    <link:label id="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_label_en-US" xlink:label="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions</link:label>
    <link:label id="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_documentation_en-US" xlink:label="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:href="nktr-20221231.xsd#nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:to="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3dec1191-d048-44a8-8682-a0a869e9f696_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_a48a9341-3304-48fb-8bac-d53003942114_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability Related to Potential Future Royalties</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:href="nktr-20221231.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:to="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_193871ca-cc4e-43a5-b668-5711ff9b0808_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract_e804657f-c199-4973-b43a-9bfa5810dd1e_terseLabel_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to current year:</link:label>
    <link:label id="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract_label_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related To Current Year [Abstract]</link:label>
    <link:label id="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract_documentation_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related To Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:href="nktr-20221231.xsd#nktr_TaxPositionsRelatedToCurrentYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:to="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_fff8dce6-2502-4ab4-9626-2cbae899f19f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1946a5ef-51cf-47e5-8365-d2fca900f6fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_e0f6a5e8-17ae-47ff-940d-86dcf99a1972_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_a7a8d9d3-8be0-4cc9-b9dd-929c2f9a14ed_terseLabel_en-US" xlink:label="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and Significant Supplier Concentrations</link:label>
    <link:label id="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_label_en-US" xlink:label="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory And Significant Supplier Concentrations [Policy Text Block]</link:label>
    <link:label id="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and significant supplier concentrations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:href="nktr-20221231.xsd#nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:to="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1278dd27-ea14-420e-924b-91fdb7e64238_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a24f4972-c9f7-4e19-a67e-5ce2f8d8c327_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_7bdca24d-67c0-4fc5-ae06-ae1024f2a369_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_98a1948f-71f1-4d00-816e-68bf978b0ede_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_4baeac4c-6603-48f9-9fda-1cd1afbad6f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_fef22e4f-e88f-4547-b08c-42d9eb1cf1b7_terseLabel_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of transaction related to purchase and sale agreement if threshold is not achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_label_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_documentation_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:href="nktr-20221231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:to="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndNonCashRoyaltiesMember_7c3c5899-6e41-46f9-916e-74aab750c4ae_terseLabel_en-US" xlink:label="lab_nktr_CashAndNonCashRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And NonCash Royalties</link:label>
    <link:label id="lab_nktr_CashAndNonCashRoyaltiesMember_label_en-US" xlink:label="lab_nktr_CashAndNonCashRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And NonCash Royalties [Member]</link:label>
    <link:label id="lab_nktr_CashAndNonCashRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_CashAndNonCashRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And NonCash Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndNonCashRoyaltiesMember" xlink:href="nktr-20221231.xsd#nktr_CashAndNonCashRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndNonCashRoyaltiesMember" xlink:to="lab_nktr_CashAndNonCashRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember_1a3e1ce0-c266-4e67-b84b-4806b4786398_terseLabel_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No service period</link:label>
    <link:label id="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember_label_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance With No Service Period [Member]</link:label>
    <link:label id="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember_documentation_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance With No Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:href="nktr-20221231.xsd#nktr_EmployeeSeveranceWithNoServicePeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:to="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_5b777e9c-2bc7-4743-a574-04cd5861ec74_terseLabel_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_label_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals [Member]</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_documentation_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember" xlink:href="nktr-20221231.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SFJPharmaceuticalsMember" xlink:to="lab_nktr_SFJPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dec2b334-fee5-449c-9eb4-e619ab3902aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_8917d4ed-300b-40c5-8d81-aaa6c1e6a2be_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_188e77bf-cfa3-4b9a-b8df-f14357ac6a7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_e4e054b8-bc8c-4f6e-99d6-f5006a46805f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_5460e687-dd6c-4c67-a1c6-b1d241f65bf8_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, success-based payments</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Amount</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:href="nktr-20221231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5cf70d0a-a127-40f1-bde4-deaa3a5a1821_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_749f99b9-37ee-407d-a09b-28aa9e0149f8_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_176b6609-2b95-44e4-8202-c9cb70cab3f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_b8597c6d-db94-456c-abc2-86e7eac7f55f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage revenue from customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_8b1ae954-8a44-4d17-a9d8-65bfb8dc30e7_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_41650964-ac2f-49d8-a8ae-36d0ee95a0f2_terseLabel_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and leasehold improvements</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Leasehold Improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:href="nktr-20221231.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:to="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_810768d2-a7d0-4ce5-81db-19a71c80ad2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_804922c8-1372-4f7a-be68-f74159f0e705_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_e018cb80-b589-4adf-8776-55e57c946b53_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_29b3601f-a537-451f-ac43-6528bb593b57_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Sale of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_c8cedb67-545b-43f7-812a-8b25e0bf507c_terseLabel_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Performance Incentive Plan</link:label>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_label_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Performance Incentive Plan [Member]</link:label>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_documentation_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand seventeen performance incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:href="nktr-20221231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:to="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f50457d0-33d4-4843-b495-6e894351d17d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ca451139-d74d-49df-a6d3-81e61b112c84_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_e2e2e385-1170-4bb1-a431-bb9b086f4208_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:to="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_801f4273-92b3-4a1c-bddf-be864fd34382_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period for stock-based compensation award granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_781d4303-6b9a-420c-85b3-131be498d989_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_06fa448b-5350-4b4c-9871-4a80dc131ecd_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DeferredTaxAssetsLeaseLiability_149837fb-b867-4184-82be-0777b331fcec_terseLabel_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLeaseLiability" xlink:href="nktr-20221231.xsd#nktr_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DeferredTaxAssetsLeaseLiability" xlink:to="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_64036739-7c7f-42b8-a1f6-120254c9d6c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of restricted stock vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_07a2a9ee-875e-4036-ae6f-ae72edc93fbf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_29ad4179-9fe3-4deb-9263-05f82f3480eb_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0ff6aedc-88bc-46aa-9b0a-8c3629224331_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_be9fc1c1-4417-4cb6-b22b-c3c3033ddcbc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b03de1d6-099b-4645-882d-dac322c4ec07_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_18cf5e6b-8ce3-4060-982a-f334e9e88755_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses recorded in AOCI</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_3885934b-f2de-4a6a-9ea9-8489b08e5dc1_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_1d2d9fdd-feaa-41f4-8610-0f8578e35a52_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced if conditions occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received If Conditions Occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received, if conditions occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:href="nktr-20221231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71b6a69b-7533-463b-b554-f71f479063de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_5e1c07a8-0155-4be8-994b-70d4ae01c189_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_0863ec0a-9f5a-4f30-8653-aced088b6e55_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6a180f6b-cab4-4e98-b02f-cafc863f6005_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56224e14-17ab-4188-b545-846e309744b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_210a66aa-a732-4576-a820-7ba1516fdb4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_ffd26b33-5287-4bd6-af08-97c06c3650a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_44c8ae09-0aa5-4b40-8832-2eb0a44d5e67_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_5d0e646e-8999-4232-baef-c32197c659a8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1bdbb2ae-3750-4327-a8b6-37aac1e4fa05_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f0685b7e-e2f5-43c8-8659-8fb2d503b02f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_0c976064-cd78-4f8b-ad90-47cce37b84fe_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ce27b9e0-3692-4c79-b508-8dbfb673bfb0_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1dcc18c7-57bf-49f7-b0ad-3ee06a7dfea3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3edf63fe-e03d-4c83-ad6f-045bfa57f60d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_61a34f39-b93d-4e29-bac8-5d72733e8383_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_6df3384d-e621-4aea-bf5f-fce3f8b05932_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_084ebc1f-590b-4576-8044-ebf0fa06b153_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares available for stock options grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementOfExpenses_8ae0fb86-8474-423e-9164-7d94e75b195a_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses" xlink:href="nktr-20221231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses" xlink:to="lab_nktr_ReimbursementOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_63a6df18-60ea-45a8-9989-14e63b46f583_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cfde6d3a-3e2f-41f4-ac7e-859a0cd5ebe9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c30cfb97-9a54-4e45-85f9-fa21bdb4ccf1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_4750fbe5-9b75-43f7-854e-30ee928d474d_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:href="nktr-20221231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_415b8b50-8c22-459d-9088-d94da8119317_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures, and other</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d0798e3a-e282-4f55-824d-07414886d12b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_24b3f90c-132e-42b5-a60f-3fcce910ac3c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ded0b86d-7542-45d0-a107-c15ea34070da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_da443398-7570-4943-b422-02e603fc924f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and other credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_03a94eaa-82e0-4fc2-a67a-378f6c54df53_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense in connection with 401(k) retirement plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1cb3e9e9-f3bf-4ae7-9c41-04a71af1d14d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_907d616b-9965-4b39-adbf-5ae901c3e01c_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_label_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration Other Revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue" xlink:href="nktr-20221231.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationOtherRevenue" xlink:to="lab_nktr_LicenseCollaborationOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2dde43d9-fede-4d0b-b045-3fa9a6289957_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_bb9b2c4b-7da1-41a7-bcce-dac00b997c92_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_74d6fa92-64d3-4b46-baeb-20ebbbb0b4e2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b606f463-f14b-4341-9bc8-455c34ce04ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_fa1acaa8-0d28-4e9c-96be-f9dd8be35088_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_44d1f40a-51f1-4f25-8fab-f24faebf1038_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_027d2286-6e02-4c8b-bb0f-5c3cea6e404f_terseLabel_en-US" xlink:label="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Significant Customer Concentrations</link:label>
    <link:label id="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_label_en-US" xlink:label="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Significant Customer Concentrations [Policy Text Block]</link:label>
    <link:label id="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and significant customer concentrations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:href="nktr-20221231.xsd#nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:to="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_586e9020-dfa7-4df2-bd79-33a0e0caa7d3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3e6bbaaf-0490-43ac-ac58-8aafd93def7d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_3ee1c5b3-a737-4bcf-be1d-44f58fbb5f67_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_802cb3d4-427a-4d3f-a848-f9536b8ed406_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_91c4ea74-bec2-4e22-8e84-bc35fa4276ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_439bc962-75e2-4810-9e4a-9cd6978c888d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_2674a798-e229-4262-b313-900e1bb213a8_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FutureRoyaltiesMember_e9316ce0-bf9c-4a14-a040-de7dc9756546_terseLabel_en-US" xlink:label="lab_nktr_FutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties</link:label>
    <link:label id="lab_nktr_FutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_FutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_FutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_FutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FutureRoyaltiesMember" xlink:href="nktr-20221231.xsd#nktr_FutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FutureRoyaltiesMember" xlink:to="lab_nktr_FutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_53627a51-9064-4d67-8e67-b8cc22e72da6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_69ac3a28-0e0e-47a9-ad86-34b57d12467b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, penalties recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_eb4e04d4-d261-48d7-a8c2-c259d2d6d0e0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_abe4d96e-6966-493b-8131-62c770678b97_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_008f2fd3-349f-464b-8f83-d19f9590034a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4178e83c-da17-48bf-b82a-b85ec1c4248c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_a337232b-67c7-4833-b3c8-ae9e42aef0a1_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7f55e3ff-73ff-4ade-817f-a350d68e96b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_56bc3d3a-2364-44a1-b16d-d02c89ec327d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_fb219b09-e3f6-4cda-80c2-4b0ad69596cb_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_d50da863-0a04-4477-8e06-b19f018f27dc_terseLabel_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Liability Related to the Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:href="nktr-20221231.xsd#nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:to="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_e84f9d18-ad72-4d38-95c0-4b22a3ccc662_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c1762395-ab3b-48f6-b5ad-f8352f8d9710_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember_8458b17d-18d1-4c4f-8f53-6919e37b0996_terseLabel_en-US" xlink:label="lab_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Program Termination, Advance Paymnt To Contract Manyfacturers</link:label>
    <link:label id="lab_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember_label_en-US" xlink:label="lab_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Program Termination, Advance Paymnt To Contract Manyfacturers [Member]</link:label>
    <link:label id="lab_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember_documentation_en-US" xlink:label="lab_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Program Termination, Advance Paymnt To Contract Manyfacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember" xlink:href="nktr-20221231.xsd#nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember" xlink:to="lab_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_df6421a1-0d16-4b55-b0ed-ed34eefee7c9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1dbb54e0-82bb-4025-9ca2-5c43b3b97163_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity Under Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4a002c75-0a38-44fc-8170-95a65d8b7a83_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_cd4c06b7-6557-4f0e-85b6-12896d03dff1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cfce6d6d-f2c9-4f59-b9f3-be10589fcece_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards_e8494693-61dc-43a3-be28-17fde9b05e90_terseLabel_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration of net operating loss carryforwards</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards_label_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards_documentation_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" xlink:href="nktr-20221231.xsd#nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" xlink:to="lab_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_918836b9-881d-4d75-acc1-ed7e857efeeb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3c19592d-1308-4ff1-86df-4f65fe087d06_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_17967e94-2634-42e1-953b-7bdbeed5ab5e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2a0a84da-1cc8-4caa-8bb2-7379a0bf589d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b6b71700-b5a7-49f9-afd3-8abe257a0bab_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_6ea112c4-132c-4424-8f84-1a643d4fe43f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6ca93ef1-1d14-47d7-b6b0-e78b90468530_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_89694291-e7c0-4411-9520-b07083f4aa92_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_32149fea-4d40-42ad-baef-fb0f999bf50c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79e37d3b-1a94-4ba2-a5ad-11cf1536c7e7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6be78c6b-fbd5-40e8-9bf6-ee2d35fb4d15_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f33e6838-5b06-469d-8f06-6f062f72bf06_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_468bc35e-e6f7-44ea-bace-cdb0f10dbd84_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_147ad1fb-ecbe-4581-8aa1-8dd4f0f70b94_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f9cd357-c7db-48a8-a403-32e6a97a02d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c1e3cd10-5324-41e2-b293-4223dce07ce7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0b2e6a42-94f9-429e-b35e-f9cb949ddf24_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_716195a5-534f-4eca-935d-b3a03646cbff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_051fb882-77ff-459f-a503-e1b73b6f60b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7b977adc-f72a-42bb-a888-c28148085906_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d118eb6e-cdf4-414b-a7f6-bf2a68f87082_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_ae8af807-075c-4cf6-a6ec-3137b7f31ca5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c8cee6d9-7c0b-4cb9-ba89-5159c05e5519_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7c499f49-4788-451b-bbd9-c3bd2df93ac2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_816bb4ef-e3cf-4039-8892-03e8fb99fefd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1b302157-7612-403c-87f0-29bbc4e12d2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_42e872f2-3df0-4b1e-aad6-7235d7ed405c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_98cbcb6f-f3f0-4b36-b55a-9026cc4ffc74_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_008ff6f1-d924-4a4f-95c1-466f6a5f407d_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_1a76a03f-a5bc-43ae-a175-34e1d3b17f21_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_8d9d1f91-f2ed-440a-9f5e-907b4aff0aa8_terseLabel_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_label_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Sale Of Potential Future Royalties</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:href="nktr-20221231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:to="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ce92283e-6b29-4119-8107-2c5260e65630_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_23cc59dc-85e8-4505-89b0-bc19c93592cf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_aaadae09-dc7d-40b8-b6c9-0be554525762_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional development and regulatory milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20221231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_beb980fa-cbd7-4f79-827c-3d7ad91dd6d5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_723fdec5-4df5-4db5-b7f6-9baecfe4a633_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_875a2146-ceb6-4609-95d7-fc0fe325666c_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneDomain_5b34da20-790b-46f5-84be-7f0417d6f75a_terseLabel_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_label_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_documentation_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain" xlink:href="nktr-20221231.xsd#nktr_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneDomain" xlink:to="lab_nktr_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LeaseExtensionTerm_97eaa326-4998-4008-997e-726485a9d17f_terseLabel_en-US" xlink:label="lab_nktr_LeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_nktr_LeaseExtensionTerm_label_en-US" xlink:label="lab_nktr_LeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Extension Term</link:label>
    <link:label id="lab_nktr_LeaseExtensionTerm_documentation_en-US" xlink:label="lab_nktr_LeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeaseExtensionTerm" xlink:href="nktr-20221231.xsd#nktr_LeaseExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LeaseExtensionTerm" xlink:to="lab_nktr_LeaseExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_63a60123-41ee-4f0b-a686-90770f74ce02_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 188,560 shares and 185,468 shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6c04ce82-6ab1-42a8-a261-985b9b764f81_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RSUsAndPSUsMember_3b6d88a9-bf4f-425e-9389-85c39edb7eba_terseLabel_en-US" xlink:label="lab_nktr_RSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_nktr_RSUsAndPSUsMember_label_en-US" xlink:label="lab_nktr_RSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs [Member]</link:label>
    <link:label id="lab_nktr_RSUsAndPSUsMember_documentation_en-US" xlink:label="lab_nktr_RSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RSUsAndPSUsMember" xlink:href="nktr-20221231.xsd#nktr_RSUsAndPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RSUsAndPSUsMember" xlink:to="lab_nktr_RSUsAndPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_60c81de9-7426-4220-a1a6-c006d37bb72f_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember" xlink:href="nktr-20221231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember" xlink:to="lab_nktr_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonSecuritiesRelatedClaimsMember_d1679e80-12b7-4136-8b59-065c465a017b_terseLabel_en-US" xlink:label="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Securities Related Claims</link:label>
    <link:label id="lab_nktr_NonSecuritiesRelatedClaimsMember_label_en-US" xlink:label="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Securities Related Claims [Member]</link:label>
    <link:label id="lab_nktr_NonSecuritiesRelatedClaimsMember_documentation_en-US" xlink:label="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-securities related claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonSecuritiesRelatedClaimsMember" xlink:href="nktr-20221231.xsd#nktr_NonSecuritiesRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonSecuritiesRelatedClaimsMember" xlink:to="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d7ad85f3-ecb8-41f7-b932-56c4881188c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_718ec69e-3727-4429-87f6-90429a155c71_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching 401(k) employer contribution, maximum amount</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_92e8d48b-25c4-4e51-abd3-514b3112199d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OperatingLossCarryforwardsSubjectToExpiration_659a0ecf-725a-4f15-9381-f5bb08ee2e60_terseLabel_en-US" xlink:label="lab_nktr_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_nktr_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_nktr_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_nktr_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_nktr_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="nktr-20221231.xsd#nktr_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_nktr_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c84a964a-1ac0-46c0-a937-bbbab6d73339_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_44395125-09df-406b-a8ad-fc4c5877974a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_180204fb-aca0-4e73-98b5-82e118eae44f_terseLabel_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_label_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability [Text Block]</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_documentation_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:href="nktr-20221231.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:to="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ab65633-7e06-45af-abdd-0e79ee4bb762_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0570b4c7-6b86-4b37-809f-e5bdc8541f46_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e2c57cba-aace-4504-b5fd-aec2296b1d31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6bff2fc4-bf0b-40b0-8be2-98e82a6177c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_404a3c07-0c01-4909-ad3f-c2075dc5125c_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7c3c2e28-2eff-4919-bb5a-faea7a3a6dea_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="nktr-20221231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6110d8f5-4c22-476f-9190-e579d75c8725_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0863a969-9e3d-4faf-a6bd-7ff149a2fed4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_f9f75093-49ca-44b8-a907-c47b96e35c3b_totalLabel_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment, net</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property Plant And Equipment Net</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_documentation_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property, plant and equipment, Net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:href="nktr-20221231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:to="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0be6159c-b1a2-45be-a0ac-f41616fdd433_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_ec6c93fd-9794-4420-a46f-e12ac7eafc26_terseLabel_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:href="nktr-20221231.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:to="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_b3479880-544a-4ebb-8298-eca9b3f45888_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_98385723-7108-43c7-8756-a1740f5fe9f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_35ac33f1-392d-4af6-a88b-fe05b2b9bcd0_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d9a71e73-612f-465d-8c44-074888055406_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_426943c6-9d19-4a29-ae19-3b94f0c9c6b8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c74a135e-5245-4891-9355-b9b1e731a765_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ecd7d7f6-1fa7-4640-97c8-4462c347d84e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LesseeOperatingLeaseTableTextBlock_faede971-3277-47a0-bdd5-50d4ad52dce1_terseLabel_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Information</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseTableTextBlock_label_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease [Table Text Block]</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseTableTextBlock_documentation_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseTableTextBlock" xlink:href="nktr-20221231.xsd#nktr_LesseeOperatingLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LesseeOperatingLeaseTableTextBlock" xlink:to="lab_nktr_LesseeOperatingLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0e545609-724d-4b84-a63a-0b04456b9be9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7cc183cd-f08f-4316-8fe8-395543e660cb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_68a693ea-d470-4221-b630-c6e24e4adef4_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31471b09-c050-4b45-b107-51f836a9d24d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7bf988df-f4d4-4fd6-9b5f-7c8f64d5084a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_36363359-f31a-43cc-8137-ad05bc1f6325_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_30b964d8-8fe7-4f30-89f0-9c0310e24e5b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_5ea6e6c5-bf33-4171-ad68-0f9210ffb6a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fce3377e-c44e-4463-9728-eb759d24d25d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a1854a2d-4dc5-41c9-bf2b-4df6a7869fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dac4d05-a0ca-4003-a5a4-80dc79b2b905_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfConsecutiveTermsToExtendLease_d42442de-d3fb-4594-a708-61fa97962b2b_terseLabel_en-US" xlink:label="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive terms to extend lease</link:label>
    <link:label id="lab_nktr_NumberOfConsecutiveTermsToExtendLease_label_en-US" xlink:label="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consecutive Terms To Extend Lease</link:label>
    <link:label id="lab_nktr_NumberOfConsecutiveTermsToExtendLease_documentation_en-US" xlink:label="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive five year terms to extend lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:href="nktr-20221231.xsd#nktr_NumberOfConsecutiveTermsToExtendLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:to="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e01e0d71-369b-44f1-84c8-29892440e14c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6fd7c9f8-a774-46ee-9d3c-d02e622340e6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_193452a7-226c-4e0c-85a9-e2ef32b56dce_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_22647e3e-ec8e-416b-a970-1b494d854841_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_9e911696-d6a1-40dc-a745-ffb5f3ad77a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_99277aba-e2f4-4de4-85e0-b468597a7cb1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book value in excess of fair value</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_7c78d7dd-1d08-479c-9588-495e69a4c52a_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced under certain conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received Under Certain Conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received under certain conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:href="nktr-20221231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f5158fce-037b-4099-9229-844b2019ec5e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_2b071e6b-d979-47d9-b81c-f7eef17a6a10_terseLabel_en-US" xlink:label="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period subject to lock-up and stand-still provisions period</link:label>
    <link:label id="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_label_en-US" xlink:label="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Subject To Lock Up And Stand Still Provisions Period</link:label>
    <link:label id="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_documentation_en-US" xlink:label="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period subject to lock-up and stand-still provisions period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:href="nktr-20221231.xsd#nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:to="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3a9f076e-e039-4190-b106-70ca50e69254_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2eeb745c-db5d-45d0-824b-59bf1b7529da_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_b7ce8d35-01dd-4627-be42-5aa94abd4ae7_terseLabel_en-US" xlink:label="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Market Participant Subtenant Borrowing Rate</link:label>
    <link:label id="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_label_en-US" xlink:label="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Market Participant Subtenant Borrowing Rate [Member]</link:label>
    <link:label id="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_documentation_en-US" xlink:label="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Market Participant Subtenant Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:href="nktr-20221231.xsd#nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:to="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_45ce9199-030b-4df6-afeb-b063b7adcd89_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net capital loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_081bcac9-c831-4a4e-b08d-fc01376f20c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ff35ab21-5451-49ff-8642-aba136650480_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f93b1cba-bf54-47d4-a0a2-13193b444cd5_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81396c23-1103-4d2a-8c7d-1c987222d444_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_3ce3f7a9-3bc0-4d97-88e0-0434f639dd5c_terseLabel_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_label_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investment Maturity Period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:href="nktr-20221231.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:to="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecd6676f-f5a8-4432-813e-2160c80c0726_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f4424967-7bae-44aa-8c3a-1407f3bd14ce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_72b381fb-99d5-47f0-b150-45bfb6367441_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_42b752cc-b5c3-4f4e-a3ae-66f5ef9992ab_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0af75d34-3ee9-419c-b93a-a4bb4cc823c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_78859d73-badf-489c-a184-3b7e63a12e36_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_a1dc77c0-7f1a-45ea-9797-9f93a739a856_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_2dd817eb-6fa6-4b8d-8e63-454d41fd0184_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_492ae2a3-451a-4dcc-80b5-fa689328c8dd_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:href="nktr-20221231.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:to="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_b2ae3556-6657-4e56-b8e1-06f5b93226cd_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nktr-20221231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0e4cdcea-3736-4fea-b269-2e582c5b8243_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9defa2ab-5b1e-498f-955d-646263f4680e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f9ea2402-2f2f-422c-8840-3a8057995ebc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0b51311d-5529-41ad-92e0-6cf20e1bd610_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dd3579c7-3d80-4694-aa7d-c2e66402faed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5cccc088-4d34-478f-a22d-95ba65b1e8aa_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_40782914-1786-4a45-bcd6-ec2eb1463420_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ae09472a-00a4-4e17-a08b-f993ace20ecb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProgramTerminationNoncancellableCommitmentsMember_5be198a6-0c16-4edb-84dd-adb33c86093b_terseLabel_en-US" xlink:label="lab_nktr_ProgramTerminationNoncancellableCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Program Termination, Noncancellable Commitments</link:label>
    <link:label id="lab_nktr_ProgramTerminationNoncancellableCommitmentsMember_label_en-US" xlink:label="lab_nktr_ProgramTerminationNoncancellableCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Program Termination, Noncancellable Commitments [Member]</link:label>
    <link:label id="lab_nktr_ProgramTerminationNoncancellableCommitmentsMember_documentation_en-US" xlink:label="lab_nktr_ProgramTerminationNoncancellableCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Program Termination, Noncancellable Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProgramTerminationNoncancellableCommitmentsMember" xlink:href="nktr-20221231.xsd#nktr_ProgramTerminationNoncancellableCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProgramTerminationNoncancellableCommitmentsMember" xlink:to="lab_nktr_ProgramTerminationNoncancellableCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_ac68cc01-5960-4cca-b25d-e7e2c17ae805_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MergerAndAcquisitionRelatedClaimsMember_eb8685a5-6dab-4769-a554-fef24eb2dd01_terseLabel_en-US" xlink:label="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and Acquisition Related Claims</link:label>
    <link:label id="lab_nktr_MergerAndAcquisitionRelatedClaimsMember_label_en-US" xlink:label="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger And Acquisition Related Claims [Member]</link:label>
    <link:label id="lab_nktr_MergerAndAcquisitionRelatedClaimsMember_documentation_en-US" xlink:label="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and acquisition related claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:href="nktr-20221231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:to="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_79dceab5-d3f8-449c-b9ec-2deb78b8aa41_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5506250f-4ae5-4075-8434-87c784c06ff2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5ada87c8-b9ba-4f7c-b342-cbed0a8f7daf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_efb696a0-36a9-4d03-9496-6ce7a6a63650_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_5c63b878-c7dc-43da-835c-6717658afa81_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_c38411e1-49fb-4bd4-a96e-48be33eed348_verboseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_f224d9a2-9445-45ac-96eb-2e52bb2aac20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7c65bdba-5cc1-47f6-8767-05a2506e9000_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_612d9ca4-9085-4a84-95d0-b12dde6c664e_terseLabel_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components</link:label>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_label_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ReportableGeographicalComponentsMember" xlink:to="lab_srt_ReportableGeographicalComponentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_eea15a76-d8d2-451d-9d19-e5bbb8b0b23f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_6417e48a-0ced-4eae-a3ba-9fd0a3058b9a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_276c7b1f-6337-46d8-a645-b295083fa228_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember" xlink:href="nktr-20221231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember" xlink:to="lab_nktr_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6403e568-27e2-4005-9728-6195bcbd5d46_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_0bcd59db-b46c-41fc-a440-247fcfa451e1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_2f403601-7b82-4f25-9381-26d873fa55cd_terseLabel_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sales of future royalties</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_label_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_documentation_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:href="nktr-20221231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:to="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85862c68-f957-45f1-b60f-e2ad56072850_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3eac1655-a80b-4fc8-9924-35ba0cd57778_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5ba3cba1-05a0-4e6c-9c61-da8424e55dfd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d58f414c-41c5-4908-8df3-bd816750a8dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8f166f37-24a4-4dc0-92f8-ea1bf1f167c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar214Member_080896d0-e240-42cd-b059-f5948810cc74_terseLabel_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214</link:label>
    <link:label id="lab_nktr_Nektar214Member_label_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214 [Member]</link:label>
    <link:label id="lab_nktr_Nektar214Member_documentation_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member" xlink:href="nktr-20221231.xsd#nktr_Nektar214Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar214Member" xlink:to="lab_nktr_Nektar214Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0f652682-a579-49e8-8418-4fefb3dcb60f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_90236469-51d0-446f-83d8-099ed91c0258_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d8823597-c1dc-4c50-9699-7c597c3ce070_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_50638dba-d6f9-4513-b3f8-bded0eecaa07_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_cd7ba74c-696d-476f-b466-1e0d17b91e79_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_b699ca2c-02ac-49a5-bf8c-866f352ab811_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_9278de8d-db99-43e8-aa68-34a3473ab306_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived" xlink:href="nktr-20221231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived" xlink:to="lab_nktr_SaleOfStockConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_f0e0da4a-0da3-48f3-bf67-9f878b30e229_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_ac90f855-90c3-4f1c-89be-030872d19d4e_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by geographic area</link:label>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_label_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Areas, Revenues from External Customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:to="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_031a4aeb-91fe-47d6-994a-11e879c434fe_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bcf8b30c-7f71-4de9-b29d-9a4c6098f5eb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_9620233a-648b-4946-9059-d14a257214b2_negatedTerseLabel_en-US" xlink:label="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment and Operating lease right-of-use assets</link:label>
    <link:label id="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_label_en-US" xlink:label="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure</link:label>
    <link:label id="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_documentation_en-US" xlink:label="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:href="nktr-20221231.xsd#nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:to="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_fd56797c-4971-412c-96ca-effdb4a27cb5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e4fefc0b-14fb-4a6e-a138-d9c1897ea64c_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations of U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_aa75c6f9-0927-43ce-957a-17637fbdb642_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_98a0dd72-c58d-452d-b11f-29348dd66f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PreferredStockShareDesignated_bfead23d-8cc5-463e-b0fc-edd5dbc5d912_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated" xlink:href="nktr-20221231.xsd#nktr_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated" xlink:to="lab_nktr_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_472816df-06a5-4b15-866c-3046cadf033d_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of future royalties, net of $3.8 million of transaction costs</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Future Royalties, Net</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Future Royalties, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:href="nktr-20221231.xsd#nktr_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:to="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_a488a315-b420-46f7-bb90-28eb46501657_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_754c05e6-82a7-4b37-baba-27aef8480b36_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_975ac261-a003-4337-b676-b412dd39dbe3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_ef676177-9758-48d9-ba83-906a9f8263bf_terseLabel_en-US" xlink:label="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plan's share limit reduction for every one restricted stock unit granted</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_label_en-US" xlink:label="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Plans Share Limit For Every One Share</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_documentation_en-US" xlink:label="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation plan's share limit for every one share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:href="nktr-20221231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:to="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5692fa3a-3ae1-437a-917f-20d0d195d3f2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_50fc9ee8-3086-4823-8e71-c1255a75012b_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5ac27d36-0d93-45d5-a369-890827d64e1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_45432bb9-313d-4618-861b-33f8302e245f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2b3d984e-1de1-4cd8-98f2-85cb6003c8b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0be230f5-4bde-4d36-be1b-8d8aafc0c8e7_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_3f2ca721-e0c4-4d73-86ba-9b7ce88d881c_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (gain) loss on sale or disposal of property, plan and equipment, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_6b42b4a3-d200-4e6e-be56-c7235e8e9c85_terseLabel_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of transaction related to purchase and sale agreement</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_label_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_documentation_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:href="nktr-20221231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:to="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_60cd39e5-c45c-48f9-aa17-221a2c22239b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_dace188c-f218-4580-b98e-1f294b677133_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e9e20638-f600-49c7-a471-49f4cc4bd6e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_66ffa72f-c0b6-443c-9ce2-72f1943d1104_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized during the period</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2d14a35c-5523-45d0-8a9e-0c4de33abe27_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_0a8f65cb-25e5-48f2-af40-33dd53d1af61_terseLabel_en-US" xlink:label="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable recognized in exchange for long-term liabilities</link:label>
    <link:label id="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_label_en-US" xlink:label="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities</link:label>
    <link:label id="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_documentation_en-US" xlink:label="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:href="nktr-20221231.xsd#nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:to="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_00f90668-7005-45cc-8faa-2572978b535e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_37348719-d505-4067-a501-4461e0987276_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_37e98039-49e1-42bb-96f6-6d2c32472b53_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NKTR181Member_ff41d19a-cf7d-4822-8728-bc122a1d3684_terseLabel_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181</link:label>
    <link:label id="lab_nktr_NKTR181Member_label_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:label id="lab_nktr_NKTR181Member_documentation_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member" xlink:href="nktr-20221231.xsd#nktr_NKTR181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NKTR181Member" xlink:to="lab_nktr_NKTR181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ab324148-ee24-493d-9ba6-5ebfbfe68e63_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56cbb17f-045e-4aa9-a2c8-cb57c8dbd12d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_6819b9da-6083-472e-be09-1ec4604a8505_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_35c5f0ac-83df-4fb1-89bb-c4588898f981_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneAxis_6b2b4e5a-4178-49af-8f27-2d5809514b67_terseLabel_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_label_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_documentation_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis" xlink:href="nktr-20221231.xsd#nktr_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneAxis" xlink:to="lab_nktr_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_3a7dcd5a-1bb1-48db-a576-9e8cf1075f6d_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeMember_89b9d368-5253-485f-840d-c2f5a8695bb7_terseLabel_en-US" xlink:label="lab_nktr_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_nktr_EmployeeMember_label_en-US" xlink:label="lab_nktr_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_nktr_EmployeeMember_documentation_en-US" xlink:label="lab_nktr_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeMember" xlink:href="nktr-20221231.xsd#nktr_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeMember" xlink:to="lab_nktr_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_1a5aba77-d88b-484f-b3ba-f4771e3fa5a8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation matters, liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_d0c150e5-9d68-44e4-90dc-003181a5bffb_terseLabel_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties</link:label>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_label_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds</link:label>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_documentation_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:href="nktr-20221231.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:to="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bd3e460e-fc8a-497e-860f-30253d763e64_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4f22e888-da42-4f7d-a9b6-20132f825406_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c24eb5d2-e6a7-4565-bf41-289b66906220_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_68d474ef-57ce-41cb-9a5d-89cba469047b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a457c767-dc8a-4001-a35a-bcc8246477d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_148a6583-77de-4b1b-80a3-3c50b46dc548_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProgramTerminationMember_0304ad50-a59a-468b-8590-33bea30ed4e3_terseLabel_en-US" xlink:label="lab_nktr_ProgramTerminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Program Termination</link:label>
    <link:label id="lab_nktr_ProgramTerminationMember_label_en-US" xlink:label="lab_nktr_ProgramTerminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Program Termination [Member]</link:label>
    <link:label id="lab_nktr_ProgramTerminationMember_documentation_en-US" xlink:label="lab_nktr_ProgramTerminationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Program Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProgramTerminationMember" xlink:href="nktr-20221231.xsd#nktr_ProgramTerminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProgramTerminationMember" xlink:to="lab_nktr_ProgramTerminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_5f38c9d2-1839-4552-bbd6-3117f612e7d4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2022 or 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_3b20b193-721e-4c2a-bfb7-c0225145486b_negatedTerseLabel_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, net</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:href="nktr-20221231.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:to="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_6fd73382-2a7d-4102-90e2-fde4071a2edd_periodStartLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties&#8212;beginning balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_967bfd97-8e4c-4345-8431-ed8bc6a0ae05_periodEndLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties &#8211; ending balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_c6b64221-8522-40e2-87ad-e916cabb1086_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_594f23ba-cb21-410b-8fb4-e070c27e7cc0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_09df92b0-1479-4efd-88b6-116171ca783f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c0fa181d-44b8-46b8-b269-b2a1c150734d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3a92f851-ec00-4f1f-8c98-d56692963417_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9fb8dfe2-0be4-4308-90ff-3798dca33a38_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common stock reserved for issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LeasesLineItems_6ea30606-9052-4919-a0dd-83d71bf2577f_terseLabel_en-US" xlink:label="lab_nktr_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_nktr_LeasesLineItems_label_en-US" xlink:label="lab_nktr_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_nktr_LeasesLineItems_documentation_en-US" xlink:label="lab_nktr_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems" xlink:href="nktr-20221231.xsd#nktr_LeasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LeasesLineItems" xlink:to="lab_nktr_LeasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5e20c633-e4fa-471f-b2fb-649603cff1d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_871e60be-1b65-4d99-bd63-6cd4f9ec3555_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_ad850c1f-5bd5-4a2c-a499-105dfed11418_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_82174a34-6327-4280-9e97-875f1e5e2035_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d4462194-8004-4ff3-b672-84f80567d896_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5b4891a7-1c23-44c7-8b04-5b4ec57ffaad_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_732104c4-9354-426f-9c6b-3396ce64ce1f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_b186d7f3-52ca-4725-9194-1de281ebafd1_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of royalty rights</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Potential Future Royalties Gross</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of potential future royalties gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:href="nktr-20221231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:to="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5c9eefaf-99f0-4573-945e-05cd33242f7f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_258371f7-161c-46b0-a79b-8f51de5065a8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_bcea54a4-1dc4-4149-a014-273dfbc5a906_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of advance payments to contract manufacturers and equipment for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment From Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equipment from terminated program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:href="nktr-20221231.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_693fc458-cfeb-4573-8fef-478ee8f8e73b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_7918db5e-8619-455f-8154-3a63f71d1e08_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock_10b04ee9-3c21-4e73-a83b-1705104a773b_terseLabel_en-US" xlink:label="lab_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Costs for Terminated Program</link:label>
    <link:label id="lab_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock_label_en-US" xlink:label="lab_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Costs for Terminated Program [Policy Text Block]</link:label>
    <link:label id="lab_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Costs for Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:href="nktr-20221231.xsd#nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:to="lab_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_05930b57-de7a-41e4-957b-53a7ba54c56f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_80754751-34c8-4952-8f0b-9525bf9aa547_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_37866f06-79e6-4edb-8ad6-3b6be89ab803_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_7a8d7a47-74b5-4cc5-9f0d-79e8310d0e46_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_8ae37edb-3137-4582-887e-4e859349acfa_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_a3598bcc-2fe2-4a93-96a2-c243e3697d81_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0aedda02-e3ca-4d17-97af-35ec73d41476_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_f1afe7ca-f6c2-4156-952d-47f32d87c788_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_7ad9696c-0959-49b0-8332-1ca53d0aa33b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_90bd1c8d-0bf2-4e57-b312-3a1558be1f6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from SFJ</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3b1ae48d-7d24-4023-88c2-954b0037808a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d63e0ea9-1a19-46b2-9d52-4f06f7abd41d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3bd10fb9-94ef-421e-8722-8efa826b4dd5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d44fe218-301c-420c-af96-a30d12471711_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: portion representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cfbf46e6-41d8-4ab2-a6be-65c363a0ffe9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d931bcb0-df51-499b-a8f1-4ca794807580_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_0846d12d-5ea5-4074-82a2-5720d81abf24_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_051f76de-a022-4c46-b81f-67c6ae5b7987_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_48738019-9c25-4914-8581-7524c994dd6c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1cc1d798-0515-4629-ac57-a08a605611c1_negatedNetLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on sale or disposal of property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_73064ecd-1367-4173-bd3f-f1a432076dea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on sale or disposal of property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b517784-827f-44ea-80b8-e4eb4352cd77_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_040fe9b2-d466-49c9-9986-fda614398cb3_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_fffd02bb-cf1e-42c7-93d0-14fe4346e81e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c7d36330-8fcd-4dbe-847c-68cf2a75f20c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_67751369-cbde-42ee-bc49-2368f2f2a362_terseLabel_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty monetization proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_label_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization Proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_documentation_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds" xlink:href="nktr-20221231.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltyMonetizationProceeds" xlink:to="lab_nktr_RoyaltyMonetizationProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2d4ad25c-015d-4653-862b-1c3b205ef83a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_3fd054ba-8665-4df0-a7f7-12cf23c542de_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_a74db5ea-d759-446e-b0d5-b4940f6c903e_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_81666e2e-5d8f-4c24-8712-df440ac1c68c_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4a0e62a6-4093-4de8-b921-3d2a03f8add3_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_b0bc5b7e-e485-4f3d-af64-f65b56f8ea92_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_4d692181-7ac9-4680-a64a-4c8db31dd5a7_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_92ca9e0d-1d37-4d60-8cba-f0fe323cc984_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_82910125-0dd0-40e2-b947-baa64cda7bb3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyMember_99618145-fadf-4386-ae8f-4771ff746e3a_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_label_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember" xlink:href="nktr-20221231.xsd#nktr_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember" xlink:to="lab_nktr_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_12311a7f-ec63-4180-9d12-3adf1abbe6bf_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nktr-20221231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e046460b-3547-47bd-a74b-9c03360722bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7556b8b2-ea60-4a1d-99d4-94876d23e914_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options term under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ea54b2f1-18de-4339-8da5-40d8883189fe_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_c89b399e-a1ad-4bea-b190-67a702d60c6a_terseLabel_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sales of future royalties</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_label_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non Deductible Expense For Liability Related Sale Of Future Royalties, Amount</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_documentation_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:href="nktr-20221231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:to="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_d07767b6-074c-4e55-a930-0fc8620c4594_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_f7cadf0b-b802-47ce-a3d6-f38b6cd0f96e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_82b576c7-28b0-4d15-a0fe-719c9ddd3e2a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_4bef85c9-fab4-4391-a0ad-0663cdeffc6c_terseLabel_en-US" xlink:label="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_label_en-US" xlink:label="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_documentation_en-US" xlink:label="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:href="nktr-20221231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:to="lab_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e84c2af1-7e2e-4480-8b81-84d84b9af084_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_55e669e2-b9e8-47be-bba9-a66c2aa8d22f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4c6270bf-21b3-4725-b568-7f681e05aa65_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3537580f-aa73-4091-877c-8f012d78bcc9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value at</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9739c589-dc0c-4d8d-bb84-7d7ad67a8557_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f269a910-0eca-4c26-a78d-96590f449dd9_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneOneMember_6c3194dd-dcb8-4869-9915-1e219ec27ed1_terseLabel_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_label_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_documentation_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember" xlink:href="nktr-20221231.xsd#nktr_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneOneMember" xlink:to="lab_nktr_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_b855dafe-3db6-4cdf-ac04-575d83d3c32f_terseLabel_en-US" xlink:label="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, period may increase or decrease due to tax examination</link:label>
    <link:label id="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_label_en-US" xlink:label="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Period Increase (Decrease) Reasonable Period Of Change</link:label>
    <link:label id="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_documentation_en-US" xlink:label="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, period increase (decrease) reasonable period of change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:href="nktr-20221231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:to="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_091604dd-1331-4585-8ddb-c860413b12aa_terseLabel_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Street Facility</link:label>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_label_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Street Lease [Member]</link:label>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_documentation_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third street lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember" xlink:href="nktr-20221231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ThirdStreetLeaseMember" xlink:to="lab_nktr_ThirdStreetLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_591b8646-d693-4088-ae6b-713be72d8e48_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_d7a3caaa-1446-40fe-863e-73feb5764fbf_terseLabel_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment at cost</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property Plant And Equipment Gross</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_documentation_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property, plant and equipment, Gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:href="nktr-20221231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:to="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_8466a383-5315-433b-9e50-a8963b1ec26e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_fe6cd942-9cf3-423d-a57b-3dc293d3d818_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_674a4bf6-1b56-4d2f-8046-2e16b351c7f3_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_28cdbe44-fd11-4692-b3ed-0e0118c7bc83_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_6dd52c49-c23f-4714-8045-15df42d2e326_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_779a01e6-e11c-4c47-8b8e-9ef5ebbf7b3e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_60a52e86-a2dd-4ebe-bfa8-989a0e4765f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_054fc647-ee88-4146-abbc-143d23ee44a8_terseLabel_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties liability, measurement input</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_label_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:href="nktr-20221231.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:to="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_ed64ad8e-56e8-4c61-915c-e70b49e787e0_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_a8935d85-3017-41bf-9f4a-091ce7316dcb_terseLabel_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year two</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_label_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made For Milestone Not Achieved Year Two</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_documentation_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:href="nktr-20221231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:to="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_0263feaa-b3ab-495f-b2c8-5fe4f45abb5b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_9b843089-d3ff-43aa-934e-b8e40070ff08_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne_52f95f54-8186-4f3b-a2c4-715d4d983195_terseLabel_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year one</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne_label_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made For Milestone Not Achieved Year One</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne_documentation_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:href="nktr-20221231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:to="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SalesMilestoneRevenue_ffbc206a-91f9-46f2-b08a-3223df5b9840_terseLabel_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_label_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_documentation_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue" xlink:href="nktr-20221231.xsd#nktr_SalesMilestoneRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SalesMilestoneRevenue" xlink:to="lab_nktr_SalesMilestoneRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_0d744b59-dea2-468b-b50f-880eea38895d_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:href="nktr-20221231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ac00b094-b866-40a2-9b2d-204e8e49eabb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_90f08b4f-c5c5-473e-90ed-5126673f99c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Provision Related to Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d14e37a2-f564-4ffc-8c88-f49fc54fe890_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncomeTaxesDisclosureLineItems_321b480d-d463-4dba-b388-190c6353c039_terseLabel_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureLineItems_label_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureLineItems_documentation_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureLineItems" xlink:href="nktr-20221231.xsd#nktr_IncomeTaxesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems" xlink:to="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3457b77e-8eef-44cd-b162-42c6f982554b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring, Impairment and Other Costs of Terminated Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_14e6b1dd-ba5d-4115-b3ed-ca8101f83947_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_39e3fddd-1642-46f5-94b2-d863cb095d13_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4a0dd4fa-bf22-41bb-9d6a-e3b3301cc6a4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8ce75586-97b2-481d-b268-558448b9e559_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4239ab11-0055-4d8d-b2a2-86066ce87bf0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_44a8a9c8-a784-4ef7-95cf-0c5aa35534f1_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7bed9d7-7a09-4479-b055-1e1ce2cd055f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_398bd620-717e-4245-9b05-c9551397bc9c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BempegaldesleukinMember_4fae4f2d-1414-42b3-9b36-be057ab6e93a_terseLabel_en-US" xlink:label="lab_nktr_BempegaldesleukinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin</link:label>
    <link:label id="lab_nktr_BempegaldesleukinMember_label_en-US" xlink:label="lab_nktr_BempegaldesleukinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin [Member]</link:label>
    <link:label id="lab_nktr_BempegaldesleukinMember_documentation_en-US" xlink:label="lab_nktr_BempegaldesleukinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BempegaldesleukinMember" xlink:href="nktr-20221231.xsd#nktr_BempegaldesleukinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BempegaldesleukinMember" xlink:to="lab_nktr_BempegaldesleukinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_StockOptionsRSUsAndPSUsMember_a7e01e49-ed39-4c60-8dca-60a1996c6f91_verboseLabel_en-US" xlink:label="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, RSUs and PSUs</link:label>
    <link:label id="lab_nktr_StockOptionsRSUsAndPSUsMember_label_en-US" xlink:label="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, RSUs And PSUs [Member]</link:label>
    <link:label id="lab_nktr_StockOptionsRSUsAndPSUsMember_documentation_en-US" xlink:label="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, RSUs And PSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsRSUsAndPSUsMember" xlink:href="nktr-20221231.xsd#nktr_StockOptionsRSUsAndPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_StockOptionsRSUsAndPSUsMember" xlink:to="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_01fd3ff3-85c7-493c-940b-53fde9ba11c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_4db9fc47-fd0a-441b-b3ef-a5bc606b8d39_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_347db5d1-082d-47f0-b769-c66528ae04d7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_feef1a52-fca9-4c47-b2a5-fe8e69a1c173_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ce2d33ee-d099-429c-8055-1f535cdb08a7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7785b139-6b13-469e-a93c-faa7862aa249_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_90bd5c34-da45-4c62-b918-573d07faed6a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_e82f4fb2-e33a-412f-9402-47d161e90248_terseLabel_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for executives</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_label_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Control Severance Payment Period For Executives</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_documentation_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for executives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:href="nktr-20221231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForExecutives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:to="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_6554e8a2-db9c-4a34-92e3-9330dcedfe6d_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding phase 3 development costs on an indication by indication basis borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_label_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_documentation_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding Phase three development costs on an indication by indication basis borne.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:href="nktr-20221231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:to="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_19273acc-6308-4a47-bf47-06ca18503de3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_efc566c4-455b-432f-9973-35809d2263e6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_edb42996-a32e-4db0-8954-bc570c37b5c0_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c2714f23-9909-4ce4-b138-aa93b837855e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_f0c9c8c9-be1c-46b9-bfb1-76374b215b53_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_932c0652-ecc5-49cb-8b63-e1d4754cc41c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_c5a50ce9-fb50-45d4-be0d-56de2db018e3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_82ce878b-e957-4e2e-88e5-d995c38abdba_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1eb6fef9-aa9a-490a-80b8-dfb9866b036f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e4740958-6977-48b4-b474-eb728b7cdb6a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_02a0896d-f96f-4b6e-ab68-58eb0fca4a02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_a1501473-e37c-473e-b48d-72d58bfd91e2_terseLabel_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated Or Takeda P L C</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_label_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated Or Takeda P L C [Member]</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_documentation_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated or takeda PLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:href="nktr-20221231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:to="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_f76833bd-c6a4-4d5d-b9f4-bfa21c28ae8d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_7b79be54-1b19-4f5b-9967-c531acee72e3_terseLabel_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_label_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Laboratory And Other Equipment [Member]</link:label>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_documentation_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing laboratory and other equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:href="nktr-20221231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:to="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_786cc5a8-dc70-49aa-8fec-8b13af398721_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AreaOfLeasedSpace_c79bfa32-6608-4d7c-9116-bec18b81ed9b_terseLabel_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease space (in sq ft)</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpace_label_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Leased Space</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpace_documentation_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased space.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpace" xlink:href="nktr-20221231.xsd#nktr_AreaOfLeasedSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AreaOfLeasedSpace" xlink:to="lab_nktr_AreaOfLeasedSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_4817f50a-984b-4cbd-87a4-893186f652fb_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358Member_5a0d1b5c-1e24-4704-8514-d0616e3aeb05_terseLabel_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:label id="lab_nktr_Nektar358Member_label_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358 [Member]</link:label>
    <link:label id="lab_nktr_Nektar358Member_documentation_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member" xlink:href="nktr-20221231.xsd#nktr_Nektar358Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358Member" xlink:to="lab_nktr_Nektar358Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ebfc0efc-f1df-4475-8273-cece4905c3d5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_c45b725a-6de2-4065-8b2f-13b271dccb4f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of right-of-use assets and property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_1ffdebb5-cd43-41a5-bbd5-32223a114e55_totalLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total impairment of sublease assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ffcc91b8-6c7a-4cbc-b98d-a99c94985bdd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_83147d2b-0fb9-46ed-b6ab-36ece1260a3f_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_90f472c5-4942-462c-b280-a8715a49b197_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets recognized in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_5eeb414a-11a5-478a-bf0b-9ee150a58148_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_13d8544e-67a8-4180-b147-71b15cf8c437_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_1ede857c-ab93-484c-9c9d-563728d30e68_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_4dfa6d4a-0fd2-46c8-8b58-337f3236207b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>nktr-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6319d4c-7e41-446e-a208-11c24c30fce3,g:5a9b6e6c-7a94-44cb-81e7-2ed70e787342-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/Cover" xlink:type="simple" xlink:href="nktr-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_40ebe890-5c39-433e-8b96-c1585433bfb0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_DocumentType_40ebe890-5c39-433e-8b96-c1585433bfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_35d130cf-78bc-4ccd-aa8d-2fca294a7b48" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_DocumentAnnualReport_35d130cf-78bc-4ccd-aa8d-2fca294a7b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f2116a81-9d4b-4b74-b41b-342003e79961" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_DocumentPeriodEndDate_f2116a81-9d4b-4b74-b41b-342003e79961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e9cc1dad-922c-45dd-9dd7-2afae0e400ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_CurrentFiscalYearEndDate_e9cc1dad-922c-45dd-9dd7-2afae0e400ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ac4b8578-dd4a-43e2-ab10-1b523cdedc26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_DocumentTransitionReport_ac4b8578-dd4a-43e2-ab10-1b523cdedc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_edeb67ca-b335-496c-8c61-d6c48fd726d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityFileNumber_edeb67ca-b335-496c-8c61-d6c48fd726d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8e3e98bc-18bb-495f-97d0-c29231e6d02c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityRegistrantName_8e3e98bc-18bb-495f-97d0-c29231e6d02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_993e6dd0-b642-44f8-882d-0434a92292f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_993e6dd0-b642-44f8-882d-0434a92292f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2c9ae0a3-fa84-4c6b-8b5d-f3697760ee89" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityTaxIdentificationNumber_2c9ae0a3-fa84-4c6b-8b5d-f3697760ee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6db72fd8-2993-4873-be66-d28c2e882621" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityAddressAddressLine1_6db72fd8-2993-4873-be66-d28c2e882621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1b5fd9d5-c065-4e9b-9492-e0c19b1b6bcd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityAddressCityOrTown_1b5fd9d5-c065-4e9b-9492-e0c19b1b6bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4e642806-b437-4b8a-97ec-4a43ee36871c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityAddressStateOrProvince_4e642806-b437-4b8a-97ec-4a43ee36871c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9c6514a3-1e54-486d-ad91-1b8f064bb3e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityAddressPostalZipCode_9c6514a3-1e54-486d-ad91-1b8f064bb3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2a24ba28-f07c-440c-8835-44db0b0f2d6e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_CityAreaCode_2a24ba28-f07c-440c-8835-44db0b0f2d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f311db2b-dfa4-46bb-bd68-61de432c5da1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_LocalPhoneNumber_f311db2b-dfa4-46bb-bd68-61de432c5da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b68ecfa6-b0dd-422a-b01a-c775fe382813" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_Security12bTitle_b68ecfa6-b0dd-422a-b01a-c775fe382813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_158afae4-0743-48b1-9e0a-96becddbb742" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_TradingSymbol_158afae4-0743-48b1-9e0a-96becddbb742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fcd6d905-1f69-4a01-963e-d3de63f65444" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_SecurityExchangeName_fcd6d905-1f69-4a01-963e-d3de63f65444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7541f862-8f92-4502-8700-9b6050cf4905" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7541f862-8f92-4502-8700-9b6050cf4905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_9000b763-39b7-4f12-bd05-08f192a413bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityVoluntaryFilers_9000b763-39b7-4f12-bd05-08f192a413bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_84e7cdae-2065-40b2-b5c0-2bf6ea6df992" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityCurrentReportingStatus_84e7cdae-2065-40b2-b5c0-2bf6ea6df992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_83712c83-72af-4080-8821-48b6d421306c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityInteractiveDataCurrent_83712c83-72af-4080-8821-48b6d421306c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8833d9fc-4676-4e5e-b1a3-6d028edd0b3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityFilerCategory_8833d9fc-4676-4e5e-b1a3-6d028edd0b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b59070d7-0ddf-4467-9f43-867ed10abb8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntitySmallBusiness_b59070d7-0ddf-4467-9f43-867ed10abb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f9dfadc0-fb1e-4113-936f-34e24f83b77d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityEmergingGrowthCompany_f9dfadc0-fb1e-4113-936f-34e24f83b77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_6b3e1b6b-fad1-4904-90b6-bb44db884260" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_IcfrAuditorAttestationFlag_6b3e1b6b-fad1-4904-90b6-bb44db884260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_41492a28-c77e-4f89-87d9-681d8b5b6969" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityShellCompany_41492a28-c77e-4f89-87d9-681d8b5b6969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_d87403db-a716-4b31-a820-f531e83e2a9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityPublicFloat_d87403db-a716-4b31-a820-f531e83e2a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_344fef37-30cc-477c-a39a-d3a9f38754b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_344fef37-30cc-477c-a39a-d3a9f38754b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a171265a-e48c-4ee1-bbdd-51b62ea7b49b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a171265a-e48c-4ee1-bbdd-51b62ea7b49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_59c649bd-34d2-4659-918e-c73aa31a52ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_AmendmentFlag_59c649bd-34d2-4659-918e-c73aa31a52ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f4d7d44f-4d9b-4f68-bc75-892d33c5a243" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_DocumentFiscalYearFocus_f4d7d44f-4d9b-4f68-bc75-892d33c5a243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_291bacd6-faff-4dd9-811c-13fd205feb09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_291bacd6-faff-4dd9-811c-13fd205feb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_65111368-608d-4ec0-a8b0-504895cbdfaf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbc4d3fa-046b-422b-bd53-b50a83f6f6d9" xlink:to="loc_dei_EntityCentralIndexKey_65111368-608d-4ec0-a8b0-504895cbdfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/AuditInformation" xlink:type="simple" xlink:href="nktr-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AuditorInformationAbstract_da9586aa-de1b-41a7-b019-9edfa817509d" xlink:href="nktr-20221231.xsd#nktr_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_2d54cbe3-7d52-4c0f-9a43-067d79028310" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_AuditorInformationAbstract_da9586aa-de1b-41a7-b019-9edfa817509d" xlink:to="loc_dei_AuditorName_2d54cbe3-7d52-4c0f-9a43-067d79028310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_cb824257-2207-4c1c-bca2-c8c631752344" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_AuditorInformationAbstract_da9586aa-de1b-41a7-b019-9edfa817509d" xlink:to="loc_dei_AuditorLocation_cb824257-2207-4c1c-bca2-c8c631752344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_849006fa-5a8b-4f15-8527-45bfea83c1f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_AuditorInformationAbstract_da9586aa-de1b-41a7-b019-9edfa817509d" xlink:to="loc_dei_AuditorFirmId_849006fa-5a8b-4f15-8527-45bfea83c1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_99500c72-3291-44ec-833c-9df34358781b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_869824cc-da73-4870-aaa3-eedbdf59037c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_99500c72-3291-44ec-833c-9df34358781b" xlink:to="loc_us-gaap_AssetsAbstract_869824cc-da73-4870-aaa3-eedbdf59037c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_cb8add20-3321-4d12-98f4-d133b7c32658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869824cc-da73-4870-aaa3-eedbdf59037c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_cb8add20-3321-4d12-98f4-d133b7c32658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3df79ec-51fd-4e65-9c2c-66ccf5595d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb8add20-3321-4d12-98f4-d133b7c32658" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3df79ec-51fd-4e65-9c2c-66ccf5595d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f014b682-a34e-49bf-a128-6b8aa035d7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb8add20-3321-4d12-98f4-d133b7c32658" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f014b682-a34e-49bf-a128-6b8aa035d7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8f920753-df03-4d9f-b898-b724a6c7773b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb8add20-3321-4d12-98f4-d133b7c32658" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8f920753-df03-4d9f-b898-b724a6c7773b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5438d5c3-9918-4a86-8c42-a5f3aeb53cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb8add20-3321-4d12-98f4-d133b7c32658" xlink:to="loc_us-gaap_InventoryNet_5438d5c3-9918-4a86-8c42-a5f3aeb53cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d84a4160-0bd6-41d5-a4e3-bf4ce0189b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb8add20-3321-4d12-98f4-d133b7c32658" xlink:to="loc_us-gaap_OtherAssetsCurrent_d84a4160-0bd6-41d5-a4e3-bf4ce0189b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7927394f-e2ab-488f-8950-4536469b6e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb8add20-3321-4d12-98f4-d133b7c32658" xlink:to="loc_us-gaap_AssetsCurrent_7927394f-e2ab-488f-8950-4536469b6e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4934e021-0006-4310-ab71-ac99e5686e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869824cc-da73-4870-aaa3-eedbdf59037c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4934e021-0006-4310-ab71-ac99e5686e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_71450421-cb42-4d87-b9dc-bf3758bc9ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869824cc-da73-4870-aaa3-eedbdf59037c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_71450421-cb42-4d87-b9dc-bf3758bc9ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_470ae542-08f1-4fcb-9f23-52e91cc5c4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869824cc-da73-4870-aaa3-eedbdf59037c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_470ae542-08f1-4fcb-9f23-52e91cc5c4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c9126235-fd06-4d75-8a8b-760d409b5322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869824cc-da73-4870-aaa3-eedbdf59037c" xlink:to="loc_us-gaap_Goodwill_c9126235-fd06-4d75-8a8b-760d409b5322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6903bd07-1fa1-47d0-a94b-0c8dbc32c51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869824cc-da73-4870-aaa3-eedbdf59037c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6903bd07-1fa1-47d0-a94b-0c8dbc32c51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e0b54deb-bc2d-4fe9-8c19-b9c55f87d2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_869824cc-da73-4870-aaa3-eedbdf59037c" xlink:to="loc_us-gaap_Assets_e0b54deb-bc2d-4fe9-8c19-b9c55f87d2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_99500c72-3291-44ec-833c-9df34358781b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c6157ff1-b1af-40c4-a612-ad52df06b2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c6157ff1-b1af-40c4-a612-ad52df06b2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_47a214ba-cf78-4e3f-b212-12aff70954df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6157ff1-b1af-40c4-a612-ad52df06b2da" xlink:to="loc_us-gaap_AccountsPayableCurrent_47a214ba-cf78-4e3f-b212-12aff70954df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_924c4213-cd2f-4203-add9-cc0820c65977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6157ff1-b1af-40c4-a612-ad52df06b2da" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_924c4213-cd2f-4203-add9-cc0820c65977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_06218575-691b-4d0a-a826-7ee2c235e12b" xlink:href="nktr-20221231.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6157ff1-b1af-40c4-a612-ad52df06b2da" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_06218575-691b-4d0a-a826-7ee2c235e12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b5af96da-c6ed-4610-bb02-3a7a0a2c3b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6157ff1-b1af-40c4-a612-ad52df06b2da" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b5af96da-c6ed-4610-bb02-3a7a0a2c3b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_88a1f97e-5656-4f52-b65b-2dadfb161096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6157ff1-b1af-40c4-a612-ad52df06b2da" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_88a1f97e-5656-4f52-b65b-2dadfb161096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8508bfa1-44ad-42cd-8ecb-e5dace9a59d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6157ff1-b1af-40c4-a612-ad52df06b2da" xlink:to="loc_us-gaap_LiabilitiesCurrent_8508bfa1-44ad-42cd-8ecb-e5dace9a59d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1442620e-5954-4d71-a010-3b53eeb9e9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1442620e-5954-4d71-a010-3b53eeb9e9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e0a989f9-b756-4241-8a57-beb4112ade8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e0a989f9-b756-4241-8a57-beb4112ade8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_5163cd85-e7bd-448c-858c-d62aaa543333" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_5163cd85-e7bd-448c-858c-d62aaa543333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9d77ca6c-0087-4aa6-b3f2-386427151c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9d77ca6c-0087-4aa6-b3f2-386427151c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_10934a1c-6263-43d6-8a07-aed5fb2e7cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:to="loc_us-gaap_Liabilities_10934a1c-6263-43d6-8a07-aed5fb2e7cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7a3ebbf5-21f6-4b77-97f9-f02658805dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7a3ebbf5-21f6-4b77-97f9-f02658805dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7938e927-1e0e-49d8-b6bb-c27e6fb5c40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7938e927-1e0e-49d8-b6bb-c27e6fb5c40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2ede3c2d-ce01-4478-a1d0-a72b5e96e57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7938e927-1e0e-49d8-b6bb-c27e6fb5c40f" xlink:to="loc_us-gaap_PreferredStockValue_2ede3c2d-ce01-4478-a1d0-a72b5e96e57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7fb2ba59-ec38-44bc-b823-f7c1ad9147b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7938e927-1e0e-49d8-b6bb-c27e6fb5c40f" xlink:to="loc_us-gaap_CommonStockValue_7fb2ba59-ec38-44bc-b823-f7c1ad9147b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3943615a-a261-4181-830b-073efb6a3f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7938e927-1e0e-49d8-b6bb-c27e6fb5c40f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3943615a-a261-4181-830b-073efb6a3f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c27f1137-ec51-4b5f-a7e3-1a67e6414a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7938e927-1e0e-49d8-b6bb-c27e6fb5c40f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c27f1137-ec51-4b5f-a7e3-1a67e6414a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_90e6ed52-c9a4-4823-9404-c5df1bc69d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7938e927-1e0e-49d8-b6bb-c27e6fb5c40f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_90e6ed52-c9a4-4823-9404-c5df1bc69d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_968c24b5-2179-4ef9-a071-3c3ea7f40f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7938e927-1e0e-49d8-b6bb-c27e6fb5c40f" xlink:to="loc_us-gaap_StockholdersEquity_968c24b5-2179-4ef9-a071-3c3ea7f40f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d02c07fa-c037-4f1b-90ff-c4ec57388ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61774de1-5add-4c57-8b1c-bb14614fc3c0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d02c07fa-c037-4f1b-90ff-c4ec57388ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e1064e9-9d8a-4b4c-a2de-63d2d08f2292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e1064e9-9d8a-4b4c-a2de-63d2d08f2292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9f422584-bda4-4ebc-8923-73412e8934f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9f422584-bda4-4ebc-8923-73412e8934f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated_be0664f8-273d-47fe-947b-81bfc9a5bd2e" xlink:href="nktr-20221231.xsd#nktr_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:to="loc_nktr_PreferredStockShareDesignated_be0664f8-273d-47fe-947b-81bfc9a5bd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_211ecacf-9e12-408d-90d1-21333761ab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_211ecacf-9e12-408d-90d1-21333761ab4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_db5001d6-4892-4c51-a756-ca39c019f0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_db5001d6-4892-4c51-a756-ca39c019f0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_49a9b8c9-de76-4eff-97e9-8d4add039017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_49a9b8c9-de76-4eff-97e9-8d4add039017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_abf516d4-c4e6-4b5e-99d3-0cb147392fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_abf516d4-c4e6-4b5e-99d3-0cb147392fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_14ffa041-fa81-42c6-85bf-0794ca835b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:to="loc_us-gaap_CommonStockSharesIssued_14ffa041-fa81-42c6-85bf-0794ca835b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_541a238b-9dd6-449e-8a64-793d6fb9266b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c91d220d-9a8c-45e6-8931-e80c4228dec9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_541a238b-9dd6-449e-8a64-793d6fb9266b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c0d1b46a-11b3-4bef-9e42-3a41e292a56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_057a11ce-9815-4e11-b713-4434866d889f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c0d1b46a-11b3-4bef-9e42-3a41e292a56e" xlink:to="loc_us-gaap_StatementTable_057a11ce-9815-4e11-b713-4434866d889f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d54d39ee-b5de-46b6-92af-6fedb10f8ed8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_057a11ce-9815-4e11-b713-4434866d889f" xlink:to="loc_srt_ProductOrServiceAxis_d54d39ee-b5de-46b6-92af-6fedb10f8ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d54d39ee-b5de-46b6-92af-6fedb10f8ed8" xlink:to="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_90f0777b-e86f-4a34-a3b6-5b6262f9f88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:to="loc_us-gaap_ProductMember_90f0777b-e86f-4a34-a3b6-5b6262f9f88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_75aa332a-c9e8-4180-87d8-f39cf11d3ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:to="loc_us-gaap_RoyaltyMember_75aa332a-c9e8-4180-87d8-f39cf11d3ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_2f0a91ec-1ae7-457d-9c76-9df00012cb24" xlink:href="nktr-20221231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_2f0a91ec-1ae7-457d-9c76-9df00012cb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_2299a5c0-210a-4d6b-8053-cde25d490d1d" xlink:href="nktr-20221231.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b583d371-053c-42a3-b89a-a7143ac27555" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_2299a5c0-210a-4d6b-8053-cde25d490d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_057a11ce-9815-4e11-b713-4434866d889f" xlink:to="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d38e2246-655f-4a1b-86dd-f07197ba6773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_RevenuesAbstract_d38e2246-655f-4a1b-86dd-f07197ba6773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29d8972c-abb7-4e8d-a85a-2d4b0bab86c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d38e2246-655f-4a1b-86dd-f07197ba6773" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29d8972c-abb7-4e8d-a85a-2d4b0bab86c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d810dbbd-183b-4aba-9023-190f2b9e7e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d810dbbd-183b-4aba-9023-190f2b9e7e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_186cd0bb-6606-4e0c-b8cd-d9147b703522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_186cd0bb-6606-4e0c-b8cd-d9147b703522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_853d2618-4228-41ff-a2bb-12090332d425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_853d2618-4228-41ff-a2bb-12090332d425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_d0f52b9e-f912-49af-86f5-690c3bd37bde" xlink:href="nktr-20221231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_d0f52b9e-f912-49af-86f5-690c3bd37bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ba04673d-04c5-4f36-8c5c-1d3c2f51af1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_958f642d-9f90-4229-bd28-81227c718dcc" xlink:to="loc_us-gaap_CostsAndExpenses_ba04673d-04c5-4f36-8c5c-1d3c2f51af1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_69e561a8-f305-4945-b159-d686597233f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_OperatingIncomeLoss_69e561a8-f305-4945-b159-d686597233f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_57fa1ead-af20-4e8f-833d-6e42f99fbe6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_57fa1ead-af20-4e8f-833d-6e42f99fbe6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1d554f96-1e6b-41a0-a9ee-89b2fc80387e" xlink:href="nktr-20221231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1d554f96-1e6b-41a0-a9ee-89b2fc80387e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_33f1bbd9-766c-4500-8838-9a251d399b15" xlink:href="nktr-20221231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_33f1bbd9-766c-4500-8838-9a251d399b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1f078254-1a34-46da-a142-79bc7f1b835f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1f078254-1a34-46da-a142-79bc7f1b835f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3ee80b6f-90c3-4198-958a-bc76cc61cf14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_us-gaap_InterestExpense_3ee80b6f-90c3-4198-958a-bc76cc61cf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3f0915bf-4d42-418b-b0e7-8552d04c7d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee2fd767-8225-487a-8c28-eff4c3dd3340" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3f0915bf-4d42-418b-b0e7-8552d04c7d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12b4be3b-2156-43bd-97a0-0d3ecbbb5f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12b4be3b-2156-43bd-97a0-0d3ecbbb5f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_810c61c9-4304-4dde-8f83-2c48f0b99998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_810c61c9-4304-4dde-8f83-2c48f0b99998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_493ed87a-1732-4d1f-bb6c-ba11cdd8c688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_NetIncomeLoss_493ed87a-1732-4d1f-bb6c-ba11cdd8c688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b4f78dfa-4b0b-4868-b17e-75a2abb275d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_EarningsPerShareBasic_b4f78dfa-4b0b-4868-b17e-75a2abb275d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_98b082b0-c833-4535-a479-e6d3421ff2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_98b082b0-c833-4535-a479-e6d3421ff2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_512175d3-a550-400f-bad6-c7154b876912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_512175d3-a550-400f-bad6-c7154b876912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32c616e7-5f17-48b6-9d57-bebed31c636c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37281232-17fc-41f5-affb-93d3848d3a1a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32c616e7-5f17-48b6-9d57-bebed31c636c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47265716-e864-49af-a47c-40814300e0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e88ca3b-9be2-40cc-9e46-ca3ac493e3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47265716-e864-49af-a47c-40814300e0cc" xlink:to="loc_us-gaap_NetIncomeLoss_0e88ca3b-9be2-40cc-9e46-ca3ac493e3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4633e9e8-d0b5-404d-a8cc-ecd62dfbb171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47265716-e864-49af-a47c-40814300e0cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4633e9e8-d0b5-404d-a8cc-ecd62dfbb171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_41a10bfb-d565-4203-839e-55c80a20a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4633e9e8-d0b5-404d-a8cc-ecd62dfbb171" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_41a10bfb-d565-4203-839e-55c80a20a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_59442c94-0324-48fc-bdc9-75c8cf5b0fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4633e9e8-d0b5-404d-a8cc-ecd62dfbb171" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_59442c94-0324-48fc-bdc9-75c8cf5b0fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e18274b-e86b-4165-b0eb-5a02f51324d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4633e9e8-d0b5-404d-a8cc-ecd62dfbb171" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e18274b-e86b-4165-b0eb-5a02f51324d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_45cfbcc6-dc21-4bd9-bf22-93241c72052c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47265716-e864-49af-a47c-40814300e0cc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_45cfbcc6-dc21-4bd9-bf22-93241c72052c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_760afd36-13dd-450c-9baf-415ab5b00270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffb911b0-5640-4ec7-9486-0120bf0d5861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_760afd36-13dd-450c-9baf-415ab5b00270" xlink:to="loc_us-gaap_StatementTable_ffb911b0-5640-4ec7-9486-0120bf0d5861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_123410e0-1cd4-46f3-923f-05bb3438c184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffb911b0-5640-4ec7-9486-0120bf0d5861" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_123410e0-1cd4-46f3-923f-05bb3438c184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_123410e0-1cd4-46f3-923f-05bb3438c184" xlink:to="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_de462e73-5207-42fc-91af-9a52e6bc605e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:to="loc_us-gaap_CommonStockMember_de462e73-5207-42fc-91af-9a52e6bc605e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_48336abc-531f-44c5-a015-04a3f6e2a888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_48336abc-531f-44c5-a015-04a3f6e2a888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e205be80-77a2-4654-a92f-8a1a0aef49f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e205be80-77a2-4654-a92f-8a1a0aef49f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_43cad262-f5dc-46ae-9440-f3edd9f38c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_efce9520-ca01-412c-878f-dc0302557982" xlink:to="loc_us-gaap_RetainedEarningsMember_43cad262-f5dc-46ae-9440-f3edd9f38c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0978b387-13d7-4b0e-864f-db77cd130eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffb911b0-5640-4ec7-9486-0120bf0d5861" xlink:to="loc_us-gaap_StatementLineItems_0978b387-13d7-4b0e-864f-db77cd130eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0978b387-13d7-4b0e-864f-db77cd130eea" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c65c4113-a4bc-4a85-98ed-be2af841b7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c65c4113-a4bc-4a85-98ed-be2af841b7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_68d1c164-4bcd-4871-9e0c-887e3b3aeb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_StockholdersEquity_68d1c164-4bcd-4871-9e0c-887e3b3aeb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_67faed7a-1056-423d-9088-8d2c8f6d22ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_67faed7a-1056-423d-9088-8d2c8f6d22ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c2932614-8458-48af-9df2-cbf0b23e4f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c2932614-8458-48af-9df2-cbf0b23e4f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7589d248-d6af-4184-95fc-55c7af25ee61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7589d248-d6af-4184-95fc-55c7af25ee61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ada000c-e20c-4363-bc66-d2279429f6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ada000c-e20c-4363-bc66-d2279429f6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3d53af14-8488-4ca3-8ff3-7ad57480e311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3d53af14-8488-4ca3-8ff3-7ad57480e311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_152a11f1-3fa5-4154-90f3-6e94ed922f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_21bfd921-1df0-4fec-8aae-270543fa47a9" xlink:to="loc_us-gaap_StockholdersEquity_152a11f1-3fa5-4154-90f3-6e94ed922f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e645f6fe-7d3b-4644-923d-df14a00e1ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0978b387-13d7-4b0e-864f-db77cd130eea" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e645f6fe-7d3b-4644-923d-df14a00e1ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_57f98c78-40e9-4d73-b8c6-98b20fed3d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f8c92db-3104-43cb-a165-ee14417162da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_57f98c78-40e9-4d73-b8c6-98b20fed3d93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f8c92db-3104-43cb-a165-ee14417162da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_49056a21-c255-4f7c-89ce-309210e9722a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f8c92db-3104-43cb-a165-ee14417162da" xlink:to="loc_us-gaap_ProfitLoss_49056a21-c255-4f7c-89ce-309210e9722a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f8c92db-3104-43cb-a165-ee14417162da" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_91ad0c3c-45a5-4623-9b42-df9694e1c371" xlink:href="nktr-20221231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_91ad0c3c-45a5-4623-9b42-df9694e1c371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_7a25303b-ccea-4e2c-a943-cc503d906487" xlink:href="nktr-20221231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_7a25303b-ccea-4e2c-a943-cc503d906487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_bbc2a3bd-47fe-412c-ae58-36a627a8735e" xlink:href="nktr-20221231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_bbc2a3bd-47fe-412c-ae58-36a627a8735e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_eca72474-645f-417d-9359-3aebd3825386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_eca72474-645f-417d-9359-3aebd3825386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a1ae04cc-2fed-4d61-9dc2-50ad95133196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a1ae04cc-2fed-4d61-9dc2-50ad95133196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9abc35e9-e129-4024-828e-0660cec62ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9abc35e9-e129-4024-828e-0660cec62ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e5c62d66-eca7-4611-8b65-75a13224a8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_us-gaap_DepreciationAndAmortization_e5c62d66-eca7-4611-8b65-75a13224a8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e3958c42-4e05-4cd3-9c77-3abbaacbbd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e3958c42-4e05-4cd3-9c77-3abbaacbbd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4ee8c4da-e00d-4809-858e-f515ff35064e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_us-gaap_AssetImpairmentCharges_4ee8c4da-e00d-4809-858e-f515ff35064e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c9d98449-78f2-4414-b12d-9c1c903752a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c9d98449-78f2-4414-b12d-9c1c903752a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_e17ff804-f932-498e-88d9-18e4f8d788b2" xlink:href="nktr-20221231.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_e17ff804-f932-498e-88d9-18e4f8d788b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_8e0bdb91-eef4-49e6-85a2-c7a7ae44d905" xlink:href="nktr-20221231.xsd#nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_8e0bdb91-eef4-49e6-85a2-c7a7ae44d905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_438b6e75-7acc-4458-b10c-7732a7cd7a01" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_08ea85d0-7c01-483f-b313-e43ec70b9793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_08ea85d0-7c01-483f-b313-e43ec70b9793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_934e5eef-81eb-4fe8-aa77-df36f8be5da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_934e5eef-81eb-4fe8-aa77-df36f8be5da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_f83c74ce-6fd8-4547-9232-4018ceb6cb97" xlink:href="nktr-20221231.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_f83c74ce-6fd8-4547-9232-4018ceb6cb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c3ef285c-5fdb-4cf9-b8da-0b0ee7939307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c3ef285c-5fdb-4cf9-b8da-0b0ee7939307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_108b0dcb-f661-4880-80b4-806abe0b0968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_108b0dcb-f661-4880-80b4-806abe0b0968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0b2d7357-8cbd-4718-8cc8-97b227bf583b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0b2d7357-8cbd-4718-8cc8-97b227bf583b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_a60c4485-0070-4935-ac38-929d75455c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_a60c4485-0070-4935-ac38-929d75455c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_690462fd-27be-4a82-8e6f-a16123af0d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bbe5bc0-62f7-4473-b7b3-e192c94d6eb9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_690462fd-27be-4a82-8e6f-a16123af0d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c97cd17-dfb1-4d6a-82ba-bf2be22c22b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f8c92db-3104-43cb-a165-ee14417162da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c97cd17-dfb1-4d6a-82ba-bf2be22c22b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7faebbda-e350-4822-87b9-1be5afc87ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_57f98c78-40e9-4d73-b8c6-98b20fed3d93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7faebbda-e350-4822-87b9-1be5afc87ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c3aebb64-ce7c-46c2-b32f-2ea2e895b338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7faebbda-e350-4822-87b9-1be5afc87ac2" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c3aebb64-ce7c-46c2-b32f-2ea2e895b338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0c6b7164-ae22-4cc8-9336-4eaccbde02e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7faebbda-e350-4822-87b9-1be5afc87ac2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0c6b7164-ae22-4cc8-9336-4eaccbde02e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2429244d-b743-450c-b3e1-b4c2b2ff09f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7faebbda-e350-4822-87b9-1be5afc87ac2" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2429244d-b743-450c-b3e1-b4c2b2ff09f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_43c99384-ce71-427c-ae91-d53029dfe1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7faebbda-e350-4822-87b9-1be5afc87ac2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_43c99384-ce71-427c-ae91-d53029dfe1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da0ac286-25e9-4c9d-bda9-1e60d69151e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7faebbda-e350-4822-87b9-1be5afc87ac2" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da0ac286-25e9-4c9d-bda9-1e60d69151e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98a93df7-3f1c-449e-ad13-16bc49a237bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7faebbda-e350-4822-87b9-1be5afc87ac2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98a93df7-3f1c-449e-ad13-16bc49a237bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71a34efa-ac20-4c95-b5ad-828b73ef1103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_57f98c78-40e9-4d73-b8c6-98b20fed3d93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71a34efa-ac20-4c95-b5ad-828b73ef1103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_c387d02b-81bc-49a0-8de8-b4771e0df26e" xlink:href="nktr-20221231.xsd#nktr_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71a34efa-ac20-4c95-b5ad-828b73ef1103" xlink:to="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_c387d02b-81bc-49a0-8de8-b4771e0df26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_57e6f9ce-43a2-483a-a79c-53dccb0486a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71a34efa-ac20-4c95-b5ad-828b73ef1103" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_57e6f9ce-43a2-483a-a79c-53dccb0486a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_f826b4cd-910f-4344-9934-6bc0afb063d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71a34efa-ac20-4c95-b5ad-828b73ef1103" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_f826b4cd-910f-4344-9934-6bc0afb063d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_9c15c159-1f98-442c-8a63-1f7fd3244804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71a34efa-ac20-4c95-b5ad-828b73ef1103" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_9c15c159-1f98-442c-8a63-1f7fd3244804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_93573cd3-d95f-46dc-b3eb-512d98af56b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71a34efa-ac20-4c95-b5ad-828b73ef1103" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_93573cd3-d95f-46dc-b3eb-512d98af56b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5b741cc1-0005-4f4e-a7a0-46b89b4d2fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_57f98c78-40e9-4d73-b8c6-98b20fed3d93" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5b741cc1-0005-4f4e-a7a0-46b89b4d2fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69489408-e4e6-4bb4-bec3-a358276058ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_57f98c78-40e9-4d73-b8c6-98b20fed3d93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69489408-e4e6-4bb4-bec3-a358276058ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13646005-dfd6-4898-b1f3-9d00f328a503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_57f98c78-40e9-4d73-b8c6-98b20fed3d93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13646005-dfd6-4898-b1f3-9d00f328a503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283b07ee-ece2-478b-bf96-94b2168fddf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_57f98c78-40e9-4d73-b8c6-98b20fed3d93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283b07ee-ece2-478b-bf96-94b2168fddf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1524814d-5fc7-49fa-8674-e033c75b0727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_57f98c78-40e9-4d73-b8c6-98b20fed3d93" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1524814d-5fc7-49fa-8674-e033c75b0727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_98f6ff9d-ddf2-49cf-9aab-d8c6b274c25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1524814d-5fc7-49fa-8674-e033c75b0727" xlink:to="loc_us-gaap_InterestPaidNet_98f6ff9d-ddf2-49cf-9aab-d8c6b274c25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_302f8973-3c83-4106-92b8-740b3553ffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1524814d-5fc7-49fa-8674-e033c75b0727" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_302f8973-3c83-4106-92b8-740b3553ffc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1a59bd11-9b94-4a1f-8306-331ee834def8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1524814d-5fc7-49fa-8674-e033c75b0727" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1a59bd11-9b94-4a1f-8306-331ee834def8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_a00f73f3-8672-4e32-9fc9-fd0f66089c5f" xlink:href="nktr-20221231.xsd#nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1524814d-5fc7-49fa-8674-e033c75b0727" xlink:to="loc_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_a00f73f3-8672-4e32-9fc9-fd0f66089c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="nktr-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a189a4cb-c8df-4dab-852a-f23c62467225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts_810db36c-d5dc-4165-b479-ba82370c1855" xlink:href="nktr-20221231.xsd#nktr_SaleOfFutureRoyaltiesTransactionCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a189a4cb-c8df-4dab-852a-f23c62467225" xlink:to="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts_810db36c-d5dc-4165-b479-ba82370c1855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20221231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2c3d94f-da4c-4937-b327-f51f25fc2619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_29d52e6b-1468-423d-bf63-7170928bd02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2c3d94f-da4c-4937-b327-f51f25fc2619" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_29d52e6b-1468-423d-bf63-7170928bd02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20221231.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d0d12a36-3911-46c7-8194-08bcbd230f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_dd63faca-d923-46b5-85f2-776a8ce8f46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d0d12a36-3911-46c7-8194-08bcbd230f1b" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_dd63faca-d923-46b5-85f2-776a8ce8f46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20221231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_69bac200-650e-42ed-b5ae-f41641f13f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ec54ecc7-b14d-4114-af4f-e5c6228b57d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_69bac200-650e-42ed-b5ae-f41641f13f09" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ec54ecc7-b14d-4114-af4f-e5c6228b57d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="nktr-20221231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_74d8815f-6995-47a7-85cc-0b387d8360f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a39de671-554f-4384-ad55-1e6cdb851d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_74d8815f-6995-47a7-85cc-0b387d8360f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a39de671-554f-4384-ad55-1e6cdb851d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeases" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4cddf746-4bfb-47ea-a0e8-fba4ec0695a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1183410d-9643-4e9c-864a-d5d858c4da46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cddf746-4bfb-47ea-a0e8-fba4ec0695a3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1183410d-9643-4e9c-864a-d5d858c4da46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="simple" xlink:href="nktr-20221231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ab96c082-4710-49fa-aa5e-351281b5e446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_d63ec1be-2f80-4575-ab39-beb9d388d8e9" xlink:href="nktr-20221231.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ab96c082-4710-49fa-aa5e-351281b5e446" xlink:to="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_d63ec1be-2f80-4575-ab39-beb9d388d8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20221231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_bd837819-e3d9-44df-91f0-5730f68b6f63" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_a68315e9-96fa-4e43-a023-11dd70c47a3a" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_bd837819-e3d9-44df-91f0-5730f68b6f63" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_a68315e9-96fa-4e43-a023-11dd70c47a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fea80549-ec4f-4998-a085-86692d968936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a147b21b-c8a5-470f-9af4-1b97f60428ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fea80549-ec4f-4998-a085-86692d968936" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a147b21b-c8a5-470f-9af4-1b97f60428ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquity" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cab911d6-ea92-46a6-a3ad-a0642e3ea8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_544f9814-da1c-4231-8582-633793ca2af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cab911d6-ea92-46a6-a3ad-a0642e3ea8dd" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_544f9814-da1c-4231-8582-633793ca2af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20221231.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee0c1283-7f5e-46f7-a4cc-2c344e351812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1f2715ff-fd7e-4633-b3f8-4944da5c1504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee0c1283-7f5e-46f7-a4cc-2c344e351812" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1f2715ff-fd7e-4633-b3f8-4944da5c1504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgram"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6a2baa5a-f8ae-4a28-9239-d4ff9733a4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_e89d83b1-1823-49dc-80b8-3d75af767503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6a2baa5a-f8ae-4a28-9239-d4ff9733a4b3" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_e89d83b1-1823-49dc-80b8-3d75af767503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b832b3e0-4307-4818-96a6-644d698ed8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8f3737e7-09df-49f3-a1b8-6157c79a6423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b832b3e0-4307-4818-96a6-644d698ed8f3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8f3737e7-09df-49f3-a1b8-6157c79a6423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_372947bc-0e2a-44b6-8fcf-2c78d4d6f87e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4d7ddcf3-bdee-4c93-8e37-582eec6c1687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_372947bc-0e2a-44b6-8fcf-2c78d4d6f87e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4d7ddcf3-bdee-4c93-8e37-582eec6c1687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReporting" xlink:type="simple" xlink:href="nktr-20221231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d4cbb322-48d9-4f47-a9d3-9273ac93ceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_edb45314-5ec4-4648-9f9d-f2f43d7b4068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d4cbb322-48d9-4f47-a9d3-9273ac93ceb3" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_edb45314-5ec4-4648-9f9d-f2f43d7b4068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock_412e0134-7f03-4ab5-9276-ac718cd5b742" xlink:href="nktr-20221231.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_nktr_OrganizationPolicyTextBlock_412e0134-7f03-4ab5-9276-ac718cd5b742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_bb2abc29-a83f-42a0-9f38-221d87d4cb03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_bb2abc29-a83f-42a0-9f38-221d87d4cb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_56ae02c3-a163-481b-99ff-f904ae716513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_56ae02c3-a163-481b-99ff-f904ae716513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e7c2a733-3870-4e86-93ad-b4436a667cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e7c2a733-3870-4e86-93ad-b4436a667cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_d5ac9835-9eb9-4bac-8c78-d0c4a84f3b09" xlink:href="nktr-20221231.xsd#nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_d5ac9835-9eb9-4bac-8c78-d0c4a84f3b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_f56278e3-2128-4a02-8ab0-ed59f64644bd" xlink:href="nktr-20221231.xsd#nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_f56278e3-2128-4a02-8ab0-ed59f64644bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_caa23bf1-31fb-4efb-ad7d-b57c25eea2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_caa23bf1-31fb-4efb-ad7d-b57c25eea2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5239657e-9cf4-492a-8129-081db6ca9c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5239657e-9cf4-492a-8129-081db6ca9c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_cb5e1b7c-dd21-47d2-83d1-491aa504d854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_cb5e1b7c-dd21-47d2-83d1-491aa504d854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_b2783363-fc2f-4a9f-9448-713047ef2113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_b2783363-fc2f-4a9f-9448-713047ef2113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_de0b1720-86c7-408f-a581-686b608b8f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_de0b1720-86c7-408f-a581-686b608b8f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1a539e12-b7e2-4e60-b2e6-543fd514b951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1a539e12-b7e2-4e60-b2e6-543fd514b951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock_43e75e05-1d80-4a0a-bed9-940649fe1e6f" xlink:href="nktr-20221231.xsd#nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock_43e75e05-1d80-4a0a-bed9-940649fe1e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_880ef58a-51ea-4d54-8605-efa8fd409b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_880ef58a-51ea-4d54-8605-efa8fd409b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f420f998-392f-4623-bc47-6a677a221550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f420f998-392f-4623-bc47-6a677a221550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b9e1ab96-6ec5-4765-9def-d37911170797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b9e1ab96-6ec5-4765-9def-d37911170797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_05fdece6-3bf4-4baa-a41f-04ac78207ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_05fdece6-3bf4-4baa-a41f-04ac78207ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a6ea6668-9af0-4390-ad7a-e7bab817ff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f094d7d9-7cd8-479d-84d6-fbb1676f12ac" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a6ea6668-9af0-4390-ad7a-e7bab817ff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_56ba495a-92d6-471f-a613-edfc9b15e82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b6531191-50ab-49c7-bf4e-4e654163f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_56ba495a-92d6-471f-a613-edfc9b15e82c" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b6531191-50ab-49c7-bf4e-4e654163f5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_05f59d65-9700-4432-9ec9-8613f9f8863d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_56ba495a-92d6-471f-a613-edfc9b15e82c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_05f59d65-9700-4432-9ec9-8613f9f8863d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_dad45ea0-1043-4aa7-9f43-d0e93bfcacd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9e46ea5a-118b-4b64-aabe-a21ad873cc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dad45ea0-1043-4aa7-9f43-d0e93bfcacd2" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9e46ea5a-118b-4b64-aabe-a21ad873cc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c0eefb15-fc1b-4486-af1f-13ba59643260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_23e3b3a6-62a0-4a24-9d38-6b405dfd800a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c0eefb15-fc1b-4486-af1f-13ba59643260" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_23e3b3a6-62a0-4a24-9d38-6b405dfd800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c6e72de1-e45a-4df9-88f6-7fcc6c27980a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseTableTextBlock_17b00d54-93bc-4601-91aa-797e7c193bfe" xlink:href="nktr-20221231.xsd#nktr_LesseeOperatingLeaseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6e72de1-e45a-4df9-88f6-7fcc6c27980a" xlink:to="loc_nktr_LesseeOperatingLeaseTableTextBlock_17b00d54-93bc-4601-91aa-797e7c193bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_865da1bb-e4fd-4723-8a86-db1d6d00535c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6e72de1-e45a-4df9-88f6-7fcc6c27980a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_865da1bb-e4fd-4723-8a86-db1d6d00535c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_00ac6516-4430-4bce-8a1b-a1f004c7ad55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6e72de1-e45a-4df9-88f6-7fcc6c27980a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_00ac6516-4430-4bce-8a1b-a1f004c7ad55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cff10fde-6f38-4264-9ee5-6d0613020586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_e95b7669-a972-4b16-b0a1-5298add3972f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cff10fde-6f38-4264-9ee5-6d0613020586" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_e95b7669-a972-4b16-b0a1-5298add3972f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_213687c9-4a3b-4263-84b5-6e47452a3ef3" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_9d78468c-9781-407e-b8fc-c153f6a0d8f5" xlink:href="nktr-20221231.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_213687c9-4a3b-4263-84b5-6e47452a3ef3" xlink:to="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_9d78468c-9781-407e-b8fc-c153f6a0d8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_45317c87-d3a8-4298-aac8-288d76b9968e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_8f65432e-b580-4e04-a6c0-5d05280d81a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_45317c87-d3a8-4298-aac8-288d76b9968e" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_8f65432e-b580-4e04-a6c0-5d05280d81a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49f449ab-4831-46ed-8668-b27fc8ff6c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_768e97b4-da4e-49e9-80dc-2c5df14054a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49f449ab-4831-46ed-8668-b27fc8ff6c79" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_768e97b4-da4e-49e9-80dc-2c5df14054a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_53f6f18a-7c5e-4933-9893-23acde44ab27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3989982c-3aba-49f0-b652-14745f1daa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_53f6f18a-7c5e-4933-9893-23acde44ab27" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3989982c-3aba-49f0-b652-14745f1daa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b2ed0393-f68c-40b0-888d-ba84026a47c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_53f6f18a-7c5e-4933-9893-23acde44ab27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b2ed0393-f68c-40b0-888d-ba84026a47c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f2269cc-aa32-4b17-b9b0-8573d17811e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fe434399-a543-424e-bae7-968f53c67f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f2269cc-aa32-4b17-b9b0-8573d17811e1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fe434399-a543-424e-bae7-968f53c67f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_630a03d0-c42b-4392-8e38-8f55e67d5489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f2269cc-aa32-4b17-b9b0-8573d17811e1" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_630a03d0-c42b-4392-8e38-8f55e67d5489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0461e2e8-f31a-477d-afb2-a1248a597ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f2269cc-aa32-4b17-b9b0-8573d17811e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0461e2e8-f31a-477d-afb2-a1248a597ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_69a275e0-4f3d-4603-827f-81423c0f6991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f2269cc-aa32-4b17-b9b0-8573d17811e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_69a275e0-4f3d-4603-827f-81423c0f6991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4c4e7ea3-701b-4470-8d99-4db0365f2ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8ee09627-a6f3-4bea-8504-2cea85a1648a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c4e7ea3-701b-4470-8d99-4db0365f2ac8" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8ee09627-a6f3-4bea-8504-2cea85a1648a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_575aee0b-a547-4bd5-beca-81064e50e4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c4e7ea3-701b-4470-8d99-4db0365f2ac8" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_575aee0b-a547-4bd5-beca-81064e50e4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e008b3be-da5e-47f4-a163-520f30ce638a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c4e7ea3-701b-4470-8d99-4db0365f2ac8" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e008b3be-da5e-47f4-a163-520f30ce638a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_05268d74-67ab-4dba-bb1b-af9b244924e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c4e7ea3-701b-4470-8d99-4db0365f2ac8" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_05268d74-67ab-4dba-bb1b-af9b244924e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_7da474bb-8684-4654-b8a7-5df5839a7a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c4e7ea3-701b-4470-8d99-4db0365f2ac8" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_7da474bb-8684-4654-b8a7-5df5839a7a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="nktr-20221231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_758b949c-369e-42a3-8135-70ad72bb44af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_f1f050df-2ac9-4d2c-a4bc-bec88089d559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_758b949c-369e-42a3-8135-70ad72bb44af" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_f1f050df-2ac9-4d2c-a4bc-bec88089d559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c50554e3-3c9f-4ba8-832c-1e704978fb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:href="nktr-20221231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c50554e3-3c9f-4ba8-832c-1e704978fb1d" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c60ad38e-d70f-4c75-9a76-aced2e2f949e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_srt_RangeAxis_c60ad38e-d70f-4c75-9a76-aced2e2f949e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f4d886d-a1b4-4bb5-be16-a9063818a45b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c60ad38e-d70f-4c75-9a76-aced2e2f949e" xlink:to="loc_srt_RangeMember_9f4d886d-a1b4-4bb5-be16-a9063818a45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_30cc0cc6-253e-4b66-baa4-23af56570b25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f4d886d-a1b4-4bb5-be16-a9063818a45b" xlink:to="loc_srt_MinimumMember_30cc0cc6-253e-4b66-baa4-23af56570b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1dd703a-911f-4960-a290-503ac7bcab44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f4d886d-a1b4-4bb5-be16-a9063818a45b" xlink:to="loc_srt_MaximumMember_b1dd703a-911f-4960-a290-503ac7bcab44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_722c30a8-392b-4bb2-832a-c5629166eebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_722c30a8-392b-4bb2-832a-c5629166eebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1d08600-3760-4707-a60a-8bccb007ca10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_722c30a8-392b-4bb2-832a-c5629166eebc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1d08600-3760-4707-a60a-8bccb007ca10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_9ed74e5d-7dbb-4a37-862b-dd0577bda0b3" xlink:href="nktr-20221231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1d08600-3760-4707-a60a-8bccb007ca10" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_9ed74e5d-7dbb-4a37-862b-dd0577bda0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_5ef60188-64d1-4645-aa40-22a7a1efa709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1d08600-3760-4707-a60a-8bccb007ca10" xlink:to="loc_us-gaap_BuildingMember_5ef60188-64d1-4645-aa40-22a7a1efa709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f749659f-5715-4381-a8dd-bfc5a39c5c90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_srt_ProductOrServiceAxis_f749659f-5715-4381-a8dd-bfc5a39c5c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e746001-404b-4d50-82b2-e4ebd343b5e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f749659f-5715-4381-a8dd-bfc5a39c5c90" xlink:to="loc_srt_ProductsAndServicesDomain_1e746001-404b-4d50-82b2-e4ebd343b5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndNonCashRoyaltiesMember_1b41c1cf-4592-4b0a-9b6a-2b3bf490a719" xlink:href="nktr-20221231.xsd#nktr_CashAndNonCashRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1e746001-404b-4d50-82b2-e4ebd343b5e5" xlink:to="loc_nktr_CashAndNonCashRoyaltiesMember_1b41c1cf-4592-4b0a-9b6a-2b3bf490a719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_0f082eb8-5972-458e-be45-15c027750d81" xlink:href="nktr-20221231.xsd#nktr_NKTR181Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1e746001-404b-4d50-82b2-e4ebd343b5e5" xlink:to="loc_nktr_NKTR181Member_0f082eb8-5972-458e-be45-15c027750d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_61b3df13-b93d-4aae-9fa1-0ce3756a5661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_TypeOfArrangementAxis_61b3df13-b93d-4aae-9fa1-0ce3756a5661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe0b2bd-aa5e-42a4-adf4-9a15cb491897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_61b3df13-b93d-4aae-9fa1-0ce3756a5661" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe0b2bd-aa5e-42a4-adf4-9a15cb491897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_a363a420-ea3d-41e9-b6a3-2a9261e16952" xlink:href="nktr-20221231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe0b2bd-aa5e-42a4-adf4-9a15cb491897" xlink:to="loc_nktr_BMSCollaborationAgreementMember_a363a420-ea3d-41e9-b6a3-2a9261e16952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_52e8b453-597f-486f-a502-974bc91ea0b1" xlink:href="nktr-20221231.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe0b2bd-aa5e-42a4-adf4-9a15cb491897" xlink:to="loc_nktr_Nektar358Member_52e8b453-597f-486f-a502-974bc91ea0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_71e99251-5f28-4104-a75b-7e67e3e27beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_71e99251-5f28-4104-a75b-7e67e3e27beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1e6197e-a269-4f0f-8b62-2614fb823a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_71e99251-5f28-4104-a75b-7e67e3e27beb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1e6197e-a269-4f0f-8b62-2614fb823a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsRSUsAndPSUsMember_64ee5d51-456a-4ac9-9e80-5fec697808fb" xlink:href="nktr-20221231.xsd#nktr_StockOptionsRSUsAndPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1e6197e-a269-4f0f-8b62-2614fb823a3a" xlink:to="loc_nktr_StockOptionsRSUsAndPSUsMember_64ee5d51-456a-4ac9-9e80-5fec697808fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_bcb6e5ee-14c5-4a97-b6df-feb653b767b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_bcb6e5ee-14c5-4a97-b6df-feb653b767b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_dd13113d-3dbe-4a1e-8beb-9279ac837f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_bcb6e5ee-14c5-4a97-b6df-feb653b767b3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_dd13113d-3dbe-4a1e-8beb-9279ac837f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_22f91c66-e771-4972-98ad-6feb1c99f7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_dd13113d-3dbe-4a1e-8beb-9279ac837f6b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_22f91c66-e771-4972-98ad-6feb1c99f7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProgramTerminationMember_a4aa56ac-6908-4a0e-865d-903c29330f04" xlink:href="nktr-20221231.xsd#nktr_ProgramTerminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_dd13113d-3dbe-4a1e-8beb-9279ac837f6b" xlink:to="loc_nktr_ProgramTerminationMember_a4aa56ac-6908-4a0e-865d-903c29330f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember_ac225a09-63dd-459c-a959-e4eb93f33bfd" xlink:href="nktr-20221231.xsd#nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ProgramTerminationMember_a4aa56ac-6908-4a0e-865d-903c29330f04" xlink:to="loc_nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember_ac225a09-63dd-459c-a959-e4eb93f33bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProgramTerminationNoncancellableCommitmentsMember_b15c8b71-dced-464e-9374-2b582b8c6429" xlink:href="nktr-20221231.xsd#nktr_ProgramTerminationNoncancellableCommitmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ProgramTerminationMember_a4aa56ac-6908-4a0e-865d-903c29330f04" xlink:to="loc_nktr_ProgramTerminationNoncancellableCommitmentsMember_b15c8b71-dced-464e-9374-2b582b8c6429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d69ca878-4146-4c97-bcde-31ddbf0d2c54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d69ca878-4146-4c97-bcde-31ddbf0d2c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ab85db1f-100d-420d-9fdd-c2112c7b9a7a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d69ca878-4146-4c97-bcde-31ddbf0d2c54" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ab85db1f-100d-420d-9fdd-c2112c7b9a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_322e49b5-748e-48ce-8b46-4a96f665c0e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ab85db1f-100d-420d-9fdd-c2112c7b9a7a" xlink:to="loc_srt_ParentCompanyMember_322e49b5-748e-48ce-8b46-4a96f665c0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7c0a5071-d877-4d13-b316-3202a4273827" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_dei_LegalEntityAxis_7c0a5071-d877-4d13-b316-3202a4273827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f17d4751-eb1e-4e5b-9bd9-c9655b39f355" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7c0a5071-d877-4d13-b316-3202a4273827" xlink:to="loc_dei_EntityDomain_f17d4751-eb1e-4e5b-9bd9-c9655b39f355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_67d75544-f089-4df4-97c2-a55176f5589e" xlink:href="nktr-20221231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f17d4751-eb1e-4e5b-9bd9-c9655b39f355" xlink:to="loc_nktr_EliLillyAndCompanyMember_67d75544-f089-4df4-97c2-a55176f5589e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cc30a27-7061-42f4-aed9-754e7d65daa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cc30a27-7061-42f4-aed9-754e7d65daa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c017f4a-71d6-4dc1-8483-83302a040bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cc30a27-7061-42f4-aed9-754e7d65daa6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c017f4a-71d6-4dc1-8483-83302a040bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_24acf6ad-5c43-4198-bfe5-2a52e02bef8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c017f4a-71d6-4dc1-8483-83302a040bdf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_24acf6ad-5c43-4198-bfe5-2a52e02bef8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_285a237c-6fcb-437b-88e6-f42630de1aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_285a237c-6fcb-437b-88e6-f42630de1aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3f1b297c-f230-408c-a66f-8c24dfdefc40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_285a237c-6fcb-437b-88e6-f42630de1aa9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3f1b297c-f230-408c-a66f-8c24dfdefc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_18c49bca-cb5b-4520-bd60-22744b1eb108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3f1b297c-f230-408c-a66f-8c24dfdefc40" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_18c49bca-cb5b-4520-bd60-22744b1eb108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:href="nktr-20221231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_447ab4cb-797f-4063-8820-6ed527cc4786" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f6a9d524-0a08-4f14-b7e4-a34eafdd4b96" xlink:href="nktr-20221231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f6a9d524-0a08-4f14-b7e4-a34eafdd4b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_57bdc59a-332a-49b9-8c53-2ddb86038c79" xlink:href="nktr-20221231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_57bdc59a-332a-49b9-8c53-2ddb86038c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17e6cbeb-bf64-4129-bfe2-89558e0d54db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17e6cbeb-bf64-4129-bfe2-89558e0d54db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_f9f8492f-5a02-48ca-965f-074d9a54a23f" xlink:href="nktr-20221231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_f9f8492f-5a02-48ca-965f-074d9a54a23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e35423ca-8eb0-4c1e-bfce-b888aab45295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e35423ca-8eb0-4c1e-bfce-b888aab45295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_c394650b-077e-41a3-a1ae-274d828b39c4" xlink:href="nktr-20221231.xsd#nktr_SalesMilestoneRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_SalesMilestoneRevenue_c394650b-077e-41a3-a1ae-274d828b39c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f2ef7deb-175d-41fd-a40f-078ec8038e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f2ef7deb-175d-41fd-a40f-078ec8038e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_fb973bdb-78e1-4376-a06c-e1623e90c40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_fb973bdb-78e1-4376-a06c-e1623e90c40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_bf29fe00-1e6c-4203-9971-d124696fa1ab" xlink:href="nktr-20221231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_bf29fe00-1e6c-4203-9971-d124696fa1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_de34bcb1-fcd5-484d-b1c0-5411e62ba149" xlink:href="nktr-20221231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_de34bcb1-fcd5-484d-b1c0-5411e62ba149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_31cfb057-509e-4ab9-ba9b-e5e1f9ca6387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_31cfb057-509e-4ab9-ba9b-e5e1f9ca6387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_442b5f05-5b0c-44ee-b839-4aefa2f68bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_423e05bc-00c5-454f-8f03-0140e6f509e4" xlink:to="loc_us-gaap_RestructuringCharges_442b5f05-5b0c-44ee-b839-4aefa2f68bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6b0af8af-c3d5-43b7-84d9-fc799881d95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_501a761f-19ce-4852-83a0-7f214a9ea128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6b0af8af-c3d5-43b7-84d9-fc799881d95b" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_501a761f-19ce-4852-83a0-7f214a9ea128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a23585d-c367-4f8b-bb28-2d10c74fd2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_501a761f-19ce-4852-83a0-7f214a9ea128" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a23585d-c367-4f8b-bb28-2d10c74fd2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ee615742-5781-4504-831c-912489827936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_501a761f-19ce-4852-83a0-7f214a9ea128" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ee615742-5781-4504-831c-912489827936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9c3cb6fb-a1ea-4520-b7ac-8fa58ac85660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_501a761f-19ce-4852-83a0-7f214a9ea128" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9c3cb6fb-a1ea-4520-b7ac-8fa58ac85660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_056cef02-47a3-42f4-b916-cdd8cbe56287" xlink:href="nktr-20221231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_501a761f-19ce-4852-83a0-7f214a9ea128" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_056cef02-47a3-42f4-b916-cdd8cbe56287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_5a568eac-e369-407c-9352-cf1110016428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_309d374a-a884-4bd6-8069-c7527648a6e5" xlink:href="nktr-20221231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5a568eac-e369-407c-9352-cf1110016428" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_309d374a-a884-4bd6-8069-c7527648a6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9df30d5d-21ed-43a0-b999-61b3b08634f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_309d374a-a884-4bd6-8069-c7527648a6e5" xlink:to="loc_srt_RangeAxis_9df30d5d-21ed-43a0-b999-61b3b08634f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7f44a1e-a512-40b1-911d-875f44a70649" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9df30d5d-21ed-43a0-b999-61b3b08634f0" xlink:to="loc_srt_RangeMember_d7f44a1e-a512-40b1-911d-875f44a70649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4661951b-bc3d-48b6-874d-f70bf27f7c03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d7f44a1e-a512-40b1-911d-875f44a70649" xlink:to="loc_srt_MinimumMember_4661951b-bc3d-48b6-874d-f70bf27f7c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_36ed9bca-7c30-493b-84b9-ef295f018bd5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d7f44a1e-a512-40b1-911d-875f44a70649" xlink:to="loc_srt_MaximumMember_36ed9bca-7c30-493b-84b9-ef295f018bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:href="nktr-20221231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_309d374a-a884-4bd6-8069-c7527648a6e5" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InvestmnetsTargetMaturityPeriod_eb8066bf-30f4-4649-9550-0baed76eeea5" xlink:href="nktr-20221231.xsd#nktr_InvestmnetsTargetMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_nktr_InvestmnetsTargetMaturityPeriod_eb8066bf-30f4-4649-9550-0baed76eeea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InvestmentsWeightedAverageMaturityPeriod_11fd82f5-5e93-48ef-a448-c5e8944b3737" xlink:href="nktr-20221231.xsd#nktr_InvestmentsWeightedAverageMaturityPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_nktr_InvestmentsWeightedAverageMaturityPeriod_11fd82f5-5e93-48ef-a448-c5e8944b3737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_76037234-0c86-4620-a3de-dc6a98cb8047" xlink:href="nktr-20221231.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_76037234-0c86-4620-a3de-dc6a98cb8047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c7593ae0-1a25-41c9-b6fb-bd11d97de2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c7593ae0-1a25-41c9-b6fb-bd11d97de2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_deac17e7-9fce-4b1b-b7c9-5de90cca101d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_InterestReceivableCurrent_deac17e7-9fce-4b1b-b7c9-5de90cca101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b6297493-3e7d-47cc-8bf1-00aea1566aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b6297493-3e7d-47cc-8bf1-00aea1566aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_053e2926-4563-4f2c-8ac8-6505b5f9308a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_053e2926-4563-4f2c-8ac8-6505b5f9308a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_72058ae6-de77-4dbe-b4ef-2803b63e9a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_78e04dbf-5055-46c4-9cbc-d7db6ef5347b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_72058ae6-de77-4dbe-b4ef-2803b63e9a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_492c7958-cc60-42de-8395-e7d3ac2d8d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1923763f-fd40-477f-92a2-015454d8ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_492c7958-cc60-42de-8395-e7d3ac2d8d84" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1923763f-fd40-477f-92a2-015454d8ee3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5e55f1c5-e6ea-4006-94ef-b3de7deb4896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1923763f-fd40-477f-92a2-015454d8ee3f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5e55f1c5-e6ea-4006-94ef-b3de7deb4896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5e55f1c5-e6ea-4006-94ef-b3de7deb4896" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6514d337-e154-4641-aa09-e98b705040f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6514d337-e154-4641-aa09-e98b705040f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2d620c50-0372-45f1-aaa7-ac018b6dba23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_CommercialPaperMember_2d620c50-0372-45f1-aaa7-ac018b6dba23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_dfd59140-610f-4598-8a6c-bea6ad2de09f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_dfd59140-610f-4598-8a6c-bea6ad2de09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ba891623-7a30-4937-bc6e-10a56d660ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ba891623-7a30-4937-bc6e-10a56d660ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e60f12b0-ef2b-434b-b8d9-115c83993593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c157bfa5-632f-45e6-98c0-5343dc8274ff" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e60f12b0-ef2b-434b-b8d9-115c83993593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d8bb376-80cc-482c-b515-1cdd4317b615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1923763f-fd40-477f-92a2-015454d8ee3f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d8bb376-80cc-482c-b515-1cdd4317b615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d2d60bc-6de0-4067-bb44-344b8b2e12b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d8bb376-80cc-482c-b515-1cdd4317b615" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d2d60bc-6de0-4067-bb44-344b8b2e12b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_98a67aee-da03-41ed-abe3-f1ee4a135054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d2d60bc-6de0-4067-bb44-344b8b2e12b0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_98a67aee-da03-41ed-abe3-f1ee4a135054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8aff77a7-bb87-4b94-afc0-ae842732fb16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d2d60bc-6de0-4067-bb44-344b8b2e12b0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8aff77a7-bb87-4b94-afc0-ae842732fb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1923763f-fd40-477f-92a2-015454d8ee3f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab057737-178a-4671-8582-7a48f2dc94de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab057737-178a-4671-8582-7a48f2dc94de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6b9a47ea-62de-4444-abea-ae8f6cb55ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6b9a47ea-62de-4444-abea-ae8f6cb55ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dc2f0c3d-1a21-4d68-bca0-c34648a6004d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dc2f0c3d-1a21-4d68-bca0-c34648a6004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9ae2f7b0-0a02-4bd1-82df-d2dae086b166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9ae2f7b0-0a02-4bd1-82df-d2dae086b166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_92c13978-df8d-44bf-9df5-8fbc53570fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_92c13978-df8d-44bf-9df5-8fbc53570fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_5f86d6c2-eaf0-4e48-b061-3f7a7e05df79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_us-gaap_Cash_5f86d6c2-eaf0-4e48-b061-3f7a7e05df79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c743e03f-1b34-43c0-9f1f-655c95f3b7ce" xlink:href="nktr-20221231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72eae978-9b0c-432b-926d-9896b86d083c" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c743e03f-1b34-43c0-9f1f-655c95f3b7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#InventoryScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fb547acd-95fb-4f59-a81d-5ecae7ca2981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1f421460-18a5-4a5c-ba25-bb2d45adaa11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fb547acd-95fb-4f59-a81d-5ecae7ca2981" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1f421460-18a5-4a5c-ba25-bb2d45adaa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d661d368-c9f6-4eb7-9ab1-e6f007698fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fb547acd-95fb-4f59-a81d-5ecae7ca2981" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d661d368-c9f6-4eb7-9ab1-e6f007698fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_07f40824-d1ee-40aa-8bb7-a1bafca8fbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fb547acd-95fb-4f59-a81d-5ecae7ca2981" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_07f40824-d1ee-40aa-8bb7-a1bafca8fbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ec020575-ff7a-4df7-bf08-e146c1c017a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fb547acd-95fb-4f59-a81d-5ecae7ca2981" xlink:to="loc_us-gaap_InventoryNet_ec020575-ff7a-4df7-bf08-e146c1c017a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_28251be7-98e1-4e5a-9901-ea09839241d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82bcb834-6bf2-463f-8528-a54264453590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_28251be7-98e1-4e5a-9901-ea09839241d3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82bcb834-6bf2-463f-8528-a54264453590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_060f9e70-7cea-4d97-acad-3ab2620494eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82bcb834-6bf2-463f-8528-a54264453590" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_060f9e70-7cea-4d97-acad-3ab2620494eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_060f9e70-7cea-4d97-acad-3ab2620494eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_c26aa939-ce69-463e-a8cd-23bcb795bfc8" xlink:href="nktr-20221231.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_c26aa939-ce69-463e-a8cd-23bcb795bfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_ddf8f32f-4409-4b0d-88c3-968a04bbcbda" xlink:href="nktr-20221231.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_nktr_LaboratoryEquipmentMember_ddf8f32f-4409-4b0d-88c3-968a04bbcbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember_2eba4752-1844-445f-967b-2e301d3a1908" xlink:href="nktr-20221231.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_nktr_ComputerFurnitureAndOtherMember_2eba4752-1844-445f-967b-2e301d3a1908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_75c1a0fe-3a6e-421d-8445-467da2c67401" xlink:href="nktr-20221231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_75c1a0fe-3a6e-421d-8445-467da2c67401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c2163073-924d-484f-b95a-e98abe7405dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_535a8841-a3f8-499b-92d2-98638147a3c5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c2163073-924d-484f-b95a-e98abe7405dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82bcb834-6bf2-463f-8528-a54264453590" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_128632c7-b63f-49d5-acd1-3529b818a98c" xlink:href="nktr-20221231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_128632c7-b63f-49d5-acd1-3529b818a98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_40f839e6-75f7-4607-ad6e-9ae841dfb82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_40f839e6-75f7-4607-ad6e-9ae841dfb82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_0c0b5e26-3939-423f-8e63-519ae2daefc9" xlink:href="nktr-20221231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_0c0b5e26-3939-423f-8e63-519ae2daefc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_dc759b93-e13a-4a73-8c1a-de771e865a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_us-gaap_ConstructionInProgressGross_dc759b93-e13a-4a73-8c1a-de771e865a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_abb0ee83-9fc8-491a-be6f-374f459995cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_92dab17c-68d2-4358-8e59-c5cce3a43076" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_abb0ee83-9fc8-491a-be6f-374f459995cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#PropertyPlantandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0fce115e-bd80-4763-8a04-18ad549c0b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3c83e33a-d2ce-456b-b37a-8c682308ec65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0fce115e-bd80-4763-8a04-18ad549c0b58" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3c83e33a-d2ce-456b-b37a-8c682308ec65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8b3d81f6-d90b-4fe4-80d4-5c2eac71a985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_f00a0e18-66a6-427b-96ac-63fe76847432" xlink:href="nktr-20221231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b3d81f6-d90b-4fe4-80d4-5c2eac71a985" xlink:to="loc_nktr_ScheduleOfLeasesTable_f00a0e18-66a6-427b-96ac-63fe76847432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_fdc69b57-0dba-459c-8b11-e53e5c15a4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_f00a0e18-66a6-427b-96ac-63fe76847432" xlink:to="loc_us-gaap_LeaseContractualTermAxis_fdc69b57-0dba-459c-8b11-e53e5c15a4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_87de3485-bf96-433c-8ae3-b32071392fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_fdc69b57-0dba-459c-8b11-e53e5c15a4a7" xlink:to="loc_us-gaap_LeaseContractualTermDomain_87de3485-bf96-433c-8ae3-b32071392fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_933f7ad9-1126-42e9-8e87-626bfc75dc01" xlink:href="nktr-20221231.xsd#nktr_MissionBayLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_87de3485-bf96-433c-8ae3-b32071392fd9" xlink:to="loc_nktr_MissionBayLeaseMember_933f7ad9-1126-42e9-8e87-626bfc75dc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_4a4b3ce1-d4ab-454d-b4e3-b196243c3d94" xlink:href="nktr-20221231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_87de3485-bf96-433c-8ae3-b32071392fd9" xlink:to="loc_nktr_ThirdStreetLeaseMember_4a4b3ce1-d4ab-454d-b4e3-b196243c3d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4d1f5554-9c81-404e-a5d4-f8a65fb567d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_f00a0e18-66a6-427b-96ac-63fe76847432" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4d1f5554-9c81-404e-a5d4-f8a65fb567d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94e11655-f80d-4e9d-b1b7-ba933d36159f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4d1f5554-9c81-404e-a5d4-f8a65fb567d8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94e11655-f80d-4e9d-b1b7-ba933d36159f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_5b57857a-d4d3-4e00-8ce1-af0b5f761148" xlink:href="nktr-20221231.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94e11655-f80d-4e9d-b1b7-ba933d36159f" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_5b57857a-d4d3-4e00-8ce1-af0b5f761148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:href="nktr-20221231.xsd#nktr_LeasesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_f00a0e18-66a6-427b-96ac-63fe76847432" xlink:to="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpace_b013e56c-ee38-40f1-8de7-b29374238d52" xlink:href="nktr-20221231.xsd#nktr_AreaOfLeasedSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_nktr_AreaOfLeasedSpace_b013e56c-ee38-40f1-8de7-b29374238d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1bf7fcd6-9aeb-4d6a-92cf-211adc130304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_us-gaap_AssetImpairmentCharges_1bf7fcd6-9aeb-4d6a-92cf-211adc130304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_94ceab3a-5017-4e37-9125-37ffd0a362e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_us-gaap_OperatingLeasePayments_94ceab3a-5017-4e37-9125-37ffd0a362e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab5f37f5-2168-4cf3-a2bf-5fa3afb3c33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab5f37f5-2168-4cf3-a2bf-5fa3afb3c33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_69ed6ba5-4609-444b-b973-a22e7d14f5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_69ed6ba5-4609-444b-b973-a22e7d14f5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasesIncomeToBeReceived_ca7074b2-fd00-4b33-a9b8-7300345fa6ce" xlink:href="nktr-20221231.xsd#nktr_SubleasesIncomeToBeReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_ff75fb12-ad18-45e7-9876-c396c4647b3b" xlink:to="loc_nktr_SubleasesIncomeToBeReceived_ca7074b2-fd00-4b33-a9b8-7300345fa6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesScheduleofOperatingLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_79e0942b-a557-491c-9225-8a3840d65072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_78e25900-7420-4745-8c6e-69e92a112523" xlink:href="nktr-20221231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79e0942b-a557-491c-9225-8a3840d65072" xlink:to="loc_nktr_ScheduleOfLeasesTable_78e25900-7420-4745-8c6e-69e92a112523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ee57d817-94d0-4c29-8df9-aa69cde7d827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_78e25900-7420-4745-8c6e-69e92a112523" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ee57d817-94d0-4c29-8df9-aa69cde7d827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_1a78a1ed-b88a-4c48-b0b7-791df8a3263f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ee57d817-94d0-4c29-8df9-aa69cde7d827" xlink:to="loc_us-gaap_LeaseContractualTermDomain_1a78a1ed-b88a-4c48-b0b7-791df8a3263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_99bc68f7-e638-4eb5-b271-e9e83a1bad64" xlink:href="nktr-20221231.xsd#nktr_MissionBayLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_1a78a1ed-b88a-4c48-b0b7-791df8a3263f" xlink:to="loc_nktr_MissionBayLeaseMember_99bc68f7-e638-4eb5-b271-e9e83a1bad64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_df182449-3e5f-4d45-8d8c-73f9d0083d60" xlink:href="nktr-20221231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_1a78a1ed-b88a-4c48-b0b7-791df8a3263f" xlink:to="loc_nktr_ThirdStreetLeaseMember_df182449-3e5f-4d45-8d8c-73f9d0083d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_ed484d86-4a82-48bc-a7fc-a6add6ae1a6d" xlink:href="nktr-20221231.xsd#nktr_LeasesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_78e25900-7420-4745-8c6e-69e92a112523" xlink:to="loc_nktr_LeasesLineItems_ed484d86-4a82-48bc-a7fc-a6add6ae1a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfConsecutiveTermsToExtendLease_c2f02514-1502-4afd-8221-8dfe53224c9d" xlink:href="nktr-20221231.xsd#nktr_NumberOfConsecutiveTermsToExtendLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_ed484d86-4a82-48bc-a7fc-a6add6ae1a6d" xlink:to="loc_nktr_NumberOfConsecutiveTermsToExtendLease_c2f02514-1502-4afd-8221-8dfe53224c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeaseExtensionTerm_73606246-739b-40ed-959c-5549156cec07" xlink:href="nktr-20221231.xsd#nktr_LeaseExtensionTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_ed484d86-4a82-48bc-a7fc-a6add6ae1a6d" xlink:to="loc_nktr_LeaseExtensionTerm_73606246-739b-40ed-959c-5549156cec07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesScheduleofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a6635059-a27e-4c13-85e7-d3751a71afd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_fbffc320-2815-4ab8-b80a-a67d89ee90d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a6635059-a27e-4c13-85e7-d3751a71afd9" xlink:to="loc_us-gaap_OperatingLeaseCost_fbffc320-2815-4ab8-b80a-a67d89ee90d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f17f6fd5-ce27-4628-bbab-caaa79fc61ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a6635059-a27e-4c13-85e7-d3751a71afd9" xlink:to="loc_us-gaap_VariableLeaseCost_f17f6fd5-ce27-4628-bbab-caaa79fc61ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8d82cabf-db65-4810-bb49-6049b0cdc5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a6635059-a27e-4c13-85e7-d3751a71afd9" xlink:to="loc_us-gaap_LeaseCost_8d82cabf-db65-4810-bb49-6049b0cdc5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_de15a38b-6461-49c1-ae1b-8fa945992e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_de15a38b-6461-49c1-ae1b-8fa945992e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3f9eae9c-59ee-4016-b0fb-a4b45fd276b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3f9eae9c-59ee-4016-b0fb-a4b45fd276b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6e77bf58-bb79-4b24-b49c-0c228355b184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6e77bf58-bb79-4b24-b49c-0c228355b184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a74f06b1-6035-4333-bbf6-c9deb4283c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a74f06b1-6035-4333-bbf6-c9deb4283c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7b63e8d2-19c7-4ef7-ade6-8c8de26fef2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7b63e8d2-19c7-4ef7-ade6-8c8de26fef2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1f01818f-91c5-4841-baf7-a5993310db6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1f01818f-91c5-4841-baf7-a5993310db6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d854da0d-6137-4e64-aa38-07e609a3ca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d854da0d-6137-4e64-aa38-07e609a3ca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fed106db-ab4d-43e1-b9d7-640ff572d660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fed106db-ab4d-43e1-b9d7-640ff572d660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_49627f1d-7e44-460e-9b02-547572fa080a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_OperatingLeaseLiability_49627f1d-7e44-460e-9b02-547572fa080a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bea1aa18-2e17-443a-8e8a-945644e3c2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bea1aa18-2e17-443a-8e8a-945644e3c2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_760101c3-26d8-4d94-af5c-3801cae6b591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4fdfb28-792c-4e16-bbb7-795b49aba612" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_760101c3-26d8-4d94-af5c-3801cae6b591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="simple" xlink:href="nktr-20221231.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_48eea5d7-2dfe-427a-b1ee-f8c42980ef68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_814d68bd-a234-4cfa-ac26-9c9c2611441f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_48eea5d7-2dfe-427a-b1ee-f8c42980ef68" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_814d68bd-a234-4cfa-ac26-9c9c2611441f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27cd6afe-7064-4d81-8c65-46bb16b32106" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_814d68bd-a234-4cfa-ac26-9c9c2611441f" xlink:to="loc_srt_CounterpartyNameAxis_27cd6afe-7064-4d81-8c65-46bb16b32106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4bdd03ad-3112-43c1-807e-2f37558ec4cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_27cd6afe-7064-4d81-8c65-46bb16b32106" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4bdd03ad-3112-43c1-807e-2f37558ec4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_21661015-8cc5-4238-833a-2cf9b8bc8457" xlink:href="nktr-20221231.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4bdd03ad-3112-43c1-807e-2f37558ec4cb" xlink:to="loc_nktr_SFJPharmaceuticalsMember_21661015-8cc5-4238-833a-2cf9b8bc8457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e217ea66-41fc-4b26-ae0d-dc43501cd864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_814d68bd-a234-4cfa-ac26-9c9c2611441f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e217ea66-41fc-4b26-ae0d-dc43501cd864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_f57ff1c6-7783-4179-95c4-304c19b59e00" xlink:href="nktr-20221231.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e217ea66-41fc-4b26-ae0d-dc43501cd864" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_f57ff1c6-7783-4179-95c4-304c19b59e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_d6523d2e-6f34-4a48-b58d-780e92349226" xlink:href="nktr-20221231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e217ea66-41fc-4b26-ae0d-dc43501cd864" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_d6523d2e-6f34-4a48-b58d-780e92349226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_139ec487-7359-4d20-bb50-43e1a40cad58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff57519a-4321-4711-85f4-0f7ab5c3b1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_139ec487-7359-4d20-bb50-43e1a40cad58" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff57519a-4321-4711-85f4-0f7ab5c3b1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_079fb43f-ff8c-4bb5-8ee8-016d70124518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff57519a-4321-4711-85f4-0f7ab5c3b1bd" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_079fb43f-ff8c-4bb5-8ee8-016d70124518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ea068d3b-a4ea-43df-966c-c202a444b644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_079fb43f-ff8c-4bb5-8ee8-016d70124518" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ea068d3b-a4ea-43df-966c-c202a444b644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_af3a204d-1591-4e98-b945-5738bd0fcea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ea068d3b-a4ea-43df-966c-c202a444b644" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_af3a204d-1591-4e98-b945-5738bd0fcea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c580168f-ea45-46c9-8e8f-bf98f614cc10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff57519a-4321-4711-85f4-0f7ab5c3b1bd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c580168f-ea45-46c9-8e8f-bf98f614cc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78daa9ea-cea4-4a50-a1ef-2f0671f5f424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c580168f-ea45-46c9-8e8f-bf98f614cc10" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78daa9ea-cea4-4a50-a1ef-2f0671f5f424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1e8328a9-86fb-4173-ad16-8a992ae6b2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78daa9ea-cea4-4a50-a1ef-2f0671f5f424" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1e8328a9-86fb-4173-ad16-8a992ae6b2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ea6610e4-b23c-4bba-92e3-a9b3cce21277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff57519a-4321-4711-85f4-0f7ab5c3b1bd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ea6610e4-b23c-4bba-92e3-a9b3cce21277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ea6610e4-b23c-4bba-92e3-a9b3cce21277" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_80e49566-b554-4d19-9380-af81fc1cb1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_80e49566-b554-4d19-9380-af81fc1cb1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_16bf562e-12ca-472e-8373-e2ec293bcdda" xlink:href="nktr-20221231.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_16bf562e-12ca-472e-8373-e2ec293bcdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b3cf0db9-e3b7-4d5f-a54e-01eec03d6117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b3cf0db9-e3b7-4d5f-a54e-01eec03d6117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_cb6a3578-9d2f-43b4-ae9f-666d7e9f0fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_cb6a3578-9d2f-43b4-ae9f-666d7e9f0fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b3c9b046-c6da-4bbb-bb05-c501c195adb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cb94fdee-d1dd-4a11-add9-24527d07b311" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b3c9b046-c6da-4bbb-bb05-c501c195adb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_f60090a3-3c9b-408e-8d07-6d0e351f24e9" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_f60090a3-3c9b-408e-8d07-6d0e351f24e9" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_50fdb780-3ba4-4ce1-baca-23cd1f088536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:to="loc_us-gaap_TypeOfArrangementAxis_50fdb780-3ba4-4ce1-baca-23cd1f088536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50fdb780-3ba4-4ce1-baca-23cd1f088536" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_095fb2a6-8a47-4af9-98ac-c27970cd1ba7" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_095fb2a6-8a47-4af9-98ac-c27970cd1ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_a4e2d576-db25-42cc-9fd8-3a9a18b54cc7" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_a4e2d576-db25-42cc-9fd8-3a9a18b54cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_cfe42540-5b7e-4613-a0bd-1a2a27cd2b4b" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70a8cef7-fd03-4031-9ad3-a0d0749a91a0" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_cfe42540-5b7e-4613-a0bd-1a2a27cd2b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5dd64ec2-c3ff-46f5-949c-2c3b664e9d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5dd64ec2-c3ff-46f5-949c-2c3b664e9d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b677e9e0-7d16-47a0-97a0-8e0a05a94c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5dd64ec2-c3ff-46f5-949c-2c3b664e9d28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b677e9e0-7d16-47a0-97a0-8e0a05a94c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FutureRoyaltiesMember_c3081f3b-b88f-4349-b44b-62121be269c4" xlink:href="nktr-20221231.xsd#nktr_FutureRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b677e9e0-7d16-47a0-97a0-8e0a05a94c82" xlink:to="loc_nktr_FutureRoyaltiesMember_c3081f3b-b88f-4349-b44b-62121be269c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_147efa77-c53f-41f6-a568-d757fe3020b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_147efa77-c53f-41f6-a568-d757fe3020b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_007f7d28-d7bd-43cb-bdb0-2f31bb201d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_147efa77-c53f-41f6-a568-d757fe3020b2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_007f7d28-d7bd-43cb-bdb0-2f31bb201d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_78f68f4f-532d-4391-9d4e-ea6d6b145e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_007f7d28-d7bd-43cb-bdb0-2f31bb201d04" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_78f68f4f-532d-4391-9d4e-ea6d6b145e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputInceptionDiscountRateMember_6d16c85e-f52d-4543-b16a-e54f7adc62dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputInceptionDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_007f7d28-d7bd-43cb-bdb0-2f31bb201d04" xlink:to="loc_us-gaap_MeasurementInputInceptionDiscountRateMember_6d16c85e-f52d-4543-b16a-e54f7adc62dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_dff1e34e-1089-4e3a-9252-e45f32162d84" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_db2ee59b-9609-4a96-8777-bdbe895a9fd9" xlink:href="nktr-20221231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_db2ee59b-9609-4a96-8777-bdbe895a9fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_381aa3ab-4e2e-40ae-81da-e8a73c9fb729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_381aa3ab-4e2e-40ae-81da-e8a73c9fb729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_6a247666-7dd0-4e1e-8e80-59f22e1496a2" xlink:href="nktr-20221231.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_6a247666-7dd0-4e1e-8e80-59f22e1496a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_ca2380e5-2bbb-4b1f-8f6d-66174b5012a7" xlink:href="nktr-20221231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_ca2380e5-2bbb-4b1f-8f6d-66174b5012a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_6250178a-90e2-4a66-98a7-7402dfd5310b" xlink:href="nktr-20221231.xsd#nktr_TransactionCostsRelatedToRevisedRoyaltyPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_6250178a-90e2-4a66-98a7-7402dfd5310b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_48f47591-e552-4492-ba5a-04e4f5b5dcbc" xlink:href="nktr-20221231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_48f47591-e552-4492-ba5a-04e4f5b5dcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_6d0c8ecc-32c0-48e1-9997-7a030c30eb06" xlink:href="nktr-20221231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_6d0c8ecc-32c0-48e1-9997-7a030c30eb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_7fae5a5d-a53b-48b7-ab01-fc90cb2dafe7" xlink:href="nktr-20221231.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_7fae5a5d-a53b-48b7-ab01-fc90cb2dafe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_e2307690-92f9-4b04-a955-32370b1463a6" xlink:href="nktr-20221231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_e2307690-92f9-4b04-a955-32370b1463a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_b515b043-6668-4180-bbf9-1c119507a040" xlink:href="nktr-20221231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_b515b043-6668-4180-bbf9-1c119507a040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_0443d9d6-6e7f-45a8-ab21-c8c7e8d1f89e" xlink:href="nktr-20221231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_1ff385a8-cafa-4049-86a1-99c5234ac452" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_0443d9d6-6e7f-45a8-ab21-c8c7e8d1f89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20221231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_956bf6a9-940d-48e6-bd6a-135828abeb37" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_eec96f07-a141-4a43-b97c-57ee2d01a010" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_956bf6a9-940d-48e6-bd6a-135828abeb37" xlink:to="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_eec96f07-a141-4a43-b97c-57ee2d01a010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_5d2fbfa6-3c5a-4ae4-a126-713b707163e0" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_956bf6a9-940d-48e6-bd6a-135828abeb37" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_5d2fbfa6-3c5a-4ae4-a126-713b707163e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c2e87a69-e05b-4089-903c-d0483622eb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_5d2fbfa6-3c5a-4ae4-a126-713b707163e0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c2e87a69-e05b-4089-903c-d0483622eb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38788017-4891-4aba-984a-e0b3a790e57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c2e87a69-e05b-4089-903c-d0483622eb7c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38788017-4891-4aba-984a-e0b3a790e57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_a019f463-668d-4500-aa14-15b677a30f0f" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38788017-4891-4aba-984a-e0b3a790e57c" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_a019f463-668d-4500-aa14-15b677a30f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_8e595b24-79fd-4b13-8106-707d5b8ff8d4" xlink:href="nktr-20221231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38788017-4891-4aba-984a-e0b3a790e57c" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_8e595b24-79fd-4b13-8106-707d5b8ff8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_f3238c98-02fd-45fe-878e-acb5fca6cf0d" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_5d2fbfa6-3c5a-4ae4-a126-713b707163e0" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_f3238c98-02fd-45fe-878e-acb5fca6cf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_f3238c98-02fd-45fe-878e-acb5fca6cf0d" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_94ca88c9-0dea-40db-b7d4-dda8ec9851c7" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_94ca88c9-0dea-40db-b7d4-dda8ec9851c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_a979cf62-7828-4a4e-8015-5c45fd0c1f67" xlink:href="nktr-20221231.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_a979cf62-7828-4a4e-8015-5c45fd0c1f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_fcee4e80-a614-4526-8fa9-e5aab9af18f8" xlink:href="nktr-20221231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_fcee4e80-a614-4526-8fa9-e5aab9af18f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b0ccb828-c8bc-4776-99ba-bcf96b8a985e" xlink:href="nktr-20221231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b0ccb828-c8bc-4776-99ba-bcf96b8a985e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_1b4c491a-2629-43d6-bf9a-1b4ed3e1256a" xlink:href="nktr-20221231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_1b4c491a-2629-43d6-bf9a-1b4ed3e1256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_3ec00082-59b0-4ba8-8674-b0b740fb1d75" xlink:href="nktr-20221231.xsd#nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_3ec00082-59b0-4ba8-8674-b0b740fb1d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_27d81000-7000-4db8-b613-07993a9f3c20" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_27d81000-7000-4db8-b613-07993a9f3c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_cd8347cd-d2be-422f-994c-feae4de9c55c" xlink:href="nktr-20221231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_cd8347cd-d2be-422f-994c-feae4de9c55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_8f5a74d3-5de0-4fee-afc7-00fa6d7e9dc3" xlink:href="nktr-20221231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_92c81408-9ccb-4059-87a5-0191dc5b9758" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_8f5a74d3-5de0-4fee-afc7-00fa6d7e9dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_163f979e-aa67-4314-96cb-e87fb623d33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ae5f4e2b-91fc-43c6-aede-a7d4c34381c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_163f979e-aa67-4314-96cb-e87fb623d33f" xlink:to="loc_us-gaap_LossContingenciesTable_ae5f4e2b-91fc-43c6-aede-a7d4c34381c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_af66958a-64fe-424e-9f94-20d914e6f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ae5f4e2b-91fc-43c6-aede-a7d4c34381c1" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_af66958a-64fe-424e-9f94-20d914e6f99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_af66958a-64fe-424e-9f94-20d914e6f99b" xlink:to="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_ec9f3299-0c1b-4bb1-b2fb-07340e018fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_ec9f3299-0c1b-4bb1-b2fb-07340e018fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_ea33ee76-4032-4fba-8370-61787a56e4c6" xlink:href="nktr-20221231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:to="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_ea33ee76-4032-4fba-8370-61787a56e4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuritiesRelatedClaimsMember_660ac26e-9f7e-4b70-9ddb-7d0a48a8c6ed" xlink:href="nktr-20221231.xsd#nktr_SecuritiesRelatedClaimsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:to="loc_nktr_SecuritiesRelatedClaimsMember_660ac26e-9f7e-4b70-9ddb-7d0a48a8c6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonSecuritiesRelatedClaimsMember_4cb6090e-8afe-4f70-835e-336d80785e7f" xlink:href="nktr-20221231.xsd#nktr_NonSecuritiesRelatedClaimsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4cb8338d-56a9-47ca-9a88-5919510c7090" xlink:to="loc_nktr_NonSecuritiesRelatedClaimsMember_4cb6090e-8afe-4f70-835e-336d80785e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f1ca8ebe-7555-47ed-b0c2-af4b8b6649d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ae5f4e2b-91fc-43c6-aede-a7d4c34381c1" xlink:to="loc_srt_RangeAxis_f1ca8ebe-7555-47ed-b0c2-af4b8b6649d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9fb92912-230e-41e5-9450-32897b43ddde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f1ca8ebe-7555-47ed-b0c2-af4b8b6649d9" xlink:to="loc_srt_RangeMember_9fb92912-230e-41e5-9450-32897b43ddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_691de37f-656b-4f89-8620-fbcfc01814d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9fb92912-230e-41e5-9450-32897b43ddde" xlink:to="loc_srt_MaximumMember_691de37f-656b-4f89-8620-fbcfc01814d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_08176748-508c-434d-8dc0-24ec7ea16ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ae5f4e2b-91fc-43c6-aede-a7d4c34381c1" xlink:to="loc_us-gaap_LossContingenciesLineItems_08176748-508c-434d-8dc0-24ec7ea16ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_198096ec-d8bc-4910-a516-eb4ff2ab0c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_08176748-508c-434d-8dc0-24ec7ea16ee1" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_198096ec-d8bc-4910-a516-eb4ff2ab0c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_e753fd0c-20cc-44a6-a59d-abe97196b8be" xlink:href="nktr-20221231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_08176748-508c-434d-8dc0-24ec7ea16ee1" xlink:to="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_e753fd0c-20cc-44a6-a59d-abe97196b8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8803518b-e742-4819-81bc-185e0ee49016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9fab8c39-d356-4e9c-a41a-9aece9c955b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8803518b-e742-4819-81bc-185e0ee49016" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9fab8c39-d356-4e9c-a41a-9aece9c955b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4c2836fe-93c9-448b-964c-1acd106c892c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9fab8c39-d356-4e9c-a41a-9aece9c955b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4c2836fe-93c9-448b-964c-1acd106c892c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c2836fe-93c9-448b-964c-1acd106c892c" xlink:to="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9fd09881-a31c-4464-87e2-d9f051e3ebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:to="loc_us-gaap_CommonStockMember_9fd09881-a31c-4464-87e2-d9f051e3ebb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e387d7dc-0c13-4eae-b9e7-00e7ea1e2485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e387d7dc-0c13-4eae-b9e7-00e7ea1e2485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7c1f6ed9-d364-4045-9642-6a831cbbf46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_382a15d5-7b78-406c-a058-8ad1aa973577" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7c1f6ed9-d364-4045-9642-6a831cbbf46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9fab8c39-d356-4e9c-a41a-9aece9c955b2" xlink:to="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15eeb4d2-05c0-4dd1-b605-457908548623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15eeb4d2-05c0-4dd1-b605-457908548623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_45d9e1b4-9bad-456c-b053-5cad1ab5527e" xlink:href="nktr-20221231.xsd#nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:to="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_45d9e1b4-9bad-456c-b053-5cad1ab5527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockValueAuthorizedInTransaction_29f8b277-5d75-493a-b360-1d878bf83007" xlink:href="nktr-20221231.xsd#nktr_SaleOfStockValueAuthorizedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:to="loc_nktr_SaleOfStockValueAuthorizedInTransaction_29f8b277-5d75-493a-b360-1d878bf83007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e6f981a6-9c14-4ab0-8cef-a6da9f210181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5e80f881-5ce3-42b6-9a61-8eef2aea3aeb" xlink:to="loc_us-gaap_StockholdersEquity_e6f981a6-9c14-4ab0-8cef-a6da9f210181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4b0b49db-17fd-4188-9720-f4d18b8fb20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d78a0707-cfbd-45e9-a184-69954ebc1dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4b0b49db-17fd-4188-9720-f4d18b8fb20f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d78a0707-cfbd-45e9-a184-69954ebc1dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5d5ae51-013b-43f5-9398-409ef2f9abfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a0707-cfbd-45e9-a184-69954ebc1dc5" xlink:to="loc_us-gaap_AwardTypeAxis_f5d5ae51-013b-43f5-9398-409ef2f9abfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36c4e3ed-cb33-4753-a50c-fb5c49b1c729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f5d5ae51-013b-43f5-9398-409ef2f9abfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36c4e3ed-cb33-4753-a50c-fb5c49b1c729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_d0849a5f-992b-474b-86f4-d0baf6f3012b" xlink:href="nktr-20221231.xsd#nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36c4e3ed-cb33-4753-a50c-fb5c49b1c729" xlink:to="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_d0849a5f-992b-474b-86f4-d0baf6f3012b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6332c2b7-c35c-4c10-bcc6-fe12fab5e4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a0707-cfbd-45e9-a184-69954ebc1dc5" xlink:to="loc_us-gaap_PlanNameAxis_6332c2b7-c35c-4c10-bcc6-fe12fab5e4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_475285c9-237d-4dc6-8f77-dd17e98952b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6332c2b7-c35c-4c10-bcc6-fe12fab5e4cd" xlink:to="loc_us-gaap_PlanNameDomain_475285c9-237d-4dc6-8f77-dd17e98952b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_d837ab17-0117-4911-892e-09602bd596ae" xlink:href="nktr-20221231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_475285c9-237d-4dc6-8f77-dd17e98952b6" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_d837ab17-0117-4911-892e-09602bd596ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_8da7e3d2-ab34-443e-b380-123c8fa22d6c" xlink:href="nktr-20221231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_475285c9-237d-4dc6-8f77-dd17e98952b6" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_8da7e3d2-ab34-443e-b380-123c8fa22d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_767a3036-2162-46d9-bf63-9ad2e1c60937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d78a0707-cfbd-45e9-a184-69954ebc1dc5" xlink:to="loc_us-gaap_ClassOfStockLineItems_767a3036-2162-46d9-bf63-9ad2e1c60937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a165476-9792-47b3-b43c-0be1a95c816a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_767a3036-2162-46d9-bf63-9ad2e1c60937" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a165476-9792-47b3-b43c-0be1a95c816a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd19e6d9-ca8b-4ef8-b31b-5cace62954fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_f37a7948-66a1-496f-b9a6-c61ac4aa8a34" xlink:href="nktr-20221231.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd19e6d9-ca8b-4ef8-b31b-5cace62954fe" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_f37a7948-66a1-496f-b9a6-c61ac4aa8a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e0d0e796-105c-4e5c-afe5-dadec6be089e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_f37a7948-66a1-496f-b9a6-c61ac4aa8a34" xlink:to="loc_dei_LegalEntityAxis_e0d0e796-105c-4e5c-afe5-dadec6be089e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ceb4848a-71e7-4f78-bdbb-ba90e46a6dc7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e0d0e796-105c-4e5c-afe5-dadec6be089e" xlink:to="loc_dei_EntityDomain_ceb4848a-71e7-4f78-bdbb-ba90e46a6dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_189600e3-19eb-4a7b-b5c9-4d9baca60e34" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ceb4848a-71e7-4f78-bdbb-ba90e46a6dc7" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_189600e3-19eb-4a7b-b5c9-4d9baca60e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_8dd80f3d-5f96-4ce6-8a33-f6a54b1d3ac1" xlink:href="nktr-20221231.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ceb4848a-71e7-4f78-bdbb-ba90e46a6dc7" xlink:to="loc_nktr_OtherPartnerMember_8dd80f3d-5f96-4ce6-8a33-f6a54b1d3ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f55feca2-3248-4b6d-8a1d-28df67958e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_f37a7948-66a1-496f-b9a6-c61ac4aa8a34" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f55feca2-3248-4b6d-8a1d-28df67958e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1cd6619b-9dc5-4e61-af7b-74bb669c9201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f55feca2-3248-4b6d-8a1d-28df67958e8d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1cd6619b-9dc5-4e61-af7b-74bb669c9201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BempegaldesleukinMember_07d190ba-76be-4850-aecd-7fcdf8dbad1d" xlink:href="nktr-20221231.xsd#nktr_BempegaldesleukinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1cd6619b-9dc5-4e61-af7b-74bb669c9201" xlink:to="loc_nktr_BempegaldesleukinMember_07d190ba-76be-4850-aecd-7fcdf8dbad1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_ebc55657-90e4-4b49-ba9d-21e634c1557b" xlink:href="nktr-20221231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_f37a7948-66a1-496f-b9a6-c61ac4aa8a34" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsLineItems_ebc55657-90e4-4b49-ba9d-21e634c1557b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_e7765eef-8a09-4c79-b234-3029bfbb8ca9" xlink:href="nktr-20221231.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_ebc55657-90e4-4b49-ba9d-21e634c1557b" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_e7765eef-8a09-4c79-b234-3029bfbb8ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e90eb362-569f-4f28-9c74-84b9f25c1db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e90eb362-569f-4f28-9c74-84b9f25c1db5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b2ff2d85-7f81-4823-b164-8b00eaefa39e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b2ff2d85-7f81-4823-b164-8b00eaefa39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8a0b565e-42f6-41c8-9abe-8cc1b35c1bb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b2ff2d85-7f81-4823-b164-8b00eaefa39e" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8a0b565e-42f6-41c8-9abe-8cc1b35c1bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_29ecda9c-1fc7-4b2a-9372-34cdb1b6bd52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8a0b565e-42f6-41c8-9abe-8cc1b35c1bb2" xlink:to="loc_srt_ParentCompanyMember_29ecda9c-1fc7-4b2a-9372-34cdb1b6bd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a9bface7-2704-4f9e-84ab-767830c68a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a9bface7-2704-4f9e-84ab-767830c68a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a4175b8-a18f-4b02-a517-d79bd6620b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a9bface7-2704-4f9e-84ab-767830c68a58" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a4175b8-a18f-4b02-a517-d79bd6620b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_5c2c76e7-8fa5-4b64-b755-d292db290404" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a4175b8-a18f-4b02-a517-d79bd6620b35" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_5c2c76e7-8fa5-4b64-b755-d292db290404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_15f8231b-c88f-4145-98f6-7c65d7c21822" xlink:href="nktr-20221231.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a4175b8-a18f-4b02-a517-d79bd6620b35" xlink:to="loc_nktr_Nektar358Member_15f8231b-c88f-4145-98f6-7c65d7c21822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d1328f3a-0093-4e7a-9bff-608ce9326ed1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_srt_ProductOrServiceAxis_d1328f3a-0093-4e7a-9bff-608ce9326ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4363a8c4-7f20-4a52-ac12-4f3c41a66b18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d1328f3a-0093-4e7a-9bff-608ce9326ed1" xlink:to="loc_srt_ProductsAndServicesDomain_4363a8c4-7f20-4a52-ac12-4f3c41a66b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_59ff004e-ad72-480a-8a80-67ab8ea7812e" xlink:href="nktr-20221231.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4363a8c4-7f20-4a52-ac12-4f3c41a66b18" xlink:to="loc_nktr_Nektar214Member_59ff004e-ad72-480a-8a80-67ab8ea7812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_edd937ab-8237-4f00-a80f-f7272593e7eb" xlink:href="nktr-20221231.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4363a8c4-7f20-4a52-ac12-4f3c41a66b18" xlink:to="loc_nktr_Nektar358Member_edd937ab-8237-4f00-a80f-f7272593e7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a9eee41c-dfa0-4af0-becc-28e2e091a6e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_dei_LegalEntityAxis_a9eee41c-dfa0-4af0-becc-28e2e091a6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a9eee41c-dfa0-4af0-becc-28e2e091a6e7" xlink:to="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_db05ec8c-3d48-481f-9ae8-d5975aa623c7" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_db05ec8c-3d48-481f-9ae8-d5975aa623c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_b59b5ecd-9a06-4248-99c8-9597670b6eac" xlink:href="nktr-20221231.xsd#nktr_EliLillyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:to="loc_nktr_EliLillyMember_b59b5ecd-9a06-4248-99c8-9597670b6eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_bf9aa363-824f-43f9-9361-b7239e83d3a5" xlink:href="nktr-20221231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:to="loc_nktr_EliLillyAndCompanyMember_bf9aa363-824f-43f9-9361-b7239e83d3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_e6ee9403-2b00-47a7-81de-6e75399ef2a3" xlink:href="nktr-20221231.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_03cb0e7d-f6ba-4c48-82d5-98a965a1afa5" xlink:to="loc_nktr_OtherPartnerMember_e6ee9403-2b00-47a7-81de-6e75399ef2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_19e83573-5aff-46ce-b005-bfb6d7ba55da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_19e83573-5aff-46ce-b005-bfb6d7ba55da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0696b614-73ff-45d7-a550-58cb96839bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_19e83573-5aff-46ce-b005-bfb6d7ba55da" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0696b614-73ff-45d7-a550-58cb96839bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_651d2f74-aef4-4d76-86ee-61a478b7489c" xlink:href="nktr-20221231.xsd#nktr_OpdivoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0696b614-73ff-45d7-a550-58cb96839bcf" xlink:to="loc_nktr_OpdivoMember_651d2f74-aef4-4d76-86ee-61a478b7489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_58da2e04-f5a7-4352-bba6-5eaf3b316654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_58da2e04-f5a7-4352-bba6-5eaf3b316654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf1293be-d9a2-4cb0-b790-3d7be8b53bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_58da2e04-f5a7-4352-bba6-5eaf3b316654" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf1293be-d9a2-4cb0-b790-3d7be8b53bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_0a87d282-2e15-4946-b890-6f6f38e55651" xlink:href="nktr-20221231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf1293be-d9a2-4cb0-b790-3d7be8b53bbb" xlink:to="loc_nktr_SharePurchaseAgreementMember_0a87d282-2e15-4946-b890-6f6f38e55651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_5d3ccd9b-ba58-45d7-80d9-219ad9f9a380" xlink:href="nktr-20221231.xsd#nktr_MilestoneAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_nktr_MilestoneAxis_5d3ccd9b-ba58-45d7-80d9-219ad9f9a380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_799b4b1b-8671-403b-af3f-7fca316d7abe" xlink:href="nktr-20221231.xsd#nktr_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneAxis_5d3ccd9b-ba58-45d7-80d9-219ad9f9a380" xlink:to="loc_nktr_MilestoneDomain_799b4b1b-8671-403b-af3f-7fca316d7abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_22b6924a-bf91-42ca-926c-67d4fcb75cc6" xlink:href="nktr-20221231.xsd#nktr_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_799b4b1b-8671-403b-af3f-7fca316d7abe" xlink:to="loc_nktr_MilestoneOneMember_22b6924a-bf91-42ca-926c-67d4fcb75cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea28372a-2a5e-4db9-8ad0-45afbac7883e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_srt_RangeAxis_ea28372a-2a5e-4db9-8ad0-45afbac7883e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a76c1c0a-bf6e-4dee-9d8f-1e95f4861e9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ea28372a-2a5e-4db9-8ad0-45afbac7883e" xlink:to="loc_srt_RangeMember_a76c1c0a-bf6e-4dee-9d8f-1e95f4861e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6d476037-7971-45c6-aa6f-33fb8bc79fa7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a76c1c0a-bf6e-4dee-9d8f-1e95f4861e9b" xlink:to="loc_srt_MaximumMember_6d476037-7971-45c6-aa6f-33fb8bc79fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b9f96040-b298-4870-a868-074245d4e3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b9f96040-b298-4870-a868-074245d4e3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_72ee96e8-9fb4-4643-9c6f-0f8b0635b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b9f96040-b298-4870-a868-074245d4e3c9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_72ee96e8-9fb4-4643-9c6f-0f8b0635b5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17182af9-c308-41d9-be61-74d2c47286d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_72ee96e8-9fb4-4643-9c6f-0f8b0635b5c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17182af9-c308-41d9-be61-74d2c47286d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e7b9b6af-294d-405b-9f64-caeeb9430faa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_srt_CounterpartyNameAxis_e7b9b6af-294d-405b-9f64-caeeb9430faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d5421d7-de17-420d-b333-99eacd4b70fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e7b9b6af-294d-405b-9f64-caeeb9430faa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d5421d7-de17-420d-b333-99eacd4b70fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_69bd1240-415f-4693-8561-dd9087a81ee6" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d5421d7-de17-420d-b333-99eacd4b70fa" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_69bd1240-415f-4693-8561-dd9087a81ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ca29b372-2066-47ad-9eea-00bf4c35c21f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_9706ee03-a423-4377-b812-6aacb41ad2ac" xlink:href="nktr-20221231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_9706ee03-a423-4377-b812-6aacb41ad2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_05ef0393-d05d-4d6a-baab-f4296bfb67de" xlink:href="nktr-20221231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_05ef0393-d05d-4d6a-baab-f4296bfb67de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_fb183793-3da0-49e7-8bac-557f078f9b7f" xlink:href="nktr-20221231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_fb183793-3da0-49e7-8bac-557f078f9b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_09eb0955-32c3-4423-979d-c284d3a007c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_us-gaap_SharesIssued_09eb0955-32c3-4423-979d-c284d3a007c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_e905bcec-16f8-47a7-9ea7-7dd80e7d1138" xlink:href="nktr-20221231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_e905bcec-16f8-47a7-9ea7-7dd80e7d1138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_55e3344a-3aa7-45e7-a62d-f5f28d4f58ef" xlink:href="nktr-20221231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PotentialDevelopmentMilestones_55e3344a-3aa7-45e7-a62d-f5f28d4f58ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_d0a88a5b-54a7-40c5-a509-50a87c4fac95" xlink:href="nktr-20221231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_ReimbursementOfExpenses_d0a88a5b-54a7-40c5-a509-50a87c4fac95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_32b97497-443d-496c-98ab-e18169dbb1a4" xlink:href="nktr-20221231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_32b97497-443d-496c-98ab-e18169dbb1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_5f85c461-4968-40fd-b464-381e8ddf856c" xlink:href="nktr-20221231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_5f85c461-4968-40fd-b464-381e8ddf856c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_28946935-39ae-4c9f-93ab-0758af7c8aa5" xlink:href="nktr-20221231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_28946935-39ae-4c9f-93ab-0758af7c8aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_b1e5f4d4-15dd-4549-ab70-287d8bfd6c2c" xlink:href="nktr-20221231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_b1e5f4d4-15dd-4549-ab70-287d8bfd6c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_ca15c8d9-a0a5-441a-a287-5da6d88eaa6a" xlink:href="nktr-20221231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_ca15c8d9-a0a5-441a-a287-5da6d88eaa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_14f51dfa-e2d3-4f8c-a0b7-57d91dc13781" xlink:href="nktr-20221231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_14f51dfa-e2d3-4f8c-a0b7-57d91dc13781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_0063faa0-c7e5-4da0-b480-d3526d079183" xlink:href="nktr-20221231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_0063faa0-c7e5-4da0-b480-d3526d079183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b03eefe3-2cef-4e0f-bdea-ba9094551a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a335bc5-1b45-4450-8d36-73e70c249dfd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b03eefe3-2cef-4e0f-bdea-ba9094551a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c162948-3f82-4dc4-a798-ca7a49cfccce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c162948-3f82-4dc4-a798-ca7a49cfccce" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_4ee9122f-06ba-4af0-a20f-67202346bfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_4ee9122f-06ba-4af0-a20f-67202346bfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0b33f7bd-47b6-4fbc-9146-cf925cd6821c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_4ee9122f-06ba-4af0-a20f-67202346bfa9" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0b33f7bd-47b6-4fbc-9146-cf925cd6821c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_daa06dbe-ab79-44d6-afae-388293a9a8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0b33f7bd-47b6-4fbc-9146-cf925cd6821c" xlink:to="loc_us-gaap_EmployeeSeveranceMember_daa06dbe-ab79-44d6-afae-388293a9a8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_697673ee-42cd-4dbf-99b9-0ae878268133" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_srt_ProductOrServiceAxis_697673ee-42cd-4dbf-99b9-0ae878268133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e0372062-7e4b-4a06-963f-f81efd608b48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_697673ee-42cd-4dbf-99b9-0ae878268133" xlink:to="loc_srt_ProductsAndServicesDomain_e0372062-7e4b-4a06-963f-f81efd608b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_8c62655a-84da-4654-97fb-3917993772ef" xlink:href="nktr-20221231.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e0372062-7e4b-4a06-963f-f81efd608b48" xlink:to="loc_nktr_Nektar214Member_8c62655a-84da-4654-97fb-3917993772ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8bfc7906-92ee-43f8-b1f7-28f5cf2c5948" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_dei_LegalEntityAxis_8bfc7906-92ee-43f8-b1f7-28f5cf2c5948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_545ea326-b834-4c70-99e8-785cc46bef2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8bfc7906-92ee-43f8-b1f7-28f5cf2c5948" xlink:to="loc_dei_EntityDomain_545ea326-b834-4c70-99e8-785cc46bef2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_bd270444-4307-4dc0-a3df-520f15a001c7" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_545ea326-b834-4c70-99e8-785cc46bef2b" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_bd270444-4307-4dc0-a3df-520f15a001c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_db16d1fa-bff9-471b-8e20-d9c117881869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_db16d1fa-bff9-471b-8e20-d9c117881869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_eeac9738-c03b-44a7-947a-f7ddc904424e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_db16d1fa-bff9-471b-8e20-d9c117881869" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_eeac9738-c03b-44a7-947a-f7ddc904424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_48708260-b702-4e7b-897c-c6ea489e380b" xlink:href="nktr-20221231.xsd#nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eeac9738-c03b-44a7-947a-f7ddc904424e" xlink:to="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_48708260-b702-4e7b-897c-c6ea489e380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b2d581c-aeb3-475c-8397-57a136d5779e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b2d581c-aeb3-475c-8397-57a136d5779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0bb85978-2ceb-4993-a2d3-c5ad384d9854" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b2d581c-aeb3-475c-8397-57a136d5779e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0bb85978-2ceb-4993-a2d3-c5ad384d9854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStFacilityMember_74bb382f-f160-48a8-8ba4-1cab641a5656" xlink:href="nktr-20221231.xsd#nktr_ThirdStFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0bb85978-2ceb-4993-a2d3-c5ad384d9854" xlink:to="loc_nktr_ThirdStFacilityMember_74bb382f-f160-48a8-8ba4-1cab641a5656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_be411d1a-cc0d-43e0-9440-8280b8e04ef4" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d95bb6bb-4f10-4a72-9b4f-caf9672ddc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d95bb6bb-4f10-4a72-9b4f-caf9672ddc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_6d1ec03c-0058-4938-8314-cf10d2d3b9fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_dei_EntityNumberOfEmployees_6d1ec03c-0058-4938-8314-cf10d2d3b9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_1c0c5e78-ba84-4bc4-a660-d2d865b8bf90" xlink:href="nktr-20221231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_nktr_ReimbursementOfExpenses_1c0c5e78-ba84-4bc4-a660-d2d865b8bf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OperatingLeaseMeasurementInput_b78b8799-8edb-4e4d-bca8-05544a15b583" xlink:href="nktr-20221231.xsd#nktr_OperatingLeaseMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_nktr_OperatingLeaseMeasurementInput_b78b8799-8edb-4e4d-bca8-05544a15b583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_066f1b1f-f284-4fae-a2e7-9da1daa08918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_us-gaap_AssetImpairmentCharges_066f1b1f-f284-4fae-a2e7-9da1daa08918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_95708993-baa9-486b-8cd9-853bebd67998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8c9adfbc-6666-43ac-883a-7305cb4d338d" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_95708993-baa9-486b-8cd9-853bebd67998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0abdda73-5f1e-4dc5-8fd0-32941ca67786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_f944bdfb-b7d8-44c0-9b08-077c70496c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0abdda73-5f1e-4dc5-8fd0-32941ca67786" xlink:to="loc_us-gaap_BusinessExitCosts1_f944bdfb-b7d8-44c0-9b08-077c70496c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_591c1ef9-e29b-4538-b35c-080841af75a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0abdda73-5f1e-4dc5-8fd0-32941ca67786" xlink:to="loc_us-gaap_SeveranceCosts1_591c1ef9-e29b-4538-b35c-080841af75a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_da85106b-a7b4-4acc-b239-299991cf3b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0abdda73-5f1e-4dc5-8fd0-32941ca67786" xlink:to="loc_us-gaap_AssetImpairmentCharges_da85106b-a7b4-4acc-b239-299991cf3b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cbf83dd5-44de-4e07-8be5-df7d291b9f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0abdda73-5f1e-4dc5-8fd0-32941ca67786" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cbf83dd5-44de-4e07-8be5-df7d291b9f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_42b58997-1588-4bd6-8a92-1f3418c33c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0abdda73-5f1e-4dc5-8fd0-32941ca67786" xlink:to="loc_us-gaap_LossOnContractTermination_42b58997-1588-4bd6-8a92-1f3418c33c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_549ca89e-141e-4906-a4f2-e221c1609019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0abdda73-5f1e-4dc5-8fd0-32941ca67786" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_549ca89e-141e-4906-a4f2-e221c1609019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_33db0aec-721c-4d8f-be46-6be703ff1ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1eef9b-7fb8-401a-bca8-3cbd828d33f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_33db0aec-721c-4d8f-be46-6be703ff1ea9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1eef9b-7fb8-401a-bca8-3cbd828d33f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_624d2d03-78a7-45ad-9d89-24a24f3c1e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1eef9b-7fb8-401a-bca8-3cbd828d33f2" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_624d2d03-78a7-45ad-9d89-24a24f3c1e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6e8d20b0-6539-4539-89fc-bb746180484d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_624d2d03-78a7-45ad-9d89-24a24f3c1e93" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6e8d20b0-6539-4539-89fc-bb746180484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_bbeb8a7e-76a9-4b38-ad92-f348d909e87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6e8d20b0-6539-4539-89fc-bb746180484d" xlink:to="loc_us-gaap_EmployeeSeveranceMember_bbeb8a7e-76a9-4b38-ad92-f348d909e87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember_f57b5151-bf11-42bb-9a64-6e9c97b0b846" xlink:href="nktr-20221231.xsd#nktr_EmployeeSeveranceWithNoServicePeriodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeSeveranceMember_bbeb8a7e-76a9-4b38-ad92-f348d909e87f" xlink:to="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember_f57b5151-bf11-42bb-9a64-6e9c97b0b846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_b958bddd-9bd3-4076-b95d-7ccc77d1cffa" xlink:href="nktr-20221231.xsd#nktr_EmployeeSeveranceWithServicePeriodRequirementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeSeveranceMember_bbeb8a7e-76a9-4b38-ad92-f348d909e87f" xlink:to="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_b958bddd-9bd3-4076-b95d-7ccc77d1cffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a836d388-893b-4325-ae3b-cab68787b7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1eef9b-7fb8-401a-bca8-3cbd828d33f2" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_a836d388-893b-4325-ae3b-cab68787b7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a836d388-893b-4325-ae3b-cab68787b7f4" xlink:to="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_af7bc208-652c-4ec7-8adb-ef6da23b9964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:to="loc_us-gaap_RestructuringReserve_af7bc208-652c-4ec7-8adb-ef6da23b9964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_507f0636-5ead-4d64-9221-4b875876aefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:to="loc_us-gaap_RestructuringCharges_507f0636-5ead-4d64-9221-4b875876aefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_a0d21630-995e-47f1-8b19-9fef534b0b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:to="loc_us-gaap_PaymentsForRestructuring_a0d21630-995e-47f1-8b19-9fef534b0b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_53b791e5-c8ea-4e39-b1f5-4d3c0a83cb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1bd74ea-9d8b-43fc-9458-7f9e30ca973d" xlink:to="loc_us-gaap_RestructuringReserve_53b791e5-c8ea-4e39-b1f5-4d3c0a83cb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f1256a68-8423-4a95-adb6-7b91d826695d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f1256a68-8423-4a95-adb6-7b91d826695d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9468ff50-e260-432f-a9ac-cc11fe220769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9468ff50-e260-432f-a9ac-cc11fe220769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ef78888a-c2ac-4736-8691-8e636aa10352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9468ff50-e260-432f-a9ac-cc11fe220769" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ef78888a-c2ac-4736-8691-8e636aa10352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_50cdc20f-1d1a-43ea-85fa-995976c67001" xlink:href="nktr-20221231.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ef78888a-c2ac-4736-8691-8e636aa10352" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_50cdc20f-1d1a-43ea-85fa-995976c67001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_c82da3b7-7e35-4c80-9d0b-82d5be0fafee" xlink:href="nktr-20221231.xsd#nktr_SubleaseOperatingLeaseRightOfUseAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ef78888a-c2ac-4736-8691-8e636aa10352" xlink:to="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_c82da3b7-7e35-4c80-9d0b-82d5be0fafee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a5f68345-c192-405f-b294-25cd1df3d85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a5f68345-c192-405f-b294-25cd1df3d85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3c790cc6-6bbc-420e-84c6-7f4ed9863336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a5f68345-c192-405f-b294-25cd1df3d85e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3c790cc6-6bbc-420e-84c6-7f4ed9863336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5b0561c8-6061-444d-976f-1a0e37ecae08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3c790cc6-6bbc-420e-84c6-7f4ed9863336" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5b0561c8-6061-444d-976f-1a0e37ecae08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a90fefe8-0075-4b5e-90bd-2a142f564c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5b0561c8-6061-444d-976f-1a0e37ecae08" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a90fefe8-0075-4b5e-90bd-2a142f564c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_66d967bc-108c-4b0e-ac62-e10c17105f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5b0561c8-6061-444d-976f-1a0e37ecae08" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_66d967bc-108c-4b0e-ac62-e10c17105f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4492261-494a-4f83-b5fe-00207dc3f35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4492261-494a-4f83-b5fe-00207dc3f35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b1014b6-b23d-428e-bd5d-fface91c70df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4492261-494a-4f83-b5fe-00207dc3f35d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b1014b6-b23d-428e-bd5d-fface91c70df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_16ada25a-322e-4f93-adf0-fddf6c6b6708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b1014b6-b23d-428e-bd5d-fface91c70df" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_16ada25a-322e-4f93-adf0-fddf6c6b6708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3522c8c7-1063-4ff2-a54b-c6d5d34ec093" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_3ebd92e7-315d-4e63-b6bd-be9b74a954cd" xlink:href="nktr-20221231.xsd#nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:to="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_3ebd92e7-315d-4e63-b6bd-be9b74a954cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_78dde971-3e10-4a5f-8596-d6eb6cbb5c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_78dde971-3e10-4a5f-8596-d6eb6cbb5c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_0d5060fd-cac7-4a61-af32-9d0d50fdb063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:to="loc_us-gaap_AdjustmentForAmortization_0d5060fd-cac7-4a61-af32-9d0d50fdb063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_66f24fbf-03de-43d7-ae60-7eb054f4ef69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2eb9ad11-cca9-4dc1-80cc-e17e7359eb94" xlink:to="loc_us-gaap_AssetImpairmentCharges_66f24fbf-03de-43d7-ae60-7eb054f4ef69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_24309392-f9e7-4473-b0ad-2ed1b66ce3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af0e0934-5146-4d8b-b8ca-e55c41063d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_24309392-f9e7-4473-b0ad-2ed1b66ce3c7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af0e0934-5146-4d8b-b8ca-e55c41063d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_7e8ee746-9916-4713-8ccd-8831d6205e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af0e0934-5146-4d8b-b8ca-e55c41063d94" xlink:to="loc_us-gaap_RestructuringPlanAxis_7e8ee746-9916-4713-8ccd-8831d6205e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_226aad73-fc7f-429e-80ed-6fcb5e6e806c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_7e8ee746-9916-4713-8ccd-8831d6205e52" xlink:to="loc_us-gaap_RestructuringPlanDomain_226aad73-fc7f-429e-80ed-6fcb5e6e806c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_52364acf-c509-49dd-9971-b012a56cdac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_226aad73-fc7f-429e-80ed-6fcb5e6e806c" xlink:to="loc_us-gaap_FacilityClosingMember_52364acf-c509-49dd-9971-b012a56cdac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af0e0934-5146-4d8b-b8ca-e55c41063d94" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2be18577-0400-42cf-a4fd-521fdb8acbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2be18577-0400-42cf-a4fd-521fdb8acbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d567d54c-1ac9-43dc-830d-2c2c550ae383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d567d54c-1ac9-43dc-830d-2c2c550ae383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_b6fb9ebf-254c-4450-8836-0e6fa3fc3f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07a147d4-aaf4-4e53-a199-baf35b4c401a" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_b6fb9ebf-254c-4450-8836-0e6fa3fc3f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e37875cf-70f4-4a48-99b2-b92fc5d11b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e37875cf-70f4-4a48-99b2-b92fc5d11b47" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_abffaefa-607f-44d7-837f-96d500fb46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:to="loc_us-gaap_AwardTypeAxis_abffaefa-607f-44d7-837f-96d500fb46d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_abffaefa-607f-44d7-837f-96d500fb46d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a81b7ab9-d081-4d1e-9b74-ab648bcd50fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a81b7ab9-d081-4d1e-9b74-ab648bcd50fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RSUsAndPSUsMember_ce74e84c-94f5-4aad-9083-a6cb58b58d5c" xlink:href="nktr-20221231.xsd#nktr_RSUsAndPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:to="loc_nktr_RSUsAndPSUsMember_ce74e84c-94f5-4aad-9083-a6cb58b58d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9e9d7f3a-c722-4ab0-9a1d-416789177d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:to="loc_us-gaap_EmployeeStockMember_9e9d7f3a-c722-4ab0-9a1d-416789177d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_58215507-0cfb-4d7d-a926-100e75a9a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dca85fe-2d82-4607-9e93-776e81a69c77" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_58215507-0cfb-4d7d-a926-100e75a9a1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0146db76-6cd4-4e08-9ad3-f004478f3bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:to="loc_us-gaap_PlanNameAxis_0146db76-6cd4-4e08-9ad3-f004478f3bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ea21383f-e696-44d6-b9a8-4eab1569e876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0146db76-6cd4-4e08-9ad3-f004478f3bca" xlink:to="loc_us-gaap_PlanNameDomain_ea21383f-e696-44d6-b9a8-4eab1569e876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_9520a822-8f5b-4947-aec8-a34b59018c45" xlink:href="nktr-20221231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ea21383f-e696-44d6-b9a8-4eab1569e876" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_9520a822-8f5b-4947-aec8-a34b59018c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_443dbc6d-a957-4ca5-aa49-6452c1e85724" xlink:href="nktr-20221231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ea21383f-e696-44d6-b9a8-4eab1569e876" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_443dbc6d-a957-4ca5-aa49-6452c1e85724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fbdb5ae2-3243-4cc2-8e45-9c05f8b62811" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:to="loc_srt_TitleOfIndividualAxis_fbdb5ae2-3243-4cc2-8e45-9c05f8b62811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76e8a2ab-0a9e-49ea-a601-b20fa2262cde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_fbdb5ae2-3243-4cc2-8e45-9c05f8b62811" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76e8a2ab-0a9e-49ea-a601-b20fa2262cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeMember_4e3c6bc6-064c-46e8-91fe-4bed67de489d" xlink:href="nktr-20221231.xsd#nktr_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76e8a2ab-0a9e-49ea-a601-b20fa2262cde" xlink:to="loc_nktr_EmployeeMember_4e3c6bc6-064c-46e8-91fe-4bed67de489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_de9a0526-9a87-4cfd-ba3c-e7108cb50afd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76e8a2ab-0a9e-49ea-a601-b20fa2262cde" xlink:to="loc_srt_DirectorMember_de9a0526-9a87-4cfd-ba3c-e7108cb50afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6d1c15f-e02c-49a3-a606-bc4324ff12bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cb106843-bad8-4ffa-b027-3cecbb0b7daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cb106843-bad8-4ffa-b027-3cecbb0b7daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_d10574d1-88c1-41ce-bcb3-7bb1f20edc62" xlink:href="nktr-20221231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_d10574d1-88c1-41ce-bcb3-7bb1f20edc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fa4684d2-77bb-4c9b-a0ce-bf9cb1006a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fa4684d2-77bb-4c9b-a0ce-bf9cb1006a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_85b394f8-51c7-4465-a888-204f638c4114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_85b394f8-51c7-4465-a888-204f638c4114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_599bacf3-819e-4843-88fb-da2366b1d851" xlink:href="nktr-20221231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForExecutives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_599bacf3-819e-4843-88fb-da2366b1d851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_69f089d0-69b7-4678-861d-34d26a9677f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_69f089d0-69b7-4678-861d-34d26a9677f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_576d123c-ff48-4ad0-b945-5d186f728eaa" xlink:href="nktr-20221231.xsd#nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_576d123c-ff48-4ad0-b945-5d186f728eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7f4b251d-f346-466d-bcbf-1e7d7d8cc811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7f4b251d-f346-466d-bcbf-1e7d7d8cc811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c6700546-b6df-448c-83df-4e9bf92e8a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c6700546-b6df-448c-83df-4e9bf92e8a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2e992d48-0f45-4aba-968d-8c48df83c618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2e992d48-0f45-4aba-968d-8c48df83c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_012556ad-f3b1-4a07-8fa8-9e83f69256fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_012556ad-f3b1-4a07-8fa8-9e83f69256fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ee6977df-6b17-4750-bde2-3f5a28deb04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ee6977df-6b17-4750-bde2-3f5a28deb04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cc3bcc9f-5d98-4ef9-b7e0-f31bed279ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cc3bcc9f-5d98-4ef9-b7e0-f31bed279ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4926f69f-a401-4b75-848f-409c96e6093d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4926f69f-a401-4b75-848f-409c96e6093d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2632e90d-c0e2-4cb6-bca0-5e5ef1558e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2632e90d-c0e2-4cb6-bca0-5e5ef1558e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_23116c5b-66d2-4702-a2ae-25b6f60b664c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_23116c5b-66d2-4702-a2ae-25b6f60b664c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_be73edd6-ca1f-461c-8bfa-094f57d8d9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7139151-cc8c-4462-bfa9-435bf246690c" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_be73edd6-ca1f-461c-8bfa-094f57d8d9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1781e4dc-f0eb-49f3-b036-6d37e8cb2a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e72e238-97ae-423e-ac11-213af1d0dc77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1781e4dc-f0eb-49f3-b036-6d37e8cb2a79" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e72e238-97ae-423e-ac11-213af1d0dc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6e1b01f8-37e8-4fa9-b1c9-17c0442291a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e72e238-97ae-423e-ac11-213af1d0dc77" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6e1b01f8-37e8-4fa9-b1c9-17c0442291a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6e1b01f8-37e8-4fa9-b1c9-17c0442291a8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_647f42b6-1ba4-47fc-b9e0-cf325336eb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:to="loc_us-gaap_CostOfSalesMember_647f42b6-1ba4-47fc-b9e0-cf325336eb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16d0c4c6-be6a-44b0-b757-9dbf34c807d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16d0c4c6-be6a-44b0-b757-9dbf34c807d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2e695a82-87f9-4b9e-951f-1c3f29e28de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2e695a82-87f9-4b9e-951f-1c3f29e28de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_e5b556d1-2e28-4609-9503-b1e1f19b6654" xlink:href="nktr-20221231.xsd#nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e2e7d22-fa6f-4759-b01d-a70f827a2f4a" xlink:to="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_e5b556d1-2e28-4609-9503-b1e1f19b6654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_41eaa7f4-858c-4573-a25d-ad2d0757c9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e72e238-97ae-423e-ac11-213af1d0dc77" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_41eaa7f4-858c-4573-a25d-ad2d0757c9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_33280e02-afe8-4e70-820e-334ac2bbd9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_41eaa7f4-858c-4573-a25d-ad2d0757c9db" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_33280e02-afe8-4e70-820e-334ac2bbd9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714bf3d4-f7bf-4810-bb2d-33da7265af5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b38cd99-5b85-43d2-b9da-9a9e4c328a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714bf3d4-f7bf-4810-bb2d-33da7265af5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b38cd99-5b85-43d2-b9da-9a9e4c328a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4610f8b7-70b7-4f66-a87c-c731f5cc2bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714bf3d4-f7bf-4810-bb2d-33da7265af5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4610f8b7-70b7-4f66-a87c-c731f5cc2bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_cbbc4b5c-818a-429e-9b82-a83195641781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714bf3d4-f7bf-4810-bb2d-33da7265af5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_cbbc4b5c-818a-429e-9b82-a83195641781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1dd5325a-b141-4f4e-a2d2-35df25a7fb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714bf3d4-f7bf-4810-bb2d-33da7265af5f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1dd5325a-b141-4f4e-a2d2-35df25a7fb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c258f18-2904-4c4a-b207-2ed3f03add7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714bf3d4-f7bf-4810-bb2d-33da7265af5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c258f18-2904-4c4a-b207-2ed3f03add7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5223f91-291c-4d14-bb81-0a189ed9f25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6192a32-7c0a-4a79-94a7-a462f031ecc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5223f91-291c-4d14-bb81-0a189ed9f25e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6192a32-7c0a-4a79-94a7-a462f031ecc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4fa5fe44-ff84-4e69-94a4-4cc8f7496c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6192a32-7c0a-4a79-94a7-a462f031ecc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4fa5fe44-ff84-4e69-94a4-4cc8f7496c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bc54ff2e-1644-4852-8907-14363da87bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6192a32-7c0a-4a79-94a7-a462f031ecc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bc54ff2e-1644-4852-8907-14363da87bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8743aea-4c41-443d-8025-640e36bb82ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6192a32-7c0a-4a79-94a7-a462f031ecc0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8743aea-4c41-443d-8025-640e36bb82ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_df6f784e-f138-4d24-86a3-4ced7f767348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6192a32-7c0a-4a79-94a7-a462f031ecc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_df6f784e-f138-4d24-86a3-4ced7f767348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3c57e003-b54f-45d8-8f32-e4900252433d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b6192a32-7c0a-4a79-94a7-a462f031ecc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3c57e003-b54f-45d8-8f32-e4900252433d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b1573f2-1323-41b6-8760-4f7ccb69f6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5223f91-291c-4d14-bb81-0a189ed9f25e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b1573f2-1323-41b6-8760-4f7ccb69f6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_32f12d1d-6d95-4e53-bcc1-e1e88d5e385d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b1573f2-1323-41b6-8760-4f7ccb69f6e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_32f12d1d-6d95-4e53-bcc1-e1e88d5e385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5ff9c4cf-e85e-4cd3-888f-e64177ae19ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b1573f2-1323-41b6-8760-4f7ccb69f6e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5ff9c4cf-e85e-4cd3-888f-e64177ae19ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ab2f366b-93e0-4b43-99e6-5aa1fc74467f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b1573f2-1323-41b6-8760-4f7ccb69f6e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ab2f366b-93e0-4b43-99e6-5aa1fc74467f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_87eb238a-ff67-40eb-b779-7aec5a68bcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b1573f2-1323-41b6-8760-4f7ccb69f6e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_87eb238a-ff67-40eb-b779-7aec5a68bcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0b6c4563-4c09-4bda-83d9-329b60fdfc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8b1573f2-1323-41b6-8760-4f7ccb69f6e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0b6c4563-4c09-4bda-83d9-329b60fdfc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_fc9dacae-b562-42a1-a7d4-781b7b8a0785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5223f91-291c-4d14-bb81-0a189ed9f25e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_fc9dacae-b562-42a1-a7d4-781b7b8a0785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3fb31ef0-a43b-4867-ad78-179c9ee95824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_fc9dacae-b562-42a1-a7d4-781b7b8a0785" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3fb31ef0-a43b-4867-ad78-179c9ee95824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5281a760-697a-4e47-b3b9-fc285a00d1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_fc9dacae-b562-42a1-a7d4-781b7b8a0785" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5281a760-697a-4e47-b3b9-fc285a00d1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b8c2b660-66d4-46b3-a654-180c0fe7c7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5223f91-291c-4d14-bb81-0a189ed9f25e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b8c2b660-66d4-46b3-a654-180c0fe7c7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_320a7caf-bc4d-4145-a6d0-22bafb43aebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5223f91-291c-4d14-bb81-0a189ed9f25e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_320a7caf-bc4d-4145-a6d0-22bafb43aebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e502c902-4307-4fce-9d68-bacdd1e35678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5223f91-291c-4d14-bb81-0a189ed9f25e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e502c902-4307-4fce-9d68-bacdd1e35678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_020af8f5-2929-4252-a357-3e4f10324bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5223f91-291c-4d14-bb81-0a189ed9f25e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_020af8f5-2929-4252-a357-3e4f10324bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8f244845-01fa-46b1-b772-7e4f43ec752e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa238795-1646-4b86-8ac7-103b22f085b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8f244845-01fa-46b1-b772-7e4f43ec752e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa238795-1646-4b86-8ac7-103b22f085b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8ea5c8a-b01a-4e30-a7dd-eda9047cca58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa238795-1646-4b86-8ac7-103b22f085b2" xlink:to="loc_us-gaap_AwardTypeAxis_b8ea5c8a-b01a-4e30-a7dd-eda9047cca58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9ff64b5-5241-4029-9b75-984fef39e000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b8ea5c8a-b01a-4e30-a7dd-eda9047cca58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9ff64b5-5241-4029-9b75-984fef39e000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f4c9e396-cce5-45b4-b271-52c62d925da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9ff64b5-5241-4029-9b75-984fef39e000" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f4c9e396-cce5-45b4-b271-52c62d925da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b0f683c-d60c-492c-b8c7-494f5e541ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa238795-1646-4b86-8ac7-103b22f085b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b0f683c-d60c-492c-b8c7-494f5e541ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b0f683c-d60c-492c-b8c7-494f5e541ee9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8242697f-e884-4a4b-9616-75cf56ef74bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8242697f-e884-4a4b-9616-75cf56ef74bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3359ac47-b523-4551-a0a8-1b3444a20f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3359ac47-b523-4551-a0a8-1b3444a20f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f17d09b7-ec3c-4e5e-b3c8-b598059478ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f17d09b7-ec3c-4e5e-b3c8-b598059478ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_09d8b9e1-6823-47fe-8693-44c2c918228b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_09d8b9e1-6823-47fe-8693-44c2c918228b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65b7eb02-5e9e-4625-9ad3-0e04e26280d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2fd2b5c-9e7f-4c17-87cd-7e0ded488d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65b7eb02-5e9e-4625-9ad3-0e04e26280d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b0f683c-d60c-492c-b8c7-494f5e541ee9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d3f1bfc7-2e00-488f-aafa-023b3167759a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d3f1bfc7-2e00-488f-aafa-023b3167759a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e81fcee-4152-48a8-9cc6-16e9ae65a4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e81fcee-4152-48a8-9cc6-16e9ae65a4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bed80d57-73a8-46fb-91b5-bd042574c25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bed80d57-73a8-46fb-91b5-bd042574c25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2473e392-5403-4580-a579-1cd6180d3420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2473e392-5403-4580-a579-1cd6180d3420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5bb1e254-9e6a-49bc-ab04-0acf4537f3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d9db47c0-678d-4eed-9644-966d07dcadca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5bb1e254-9e6a-49bc-ab04-0acf4537f3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_afae4671-4e35-487d-928d-c82c61ffb107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_effb2e6a-30ad-474a-8eba-e7376713a31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afae4671-4e35-487d-928d-c82c61ffb107" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_effb2e6a-30ad-474a-8eba-e7376713a31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_335cce8d-7734-4d22-b11e-8c2a9620534e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afae4671-4e35-487d-928d-c82c61ffb107" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_335cce8d-7734-4d22-b11e-8c2a9620534e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9fcf5350-77d3-4520-8922-43d4482e88a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afae4671-4e35-487d-928d-c82c61ffb107" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9fcf5350-77d3-4520-8922-43d4482e88a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cbe9a426-9054-40ce-bc6d-e3440eac612d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ebfc84ee-ac61-44b5-b613-634195185450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cbe9a426-9054-40ce-bc6d-e3440eac612d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ebfc84ee-ac61-44b5-b613-634195185450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6348fefd-8d8e-4e98-84dc-3f0629156040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ebfc84ee-ac61-44b5-b613-634195185450" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6348fefd-8d8e-4e98-84dc-3f0629156040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d9020cc5-c7ab-4b37-9397-ad1322b12624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ebfc84ee-ac61-44b5-b613-634195185450" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d9020cc5-c7ab-4b37-9397-ad1322b12624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3567710e-31bd-4924-bedd-74e50bf5c078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ebfc84ee-ac61-44b5-b613-634195185450" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3567710e-31bd-4924-bedd-74e50bf5c078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7db747ad-6329-4020-88e1-287c355cdfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ebfc84ee-ac61-44b5-b613-634195185450" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7db747ad-6329-4020-88e1-287c355cdfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_01b84c17-7466-4a59-a24a-4a7e743c82bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cbe9a426-9054-40ce-bc6d-e3440eac612d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_01b84c17-7466-4a59-a24a-4a7e743c82bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_858550b4-da15-4090-8943-ffd67bfd2175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_01b84c17-7466-4a59-a24a-4a7e743c82bc" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_858550b4-da15-4090-8943-ffd67bfd2175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e5478fdd-3560-4927-a5ef-00a745fccc58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_01b84c17-7466-4a59-a24a-4a7e743c82bc" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e5478fdd-3560-4927-a5ef-00a745fccc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_fc02811b-efa9-40c2-a774-e1f6be025a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_01b84c17-7466-4a59-a24a-4a7e743c82bc" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_fc02811b-efa9-40c2-a774-e1f6be025a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e34ddb2-ecb3-4fb1-a69a-b7b612e1efdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_01b84c17-7466-4a59-a24a-4a7e743c82bc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e34ddb2-ecb3-4fb1-a69a-b7b612e1efdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92d887a6-b758-4b64-aea3-e757f0c53c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cbe9a426-9054-40ce-bc6d-e3440eac612d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92d887a6-b758-4b64-aea3-e757f0c53c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d3e94dc8-f862-424a-a9e3-fd947d34dc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d3e94dc8-f862-424a-a9e3-fd947d34dc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_9dd659e9-42f8-4155-bde2-0af576639653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_9dd659e9-42f8-4155-bde2-0af576639653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6cc043ff-030c-4c79-9318-ab35358cd28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6cc043ff-030c-4c79-9318-ab35358cd28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards_d2ff3363-4850-436b-bf70-ba8e58e43a0b" xlink:href="nktr-20221231.xsd#nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards_d2ff3363-4850-436b-bf70-ba8e58e43a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_770f3f79-2aaa-4387-955c-9c551e06f68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_770f3f79-2aaa-4387-955c-9c551e06f68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_bc362bc0-e59a-40b5-a8a9-9cf924ca81e8" xlink:href="nktr-20221231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_bc362bc0-e59a-40b5-a8a9-9cf924ca81e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_e2d82c3c-ff9e-4d1c-a630-8dd608b74054" xlink:href="nktr-20221231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_e2d82c3c-ff9e-4d1c-a630-8dd608b74054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_0dedfcc5-13c7-4511-bc4d-10e74d88f321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_0dedfcc5-13c7-4511-bc4d-10e74d88f321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_79d92028-a7fd-43aa-9ba9-3a5502f19b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_79d92028-a7fd-43aa-9ba9-3a5502f19b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c636bef6-cafd-41cc-8f42-985ac56fa78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e36ba07-ed5b-4501-873a-2580c76c1c68" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c636bef6-cafd-41cc-8f42-985ac56fa78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d85a1c1e-2ef8-4e58-a1d8-a2306d43755f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d85a1c1e-2ef8-4e58-a1d8-a2306d43755f" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_15db5c45-cf2e-41a5-825e-e72da36205a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_15db5c45-cf2e-41a5-825e-e72da36205a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_56f66cd0-3ae4-4873-a053-e02f0ff65b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_56f66cd0-3ae4-4873-a053-e02f0ff65b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_cc1e2870-bea6-413d-a5e6-3f1e923a2303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_cc1e2870-bea6-413d-a5e6-3f1e923a2303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLeaseLiability_5e5805a7-5c35-4275-ac03-d8dd7ca22522" xlink:href="nktr-20221231.xsd#nktr_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_nktr_DeferredTaxAssetsLeaseLiability_5e5805a7-5c35-4275-ac03-d8dd7ca22522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9531e9f0-71ab-4c59-9d7f-23f32aff7530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9531e9f0-71ab-4c59-9d7f-23f32aff7530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_af78cb87-acd4-45ac-8218-63f3d839b2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_af78cb87-acd4-45ac-8218-63f3d839b2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_116319ab-b1b7-4bf4-8a92-db8ced721f2b" xlink:href="nktr-20221231.xsd#nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_116319ab-b1b7-4bf4-8a92-db8ced721f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_666b0191-c69a-4e3a-93b4-24d0dfaf671c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_666b0191-c69a-4e3a-93b4-24d0dfaf671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4ee91e91-a467-4e21-91a4-8b5bb3724873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4ee91e91-a467-4e21-91a4-8b5bb3724873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_97cdfb0b-a936-49a7-845e-73a6cc5e1bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_97cdfb0b-a936-49a7-845e-73a6cc5e1bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8bcd7034-6ab3-48be-bd78-46b85603a124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a7aac24e-a7d3-45c0-8d26-ded34aa676c9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_8bcd7034-6ab3-48be-bd78-46b85603a124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_85606da1-6e95-4ec8-bbe4-5808002e9b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d85a1c1e-2ef8-4e58-a1d8-a2306d43755f" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_85606da1-6e95-4ec8-bbe4-5808002e9b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2a4a1870-1f43-499e-acd1-079ef112e383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_85606da1-6e95-4ec8-bbe4-5808002e9b13" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2a4a1870-1f43-499e-acd1-079ef112e383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_258926ae-1767-4e1a-a353-5b14eddeda98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_85606da1-6e95-4ec8-bbe4-5808002e9b13" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_258926ae-1767-4e1a-a353-5b14eddeda98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_f9dff385-4f97-452a-86ef-4deba9741867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_85606da1-6e95-4ec8-bbe4-5808002e9b13" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_f9dff385-4f97-452a-86ef-4deba9741867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8fc4f478-c607-4959-b278-bc681ee98a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_85606da1-6e95-4ec8-bbe4-5808002e9b13" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8fc4f478-c607-4959-b278-bc681ee98a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_6239e298-1e99-480e-b089-ba385fc8bfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_85606da1-6e95-4ec8-bbe4-5808002e9b13" xlink:to="loc_us-gaap_DeferredTaxLiabilities_6239e298-1e99-480e-b089-ba385fc8bfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f2674be1-45c2-4eb9-bdb5-fe7b3b8f0a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d85a1c1e-2ef8-4e58-a1d8-a2306d43755f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f2674be1-45c2-4eb9-bdb5-fe7b3b8f0a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b8759cbe-2b0f-4700-810d-e0389f2092ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureTable_cb0fa5cc-93f1-4f10-bd31-61a441f85e2f" xlink:href="nktr-20221231.xsd#nktr_IncomeTaxesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b8759cbe-2b0f-4700-810d-e0389f2092ad" xlink:to="loc_nktr_IncomeTaxesDisclosureTable_cb0fa5cc-93f1-4f10-bd31-61a441f85e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b6b843a4-0a0f-46c2-bd73-7fcac964b7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureTable_cb0fa5cc-93f1-4f10-bd31-61a441f85e2f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b6b843a4-0a0f-46c2-bd73-7fcac964b7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bce76e04-5186-48c5-bdec-2f45546a877e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b6b843a4-0a0f-46c2-bd73-7fcac964b7dc" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bce76e04-5186-48c5-bdec-2f45546a877e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6a089b5d-857a-430b-abaf-d73f4a67ca4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bce76e04-5186-48c5-bdec-2f45546a877e" xlink:to="loc_us-gaap_DomesticCountryMember_6a089b5d-857a-430b-abaf-d73f4a67ca4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_7fe6aaee-8422-45d5-8641-594506195600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bce76e04-5186-48c5-bdec-2f45546a877e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_7fe6aaee-8422-45d5-8641-594506195600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:href="nktr-20221231.xsd#nktr_IncomeTaxesDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureTable_cb0fa5cc-93f1-4f10-bd31-61a441f85e2f" xlink:to="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1d91a69e-6808-439f-9716-c0b53c28f3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1d91a69e-6808-439f-9716-c0b53c28f3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ee3b524b-7bbd-4169-81b4-e861c349d8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ee3b524b-7bbd-4169-81b4-e861c349d8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OperatingLossCarryforwardsSubjectToExpiration_95319bbc-f52e-48dd-94ca-9e3a328f2475" xlink:href="nktr-20221231.xsd#nktr_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_nktr_OperatingLossCarryforwardsSubjectToExpiration_95319bbc-f52e-48dd-94ca-9e3a328f2475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7c7c246d-89e4-4988-9de9-df5748087c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7c7c246d-89e4-4988-9de9-df5748087c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_4c1e87a5-72b7-4d34-aa4f-3cedeb66b829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_4c1e87a5-72b7-4d34-aa4f-3cedeb66b829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_57f5adc2-77aa-4a4c-93e5-f8aa953a1b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_57f5adc2-77aa-4a4c-93e5-f8aa953a1b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_8cf0823d-e9b8-4f36-81b8-71033ecad327" xlink:href="nktr-20221231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_4dbde57e-d43f-4648-b497-2a4341df79dc" xlink:to="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_8cf0823d-e9b8-4f36-81b8-71033ecad327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_66428d96-5adc-49d2-a76c-801cdeb50871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2daf0cb7-8d1a-47c6-ab7e-4398691f708c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66428d96-5adc-49d2-a76c-801cdeb50871" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2daf0cb7-8d1a-47c6-ab7e-4398691f708c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_75db40b6-1bd0-41d1-9fc5-b37888e1c60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2daf0cb7-8d1a-47c6-ab7e-4398691f708c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_75db40b6-1bd0-41d1-9fc5-b37888e1c60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract_3a94006f-5794-42ce-80db-74b33d429275" xlink:href="nktr-20221231.xsd#nktr_TaxPositionsRelatedToCurrentYearAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2daf0cb7-8d1a-47c6-ab7e-4398691f708c" xlink:to="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract_3a94006f-5794-42ce-80db-74b33d429275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_00c76d67-80f7-45c4-a20c-71ca5c565175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract_3a94006f-5794-42ce-80db-74b33d429275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_00c76d67-80f7-45c4-a20c-71ca5c565175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_de70b8f7-9a99-49fa-9105-49cd21f173dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract_3a94006f-5794-42ce-80db-74b33d429275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_de70b8f7-9a99-49fa-9105-49cd21f173dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_330ddab1-1471-4b6b-81a1-0deb02d38a52" xlink:href="nktr-20221231.xsd#nktr_TaxPositionsRelatedToPriorYearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2daf0cb7-8d1a-47c6-ab7e-4398691f708c" xlink:to="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_330ddab1-1471-4b6b-81a1-0deb02d38a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5c364c25-0748-4352-9f55-c8cd191fb5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_330ddab1-1471-4b6b-81a1-0deb02d38a52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5c364c25-0748-4352-9f55-c8cd191fb5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f2cbff13-6e6b-4764-90d4-5eb36638673b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_330ddab1-1471-4b6b-81a1-0deb02d38a52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f2cbff13-6e6b-4764-90d4-5eb36638673b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_16c0e5b7-2450-46e5-aa96-0b0eb049a79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_330ddab1-1471-4b6b-81a1-0deb02d38a52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_16c0e5b7-2450-46e5-aa96-0b0eb049a79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_fcf073d0-be11-47c7-ae22-3af03e0907e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_330ddab1-1471-4b6b-81a1-0deb02d38a52" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_fcf073d0-be11-47c7-ae22-3af03e0907e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e3eda419-c40b-4f46-a801-2b710f69cb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2daf0cb7-8d1a-47c6-ab7e-4398691f708c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e3eda419-c40b-4f46-a801-2b710f69cb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20221231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8a23247b-0651-456c-9ec4-0752ab373c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8a23247b-0651-456c-9ec4-0752ab373c7b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_54069b3a-3aa4-4ab6-a2c1-15b6721e238b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_54069b3a-3aa4-4ab6-a2c1-15b6721e238b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07efec40-a304-4603-84c7-5a4732fa5321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_54069b3a-3aa4-4ab6-a2c1-15b6721e238b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07efec40-a304-4603-84c7-5a4732fa5321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a40603e9-421f-41d0-b12c-e16480df383b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07efec40-a304-4603-84c7-5a4732fa5321" xlink:to="loc_us-gaap_SalesRevenueNetMember_a40603e9-421f-41d0-b12c-e16480df383b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_7855013d-65a6-4a33-b6de-fd0ba250e7df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07efec40-a304-4603-84c7-5a4732fa5321" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_7855013d-65a6-4a33-b6de-fd0ba250e7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7af07ff8-f396-41d4-8cd8-2b70d04a0ae8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:to="loc_srt_MajorCustomersAxis_7af07ff8-f396-41d4-8cd8-2b70d04a0ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7af07ff8-f396-41d4-8cd8-2b70d04a0ae8" xlink:to="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UCBPharmaMember_bf3cf7ca-20f0-4db7-b490-ac9b9eb6fcc4" xlink:href="nktr-20221231.xsd#nktr_UCBPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_UCBPharmaMember_bf3cf7ca-20f0-4db7-b490-ac9b9eb6fcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_51aaf3cb-e32d-4f0b-b423-3a41ed912f70" xlink:href="nktr-20221231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_51aaf3cb-e32d-4f0b-b423-3a41ed912f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_52300469-5c4e-4622-aeda-b236b78f813c" xlink:href="nktr-20221231.xsd#nktr_AstraZenecaAbMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_AstraZenecaAbMember_52300469-5c4e-4622-aeda-b236b78f813c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PfizerMember_18aab4b0-20ea-4229-9586-0ebfa5f24595" xlink:href="nktr-20221231.xsd#nktr_PfizerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_PfizerMember_18aab4b0-20ea-4229-9586-0ebfa5f24595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_2d3bf5a9-7a33-4f59-9ee5-f85359774e15" xlink:href="nktr-20221231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c70ce75c-ee08-4e19-b2cd-67b7af17f27b" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_2d3bf5a9-7a33-4f59-9ee5-f85359774e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_418027ea-0f0a-4696-b382-08248f57213d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_418027ea-0f0a-4696-b382-08248f57213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e2f927c4-ff03-4f7c-85c4-cc824264b96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_418027ea-0f0a-4696-b382-08248f57213d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e2f927c4-ff03-4f7c-85c4-cc824264b96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_63d51ac5-1771-4b10-98ab-20bd6624b840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e2f927c4-ff03-4f7c-85c4-cc824264b96f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_63d51ac5-1771-4b10-98ab-20bd6624b840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_bda79080-c6d8-4f25-a4e6-ca0f42e671cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e2f927c4-ff03-4f7c-85c4-cc824264b96f" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_bda79080-c6d8-4f25-a4e6-ca0f42e671cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a2555d73-4ba8-4e13-ad6a-f0d7edf1fd8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:to="loc_srt_StatementGeographicalAxis_a2555d73-4ba8-4e13-ad6a-f0d7edf1fd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c524e8d1-bce7-437e-885b-097a518c1907" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a2555d73-4ba8-4e13-ad6a-f0d7edf1fd8f" xlink:to="loc_srt_SegmentGeographicalDomain_c524e8d1-bce7-437e-885b-097a518c1907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_53a42eaa-55d4-40d3-92fb-1befa2fd4f93" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c524e8d1-bce7-437e-885b-097a518c1907" xlink:to="loc_country_US_53a42eaa-55d4-40d3-92fb-1befa2fd4f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84c3821b-7163-4768-9d68-ccd730cad413" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfOperatingBusinessSegment_0029422d-6fdf-4dbb-aa3c-8acb0aa235b4" xlink:href="nktr-20221231.xsd#nktr_NumberOfOperatingBusinessSegment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:to="loc_nktr_NumberOfOperatingBusinessSegment_0029422d-6fdf-4dbb-aa3c-8acb0aa235b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e0829c03-95ec-4690-b9d3-76fdb39f0348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e0829c03-95ec-4690-b9d3-76fdb39f0348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_36210071-3bfd-42a0-8ea1-fef262005266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_feb03bdb-fc99-4436-902e-b589ffeb4055" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_36210071-3bfd-42a0-8ea1-fef262005266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="simple" xlink:href="nktr-20221231.xsd#SegmentReportingRevenuebyGeographicAreaDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a22d852b-e741-452b-a734-42e968c52ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9c25d3bd-d7df-4c5d-ae77-70e445684ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a22d852b-e741-452b-a734-42e968c52ebb" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9c25d3bd-d7df-4c5d-ae77-70e445684ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_96e86926-39e5-494d-8b5c-dec09c5075f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9c25d3bd-d7df-4c5d-ae77-70e445684ba4" xlink:to="loc_srt_StatementGeographicalAxis_96e86926-39e5-494d-8b5c-dec09c5075f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5436af3f-5899-47b5-8e8b-500573a47908" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_96e86926-39e5-494d-8b5c-dec09c5075f3" xlink:to="loc_srt_SegmentGeographicalDomain_5436af3f-5899-47b5-8e8b-500573a47908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_787e8d65-af13-4827-9d81-9f01e0c900f2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5436af3f-5899-47b5-8e8b-500573a47908" xlink:to="loc_country_US_787e8d65-af13-4827-9d81-9f01e0c900f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_80640532-2918-4583-b6ac-46713b6001e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5436af3f-5899-47b5-8e8b-500573a47908" xlink:to="loc_us-gaap_NonUsMember_80640532-2918-4583-b6ac-46713b6001e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_405ade8b-d571-4016-b128-b06476b53123" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9c25d3bd-d7df-4c5d-ae77-70e445684ba4" xlink:to="loc_srt_ConsolidationItemsAxis_405ade8b-d571-4016-b128-b06476b53123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c9f96ecc-1c76-42d0-a71a-4fb70e2c6a68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_405ade8b-d571-4016-b128-b06476b53123" xlink:to="loc_srt_ConsolidationItemsDomain_c9f96ecc-1c76-42d0-a71a-4fb70e2c6a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_aa7b0641-0996-46e4-955e-d8fb7c5505a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c9f96ecc-1c76-42d0-a71a-4fb70e2c6a68" xlink:to="loc_srt_ReportableGeographicalComponentsMember_aa7b0641-0996-46e4-955e-d8fb7c5505a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_49aa6714-81bc-41e9-ac04-cf92f028c186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9c25d3bd-d7df-4c5d-ae77-70e445684ba4" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_49aa6714-81bc-41e9-ac04-cf92f028c186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_a6a6125b-6084-490f-ad38-68915695b214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_49aa6714-81bc-41e9-ac04-cf92f028c186" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_a6a6125b-6084-490f-ad38-68915695b214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb3854bf-98fd-4492-8a60-e015889a2129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_a6a6125b-6084-490f-ad38-68915695b214" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb3854bf-98fd-4492-8a60-e015889a2129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>nktr-20221231_g1.jpg
<TEXT>
begin 644 nktr-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ?I"84# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_AH3X6?]%+\'_P#@^M?_ (Y0!Z!17"6OQZ^&=]<+!;?$7PG<3-G;'%KEJS'
MR< /Z"NXAF2XB26)UDB=0RNAR&!Y!![B@!]%%5-4U:RT/3;G4-2O+?3["V0R
MSW5U*L442#JS,Q 4#U)H MT5P=O\?/AC>7$4$'Q&\)33RL$CCCURU9G8G
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M_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\
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M .#ZU_\ CE'_  T)\+/^BE^#_P#P?6O_ ,<H ] HKS__ (:$^%G_ $4OP?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'S/^W=^V-8_LB_#"*]M88-2\:ZTSV^BZ;.3Y>5
M \RXEQSY<>Y> 069E' )(_$RWM_C#^VI\5BD?]L_$3QA=@N=[Y2VBW<G)(CM
MX02!_"@) [UZ[_P50^)ES\0OVQ/%%BT[2:;X9AM]&LXSP$VQB2;CU\Z27GN
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M^ U^?/\ P18^)G_"/_'+Q=X*GDV6_B32!=0J3]ZXM7RH _ZYS3'_ (!7J?\
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M_:CXYU1&EL]"T-;LPK]Z9Q&HCC'H7<JN>VZOYMO%G_(U:S_U^S?^C&K^@?\
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M )'[X6?]@R]_]&QU\;? +]CGXI?M-:/JNI^ -%MM4L]+G6VNGGOX;<J[+N
MD8$\>E?9/_!<'_D?OA9_V#+W_P!&QUM?\$>OC)X!^&7PW^(5KXP\<>&_"=S=
M:M!)!#KFKV]F\J"$@L@E=2P!XR* /G#_ (=/_M)?]"AI_P#X.[3_ ..5ZI^R
MO_P3;^//PO\ VBOA]XL\0^&+*TT31]7AN[R:/5K:1DC4\D*KDGZ 5^H'_#6/
MP0_Z+)\/_P#PJ+'_ ..UU7@7XL>"/BA]N_X0WQEX?\6_8=GVO^PM4@O?L^_=
ML\SRG;;NV/C.,[6QT- '5T444 >4_M6>./\ A7/[-?Q-\1"3RI[/P_>?9WSC
M$[Q-'%_Y$=*_G0\!?#GQ3\4M>_L3PAH&H>)-7\II_L6FV[32^6N-S;5&<#(Y
M]Q7[7_\ !7CQO_PBO['E_IBR;)/$>L66F!0>2JLURWX?Z, ?KCO7YF_L"?M/
M>$?V2_B%XG\:>)-'U/7+ZXTC^S-.M-.$8&YYHY)&=W8; !$HR Q^;&,9- '$
M_P##%/Q[_P"B0^,/_!3+_A7Z8_\ !('X-^.O@_X;^)L/C;PGJWA66^N[![5-
M5M7@,RHDX8KN'.-RY^HJKX!_X+6?#C7-8AM/%7@K7?"UI*X3[?;S1W\<0/\
M%(H"/@?["L?0&OT \(^+M%\>>&M.\0^'=3MM8T3481/:7UHX>.5#W!_,$'D$
M$'!% &O7/?$+P%HGQ1\#ZWX2\1V:WVB:Q:O:74#=2C#&5/9@<,&Z@@$=*Z&B
M@#^:K]HKX'>(?V7_ (U:SX,U.25;G39UN-/U*/,?VFW)W07"$="0.<'Y65AG
M*U^X7[ W[4D/[4GP'T_5+V=#XPT;;IVO0C )F5?DGQV651N] V]1]VN%_P""
MG'[(_P#PT5\'6\2>'[+SO'GA.-[FS6)<R7MK]Z:VXY9L#>@Y.Y2H^^:_*_\
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M/@_QI8Q:=KUO%'/)!#<).H21=RG>A(Y!]:_IOK\(?^"MG_)Z7B#_ +!FG_\
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MW^U>'X&DU/4X6!*RP0*7\MO]EW\M#[.:_H?@@CM88X88UBAC4(D<:A550,
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MR027*P37$<"E$&6.YR!W]:^A/^'3_P"TE_T*&G_^#NT_^.5>_P""25];:?\
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MDU^&W_!'K_D\!/\ L7[[^<5?N30!^>O_  6P_P"3;?!O_8VP_P#I'=5\U?\
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M^UO%K%O%-]@T31KN>ZF13Y8\Q1$B,?4ER0.^P^AK[^_X*V?\F6^(/^PGI_\
MZ/% 'XD?#'XC:Y\(_B!H/C+PW=&SUO1;M+NVDYVDCJC#NC*2K+W5B.]?T??L
M_P#QLT/]H;X2>'O'>@-BTU2 &:V+9>UN%^66!_='!&>XP1P17\W7A7P'K7C2
MQ\276CV;7D?A_3&UC4 G+1VJSPPM(!W"M.A/HNX] :^RO^"5'[67_"D_BT?
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M::?]EL;N1  ;BUPH#1MZ#.U@RY. 3]&T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJE]*([9EE;<]J[L<(WF,S(3PV]ER"%#?JM]HB,'GB1##MW^9N&W;C.<^F.]
M'C/[:E]!IW[)'Q>EN&"QMX8OH06_OO"R(/\ OIEK\&/V2[::\_:F^#\<#%9?
M^$OTE@P&=H%Y$2<>P!K] _\ @JU^W!X9U[P7+\&_ 6L6^N7%Y<))XAU&PE$E
MO#'&P=+99%.'<R*I?!(4)M/)(7P+_@DG\#;SXE?M-6OB^:V8^'_!<#WTTS(3
M&]U(C1V\6?[V6>7_ +8^] 'W9_P6%_Y,_?\ [&"Q_E+7QE_P1]\+V?CCXG?%
M;PYJ"[K#6/!5QI]PN,YCEGBC<?DQK[-_X+"_\F?O_P!C!8_REKY*_P"")?\
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M'8I'YC?2<5\I? ']@GXM_M*>")?%G@W3=/?18[Q[$3:A>K;F21%5F*@CE1O
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M9G\2:#9^3X%\6R275HL2XCLKK[T]MQPHR=Z#CY6*C[AKG/\ @EQ_R?9\,O\
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MN5=EW  2,">/2OLG_@N#_P C]\+/^P9>_P#HV.O2O^"(?_)+/B7_ -AFW_\
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MV9+$X 'GIS0!]@?\.;?CW_S^>#__  :2_P#QBC_AS;\>_P#G\\'_ /@TE_\
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M9/'O@K5/#EO=-LANKB,/;R/C.P2H63=CG;G/!XKZ*_X)#_\ )Y.F_P#8&O\
M_P! 6OVG^+'PM\._&GX>ZUX,\56*W^B:M 89D.-R'JLB'^%T8!E;L0* /Y\_
MV3_V<])_:9^(<7A.^^(ND>!+V<JMK'J%M+-->MW6$#;&SCLK2*QSP#S7[K_L
MQ?LL^"?V4O K>'?"-O++<73)-J>K79#7-_,HP&<CA5&3M1>%R>I+$_@3^T-\
M#?$G[+_QDU;P9K+R)>:;,)[#4H08Q=6Y.8;B,YXR!V/RLK+G*FOV7_X)M_MB
M']ISX3MI/B*\63XA>&42#4BQ :^@/$5V!W)QM?'1QG@.HH R_P#@KS_R9MJ/
M_8:L/_0VK\=?V??@#XF_:4^(L/@KPE)81ZQ+;2W2MJ4S11;(P"WS*K'//I7[
M%?\ !7G_ ),VU'_L-6'_ *&U?GS_ ,$DKZVT_P#;#TZ:ZN(K:$:-?#S)G"+G
M8O&30!N?\.;?CW_S^>#_ /P:2_\ QBC_ (<V_'O_ )_/!_\ X-)?_C%?M3_P
MEFA_]!G3_P#P*C_QH_X2S0_^@SI__@5'_C0!Q_[.7@#4_A7\!_ /@_6FMWU;
M0]&MK"Z:U<O$9(XPK;6(!(R.N!7HU5;'5+/5%9K.[@NU4X9H)%< ^AP:M4 ?
MCM_P6X_Y+1\//^Q?D_\ 2EZ]J_X(C_\ )%_B'_V,$?\ Z3)7BO\ P6X_Y+1\
M//\ L7Y/_2EZ]J_X(C_\D7^(?_8P1_\ I,E 'Z/U\5_\%>%+?L:ZF0"0NLV!
M/M\YK[4KY8_X*=>#[GQA^Q5\0$LXFFN=.6UU,(N?N0W,;2L?98O,;\* /S;_
M ."/<BK^V%$&(!;0+X+[G,9_D#7[EU_.U^P7\<-*_9\_:@\)^*M?D,'A]O.T
M_4)PI/D131E/-('.$<HQQSA3CFOZ%]$US3?$VDVNJ:1J%KJNF72"6WO+*99H
M9D/1D=20P]P: /@/_@MA_P FV^#?^QMA_P#2.ZKYL_X(GJQ_:/\ &;;3M'A.
M4%L< F\M<#]#^5>C?\%GOCQX7\0:-X0^&6C:M:ZKK=AJ3ZKJD5I()!9;8FBC
MCD(X#MYLAV]0%!(&X9Y[_@B'X5NKCXC?$OQ)Y;"RM-*M].,F.#)-,9 ![@0'
M\QZT ?4?_!7G_DS;4?\ L-6'_H;5^+WPE^#OC#XY^+E\,>!]&;7==:WDNELU
MN(H28XQER&E=5) [9R>P-?M#_P %>?\ DS;4?^PU8?\ H;5\ ?\ !(?_ )/)
MTW_L#7__ * M 'SK\7/V:_B?\!UM9/'O@K5/#EO=-LANKB,/;R/C.P2H63=C
MG;G/!XKI?V3_ -G/2?VF?B'%X3OOB+I'@2]G*K:QZA;2S37K=UA VQLX[*TB
ML<\ \U_09\6/A;X=^-/P]UKP9XJL5O\ 1-6@,,R'&Y#U61#_  NC ,K=B!7\
MZG[0WP-\2?LO_&35O!FLO(EYILPGL-2A!C%U;DYAN(SGC('8_*RLN<J: /WV
M_9B_99\$_LI>!6\.^$;>66XNF2;4]6NR&N;^91@,Y'"J,G:B\+D]26)\7_X*
MV?\ )EOB#_L)Z?\ ^CQ5G_@FW^V(?VG/A.VD^(KQ9/B%X91(-2+$!KZ \178
M'<G&U\='&> ZBJW_  5L_P"3+?$'_83T_P#]'B@#X6_X(T:7::W^TIXUT[4+
M:*\L+SP->V]Q;3*&CEC>\L59&!Z@@D$>]>&_MO?LPWO[*?QTU'0(5F;PS?$Z
MAH%ZV3OM68_NRW=XF^1NYPK8 85[Y_P14_Y.F\4_]B9=?^EUC7Z,?MZ?LKV_
M[5'P-OM*M(8QXQT?=J&@7+8!\\+\\!/9)5&T]@P1C]V@#X#^*G[6 _:4_P""
M9%Y8:U>"7QUX6UC3;'5/,;]Y=1980W7OO"E6/]]&/ 85F_\ !$__ ).2\9?]
MBE-_Z66M? 4S:AHLNH:=+]HL9&)MKRU?<A)1P2DB^SH#@]"OM7W[_P $3_\
MDY+QE_V*4W_I9:T ?LKJ>F6>M:=<Z?J-I!?V%U&T,]K=1K)%+&PPR.K AE()
M!!X-12:!IDNA'1)-.M9-':V^QMI[PJT!@V[/*,9&TIM^7;C&.*OT4 16UM#9
MV\5O;Q)!!$@CCBC4*J*!@* .  .U2T44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-_UTV#W/2OV1^ WP'\(_LX_#FQ\&>#+%K73;<F6:>9M\]W,P&^:5\#<[8'8
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M'^^BFN/7]FO]H#QG<PV<OPT^(6HM%)Y"_;=&O?+A8?PEI$VIC/<C&:_I"HH
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M7J)G)B9E^>,_[2-N0^ZF@#KZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M[Q'_ (:2_;]5?[8/P.T,Z?CS?L/V%]^W'39]L\W=[8SGMVH _2JBOC_]C?\
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M@2YM+RU</'-&PRK*1U!!H TJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBO"OVR?C1XY^ _PCA\2?#WPC_PFFO/J<-HVF_9)[G$+I(6DV0D-P449Z?-
M0![K17CWB3]HBP^%?[,^G?%GXAV5UI:KHUC?:CIUG;,9H[FX6(>0D;D$'S9
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M/G[2GPJ^)DG[.WBCP3J7A>]M5N+FU@GF^TP)<K* [&),!090<Y!#D=*_82@
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MAKXDFCBMYI;F2=(87E$7G0&3YX6B)!:'E""<9)#CUC_@MI_R0+P+_P!C,/\
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MHQ'%#&H 5$4<*H   '3%?EMI^/A__P %L[K^TQY5OK@;[+/+R&\[21LVD_\
M316C^O'2OU3H \Q_:0^ NB?M*?!_7O >MLELM_%NM-0, F>PN5YBG1<C)4]0
M&7<I9<@,:H_LL_ )OV9O@[IO@ >)[OQ7;V$TLD%W=P+"8UD;>8U0,V%#EV&2
M?OFO4-9UBR\/:/?:KJ5S'9Z=8P27-S<2G"11(I9W)] H)_"O'_'GQW\->-_V
M9_B;XQ^&WBC3?$QTKPYJ4\5QI-RLIAN([221%< Y1\A3M8 X(XH ^<OB9_P4
M<\7>,OB[>_#+]FSX>1_$C7=/>2.\UC4'(L R<,4VO&!&&^7S9)$4D84$%6.-
MJ/[?7Q[_ &;=>TD?M'_!VRTWPIJ$GD+KOA23S!&W7_GO+&S8S^[+1L0"1G'-
M[_@B[X/TO2_V</$GB.&"(ZQJWB&6WN;E?O\ DP0Q>5$?96DE8?\ 74U]*_MN
M>$=+\:?LE_%>SU6"&:&V\.WFHPM,,B.>WA::)QZ$/&O3_P"M0!VWBCXG6D'P
M3UGX@^&I[;6+*'0)]<TZ;),-RJV[31DXP=K8&>AY[5\%?#G_ (*>?%OXY>$;
M/1_AE\([3Q9\3V:2;4!")4TG3;??MAWEI%)=^2<RHHXP2<A=_P#82\27>O?\
M$N?&MM=-(ZZ3I_B"Q@:0D_N_L[R@#/8&9A^%6/\ @BKH-I9_LV^+-72)1?7W
MBF:&68+\QCBM;<QJ3W ,DA_X&: ,/PG_ ,%+?B7\%_BU%X(_:@\ 6'@R"XMV
MGCU31XI"8UPVU]HEF2=&92FZ)A@^N#5WQ'^VE^UIXNT27Q]\-_@%90_#-8S=
MVLFN*TVH7=L%8B7RDN8W*LOS@1QMVPS@\\A_P6*T*TUOXK_L]VEQ&"FH7-Y9
MSMW:,SV8Q_X^WYU^H-O;Q6L$<$$:0PQJ$2.-0JJH&  !T ':@#YZ_8C_ &OK
M#]L#X8W>N#3!H7B'2;E;/5=-24R1JY0,DL;$ ^6XW8!Y!5AS@,?./VQ/V^KS
M]D_X\^"_#%[H]E>>#]3TLZEJ5WY<CWJ8DF0)" X7),:@;AC+<D#IY'_P2#1;
M?XE?M,V\0$<$>L6 2->%4>=J0X';@#\JH?\ !0#P=IOQ _X*+?L[^']8ACN=
M*OH+-+JWF^Y-&+Z9FC/LP&W\: .N;]J/]M;Q7X?/C[PK\"?#MOX(EC:[L],U
M"1I=3FM>H?8+F.1FV@[0L2EMV0C K7T+^QK^V5X?_:Z\'7]S;V#^'?%FC2+#
MK&@32>8T!;.R1&P"T;;6'(!4J01T+?0_3@<"OR_^"MNGPY_X+*?$?0="58-*
MU>TN)+N&W&(\S6EO>N2.Q\[]2?6@#Z)_;$_;]T[]G/Q'I_@'PEX<G\??%'4T
M0V^C6VXQVV\XC\W8"[._58D&2.25!7=Y+XB_:R_;1^$^B2>,O'?P&\.3^#80
M)[N'2+@F[M8<\E]EU,R_+R6,9"]6VXQ7&_L=:;#\0_\ @JE\>O$>OPI<ZEX?
MEU2/3A-RT)2[CLXY%^EN"GTDK]0)X([J&2&:-989%*/'(H964C!!!Z@B@#R_
M]FW]H[PI^U%\,[7QGX3>:.!I6MKNPNP!<65PH!:)P"1T96!!P58'U ^9/B+^
MW7\5_B!\;/$GPU_9M^&^G^-)_"\QM=8UW7'9+6.8.R.J_O854!D=0S.2Y1MJ
MD#)\S_X)B)'X#_;"_:2^'^D@IX<L[VY^SQ1,?*C%MJ$D,8 ]=DI'_ >]8WB;
MX/\ [2O["?QW^('C?X0>&8_'W@'Q5?/?3Z?#;M>,$,DDB1R0(PG$D7FR*)$R
MI!RW)V@ [ZX_X*!?'/\ 9O\ &F@Z9^TI\*=,T;PYJTGD1:_X;D+!<8#2'$TR
M2$9W&/,;8.0.,'Z'_;F_:>UC]E_X%6?CSPOI^F:[<7&J6UDD=^7:!HI8Y'W@
MQLI)^08YQS7RWH7_  5 ^%?Q:U+3?!_[0WP?&AR6]VL@;5K1-3L;6XVE!-)!
M-&KQ *[C(60C/XCO/^"NUQIUW^Q;HD^D26TNDRZ]I[V<EF5,#0FWG,9C*\;"
MN,8XQC% '$?\%&/BI\6/''['^@:A:^#-*D^''B;PYHVL>(-<2Y59M/O99X95
MABB:;>R%C$,[&X8Y/!QZ)_P3+\9?&W4OAOX.T3Q-X"TG2OA-;>'V;1_$MO>Q
MO=7<@E41J\0G9E!5I3S&OW!TSSE?M<?\HB]%_P"Q9\+_ /H=E7J'[,GB*Y\(
M_P#!-KP]KMGO^UZ7X*N[V'R_O;XXIG7'OE10!P?QB_X*&^+M0^-FH_"3]GWX
M=+\2/%.EN\.H:C=RD6<$J';(N%9 $1CL:1Y$7=P,\$\[??MY?'W]G#6M)D_:
M/^#MCIGA#4)OL_\ ;_A23S1 QY&X">9&/7Y"T;$ E<XP?EK_ ()Y?&_XH_!?
MP+XIO? /P%U/XH?VQJ86\\0VCRC88XU(MR4B?)7S"_)_Y:CCN?<?V@/VB?V@
M_P!H+X/^)? &K?LF>(+2UUFW$2W8-Q*UM*K!XY54VXR5=5.,CIUH _3'P_KV
MG^*M"T[6=)NX[_2]0MX[JUNH3E)HG4,CJ?0@@_C6A7R[_P $V- \8^#_ -D_
MP[X<\<:)JF@:QI%W>6R6FK1-'-Y!F:2,@-SMQ(5'LN!TKZBH _,O_@N#_P B
M#\+/^PG>_P#HJ.OI3]L+]I;7?V4_V:/#_C3P]I>GZO?R75CIYM]3$GE;)('8
MM\C*<@QCOW-?-?\ P7!_Y$'X6?\ 83O?_14==K_P5F_Y,=\-?]AG3/\ TFFH
M HR?MT_M"_'JV>Z_9W^#EKK?A^SC6*Z\2:]F*&YN @,HMEDGA&%;( W.V,95
M2<5U'[(W_!0CQ-\4/C1>_!SXO^"K?P/\0HUE-O\ 9!)%#+)&GF-"T4K,RMY8
M+JP=E90<8X+?0G['GANS\)_LJ_"73[*&.&+_ (1C3[EQ$@4-+- DLKX'=GD=
MB>Y)-?$_[3=O':_\%??@G)"@CDGTZQ>5EX+MYMXF3_P%0/H* /L[]K']JGPQ
M^R7\,V\4:_#)J5]=2&VTO1[>0)+>S[2<;CG8BCEGP=H(X)(!^4]!_:P_;9UK
MP^GC^'X!Z!<^!F3[6FFH7BU*6UY8,B-<F4L5Q@B [L@JA!KDO^"B5O'X^_X*
M'?LZ>!M:1;KPTXTZ:2TG'[J7[1J4B3H?]]+>-3^%?J'TX' H _)3]BWXL:=\
M<O\ @J-XM\=:59W6GV.LZ)/,MI?*%FA98+6-T;!(R'1AGOC-?='[9'[9'AW]
MD+P787]]82>(/$NL2/#I&AP2B-KAE WR.^#LC7<H) ))90!U(^2?@AX/T_P/
M_P %DOB9INF11P6DNFW&H>7&>!)<V]K<2\=LR2N<>_I7G'[9_C?Q#_P]&T.7
M2O!5U\1K_P *VEFVF^&8RQ^U,MLUUN0!6X1Y#(<*?]4>G4 'NR_M-?MQOH?_
M  F"_L_>'QX8\K[1_9;.XU/RL9SY7VKS=V.-OD[O]BOI/]D7]KOPS^UQX'N]
M6TBTGT37=+D6WUC0KM@TEI(P)4JP WQMA@K8!RK @$5\\?\ #=_[2_\ T:-X
M@_[_ %S_ /(]>=?L-^$_BM9_MW>+_'VN_"7Q!\.?#/C"RO&N[:XMI1:03LT<
MV2[(H):1'(XR/,(]: /9_%7[=GC'X(_M@V?PL^+'A[1-*\#:S)C1_%5@)H]\
M<C8@DE+NR@!AY<@XVD[L[0,^H?MO_M@:;^R+\,8M4C@M]6\8:M+]GT71YV(6
M9A@R2R;2&\M 1G')9D'&<C#_ ."DGP.\(_%[]F7Q'J?B.^M="U#PK;R:KI>M
M7 XAE  ,+8&2LV%CVC)+&,@$J ?@C_@G9;0_M>?M-Z?K7Q=\4_\ "0ZGX'T2
MV&@:'?\ /VL0'8C=,,(CB1@?F=W#'(5J /U6_9W\3?$#QI\)]&U_XEZ/IOAW
MQ-J2?:FTC34D46D+8,:2>8['S,?,PXV[MN,J2?2J** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *_*?QU+_PVE_P58TCPY'B]\&?#@_Z2H^:-A9N))RPZ?/=ND!]54?2O
MU8K)TKPCH6@WL]YINBZ?IUW<9$UQ:VL<4DF3D[F4 GGGGO0!K5\B_P#!43X'
M_P#"Y/V5-<O;.W\[7/"3C7K3:/F,<8(N4^GDL[8[F-:^NJ9-#'<0R12QK+%(
MI5XW *LI&""#U% 'Y=Z1\=O^%V?\$??&D%Y<";7_  I9V^@WV3\S)%<V_P!G
MD/?F$H,]V1Z^I_\ @F7_ ,F.?##_ *XWW_I?<U]!6O@'PQ8Z?=V-MX<TFWL;
MS;]IMHK&)8YMIRN]0N&P>F>E:FEZ79:)8Q66G6=O86<61';VL2QQIDDG"J !
MR2?QH _-3]J/_E+Q\#/^P98_^C[ZOT*^+/\ R2OQE_V!;W_T0]:]UX7T:^UB
M#5KG2+&XU6W 6&^EMD:>,#) 5R-PQD]#W-:,T*7$3Q2HLD3J59'&0P/!!'<4
M ? ?_!%3_DUGQ3_V.=U_Z0V->=?M :?XJ_8'_;@O/C[I^A7WB+X8>+XVAUUK
M.+<UL92GG1%NB-YL4<R%L!N4SU-?IIHGA[2O#5J]KI&F6>E6SN9&AL;=(4+D
M %B% &< #/L*M7EG!J%K+;74$=S;3*4DAF0.CJ>H(/!'M0!\2?$#_@KM\#]#
M\#S:AX3O=2\6>)I(B+30UTV>V(E/"B6210@7.,["YQT!-9?_  2S_9X\8^!]
M-\<?%CXB64VG>*?'=RLT5G=1F*=(-[RR2R)@;#+))D*>0$!_BKZ_T;X(?#GP
MYKQUS2? 'A?2]:WB3^TK/1K:&YW#(#>8J!L\GG/>NVH _,O]B;_E*5^TA_UQ
MU3_TY6U?:G[8G_)J'QA_[%+5/_262O3+'POHVF:I<ZG9Z18VFI761/>06R)-
M+D@G<X&6R0#R>HJ]>6=OJ-I-:W<$=U:S(8Y89D#HZD8*LIX(([&@#X@_X)3Z
M'9^*/V%SHVHQ>=I^HZAJ=G<QYQOCDPCC/N":^>?@+\:-:_X)9?$7QA\+?BGX
M>UB]^'>JZB^H:)KVGPJX<A0GFH"0KAXUAWJ&W1LG0YK]6++P_9:'I,MAHEI:
MZ+$0QC6SMTC2-R/O;  "<\].<5^>WP?_ ."C \,^(?%OPU_:VL;3PYK^FW02
M"Y719)K2=,$$.B"3.3ADD5=C*W48R0#R7]O+]N:7]J?X'ZYH7PL\+:XWP^TN
MXM;GQ-XHU*W6&+_7*MO;H,G[TK1/R0_R?=VAC7W;_P $\T:/]B_X4A@5/]EL
M>?0S2$?I7QS^V]^V)X1_:>^'^F_ ;X 6%WXTU+7[Z#SVL--EMH(HHI!((XUD
M1#G>J,S[0BJK$GG(_1+X"?#8_!WX*^!_!+R)-/H6D6UE/+&24DF6,"5ER.A?
M<1[&@#O:_,#X$?\ *9+XI?\ 7E=_^B;:OT_K+M_"NBVNLRZO#H]A#JTP(DOX
M[9%G<'&09 -QZ#OVH O7EG!J-G/:74$=S:SQM%+#,H9)$8896!X(()!!K\#/
MV^_V:]:_9.^(VI>&M*FNA\+O%%VFM:3&6)B$L2R)Y+9_Y:0"XD4'NDJDY)./
MWYK-USPSI'B:&.'6-*L=6AC;>D=];),JMC&0&!P<4 >-:3\+[;XU?L2Z%X&N
M[@V<6O>![*R%RJ[C"[6<>R3'?:P5L=\5\1?L:_M=+^PW9ZG\"OC_ *5J7A1-
M*NYKG2=76SDGA\J1R77"*6>,OO=)$# [F!Q@5^J%O;Q6=O%!!$D$$2A(XXU"
MJB@8  '  ':L;Q5X%\->.K1;7Q+X>TKQ#:J"!#JME%<H,XS\LBD=A^5 'YZ_
MM%_\%&M7^-&L>'OAQ^RC)JFM>+-0O$DN->CTW9''$/X%2Y3A<G+R2*JJJ]]Q
M*^Y?MP:;KVC?\$Z_&ECXIU?^W_$L&BV*:GJ8BCB6YN1<V_FNJ(JJJELX 48&
M*^D_!_PZ\*?#VWDM_"OAC1O#-O)M#Q:/I\5HK8&!D1J <#I6QJ6EV>LV,MEJ
M%I!?6<PQ);W,:R1N <X*L"#R!^5 'R-^PC\/M#^*W_!.'P7X0\26:WVAZQI^
MH6EU">NUK^YPRG^%E.&5NH901TKYT_8Q^)6N?L,_M-:Y^S7\1;QCX6UB\$WA
MW59_EB$TO$+KGHEP %(!(65<=W-?J)I>EV6B6,5EIUG;V%G%D1V]K$L<:9))
MPJ@ <DG\:HZQX/T'Q%=0W6JZ)INIW,(VQ37EI'*Z#.<*6!(YYXH _.O_ (+)
M6%[HNI? KQU'IUQ=Z1H.J78OIHE)5&9[22)">BEA#+C/7%7?VPOC)IW[=W[$
M/B?5OA%!K%['X:URTN=6T^XMA'</"D3,^$5FW*OFJYP3_JF(SC-?HEK&BZ?X
MBTRXT[5;"UU/3[A=DUI>0K-%(OHR,""/J*I>%_!/AWP1:RVWAS0=+T"VE;?)
M#I=G';([>I"* 30!\%_LA_\ !13]G?X=_LV^#?#>KZR?!FLZ'ID5K?:6NDW,
MGGW"J!).C0QLK>:^7Y(;+'=C&:^4/VW/VAM9_:"^+'PV^*$?A/5?#WPDTG48
M['1-6U:#RCJ#K*DUQ-CG"D*H&,C$9YW95?V%N/@7\-KS7'UJX^'OA6?69"2^
MHR:+;-<,2<DF0IN.3SUKI=8\,Z/XALXK35=)L=3M86#1P7ELDJ(0, A6! ."
M1QZT ?$O_!8R9+C]D*PEB=9(G\2V3*Z'(8&&X((/<5]6_L]_\D"^&G_8LZ9_
MZ2QUUVI^&](UK38]/U'2K*_L(RI2UNK=)(EVC"X5@0,#@<<5>M[>*SMXH((D
M@@B4)''&H544#   X  [4 24444 ?+__  4T_P"3'/B?_P!<;'_TOMJJ_P#!
M+C_DQ/X9?]Q/_P!.EW7U!JFEV6MV,MEJ-G;W]G+@26]U$LD;X((RK @\@'\*
M32])L=#L(K'3;*WT^RBSY=M:Q+%&F22<*H &22?J30!;K\R_^",/_(5^/O\
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M,26]S&LD;@'."K @\@?E1INEV>C6,5EI]I!8V<(Q';VT:QQH"<X"J !R3^=
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M/\#/#\_BWQ8ETYN?$HTY[4"W8!1&S2*LGE*279I%"IM&,[C7Z$_M+?M':?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BOF*Q_;(DU_
M]N&X^ 6G>'UAMM)L9+K4M8NI<O+)]GCF1(47A5 E7+,22<@ 8R?/O^"FW[4'
MQ"_9KL/AI+X"U6#2WUN^NH+TSV<5QYB((2H'F*=OWVZ>M 'V]1110 4444 %
M%%% !17E?[5'CS6?A?\ LZ_$'Q9X>N$M-;T?2)KNSGDB614D4<$JP(/T(KXX
M_P"";W_!1;7OCMXRU+X??%/4;2;Q+=@W6A:A%;QVRW 5?WML50!=X ,BG&2!
M(#T7(!^C=%%?#6F_M2_$2X_X*C:K\%Y-6MS\/K>V62/3_L47F!CI,5S_ *W;
MO_UK$]?;I0!]RT45\%_\%#OVOOB/\*/B)X.^''P<GA_X2Z[TZ[UO4E:TBN6^
MS1QNZ(JN" VV"X<CKA4QUH ^]**^?/V$_P!HN;]IS]G30O%6IS12^);:233-
M:$2*B_:HL'?M' WQM')@  ;R!TKZ!DD6*-G=@B*,LS'  ]30 ZBOS/\ $W[;
M7Q\_:P^*6N>$?V7=(M-/\,Z*_EW/BN_BA<R D@2EI@T<:.5;8@1I& W<<A8M
M7T'_ (*'?!_2[GQ(WBG1?'MK:*9KC2+>.VN9'11DD(8(G/&?EC;<>P/% 'Z:
MT5\S_L,_MH:=^V%X!U"[FTZ/0_%^B21PZOID3EHOG#>7-$3SL?:XP>5*D$GA
MC\]?ML?M3?'?P7^V!X:^$OPGUS3[$:YIMF;:VOK&WD5KF62923)(A(!"+[#%
M 'Z.T5^<5]8?\%'+6-6BU'PM>$G!2!=.!'O\Z**R?"?_  4<^,G[/OQ(TSP?
M^U!X BT;3[]MJ:]I\&QHU) ,H,;O#<1ID;A$0R@_Q'Y2 ?IG15;3=2M=8TZU
MO[&XCN[*ZB6>"XA8,DL; ,KJ1P0000?>LGQ]XTTWX;^!]?\ %>L2>3I6BV$V
MH7+#KY<2%V ]20, =R0* -^BORG_ &4O^"BGQ?\ $GQ^\!67Q3N+1? /CXW%
MOI'E6,,*QRF=X8=LBJ&;$T?DD,>D@8]J_5B@ HKS?]H+X^^%/V:_AGJ'C;Q?
M<21V%NRPP6MN T]Y.V=D,2DC+'!/)P K$D &O@+PO\>OVU_VS#/K_P +;#2O
MACX$:1HK6[NH8=LZYQ_KIXY'E(Z%X8U7/'44 ?J+17YC>,/B%^W;^R38OXF\
M7R:#\6/!UDI>^:TMXY%MXP>79HHH)U&.=Y5E4#YN.*^U/V5_VI/"?[6'PW7Q
M1X:\RSNK=Q;:II%R09K&XV@[21]Y".5<<,,\ AE ![+1110 45^2OPR_:@_;
M%_:(^)_C[PY\-_$F@R1^&[R57CO["SAV0^>\<8#-&=Q^2O0=6U7_ (*-^$DG
MU!K/P_XDM[1#*]M:1:<YF4#)"H"DC$?W5Y)X&: /TIKE?''PI\$_$Z**/QAX
M0T+Q4D((B&M:;#=^6#UV^8IV_A7SA^P;^W0W[5EKKGAOQ3HT/AGXC^'UWWVG
MP!UBN(M^QI8T<EXRCD(Z,3M++R=V%W_CQKG[0EA^TM\,;/X=Z?\ :/A3.]K_
M ,)1<>3:MY:FZ83?-(?,&(<'Y/PYH ]O\"_";P1\+XIH_!W@_0?"J3 "7^Q=
M-AM/-QTWF-1NZ=\UU=%% !117S%\9_VR)/AS^U;\-?@CIOA];J]\3&&YO=7N
MI<1V]N[S*$B1>6D)A;YF("Y'#9X /IVBBB@ HHHH **** "BOB']F/\ :@^(
M7Q+_ &[?C/\ #/7]5@NO"'AJ*^;3;2.SBC>(Q7L,29D50S81V')/7-?;U !1
M110 4444 %%%% !17AG[;WQ2\1?!7]ESQSXT\)W<=CX@TN*U:UN)84F5"]W#
M&V4<%3\KL.1WJQ^Q?\3?$'QD_9B\">,O%-U'>Z_JMM-)=W$<*Q*[+<2H,(H"
MCY57H.U 'M=%%% !1110 4444 %%%% !1110 45\)?\ !.G]JKXC_M#?$OXN
MZ/XWU>WU*P\.RPKIT<-E% 8PTTZ')106XC7KZ5]VT %86K> _#.OZY8:UJGA
MW2=2UBP*FTU"[L8I;BWVMN7RY&4LF&Y&",'FMVB@ HHKYU_;]^,?BGX"_LQ>
M(O&7@V]CT_7[.YLXX;B:W2=562X1'^1P5.58]J /HJBO*_V5_'FL_%#]G7X?
M>+/$-PEWK>L:1#=WD\<2QJ\C#DA5  ^@%>J4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !17SK^W[\8_%/P%_9B\1>,O!M['I^OV=S9QPW$UNDZJLEP
MB/\ (X*G*L>U=M^ROX\UGXH?LZ_#[Q9XAN$N];UC2(;N\GCB6-7D8<D*H 'T
M H ]4HHKYB_;,_;(D_9?U3X?:!IWA]=9USQE?&UM[BYEVVUI&DL*2.RCYG;]
M^N%! X))XP0#Z=HKQ3]M#XF^(/@W^S%X[\9>%KJ.RU_2K:&2TN)(5E5&:XB0
MY1@5/RLW4=ZK_L0_%+Q%\:OV7/ WC3Q9=QWWB#5(KIKJXBA2%7*7<T:X1 %'
MRHHX':@#W.BBB@ HHHH ***S_$%W+I^@ZE=0G;-#;22(Q&<,$)''U% &A17Y
M%?LY_M)?MM_M3:7K5_X$\2^'KBWTB:."Z-]8V4!#.I9< Q<\*:]=GTO_ (*-
M0PNZ:QX2G91D1QIIX9O89C _,T ?HQ17Y[_LN?\ !07XA2?'I/@C^T%X6M?#
M/BZX<6]EJ%M'Y&ZX*AHXY4W,C"4?<DC.TDJ,'=N'OW[?OQC\4_ 7]F+Q%XR\
M&WL>GZ_9W-G'#<36Z3JJR7"(_P C@J<JQ[4 ?15%?E_\+/&G[?OQC^'NB^-/
M#?B#PM-HFKPF>U:XM[&*1E#,O*F+@Y4TWQ1^T)^WC^SCIK^*/'W@K1_%7A6V
M&^\DAM[>58$_B+&SD#Q@ 9WLI09YSTH _4*BO%OV4OVJ/"O[67PV3Q/X>5["
M_MG%OJNC3N&FL)\9"D@#<C 95P!D9X!#*.S^,WQB\,_ 7X<:QXW\6W;6FBZ:
M@9Q&H:69V(5(HUR-SLQ  S[D@ D ';45^8OA_P#:9_;"_;/NKG5/@MH6E_#7
MP'%.\5OK&I10R&<#C:TLZ2>81SGR8L*>"<BI?%&G_P#!0GX"6=UXBD\3:)\3
M]+LE$]SI]A;PW1=!R<1F""=L=Q$<^QQD 'Z:T5\U?L1?MJ:-^U_X+OY38+X?
M\8Z*RQZMHWF;U ;.R:$G!,;;2,'E2"#GY6;Z5H **;)(L4;.[!$499F. !ZF
MOS1\3?MM?'S]K#XI:YX1_9=TBTT_PSHK^7<^*[^*%S("2!*6F#1QHY5MB!&D
M8#=QR% /TPHK\RM7T'_@H=\']+N?$C>*=%\>VMHIFN-(MX[:YD=%&20A@B<\
M9^6-MQ[ \5]._L,_MH:=^V%X!U"[FTZ/0_%^B21PZOID3EHOG#>7-$3SL?:X
MP>5*D$GAB ?3%%%% !1110 4444 %%%?)_\ P4J^/WC3]G#X Z9XH\":C#IF
MLS^(+>P>::UCN%,+P7#LNUP1G=&G/7B@#ZPHKQS4/B1KUO\ L>W/CY+E!XG3
MP(VNK<^2NW[6-/,V_9C;C?SMQCM7G7_!-_X\^,OVBOV>[CQ5XYU"'4M:36[F
MR6:&VCMU\I(X64;4 '5VYQWH ^J**^8OVV/VY/#_ .R+H-C:1V/_  DGCO6$
M9M+T-'VJJ@[?/G(Y6/=P !ER"!C#,OSGI.D_\%#/C9:#Q OB/P]\+K&X'GV^
MC7<$$#J,<#;Y$\RY_NROG/4"@#]*:*_,NR_;>_:"_8^^(VD^&_VG-#M=>\*Z
MM*5A\5:3!$KA1@,\?D*L<@7(+1LB28.1G@']*-'UBR\0:18ZIIMS'>Z=?0)<
MVUS"VY)8G4,CJ>X*D$?6@"Y6%JW@/PSK^N6&M:IX=TG4M8L"IM-0N[&*6XM]
MK;E\N1E+)AN1@C!YK=HH **** "BBB@ HKYF_P""A_QN\7?L^_LWWGB[P3?Q
M:=KL>I6ELL\UM'.H1V(8;7!';KBOEWX=^*O^"@7Q3^'^B^,?#^O>%KC1]8M%
MO;/S8+&.5XV&1E3%P?J: /T[HK\M/%O[6G[9_P"R;_9^O_&'P7I'B/P;-<+%
M<7$$< VY(^036K8A8_PF5""20,]OT=^$OQ0T/XT_#;P]XW\-S--HVM6JW,'F
M !T.2KQN 2 Z.K(P!."IH ZZBOF7]C'7/VA-:NO'P^.VG_888;JW'A_]S:Q[
MXB9_-/[@G/ A^]SSQWKZ:H ***CN)UM;>69@2L:ER%ZX S0!)17S-^Q/^V%+
M^V%9^.M9BT!/#VBZ/J,-GI\#RF6XDC:,L7F8?*&/'RJ,+TRW6OIF@ HHHH *
M*** "BO%/VT/B;X@^#?[,7COQEX6NH[+7]*MH9+2XDA6549KB)#E&!4_*S=1
MWJO^Q#\4O$7QJ_9<\#>-/%EW'?>(-4BNFNKB*%(5<I=S1KA$ 4?*BC@=J /<
MZ*** "BBB@ HHHH ***^(?VG/VH/B%\-/V[?@Q\,] U6"U\(>)8K%M2M)+.*
M1Y3+>S1/B1E++E$4<$=,T ?;U%%% !1110 4444 %%%% !1110 45\0_\%0O
MVH/B%^S)X2\!WWP_U6#2KG5KZY@NVGLXKD.J1HR@"13CECTK[.\/W<NH:#IM
MU,=TTUM'([ 8RQ0$\?4T :%%%% !1110 45\0_#?]J#XA>(O^"D_CGX0WVJP
M2^!-+L9)[6Q6SB61&$%NX)E"[S\TC]3WK[>H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?&WPG_X**?'2W^&_A5?%OCKQ1J&H:'I5M,Q$%O(UY'*UQ*!C*(L+$Y90.I8
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M/QH 9\7O$W[>W[-/AR;XC^(O%_AKQ?X=M&274=+T^R@FCM8RV/WBBVAD" D
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MY,DD;<@;V8H<J3T9KW_!6#_DR7Q?_P!?NG?^E<5 ';?\$\?^3+?A5_V#&_\
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M9'_!0/P_I7A?]A#XF:;HNFV>D:;#90>59V$"0PIF\A)VH@ &22>!WIO_  3
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MBR@8R67Y]\.^'O\ @H/\0_#T/C$>./"7@QKA#<6_A.]L8%E"$E@C@VLNPD8
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M""Q=0",EA\^Z!X?_ ."A6H>'H_';^,/"L5PZ?:T\"7UI;I,\?+" [;?",>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCOX?UKX=6GQ=\%^)-)O=)U:SU2WE"W5L\<<P42Q2&-V #@,@Z?WE/>OT>HH
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M#_;[_99F_:L^!4^AZ2\<7BS2;A=2T9IGV1R2A2KPN3P%=&89[,$)X!KZ4HH
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MTOP?X]^"MYJ%W#H-Q(=?\.V,?GM?0$QLC^3M)=5V2*VWYL2 CA20 >3^&_\
M@I+\99M#3PY??LR^++[XEQQB%U@MKF*S>7D><\9A+QIG!*[B,9^<#FO#?V-M
M%\>Z;_P5.U5?B2\$GCE[*\O]76UD#Q0O/9I*L2D<8194CP"0-N 2 "??4_X+
M/?#0:.L4G@#QJOBPJ(SHRV]N8_/(X02^;NVYXSY6[_9I_P#P3^^"/Q%\5_'C
MQ]^TG\4M$D\,:CXGBDMM)T6ZC9)DBD>,F0HV&14CACB3<-S LV ,%@#[C^(G
M@?3?B9X#\0^$M83S-,UNPFT^X&,D)(A0L/<9R#V(%?C)^QC\*?%OQ+_:L\%_
M"+Q>/M'A[X-ZGJ>I36^TE(G2Y4LO/#*]TD/'=2W45][_ +9G_!0R/]D[QM!X
M.3P%?>(];U+2DO\ 3+I;D1VTCO))$$8!2Q*M'DJO)#+TSFJG_!,O]GWQ'\-?
M 'B;XB^/[62W\?\ Q"OSJ=W'=(5N(+?<SH) >4=WDDD*^C(#RI  /M&BBB@#
M\WO^"TOA?6?$_@3X8QZ/I%]JSQ:E>-(MC;/,4!BCP2%!Q79?\%3_  ]JNO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4R:&.XC:.6-98VZJX!!_"GT4 %%%%
M #8XTAC6.-51% 5548  Z "G444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 SR8_.
M\WRU\W;M\S W;<YQGTI]%% #6C21D9E5BAW*2,[3@C(]."1^-.HHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **PO''C;1_ASX3U7Q)KUY'8Z5IMM)=3RNP!VHI8A<D98@'"]2>*P/@
MK\;/"?Q_\ V/B_P=?_;=*N]X"2@)/$5D9")(\DH24) /48/>@#O***H7&O:9
M:ZA%8SZC:0WLO^KMI)U61^G12<GJ/SH OT444 %%%% !156\U6RT^:WBNKRW
MMI;EMD$<TJHTK>B@GYC["K5 !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O,/VE_^2)>(_\ MV_]*8J]/KS#]I?_
M )(EXC_[=O\ TIBH ]/HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,/VE_^2)>
M(_\ MV_]*8J]/KS#]I?_ )(EXC_[=O\ TIBH ]/HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS
M#]I?_DB7B/\ [=O_ $IBKT^O,/VE_P#DB7B/_MV_]*8J /3Z*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1GYL<@#'@FK?\$5_@M=LSV/BCQO8,6!V&\M)4 QR #;!OQ+&OT!KYV_;Z_:
MN/V<?V9_$?B+33(FOZ@5T;298P?W-S.K8E)[;$61QG@LBCO0!\H>$OV==&_:
MT^*7B;P9H.H7NF_![X/Z#<>"O#=^7\]IM8FC*W%V3P)"A))Q@'$)7:#QXOXF
M_P"".GQO\%R37GA#Q7X>ULA2@6VO)["Z=2.1ADV8/H9*^F_V5?VT/V5OV;_@
M5X9\$0?$U);ZU@\_4[I- U0_:;V3YIY,_9LD;CM7/.U5':O6_P#AZ-^S%_T4
MS_R@:I_\C4 ?,'_!,Y?C'\!?VBM4^!?Q)NY=$TA/#\VKV/AW4+B.X0N9TQ)9
MR(S+@[IV95;!(<D;E./7_P!K#_@J!!^R[\=G\ 3?#JZUVSM;6"XNM2;4!;,_
MFJ''D(8F#JH."2PRP8<;<GQ[]M+]M3X(^,+[X??%#X6>/([_ .*'@/54GM;-
MM)O[;^T;&0A;FU:22!5 (Y^9A\IE Y85][ZAX#^&'[57PZ\.>(/$7A#2O%.C
MZOIT-_82:M8HUQ##-&LB[7(WQG##.TB@#QWX+_\ !4+X$?&&YMK"37KGP7K%
MPRQI9>)H1;JS$XP)U9HL9QC<ZDYZ5]:YSR.17P=\0/\ @C?\%?%&M0WWA_4/
M$'@ZW\T--IUI="Y@9.ZH9@TB$^I=@/2O9_VR/$GQ-^#/[-+S?!#17U+7=-:V
MLPL=O]MN+.Q5"K31Q,&\UUVQJ<AL*S,1\N: /HNBOR4^"/\ P6@\0:#<QZ1\
M8/!RZFD3>5-JV@J+>[C(.#YELYV,V>NUH\8Z5^F/P7^-W@W]H#P+;>+? ^L)
MK&CS.T+-L:.6"5<;HI48!D<9'!Z@@C(() .ZHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\P_:7_ .2)>(_^W;_TIBKT^O,/VE_^2)>(_P#MV_\ 2F*@#T^BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5YA^TO_P D2\1_]NW_ *4Q5Z?7
MF'[2_P#R1+Q'_P!NW_I3%0!Z?1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP1@1QG.037[,?#GP/8_#/P!X<\(Z9+<3Z=H6G6^FV\MV^^5XXHU12Q[G"CH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YA^
MTO\ \D2\1_\ ;M_Z4Q5Z?7F'[2__ "1+Q'_V[?\ I3%0!Z?1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YA^TO\
M\D2\1_\ ;M_Z4Q5Z?7F'[2__ "1+Q'_V[?\ I3%0!Z?1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!8/A]XY1;7XC6MLTD%]$H6#5XXQEFVC[DP'S,H&T@%EQ@J #[NHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %9_B%=2;0-371F@36#:RBR:Z!,0GV'RR^.=N[&<=LUH44 ?C[\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8D5]G_L[_LE?#/\ 9AT46?@K08XM1DCV76N7N)M0NO\ ?EP,+T^1 J<9VYH
M\_\ VB?^"=OPQ_:9^*NF^._%5SK=O?6\$=M=V>G721PWT<9)17RA9>I!*%21
MZ'FO??AW\,_"OPE\+VOASP=H-CX=T2W^Y:6,012>[,>KL>[,2Q[DUTU% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>8?
MM+_\D2\1_P#;M_Z4Q5Z?7F'[2_\ R1+Q'_V[?^E,5 'I]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP_\ @+X-\,_$.^L=2\5Z39_8KBZT^5Y8GCC9E@^=E4LPB$88D<L">>M>HT4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *\P_:7_Y(EXC_ .W;_P!*8J]/
MKS#]I?\ Y(EXC_[=O_2F*@#T^BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF331V\,DLKK%%
M&I9Y'("JH&223T% #ZY/XF?%;PA\&_"MQXC\:^(++P[HT'!N+R3&]L9V(HRT
MCGLJ@L>PK@_A_P#MD?!WXI?%&[^'OA3QO8ZWXGMT=Q#;)(89]@RXAFV^7*5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\P_:7_Y(EXC_ .W;_P!*8J]/KS#]
MI?\ Y(EXC_[=O_2F*@#T^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KS#]I?_DB7B/_ +=O_2F*O3Z\P_:7_P"2)>(_^W;_ -*8
MJ /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***\_P#C/\>O G[/OA5_$'CSQ#:Z%8\K#'(2\]RX&=D,2Y:1OH..
MIP.: /0*^._VM/\ @IA\.OV</MFA:(\?CGQW'E#I=A,/LUF__3S,,A2/^>:Y
M;C!V9S7J.E_$?0/VTOV<?%$WPL\7W&E+J]M=:/'JZV[QW&G7)095T."&"NIR
MISM<%3G!KY._9?\ ^".^@^!]437?C%JEGXSOH9-UOH6EM(-.XZ-,[JCR_P"Y
MA5XYW@XH ]L_X)]?M,>._P!KKX8^*=5^(?A/3]/L8;O['9WME;R1VFHQ.K>;
M&(Y&?/E_*I;)!W@=5:O3_@S^QO\ ![X ^(+_ %WP1X*M-+UB[9B;Z:22YEA4
M]8X6E9O*7GHF,\9S@8]@TW3;/1=/MK#3[2"QL;:-8H+6VC$<42 8"JJ@!0!T
M JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!\[?M[:_\6?"_P"SGJ^J?!P2#Q+:W$<EY):Q++=16(#F9X$96W.#LZ#(
M7>1R!7SM^P#_ ,%.(/B]-9?#[XL7EO8>-I"(M.UXJL-OJK$X$4B@!8Y_3 "O
MT 5L!OT2K\\OVTO^"4]A\9_$I\9?"J[TOPEXDO)M^IZ;>[XK"Y8GF=#&C&*3
MNP"[7//RG)8 _0VBO.O#&J6'P-^$_@[3/B+XYTU+^RL;72[C7-:O8[1;ZZ6-
M5)#2,-S,P) )+'ODY->AHZR*K*P96&0RG((]: '4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5YA^TO_R1+Q'_ -NW_I3%
M7I]>8?M+_P#)$O$?_;M_Z4Q4 >GT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD6[M,[S/YD]S,V-\TKX&YS@#H  H    'H%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>8?M+_\ )$O$?_;M_P"E,5>GUYA^TO\ \D2\1_\ ;M_Z4Q4
M>GT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /$OVJ/V2_!/[6/@?^Q?$UO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7F'[2_P#R1+Q'_P!NW_I3%7I]>8?M
M+_\ )$O$?_;M_P"E,5 'I]%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>_B=_P %F_B-XPO?[,^&7@C3O#HF/EQ37V_4KUSV*(H1%/\ LE7^M<0/A/\
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M3X%_&KR(="\?Z=9:G-P-+ULFPN=W]Q1+A9#_ -<V:@#Z HI%8,H(.0>012T
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MX:+^ NA>)+P>3XEM-VE:_:LNQX-0APLH9?X=WRR!>PD [5[A0 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBQ1L[L$11EF8X 'J:^$/VL/^"KW@3X-_;?#_ ,.A;_$#Q?'F-KF.0_V79O\
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M@5^C=O<17EO%/!*D\$JAXY(V#*ZD9!!'!!'>@"2BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,/VE_^2)>
M(_\ MV_]*8J]/KS#]I?_ )(EXC_[=O\ TIBH ]/HHHH **** "BBB@ HHHH
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M[17PKX/_ ."QWP)\0;$U>V\4>%Y/XVOM.2:(?0P2.Q'_  $5[GX-_;L_9_\
M'?EC2_BOX<C:3 5-4N3ISDGH-MR(SGVQ0![O16=H?B32?$]F+O1]4LM6M#TG
ML;A)HS_P)216C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5YA^TO_R1+Q'_ -NW_I3%7I]>8?M+
M_P#)$O$?_;M_Z4Q4 >GT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\-_MC?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'&%91V*IMRNYI/MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,/
MVE_^2)>(_P#MV_\ 2F*O3Z\P_:7_ .2)>(_^W;_TIBH ]/HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+
MZQMM3LY[.\MXKNTN(VBFMYT#QR(PPRLIX(()!!ZU^9W[8O\ P21L]:>\\8_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOC3X<
M^%/B1IHT_P 6>&=(\36(.1;ZQ8Q74:GU D4@'W%<IX/_ &8_A'\/]434_#GP
MT\*Z/J<9S'>VND0+/'_NOMW+^!%>FT4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>8?M+_\D2\1_P#;M_Z4Q5Z?7F'[2_\ R1+Q'_V[?^E,
M5 'I]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445\Y?'C_ (*!?!3]GW[1:ZSXJBUS7H<@Z'X>VWET&'\+D$1Q
M'VD=3[&@#Z-KAOBK\</ /P/T7^U/'?BS3/#-H03&+R8>;-CJ(HAEY#[(I->/
M_L8_MR:'^V1'XK73/#.H>&KO0)(?,CNI5G26*7?L8.H&&S&^4(XX()YQ\I?$
M+_@DCX^^,G[0WBSQ7XP^)UB_AG5-0DNX;U8Y;C4FA9LI 8F"QQA%P@(=@ HP
MO\( /</AM_P58^&7Q7^.^A_#K0-#UZ2UUB?[':Z]<1)'&TY!V#R<EPC8QN."
M">5 R1E?\%%?V,?BS^U=XL\'GP;XKT^T\)6EL8+W1]4NI8(8;CS&;[5A$;S2
M4*I@C*^6,?>;'M'[.O["?PB_9EG@U'POH#7WB6-"G_"0ZQ+]HO.05;9P$BR"
M0?+5<@X.:^@Z /@KX!_\$@?A9\-_LVH^/+NY^(^M1D.;><&UTY&'/$*G=)@_
MWW*D=4%?=]I:0:?:PVMK#';6T*+'%#"@5(T P%4#@    "IJ* "BBB@ HHHH
M **** "BBB@ HKY.^+G[9FNZI\1KKX6? #PG#\2O'MHH.J:I<3;-%T3)_P"6
M\H(\QAW167G@%F!08Z_"/]M/4,:A<?';P9I5V1DZ/9>&XYK,$[LCSI(?-P/E
MQZ]^G(!]DT5\9^'_ -L#XC? KQII/A#]IKPGINA6.JS?9=,^(GAJ1WT:>4_=
M2=6^:$GGYFV^NQ5!8?8]M=0WD(EMYHYXB2!)&P9<@D$9'H01^% $M%9GB+Q1
MHW@_2Y=3U[5K'1--B_UEYJ-REO"GU=R .A[U\I_%C_@JE\ ?AEY\%EX@NO'&
MI1Y'V;PU;&:/=V_?N4B(]U9L>AZ4 ?7]8'C?Q]X;^&OAVXU[Q7KEAX>T>W'[
MR]U&X6&,'LH+'ECV4<GL*_,#XO?\%L+K4-!BM/ACX$;3=7F3$VH>(I5F6W;)
M&(H8S\YQ@AF8 'C8:\C\%?L=_M.?MY>([?Q7\2-5U#1=$D.Y-6\5*T>V,\D6
MEBNW /!&%C1NNZ@#WS]IC_@LII>F+=:)\%M(_M:ZY0^)M:A9+=/]J"W.&?V:
M3: 1RC"OS!^)GQ9\8_&3Q--X@\;>(K_Q)J\G'VB^EW"-<YV1H,+&O^R@ 'I7
MZW:'_P $4_A38ZG93ZGXQ\5:I:10J)[56MX?/F'WFW",E4/]P<C^^:^KOA+^
MR'\'?@?Y4G@[X?Z/IU['C;J,\)NKP$=Q/,6D'T# >W% 'X@?!']B[X__ !<A
MSX2\&ZMI.D7B&.75=2/]FVTL38SEY-K3)P/E0.,]NM?:OP>_X(EV<'D7?Q0\
M>R73\%]*\+Q;$SU(-S,I+ ].(E/OZ?J510!XW\&?V/\ X/\ P!>"X\%^!M-L
M-4A4A=7N5-U?<C#$3REG7.>0I ]L5[)110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>8?M+_\ )$O$?_;M_P"E,5>GUYA^TO\ \D2\1_\ ;M_Z4Q4 >GT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45\U_M#?\
M!0CX-_LWZA>:/KFN3:UXIM>)-!T.'[1<1M@$"1B5CC.".&<-@]#7RO\ "C_@
MK=XU^-'[1GA+PAX>^&%F/"^L7\=E-;K/+<ZDD;'#7'F+MC58QF1E,9&U3\X^
M]0!^C?CGXA>&?AEX?EUSQ;K^G>'-(B.&O-3N4@CW8)"@L1N8X.%&2>PKX2^-
M?_!9GX<>#KA['X=^'K_Q]<JV&O[ACIUECN4+(TKGZHH]S7K?[='["3_MDS^$
M+B'QM/X5DT,S1O#):&[MY8Y"I9UCWIMD&P#.<$<<8J'X%_\ !+WX'_!C[/>W
MNB/X]UV/#&_\2[9XE;OLM@!$!GD;E=A_>H [K4+K4/VT/V-9)_#]U??#W4/&
MVA[H))LF2U8M\R$K@M$^UEW#!:.3..<5\A_ [_@BKH^E7$5_\6/&#ZXR'/\
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M&&?NGI7Z^?"_X)^ O@MI7]G>!O"6E>&;8J%<V%LJRRX[R2'YY#P.78GBNVH
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MQK\P?VN/^"1++<7/B_X#RFVN$8SR>$KJX*X8<YLYV/RG.,1R'UPXX6OU-HH
M_'3]F_\ X*C_ !#^ &N_\(#\=M(U37K"PD^RRW=W$8]:TXCM*'QYX''WR'P<
M[FX6OU<^%OQ<\'?&OPG;^)?!'B"S\0Z/-QYUJ_S1MU*2(<-&X[JP!]JX7]I#
M]D/X;?M2:%]D\9:,HU6&,QV>O6.(K^TZX"R8^9<DG8X9><XSS7Y3_$[]EO\
M:"_X)R>,)O'7@#6KS4O"L9^?7M'C+1&$$D1W]J=P"^[!D!(PP;& #]P:*^"O
MV2O^"KW@CXQ_8_#OQ(%KX!\7OB-+QY"NEWK_ .S(Q_<,?[LAQTPY)Q7W?)>0
M0VXG>>-(#MQ*S@*<D <].21CZT 34444 %%1W%Q%9P23SRI##&I9Y)&"JH'4
MDGH*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:/P^7A?1-1N--6PDE9L^9'&BJOF1 ;")"#R2-S<A?8/@W^Q'\%?@3)%<^%O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:WC6**,$D*B@ #GT %>;?L\_%KX7_%3X>Z>_PIU;2[OP]I\$=NFFZ>HA?3U
MPL4D! :(X' 8#.,C(YKU"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HK\Q_VT/^"F'B6V\=^*_A%\&_#\>JW-G!
M=6&J:\5EFF1UB;[0;58F79Y($F96) *,0 %#'RC]D?\ X*?>-?@S:^#?"/Q7
MTB35O UZK-;>)[GSSJ(A>XD#7#2.S"YC1]ZX4!@$(R2NV@#]CZ*9%*DT:21N
MLD;@,KJ<A@>A!]*_/']O;_@IS-\"_%MCX,^%$^C:[XAM'=M=NKR)KBWM3C"V
MZ['7,F<EN3MP%ZDA0#]$:*X?X%^,K_XC?!'X>^+-56%=4U[P]I^J7:VZ%8Q-
M/;1ROL!)(7<YP,GCO7S7^W9_P43T[]D^_L_"?A_1X?$_CR\@6Z:WN)"MK8PL
MQ"F7:=S.VTX08X^8D# 8 ^S**_*GP#_P5V^(_@KQQIFE_'/X9P:#HU]MD:YT
M_3KNQNX87Y698;AW\U!GL02.021@_I=XH^)GAOPA\.+_ ,>:CJD*^%K/3CJC
MZA&P9'M]F]63^]N!&T#[Q8 =: .HHK\EO$/_  5\^+WC+Q!K%[\+OA58W?@_
M23YUQ)?6%W?7$=OT$EP\$BI#GD\@@' W-@Y^Q/V&_P!NK1/VPO#^HVTNG+X=
M\;:.BR:AI2R;XI8F)43P,>2F<!@1E2P!)!!(!]2T45#=W'V6UFFV[O+1GVYQ
MG SB@":O,/VE_P#DB7B/_MV_]*8J_,O3_P#@KM\<=4L+B\&A?#C2VD59--TZ
M]TO57N=35I6B"VYCF*2$.A4DE!D''0@;7[07[9/[6/AOX(PZO\2?AQX(\(>'
M=?N(;6UCN(+B+4)G!\X8MS>,Z >7\WF(,9 ZD4 ?K317Y5Z__P %#_VKO"?A
M7PQXNUOP!\/M.\#^(8X9K3Q4+&_N=.1),;3,\%W(T3 G!1U#Y!&WBO7/V-?V
M\_B#\=?VE-;^&7BR+P)J6GV.E3WD>L>"EN_)DFCDB4A9)Y&$B?O&&0H!(!#$
M=0#[XHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (X;B*X#F*
M5)0C%&*,#A@<$''<'M4E?$'Q,\)>+?V%?B'K7Q8\ VU]XH^#NO7;7WC3P<CF
M6?2YG.9-2L]QZ=W7. .ORX:*E^W5\0/#WQ3^'/[-WBKPKJD&LZ#J?Q-T::VO
M+<Y5AMF!!'56!R"IP5(((!% 'W94<5Q%.TJQRI(T3;) K E&P#@^AP0<>XKY
MC_:?_:?UO0_%%I\'/@Y:1>(_C-K4>><-:^'K8@9O+LX(! (*H?4$@Y19._\
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M-%<R>'?%VL6DQ##4O%5W)!"1_?#W3C>..J;NE?T$36-M<3PSRV\4LT.3%(Z
MLF>NT]OPJ>@#\@_AY_P1'\9:E$)?&WQ%T?0#@,+?1;.74&]U9G,(4^XW#^=?
M1/@O_@C3\$?#ZH^N:GXH\4SX&]+B]CMH"1UPL4:N,^[FOO.B@#P3P9^P;^S]
MX#V'2_A3X>F=#E7U6!M18'US<M(<U[5H?AW2O#-DMGH^F6>DVB_=M[&W2&,?
M15 %:-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9# C@@CN*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC/$7[,7Q?\)AFUCX6^,=/C7GSIM"N1'VZ/LVGJ.] ']#G_#0GPL_Z*7X/_\
M!]:__'*/^&A/A9_T4OP?_P"#ZU_^.5^ 7P5_8\^*/Q]L_%#^$O#-W<7.@P1S
M/!=H+87#-(%,222E5\P#+[2>51N^T-L:M_P3\_:(T5"UQ\*-=D 7=_H@CN3U
MQTB=N?:@#]Y?^&A/A9_T4OP?_P"#ZU_^.4?\-"?"S_HI?@__ ,'UK_\ '*_
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M@#XGU/X1:=_:?CF&./[)"MN+B54,BB5XHCD22*A8JI!R1T;[I]AHH _$6/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MON7]O']J+7_V3?@_9>+/#WAB+Q'=W6IQV#O>%Q;6BLCMYDFS#')0*.0,MUZ
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MH9_V@OV?-,FU6Y6?Q?X<?^Q-<_>!VDFB "3Y!^82IM;<."V\#I0!Z;^S_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]2T+PG<:CJ+ZG<BZO;_5)5>:5@NU% 155549P ,\G)->VT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4G7@\BEHH ^+/VJ/^"7'PT^/
M2WFM^%HX_A[XTDRYNM/A'V&Z?K^_MQ@ D_QQ[3DY(?I7P+I?BW]IO_@E_P"+
M$TW48);CP=-.0EK<E[O0K_G),$@P89".>-C]"RD<5^YM9GB3PSI'C+0[S1=>
MTRSUG2+R,Q7%C?P+-#,I[,C @CZT ?,_[+/_  49^%W[3"VFDF[_ .$.\;2
M*= U:50)G]+:;A9O9?E?K\F.:^JZ_,']J?\ X([V.IM=^(_@A?+I5[S*?"NI
M3'R'/7%O<,<QGT63(R?OJ.*\7^"O_!1#XV?L>>)U\ ?&30]3\1:18E8WL=:S
M'JMG'T#0SMQ-'CD!]P( "NHH _::BO*O@'^T]\./VEO#_P#:G@3Q##J$L:!K
MK2YOW5]9YXQ+"3N SQN&5)Z,:]5H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M".# ,(8<,& X/WV&Y&^P?AG\.- ^$7@/1?!WA>Q73M"TBW%O;0+R<9)9F/\
M$[,69FZEF)[UT]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>>?&K]G_ , _M">&6T+QYX<M
M=;M@&\BX==ES:L1]^&5<,AZ=#@XP01Q7H=% 'XU?'W_@F#\5?V;?$'_"=_ [
M6]4\2:?8,9X5T^0PZW8@>@CQYXQQF,!CG'EXR:[W]E__ (+"76FW$'ACX[:;
M(6C;R#XHTVVVRQL#@_:K91S@]6B (QCRSUK]6*^;?VH/V!?A;^U%!<7VK:;_
M ,(_XO9,1>)=)14N"P''G)]V=>GWOFP,!EH ]U\$^.O#WQ(\-VGB#PMK5CK^
MBW2[H;[3YEEC;U&0>".A4\@\$"MVOPU\7?!']I3_ ()H>+)_$_A?4;B\\)LX
M\W6-)1KC3+E,\+>6S9\LXXRPX)PDA/-?;7[*W_!6+P!\8OL>@_$-8/AYXMDQ
M&+B:3_B573_[$K',)/\ =D..@#L3B@#[PHID4J31I)&ZR1N RNIR&!Z$'TI]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M _[5'_!)/P+\5_MFO?#*2W^'WBEP7.GJA_LFZ?WC49MR?6,%1C_5Y.:^_**
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MW\"?'[PNFO\ @3Q'9Z]8\":.%ML]LQ&=DT38>-O9@,]1D<T =]1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^;?VHOV!OA=^U';SWNJZ=_PCWB\KB+Q+I**EP2.GGK]V=>@^;YL<*RU])44
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M.":]9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,".XH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>8?M+_\D2\1_P#;M_Z4Q5Z?7F'[2_\ R1+Q'_V[?^E,5 'I
M]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5XG\</V,_@_\ M#":?QCX,LIM7D7
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MT>R(C?3]<W1ZI9Q] T$[9\U,#@/N4@ *ZCF@#]J:*\I^ 7[3_P ./VEO#_\
M:G@7Q##?RQH'NM+G_=7UGGC$L).0,\;AE2>C&O5J "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#C/PU>ZM9V>I:5KTNIR0W$ZQE;26W@42_,?NAX9 3T'&>M?,/[+*CX^?\
M!5*[\4:,/M&B+XCU;Q#]HBZ"T0R^2Y]F9X%^KT ?MW1110!0U37M,T/RO[1U
M&TT_S<^7]JG6/?C&<;B,XR/S%>4_M$^+M"U3X.>(+:SUK3[NYD^S[(8+J-W;
M%Q$3@ Y/ )_"O3/$7@W0_%OV?^VM)M-4^S[O*^U1!]F[&[&>F=H_(5Y)^T!\
M-?"GA_X1Z]?Z;X>T^QO8?L_EW$%NJNN;B-3@@=P2/QH ]THHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O,/VE_^2)>(_P#MV_\ 2F*O3Z\P_:7_ .2)>(_^W;_TIBH ]/HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./\ &GP;\!?$
M97'BOP5X?\2%QM+:KI<%RWX,ZD@^XZ5X)XT_X)@_LY>,S))_P@G]A7+_ /+?
M1=0N+?'TCWF,?]\5]5T4 ?G)XN_X(E_#;4/,;PUX]\3:([<A=1CM[Y%YZ *L
M1Q]6S[UXIXN_X(C_ ! T_P QO#'Q$\.ZR%Y0:I;3V#-S_L"8 X]_Q[U^PU%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,/
MVE_^2)>(_P#MV_\ 2F*O3Z\P_:7_ .2)>(_^W;_TIBH ]/HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3M1N[<[BBDG:LNS\UKSCQ+_P1?\ @KJNY])U_P 8:'*>B+>03Q#\'AW>G\5
M'T_X=_:\^"/BL+_9OQ9\'RNW2&;68(93_P  D96[>E>%_P#!-N^MK[4/VCI;
M:XBN(I/B?JLR/$X8,C$%6!'4'!P>AKP+Q%_P0YMVW/H/Q=DC'\,.HZ$'_.1)
MQ_Z#7R]\(?\ @G#\3_B]>^.Y/!?B'P_'-X-\1W7ARX:]NI[66::$A3)%LB<;
M2&/WF!X[T ?O?17XJ?\ #'O[=?PSY\/ZQXEFMX^<:+XT4(>_^K>X0MR3QM/>
ME_X6Q_P4&^%I_P!(LO'=W!%]\S^'8M4CP.3ND$,F!QUW#Z\T ?M517XL0_\
M!6#]I?X<RK#XK\,Z).P8(ZZ[H-Q:2$]P-DD8#?*W8]^...UT'_@N%XFM]G]M
M?"K2=0_O?8-7EM<\=M\<N.?K_6@#]<J*_-+0_P#@M]X,N%']L_#'7; ]_L.H
M0W/;_:6/OG_/%>B:'_P60^ FK8%U:^+M&][W2XF';_GE,_\ D4 ?=-%?+6@_
M\%.OV:]>V*GQ(CLI6./+O]+O8,<X&6:';[_>Z=:]$T']L3X&>)=HL/BWX-9V
MQMCN-:@@=LYX"R,I)XZ8H ]AHK!T/Q]X8\4!#HWB/2=6#XV_8;Z*;=D9&-K'
M.16]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5YA^TO_P D2\1_]NW_ *4Q5Z?7F'[2_P#R1+Q'_P!NW_I3%0!Z
M?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R__P %+O"FM>-/
MV,_'>E>'])O=;U.1["1++3X&GF=4O8&<JB@L<*"3@< $]J^H** /C+0_^"C.
MCZ;HNGV<OP,^-S2V]O'$Q3PBA!*J <?Z1TXJ[_P\FT/_ *(7\</_  D(_P#Y
M(K[ HH ^/_\ AY-H?_1"_CA_X2$?_P D56_X)KV6LS:)\:/$6J>&M;\,6_B3
MQ_J&KV%KKUBUI<F"54=24;TW8)4D9! )Q7V310 4444 ,EB2:-XY$62-P59&
M&0P/4$>E<5KOP+^&_BC?_;/P^\*ZOO)+?;M%MI]V3DYW(<Y(S7<44 >":Y^P
M7^SWXB+&Z^$WAR+=U^PVQM.^>/)*X_R.E>=:Y_P2?_9NU;/V;PCJ&C$]['6K
MMO7_ )ZR/Z_I7V!10!^?>N_\$5_@W?!FTOQ3XSTN0]%DNK6>,<>A@#=>?O?E
M7G>O?\$.=/DWMHOQ=NK;&2L=_H*S9XX!99TQSGG:?I7ZD44 ?CKKG_!$?XCV
MY?\ L?XA>%[\<[?MT5S;9],[4DQ^N/>L+_AUA^U'X)PN@^)M)<)A5_L?Q'<0
M# Y&-\<>!GI7[3T4 ?BO_P ,T_\ !0#P6N;#5_&L]N@^[9^.(Y4R3S^Z:ZSG
MWV_C2_\ "8?\%#? I)\CQ]<^7EO^03!J>=O'_/*3/TYS[U^T]% 'XL?\-U?M
MN^"R%UWP_K+LN$;^V/!)@.[KSLACY(_2I;7_ (+*?'7P_,L&M>$?!\Y(+[9]
M.N[>4@\ C_2,8R#_  ^O-?M%4-U:07UNT%S#'<0MC='*@93@Y&0?<4 ?D?IO
M_!<#Q9$I_M#X6Z-=-@8-MJDT(SW^\C__ %O>NPTS_@N1IDK?\3#X/7=JNX#-
MKXA68[>Y^:V3GV_45^BNI_!GX?ZTQ;4? WAN_8N9";K2+>0ECU;YD//O7(:E
M^QW\"]6Q]H^#_@D$;OF@T&VA)SUR409_'I0!\CZ5_P %M?AA,5_M+P%XNM!N
M^;[*;6?"^HW2ID^WZUUVD_\ !9+X":CL^T6GC#2]V<_:]+B;;CU\N=^OMGK7
MK>I_\$Z/V<=64B?X5Z6@*%/]%N+FWX/_ %SE7GWZUR.K?\$H?V;-0#_9_!M]
MI>X #[)KEXVWW'F2OS]: ':7_P %6_V:]0"^?XUO=,RFX_:M#O6P?[O[N)^?
MTXZUUVF_\%%/V<M44F'XJZ2GRAO])AN(.O\ OQCGVKR'5O\ @C9\!=1W_9[W
MQAI>XC'V35(6VX]/,@?K[YZUR&J?\$2?AE,3_9OC[Q9:#?D?:EM9_E]/EC3G
MIS^E 'UQI_[9'P)U/(A^,'@E,#=_I&NVT/\ Z&XY]JZC3?CQ\--8P+#XB>%+
M[*>8/LVMVTGR\?-PYXY'/O7Y[:E_P0XTF7?_ &?\7[VU^?*_:= 2;"^AVW"9
M/3GCZ5RVJ?\ !#O7X?,_L[XM:;=8/R?:M$DAR/4[9GP?SH _5O3?$FDZUL_L
M_5+*_P!Z>8OV:X23*_WAM)XY'-:-?C7JG_!$OXJ0^;_9WCKP?=8QY?VIKJ#=
MTSG;"^._KT[5F_\ #IW]IGPKG^Q_%.@/Y*XC_LS7[J'(/4+NA3'7OB@#]IJ*
M_%H?L0_MR>%BO]D>(=>;R%)B_LSQR8>H.57=.F#R?0<T#X4_\%#O">P?;O'L
M_DJ9!_Q5,%_D<\'_ $A]QZ_*<GIQTH _:6BOQ97QQ_P4.\*[ +;Q[/L_>C.B
M07WX']T^>GW3^5*G[87[>?AORQJGA_Q5*=WF#^T? (BWJ,97Y;5./ISSUH _
M:6BOQ93_ (*D?M4>'MG]I^%]-E\QMR?VAX;N(MP&,J-KID?KSUJS8?\ !;#X
MOQ;A?>#/!-P<\?9[>\BP.X.;AJ /V=HK\B['_@N#XJCW_;?A9H]QG&SR-5EB
MQUSG,;9[>E=1I_\ P7*M)&87OP;F@ '#6_B029/T-JN/S- 'ZF45^;>F_P#!
M;KP!*P^W_#GQ);#9D_9KFWF^;CCDIQUY_2NGTW_@M+\$;ORUN_#GCBQ<KEV:
MPM'C4^@*W.X_]\T ??M%?%6F?\%>?V>;_P KS]1\0:;OSN^U:.[;.O7RRW7V
MSUKI]-_X*D?LSZCY8;XB-9R.VT1W.B:@N/<L("H'U- 'U=17SUIG_!03]G;5
MMOD?%?0TW/L'VHRV_/OYB+@<]3Q75Z9^UQ\$-8VBU^+W@=G9_+6.3Q!:QNS<
M<!6D!/7TH ]:KPS]K;]IBX_9C\&^&]5L/"$OC;5O$&O6^@6.E1WZV6^:5)&4
MF4H^.8]H&WJW45Z)I?QB\!:WM_L[QOX<O]S^6OV75K>3+?W1M<\\CCWKY<_X
M*/:A:ZEHOP#EM+F&ZB_X6IHZ^9"X=<[9N,B@#2_X:M_:2_Z- U#_ ,+BT_\
MC%'_  U;^TE_T:!J'_A<6G_QBOL"B@#X]E_:R_:/AC>1_P!D+4%1 68_\)Q:
M< ?]N]>S?LJ_M 1?M/?!'1/B%%HC^'?[1DN(GTU[D7/E-%,\9Q)L3<#M!^Z.
MN.V3ZCJW_(*O?^N+_P#H)KY*_P""3_\ R9+X0_Z_=1_]*Y: /L"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KS#]I?\ Y(EXC_[=O_2F*O3Z\P_:7_Y(EXC_
M .W;_P!*8J /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?VAX"\)76%PWV8W4.6]1NE? ]N?K716?_!<3Q$D*"Z^$^ES2C[S0ZS)&IY[
MQ-CCW-?JQJGA/0];\W^T=&T^_P#-QYGVJUCDWXQC.X'/0?E7.WWP+^&^I2+)
M>?#[PK=2*-H>?1;9R!Z9*=* /SJL_P#@N7;238N_@Q+#%C[T/B82-GZ&T7^=
M;=E_P7 \)21$W?PNUJ"3=PL.IPR#'KDHO/7C%?;=[^R9\$=0683_  ?\",TI
M)>1?#=FKDDY)W",'/OFL&^_86_9_U'8)?A)X739G'D6(AZ^NS&?QH ^8K/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>8?M+_\D2\1_P#;
MM_Z4Q5Z?7F'[2_\ R1+Q'_V[?^E,5 'I]%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS+$H9"RDJ2#D9!(XX)KU"B@ HHHH IZKHVGZ[:FUU*QMM0MCR8;J%94/;[K
MBO(O%_[%OP)\=;SJWPH\+&1^6FLM.2SE;W+P[&/YU[310!\3>+_^"0/[/GB0
M2?V;9^(O"K-]W^RM6:0+S_T\K+GTZ_XUX?XP_P""'MA)YDGA7XJW-OC)2WUC
M2%ESZ RQRKCZ[#]*_4FB@#\6M1_X))?M%?#>\>^\&>)]#OI0<I)HVL3V-R<<
MC.]$4'/3#FJHL?\ @H/\#_N'X@WR0X "RQ^(EQU&%S/Q^'M7[7T4 ?BOI_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KS#]I?_DB7B/_ +=O_2F*O3Z\P_:7_P"2
M)>(_^W;_ -*8J /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D90RD$9!X(-+10!Y1X\_91^#GQ,\U_$GPT\,ZC<2_?NQIT<-R?
M^VT863_QZOG+QY_P1Y^ _BE9'T/_ (2'P;,>473M1^T0CV*W"R,1]&!]Z^Y*
M* /R.\>_\$0_$MJTDG@OXEZ7J:G)2WUVPDLROH#)$9=WUVCZ5YU_PRI^V_\
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M%T.]DU+1-/NY0HEN+>.5PHP,LH)Q[<T 7J*** "BBB@ HHHH **** "BBB@
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ME1>$OL6?,THZG]L\WIB7R]FS;^.<_A0!U%%%% !1110 4444 %%%% !1110
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M?B#\0/%:^,+GQ!/'-=>%XK4V0MHQ&DL4AF?]X^YR40#IM&[KNX .Y_X*J?\
M)CGC[_KMIO\ Z7V]?3_A/_D5=&_Z\H?_ $6M?,'_  54_P"3'/'W_7;3?_2^
MWKZ?\)_\BKHW_7E#_P"BUH UJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+_#;_H8__)&Y_P#C=>GT4 >8?\-+_#;_ *&/_P D;G_XW1_PTO\ #;_H8_\
MR1N?_C=>GT4 >8?\-+_#;_H8_P#R1N?_ (W1_P -+_#;_H8__)&Y_P#C=>GT
M4 >8?\-+_#;_ *&/_P D;G_XW1_PTO\ #;_H8_\ R1N?_C=>GT4 >8?\-+_#
M;_H8_P#R1N?_ (W1_P -+_#;_H8__)&Y_P#C=>GT4 >8?\-+_#;_ *&/_P D
M;G_XW1_PTO\ #;_H8_\ R1N?_C=>GT4 >8?\-+_#;_H8_P#R1N?_ (W1_P -
M+_#;_H8__)&Y_P#C=>GT4 >8?\-+_#;_ *&/_P D;G_XW1_PTO\ #;_H8_\
MR1N?_C=>GT4 >8?\-+_#;_H8_P#R1N?_ (W1_P -+_#;_H8__)&Y_P#C=>GT
M4 >8?\-+_#;_ *&/_P D;G_XW1_PTO\ #;_H8_\ R1N?_C=>GT4 >8?\-+_#
M;_H8_P#R1N?_ (W1_P -+_#;_H8__)&Y_P#C=>GT4 >8?\-+_#;_ *&/_P D
M;G_XW1_PTO\ #;_H8_\ R1N?_C=>GT4 >8?\-+_#;_H8_P#R1N?_ (W1_P -
M+_#;_H8__)&Y_P#C=>GT4 >8?\-+_#;_ *&/_P D;G_XW1_PTO\ #;_H8_\
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M,?\ Y(W/_P ;H_X:7^&W_0Q_^2-S_P#&Z]/HH \P_P"&E_AM_P!#'_Y(W/\
M\;H_X:7^&W_0Q_\ DC<__&Z]/HH \P_X:7^&W_0Q_P#DC<__ !NC_AI?X;?]
M#'_Y(W/_ ,;KT^B@#S#_ (:7^&W_ $,?_DC<_P#QNC_AI?X;?]#'_P"2-S_\
M;KT^B@#S#_AI?X;?]#'_ .2-S_\ &Z/^&E_AM_T,?_DC<_\ QNO3Z* /,/\
MAI?X;?\ 0Q_^2-S_ /&Z/^&E_AM_T,?_ )(W/_QNO3Z* /,/^&E_AM_T,?\
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M#_AI?X;?]#'_ .2-S_\ &Z/^&E_AM_T,?_DC<_\ QNO3Z* /,/\ AI?X;?\
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MW/\ \;KT^B@#S#_AI?X;?]#'_P"2-S_\;H_X:7^&W_0Q_P#DC<__ !NO3Z*
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M;G_XW7I]% 'F'_#2_P -O^AC_P#)&Y_^-T?\-+_#;_H8_P#R1N?_ (W7I]%
M'F'_  TO\-O^AC_\D;G_ .-T?\-+_#;_ *&/_P D;G_XW7I]% 'F'_#2_P -
MO^AC_P#)&Y_^-T?\-+_#;_H8_P#R1N?_ (W7I]% 'F'_  TO\-O^AC_\D;G_
M .-T?\-+_#;_ *&/_P D;G_XW7I]% 'F'_#2_P -O^AC_P#)&Y_^-T?\-+_#
M;_H8_P#R1N?_ (W7I]% 'F'_  TO\-O^AC_\D;G_ .-T?\-+_#;_ *&/_P D
M;G_XW7I]% 'F'_#2_P -O^AC_P#)&Y_^-T?\-+_#;_H8_P#R1N?_ (W7I]%
M'F'_  TO\-O^AC_\D;G_ .-T?\-+_#;_ *&/_P D;G_XW7I]% 'F'_#2_P -
MO^AC_P#)&Y_^-T?\-+_#;_H8_P#R1N?_ (W7I]% 'F'_  TO\-O^AC_\D;G_
M .-T?\-+_#;_ *&/_P D;G_XW7I]% 'F'_#2_P -O^AC_P#)&Y_^-T?\-+_#
M;_H8_P#R1N?_ (W7I]% 'F'_  TO\-O^AC_\D;G_ .-T?\-+_#;_ *&/_P D
M;G_XW7I]% 'F'_#2_P -O^AC_P#)&Y_^-T?\-+_#;_H8_P#R1N?_ (W7I]%
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MVHN3@C X/J/[8W[5^@_LG?"B\U^[DM;SQ/=*T.AZ+*YW7D_ W$#GRDSN=N.
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MIRS1ANX4MM![A: /5**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU(QR7F:!/,/XONH ])HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y7XG?$[PU\'? ^J^+
MO%NJ0Z1H6FQ&2:XE/+'^%$7JSL<!5')) KXT_81_X*)>*OVN/CEXB\(ZKX8T
M?0]$L]%N-6M9+-I6N?DN;>)$D9G*GY9SDA1R!C XKSCXM?L.?&W]K3]HKQ;J
MGQ*\3WFB?"32=5NCHUO)<H\LEJK$(+6W7*1[E !ED 8CG#UXE_P14_Y.F\4_
M]B9=?^EUC0!^KO[1'[0?A3]F7X97WC7Q=-+]BA=8+>SM0IN+R=L[88E8@%B
MS')P%5B>E?G->?\ !:;QO=W%SJFD_!^R/A>WEV2237L\C+DC:'F6,(K$9XVG
MJ/3G[A_;"_8YT?\ ;"T'P]I6M>)M4\/0:+/+<Q+IZ1NDTCJJYD5QSM56 P1]
M\YS5Z3PS\/?V0_V2)M#UXVDW@KP[H;VU]]IA2,:FS(1("G1I)Y&(V\Y:3'-
M%/\ 8]_;,\)?M?\ @^\O]'MY=$\0Z6435-"NI%=X"P^62-QCS(F(8!L*<J05
M'&:?[>G[3VJ?LG_ K_A+M!M--O\ 7[K5+?3;&WU5'>W+.'=RRHZ,<1Q/C##D
MC.>A^!?^")?A/5[CXR>/?$L:S)H-IH(T^9]O[M[B6XBDC7/<A(9#QTW#UY],
M_P""LEW-\5OCI\!_@K8S,LNIW@N;E%[?:KA+:)SZ;1'<'Z$T ?1?CO\ ;HLO
M@#^R_P##_P"(/Q-L8+GQIXKTZ&[M_#FA PB622(2D 2NYCCC5XP[$M@L, Y
MKY(C_P""TWCN%X]7NO@_8?\ ",RR&..1;V=2S#.5$YC*%AQQM['UX^MOVMO^
M">?AO]J_6/#M_>^+-5\,+H.G#3;*QL8(I;9$W,V[:P#;C\@^]C$8^M7OVYM2
M\ _!G]B'Q?X>U2UL;;29-$.@Z%I>Q1NNC'LMO*3UC8++D=!&3VH ]-_9I_:4
M\)?M2_#6#Q?X3DFB02&VO=-N]HN+*< $QR!21R"&5@<$$=#D#Y)_:>_X*U:=
M\+_B-?\ @3X:^$5\<:O83M9W6I7%PR6PNE;:T4,:*6FP<J6W*,CC<.:\H_X)
M3MKGPQ_9C_:'^)+":'2[>Q,^GEUPCSV5I<RRNN>O^LB&>G&.W'+_ /!%7PG:
MZ]\;O'OBB]B%U?Z5HZ1033#>R/<3?.X)Z,5B9<]<,WJ: /J?]C?_ (*A:!^T
MAXUB\"^*O#P\$^+KK<-/,=R9[6^=5+-&"RJT4F 2%.0V"-V< _<M?B%_P4SC
M7X*_M]V7B_08OL%Z\.F>),P+LS<1R%2X[98VX)/<DYY)K]NXY%FC5T.Y& 8$
M=P: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >2_M._M&^&_P!F'X4:KXOU^YA-RL;1
MZ7IK/B34+O:?+A0=<9P68?=7)/2O%?\ @G?^VGXH_;$L_'<WB70](T5O#\ED
MD TD2XD\X3EM_F.W3REQC'4U\6_%+]AOXT_$7PA\2_C/\=_%%W;G0])O;W2=
M*FN5N+J38&:)"JYBMH>AV+\QY&U2=U>F?\$-?^05\9/^NVD_^@WE 'VC^UQ^
MV%X0_9#\%VFKZ_#-J^L:E(T6F:'9R*DURRC+.S'[D:Y4,^#@LH )-?"$/_!:
M;QW;R0ZM??!^P_X1F:3RXI$O9T+$$[E6<QE&;&. O8^O'US^V!_P3ZT']K_Q
M=I'B#5_&6L:!<:98?8(+6TABEM\>8[E]K -N)< _-C"#CO3_ -OS5O 7PA_8
MC\5^'=2M;*VTZ?2ET/0-*VKDW.T+;^4I[Q;1(2.@C)H ]7_9M_:0\)?M1_#6
MW\8^$I)HX?-:VO-/NPHN+*=0"8Y I(Z$,"#@JP/J!XE_P4*_;+\5_LJP> -.
M\#:5HVL^)/%%W/&+?689946*,1J-JQRQD,SS( 22.&X]/$_^"(?A?5;'X<?$
MS7[@2KH^I:G:6MHK+A3)!'(9F7UXGB!_W?K67^T$H_: _P""N'PV\&!O/TOP
M9#:SW,?6,/"CZ@^?7=F",_0#UH ^E/VP/V^O#W['^CZ-I>IZ>OBOX@ZC:"<:
M/I\WV>"(#Y3-*[;VCC9PP1<,QVGIC-?)VB_\%I/%^DZI83^+_A';P>'[U@\<
MME=30S-#P"\9E4K*1R>-H/ R.M?4'QP_X)N^$OCQ^T);?%37O%.JM*ES923Z
M#)!%)9RPV_ECR!P&"N$;=DGF0GVKC/\ @L)XT\(Z'^R_#X7U(6LOB;5M2MVT
M2UPIE@$3AIIU'54$>8R1WE H ^P?A#\6O#?QR^'>B^-?"=Y]MT358?,B+@+)
M$P.'BD4$[71@589/(X)&#7DG[;7[8FB_LC_#-M1#6>I>--0(CT70YW/[\[@'
MED"G<(D&23QD[5!R>/#?^"9_AOQAX9_X)[^([S3!<#7=6FU?4?#T>Q=X;R%B
MAV!N#F>%F&[@[O2OC;X_?L+_ !.\(_ ;Q?\ '#XV^*+B\\:F:SCM]+:[%Y,/
M-G2-C<39*C:K$+'&2!Q\P VT ?IM^P3^TYKW[6/P7U#QEXBTK3M'OK?6I],6
MWTL2>442&!PQWLQW9E/?' KZ1KX*_P"",/\ R:AK?_8VWG_I+:5]ZT %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ@_X+8?\ )R7@W_L4
MH?\ TLNJ_9^OS(_X*B?L<?&#]HKXW>&M?^'OA#_A(-)L_#T=C/<?VG9VVR87
M-PY3;-,C'Y9$.0,<]>M 'Z0^$_\ D5=&_P"O*'_T6M?GM_P4>_X*(7?P[O;S
MX1?"JZ9_&,P^S:OK5I\S:?O&/L]OC_EX.1EA_J\X'S\I]T>+O^$IT/X+ZL/"
MFG"_\:6NA2)I=BTD:J]\("(E+.P0#S-N26 QFOQ0TW_@G3^USI'BR+Q/9^![
MJW\0Q77VY-37Q'IGGK<;MWFA_M6=^[G=USS0!]I_\$X_^"==Q\([JT^*OQ0M
MMWC>5#)I6BS'=_98<$&:;UN""0%_Y9@G.7/R;O\ P64^(P\+_LR:9X7BEVW/
MBC6H8WCSC=;VX,SGWQ(+?\Z^8?\ A1__  48_P"@EXP_\+6Q_P#DNOHC]KS]
MG+XH_M#_ +17P T^?PS=7O@#PW;VDVO:M+<PE%FDF1KQ2"^YCY=O&,@$$MWH
M ^P/V9_AR/A'^S]\/O"!C\J?2]%MHKE<8_T@H'G./>1G/XUY7_P4T_Y,<^)_
M_7&Q_P#2^VKZ@KP?]N?X9^)?C%^RKX\\'^$--_M?Q'J<5JMI9>?%!YA2\@D;
MYY65!A$8\L.F.M 'S%_P1+_Y(%XZ_P"QF/\ Z2P5]X?$KQQ9_#/X=^)O%NH$
M?8M#TVXU&4$XW+%&S[1[G;@>YKY4_P""7'[/7Q _9S^$/BS1/B'H'_"/:G?:
MZ;RW@^V6]SOA^SQ)NW0R.H^96&"0>.E>N?MO>!?%WQ-_9;\=^%/ NEG6?$^K
M006MM9BYBM]Z&YB,V7E=4&(A(>3SC'>@#X%_X)!>"[[XL?'CXE_&?Q,_]HZK
M:*8TN9ADM>WKN\TJ^A"(R_2;'T_6ZOC_ /X)A_L[^,/V<?@1KFC>/-"70?$F
MH>()KTP?:X+DFW\B!(SOA=U^\DG&<\GUK[ H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "OQ+_:L_Y2_6G_ &-OA;_T1I]?MI7Y<?M _L6_&7QO_P %'K?XHZ+X.^V^
M!%\0Z!?-JW]J64>(;:&S6=_*>82_*89.-F3MX!R,@'ZCU^3'[?W[>6N?&CQ5
M-\"/@@+K4K>\N#INI:EI8+S:K*3M:UMRO_+'.0[C[^"/N E_T!_;"TSXA:_^
MSGXRT7X6Z:^I^,]6MET^VCCNH;9HXI759W$DKHH(B,F/F!R01TK\AO __!/?
M]L#X9^(8M>\*>#;SP_K4*-''?Z?XDTR*9%888*PNLC()!QV)'>@#]&?^"?/[
M!5G^RGX?E\1^)'AU+XE:O;"*ZEB.Z'3H"0QMHC_$20I=^A*@#@9;Q+_@L#K-
MSX]\8?!+X-Z7+_IVN:F;N2/KAY9$M;9L=^7N/RKA/AC\&?V_;'XE>$[GQ)J'
MBMO#L.KVDFI+-XPLI4-J)D,P9!=$L-@;*@$GI@U[IXI_9W^(GQ2_X*A:+\1=
M<\,3P?#3PM:Q)I^JS31%)FAMW>,*@<N/]*F=AE>B>] 'W9H6BVGAO0]/TFPB
M\FQL+>.UMXQ_!&BA5'X "O@[_@M7_P FL^%O^QSM?_2&^K[_ *^/_P#@J!\!
M?'?[1/P"T#PW\/="_P"$@UJU\36^H36WVN"VVP+:W<;/NFD13AI8Q@'/S=,
MX +?_!*O_DQSP#_UVU+_ -+[BO@[X\:EJ?[9'_!3"W^&'B_5KRQ\&Z?KTFBV
MUA%(46&"W1FE* C DG,3?.03\ZCD*HK]'OV ?A1XJ^"7[*OA'P?XTTO^QO$=
MA+?-<V7VB*?8)+R:1/GB=D.4=3PQQG!YKYA_;H_X)V^//%OQD3XS?!"[1?%$
MDT-Y=Z6UZMK<+>1;0EQ;2N0@R%4LKLN"I()W8 !P/_!2K]AKX7?L_P#P=T?X
MA?#33KCP?JMAJUO9RPQZA<3+<*ZN5=3*[,LB,BD%2.-V1G!'VA_P3N^+WB'X
MV?LH>$O$'BJXDOM<B:XT^:_E^_="&5D21CW8J%#-W96/>O@OQE^S/^VY^V+?
MZ!H'Q4":3X<TZ7?]LU&6Q@MXGQ@S-#:G?+(5) ^7 R1E02:_4OX$_!W1O@#\
M)/#7@'02\FG:+;>5Y\OWYY68O+*WH7D=VP.!NP. * .]HHHH **** "BBB@
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MI_LS?LK_ !#_ ."BGQ6NOB]\6K^ZC\$O<_O;GF-K\(QQ9V:_\LX4/REQP/F
M)?<5ZG]NS]CG]IC]I#]I+Q+XGTWP&^H>&+<II^ALVMZ?&HM(UP&5'N R[W,D
MA# '+]!TKE_#O[-G_!0/PCH=CHNB'Q-I.D6,2P6MC9^,-/BAAC48"JHNL 4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^.] <"SU2W#2VY8%[6=?EE@?_:1P1[C!'!%?"_\ P4V_;6^+/[-7QH\-^'?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKC_A[\7_
M  ;\5Y->C\(^(;/7GT*_?3=2%J2?L]PO5#D#(ZX894X."<&NPH **** "BBB
M@ HHHH ***^&O^"HW[4OQ$_9CT'X>W7P^U:WTJ;6+F]CO&GLHKG>L:0E,"13
MC!=NGK0!]RT5\)_\$T?V[M5_:8L]=\(^/[VVE\>::3>VUQ#"D"WUF2 V$4 ;
MXV(!P!E74]F->Y?MU_%CQ)\#_P!E7QOXV\(7D=AXBTO[#]EN)8$F5/,OK>%\
MHX*G*2..1WS0![U17Q#_ ,$O?VH/B%^TWX2\>7WQ U6#5;G2;ZV@M&@LXK8(
MKQNS B-1GE1UK[>H **_'3]K3_@J/\5O#'[0GC+0/AMX@L;#PEHUX=-MP^FP
M7!EEB 2:3>Z$D&4/C!QM"U^@W["'[1D_[3G[.NB>*=4FAE\36LLFF:T(4"+]
MJC(._:.!OC:-\   N0.E 'T+117Y,_M2?\%5?B#KGQ2OO ?P%LXX[:UNVL(=
M7AL!J%[J4RG:3;Q,K($R#M^1F8 -QG% 'ZS45^)&M?M2?MV_!W3)/$'B@>*;
M'1$91/<:WX6@-LN<@!G-N-F2?[RY.*^\_P!@']ORW_:ZLM3T#7]-MM!\?:1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/V>_C;??"GQB\NF^'_$E\;-H;S*?V;JRGRU+ _=WE1"WN(R<!36A_P %L/\
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M/G>YD*%2$7>(_F &,@=Z^"_^"SKJW[6&C ,"5\)V8(!Z'[3=G!_ C\Z_5_\
MYM8_[DS_ -L: /P8_9)\9?&#P/\ $R\U#X):=>:GXN?2Y89H;+35OG%H9(B[
M>6RL -ZQ?-CC('>OTH_;B_:V^,W[/?P#^ NLZ;J$>A>,O$6F!O$<=YID+/\
M:UM;9Y%,;H1&1)))E0!CIVKY?_X(Q,%_:PUD$@%O"=X![_Z3:5[M_P %QO\
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M>+&_L"S"GY@DJDW#^N!"LBY[,Z5^9/P3_8SF^)O[#OQ7^*QM9'UG2KN*?10
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M^->-_M,_M=>!/V3[/PS=>-SJ#1Z]=O:P+IL*S/&J)N>9E+*=BED!VY.7& :
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MC+X??LG^%/#/CK2+K1-<TN:\A%G>@"583<221YY/&'P/8"@#Z5HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ5A+#TWX_AK[#HH _%KX4?MF_M$_L-ZWK^A_%;P?XA\8VEW.+EQXIO;GS4<
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M;7K:^A%U#&QAO%V!#O)"H5"G_6R,3SQ]_P!% !1110 4444 %%%% !7YJ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\^_M<
M?MF>&/V/=.\-7GB71-6UI-=EGB@72A%F,Q!"Q;S'7KY@QC/0T ?05%?G5_P^
MT^%G_0B^,/\ OFU_^/5M>'?^"T'P3U2XCAU/0/&6B;FP;B2RMYH4'J2DY?\
M)#TH ^^Z*YGX<_$GPS\7/!VG^*O"&L6^NZ!?J6M[RW)P<'!4J0&5@0058 @C
M!%?+W[1__!3GP'^S3\6-3\ Z[X5\1:IJ5A%!*]SIX@\EA+$LB@;Y%/ 8 \4
M?8]%?G5_P^T^%G_0B^,/^^;7_P"/5[W^SS_P42^#7[2&NPZ!H>K7FA>);C/V
M?1_$%NMO-<8&2(G5GC=O]D/N."<8!H ^FJ**\Z^.'[07@/\ 9T\)GQ#X\UZ'
M1[-B4MX,&2YNW&/DAB7YG/(S@8&<D@<T >BT5^;.M?\ !;KP);ZDT>E?#CQ!
M?V DVBXNKR"WD*?WO+&\9]MWXU[)\ ?^"I/P:^.GB"U\/33:AX)U^\D6&TM]
M>C18;F1L (DR,R@D\ /LR< 9)Q0!]A4444 %%>?_ !N^/'@G]GCP3-XI\=:U
M'I&F*WE0IM,D]S*02(HHQR['!Z<  DD $U\,:S_P6[\"V^K&+2OAOX@OM-WD
M?:;J\@MY2O8^6-XSUXWT ?I/17RG^S7_ ,%)/A)^TIX@A\-V,U_X6\57#%+7
M2M<C5#=X4L?*E1F0G /RL58]@:^K* "BBB@ HHHH **** "BBOCSX\?\%,O
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M117QY;_\%,O MQ^TD?@ROA;Q$-='B)O#GV\B#[+YRS&+S/\ 6;MF1G[N<=J
M/L.BBB@ HHHH **** "BBB@ HKYY_:Z_;3\+_L=V_A:;Q+H>KZTOB![E(!I(
MBS'Y(B+;_,=>OFKC&>AKTGX$_&#3?CY\)_#WC[1[*ZT_3=:B>6&VOMOG(%E>
M,AMI(ZH3P>] '>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=>'?#_@\6WBS69-=NM-N+.Z-K:W,@ D-NJW*E%? )!+<@8P.* /WOHK\5O\
MA]7\;_\ H5OA_P#^"Z^_^3*/^'U?QO\ ^A6^'_\ X+K[_P"3* /VIHKY[_88
M_:1U_P#:F^!B>-/$GAR'PYJ*ZC/8;;4.+>[5%1A/"')8+ERGWF^:-N>P^A*
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MP4C\17UI#I_B;3+DZ=K%K;9$1F"JRRQ@DD(ZL#@DX(89.,D _&S]DGP!X?\
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MZ 8.?I0!^>G_  6L^.'/@OX3:?<=,Z_JJ(?]Z*V0X_[;L5/_ $S/I7PWXH\
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MY]FKMRUC<,S #UV2B7/H)$%?/7_!;6&X7X[^ Y6)^R-X;VQ^F\74Q?\ 1DH
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M;;)*RL?2'VH _7K]G_XRVO[0'PGT3Q[I^C:AH6G:N)'M;75-@G,:R,@<A&8
M,5)'/((/>O1*Q/!'A'3OA_X-T+PQI$7DZ7HUC#I]K'W$42!%S[X45MT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17FO[2/Q3U/X)_ WQA
MXXT?0G\2:EHMG]HATU-V)"752S;>=B!B[8_A1NG6ORA?_@M9\;2S;?"O@ +G
M@-I]\2!]?ME '[445^*W_#ZOXW_]"M\/_P#P77W_ ,F4?\/J_C?_ -"M\/\
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MH8_^"T_QMAC6./PG\/D10%55TV^  '0 ?;* /VKHK\5O^'U?QO\ ^A6^'_\
MX+K[_P"3*/\ A]7\;_\ H5OA_P#^"Z^_^3* /VIHK\5O^'U?QO\ ^A6^'_\
MX+K[_P"3*/\ A]7\;_\ H5OA_P#^"Z^_^3* /VIHK\5O^'U?QO\ ^A6^'_\
MX+K[_P"3*]0_9E_X*S?%?XN?'/P=X+UWP1X:O=.UW48;"5M!MKJ*XMU=MK3Y
M>>12L8.]LJ/E5N1UH _5FOS _P""XW_(J_"3_K]U+_T7;U^G]?F!_P %QO\
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M!VX()\-\&?\ !:?X5ZUKD-GX@\)>(_#5C*0IU$"*[2+W=$(?;_NAC[5\3_\
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M]2U> _%+]@OX$?&CQM?>+O&'@&+5/$-\$%S>1:E>VOF[%"*62&9%)V@#.,G
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MSF9E1&?=,[MRL:#&<<=.30!^(7[+_P 5]7_X)Y?M:ZE%XYT6Z$5O'-H.NV<
M!E$#NDBSPY(#_-'$ZG.&0G!&X&OLK]L[_@J1\+O%?P%\1^$/AK>7GB+7?$]A
M)IDTTUC-;0V5O*NR8N9 I9RC,H"@C)R3@8/VW\<?V7/AA^T;9PP^/O"=IK-Q
M;KLM]04M!=PKG.U9HRK[<\[22OM7CG@W_@E?^SMX.UR#5#X3NM=DA(:.WUG4
M)9[<,#U:($*_^ZX9?:@#Y[_X(O\ [/\ J_AW2_%?Q7UBSDLK76;=-)T;S5VF
M>!9-\\H']PND2J>Y1_2OG7_@L1I<MC^UX+B2)TCO?#UE-&S#AP&EC)'XH1^%
M?N!9V=OIUG!:6D$=K:P1K%%!"@1(T48554<     =,5Y-^T!^R=\,?VG+.QC
M\?>'5U&[L RVFHVTSV]U K=5$B$%ESSM;*YYQF@#YU^(7Q8\&?\ !0S]DCXE
M>!/ACJ-SJWB?2]&T^_D@N;&2!C<)()UA3<!N=C;/&2/E!=<$@U\'_P#!.[XP
M_ _X;:]XH\-?';PAH-]9Z@T<MAK6O:!'J'V&:/<LD+AHGD17RO08!0YQG(_6
MW]G7]COX8_LMRZM<> ]*N[6]U1$BN[N\OI;AY$0DJN&.T $GD*#SR37._&C_
M ()[_ WX[>(I_$'B#PC]CUZX??<ZCH]R]F]PQZM(J'8[$]7*[CZT ?#GQD_;
M7_9R\,_%"PT#X8?LX?#[XG:-)%'')=KX>M[*2XNG? B@!M69A@J,E.6.!D#)
M^LOVY/@)??%/]AFZ\/\ AGPK9^'M5T6WM=;MO#&F(GE6S0@M-;0B-54D(\P7
M:HW$# &ZN[^"/[!7P3_9_P!=BUWPOX0277X>8=5U6=[R> \C,6\E8VP2-R*#
M@XS7T)0!^,7_  3#_;N\%?LV^'/$O@3XBSW&DZ)?:A_:UEJT%K)<+%,T:12Q
MRI&&< K%&5*J>CYZBNP^//\ P57\>>+OCMI.B_L],=0T"1(;&&SU#25D?5;U
MY#\R*P$J+AD0#*GY22!FOMKXO_\ !.WX#_&OQ%=^(-<\&_8==O&#7%_HUW+9
MF9LY+-&C>66/.6V;CGDFMWX%_L1_!O\ 9UU+^U?!WA"&+7,;5U?497N[J,%=
MI\MY"?+R"<[ N<D'CB@#YX_X*U+JR?L1>'5UZ2VEUT:WIHOY+-"D+7'V:?S3
M&I)(0ONP"3@8Y-6/^",/_)J&M_\ 8VWG_I+:5]=?&3X'^"?V@?"*>&/'VB_V
M]H:727BVOVN>VQ,@8*V^%T;@.W&<<]*;\%_@3X'_ &>O"<_AKX?Z'_8&B37;
MWTEK]KGN<S,J(S[IG=N5C08SCCIR: /R3_X+5_\ )TWA;_L3+7_TNOJ_335O
M^3&[W_LG+_\ IL-6OC5^QG\'?VB?%5KXD^(7@_\ X2#6K6R33X;G^T[RVVP+
M))(J;89D4X:60Y(S\W7 &/3IO ^B3^!G\'/9;O#CZ<=):R\U^;4Q>48]^[?]
MSC=NW=\YYH _'W_@B?\ \G)>,O\ L4IO_2RUKZ@_X+5_\FL^%O\ L<[7_P!(
M;ZOI?X)_L<?!_P#9U\27FO\ P]\(?\(_JUY:&QGN/[3O+G?"71RFV:9U'S1H
M<@9XZ]:ZCXU? 7P)^T3X5M?#?Q"T+_A(-%M;U-0AMOM<]MMG6.2-7W0R(QPL
ML@P3CYNF0, 'R'_P2V\)P>/?V!M?\,W4C0VNM7VK:;+(H!*I-"D;$ ]P&-?
M/[+_ ,5]7_X)Y?M:ZE%XYT6Z$5O'-H.NV< !E$#NDBSPY(#_ #1Q.ISAD)P1
MN!K]PO@[\%/!GP"\'CPMX#T;^PM!%P]U]D^U37'[U\;FWS.[<[1QG'%87QQ_
M9<^&'[1MG##X^\)VFLW%NNRWU!2T%W"N<[5FC*OMSSM)*^U 'Q)^V=_P5(^%
MWBOX"^(_"'PUO+SQ%KOB>PDTR:::QFMH;*WE79,7,@4LY1F4!01DY)P,&G_P
M1?\ V?\ 5_#NE^*_BOK%G)96NLVZ:3HWFKM,\"R;YY0/[A=(E4]RC^E?0G@W
M_@E?^SMX.UR#5#X3NM=DA(:.WUG4)9[<,#U:($*_^ZX9?:OK*SL[?3K."TM(
M([6U@C6**"% B1HHPJJHX     Z8H _"?4_^4LZ?]E3A_P#2]:^E/^"U'P+U
M?5H_!_Q6TVUEN]-TVV;1=6:-<_95,IDMY#CG:S22J2> 2@_BK[2D_89^",WQ
M:'Q-?P3GQN-5&M_VI_:U]_Q^"02"7RO/\O[X!V[=OMBO<+^PMM4L;BRO;:&\
ML[B-HIK>X0/'(C##*RG@@C@@T ?FY^QS_P %3?A=X;^ _AOPI\2[V]\/>(?#
M-A%IB316$MS#?0PJ$A9#&&*OL50P< 9!(/.!\:_M$_$36O\ @HY^V!81>!M%
MN$ANHH=$TB&X7]Y':1L[O<3X)" -++(<'"K@<D9/Z>^,O^"5_P"SMXPUJ;4A
MX3NM"DF):2WT;498("?58R2J?1 ![5[)\#/V7_AE^S?I\UMX \*VNC37"A+G
M4&9I[NX .</-(2Y7/.T$*#T H \=_;J_9MN?'7[$-UX&\*027M]X3M+.ZTRU
M5-TEPMF@0HH')<P^9@#)+8'>O@/_ ()M_M^^&?V6= \1^"O'=C?MX>U&^_M2
MTU#38A,]O<&-(I$D0D$HRQ1D%>05/!W9'ZO?M0?%C6_@7\#?$WCS0/#Z>)[W
M0XXKF33'D:/S(/-19FW*I(V1LSDXP A)K\T?A[^T%^QY^U!X_P!2OOC%\'].
M^&VLS1^>-6AUF]^RWTQ8;PZVJPA7.2VYU.<'+9Z@'B__  44_:_A_:Y\7^'+
M[P[H^H:=X#\/I<6FGW6H1!)+NZD\MKACM)5<*L ";B0,,<;\#]5?^";W_)DO
MPM_Z\KC_ -*YZ_,?_@I!\:_@UXYL_AMX$^",%F/#7A6.]FFETRS>WMO-N#"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM?PUJR1-]G7YRYLY,'&4&Y"A(WQ\]&('[TUC>+O!N@^/M NM#\2Z-8:_H]T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.S,2SL>[,23ZUU5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&7@2X^*OAW]H'6/B9:Z.\<VM:%XG@=X9(F=49HUDFDPN6&54HRC)5L\5]S_
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MV@#>66W*IR5SE0>U 'WE1110 4444 %%%% !1110 45\^_LN?!;XG_"?Q/\
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M9OB!XAEU66[BU2:_N;QDMVBB58M]Q\X 9'.!Q\_N: /<Z*** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M521S5;QU^S+\-_B=\3M)\>^+?#5MXCU[2;-;*Q&HYEMH%$C2;O)/R,^YS\S
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M_@G[^S[XK_;&^%.I:1XO^(7B#0_A5X>U*2--*T*X$5QJ5]*BO(TTKA@5C0Q
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MO$]YXWT6YL/[1\):U?#-PL:QM*8G8DL5V)*N"6VM#A<*W&;\,_\ @E;^S?\
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MCG[%?A[Q)I#-H'BN[LCJ.D7$<K1BWOXRT4]NS Y,+O&Z$GT1\94"OGWX?_\
M!3B^^&W[*6M^'/%L$S_'GPM<?\(S::9>1EI;N7#)%<RCJ3%L99!_$R)SF48^
MO/V<-6^%/P/_ &0],\0^%M6U2V^%>GVEUJL%]XA5EN!"TTCN=I12=SEM@"_-
MN7;G<"?S)\4:;\3_ (Q^(O%'[;/A_P +Z?9Z'H'B&VNK'1KBT#M<VEMA&N'
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M[0QX7:TT#,>@$N3UK]';V]M]-LY[N[GCM;6WC:6:>9PB1HHRS,QX  !))]*
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M*\#7#DM);.Y1]F3DH)$WY]+A:POV7O\ E+)^T/\ ]@9__1MA4W[1RQ_LK_\
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MB>,=2\3>)E_M+3[?3;](4L+=B3"R[XW )7#JJ!416 VGMYWX&^'_ (W^%/\
MP58^%?A#QMXGNO&0TC3YH-$UN]'[^XTTV=Z\0D.22R.\L9))/R<<8K] _P!A
MKQUI/Q _9)^%E[I$\<T=CH-II-RB=8KBVB6"5".QW1DC/4,IZ$5\J_%KQAI?
MB;_@LG\(K'3KB*YGT/0I-/OC&<F.<VVH3^63ZA)HS[;C0!<_X*-?$S5-2_:&
M^%'P:U?QQ??#3X7^(;;[9KFO6,OD&<M)+'Y+RYP%'EH/F^0&<,X8*,0>//\
M@FO'X2\#KXO_ &9OB1XH@\9P3I=6V[7XWM-1!<!\RHJ*&VEFR2RM@J1\V1[K
M^TS?? 'XW?%#P]\ _BA9377B_4H6O=(D\B2W:#<CD-%=# !?RG79DJS( RDX
M%?+_ ,:/^"<^M_LG^!_$_P 3?@E\9/$7AK^P;234[C2K^<)]HBB!9E\Z+8KG
M (5'B8,< D9H _2#X:3>)IOA[X<;QG!!;>+?L$*ZM':NKQ?:@@$K(5XVE@6
M'0$"NEKPG]B[XY:I\>OV8/"'CWQ0L%IJ]W%/%?3(@AAD>&>2$R@9P PC#'&
M"2!@"O<+2\M]0@$UK/'<PMP)(7#*<=>10!-1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]B#0/VLKCPUJLOB+4?!WBGP^S?8M9TU!(PC+!MK+N4Y5E#*RL"I)ZYKZ4HH
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MT\,_\%=_&_C33CJ'A[]F+7]=L!(8C=:9K$]Q$' !*[DT\C(!''N*^Z_VA/\
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M_P"$?_X2?[)=6]M_9WVW[)N\V0)N\SRY,8SG&WGVKY3\=?MO?M/?LU366O\
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M<\$^'[N\U&)= NKR[O[Y@9+FY>PU$/)@<(/E4!1T &23DD _6NBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** //_ -H3_D@7Q+_[%G4__262OS)_X)U_
ML#_"?]I3X W'BWQK::K/K":U<V(:SOV@3RDCB91M ZY=N:_4+XV:/>^(/@SX
M]TK3K=[O4+[0+^VMK>/[TLKV\BH@]R2!^-?.O_!+GX4^+O@Y^S3=:#XUT&[\
M.:PVOW5R+.\4!S$T<(5^">"5;\J &>%?^"5/P&\'>)](U_3M/UU=0TJ\AOK9
MI-5=E$L3AT)&.1E1Q5;_ (*V?\F6^(/^PGI__H\5]E5\M_\ !2CX:^*/BU^R
MKK7AWP?HMUX@UR;4+*6.QLP#(RI,"Q&2.@YH \Y^*7[(^I_M1?L@_ &]\*Z]
M'X<\>^$/#^F7^B7LY98BS6=L71G4%HSNBB97 ."@XYR/.-0_:J_:]_9XTJZC
M^,_P8L_B#X1AA9;W5=-C7YH<8=Y9+?S(E0C.=\2]>>M=]\>?V=?C+JGP#^ '
MB/X87M[I_C_X?:3IOVWPM)>&"*^:.W@)1T+K&[QO&RE6^\LCC/0%NI?MK?M$
M>*?#%WH.D?LH>)K'Q=<6OD"]U)W&FQRL-I?]Y"BLO4[#(/<^H!C_ +3'QX\)
M?&C_ ()@^,_%7PLT\:#H\D]GI^H:;!;);-82?:[830LJ#:<J\8RO!60=.0/I
M?]A71M/T/]C_ .$MOID<<<$F@6UU)Y:[09I5\V8GW,COD]S7DG[+G[!/_""_
ML8^)_A/X]N%;5/&;S7FJ"SD$BV$K)&L(C;HS1F&-R>A?(Y4 GS#X,?$3]I#]
MB'PH/A;XA^!^J_%KP]I,K)HGB#PI,[YA=RP1@L4AV[F.-X0H."",$ 'W5/\
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M\(>&H?#_ (I_9<\1Z_XSMX6@_MC2WD-A<R*,>:_EQ2*N>"0LF&.=NT' [_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055591216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,235,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of registrant&#8217;s definitive Proxy Statement to be filed for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055558976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370059805616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 88,227<span></span>
</td>
<td class="nump">$ 25,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">416,750<span></span>
</td>
<td class="nump">708,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,981<span></span>
</td>
<td class="nump">22,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">19,202<span></span>
</td>
<td class="nump">15,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">15,808<span></span>
</td>
<td class="nump">23,333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">545,968<span></span>
</td>
<td class="nump">795,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">32,451<span></span>
</td>
<td class="nump">60,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">53,435<span></span>
</td>
<td class="nump">117,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">710,600<span></span>
</td>
<td class="nump">1,117,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,980<span></span>
</td>
<td class="nump">9,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">9,582<span></span>
</td>
<td class="nump">15,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">12,262<span></span>
</td>
<td class="nump">26,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">14,713<span></span>
</td>
<td class="nump">15,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">18,667<span></span>
</td>
<td class="nump">17,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">68,204<span></span>
</td>
<td class="nump">85,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">112,829<span></span>
</td>
<td class="nump">125,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">155,378<span></span>
</td>
<td class="nump">195,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7,551<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">343,962<span></span>
</td>
<td class="nump">437,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2022 or 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 188,560 shares and 185,468 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,574,719<span></span>
</td>
<td class="nump">3,516,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,907)<span></span>
</td>
<td class="num">(4,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,201,193)<span></span>
</td>
<td class="num">(2,832,995)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">366,638<span></span>
</td>
<td class="nump">679,508<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 710,600<span></span>
</td>
<td class="nump">$ 1,117,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055535376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">188,560,000<span></span>
</td>
<td class="nump">185,468,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">188,560,000<span></span>
</td>
<td class="nump">185,468,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370060530576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 92,055<span></span>
</td>
<td class="nump">$ 101,907<span></span>
</td>
<td class="nump">$ 152,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">21,635<span></span>
</td>
<td class="nump">24,897<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">218,323<span></span>
</td>
<td class="nump">400,269<span></span>
</td>
<td class="nump">408,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">92,333<span></span>
</td>
<td class="nump">122,844<span></span>
</td>
<td class="nump">104,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="nump">135,930<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">468,221<span></span>
</td>
<td class="nump">548,010<span></span>
</td>
<td class="nump">578,026<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(376,166)<span></span>
</td>
<td class="num">(446,103)<span></span>
</td>
<td class="num">(425,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">33,427<span></span>
</td>
<td class="num">(8,023)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liabilities related to the sales of future royalties</a></td>
<td class="num">(28,911)<span></span>
</td>
<td class="num">(47,313)<span></span>
</td>
<td class="num">(30,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,410)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">6,667<span></span>
</td>
<td class="nump">2,569<span></span>
</td>
<td class="nump">18,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,851)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income (expense), net</a></td>
<td class="nump">11,183<span></span>
</td>
<td class="num">(77,177)<span></span>
</td>
<td class="num">(18,836)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(364,983)<span></span>
</td>
<td class="num">(523,280)<span></span>
</td>
<td class="num">(443,947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">3,215<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (368,198)<span></span>
</td>
<td class="num">$ (523,837)<span></span>
</td>
<td class="num">$ (444,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.97)<span></span>
</td>
<td class="num">$ (2.86)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.97)<span></span>
</td>
<td class="num">$ (2.86)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding used in computing basic net loss per share (in shares)</a></td>
<td class="nump">187,138<span></span>
</td>
<td class="nump">183,298<span></span>
</td>
<td class="nump">178,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding used in computing diluted net loss per share (in shares)</a></td>
<td class="nump">187,138<span></span>
</td>
<td class="nump">183,298<span></span>
</td>
<td class="nump">178,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 20,348<span></span>
</td>
<td class="nump">$ 23,725<span></span>
</td>
<td class="nump">$ 17,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">69,794<span></span>
</td>
<td class="nump">77,746<span></span>
</td>
<td class="nump">48,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,913<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 55,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of equipment and other costs for terminated program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370142586080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (368,198)<span></span>
</td>
<td class="num">$ (523,837)<span></span>
</td>
<td class="num">$ (444,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(1,114)<span></span>
</td>
<td class="num">(1,568)<span></span>
</td>
<td class="num">(927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="num">(1,636)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,750)<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (370,948)<span></span>
</td>
<td class="num">$ (525,699)<span></span>
</td>
<td class="num">$ (445,730)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055360672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,405,391<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 3,271,097<span></span>
</td>
<td class="num">$ (1,005)<span></span>
</td>
<td class="num">$ (1,864,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">23,373<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">23,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">94,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(445,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
<td class="num">(444,440)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">1,077,295<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,388,730<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
<td class="num">(2,309,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">33,238<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">33,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">94,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (525,699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
<td class="num">(523,837)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">185,468<span></span>
</td>
<td class="nump">185,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 679,508<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3,516,641<span></span>
</td>
<td class="num">(4,157)<span></span>
</td>
<td class="num">(2,832,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">185,468<span></span>
</td>
<td class="nump">185,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 758<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">57,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (370,948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,750)<span></span>
</td>
<td class="num">(368,198)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">188,560<span></span>
</td>
<td class="nump">188,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 366,638<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 3,574,719<span></span>
</td>
<td class="num">$ (6,907)<span></span>
</td>
<td class="num">$ (3,201,193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">188,560<span></span>
</td>
<td class="nump">188,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055079184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">130 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (368,198)<span></span>
</td>
<td class="num">$ (523,837)<span></span>
</td>
<td class="num">$ (444,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="num">(69,794)<span></span>
</td>
<td class="num">(77,746)<span></span>
</td>
<td class="num">(48,563)<span></span>
</td>
<td class="num">$ (403,245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liabilities related to sales of future royalties</a></td>
<td class="nump">28,911<span></span>
</td>
<td class="nump">47,313<span></span>
</td>
<td class="nump">30,267<span></span>
</td>
<td class="nump">273,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,410<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="num">(33,427)<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash research and development expense</a></td>
<td class="nump">4,951<span></span>
</td>
<td class="nump">16,703<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">57,320<span></span>
</td>
<td class="nump">94,674<span></span>
</td>
<td class="nump">94,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">13,030<span></span>
</td>
<td class="nump">14,146<span></span>
</td>
<td class="nump">14,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense</a></td>
<td class="nump">2,708<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">65,761<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on sale or disposal of property, plant and equipment, net</a></td>
<td class="num">(3,326)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram', window );">Impairment of advance payments to contract manufacturers and equipment for terminated program</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions', window );">Amortization of premiums (discounts), net and other non-cash transactions</a></td>
<td class="num">(2,435)<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">3,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">16,511<span></span>
</td>
<td class="nump">12,397<span></span>
</td>
<td class="nump">1,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,401)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
<td class="num">(2,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities', window );">Operating leases, net</a></td>
<td class="num">(2,680)<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
<td class="nump">2,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">6,906<span></span>
</td>
<td class="num">(2,586)<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,103<span></span>
</td>
<td class="num">(11,690)<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(6,153)<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">4,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="num">(12,734)<span></span>
</td>
<td class="num">(23,524)<span></span>
</td>
<td class="nump">8,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,060)<span></span>
</td>
<td class="num">(605)<span></span>
</td>
<td class="num">(5,516)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(304,007)<span></span>
</td>
<td class="num">(412,660)<span></span>
</td>
<td class="num">(313,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(467,914)<span></span>
</td>
<td class="num">(960,689)<span></span>
</td>
<td class="num">(987,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">826,229<span></span>
</td>
<td class="nump">1,166,951<span></span>
</td>
<td class="nump">1,449,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,504<span></span>
</td>
<td class="nump">41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(5,676)<span></span>
</td>
<td class="num">(14,989)<span></span>
</td>
<td class="num">(7,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales of property, plant and equipment</a></td>
<td class="nump">13,196<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">365,835<span></span>
</td>
<td class="nump">202,777<span></span>
</td>
<td class="nump">496,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfFutureRoyaltiesNet', window );">Proceeds from sale of future royalties, net of $3.8 million of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">146,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Cash receipts from development derivative liability</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">33,238<span></span>
</td>
<td class="nump">23,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">36,238<span></span>
</td>
<td class="num">(80,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(327)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">63,009<span></span>
</td>
<td class="num">(173,737)<span></span>
</td>
<td class="nump">102,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">25,218<span></span>
</td>
<td class="nump">198,955<span></span>
</td>
<td class="nump">96,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">88,227<span></span>
</td>
<td class="nump">25,218<span></span>
</td>
<td class="nump">198,955<span></span>
</td>
<td class="nump">$ 88,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">2,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities', window );">Accounts receivable recognized in exchange for long-term liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of equipment from terminated program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfEquipmentFromTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfFutureRoyaltiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of Future Royalties, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfFutureRoyaltiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370056906688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_SaleOfFutureRoyaltiesTransactionCosts', window );">Sale of future royalties transaction costs</a></td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfFutureRoyaltiesTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Future Royalties Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfFutureRoyaltiesTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055588144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes innovative medicines in the field of immunotherapy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At December&#160;31, 2022, we had approximately $505.0 million in cash and investments in marketable securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Bempegaldesleukin Program and the 2022 Restructuring Plan</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan) for the Company&#8217;s future:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 14, 2022, BMS and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 10 for additional information on our BMS Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we decided to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 6 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, subject to activities required for an orderly wind down of the studies, there will be no ongoing clinical development activities of bempegaldesleukin.    </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 25, 2022, we announced our 2022 Restructuring Plan, which was reviewed and approved by our Board of Directors on April 14, 2022. Pursuant to the 2022 Restructuring Plan, on April 26, 2022, our duly authorized officers implemented certain strategic, operational and organizational steps, including the prioritization of key Phase 2 development programs to advance our early stage research pipeline. In addition, we announced our plan to reduce our workforce by approximately 70% and to close our research facility in India.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant costs resulting from these decisions and plans. See Note 11 for additional information on the effect of the 2022 Restructuring Plan on our Consolidated Financial Statements.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation, Principles of Consolidation and Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the fair value and impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; income taxes; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. We record available-for-sale investments and cash equivalents at their estimated fair values, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. As further described in Note 11, we estimated the fair value of our lease assets for recognizing impairment charges based on management&#8217;s estimates of several unobservable inputs, including estimated time to enter a sublease, sublease rental rates and free rent periods. As further described in Note 6, we recorded the development derivative liability at its estimated fair value based on management&#8217;s estimates of several unobservable inputs, including the probabilities of success of clinical trials and various other inputs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments in Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a variety of factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#8217; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Significant Customer Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements. Our accounts receivable included $4.2 million and $21.4 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) as of December&#160;31, 2022 and December&#160;31, 2021, respectively. The remaining accounts receivable related primarily to product sales. We perform a regular review of our partners&#8217; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Significant Supplier Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract termination costs when we cancel the contract in accordance with its terms; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for additional information on the severance expense that we recognized for employees terminated in connection with our 2022 Restructuring Plan.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We report property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTMwOTA_777cbe6f-53e1-4ebb-939f-b2bf951dd6a7">three</span> to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting unit equals its fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for additional information on the long-lived asset impairment expense that we recognized in connection with our 2022 Restructuring Plan.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, under which we do not recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 5 for additional information regarding our leases.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of an invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue, including Non-cash royalty revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. We have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $69.8&#160;million, $77.7&#160;million and $79.6&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 10, we recognized $50.0&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratably over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2022 relate to the termination of the bempegaldesleukin program and the 2022 Restructuring Plan. See Note 11 for additional information.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2020 relate to the termination of the NKTR-181 program. On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and wound down Inheris and the NKTR-181 program. As a result, we wrote off $45.2&#160;million, including $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181 and $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the </span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#8217; stock to the index. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The fair value of an RSU is equal to the closing price of our common stock on the grant date. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, our income tax provision primarily relates to our Nektar India subsidiary. As a result of the 2022 Restructuring Plan and our intent to wind down our foreign subsidiaries, we have recorded a provision for the repatriation of accumulated earnings and profits from India. See Note 13 for additional information.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented. For the years ended December 31, 2022,  2021 and 2020, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, RSUs and PSUs, which totaled 21.2 million, 18.4 million and 17.4 million for the years ended December 31, 2022,  2021 and 2020, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370057873360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,227&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,218&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,828&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,977&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. All of our long-term investments as of December&#160;31, 2021 had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTUz_cabe071a-9291-4113-98c3-9850259068b6">one</span> and two years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2022 we sold no available-for-sale securities. During the years ended December 31, 2021 and 2020, we sold available-for-sale securities totaling $11.5&#160;million and $41.7&#160;million, respectively. Gross realized gains and losses on those sales were not significant. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our accrued interest receivable, which totaled $0.7&#160;million and $1.4&#160;million at December&#160;31, 2022 and December&#160;31, 2021, respectively, in other current assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(946)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,502&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,801)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,726&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2021, our gross unrealized losses totaled $0.7&#160;million. Our gross unrealized gains were not significant. As of December 31, 2022 and 2021, we assessed our marketable securities with unrealized losses and concluded that the losses were not attributable to credit. Accordingly, we have not recorded an allowance for credit losses for these securities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both December&#160;31, 2022 and 2021, we had letter of credit arrangements in favor of our landlords and certain vendors totaling $7.5&#160;million and $8.1 million, respectively. These letters of credit are secured by investments of similar amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370057049552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370062675104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Property, plant and equipment consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,889&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,385&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,205&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,829&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,263&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,652&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,386&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,731)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,039)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,921&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,347&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,451&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Laboratory and manufacturing equipment, including construction-in-process, include assets that support both our manufacturing and research and development activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment decreased significantly for the year ended December 31, 2022 as a result of our 2022 Restructuring Plan. As further disclosed in Note 11, we sold our research and development facility in India, we sold or disposed of laboratory equipment and certain computer software, and we recognized impairment charges for leasehold improvements and certain furniture and fixtures for spaces we seek to sublease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense for property, plant and equipment for the years ended December&#160;31, 2022, 2021, and 2020 was $12.2 million, $13.0 million, and $12.5 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370062531120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our leases consist of a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. 19, LLC (ARE) for our 155,215 square foot corporate office and R&amp;D facility located at 455 Mission Bay Boulevard South, San Francisco, California (the Mission Bay Facility) and a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) for an additional 135,936 square foot of office space at 360 Third Street, San Francisco, California (the Third Street Facility). The following table presents key information regarding these leases (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mission Bay Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Street Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commencement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewal terms</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMS0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmZDFjZGUwODRhMjM0MjRiODM0ZTUxNjRlODJmZWYwMl8xOQ_2b0e6231-2800-4ca2-b334-9e61b9740c93">five</span>-year terms</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMy0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmNWM1YzY0MzkwN2Q0MjkzODY0ODc2YzY1NzI1Y2VjN183_28da30aa-6692-46e9-9d13-2ccc8f191594">five</span>-year term</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The monthly base rent for both facilities will escalate over the term of the lease at various intervals. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Both leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance costs and taxes. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the Third Street Lease, our fixed annual base rent on an&#160;industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our 2022 Restructuring Plan, during the year ended December 31, 2022, we recorded impairment charges of $54.6&#160;million for our right-of-use assets which we are seeking to sublease. See Note 11 for additional information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally recognize lease expense for our operating leases on a straight-line basis over the lease term, and we continue to recognize lease expense on a straight-line basis for spaces for which we did not recognize an impairment. For spaces where we did recognize an impairment charge, the aggregate lease expense recognized over the remaining term is reduced by the amount of the impairment charge, but we recognize the remaining lease expense on an accelerated basis. The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the years ended December&#160;31, 2022, 2021 and 2010, we paid $20.1 million, $16.8&#160;million and $16.2&#160;million, respectively, of operating lease payments related to our lease liabilities, which we include in net cash used in operating activities in our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,413&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: portion representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,829&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, the weighted-average remaining lease term is 7.1 years and the weighted-average discount rate used to determine the operating lease liability was 5.8%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into subleases for certain spaces that provide recovery of $10.5&#160;million in aggregate lease payments, as well as the subtenants' share of operating expenses. The reduction to lease expense for the year ended December 31, 2022, was not significant but will increase in future periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370056897056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DevelopmentDerivativeLiabilityTextBlock', window );">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</a></td>
<td class="text">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ has primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we are the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $637.5&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin for the metastatic melanoma, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented the SFJ Agreement as a Development derivative liability in our Consolidated Balance Sheets, which we remeasured to fair value at each reporting date. As SFJ conducted the SCCHN Clinical Trial, we recorded non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remitted funding to us to support our internal costs of conducting the trial, we also recorded a corresponding increase to the development derivative liability. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Consolidated Statements of Operations. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the development derivative liability:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we valued the derivative using a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and we discount such cash flows to present value using a risk-adjusted rate. The key inputs to the valuation included our estimates of the following: (i) the probability of the  bempegaldesleukin trials meeting their primary endpoints, and if successful, the probability and timing of achieving FDA approval, (ii) the timing and the amount of costs incurred by SFJ for the SCCHN Clinical Trial, including the probability of early termination of the study based on an interim futility analysis, and (iii) each party&#8217;s cost of borrowing.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to zero as of March 31, 2022, and we recognized a corresponding gain in the Change in fair value of development derivative liability. As discussed in Note 1, on April 14, 2022, BMS and we decided to end the development for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and that all other ongoing studies in the bempegaldesleukin program would be discontinued. We also announced that SFJ and we agreed to discontinue the SCCHN Clinical Trial. Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DevelopmentDerivativeLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Derivative Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DevelopmentDerivativeLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370062534544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract', window );"><strong>Liability Related To Sale Of Potential Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liabilities Related to the Sales of Future Royalties</a></td>
<td class="text">Liabilities Related to the Sales of Future Royalties<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the 2012 Transaction Royalties.&#160;Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the effective interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. As of December 31, 2022, our prospective effective interest rate used to amortize the liability is 10%.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2020, UCB served notice of a Declaratory Judgment of Patent Invalidity, filed in the United States District Court for the District of Delaware, seeking a declaration of invalidity of certain of our patents that we had licensed to UCB and pursued similar actions in other jurisdictions. On October 14, 2021, RPI and we entered into a Letter Agreement which permitted us to enter into a Settlement Agreement, effective October 13, 2021, with UCB to effect the negotiation between RPI and UCB in which UCB and RPI agreed to a reduction in the royalty term and annual decreases in the royalty rate over the remaining royalty term in exchange for UCB&#8217;s withdrawal of all of UCB&#8217;s litigation and challenges. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded that we should account for the decrease in royalty payments to RPI as a result of these agreements as a modification of our liability. Due to the significance of the change in the estimated royalty payments, we concluded that we should treat the modification as an extinguishment of the prior liability and recognize a new liability based on the revised royalty payments and term, discounted to fair value. Accordingly, we estimated the fair value to be approximately $84.7&#160;million, reflecting a discount rate of 16.0%. As a result, we recognized a loss of $23.5&#160;million on the revaluation of the prior liability in the three months ended December 31, 2021, and we wrote off the remaining $0.9&#160;million of unamortized </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction costs. We present these charges in Loss on revaluation of liability related to the sale of future royalties line in our Consolidated Statement of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time that certain return thresholds are met as described below, of (a) MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB, as amended, (b) ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH, as amended, (c) REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $208.0&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2020, we received aggregate cash proceeds of $150.0&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $3.8&#160;million in transaction costs, which will be amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these products up to the cap, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, to be received by HCR in the first quarter of 2021. We recorded the $150.0&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. As of December 31, 2022, our prospective effective interest rate used to amortize the liability is 20%.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account of each arrangement (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties&#8212;beginning<br/>balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,865)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the 2012 Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $7.0 million and $3.0 million, respectively, as a result of worldwide net sales of MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the 12 month periods ended </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2013 and 2012 not reaching certain minimum thresholds. The 2012 Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense, as well as the loss on the revaluation described above, over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the appropriate Royalty Obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are a number of factors that could materially affect the amount and timing of royalty payments from our licensees, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI or HCR are made in U.S. dollars (USD) while significant portions of the underlying sales of the products of our licensees are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from our licensees, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the respective Royalty Obligation. Conversely, for the 2012 Purchase and Sale Agreement, if sales of these products are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the 2012 Royalty Obligation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370062530304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the normal course of business, we enter into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&#160;31, 2022, these commitments were not significant.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have recorded no liability for any litigation matters in our Consolidated Balance Sheets at either December&#160;31, 2022 or December&#160;31, 2021. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have operated in a number of foreign countries, but we are in the process of winding down our foreign subsidiaries. As of December 31, 2022, we no longer have any foreign properties and only a few remaining employees in foreign locations. We are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any of these potential indemnification obligations is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Consolidated Balance Sheets at either December&#160;31, 2022 or December 31, 2021.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification of Underwriters and Initial Purchasers of our Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with our sale of equity we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director and Officer Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification would not be material, other than retention of up to $10.0 million per incident for merger and acquisition related claims, $10.0 million per incident for securities related claims and $10.0 million per incident for non-securities related claims per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370062536912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 10, on April 3, 2018, we completed the issuance and sale of 8,284,600 shares of our common stock under a Share Purchase Agreement with BMS. These shares are unregistered and subject to certain lock-up and stand-still provisions for a five-year period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the filing of this Annual Report on Form 10-K, we had an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the SEC. The 2021 Shelf Registration Statement permitted the offering, issuance and sale by us of up to an aggregate offering price of $300.0&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which could be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities were sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement. As a result of the recent decline in our market capitalization, we are no longer a well-known seasoned issuer. Accordingly, the 2021 Shelf Registration Statement will no longer be available for us to offer and sell securities pursuant to the 2021 Shelf Registration Statement following the filing of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, shares of common stock reserved for future issuance are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and PSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2017 Performance Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,403&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated other comprehensive loss as of December 31, 2022, includes $1.8&#160;million for net unrealized losses on our available for sale securities and $5.1&#160;million for accumulated net translation losses primarily from our subsidiary in India.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370056729520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb (BMS): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (previously referred to as NKTR-214)</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and commercialization of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. In 2020, we received non-refundable milestone payments of $50.0&#160;million in aggregate for the first patient, first visit in the registrational trials in muscle-invasive bladder cancer and adjuvant melanoma.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, on March 14, 2022, we announced our registrational trial in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the trials in metastatic melanoma and adjuvant melanoma. On April 14, 2022, we announced that our registrational trials in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided that these studies and all other ongoing studies in the program will be discontinued. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. However, without further development of bempegaldesleukin, we will no longer be eligible for the development, regulatory and sales milestones under the arrangement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proportionately with the performance of the underlying services. We recognized BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. As discussed in Note 11, we terminated the development of bempegaldesleukin, and therefore, in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the bempegaldesleukin program in restructuring, impairment and other costs of program. Accordingly, during the year ended December&#160;31, 2022, we recorded $45.7&#160;million for the net reimbursement from BMS, of which we recorded $24.9&#160;million as a reduction of research and development expense for the first quarter of 2022, and $20.8&#160;million as a reduction of restructuring, impairment and other costs of terminated program for the remaining three quarters of 2022. During the years ended December&#160;31, 2021 and 2020, we recorded $101.5&#160;million and $128.2&#160;million, respectively, as a reduction of research and development expense for the net reimbursement from BMS. As of December&#160;31, 2022, we have recorded an unbilled receivable of $4.2 million from BMS in accounts receivable in our Consolidated Balance Sheet, which we received in February 2023.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NKTR-358 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop rezpegaldesleukin, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0&#160;million and are eligible for up to $250.0&#160;million in additional development and regulatory milestones. Although we are entitled to significant development milestones under this arrangement if Lilly decides to proceed to Phase 3 development, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in Phase 1B and Phase 2 development, where we share costs with 75% of the costs borne by Lilly and 25% of the costs borne by us. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to 25% of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the costs of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 development on an indication-by-indication basis in order for us to achieve the maximum royalty level under the Lilly Agreement, and further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, we will have the opportunity to receive a royalty rate up to the low twenties percent based upon our Phase 3 development cost contribution and the level of annual global product sales.  Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur. The Lilly Agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The Lilly Agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study). The primary endpoint of the Phase 2 Lupus Study was not met, and Lilly has notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baxalta Inc. / Takeda Pharmaceutical Ltd.: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology, resulting in the approval of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by the FDA in  2015, which is now marketed in the U.S., the European Union, and many other countries. We are entitled to royalties based on worldwide net sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a sales milestone upon achievement of an annual worldwide net sales target. We are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, we are entitled to single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement. As described in Note 7, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (naloxegol oxalate)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Through various sublicense arrangements to RedHill Biopharma, Kyowa Hakko Kirin Co. Ltd. and Knight Therapeutics, as of April 2020, AstraZeneca has sub-licensed all of its global commercialization rights. Our rights, including the royalty rate, royalty term and future potential sales milestones, remain unchanged as a result of these sublicenses. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally entitled to escalating double-digit royalty payments and sales milestones for net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As described in Note 7, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $40.0&#160;million of regulatory milestones, as well as royalties based on net sales, if approved, and sales milestones upon achievement of an annual net sales targets. However, given the current phase of development of the product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370062545504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Restructuring, Impairment and Other Costs of Terminated Program</a></td>
<td class="text">Restructuring, Impairment and Other Costs of Terminated Program<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, because our registrational trials in bempegaldesleukin did not meet their primary endpoints, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors, and, during April 2022, we announced the 2022 Restructuring Plan to prioritize key Phase 2 development programs, to advance our early stage research pipeline and to reduce our workforce by approximately 70% from approximately 735 to approximately 225 employees. In connection with these events, we reported the following costs in restructuring, impairment and other costs of terminated program for the year ended December&#160;31, 2022:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Severance and related benefit costs pursuant to the 2022 Restructuring Plan;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impairment of sublease assets, including right-of-use assets and property, plant and equipment resulting from the 2022 Restructuring Plan, reflecting excess office and laboratory leased spaces in San Francisco, CA; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">(Gain) loss on sale or disposal of property, plant and equipment; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract termination and other costs associated with the wind down of the bempegaldesleukin program.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In prior periods through March 31, 2022, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin program primarily in research and development expense. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Gain) loss on sale or disposal of property, plant and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical costs associated with winding down the bempegaldesleukin program primarily include clinical trial and other development expenses to transition patients from our sponsor-led trials to standard of care or our post-trial access program, as well as direct employee costs supporting these efforts. We recorded a reduction of expense of $20.8&#160;million for the net reimbursement from BMS primarily for such costs. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and Benefit Expense</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under our 2022 Restructuring Plan were entitled to receive severance payments and certain Company funded benefits. We recognized severance and benefit expense in full for employees who were notified of their termination in April 2022 and had no requirements for future service, and we recognized expense for employees who were required to render services to receive their severance ratably over the service period. This service period began in April 2022 with all affected employees terminated on or before December&#160;31, 2022, and therefore we will recognize no further expense. The following table provides details regarding the severance and other termination benefit expense. We present the liability, which we paid in January 2023, in accrued compensation on our Consolidated Balance Sheet (in thousands):</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No service period</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service period required</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Right-of-Use Assets and Property, Plant and Equipment</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2022 Restructuring Plan, we have consolidated our San Francisco operations in our Mission Bay Facility, and we have vacated our Third St. Facility and certain laboratory and office spaces at our Mission Bay Facility. We are seeking to sublease the vacated spaces, while still maintaining sufficient office and laboratory space to allow our team to develop our proprietary programs. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these plans, we reviewed each of our vacated spaces for impairment as of May 31, 2022, when management had determined which spaces we would seek to sublease, and subsequently at each reporting date or as facts and circumstances changed. As part of our impairment evaluation of each vacated space, we separately compared the estimated undiscounted income to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily leasehold improvements (collectively, sublease assets). We estimated sublease income using market participant assumptions, including the length of time to enter into a sublease and sublease payments, which we evaluated using sublease negotiations or agreements when applicable, current real estate trends and market conditions. If such income exceeded the net book value of the related assets, we did not record an impairment charge. Otherwise, we recorded an impairment charge by reducing the net book value of the assets to their estimated fair value, which we determined by discounting the estimated sublease cash flows using the estimated borrowing rate of a market participant subtenant, which we estimated to be 6.4% and 7.9% as of May 31, 2022 and December 31, 2022, respectively. We recorded the substantial majority of our impairment charges as of May 31, 2022, primarily reflecting decreased rental recovery rates for our office lease space on Third St. However, as the office lease market in San Francisco deteriorated after May 31, 2022 in the fourth quarter of 2022, we recorded an additional impairment charge of $12.0&#160;million in the three months ended December 31, 2022, for the Third St. Facility, reflecting an increase in our estimated time to enter into a sublease. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded impairment charges as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of impaired sublease assets as of May 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Fair value of impaired sublease assets &#8212; Level 3 of Fair Value Hierarchy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Book value in excess of fair value</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total impairment of sublease assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may record adjustments to impairment expense in future periods as we enter into sublease agreements or update our estimates as additional information becomes available to us. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Sale or Disposal of Property, Plant and Equipment, Net</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2022 Restructuring Plan, we terminated all research and development activities at our owned facility in India, which we sold in December 2022. We also recognized losses including excess equipment, net of sale proceeds, and the disposal of software to support the commercialization of bempegaldesleukin. We recorded the gains and losses as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total (gain) loss on sale or disposal of property, plan and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,326)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370057004640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> 2017 Performance Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our 2017 Performance Incentive Plan (2017 Plan) provides for the issuance of our common stock to members of the Board of Directors, officers or employees, certain consultants and advisors and our subsidiaries. Our 2017 Plan has been amended and restated such that an aggregate 39,200,000 shares have been authorized for issuance as of December&#160;31, 2022, including 5,000,000 shares that were approved on June 8, 2022. Under the 2017 Plan, we may issue stock options, restricted stock, performance stock, stock units, stock appreciation rights and other similar types of awards. When the 2017 Plan was approved on June&#160;14, 2017, any shares of our common stock that were available for issuance under our 2012 Performance Incentive Plan (the 2012 Plan) ceased to be available for future grants. However, options and RSUs granted under the 2012 Plan remained outstanding, and any options or RSUs that were cancelled or forfeited became available for issuance under the 2017 Plan. Shares issued for RSUs, PSUs or any other &#8220;full-value award&#8221; are counted against the share limit as 1.5 shares for every one share granted in connection with the award. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted non-qualified stock options, RSUs and PSUs to employees, officers, and non-employee directors. For our employees, the requisite service period is generally four years for stock options, and three years for RSUs and PSUs. For our directors, the requisite service is generally one year for stock options and RSUs. The maximum term of a stock option is eight years from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of our common stock on the NASDAQ Stock Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Change in Control Plan (the CIC Plan), in the event of a change of control of Nektar and a subsequent termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) within twelve months following a change of control, our employees are entitled to full acceleration of their unvested equity awards. Our Chief Executive Officer, Senior Vice Presidents and Vice Presidents (including Principal Fellows) are also entitled to full acceleration of unvested equity awards if the termination is initiated by the employee for a Good Reason Resignation (as </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defined in the CIC Plan) within twelve months following a change of control. Additionally, non-employee directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the terms of our Employee Stock Purchase Plan (ESPP), employees may purchase shares of our common stock based on a percentage of their compensation subject to certain limits. Shares are purchased at 85% of the lower of the closing price on either the first day or last day of each six-month offering period. An aggregate 3,500,000 shares have been authorized for issuance under our ESPP.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation expense resulting from PSUs and our ESPP was not significant in the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation costs of $83.1 million related to unvested stock-based compensation awards are expected to be recognized as expense over a weighted-average period of 2.3 years.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Black-Scholes Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The average risk-free interest rate is based on the U.S.&#160;treasury yield curve in effect at the time of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of zero. Our estimate of expected volatility is based on the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. We estimated the weighted-average expected life based on the contractual and vesting terms of the stock options, as well as historical cancellation and exercise data.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:51.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited &amp; canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The intrinsic value of options exercised during the year ended December&#160;31, 2022 was not significant and totaled $17.3 million and $15.9 million during the years ended December 31, 2021 and 2020, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of RSU Activity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU award activity is as follows (in thousands except for per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair values of RSUs granted during the years ended December&#160;31, 2022, 2021 and 2020 were $4.14, $14.68 and $19.24, respectively. The fair value of RSU's that vested in the years ended December&#160;31, 2022, 2021 and 2020 totaled $17.5 million, $45.3 million and $33.3 million, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Retirement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of 60% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $12,000 per participant for the year ended December 31, 2022, and up to a maximum of $6,000 per participant for the years ended December 31, 2021 and 2020. For the years ended December&#160;31, 2022, 2021, and 2020, we recognized $2.5&#160;million, $3.6&#160;million and $3.5&#160;million, respectively, of compensation expense in connection with our 401(k) retirement plan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370057086544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Loss before provision for income taxes includes the following components (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364,983)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(523,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,947)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The provision for income taxes consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,647)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets and Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828,008&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,843&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(816,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785,748)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,773&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in foreign subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,178)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,405)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S.&#160;earnings history, other than income resulting from revenue recognized from the BMS Collaboration Agreement, and projected future losses, we have fully reserved our net U.S.&#160;deferred tax assets with a valuation allowance. The valuation allowance increased by $30.5&#160;million and $115.6&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net deferred tax liability position reflects the provision for the withholding taxes associated with the repatriation of accumulated earnings and profits from India.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Operating Loss and Tax Credit Carryforwards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, we had a net operating loss carryforward for federal income tax purposes of approximately $2.4&#160;billion, of which $1.3&#160;billion is subject to expiration beginning in 2023 and a total state net operating loss carryforward of approximately $0.7&#160;billion, portions of which will begin to expire in 2027. We have federal tax credits of approximately $123.8&#160;million, which will begin to expire in 2023 and state research credits of approximately $48.8&#160;million which have no expiration date. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized tax benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have the following activity relating to unrecognized tax benefits (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we are eventually able to recognize our uncertain tax positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Adjustments to the substantial majority of our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carryforwards rather than resulting in a cash outlay.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We file income tax returns in the U.S., California, Alabama, certain other states and India. As a result of our net operating loss and research credit carryforwards, substantially all of our domestic tax years remain open and subject to examination. We may be subject to examination in India from time to time, but we do not believe that any liability resulting from such an examination would have a material effect on our financial position or results of operations.</span></div>Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. During the years ended December&#160;31, 2022, 2021 and 2020, no significant interest or penalties were recognized relating to unrecognized tax benefits. Although it is reasonably possible that certain unrecognized tax benefits could change in the future, we do not anticipate any significant changes over the next twelve months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370062541808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in one business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from UCB Pharma, Baxalta / Takeda, AstraZeneca and Pfizer represented 37%, 25%, 14% and 11% of our revenue, respectively, for the year ended December&#160;31, 2022. Revenue from UCB Pharma, Baxalta / Takeda, AstraZeneca and Pfizer represented 36%, 23%, 16% and 13% of our revenue, respectively, for the year ended December&#160;31, 2021. Revenue from BMS, UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 33%, 23%, 14% and 13% of our revenue for the year-ended December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of World</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>&#160;&#160;&#160;&#160;At December&#160;31, 2022, all of our property, plant and equipment was located in the United States. At December&#160;31, 2021, $56.1&#160;million, 93%, of the net book value of our property, plant and equipment was located in the United States with the remainder in India.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370059508976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes innovative medicines in the field of immunotherapy.</span></div>&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation, Principles of Consolidation and Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation, Principles of Consolidation and Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the fair value and impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; income taxes; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. We record available-for-sale investments and cash equivalents at their estimated fair values, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. As further described in Note 11, we estimated the fair value of our lease assets for recognizing impairment charges based on management&#8217;s estimates of several unobservable inputs, including estimated time to enter a sublease, sublease rental rates and free rent periods. As further described in Note 6, we recorded the development derivative liability at its estimated fair value based on management&#8217;s estimates of several unobservable inputs, including the probabilities of success of clinical trials and various other inputs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments in Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a variety of factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#8217; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock', window );">Accounts Receivable and Significant Customer Concentrations</a></td>
<td class="text">Accounts Receivable and Significant Customer Concentrations&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements.We perform a regular review of our partners&#8217; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock', window );">Inventory and Significant Supplier Concentrations</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Significant Supplier Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract termination costs when we cancel the contract in accordance with its terms; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We report property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTMwOTA_777cbe6f-53e1-4ebb-939f-b2bf951dd6a7">three</span> to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting unit equals its fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, under which we do not recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 5 for additional information regarding our leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of an invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue, including Non-cash royalty revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. We have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $69.8&#160;million, $77.7&#160;million and $79.6&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 10, we recognized $50.0&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratably over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock', window );">Restructuring, Impairment and Other Costs for Terminated Program</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2022 relate to the termination of the bempegaldesleukin program and the 2022 Restructuring Plan. See Note 11 for additional information.</span></div>Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2020 relate to the termination of the NKTR-181 program. On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and wound down Inheris and the NKTR-181 program.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the </span></div>volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#8217; stock to the index. &#8226;The fair value of an RSU is equal to the closing price of our common stock on the grant date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, our income tax provision primarily relates to our Nektar India subsidiary. As a result of the 2022 Restructuring Plan and our intent to wind down our foreign subsidiaries, we have recorded a provision for the repatriation of accumulated earnings and profits from India. See Note 13 for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and significant customer concentrations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory and significant supplier concentrations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring, Impairment and Other Costs for Terminated Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370056857424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,227&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,218&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,828&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,977&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text">Our portfolio of cash and investments in marketable securities includes (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(946)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,502&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,801)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,726&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370057085760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">Inventory consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370057166544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text">Property, plant and equipment consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,889&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,385&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,205&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,829&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,263&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,652&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,386&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,731)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,039)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,921&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,347&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,451&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>We recorded the gains and losses as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total (gain) loss on sale or disposal of property, plan and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,326)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370058546272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LesseeOperatingLeaseTableTextBlock', window );">Schedule of Operating Lease Information</a></td>
<td class="text">The following table presents key information regarding these leases (dollars in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mission Bay Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Street Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commencement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewal terms</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMS0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmZDFjZGUwODRhMjM0MjRiODM0ZTUxNjRlODJmZWYwMl8xOQ_2b0e6231-2800-4ca2-b334-9e61b9740c93">five</span>-year terms</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMy0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmNWM1YzY0MzkwN2Q0MjkzODY0ODc2YzY1NzI1Y2VjN183_28da30aa-6692-46e9-9d13-2ccc8f191594">five</span>-year term</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense</a></td>
<td class="text">The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments for Operating Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,413&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: portion representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,829&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LesseeOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LesseeOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370058303280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the development derivative liability:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370057070960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract', window );"><strong>Liability Related To Sale Of Potential Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock', window );">Schedule of Liability Related to Potential Future Royalties</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account of each arrangement (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties&#8212;beginning<br/>balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,865)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To Sale Of Potential Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370056275504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, shares of common stock reserved for future issuance are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and PSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2017 Performance Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,403&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370057067632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of License, Collaboration and Other Revenue</a></td>
<td class="text">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370050408608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring, Impairment and Other Costs of Terminated Program</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Gain) loss on sale or disposal of property, plant and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table provides details regarding the severance and other termination benefit expense. We present the liability, which we paid in January 2023, in accrued compensation on our Consolidated Balance Sheet (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No service period</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service period required</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded impairment charges as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of impaired sublease assets as of May 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Fair value of impaired sublease assets &#8212; Level 3 of Fair Value Hierarchy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Book value in excess of fair value</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total impairment of sublease assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text">Property, plant and equipment consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,889&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,385&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,205&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,829&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,263&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,652&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,386&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,731)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,039)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,921&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,347&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,451&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>We recorded the gains and losses as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total (gain) loss on sale or disposal of property, plan and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,326)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055470752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, shares of common stock reserved for future issuance are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and PSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2017 Performance Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,403&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity Under Equity Incentive Plans</a></td>
<td class="text">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:51.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited &amp; canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>_______________________________________________________________(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Award Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU award activity is as follows (in thousands except for per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370059802912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before Income Tax, Domestic and Foreign</a></td>
<td class="text">Loss before provision for income taxes includes the following components (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364,983)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(523,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,947)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text">The provision for income taxes consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Provision Related to Continuing Operations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,647)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828,008&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,843&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(816,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785,748)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,773&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in foreign subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,178)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,405)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">We have the following activity relating to unrecognized tax benefits (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370057016880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of Revenue by Geographic Area</a></td>
<td class="text">The following table sets forth revenue by geographic area (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of World</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054358160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 14, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 23, 2017</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 504,977,000<span></span>
</td>
<td class="nump">$ 798,783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NetExpenseReimbursementsFromCollaborationPartner', window );">Net expense reimbursements from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment', window );">Number of reporting unit evaluated for goodwill | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,055,000<span></span>
</td>
<td class="nump">101,907,000<span></span>
</td>
<td class="nump">$ 152,915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Development Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,726,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percent of positions eliminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember', window );">Stock Options, RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average antidilutive securities excluded from computation of earnings per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_SalesMilestoneRevenue', window );">Sales milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Nektar's | Eli Lilly And Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_CashAndNonCashRoyaltiesMember', window );">Cash And NonCash Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,800,000<span></span>
</td>
<td class="nump">$ 77,700,000<span></span>
</td>
<td class="nump">$ 79,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NKTR181Member', window );">NKTR - 181 | Program Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="nump">$ 45,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NKTR181Member', window );">NKTR - 181 | Program Termination, Advance Paymnt To Contract Manyfacturers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="nump">19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NKTR181Member', window );">NKTR - 181 | Program Termination, Noncancellable Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Nektar-358 | Nektar's | Eli Lilly And Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NetExpenseReimbursementsFromCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net expense reimbursements from collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NetExpenseReimbursementsFromCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units to evaluate goodwill for impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SalesMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SalesMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_CashAndNonCashRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_CashAndNonCashRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NKTR181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NKTR181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=nktr_ProgramTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=nktr_ProgramTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=nktr_ProgramTerminationNoncancellableCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=nktr_ProgramTerminationNoncancellableCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370058204512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Estimated Fair Value at</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 88,227<span></span>
</td>
<td class="nump">$ 25,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">416,750<span></span>
</td>
<td class="nump">708,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,828<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 504,977<span></span>
</td>
<td class="nump">$ 798,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370060537856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_InvestmnetsTargetMaturityPeriod', window );">Target maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_InvestmentsWeightedAverageMaturityPeriod', window );">Weighted average maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,504<span></span>
</td>
<td class="nump">$ 41,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_InvestmentsWeightedAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments, Weighted Average Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_InvestmentsWeightedAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_InvestmnetsTargetMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investmnets, Target Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_InvestmnetsTargetMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LongTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LongTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054316720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 429,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,801)<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">427,726<span></span>
</td>
<td class="nump">762,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">8,798<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">504,977<span></span>
</td>
<td class="nump">798,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">84,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">83,522<span></span>
</td>
<td class="nump">278,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Corporate commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">345,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">344,204<span></span>
</td>
<td class="nump">478,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. government agencies | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">47,054<span></span>
</td>
<td class="nump">23,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">$ 21,399<span></span>
</td>
<td class="nump">$ 10,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370058180736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,575<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">10,749<span></span>
</td>
<td class="nump">9,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,878<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 19,202<span></span>
</td>
<td class="nump">$ 15,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055180992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">$ 154,652<span></span>
</td>
<td class="nump">$ 201,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(124,731)<span></span>
</td>
<td class="num">(148,039)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentNet', window );">Depreciable property, plant and equipment, net</a></td>
<td class="nump">29,921<span></span>
</td>
<td class="nump">53,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction-in-progress</a></td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">7,163<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">32,451<span></span>
</td>
<td class="nump">60,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember', window );">Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">74,889<span></span>
</td>
<td class="nump">97,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">24,243<span></span>
</td>
<td class="nump">42,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">26,205<span></span>
</td>
<td class="nump">28,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">25,052<span></span>
</td>
<td class="nump">22,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures, and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">$ 4,263<span></span>
</td>
<td class="nump">$ 10,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciable Property, plant and equipment, Gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciable Property, plant and equipment, Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370058502384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370059584704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">$ 65,761<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">$ 20,100<span></span>
</td>
<td class="nump">$ 16,800<span></span>
</td>
<td class="nump">$ 16,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, percent</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_SubleasesIncomeToBeReceived', window );">Subleases aggregate lease payments</a></td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember', window );">Sublease Property, Plant And Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">$ 54,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember', window );">Mission Bay Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_AreaOfLeasedSpace', window );">Lease space (in sq ft) | ft&#178;</a></td>
<td class="nump">155,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember', window );">Third Street Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_AreaOfLeasedSpace', window );">Lease space (in sq ft) | ft&#178;</a></td>
<td class="nump">135,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of leased space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SubleasesIncomeToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subleases Income, To Be Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SubleasesIncomeToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055248544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Schedule of Operating Lease Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>term</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember', window );">Mission Bay Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NumberOfConsecutiveTermsToExtendLease', window );">Number of consecutive terms to extend lease</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LeaseExtensionTerm', window );">Lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember', window );">Third Street Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NumberOfConsecutiveTermsToExtendLease', window );">Number of consecutive terms to extend lease</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LeaseExtensionTerm', window );">Lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease extension term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LeaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfConsecutiveTermsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive five year terms to extend lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfConsecutiveTermsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370060483984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Schedule of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 17,057<span></span>
</td>
<td class="nump">$ 19,153<span></span>
</td>
<td class="nump">$ 18,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">8,974<span></span>
</td>
<td class="nump">8,179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 27,757<span></span>
</td>
<td class="nump">$ 28,127<span></span>
</td>
<td class="nump">$ 27,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370051443680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 19,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">21,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">22,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">22,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">23,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2028 and thereafter</a></td>
<td class="nump">51,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">161,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: portion representing interest</a></td>
<td class="num">(29,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">131,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(18,667)<span></span>
</td>
<td class="num">$ (17,441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">$ 112,829<span></span>
</td>
<td class="nump">$ 125,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370056879712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details) - SFJ Pharmaceuticals<br></strong></div></th>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CollaborativeArrangementCommittedFunding', window );">Committed funding</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount', window );">Collaborative arrangement, success-based payments</a></td>
<td class="nump">$ 637,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementCommittedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementCommittedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370059481408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details) - Development Derivative Liability - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</a></td>
<td class="nump">$ 27,726<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense', window );">Non-cash research and development expense</a></td>
<td class="nump">4,951<span></span>
</td>
<td class="nump">16,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Cash receipts from SFJ</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in the fair value of development derivative liability</a></td>
<td class="num">(33,427)<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054676240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 24, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24,410<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement | Future Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments', window );">Transaction costs related to revised royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement | Future Royalties | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved', window );">Payment of transaction related to purchase and sale agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved', window );">Payment of transaction related to purchase and sale agreement if threshold is not achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds', window );">Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties', window );">Transaction costs related to sale of potential future royalties</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement | Measurement Input, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember', window );">Pursuant to the 2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo', window );">Payment made for milestone not achieved year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne', window );">Payment made for milestone not achieved year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment made for milestone not achieved year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment made for milestone not achieved year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltiesLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltiesLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Related To Revised Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TransactionCostsRelatedToRevisedRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nktr_FutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nktr_FutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputInceptionDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputInceptionDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370050515856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">130 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties&#8212;beginning balance</a></td>
<td class="nump">$ 198,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(69,794)<span></span>
</td>
<td class="num">$ (77,746)<span></span>
</td>
<td class="num">$ (48,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(403,245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">28,911<span></span>
</td>
<td class="nump">47,313<span></span>
</td>
<td class="nump">$ 30,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">157,461<span></span>
</td>
<td class="nump">198,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,461<span></span>
</td>
<td class="nump">157,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(2,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,083)<span></span>
</td>
<td class="num">(2,083)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">155,378<span></span>
</td>
<td class="nump">195,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,378<span></span>
</td>
<td class="nump">155,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties&#8212;beginning balance</a></td>
<td class="nump">78,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(33,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(316,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">10,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">55,167<span></span>
</td>
<td class="nump">78,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,167<span></span>
</td>
<td class="nump">55,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">55,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,167<span></span>
</td>
<td class="nump">55,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties&#8212;beginning balance</a></td>
<td class="nump">120,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(35,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">18,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">102,294<span></span>
</td>
<td class="nump">$ 120,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,294<span></span>
</td>
<td class="nump">102,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(2,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,083)<span></span>
</td>
<td class="num">(2,083)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">$ 100,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,211<span></span>
</td>
<td class="nump">$ 100,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities on sale of future royalties, unamortized transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PartialRepaymentOfRoyaltySaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Partial repayment of royalty sale proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PartialRepaymentOfRoyaltySaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltyMonetizationProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltyMonetizationProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370060531232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember', window );">Merger and Acquisition Related Claims | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember', window );">Securities Related Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember', window );">Non-Securities Related Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations under director and officer indemnifications per incident.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054261696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 03, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod', window );">Stock issued during period subject to lock-up and stand-still provisions period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_SaleOfStockValueAuthorizedInTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Losses recorded in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(366,638,000)<span></span>
</td>
<td class="num">$ (679,508,000)<span></span>
</td>
<td class="num">$ (1,077,295,000)<span></span>
</td>
<td class="num">$ (1,405,391,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock to Bristol-Myers Squibb (in shares)</a></td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Losses recorded in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
<td class="num">$ (19,000)<span></span>
</td>
<td class="num">$ (18,000)<span></span>
</td>
<td class="num">$ (17,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Losses recorded in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Foreign Currency Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Losses recorded in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockValueAuthorizedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock Value Authorized In Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockValueAuthorizedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period subject to lock-up and stand-still provisions period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370060563136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for issuance</a></td>
<td class="nump">27,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember', window );">2017 Performance Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for issuance</a></td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for issuance</a></td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember', window );">Share-based Payment Arrangement, Option, RSUs And PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for issuance</a></td>
<td class="nump">23,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055263696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - License, Collaboration and Other Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 1,913<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 55,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Bempegaldesleukin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 1,913<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 5,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BempegaldesleukinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BempegaldesleukinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370053763648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Jul. 23, 2017</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NetExpenseReimbursementsFromCollaborationPartner', window );">Net expense reimbursements from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,981<span></span>
</td>
<td class="nump">$ 5,981<span></span>
</td>
<td class="nump">22,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol-Myers Squibb | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,700<span></span>
</td>
<td class="nump">$ 101,500<span></span>
</td>
<td class="nump">$ 128,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Bristol-Myers Squibb | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly And Company | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Nektar's | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Nektar's | Nektar-358 | Eli Lilly And Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions', window );">Percentage of regulatory milestones payments will be reduced under certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Nektar's | Nektar-358 | Eli Lilly And Company | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NetExpenseReimbursementsFromCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net expense reimbursements from collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NetExpenseReimbursementsFromCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received under certain conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054733280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,761<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Book value in excess of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nktr_ThirdStFacilityMember', window );">Third St. Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Book value in excess of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember', window );">Measurement Input, Market Participant Subtenant Borrowing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OperatingLeaseMeasurementInput', window );">Operating lease, measurement input</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percent of positions eliminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Entity number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OperatingLeaseMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OperatingLeaseMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nktr_ThirdStFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nktr_ThirdStFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370050389040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</a></td>
<td class="nump">$ 31,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and benefit expense</a></td>
<td class="nump">30,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">65,761<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on sale or disposal of property, plant and equipment, net</a></td>
<td class="num">(3,326)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract termination and other restructuring costs</a></td>
<td class="nump">10,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="nump">$ 135,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370051451296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of March 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="nump">30,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="num">(27,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of December 31, 2022</a></td>
<td class="nump">3,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithNoServicePeriodMember', window );">No service period</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of March 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="nump">22,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="num">(22,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithServicePeriodRequirementMember', window );">Service period required</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of March 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="nump">7,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="num">(4,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of December 31, 2022</a></td>
<td class="nump">$ 3,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithNoServicePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithNoServicePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithServicePeriodRequirementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithServicePeriodRequirementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055444640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Book value in excess of fair value</a></td>
<td class="nump">$ 67,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility</a></td>
<td class="num">(2,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Total impairment of sublease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,761<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (88,829)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="num">(20,954)<span></span>
</td>
<td class="num">(20,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember', window );">Sublease Property, Plant And Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Book value in excess of fair value</a></td>
<td class="nump">56,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility</a></td>
<td class="num">(1,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Total impairment of sublease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember', window );">Sublease Property, Plant And Equipment | Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,481)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember', window );">Sublease Property, Plant And Equipment | Estimate of Fair Value Measurement | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="num">(16,174)<span></span>
</td>
<td class="num">(16,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember', window );">Sublease Operating Lease Right of Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Book value in excess of fair value</a></td>
<td class="nump">11,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility</a></td>
<td class="num">(397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Total impairment of sublease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember', window );">Sublease Operating Lease Right of Use Assets | Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,348)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember', window );">Sublease Operating Lease Right of Use Assets | Estimate of Fair Value Measurement | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="num">$ (4,780)<span></span>
</td>
<td class="num">$ (4,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370058072352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales</a></td>
<td class="nump">$ 13,196<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">32,451<span></span>
</td>
<td class="nump">$ 60,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=us-gaap_FacilityClosingMember', window );">Facility Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales</a></td>
<td class="nump">13,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">9,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Total (gain) loss on sale or disposal of property, plan and equipment, net</a></td>
<td class="num">$ (3,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370050922752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ChangeInControlSeverancePaymentPeriodForExecutives', window );">Change in control severance payment period for executives</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 83,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized over a weighted-average period</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum 401(k) per employee, percentage of annual salary</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer', window );">Matching 401(k) employer contribution, maximum amount</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Compensation expense in connection with 401(k) retirement plan</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember', window );">2017 Performance Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized | shares</a></td>
<td class="nump">39,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare', window );">Share-based compensation plan's share limit reduction for every one restricted stock unit granted</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options term under equity incentive plans</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2017 Performance Incentive Plan | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2017 Performance Incentive Plan | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_RSUsAndPSUsMember', window );">RSUs and PSUs | 2017 Performance Incentive Plan | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for stock options grants (in shares) | shares</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="nump">$ 14.68<span></span>
</td>
<td class="nump">$ 19.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock vested</a></td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="nump">$ 45,300,000<span></span>
</td>
<td class="nump">$ 33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ChangeInControlSeverancePaymentPeriodForExecutives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in control severance payment period for executives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ChangeInControlSeverancePaymentPeriodForExecutives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation plan's share limit for every one share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nktr_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nktr_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktr_RSUsAndPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktr_RSUsAndPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054793760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 57,320<span></span>
</td>
<td class="nump">$ 94,674<span></span>
</td>
<td class="nump">$ 94,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">2,779<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">27,727<span></span>
</td>
<td class="nump">54,821<span></span>
</td>
<td class="nump">57,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">24,488<span></span>
</td>
<td class="nump">37,074<span></span>
</td>
<td class="nump">33,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,281<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370058185056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Average volatility factor</a></td>
<td class="nump">77.90%<span></span>
</td>
<td class="nump">63.80%<span></span>
</td>
<td class="nump">64.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected life</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 8.07<span></span>
</td>
<td class="nump">$ 10.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370060490880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">13,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">6,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited and canceled (in shares) | shares</a></td>
<td class="num">(5,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">14,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">4.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">12.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited and canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">20.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Life (in Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">5 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable (in shares) | shares</a></td>
<td class="nump">6,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life, Exercisable</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370053514688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details) - Restricted Stock Units (RSU) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units Issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">9,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">7,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and released (in shares)</a></td>
<td class="num">(2,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited and canceled (in shares)</a></td>
<td class="num">(5,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">9,312<span></span>
</td>
<td class="nump">9,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 16.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">4.14<span></span>
</td>
<td class="nump">$ 14.68<span></span>
</td>
<td class="nump">$ 19.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share)</a></td>
<td class="nump">17.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited and canceled (in dollars per share)</a></td>
<td class="nump">15.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 6.81<span></span>
</td>
<td class="nump">$ 16.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370059765616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (371,900)<span></span>
</td>
<td class="num">$ (524,440)<span></span>
</td>
<td class="num">$ (445,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">6,917<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (364,983)<span></span>
</td>
<td class="num">$ (523,280)<span></span>
</td>
<td class="num">$ (443,947)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055110272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(608)<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">2,708<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax expense</a></td>
<td class="nump">2,708<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 3,215<span></span>
</td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370060490400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate</a></td>
<td class="num">$ (76,647)<span></span>
</td>
<td class="num">$ (109,889)<span></span>
</td>
<td class="num">$ (93,229)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(987)<span></span>
</td>
<td class="num">(4,727)<span></span>
</td>
<td class="num">(3,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">51,108<span></span>
</td>
<td class="nump">97,914<span></span>
</td>
<td class="nump">87,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards', window );">Expiration of net operating loss carryforwards</a></td>
<td class="nump">12,348<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock-based compensation</a></td>
<td class="nump">15,778<span></span>
</td>
<td class="nump">6,627<span></span>
</td>
<td class="nump">7,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount', window );">Non-cash interest expense on liability related to sales of future royalties</a></td>
<td class="nump">6,071<span></span>
</td>
<td class="nump">9,936<span></span>
</td>
<td class="nump">6,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount', window );">Non-cash royalty revenue related to sales of future royalties</a></td>
<td class="num">(7,112)<span></span>
</td>
<td class="num">(7,891)<span></span>
</td>
<td class="num">(7,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,940<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">2,656<span></span>
</td>
<td class="nump">3,361<span></span>
</td>
<td class="nump">3,139<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 3,215<span></span>
</td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054343104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 545,508<span></span>
</td>
<td class="nump">$ 564,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and other credits</a></td>
<td class="nump">142,198<span></span>
</td>
<td class="nump">139,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Net capital loss carryforwards</a></td>
<td class="nump">38,445<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DeferredTaxAssetsLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">28,254<span></span>
</td>
<td class="nump">34,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">22,110<span></span>
</td>
<td class="nump">33,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">24,134<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">13,424<span></span>
</td>
<td class="nump">23,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">13,935<span></span>
</td>
<td class="nump">17,290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">828,008<span></span>
</td>
<td class="nump">813,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(816,235)<span></span>
</td>
<td class="num">(785,748)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">11,773<span></span>
</td>
<td class="nump">28,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(11,335)<span></span>
</td>
<td class="num">(27,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Investment in foreign subsidiary</a></td>
<td class="num">(2,451)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(392)<span></span>
</td>
<td class="num">(564)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(14,178)<span></span>
</td>
<td class="num">(27,768)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (2,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Liability Related to the Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054537680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 30,500<span></span>
</td>
<td class="nump">$ 115,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
<td class="nump">987<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
<td class="nump">$ 3,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized tax benefits, penalties recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange', window );">Unrecognized tax benefits, period may increase or decrease due to tax examination</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
<td class="nump">123,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
<td class="nump">$ 48,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits, period increase (decrease) reasonable period of change</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054261280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 80,604<span></span>
</td>
<td class="nump">$ 78,665<span></span>
</td>
<td class="nump">$ 77,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_TaxPositionsRelatedToCurrentYearAbstract', window );"><strong>Tax positions related to current year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">2,371<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Reductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_TaxPositionsRelatedToPriorYearsAbstract', window );"><strong>Tax positions related to prior years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">5,272<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(490)<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapses in statute of limitations</a></td>
<td class="num">(409)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 85,845<span></span>
</td>
<td class="nump">$ 80,604<span></span>
</td>
<td class="nump">$ 78,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TaxPositionsRelatedToCurrentYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Positions Related To Current Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TaxPositionsRelatedToCurrentYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TaxPositionsRelatedToPriorYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Positions Related To Prior Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TaxPositionsRelatedToPriorYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370054708224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NumberOfOperatingBusinessSegment', window );">Number of operating business segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 32,451<span></span>
</td>
<td class="nump">$ 60,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | UCB | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Baxalta Incorporated Or Takeda P L C | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Astra Zeneca Ab | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Pfizer | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | BMS | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment | Geographic Concentration Risk | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfOperatingBusinessSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfOperatingBusinessSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_UCBPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_UCBPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_AstraZenecaAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_AstraZenecaAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140370055486352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenue by Geographic Area (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 92,055<span></span>
</td>
<td class="nump">$ 101,907<span></span>
</td>
<td class="nump">$ 152,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Reportable Geographical Components</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9,841<span></span>
</td>
<td class="nump">10,114<span></span>
</td>
<td class="nump">64,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Reportable Geographical Components</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 82,214<span></span>
</td>
<td class="nump">$ 91,793<span></span>
</td>
<td class="nump">$ 87,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>nktr-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20221231.xsd" xlink:type="simple"/>
    <context id="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16b49844a173491ea91b890806242f5c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0b2a1c9a44244244898eecdde8576b9e_I20230221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="i36ac95832e534e18a6137ad8de7f1444_D20220531-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i809049297a1d4491a7387259a291ce70_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffeba43c66e94db7b8603276d878e2a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba9224c1c3bd45fd8d3b954982ffff11_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if399252e1f284f4aadda7ec3f6d82e87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b547e794cef44a7b04668aed100c659_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ee714b03e314804b75754b42ac2d14e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id3b02b8a4045435d96c81a09160eff2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff94ac8dace24c4e96ac5e215d7b240c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2592f70effb34a4d89f653e896ef7a34_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7ce1c72e26324dd38e6bc70f0d447453_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3503693dbb724782841e65e8f113c6fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife468d8852de4a56a284ece7b19844fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2b34672efed424da1803ccc001fd4f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3787df08c6d74cf98da1829469ef1b09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14d92114cae74251becb89962c58cc74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c9d9fd3ecfa4c9086a8279fc8984311_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id08cf5e99f4c4729b75cd9f892d3dd95_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac079dca38e543e29cee54f4bb8d8c85_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8982bed90c24581aca18ab4ef0fbd1b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f208c2b206d4f43af4e746f193bb362_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i987ef113f8824c15b8f15d8db5465d6d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic44c951d25d843329584f5aa34d0f5ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38e6cce64ebb4bf1829c2e2305936cf8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i998d6d8b90244039983cd9cc2d9e138d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1950a10af3724176843a6dc1e9e84e54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib04a5ee614c94e08a816a4c6381aec19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ebfebc03d28484bb3537335575f477e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96a8e3652a3d447ea7e5a6799fd339b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i448f61765d3a4f728112443592038e8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic10a28643df74c40af9cdf7c813b5a44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38a4fdda5691415fa69f3baedf60a37e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73ad8acf8f34426eb3f1aeef9273f29b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id748358d445d433fb8c8c90c82d6f1a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ef15d4863f04c8db682812ea8b05dc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i746ebde8a5a14d7fab51bbdd9974e2fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id726a6530b544c1ea713e5fd50d15fea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49140130df5b432e8dbcb7033e45422d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i935ae0dae4f141c8bb7ac64103e6fe70_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic6bae5374b2b41c484f1e8a2efee68bf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idab357fe657f4da88592a410901a0389_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia6c3d2d7dc6d4a638d0a5df9eb67618a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0edd83c86ce440bd97d489289b92afbc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f9c9a3627d54feea3a17351378935e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e18c528c36849c0a6d2470e6cf2054f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2410d2e734464c24a881fc5993536b43_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7395e5dc92e34456b97e26b144017d8e_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i33ecf05d707f40b5927205653bd6a5c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa285e8d668f45b28f17028c2066a303_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idfdbb2c2768a43c9b3cbce49b01157c7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i714c46f612124cfcade9ea69f3665fc3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i82b4b2a5e5094624ba910d5a452b36cf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6021c4787edd4734a14b823201617271_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i889f3563e17448ed9a713f77242ff320_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic66d4e5d50724998a83872fccfd73607_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib2e6c9c34e274b01a7184f32edcfcc5c_D20200114-20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:ProgramTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-14</startDate>
            <endDate>2020-01-14</endDate>
        </period>
    </context>
    <context id="id12f39942a7f4712bbddc41b4ff72c32_D20200114-20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:ProgramTerminationAdvancePaymntToContractManyfacturersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-14</startDate>
            <endDate>2020-01-14</endDate>
        </period>
    </context>
    <context id="ieee6e806d4bd4db3ac3280df3387e625_D20200114-20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:ProgramTerminationNoncancellableCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-14</startDate>
            <endDate>2020-01-14</endDate>
        </period>
    </context>
    <context id="if4204e31ff284f828fdbd3d7d5d1e925_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i799848d20d124621af203b62f338ec15_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2827b996b8d84b178c45819a76165160_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9e50785bed64ddaac9dcc4ee38f8d0b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81ee4e8815e44e2eaf7870c781941a30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f814cb3446b46a5b7c97104c33668a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71e9c0aab9a347229701114a13ba3b14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70cb12d6ed274cb3bc4aae55062cef33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24cdb13ced474b1e9afa182b37799a5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib4b3e1815f004636b2e747e17d73a6f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id00bc4b3a9074f93bce79a9e4c8911e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52837a82692c4071bbd19aa6f8dfc744_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ddb90dcdc5b4e7aa2740103176d7a92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iedbeaf00736c4ec5b4e73d8f63d31829_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a690bee3fdb41e69aa7a67bfdee3e57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8386997073541c38bb72fe0270ebcf7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b488f3b36c44ef2a771d6736c3a2bbd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie418bae4d52d43e884dd28a74b932d6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98a44796e8144efd8952281ed5f82527_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3264cdda22e4ccb9b495d63ecf07335_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida76ac790e3346c9abae40c1d17bbf09_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i229a4d508cf44e958dcc2e374b94852b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea5bf9ea7884421aab5dcf25a470d1db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89433d88568a4bbd9019d46526e1fb80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4700d3b1885a4b0d8c4f82c6feb9dcfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c4d7fb18f6d46d8988b427878e0c23f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f516ae040844d74a523bf6793681072_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48c8e42537d84cce85b95bb5c5b6d70c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i428577ef84824447b2265e91b8e6ca13_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iefb7645eeeaf42b793851c3bab72abca_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="ibcf73feefa4248f9bc901c6de5114e62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i296d2b099c6744c69a9b940e65fc438f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2cd1c1703c6a49d18229ba501627fd87_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if7b11067296644fba18e31a4fd031969_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b7c3411cc864b8fa20d76eb1a6c16ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie67fe37584df4144b73e3e9eab99c4d3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96e50a20c84741bf96617a4a3059d745_D20120224-20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-24</startDate>
            <endDate>2012-02-24</endDate>
        </period>
    </context>
    <context id="i0ee1e09ac15b43f982a08e4065ea0c1c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputInceptionDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic27548c7b9c047ce81417f7851d5a13b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bb7eac326dd4bd1860d0018b43342d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8f403286c134e56995c7fac6aabe42c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d861344a14b4ed19a94c299e3f1bd9c_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="i0a46e523740a48e4bc313c9c8f371a46_D20201230-20201230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="ib9e6083883184909bf4a11a730aefa63_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee97d6bd60ef4aa78a34aa3a4e187ea1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib56808f00dc44ceea4a81c7aadbb5013_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58214773cc764c89b77413cc27cba0d6_I20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-24</instant>
        </period>
    </context>
    <context id="i50db82185e724189a23e8bcbadd1f46d_I20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-16</instant>
        </period>
    </context>
    <context id="i5e27ff45c6344a70a6715b2e56bebc4a_I20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2012-02-24</instant>
        </period>
    </context>
    <context id="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0211a1334ced40e2833626cd80c87266_D20120225-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2012-02-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0f4ba6c9266400796c445c6f33d98d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb1ef455fc644610936464822e51b81e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfb29fc19c9d46639cf8c5115010c1ec_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="i11ff6330b45e466abdfd7de31f51f2d6_D20130301-20130331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="i01976cfee21a4bc1ac8121bef4c3c1f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07893b3959254f9ebfe26a0ff8ffc37b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id78314c12234445bbd7f0667b5fef4fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:MergerAndAcquisitionRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie58f9f4376a2484a87512c90b4835ff7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:SecuritiesRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c5fd482c6864667b05d8be19b108140_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:NonSecuritiesRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3995f200366f48ddae334a6ff1b42719_D20180403-20180403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="i5004dfaad50e4a37b683b94437e9c3fe_D20180403-20180403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="i9dee2bf1b1104b36a37ca5af4f6c6e08_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:ShareBasedPaymentArrangementOptionRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a12065b592f45eb91672b4c2ecfc993_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a09c769b2cf4b7d96bd94af49863ae2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib0a2b75f3c2c497e821c32654dcf273d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b2e426dae1d4dcb82e953621113a971_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41101ca7c6074352b2c8edbbded90a47_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic6f6ddc21ca64160889eff82cd22dac0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb79cd1e8a9d4e9b956b054364d945b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b00cf7a680342eabe29c33d1f30ca48_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd4d0375d0754d04bfbcb3001a3a73ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1acc968e13bf49b2af89cb89994d8c21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a0cc81cd3464c5b93834a7c5444f287_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i518ea15aaef14db7aa415c20c69633ba_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="if2e2d3e9e2a7461daef194bc19d22bb4_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i93f5d9b4d79b4feca3f3a4d2b14a9583_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i034999d286934f979052476fb5f2c14a_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="if6238407fbe54f7f8ccc426559162694_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i3c808ebe93bd410caafb0853708fc73f_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ibcde63790f2b4c09a640ee1fb4bcaf0e_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i4cbcedb2872f472f8169616cf817be26_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia59bf42370df4deeb31e0accd2bdaf1a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d8701f92c324d04925cd7cef5dec02f_D20220401-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28f996738350426c90cc53b744993a58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i398cab648ac141a89899e3e28583c043_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if58625a341de4335a5fee3c3a3737dae_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="iebb537ce80dc447d8acffa6a5eb73666_I20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-23</instant>
        </period>
    </context>
    <context id="ib0f6b7f71328485db76064f93dc003eb_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="i45d02ce2e1364896bbbc49fa46ce2648_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="i22df0cf6959c4db1b5ac09a71e43c84c_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="if7a7eeedf4d74cc9a9917ed4c99c02c8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79208888512146d7bc75e741ef3f64e2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i81256841f310427f8d19dc50d08b735c_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="idcc20cfb1c4a48679a78206fc2ea8b1d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2ac9a278cf47443e98c7cfa38fb872b4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icb69ada362dc437e9819aaa096864a94_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2c9b0c23b6004aa1922ed92ae6e42a1c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie391f9f234c444d2ae0b217cc409af4b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i761caeec68a54ac890af6ea722b34752_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id3cbdfb27cfb4debb4992b2d68d5cf26_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iab6c152af63d4a498aafc8fa69bf4bca_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i948d3d10847d41cbaa8d5e99b9e0ca18_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nktr:ThirdStFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i678b972618854ccfa5f8b75959d9a207_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i44bbfe0cc7fd4079a8fc3d2aa0c332c7_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i61c9135dab8146c78e84573062004417_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i97e18421949d4c96bbefcd9f889dee65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21602aeba0af4306b9db2ff5a747c939_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4cf06f89dab34bc49d9056719d6cf796_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic43d66fd88c34d01b4ff0cd1a46695cd_D20220601-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idedb361025fe4dc4be9515a9ddc5cd78_D20220601-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee4cee9d0d7e4f278ad6b604a58efaa1_D20220601-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie0ef1164091d46e7b57ab43df8707987_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac8a6dd98aab4d3dbbc732084af7018f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9e4effa18ad3427aa1e582fbe34e43d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6b03bb908cf46a1975c75a41487f342_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i63c718ae96904cc5b999aca6b38e6acc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i14542c4fb8594026a9f1f2689a366572_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:RSUsAndPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2c9ec41962e341438be60878bcaa9e09_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6fa5c4f56ceb45109dc0bac18906c879_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20e80ebc90964b95852b0af70c1a0bed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e36b8afe0164eeca7a3f8aee4dc3069_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ided66bf243294649aa10f28f877a38bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1da4578eb344c37a4ac66d8094312cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i833b94c48c5d400b9f223dd465244748_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5cb540e2259a4eb5ba670a48eb66248a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2c7e882eb974894b44df7c39cfa9ea3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if13a72164f93445d97d6df5a196ca7b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6627c3421cb942dfafa0a03fa35c32f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25f55b5dda92449f87631aec26801a47_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic3b60fd0890f4d5ea688cd88f60c0fdc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3928dcd65fad4307afa1ad19230facf4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76c5c0679b2b4b999749ec226dd1c85a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3119b6ee8f3b4dde9cd9450833493c0f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05810fa0da244bacbdcde63b4b7a095b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1708b7bc3884af6be169aa6e4bd9ee9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia5f2ce65d9b74f5ab00210112601e860_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief64bc46a28844f3b364287244422030_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61ca801a96804d5caed8be9bb6955df9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec82e56d740a40949cb39ff40fc8cd9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5277dcb595b47198bdeb0c40ae34d2c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1aa7a7c1e8844691b326d42966bf4551_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0beac0b0ae64d58915ff881a46e62b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0201532ad324c8c9dbec3f1607c4d7b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i72308160e9054ecaaaa7ec0beb1ff284_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7bf92b2d15d544d6937956567cbd8076_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifdc6254636f546a2a43ce040c6c6085e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaa8e4e763a2449e0a04e0609515b8c63_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if00a63dfc4ab4080a7c7be10c52a4120_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b3e0f8c46714fc9be46c65f8de72fe0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8bd42991fff149128d3dc16bf7316b6f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id07a9952dc4c450b824484980ebe8928_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7daa5860832a47c08be4e2bbcc929c50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56fc82462fb045c19add828b177099e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib462fc56afce4ed7b4b6728742f20fd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d4868926af54225af1a855f5d4d34d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14494e5a12494d72a7acb39246fa450e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i06754ac5c8fe4627adbc24980fd082b4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i86844cf0f9cb4932bc6509504c7a663f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaecd4f6f9c444958b8f0e06d42b1c2aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71e1f0e358824a6bbe3fb5fb2404dc19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i057ece2c908047309cf984bb11af2ec4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i78596537cc1e4bba8d4c10682953227a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i836074eda2e7444d9c8ad2e1bd97d05c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54faac177aa94cc8a0cc84d3f8d86a9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="reporting_unit">
        <measure>nktr:reporting_unit</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="term">
        <measure>nktr:term</measure>
    </unit>
    <unit id="segment">
        <measure>nktr:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF80L2ZyYWc6MDM1YTc3YmZkOTY0NDdiNjg2YTI1Y2IyZTFmMzRiNGEvdGFibGU6YjVkNTI3ZDUyZGEwNDE2ZmFkNWJjNDk4ZmJmZDkwNzAvdGFibGVyYW5nZTpiNWQ1MjdkNTJkYTA0MTZmYWQ1YmM0OThmYmZkOTA3MF8yLTEtMS0xLTM5ODM2_00bf7fb3-8fbf-4e85-bb75-6ceff41e4cca">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF80L2ZyYWc6MDM1YTc3YmZkOTY0NDdiNjg2YTI1Y2IyZTFmMzRiNGEvdGFibGU6YjVkNTI3ZDUyZGEwNDE2ZmFkNWJjNDk4ZmJmZDkwNzAvdGFibGVyYW5nZTpiNWQ1MjdkNTJkYTA0MTZmYWQ1YmM0OThmYmZkOTA3MF8zLTEtMS0xLTM5ODM2_d808af98-870e-4a0c-a4a1-41cd99c4b0bc">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF80L2ZyYWc6MDM1YTc3YmZkOTY0NDdiNjg2YTI1Y2IyZTFmMzRiNGEvdGFibGU6YjVkNTI3ZDUyZGEwNDE2ZmFkNWJjNDk4ZmJmZDkwNzAvdGFibGVyYW5nZTpiNWQ1MjdkNTJkYTA0MTZmYWQ1YmM0OThmYmZkOTA3MF80LTEtMS0xLTM5ODM2_dba9f2fa-25a5-4f67-b92f-15e375533776">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF80L2ZyYWc6MDM1YTc3YmZkOTY0NDdiNjg2YTI1Y2IyZTFmMzRiNGEvdGFibGU6YjVkNTI3ZDUyZGEwNDE2ZmFkNWJjNDk4ZmJmZDkwNzAvdGFibGVyYW5nZTpiNWQ1MjdkNTJkYTA0MTZmYWQ1YmM0OThmYmZkOTA3MF81LTEtMS0xLTM5ODM2_45fefbe0-c8d6-47db-a3f8-02e96a766aa2">0000906709</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iaa285e8d668f45b28f17028c2066a303_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTMwOTA_777cbe6f-53e1-4ebb-939f-b2bf951dd6a7">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="ic9e50785bed64ddaac9dcc4ee38f8d0b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTUz_cabe071a-9291-4113-98c3-9850259068b6">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LeaseExtensionTerm
      contextRef="i7f516ae040844d74a523bf6793681072_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMS0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmZDFjZGUwODRhMjM0MjRiODM0ZTUxNjRlODJmZWYwMl8xOQ_2b0e6231-2800-4ca2-b334-9e61b9740c93">P5Y</nktr:LeaseExtensionTerm>
    <nktr:LeaseExtensionTerm
      contextRef="i48c8e42537d84cce85b95bb5c5b6d70c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMy0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmNWM1YzY0MzkwN2Q0MjkzODY0ODc2YzY1NzI1Y2VjN183_28da30aa-6692-46e9-9d13-2ccc8f191594">P5Y</nktr:LeaseExtensionTerm>
    <dei:DocumentType
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ1_4b77c832-7634-4dec-83fd-0c02cadc6cc0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6YjVhNDk2MTI4ZjIyNGRjODlmZDI0ZGI0MmU5ZGRhOWYvdGFibGVyYW5nZTpiNWE0OTYxMjhmMjI0ZGM4OWZkMjRkYjQyZTlkZGE5Zl8wLTAtMS0xLTM5ODM2_f754f679-407b-41bb-8551-186cc6d282d0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8yNjk_7535c695-8a41-49fd-af38-72e04b8d3264">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8yNjk_1fe5cb20-1d37-4a9f-8304-0f5bf4e03da9">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6NWNmMDdlYjU0ZDFmNGUzZWI0NjJiZTVkNTU5NDI0MWMvdGFibGVyYW5nZTo1Y2YwN2ViNTRkMWY0ZTNlYjQ2MmJlNWQ1NTk0MjQxY18wLTAtMS0xLTM5ODM2_e863f63e-a68a-4ac2-a85c-c96468083b1f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODM5_a089ec18-d243-435a-8d4b-812bb5111625">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQw_9dea91f6-6848-416d-b85a-fbcd2b249f6d">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ODUzNzhiNzRiYmExNGRhMWI3ZGE0MGFhY2EyYTI5MTQvdGFibGVyYW5nZTo4NTM3OGI3NGJiYTE0ZGExYjdkYTQwYWFjYTJhMjkxNF8wLTAtMS0xLTM5ODM2_a92c9662-3d36-47d5-a245-396b160c9a58">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ODUzNzhiNzRiYmExNGRhMWI3ZGE0MGFhY2EyYTI5MTQvdGFibGVyYW5nZTo4NTM3OGI3NGJiYTE0ZGExYjdkYTQwYWFjYTJhMjkxNF8wLTItMS0xLTM5ODM2_bd849490-fdac-44d3-b546-c4d95b152950">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ2_ee176120-e290-4b43-8af6-52501083ba93">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODM1_cb61fc57-fef2-44bb-a5fd-61679be1124c">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODMz_01dbcebe-cca4-44ba-a3f0-a0b38f00b491">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQx_a7f67411-e029-414d-9941-43b685c71b8c">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODM2_2e1dfe1d-946b-4d00-a3f5-f5b0d366d6ba">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODM3_b5924a08-d6fe-4882-92c7-dcb63f01cf81">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ZjkzYTUxNDdjZjg2NDdhMjg2ZWRlNzU0ZGQ0YmNhZmUvdGFibGVyYW5nZTpmOTNhNTE0N2NmODY0N2EyODZlZGU3NTRkZDRiY2FmZV8xLTAtMS0xLTM5ODM2_b2ec5fb7-b7ac-410b-bd73-1e289d366fb9">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ZjkzYTUxNDdjZjg2NDdhMjg2ZWRlNzU0ZGQ0YmNhZmUvdGFibGVyYW5nZTpmOTNhNTE0N2NmODY0N2EyODZlZGU3NTRkZDRiY2FmZV8xLTEtMS0xLTM5ODM2_a258a48e-5433-462c-9d2c-954a2af5d779">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6ZjkzYTUxNDdjZjg2NDdhMjg2ZWRlNzU0ZGQ0YmNhZmUvdGFibGVyYW5nZTpmOTNhNTE0N2NmODY0N2EyODZlZGU3NTRkZDRiY2FmZV8xLTItMS0xLTM5ODM2_9c85cddc-e479-4339-aea1-5f13c657f219">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8xMDk5NTExNjMzMDcz_ec8ddf18-f5ff-4757-a9dc-34eb22bd01e7">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQy_e9aef6e9-7bf8-441a-a7d3-b150c1fe6555">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ3_f0c1d330-f6f1-4a68-a91d-9b1a04f49a59">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ4_876474bf-ea21-41a0-921e-32fa43b0b18b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6Y2M3OTRhM2U0YjczNDVlZWJkMWIxNGNkNWU2OTBhYmQvdGFibGVyYW5nZTpjYzc5NGEzZTRiNzM0NWVlYmQxYjE0Y2Q1ZTY5MGFiZF8wLTAtMS0xLTM5ODM2_7f556159-9761-4569-9be0-2e7143af2a8d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6Y2M3OTRhM2U0YjczNDVlZWJkMWIxNGNkNWU2OTBhYmQvdGFibGVyYW5nZTpjYzc5NGEzZTRiNzM0NWVlYmQxYjE0Y2Q1ZTY5MGFiZF8xLTQtMS0xLTM5ODM2_309f37b4-7371-420e-bbae-530a3177876f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGFibGU6Y2M3OTRhM2U0YjczNDVlZWJkMWIxNGNkNWU2OTBhYmQvdGFibGVyYW5nZTpjYzc5NGEzZTRiNzM0NWVlYmQxYjE0Y2Q1ZTY5MGFiZF8yLTEtMS0xLTM5ODM2_7c2c687e-4203-4d89-ad60-424bd66456b4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQz_7791308e-99a3-49ce-a793-5b9557a62267">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8xODE0MTk0MTg2MzYwOA_154be084-fb3b-4c82-b045-8b9bea7041dc">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i16b49844a173491ea91b890806242f5c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zMzc3_6af691df-389d-468a-808d-0bb0e044aba1"
      unitRef="usd">704000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0b2a1c9a44244244898eecdde8576b9e_I20230221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zNDYx_c6c67642-042b-416f-bb48-22a2101ad17d"
      unitRef="shares">189235139</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xL2ZyYWc6YWM2MTlmOThmNTNhNDZmMjhjNTM5OTBhMTYwNTE3MWEvdGV4dHJlZ2lvbjphYzYxOWY5OGY1M2E0NmYyOGM1Mzk5MGExNjA1MTcxYV8zODQ0_fbf03d37-0368-40be-a33b-1e7b1264d897">Portions of registrant&#x2019;s definitive Proxy Statement to be filed for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <nktr:OperatingLeaseMeasurementInput
      contextRef="i36ac95832e534e18a6137ad8de7f1444_D20220531-20220531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF81OC9mcmFnOjE0ZTQzZjUzZjE0ODRjNWZiMjg1ZDZlYjNlYWRlYzFhL3RleHRyZWdpb246MTRlNDNmNTNmMTQ4NGM1ZmIyODVkNmViM2VhZGVjMWFfMTA5OTUxMTYzMzYwNTE_4ce5c355-8571-49b9-a6c2-9650b68ddc20"
      unitRef="number">0.064</nktr:OperatingLeaseMeasurementInput>
    <nktr:OperatingLeaseMeasurementInput
      contextRef="i809049297a1d4491a7387259a291ce70_D20221231-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF81OC9mcmFnOjE0ZTQzZjUzZjE0ODRjNWZiMjg1ZDZlYjNlYWRlYzFhL3RleHRyZWdpb246MTRlNDNmNTNmMTQ4NGM1ZmIyODVkNmViM2VhZGVjMWFfMTA5OTUxMTYzMzYwNTk_c4d2abb8-451c-478f-8d3a-f51a150cb575"
      unitRef="number">0.079</nktr:OperatingLeaseMeasurementInput>
    <dei:AuditorFirmId
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF82NC9mcmFnOjA0NDMzMjQ0MWJkMjQxZDg4OThhNTRhMDhmOGFkNjc2L3RhYmxlOmI2ZjAzNjM5ZDA1MTQyMDE5NGI1MTlhOGU0OTJhODRiL3RhYmxlcmFuZ2U6YjZmMDM2MzlkMDUxNDIwMTk0YjUxOWE4ZTQ5MmE4NGJfMS0wLTEtMS0zOTgzNi90ZXh0cmVnaW9uOjNlNGU5MDQ0YmIxMjRhYTI5OGU4NDBjNTAxODRhNmY3Xzcy_78909f2d-2b7f-463a-94de-b13ee5b34f22">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF82Ny9mcmFnOmRhMmRlMzFiNjcyMjQ0YjlhOWUzNmU0YTBkMWE0NDM2L3RleHRyZWdpb246ZGEyZGUzMWI2NzIyNDRiOWE5ZTM2ZTRhMGQxYTQ0MzZfNzcxMA_2d29b15d-ec13-4488-b375-1f559016b08f">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF82Ny9mcmFnOmRhMmRlMzFiNjcyMjQ0YjlhOWUzNmU0YTBkMWE0NDM2L3RleHRyZWdpb246ZGEyZGUzMWI2NzIyNDRiOWE5ZTM2ZTRhMGQxYTQ0MzZfNzcxMQ_5c67fc2c-232a-4f15-919d-05bde6fcf560">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNC0xLTEtMS0zOTgzNg_bfbc7a31-4dac-4308-8560-8ba5e2fcbb05"
      unitRef="usd">88227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNC0zLTEtMS0zOTgzNg_dac7a712-6d78-4c90-bbae-ac8644c8ca7d"
      unitRef="usd">25218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNS0xLTEtMS0zOTgzNg_14fb2016-8145-436d-a7ed-e2ce5a5ea973"
      unitRef="usd">416750000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNS0zLTEtMS0zOTgzNg_d7716f55-3e15-4718-af6b-688e24894454"
      unitRef="usd">708737000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNi0xLTEtMS0zOTgzNg_e05d73e9-c771-47a2-b35c-3c99d7333ad1"
      unitRef="usd">5981000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNi0zLTEtMS0zOTgzNg_fb86b52d-5850-48f2-8b19-1a85e18c7cc3"
      unitRef="usd">22492000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNy0xLTEtMS0zOTgzNg_7a132462-7766-44bf-90ca-fa58cf8bdf5a"
      unitRef="usd">19202000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfNy0zLTEtMS0zOTgzNg_42957f17-d25b-42d6-92d4-18bd272d1198"
      unitRef="usd">15801000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfOC0xLTEtMS0zOTgzNg_38b7dd37-ff0c-4743-805e-14c763655bef"
      unitRef="usd">15808000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfOC0zLTEtMS0zOTgzNg_da6af886-467f-4476-91bb-754d8300a41a"
      unitRef="usd">23333000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfOS0xLTEtMS0zOTgzNg_4e5037bc-423c-481e-a462-7f2337e1972e"
      unitRef="usd">545968000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfOS0zLTEtMS0zOTgzNg_0d35978c-4217-4dfb-95c5-904b47aebb3d"
      unitRef="usd">795581000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTAtMS0xLTEtMzk4MzY_415c2a15-643a-48ee-90f5-e0ff4cb9ab81"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTAtMy0xLTEtMzk4MzY_fc9d325d-6e2b-48d7-8815-5c56b5e14c42"
      unitRef="usd">64828000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTEtMS0xLTEtMzk4MzY_085e932f-f95f-49e4-adc0-c4cfa8103ff5"
      unitRef="usd">32451000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTEtMy0xLTEtMzk4MzY_9e7bd0a6-64ab-4026-ad8f-64ed3141dbed"
      unitRef="usd">60510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTItMS0xLTEtMzk4MzY_dc896d1c-7deb-4282-9fdc-d0e22c961a1c"
      unitRef="usd">53435000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTItMy0xLTEtMzk4MzY_46fe935f-0de6-4193-ac77-e8d95c291780"
      unitRef="usd">117025000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTMtMS0xLTEtMzk4MzY_7bde027f-09d3-4751-a2bd-fd1acd406df2"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTMtMy0xLTEtMzk4MzY_77c0e68c-0f9a-4cc8-885f-d33587e20d5a"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTQtMS0xLTEtMzk4MzY_bd4d022b-c1e8-4405-91a0-9d19a9bd7a76"
      unitRef="usd">2245000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTQtMy0xLTEtMzk4MzY_2d7c6b00-7d0a-43b4-bc95-c9ab90abd763"
      unitRef="usd">2744000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTUtMS0xLTEtMzk4MzY_05fc4191-96dd-4830-bd83-f203a68ba355"
      unitRef="usd">710600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTUtMy0xLTEtMzk4MzY_4e6d26c3-6a65-488b-aed3-5d0adf09fdb7"
      unitRef="usd">1117189000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTgtMS0xLTEtMzk4MzY_a96981ec-1904-41e6-b0c3-8647b9ca4002"
      unitRef="usd">12980000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTgtMy0xLTEtMzk4MzY_2822bb91-5fc6-474e-ae3f-e69a7a18628c"
      unitRef="usd">9747000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTktMS0xLTEtMzk4MzY_226c86cc-2146-4d27-b90f-9e63c6b53f7b"
      unitRef="usd">9582000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMTktMy0xLTEtMzk4MzY_1f3434fb-ea57-40d5-866e-eab5e76e23ba"
      unitRef="usd">15735000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjAtMS0xLTEtMzk4MzY_4cfcbc95-e0f8-4382-92fb-70671b706445"
      unitRef="usd">12262000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjAtMy0xLTEtMzk4MzY_24efe366-13be-45d6-9c8d-a4f9ec76f5ca"
      unitRef="usd">26809000</nktr:AccruedClinicalTrialExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjEtMS0xLTEtMzk4MzY_37fe0859-7cbf-4dcb-9b03-4aef6e3d7188"
      unitRef="usd">14713000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjEtMy0xLTEtMzk4MzY_d26a36e4-e65e-4264-a50f-378e54a18207"
      unitRef="usd">15468000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjItMS0xLTEtMzk4MzY_b597e1a9-11ae-431f-85ff-cf1b8c569452"
      unitRef="usd">18667000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjItMy0xLTEtMzk4MzY_baac18d7-f0b4-4c39-aab1-497ee66c1887"
      unitRef="usd">17441000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjMtMS0xLTEtMzk4MzY_0c34e6c6-98b2-4deb-8824-1f2d82b35f8a"
      unitRef="usd">68204000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjMtMy0xLTEtMzk4MzY_745f687c-5035-49cd-bf66-47b8b8a2cc74"
      unitRef="usd">85200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjQtMS0xLTEtMzk4MzY_4a048ad3-2229-4298-9872-4cb5205c870d"
      unitRef="usd">112829000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjQtMy0xLTEtMzk4MzY_5062280e-a4df-416e-9a46-45779513a921"
      unitRef="usd">125736000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjUtMS0xLTEtMzk4MzY_1d64cb82-e0f3-4111-b050-bcb58e83fa9d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjUtMy0xLTEtMzk4MzY_e52219bf-57e8-425a-9c7c-758f276fbf63"
      unitRef="usd">27726000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjYtMS0xLTEtMzk4MzY_b4650791-b6c4-4071-aefe-fc6011bf41fa"
      unitRef="usd">155378000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjYtMy0xLTEtMzk4MzY_542bb35d-4b9d-47c4-8b27-7c279f0356f1"
      unitRef="usd">195427000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjctMS0xLTEtMzk4MzY_c4533197-6f9b-45e3-a006-6b358e001ca0"
      unitRef="usd">7551000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjctMy0xLTEtMzk4MzY_d425882f-85d2-41ad-8492-b161eb5f747e"
      unitRef="usd">3592000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjgtMS0xLTEtMzk4MzY_c66e8ab4-e4d3-4978-9819-90c1995fe488"
      unitRef="usd">343962000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjgtMy0xLTEtMzk4MzY_061f086a-f5ba-42e9-9ea0-d9bd774694a0"
      unitRef="usd">437681000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjktMS0xLTEtMzk4MzY_6246198d-264c-4cd8-8ada-6a2e2e2870a6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMjktMy0xLTEtMzk4MzY_e1430153-aa43-4694-ac0e-20b7215fdc79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF8yMQ_4dad132a-411a-44bd-8e56-783a5ca8ad1a"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF8yMQ_d056c25a-bde2-469f-a720-3e00f4cc777b"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF8zNQ_b4f5e184-56d9-4e37-91c3-c2950fc1f409"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF8zNQ_df7b547a-9c29-4268-a1fe-3730e96e973b"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_2a6f5f8f-9ef9-4264-b8d9-64cee7ba8c86"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_4c6908a5-44e7-4d46-b1b2-4a1aecc8b0b3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_a3cb3cbd-a9d1-474f-8080-c1f4bea17e0b"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_b90eb74a-ef23-4f49-99a2-5bc10d9dd1b1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_bb020b7e-a4e4-4675-9f42-c71fa7ae0b99"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4M2I5YTMwMjhlZWE0N2FlODkzZDVhNzgxODk0MjBiZF81Nw_ef74d774-8e7e-4e91-8869-154c21c16db6"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockValue
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMS0xLTEtMzk4MzY_3b2fd877-806b-4e34-8174-c6ecdff658eb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzEtMy0xLTEtMzk4MzY_e9744415-d750-4266-b662-ae138c803502"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl8xOA_93f4cfbe-cda7-4607-a629-1f9ffc1a3780"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl8xOA_e153b34f-13b3-4cc6-9569-71f8d6a113da"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl8zMg_1050baa7-d526-487e-96b4-c41398c97142"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl8zMg_73b0b8b1-1a4e-495e-8ad0-c13a9c21cbd0"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl81NA_2b1c069a-f1c9-4fbf-bfe8-1f417e2747cb"
      unitRef="shares">188560000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl81NA_b9d5af2e-46f5-48e6-933f-575b5fa337a5"
      unitRef="shares">188560000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl82OA_c4034a33-3ada-4ca4-bf3f-f981273c41a8"
      unitRef="shares">185468000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjozNTk4ZjViNGQzZjk0MmYwYjUxYzU1M2JjOWFjZjdkMl82OA_ef50b3e7-f98d-49bd-8955-fd1eae594e9c"
      unitRef="shares">185468000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMS0xLTEtMzk4MzY_1f8358e0-67ce-4f31-898d-42216a5be986"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzItMy0xLTEtMzk4MzY_8a49c1ab-3842-4b93-a6ea-675bbec32040"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzMtMS0xLTEtMzk4MzY_95690f8a-4116-433a-8ac2-365955aa0606"
      unitRef="usd">3574719000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzMtMy0xLTEtMzk4MzY_3857e2ae-e812-44c2-b784-03071374da5e"
      unitRef="usd">3516641000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzQtMS0xLTEtMzk4MzY_694a3c0e-1ae1-4e66-83c7-364b2f44c83d"
      unitRef="usd">-6907000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzQtMy0xLTEtMzk4MzY_78d0b8ba-33b5-42b5-8be2-6e3c9e3ae666"
      unitRef="usd">-4157000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzUtMS0xLTEtMzk4MzY_189ce3bb-fc2b-4b19-ba27-fece5a62a3ff"
      unitRef="usd">-3201193000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzUtMy0xLTEtMzk4MzY_f690fe4c-396c-45e0-ac7d-ad4125cb739f"
      unitRef="usd">-2832995000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzYtMS0xLTEtMzk4MzY_2bb3e832-60e5-4280-b8fe-406e9556b600"
      unitRef="usd">366638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzYtMy0xLTEtMzk4MzY_544ffa2c-d462-4583-9baa-b190a706f697"
      unitRef="usd">679508000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzctMS0xLTEtMzk4MzY_ffbf2bc6-7eff-4c09-8c03-d8917f3c8618"
      unitRef="usd">710600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83MC9mcmFnOjlhMTFlYjUzZGFjYzQ1MTA5N2I0NTYxY2ZjZmM2NTkxL3RhYmxlOjE2ZjY0NDg3ZjAyMDQwZDk4ODI2MGQwZTU5OWQzMDU0L3RhYmxlcmFuZ2U6MTZmNjQ0ODdmMDIwNDBkOTg4MjYwZDBlNTk5ZDMwNTRfMzctMy0xLTEtMzk4MzY_e21647d7-fce9-42cc-be8e-1a173be6fe85"
      unitRef="usd">1117189000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba9224c1c3bd45fd8d3b954982ffff11_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMy0xLTEtMS0zOTgzNg_25de8fb9-d24e-438e-9762-8f6a71c5c92b"
      unitRef="usd">20348000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if399252e1f284f4aadda7ec3f6d82e87_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMy0zLTEtMS0zOTgzNg_968e57e5-f115-4688-8466-843336d9aa77"
      unitRef="usd">23725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b547e794cef44a7b04668aed100c659_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMy01LTEtMS0zOTgzNg_72a39aa0-0bd1-426d-84b9-84adc96d8838"
      unitRef="usd">17504000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ee714b03e314804b75754b42ac2d14e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNC0xLTEtMS0zOTgzNg_2d2f2433-d5b1-4396-b711-2e1de51cfc25"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3b02b8a4045435d96c81a09160eff2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNC0zLTEtMS0zOTgzNg_a562fba8-2f6c-467d-ae0a-94b2c9318f73"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff94ac8dace24c4e96ac5e215d7b240c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNC01LTEtMS0zOTgzNg_0996982a-a038-4430-a9f8-ed1448d2c3e3"
      unitRef="usd">30999000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2592f70effb34a4d89f653e896ef7a34_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNS0xLTEtMS0zOTgzNg_c9b0b3be-5071-48ca-afcf-c2eb5b4e3c34"
      unitRef="usd">69794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ce1c72e26324dd38e6bc70f0d447453_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNS0zLTEtMS0zOTgzNg_500a7ba1-4df7-425d-9e05-2c31c8f26453"
      unitRef="usd">77746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3503693dbb724782841e65e8f113c6fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNS01LTEtMS0zOTgzNg_5497b635-c85d-4ad0-bd11-a912effa770d"
      unitRef="usd">48563000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife468d8852de4a56a284ece7b19844fb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNi0xLTEtMS0zOTgzNg_5eacbfcc-6edc-42ff-a164-80fac4886790"
      unitRef="usd">1913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b34672efed424da1803ccc001fd4f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNi0zLTEtMS0zOTgzNg_67ef0889-1a63-4ecd-a243-b09ffbb4a12b"
      unitRef="usd">436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3787df08c6d74cf98da1829469ef1b09_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNi01LTEtMS0zOTgzNg_86cf4d70-cd5a-4bc0-b8a4-fcc7b1dba661"
      unitRef="usd">55849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNy0xLTEtMS0zOTgzNg_aff95734-eef2-4019-a9a7-aec8bee7fd42"
      unitRef="usd">92055000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNy0zLTEtMS0zOTgzNg_95ab96cf-5707-4c3b-9f08-6d2f9cd04ee7"
      unitRef="usd">101907000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfNy01LTEtMS0zOTgzNg_2acdafd8-e7c6-4674-9656-126ab75d6fce"
      unitRef="usd">152915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfOS0xLTEtMS0zOTgzNg_a372cf33-3cd0-4448-ab27-62748946100d"
      unitRef="usd">21635000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfOS0zLTEtMS0zOTgzNg_2810fb2f-ff67-4b74-9fcf-a4df47f4dd16"
      unitRef="usd">24897000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfOS01LTEtMS0zOTgzNg_eabebc0f-266c-4a6d-aee2-0b296ecea53d"
      unitRef="usd">19477000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTAtMS0xLTEtMzk4MzY_91eb53fd-9dd9-4e02-8b1f-baedec4bb7be"
      unitRef="usd">218323000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTAtMy0xLTEtMzk4MzY_a0d47773-624a-4166-8a42-c860b067af61"
      unitRef="usd">400269000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTAtNS0xLTEtMzk4MzY_aedc1b9d-51ab-4ccf-88f1-e6e6bbd1dd83"
      unitRef="usd">408678000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTEtMS0xLTEtMzk4MzY_af228767-cc90-4357-987c-d1e3066b8097"
      unitRef="usd">92333000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTEtMy0xLTEtMzk4MzY_47830201-b98d-4cd9-b250-69f9b0d596a8"
      unitRef="usd">122844000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTEtNS0xLTEtMzk4MzY_5a785520-a505-425c-a96f-d6ad9c15cab2"
      unitRef="usd">104682000</us-gaap:GeneralAndAdministrativeExpense>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTItMS0xLTEtMzk4MzY_b3fb388e-f853-460b-a587-8e538a999cc4"
      unitRef="usd">135930000</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTItMy0xLTEtMzk4MzY_e75cad05-12e6-412a-bee3-1865ae5eef3a"
      unitRef="usd">0</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTItNS0xLTEtMzk4MzY_edfa4a38-f9f1-4cdb-b905-21fcaeaf3fc9"
      unitRef="usd">45189000</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram>
    <us-gaap:CostsAndExpenses
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTMtMS0xLTEtMzk4MzY_63f8184b-b1c9-4d80-a087-8f42d475dca7"
      unitRef="usd">468221000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTMtMy0xLTEtMzk4MzY_b49c392d-1092-44cf-bf3a-4a32c88a1a5d"
      unitRef="usd">548010000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTMtNS0xLTEtMzk4MzY_b6a1b6b9-6543-44d7-b3fb-b480881fd303"
      unitRef="usd">578026000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTQtMS0xLTEtMzk4MzY_68bbb4af-c13a-4e5e-9817-c8be0990e614"
      unitRef="usd">-376166000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTQtMy0xLTEtMzk4MzY_bca23fd0-d536-4689-b310-dbe85c0d3678"
      unitRef="usd">-446103000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTQtNS0xLTEtMzk4MzY_990b5f9e-ab2b-4235-99c1-f522b0e3b392"
      unitRef="usd">-425111000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTYtMS0xLTEtMzk4MzY_58a88887-7627-4a70-877e-b953140ae3c0"
      unitRef="usd">33427000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTYtMy0xLTEtMzk4MzY_be4365d1-ff06-487d-923a-b9a484f21038"
      unitRef="usd">-8023000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTYtNS0xLTEtMzk4MzY_41ed74b9-d88f-4f62-9b7f-9195b1bf253c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTctMS0xLTEtMzk4MzY_f3a86c66-2155-422d-b895-a7f91e2ec67f"
      unitRef="usd">28911000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTctMy0xLTEtMzk4MzY_876ec188-c721-420f-8ab4-2f77417ed774"
      unitRef="usd">47313000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTctNS0xLTEtMzk4MzY_589858f8-09a4-4ee6-bf76-eb67b404b685"
      unitRef="usd">30267000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTgtMS0xLTEtMzk4MzY_f81500de-ce42-40b4-9bb9-eb3e7eb0b540"
      unitRef="usd">0</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTgtMy0xLTEtMzk4MzY_569feedc-b14d-4df5-b02f-ce6b58bcdfcb"
      unitRef="usd">-24410000</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTgtNS0xLTEtMzk4MzY_1b695837-2cca-419f-82a7-9723d39cbb69"
      unitRef="usd">0</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTktMS0xLTEtMzk4MzY_b9567ef4-c62b-4c54-815f-8017fa1d6da8"
      unitRef="usd">6667000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTktMy0xLTEtMzk4MzY_dc92c129-4031-4f96-9e3a-68863ebf5475"
      unitRef="usd">2569000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMTktNS0xLTEtMzk4MzY_7ca91f46-cbe0-4e50-ae51-ec4d8f463c28"
      unitRef="usd">18282000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjAtMS0xLTEtMzk4MzY_c3e37a49-9656-4a2c-8c1a-d3b2894471a3"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjAtMy0xLTEtMzk4MzY_e6383483-fac3-4937-a7c2-6f6f8cfbeed4"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjAtNS0xLTEtMzk4MzY_d68b5762-f65c-415b-8eaf-c7914a9f3ff5"
      unitRef="usd">6851000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjEtMS0xLTEtMzk4MzY_3351bf2e-05ce-468c-8ccd-f833af82c8c1"
      unitRef="usd">11183000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjEtMy0xLTEtMzk4MzY_6299681b-894d-4275-bd7e-b6755ed8ae2f"
      unitRef="usd">-77177000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjEtNS0xLTEtMzk4MzY_33c9db5c-c86b-4e58-add8-9bdd6769a1ee"
      unitRef="usd">-18836000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjItMS0xLTEtMzk4MzY_5cc2fa48-dc7a-440f-90ea-500109d6ffae"
      unitRef="usd">-364983000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjItMy0xLTEtMzk4MzY_80ec3a97-05d0-48a8-97c7-028edc6db529"
      unitRef="usd">-523280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjItNS0xLTEtMzk4MzY_a3d0764e-3a9e-4476-886e-eecc2bf65c36"
      unitRef="usd">-443947000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjMtMS0xLTEtMzk4MzY_79301b55-3911-4825-86b5-6415a642e222"
      unitRef="usd">3215000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjMtMy0xLTEtMzk4MzY_abff24fe-afe3-4876-9b34-8eb7d3842199"
      unitRef="usd">557000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjMtNS0xLTEtMzk4MzY_44282e5d-0a98-414b-8536-c731183cb900"
      unitRef="usd">493000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjQtMS0xLTEtMzk4MzY_c143059e-cf65-451b-88d5-007ca363627a"
      unitRef="usd">-368198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjQtMy0xLTEtMzk4MzY_512566d5-cd98-4400-97d9-c7a922b2c098"
      unitRef="usd">-523837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjQtNS0xLTEtMzk4MzY_aa4445fc-decf-4671-9b19-4a2341954f5e"
      unitRef="usd">-444440000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtMS0xLTEtMzk4MzY_1f98abe9-7964-4e23-b1ea-e3c6bff2b72e"
      unitRef="usdPerShare">-1.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtMS0xLTEtMzk4MzY_cfde8a50-078c-4f04-9bb2-599f3d2956b4"
      unitRef="usdPerShare">-1.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtMy0xLTEtMzk4MzY_4daee685-792e-4a66-a8bc-e53beedd89e2"
      unitRef="usdPerShare">-2.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtMy0xLTEtMzk4MzY_bcad4ce8-abf8-46bd-9a21-02f312119943"
      unitRef="usdPerShare">-2.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtNS0xLTEtMzk4MzY_3e55e465-fd0f-4604-8d6e-e9ac69cf54af"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjYtNS0xLTEtMzk4MzY_f23a9563-8e58-4687-9a59-e3d85668b004"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctMS0xLTEtMzk4MzY_07900a56-14df-4922-9f8f-55554219f95c"
      unitRef="shares">187138000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctMS0xLTEtMzk4MzY_91f320d9-7c08-4eab-8365-00faceec3d14"
      unitRef="shares">187138000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctMy0xLTEtMzk4MzY_6baa3a49-6188-4fd0-82df-076f8ec084d0"
      unitRef="shares">183298000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctMy0xLTEtMzk4MzY_e844fbd7-14e7-4a9e-8bc9-14eea8847714"
      unitRef="shares">183298000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctNS0xLTEtMzk4MzY_9454361c-59f5-40fc-a78e-39c9c5d3ffd7"
      unitRef="shares">178581000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83My9mcmFnOjhmOWFhNjQ3Yjc4YzQ4ODg5MzcyOTA3ZDUxOGQ0OGJkL3RhYmxlOjQzYjU0Zjg2ZGE3MDRmMTNiOWY5ZmY3ZDU4MDNjMzFhL3RhYmxlcmFuZ2U6NDNiNTRmODZkYTcwNGYxM2I5ZjlmZjdkNTgwM2MzMWFfMjctNS0xLTEtMzk4MzY_a1a48de2-75c2-42bb-9f57-b4a247214d49"
      unitRef="shares">178581000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfMi0xLTEtMS0zOTgzNg_d1d61a2b-9b8b-4e64-898d-7f673f7c31a4"
      unitRef="usd">-368198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfMi0zLTEtMS0zOTgzNg_cab0ac39-5199-4ca3-8bde-ac1e2b998afa"
      unitRef="usd">-523837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfMi01LTEtMS0zOTgzNg_536fd8cf-09fc-4fa0-a75b-4474163eab5c"
      unitRef="usd">-444440000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNC0xLTEtMS0zOTgzNg_cc460fec-91b6-455a-a75b-14c69d8f3d61"
      unitRef="usd">-1114000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNC0zLTEtMS0zOTgzNg_85262271-ba0d-4596-a4f8-409812886f49"
      unitRef="usd">-1568000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNC01LTEtMS0zOTgzNg_8f73fd78-5320-477b-83a1-0fde4f59587a"
      unitRef="usd">-927000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNS0xLTEtMS0zOTgzNg_afa60f65-d643-45ff-8f6f-48290f6a5202"
      unitRef="usd">-1636000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNS0zLTEtMS0zOTgzNg_7b474484-2ef9-4b68-836b-121ef25f6893"
      unitRef="usd">-294000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNS01LTEtMS0zOTgzNg_ee455292-dfd5-4bcc-8c37-b42d88dc030d"
      unitRef="usd">-363000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNi0xLTEtMS0zOTgzNg_446fff84-42ba-4f53-a3fc-01b584ec994b"
      unitRef="usd">-2750000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNi0zLTEtMS0zOTgzNg_95e7755e-e306-4ba5-9afe-9cc36ae9d8e2"
      unitRef="usd">-1862000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNi01LTEtMS0zOTgzNg_c8eb8f46-5cf6-43f9-953f-891c548f7955"
      unitRef="usd">-1290000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNy0xLTEtMS0zOTgzNg_cc7ad452-c690-4c91-af1d-c740897ce693"
      unitRef="usd">-370948000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNy0zLTEtMS0zOTgzNg_1ac3d8bc-d815-4c15-9fc0-01161664a244"
      unitRef="usd">-525699000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83Ni9mcmFnOmMzYjJlZjFhNGQ3ODQ3YWFhNGI0ODA1NjM0Y2YzMTg0L3RhYmxlOjNlM2NlY2UyNmViYjRkYjk5NDYwYmMxZDRiYzAzZGVkL3RhYmxlcmFuZ2U6M2UzY2VjZTI2ZWJiNGRiOTk0NjBiYzFkNGJjMDNkZWRfNy01LTEtMS0zOTgzNg_1ef04744-8189-43fd-a4c3-5e5e960323b7"
      unitRef="usd">-445730000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0c9d9fd3ecfa4c9086a8279fc8984311_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS0xLTEtMS0zOTgzNg_bd2ecb29-9916-4a92-ba8e-2427b1fa20c7"
      unitRef="shares">176505000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0c9d9fd3ecfa4c9086a8279fc8984311_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS0zLTEtMS0zOTgzNg_4430aeeb-d687-4810-8206-a289ebb96841"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id08cf5e99f4c4729b75cd9f892d3dd95_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS01LTEtMS0zOTgzNg_791422e0-b327-4eb4-9b0c-e6c52c050a69"
      unitRef="usd">3271097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac079dca38e543e29cee54f4bb8d8c85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS03LTEtMS0zOTgzNg_de2187e1-f1c5-4827-bc35-73b17652dafc"
      unitRef="usd">-1005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8982bed90c24581aca18ab4ef0fbd1b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS05LTEtMS0zOTgzNg_d4b2f976-2c91-4151-a94d-aaafe17ff76a"
      unitRef="usd">-1864718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f208c2b206d4f43af4e746f193bb362_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMS0xMS0xLTEtMzk4MzY_4bc2b064-6392-4232-96f9-10c19bfb7957"
      unitRef="usd">1405391000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i987ef113f8824c15b8f15d8db5465d6d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMi0xLTEtMS0zOTgzNg_2826b5e3-d377-4bd7-8114-615681d6701b"
      unitRef="shares">3586000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i987ef113f8824c15b8f15d8db5465d6d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMi0zLTEtMS0zOTgzNg_76592146-e518-4f5e-b5b2-daa64c10d42a"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic44c951d25d843329584f5aa34d0f5ca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMi01LTEtMS0zOTgzNg_cc04165f-c669-4087-befa-2ff3c2c1771f"
      unitRef="usd">23372000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMi0xMS0xLTEtMzk4MzY_cdefc23a-90da-4f54-8cf5-0da6465caea4"
      unitRef="usd">23373000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic44c951d25d843329584f5aa34d0f5ca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMy01LTEtMS0zOTgzNg_f794d839-4234-490d-8fad-3d3e0cf44c7e"
      unitRef="usd">94261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMy0xMS0xLTEtMzk4MzY_4c1636f3-5c39-41bf-a1ce-c14587c96b1b"
      unitRef="usd">94261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i38e6cce64ebb4bf1829c2e2305936cf8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNC03LTEtMS0zOTgzNg_78d5206d-8ca9-41f1-9d9b-202dcbdb769b"
      unitRef="usd">-1290000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i998d6d8b90244039983cd9cc2d9e138d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNC05LTEtMS0zOTgzNg_5b7a5a84-6ade-4ee6-b323-50819dfae0d7"
      unitRef="usd">-444440000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNC0xMS0xLTEtMzk4MzY_000a61ed-0cc6-4cd3-a36f-79ee77fea98d"
      unitRef="usd">-445730000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1950a10af3724176843a6dc1e9e84e54_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS0xLTEtMS0zOTgzNg_8dbb49e6-c778-4a5a-a299-dd0eb9514358"
      unitRef="shares">180091000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1950a10af3724176843a6dc1e9e84e54_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS0zLTEtMS0zOTgzNg_f0361874-dccd-4a1d-9074-0c9f1d6994e1"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib04a5ee614c94e08a816a4c6381aec19_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS01LTEtMS0zOTgzNg_abb59d16-5693-482a-8edb-6642eb2fcd06"
      unitRef="usd">3388730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ebfebc03d28484bb3537335575f477e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS03LTEtMS0zOTgzNg_76e76130-cee5-495e-9edf-a202d4a7a31c"
      unitRef="usd">-2295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96a8e3652a3d447ea7e5a6799fd339b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS05LTEtMS0zOTgzNg_5dcd9e02-79f2-4a41-907c-e6c7497b4c43"
      unitRef="usd">-2309158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i448f61765d3a4f728112443592038e8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNS0xMS0xLTEtMzk4MzY_805c9ef0-9909-412b-acdf-66fb7891d0f3"
      unitRef="usd">1077295000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic10a28643df74c40af9cdf7c813b5a44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNi0xLTEtMS0zOTgzNg_9924bcf8-4d2b-45e4-bb04-77181ff52092"
      unitRef="shares">5377000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic10a28643df74c40af9cdf7c813b5a44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNi0zLTEtMS0zOTgzNg_ff335dad-b5fd-4c00-b86f-aef8fc4b27d5"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i38a4fdda5691415fa69f3baedf60a37e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNi01LTEtMS0zOTgzNg_cae330f5-f942-4170-ae32-bbe74f699ba6"
      unitRef="usd">33237000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNi0xMS0xLTEtMzk4MzY_30121272-550e-45a5-ac78-5ef1d085a42c"
      unitRef="usd">33238000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i38a4fdda5691415fa69f3baedf60a37e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNy01LTEtMS0zOTgzNg_7fbe2e76-fae9-4be5-bb84-c76ba842e529"
      unitRef="usd">94674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfNy0xMS0xLTEtMzk4MzY_f6be11c9-4b73-4b6d-9ff3-6cc15be7be1c"
      unitRef="usd">94674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i73ad8acf8f34426eb3f1aeef9273f29b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOC03LTEtMS0zOTgzNg_de9a4026-92d5-48fb-a247-15bc8e75539a"
      unitRef="usd">-1862000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id748358d445d433fb8c8c90c82d6f1a0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOC05LTEtMS0zOTgzNg_ca21d3a0-df12-4b16-84cd-67630cb1b55a"
      unitRef="usd">-523837000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOC0xMS0xLTEtMzk4MzY_adb0908b-7fa0-4adb-81db-7467cc59bd52"
      unitRef="usd">-525699000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9ef15d4863f04c8db682812ea8b05dc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS0xLTEtMS0zOTgzNg_db58377e-54c2-4324-b057-d2744c36a0db"
      unitRef="shares">185468000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9ef15d4863f04c8db682812ea8b05dc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS0zLTEtMS0zOTgzNg_88cf5368-4913-405f-b7ec-aff933e837a3"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i746ebde8a5a14d7fab51bbdd9974e2fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS01LTEtMS0zOTgzNg_f9045f30-148a-4384-9483-a9080eb43c60"
      unitRef="usd">3516641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id726a6530b544c1ea713e5fd50d15fea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS03LTEtMS0zOTgzNg_67d1a16d-03a0-4fe2-a0b4-cac18e19bf31"
      unitRef="usd">-4157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49140130df5b432e8dbcb7033e45422d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS05LTEtMS0zOTgzNg_abe650d2-fabb-4aac-a20e-118b5d211fde"
      unitRef="usd">-2832995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfOS0xMS0xLTEtMzk4MzY_4d6f73b7-2dc6-4e55-a087-a1d1f3708c5a"
      unitRef="usd">679508000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i935ae0dae4f141c8bb7ac64103e6fe70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTAtMS0xLTEtMzk4MzY_c3aa94d0-29b2-4cb9-9732-efffbba65b7e"
      unitRef="shares">3092000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i935ae0dae4f141c8bb7ac64103e6fe70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTAtMy0xLTEtMzk4MzY_5fee223f-f51f-4f86-b5a9-370440d35dc4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic6bae5374b2b41c484f1e8a2efee68bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTAtNS0xLTEtMzk4MzY_f5c3a3f5-f9ce-4465-89c5-94a748ac9458"
      unitRef="usd">758000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTAtMTEtMS0xLTM5ODM2_da95b386-13e6-4bdf-a0f0-bd499565e8fa"
      unitRef="usd">758000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic6bae5374b2b41c484f1e8a2efee68bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTEtNS0xLTEtMzk4MzY_b7d3f0e0-38b5-4460-8eb8-1d3054041be2"
      unitRef="usd">57320000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTEtMTEtMS0xLTM5ODM2_52b1d323-8a26-4c45-85cd-df933b2dd98d"
      unitRef="usd">57320000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idab357fe657f4da88592a410901a0389_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTItNy0xLTEtMzk4MzY_2cacdc23-e492-4408-8fb0-dafd930c94b7"
      unitRef="usd">-2750000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia6c3d2d7dc6d4a638d0a5df9eb67618a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTItOS0xLTEtMzk4MzY_1a8e656c-7eee-4fa7-927b-b4a40cbe22c4"
      unitRef="usd">-368198000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTItMTEtMS0xLTM5ODM2_7a6d9869-0608-4576-920d-977356e55b4c"
      unitRef="usd">-370948000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0edd83c86ce440bd97d489289b92afbc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtMS0xLTEtMzk4MzY_485ff588-59bc-4864-a8b8-6fe67f099c77"
      unitRef="shares">188560000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0edd83c86ce440bd97d489289b92afbc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtMy0xLTEtMzk4MzY_2d611687-fe99-4d8b-9b4c-a7e340a99eef"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f9c9a3627d54feea3a17351378935e7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtNS0xLTEtMzk4MzY_f2ba3db0-96e3-4a2a-899a-f829294f529b"
      unitRef="usd">3574719000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e18c528c36849c0a6d2470e6cf2054f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtNy0xLTEtMzk4MzY_56e8cd89-df0d-448d-a97a-6afd38d7ea15"
      unitRef="usd">-6907000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2410d2e734464c24a881fc5993536b43_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtOS0xLTEtMzk4MzY_be54a041-3514-4ba3-9404-d490a4671e40"
      unitRef="usd">-3201193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF83OS9mcmFnOjNjOTdjNTkyMjg4MjRhOTg4MGM3M2FkZWE5ODE4ZmI1L3RhYmxlOjA2OTFjZDQxZDQwMDQwODc5OThjNDhmYzA3ZDczMDY2L3RhYmxlcmFuZ2U6MDY5MWNkNDFkNDAwNDA4Nzk5OGM0OGZjMDdkNzMwNjZfMTMtMTEtMS0xLTM5ODM2_bf0a029b-209f-44e9-92d7-4f1197c8efc0"
      unitRef="usd">366638000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMy0xLTEtMS0zOTgzNg_89aca290-857c-4be2-a97d-d54de58f17c9"
      unitRef="usd">-368198000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMy0zLTEtMS0zOTgzNg_dfc8e128-f3b9-40b0-8f06-1dcb2f801523"
      unitRef="usd">-523837000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMy01LTEtMS0zOTgzNg_92031950-489b-463a-b80f-0a17aea871ca"
      unitRef="usd">-444440000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNS0xLTEtMS0zOTgzNg_5e0f485b-7bff-44d3-8bfd-39606c462254"
      unitRef="usd">69794000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNS0zLTEtMS0zOTgzNg_585bc252-bf1d-41d5-87ff-69960175f503"
      unitRef="usd">77746000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNS01LTEtMS0zOTgzNg_05425f08-5dd5-4ce3-bccd-1ba275353033"
      unitRef="usd">48563000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNi0xLTEtMS0zOTgzNg_556d0fd1-4d2d-4149-921d-410c3ed1d90c"
      unitRef="usd">28911000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNi0zLTEtMS0zOTgzNg_5027a7f8-13c5-4e3a-9940-aa11250873a2"
      unitRef="usd">47313000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNi01LTEtMS0zOTgzNg_b591d68c-b586-434b-b2e1-e91c6f390790"
      unitRef="usd">30267000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNy0xLTEtMS0zOTgzNg_330d56d2-5fc2-47d0-a161-9565d296694a"
      unitRef="usd">0</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNy0zLTEtMS0zOTgzNg_8eb440f7-ffe2-40a0-a314-98deea232e13"
      unitRef="usd">-24410000</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNy01LTEtMS0zOTgzNg_9f000ee9-2fd8-4d54-aad5-cfb6229b6d1c"
      unitRef="usd">0</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOC0xLTEtMS0zOTgzNg_2ffd238d-1bb6-482f-8e3c-85ab35dd359a"
      unitRef="usd">33427000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOC0zLTEtMS0zOTgzNg_5814e028-86bd-47a5-a538-339797dd6e9f"
      unitRef="usd">-8023000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOC01LTEtMS0zOTgzNg_67094220-617d-4dce-a18e-ce557658ab53"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOS0xLTEtMS0zOTgzNg_b41d419e-bc5b-45ff-b385-788a9fb16254"
      unitRef="usd">4951000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOS0zLTEtMS0zOTgzNg_48095aea-75a8-43d0-94e7-a564bb916420"
      unitRef="usd">16703000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfOS01LTEtMS0zOTgzNg_02413bbe-e453-4395-b8c3-3d0892229a2b"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTAtMS0xLTEtMzk4MzY_f40e13d6-5dc1-4291-b24d-68650ec241d1"
      unitRef="usd">57320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTAtMy0xLTEtMzk4MzY_8968c2f7-2441-45a8-a9d5-942c5c207e4c"
      unitRef="usd">94674000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTAtNS0xLTEtMzk4MzY_a4836701-3a6b-4a9c-9c71-b55184952f78"
      unitRef="usd">94261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTEtMS0xLTEtMzk4MzY_a3a35f22-78ce-4015-93d2-ec653c1beb5c"
      unitRef="usd">13030000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTEtMy0xLTEtMzk4MzY_3d2897b0-34af-4321-a1fe-46ba9277bccd"
      unitRef="usd">14146000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTEtNS0xLTEtMzk4MzY_0a49635f-32f8-4534-9440-6d2e0d7ab64b"
      unitRef="usd">14182000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItMS0xLTEtNDUzOTA_5b79eb41-3a67-4b2e-9401-ea2354341779"
      unitRef="usd">2708000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItMy0xLTEtNDUzOTg_652d71da-7774-4b71-9f88-02b5304b21f5"
      unitRef="usd">-102000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItNS0xLTEtNDU0MDY_a7d3ca25-f1e3-46d8-a18e-1965949dd939"
      unitRef="usd">-36000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtMS0xLTEtNDYxMjY_f1a5db67-8fee-4358-8edd-47eb2d686d38"
      unitRef="usd">65761000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtMy0xLTEtNDYwODk_2080f0b1-d6ac-4397-ab19-f6b8982206cb"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtNS0xLTEtNDYwOTc_c74820fc-1903-4d64-a632-cad281284c40"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTQtMS0xLTEtNDYxNDI_007da6de-8e96-4108-9839-e3a0d5de906e"
      unitRef="usd">3326000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTQtMy0xLTEtNDYxMDU_c20cad8f-8034-4f8b-b8f9-d27c988af2fb"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTQtNS0xLTEtNDYxMTM_713275ad-ab74-4333-9eb8-bda9731aadaa"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItMS0xLTEtMzk4MzY_4bf9d008-96b0-4857-9777-96a2d8682354"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItMy0xLTEtMzk4MzY_e93e22ee-d8a1-45c7-b5d8-f63a34e2c839"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTItNS0xLTEtMzk4MzY_b09b0a40-b5a4-420e-8d25-62fc3ae181fb"
      unitRef="usd">20351000</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtMS0xLTEtMzk4MzY_65d16810-d50e-44d1-ae62-3c46a3a0f86a"
      unitRef="usd">2435000</nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions>
    <nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtMy0xLTEtMzk4MzY_88fbf253-04c1-4958-a060-dfd626cafb5a"
      unitRef="usd">-6730000</nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions>
    <nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTMtNS0xLTEtMzk4MzY_eb432a5f-8829-41c7-bd39-8b4615a4f081"
      unitRef="usd">-3943000</nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTUtMS0xLTEtMzk4MzY_97ff6a71-c937-4226-b96b-0c8cd48d65c2"
      unitRef="usd">-16511000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTUtMy0xLTEtMzk4MzY_107c6fb0-5602-4363-8735-dfd538a81d54"
      unitRef="usd">-12397000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTUtNS0xLTEtMzk4MzY_2cb8165e-a87b-4715-8ae2-272a0851d7c0"
      unitRef="usd">-1913000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTYtMS0xLTEtMzk4MzY_4dff00af-c1ae-4391-b2de-c51847bfd06f"
      unitRef="usd">3401000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTYtMy0xLTEtMzk4MzY_ae076cf0-5a47-4031-b5ad-6a3afb88b072"
      unitRef="usd">509000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTYtNS0xLTEtMzk4MzY_7a375c16-9147-402d-b77a-25654ac8121f"
      unitRef="usd">2627000</us-gaap:IncreaseDecreaseInInventories>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTctMS0xLTEtMzk4MzY_ab953907-b5fb-4f9d-b408-8392661a6326"
      unitRef="usd">2680000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTctMy0xLTEtMzk4MzY_7969c031-1713-4c2b-b9ad-652e345bc751"
      unitRef="usd">-2340000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTctNS0xLTEtMzk4MzY_50ed07d7-c691-49d2-863c-8cf8f1d7f8c1"
      unitRef="usd">-2743000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTgtMS0xLTEtMzk4MzY_fc28f501-b6aa-4a29-b286-41039559c29e"
      unitRef="usd">-6906000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTgtMy0xLTEtMzk4MzY_5a5e21a5-5928-457b-b2d5-da54b74b8497"
      unitRef="usd">2586000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTgtNS0xLTEtMzk4MzY_e382a129-ecfd-4396-bb64-3b758bea65c0"
      unitRef="usd">-4512000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTktMS0xLTEtMzk4MzY_1f5a06ff-796a-4509-a442-0077fc8c3d6a"
      unitRef="usd">3103000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTktMy0xLTEtMzk4MzY_57004979-521a-4578-9cfd-0e6ca3d0ebb9"
      unitRef="usd">-11690000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMTktNS0xLTEtMzk4MzY_014a0968-fde4-41fb-934d-ef693fab1f5b"
      unitRef="usd">2382000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjAtMS0xLTEtMzk4MzY_b8fd6624-e3fa-44d1-8f32-34dcceb1e6ce"
      unitRef="usd">-6153000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjAtMy0xLTEtMzk4MzY_aa74b952-20e3-4681-aaf2-fc5954680533"
      unitRef="usd">1203000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjAtNS0xLTEtMzk4MzY_e91237de-9b2a-4c17-b1a5-bd3bc725af18"
      unitRef="usd">4697000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjEtMS0xLTEtMzk4MzY_8a4c1179-a4ea-4631-a6b8-35f69005acf9"
      unitRef="usd">-12734000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjEtMy0xLTEtMzk4MzY_2de36933-1e80-454f-afb6-f4bd41b221a8"
      unitRef="usd">-23524000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjEtNS0xLTEtMzk4MzY_7281809a-7758-443a-920f-1c0f7537da46"
      unitRef="usd">8644000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjItMS0xLTEtMzk4MzY_c897f084-d076-41e2-8b48-dd325d4ca04d"
      unitRef="usd">-1060000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjItMy0xLTEtMzk4MzY_713ccb97-a9fa-4efb-add8-8d1d0b882a7d"
      unitRef="usd">-605000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjItNS0xLTEtMzk4MzY_7277537a-3b67-4289-abf6-4457ce846538"
      unitRef="usd">-5516000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjMtMS0xLTEtMzk4MzY_3387fa2b-44f8-469e-9bce-042af7e8f22a"
      unitRef="usd">-304007000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjMtMy0xLTEtMzk4MzY_47a44dd1-5b86-43a3-ab5a-642600d710bc"
      unitRef="usd">-412660000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjMtNS0xLTEtMzk4MzY_05cab722-1c33-4f60-b4fb-846ae945922c"
      unitRef="usd">-313287000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjUtMS0xLTEtMzk4MzY_713932f5-a19a-4f22-8452-b564bdc9fadd"
      unitRef="usd">467914000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjUtMy0xLTEtMzk4MzY_f73338a6-13fd-41bd-8044-6fce899649a9"
      unitRef="usd">960689000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjUtNS0xLTEtMzk4MzY_a471f0ee-5d4e-4ffa-8f3b-0528e72ad597"
      unitRef="usd">987533000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjYtMS0xLTEtMzk4MzY_c5891816-2398-4862-8d0d-7c752aef401e"
      unitRef="usd">826229000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjYtMy0xLTEtMzk4MzY_3930685b-0889-4b57-953f-9285a5c19915"
      unitRef="usd">1166951000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjYtNS0xLTEtMzk4MzY_28aa8c10-839c-4469-b3a9-391412fda273"
      unitRef="usd">1449304000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjctMS0xLTEtMzk4MzY_71491b18-14af-4436-9e30-ad2366198af9"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjctMy0xLTEtMzk4MzY_e843cb2d-c92d-4fe7-b2a1-d31e5907c733"
      unitRef="usd">11504000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjctNS0xLTEtMzk4MzY_b45789d5-6a35-4d72-8c42-2418e7ff61c3"
      unitRef="usd">41700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjgtMS0xLTEtMzk4MzY_f9f2afa8-a59d-4ee7-8153-2e6108bba054"
      unitRef="usd">5676000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjgtMy0xLTEtMzk4MzY_0c0de79a-2114-4dfe-ba79-58bea7f7e511"
      unitRef="usd">14989000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjgtNS0xLTEtMzk4MzY_f4e00a11-6ee2-4b2b-a9d7-53b9e0ecceb4"
      unitRef="usd">7258000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktMS0xLTEtNDM2NTE_1a57d4a2-b1ce-459f-b97e-eedefbcbd9dc"
      unitRef="usd">13196000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktMy0xLTEtNDQwOTc_c637eff4-f968-4609-b293-3ddda2f6ca5c"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktNS0xLTEtNDQwOTc_93b0e106-4e25-4093-afb0-75b7c19e08fc"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktMS0xLTEtMzk4MzY_d2df0086-a182-4666-a8a2-eff60a4351a6"
      unitRef="usd">365835000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktMy0xLTEtMzk4MzY_4b27b6f8-838a-447f-a59b-ab2585c55c80"
      unitRef="usd">202777000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMjktNS0xLTEtMzk4MzY_e37afd75-6a9e-438c-bf55-a843fc015f9c"
      unitRef="usd">496213000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <nktr:SaleOfFutureRoyaltiesTransactionCosts
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzEtMC0xLTEtMzk4MzYvdGV4dHJlZ2lvbjo4ZThiNjAyNTQyYWI0NTA0YTkyZjc1MzkzMTk3MWMzMV81MQ_99c885bd-991b-46f8-845c-6b1aa92bf639"
      unitRef="usd">3800000</nktr:SaleOfFutureRoyaltiesTransactionCosts>
    <nktr:ProceedsFromSaleOfFutureRoyaltiesNet
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzEtMS0xLTEtMzk4MzY_e89e7c06-8f2b-452c-aa63-6202f12806e6"
      unitRef="usd">0</nktr:ProceedsFromSaleOfFutureRoyaltiesNet>
    <nktr:ProceedsFromSaleOfFutureRoyaltiesNet
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzEtMy0xLTEtMzk4MzY_f75316c3-7404-46f9-a020-a2a889f05442"
      unitRef="usd">0</nktr:ProceedsFromSaleOfFutureRoyaltiesNet>
    <nktr:ProceedsFromSaleOfFutureRoyaltiesNet
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzEtNS0xLTEtMzk4MzY_2f7721aa-7be8-485f-8e90-6559f1efaf2c"
      unitRef="usd">146250000</nktr:ProceedsFromSaleOfFutureRoyaltiesNet>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzItMS0xLTEtMzk4MzY_557435f1-4710-4fa9-af52-42dc5963af35"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzItMy0xLTEtMzk4MzY_106041e8-9461-4e27-9e92-4186411a858d"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzItNS0xLTEtMzk4MzY_9c5b54ec-65f4-4168-bd0b-7f5ca939d3c3"
      unitRef="usd">250000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzMtMS0xLTEtMzk4MzY_cf642b99-0656-4c92-a61f-7b9b7aa258d1"
      unitRef="usd">750000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzMtMy0xLTEtMzk4MzY_eccc7f3b-8d84-44d8-ae20-f0b6bd2005dd"
      unitRef="usd">3000000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzMtNS0xLTEtMzk4MzY_93818e74-89bd-4bed-9adc-8dd8b4e10e76"
      unitRef="usd">0</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzQtMS0xLTEtMzk4MzY_bc1330b2-eefb-417e-aa82-406035ba21a3"
      unitRef="usd">758000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzQtMy0xLTEtMzk4MzY_a78786dc-b9ac-4db3-bae6-dd1fd7fdb326"
      unitRef="usd">33238000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzQtNS0xLTEtMzk4MzY_54d9c1f8-e99f-4cf0-a6e1-2397d3275fe3"
      unitRef="usd">23396000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzUtMS0xLTEtMzk4MzY_7638858d-f6e4-4689-9b91-7a5defcedb27"
      unitRef="usd">1508000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzUtMy0xLTEtMzk4MzY_40460a7e-9ad5-4989-963a-febb802c4798"
      unitRef="usd">36238000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzUtNS0xLTEtMzk4MzY_d3a95325-f508-4555-b8f2-8eaa290b660b"
      unitRef="usd">-80354000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzYtMS0xLTEtMzk4MzY_09852104-0992-4ed4-83d8-01f09c2a55e1"
      unitRef="usd">-327000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzYtMy0xLTEtMzk4MzY_9a99693e-9e7c-43ee-a41f-97c621ee826c"
      unitRef="usd">-92000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzYtNS0xLTEtMzk4MzY_311ca09a-714e-461a-81ba-aa188995a05a"
      unitRef="usd">20000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzctMS0xLTEtMzk4MzY_c67443ee-a24e-48ed-8276-b920f2f83322"
      unitRef="usd">63009000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzctMy0xLTEtMzk4MzY_11589d53-5cff-4432-992a-0cc4c256924a"
      unitRef="usd">-173737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzctNS0xLTEtMzk4MzY_49ad795a-84f3-47aa-be17-68ac2603fcf8"
      unitRef="usd">102592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzgtMS0xLTEtMzk4MzY_c3dfef52-950a-425b-9d57-febf6b85c0fd"
      unitRef="usd">25218000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i448f61765d3a4f728112443592038e8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzgtMy0xLTEtMzk4MzY_d39fa184-15e6-472e-ad7a-c74616959362"
      unitRef="usd">198955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f208c2b206d4f43af4e746f193bb362_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzgtNS0xLTEtMzk4MzY_1fc36739-b3f4-426e-89ab-cd8b4fe42e9a"
      unitRef="usd">96363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzktMS0xLTEtMzk4MzY_e88b15bd-4764-4b31-9647-af64cb15ac1f"
      unitRef="usd">88227000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzktMy0xLTEtMzk4MzY_1f8c34d0-be2a-4dd9-be37-c79be30e3067"
      unitRef="usd">25218000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i448f61765d3a4f728112443592038e8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfMzktNS0xLTEtMzk4MzY_3652bbb3-02d0-4da9-b417-a8965c8b9483"
      unitRef="usd">198955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDEtMS0xLTEtMzk4MzY_69460b9e-2e42-48f4-bfb3-6a9be3188798"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDEtMy0xLTEtMzk4MzY_acd4657a-c61d-4893-86fd-2c7c3f7ac740"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDEtNS0xLTEtMzk4MzY_4f94b09f-245a-4c01-9639-52a8db8f5dfd"
      unitRef="usd">9742000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDItMS0xLTEtMzk4MzY_69d43b44-6ab3-47b0-b0b0-b1877a206ae5"
      unitRef="usd">272000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDItMy0xLTEtMzk4MzY_7cc11b56-5a10-4f49-bd03-10df765d7193"
      unitRef="usd">325000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDItNS0xLTEtMzk4MzY_728989fa-7a1b-420e-94d5-254d7b454c21"
      unitRef="usd">539000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDMtMS0xLTEtMzk4MzY_0dce54e4-be83-4dc8-a7df-74b476d6011a"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDMtMy0xLTEtMzk4MzY_1c68cfe8-9e6a-431c-a00b-262f494fb534"
      unitRef="usd">1057000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDMtNS0xLTEtMzk4MzY_7080a249-ea29-4b48-8889-35d213726ec4"
      unitRef="usd">2133000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDQtMS0xLTEtMzk4MzY_dd269379-af86-4063-8994-8243456777e1"
      unitRef="usd">0</nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities>
    <nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDQtMy0xLTEtMzk4MzY_4ca7d054-c705-4f8d-ba67-c47ce0214ab7"
      unitRef="usd">0</nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities>
    <nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84Mi9mcmFnOmYyOGViZWRmYzA5MjQ4ZGY5Y2U4NjA3NjBlNmUwNGQ1L3RhYmxlOjRjMTEwY2YyMTI1ZTRlNTI4ZDZjODUyNWExMWFiZDkzL3RhYmxlcmFuZ2U6NGMxMTBjZjIxMjVlNGU1MjhkNmM4NTI1YTExYWJkOTNfNDQtNS0xLTEtMzk4MzY_947f0eb0-1982-43c4-a8d0-fb9c77b7b937"
      unitRef="usd">4000000</nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzODk_bd861817-dd1a-4c6a-8a99-4312778a1985">Organization and Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes innovative medicines in the field of immunotherapy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At December&#160;31, 2022, we had approximately $505.0 million in cash and investments in marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Results of Bempegaldesleukin Program and the 2022 Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan) for the Company&#x2019;s future:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On March 14, 2022, BMS and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 10 for additional information on our BMS Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we decided to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 6 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, subject to activities required for an orderly wind down of the studies, there will be no ongoing clinical development activities of bempegaldesleukin.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 25, 2022, we announced our 2022 Restructuring Plan, which was reviewed and approved by our Board of Directors on April 14, 2022. Pursuant to the 2022 Restructuring Plan, on April 26, 2022, our duly authorized officers implemented certain strategic, operational and organizational steps, including the prioritization of key Phase 2 development programs to advance our early stage research pipeline. In addition, we announced our plan to reduce our workforce by approximately 70% and to close our research facility in India.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have incurred significant costs resulting from these decisions and plans. See Note 11 for additional information on the effect of the 2022 Restructuring Plan on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation, Principles of Consolidation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the fair value and impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; income taxes; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. We record available-for-sale investments and cash equivalents at their estimated fair values, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. As further described in Note 11, we estimated the fair value of our lease assets for recognizing impairment charges based on management&#x2019;s estimates of several unobservable inputs, including estimated time to enter a sublease, sublease rental rates and free rent periods. As further described in Note 6, we recorded the development derivative liability at its estimated fair value based on management&#x2019;s estimates of several unobservable inputs, including the probabilities of success of clinical trials and various other inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a variety of factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#x2019; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Significant Customer Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements. Our accounts receivable included $4.2 million and $21.4 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) as of December&#160;31, 2022 and December&#160;31, 2021, respectively. The remaining accounts receivable related primarily to product sales. We perform a regular review of our partners&#x2019; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Significant Supplier Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contract termination costs when we cancel the contract in accordance with its terms; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 11 for additional information on the severance expense that we recognized for employees terminated in connection with our 2022 Restructuring Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We report property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTMwOTA_777cbe6f-53e1-4ebb-939f-b2bf951dd6a7"&gt;three&lt;/span&gt; to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting unit equals its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 11 for additional information on the long-lived asset impairment expense that we recognized in connection with our 2022 Restructuring Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, under which we do not recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see Note 5 for additional information regarding our leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of an invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty revenue, including Non-cash royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. We have sold our rights to receive sales-based royalties for CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $69.8&#160;million, $77.7&#160;million and $79.6&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 10, we recognized $50.0&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratably over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring, Impairment and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2022 relate to the termination of the bempegaldesleukin program and the 2022 Restructuring Plan. See Note 11 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2020 relate to the termination of the NKTR-181 program. On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and wound down Inheris and the NKTR-181 program. As a result, we wrote off $45.2&#160;million, including $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181 and $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#x2019; stock to the index. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The fair value of an RSU is equal to the closing price of our common stock on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2022, 2021 and 2020, our income tax provision primarily relates to our Nektar India subsidiary. As a result of the 2022 Restructuring Plan and our intent to wind down our foreign subsidiaries, we have recorded a provision for the repatriation of accumulated earnings and profits from India. See Note 13 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented. For the years ended December 31, 2022,  2021 and 2020, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, RSUs and PSUs, which totaled 21.2 million, 18.4 million and 17.4 million for the years ended December 31, 2022,  2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDc_6e5dd984-beed-4980-95c4-0d1612c6a883">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes innovative medicines in the field of immunotherapy.&lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTA0OA_502b6faf-06d7-4fa7-9949-64bace823955"
      unitRef="usd">505000000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i7395e5dc92e34456b97e26b144017d8e_D20220401-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfOTM0NTg0ODg3OTY0Mg_45af498b-1285-4878-a402-6b5d4055887e"
      unitRef="number">0.70</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDU_66f72636-decb-48e3-aa3f-e2bc9aff5ed8">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation, Principles of Consolidation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the fair value and impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; income taxes; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDg_a5da7dbc-5896-4e3a-b177-8d693deac68e">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. We record available-for-sale investments and cash equivalents at their estimated fair values, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. As further described in Note 11, we estimated the fair value of our lease assets for recognizing impairment charges based on management&#x2019;s estimates of several unobservable inputs, including estimated time to enter a sublease, sublease rental rates and free rent periods. As further described in Note 6, we recorded the development derivative liability at its estimated fair value based on management&#x2019;s estimates of several unobservable inputs, including the probabilities of success of clinical trials and various other inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTk_ca4a547d-472c-4039-97ab-69b4a1bc01be">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a variety of factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#x2019; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDk_cf992dfe-a118-4f29-979a-647f13cbc51b">Accounts Receivable and Significant Customer Concentrations&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements.We perform a regular review of our partners&#x2019; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.</nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i33ecf05d707f40b5927205653bd6a5c7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTAzNDI_61dc957f-4fbc-463c-bcac-235eddec9c6c"
      unitRef="usd">4200000</us-gaap:AccountsReceivableNetCurrent>
    <nktr:NetExpenseReimbursementsFromCollaborationPartner
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTAzNDk_2ff83262-72cd-44ca-9f0a-f741469a9362"
      unitRef="usd">21400000</nktr:NetExpenseReimbursementsFromCollaborationPartner>
    <nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MTE_6520da53-33ee-4ad2-85a1-0867722f0d84">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Significant Supplier Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;</nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTA5OTUxMTY3MDMxOQ_076de0a1-22b2-4200-b740-54f2c9e310c4">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contract termination costs when we cancel the contract in accordance with its terms; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MDA_ea8bcd07-1f43-4786-aef7-a5951aa5cddb">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We report property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTMwOTA_777cbe6f-53e1-4ebb-939f-b2bf951dd6a7"&gt;three&lt;/span&gt; to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting unit equals its fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idfdbb2c2768a43c9b3cbce49b01157c7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MTc_c7844777-5395-4f8c-8113-2bd8ec97cffc">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i714c46f612124cfcade9ea69f3665fc3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTMxNzE_cc5eb7ef-5967-4948-a85a-8404a26e3f9c">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMTM0ODQ_a8085299-794a-4324-b42e-70f8052e7bcb"
      unitRef="reporting_unit">1</nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTM_ab1b3beb-cc05-4f47-b29e-62bb1c4b1592">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, under which we do not recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see Note 5 for additional information regarding our leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTA_a215127c-4cc9-4347-a0e0-ba15770d4d41">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTQ_8c9b5c15-07bd-45da-8c97-05a4febe02d1">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of an invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty revenue, including Non-cash royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. We have sold our rights to receive sales-based royalties for CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 7. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $69.8&#160;million, $77.7&#160;million and $79.6&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 10, we recognized $50.0&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82b4b2a5e5094624ba910d5a452b36cf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjE3OTk_d73bd985-47fb-43be-baac-397733c189a8"
      unitRef="usd">69800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6021c4787edd4734a14b823201617271_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjE4MDM_e869556c-c66c-4a6f-8985-739c71054b65"
      unitRef="usd">77700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i889f3563e17448ed9a713f77242ff320_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjE4MTA_d7924372-52b6-4013-86ff-58e716359ad8"
      unitRef="usd">79600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nktr:SalesMilestoneRevenue
      contextRef="ic66d4e5d50724998a83872fccfd73607_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjM5NjM_6f11ab2f-7dfc-481a-8c2c-278928957092"
      unitRef="usd">50000000</nktr:SalesMilestoneRevenue>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzODM_450325b1-d1e4-448b-a0e1-2e47904d3928">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratably over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <nktr:RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTI_ebf7d9ba-5a48-4029-b937-aa8d4cd2b444">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring, Impairment and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2022 relate to the termination of the bempegaldesleukin program and the 2022 Restructuring Plan. See Note 11 for additional information.&lt;/span&gt;&lt;/div&gt;Amounts recorded as restructuring, impairment and other costs for terminated program for the year ended December 31, 2020 relate to the termination of the NKTR-181 program. On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and wound down Inheris and the NKTR-181 program.</nktr:RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="ib2e6c9c34e274b01a7184f32edcfcc5c_D20200114-20200114"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzI5ODUzNDkyNzU0OQ_f5976cfd-e802-4980-8c54-4bf819bb0844"
      unitRef="usd">45200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id12f39942a7f4712bbddc41b4ff72c32_D20200114-20200114"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjk2MjU_02a33864-9753-47df-92df-894fce78f77f"
      unitRef="usd">19700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ieee6e806d4bd4db3ac3280df3387e625_D20200114-20200114"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMjk3Mjc_aef8b528-259d-4e35-a02b-3263478dc40e"
      unitRef="usd">25500000</us-gaap:RestructuringCharges>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzU0MTM_6d9296cc-31f2-4fa5-814e-4f970613fe67">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the &lt;/span&gt;&lt;/div&gt;volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#x2019; stock to the index. &#x2022;The fair value of an RSU is equal to the closing price of our common stock on the grant date.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTU_aff0549c-7be7-40a3-90c5-d33fe9abd283">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2022, 2021 and 2020, our income tax provision primarily relates to our Nektar India subsidiary. As a result of the 2022 Restructuring Plan and our intent to wind down our foreign subsidiaries, we have recorded a provision for the repatriation of accumulated earnings and profits from India. See Note 13 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzODQ_cdfd80f7-aae8-46d3-89e1-7a4102e88d21">Net Loss Per Share&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if4204e31ff284f828fdbd3d7d5d1e925_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzQ2MDE_2bc206c5-5101-4669-b5c8-6e6011a7c1eb"
      unitRef="shares">21200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i799848d20d124621af203b62f338ec15_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzQ2MDU_77dcc9b3-8494-428b-9b81-8fbd969172fa"
      unitRef="shares">18400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2827b996b8d84b178c45819a76165160_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzQ2MTI_b7ae9120-4432-4dde-8813-b542c482ab7e"
      unitRef="shares">17400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzOTY_aca44250-d013-40a1-9462-d48df92378b3">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF84OC9mcmFnOmFmNzkxMmUxNWQ0ZjRhOTdiMWExOTYyZDkwNmFlNWQxL3RleHRyZWdpb246YWY3OTEyZTE1ZDRmNGE5N2IxYTE5NjJkOTA2YWU1ZDFfMzUzODg_08d81608-cd7f-42f9-b942-7cf82e9d937b">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTMzNw_9b43c8f5-7eee-4b52-aac4-6ceba888f91f">Cash and Investments in Marketable Securities&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. All of our long-term investments as of December&#160;31, 2021 had maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTUz_cabe071a-9291-4113-98c3-9850259068b6"&gt;one&lt;/span&gt; and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2022 we sold no available-for-sale securities. During the years ended December 31, 2021 and 2020, we sold available-for-sale securities totaling $11.5&#160;million and $41.7&#160;million, respectively. Gross realized gains and losses on those sales were not significant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report our accrued interest receivable, which totaled $0.7&#160;million and $1.4&#160;million at December&#160;31, 2022 and December&#160;31, 2021, respectively, in other current assets on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;At December&#160;31, 2021, our gross unrealized losses totaled $0.7&#160;million. Our gross unrealized gains were not significant. As of December 31, 2022 and 2021, we assessed our marketable securities with unrealized losses and concluded that the losses were not attributable to credit. Accordingly, we have not recorded an allowance for credit losses for these securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At both December&#160;31, 2022 and 2021, we had letter of credit arrangements in favor of our landlords and certain vendors totaling $7.5&#160;million and $8.1 million, respectively. These letters of credit are secured by investments of similar amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTMzOQ_d6a1109c-884c-45bf-8e13-e6bd4de0d50c">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfMi0xLTEtMS0zOTgzNg_f0975ae6-da67-4545-9c7e-98822d14c4b7"
      unitRef="usd">88227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfMi0zLTEtMS0zOTgzNg_81cdad59-8ad1-4997-80d8-81822e7c223a"
      unitRef="usd">25218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfMy0xLTEtMS0zOTgzNg_44c850c2-2759-48be-b763-f8a7bba04630"
      unitRef="usd">416750000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfMy0zLTEtMS0zOTgzNg_ac32cf25-706e-4594-aabc-8410ee955def"
      unitRef="usd">708737000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfNC0xLTEtMS0zOTgzNg_e1f0d837-6104-4270-b612-1d4848dcef58"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfNC0zLTEtMS0zOTgzNg_ff02a372-b402-43ce-90af-a9136f8ba00a"
      unitRef="usd">64828000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfNS0xLTEtMS0zOTgzNg_cc6471ea-048c-43ca-8d2c-f024ef6f2692"
      unitRef="usd">504977000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOmE4MDdhMjM5MjM5ZDQ3ZTJiMTExN2VhMDUxZDhhZjRiL3RhYmxlcmFuZ2U6YTgwN2EyMzkyMzlkNDdlMmIxMTE3ZWEwNTFkOGFmNGJfNS0zLTEtMS0zOTgzNg_d06ca723-3335-4b8a-851a-a3ca516c5177"
      unitRef="usd">798783000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:InvestmnetsTargetMaturityPeriod
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTQ5NzU1ODE2NTMz_66fb2c61-5e6a-447c-9841-f6989bf849cd">P2Y</nktr:InvestmnetsTargetMaturityPeriod>
    <nktr:InvestmentsWeightedAverageMaturityPeriod
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTQ5NzU1ODE2NTU5_e10f9478-eae5-4dfc-a80d-0c25aea74280">P1Y</nktr:InvestmentsWeightedAverageMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i81ee4e8815e44e2eaf7870c781941a30_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNTYw_e07c56b2-391f-4367-b399-d6256612ba08">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTA5OTUxMTYyNzkzNDY_2fa027d9-8890-448a-8150-a372e265d9f7"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfNjU0_9a79f73b-fac4-4dfc-abd1-391f1a91c9f8"
      unitRef="usd">11500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTA0NDUzNjA0NjUyNTg_79f9d0de-593b-4132-b691-89cf6e29c91b"
      unitRef="usd">41700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:InterestReceivableCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfODg2_c8efa32c-a3d7-401f-9e1b-1f06d9bd52da"
      unitRef="usd">700000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfODkz_3d3f170d-9bd0-4d7d-9b8b-92d45a3d010e"
      unitRef="usd">1400000</us-gaap:InterestReceivableCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTM0MQ_3d6b94b9-d180-4cde-97cb-0fad924e8c0a">Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi0zLTEtMS0zOTgzNg_e8c6c333-25ef-480b-bee2-983898b7b842"
      unitRef="usd">84377000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi01LTEtMS0zOTgzNg_6c5ca89c-58b8-44e6-bf73-60d40cad2da0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi03LTEtMS0zOTgzNg_b11f67e2-4971-4c80-979f-840680b9c3ef"
      unitRef="usd">855000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1411e10f9f7455aa3e2877f65b7fe7c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi05LTEtMS0zOTgzNg_126388ab-a3e6-4bed-8236-f286957e6fc5"
      unitRef="usd">83522000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f814cb3446b46a5b7c97104c33668a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMi0xMS0xLTEtMzk4MzY_c3d11e19-6e38-4c45-9a84-9cee10775a1d"
      unitRef="usd">278121000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i71e9c0aab9a347229701114a13ba3b14_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy0zLTEtMS0zOTgzNg_558f806a-cda9-4f8f-837a-27ec75f2a5ce"
      unitRef="usd">345125000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i71e9c0aab9a347229701114a13ba3b14_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy01LTEtMS0zOTgzNg_a9fb5ec5-ab28-4d25-9839-74e5853f6bd0"
      unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i71e9c0aab9a347229701114a13ba3b14_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy03LTEtMS0zOTgzNg_e33fe8de-c2e5-4bc9-8688-0ed763da3492"
      unitRef="usd">946000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71e9c0aab9a347229701114a13ba3b14_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy05LTEtMS0zOTgzNg_e4b8e64b-967f-4b1a-93b5-14cee9704d5d"
      unitRef="usd">344204000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i70cb12d6ed274cb3bc4aae55062cef33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfMy0xMS0xLTEtMzk4MzY_73a5f605-aada-4b32-86e5-e9beb0221093"
      unitRef="usd">478629000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i24cdb13ced474b1e9afa182b37799a5d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC0zLTEtMS0zOTgzNg_256b39c5-c524-45aa-bd1a-8f1129fb49cb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i24cdb13ced474b1e9afa182b37799a5d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC01LTEtMS0zOTgzNg_3ce40483-95e6-446e-9089-47863fca6a1b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i24cdb13ced474b1e9afa182b37799a5d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC03LTEtMS0zOTgzNg_42ce7662-cb59-4044-9760-3a34212a91aa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i24cdb13ced474b1e9afa182b37799a5d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC05LTEtMS0zOTgzNg_51ddbd92-c74a-4993-8b47-8f8a1404f4fc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib4b3e1815f004636b2e747e17d73a6f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNC0xMS0xLTEtMzk4MzY_fcacaab6-fa8f-4aab-b321-7e9d043db9a6"
      unitRef="usd">5875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS0zLTEtMS0zOTgzNg_51f896ab-8571-41ab-9a8b-9246dc9ab656"
      unitRef="usd">429502000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS01LTEtMS0zOTgzNg_9a167f4b-e3bf-433f-bdb1-92a105127a0a"
      unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS03LTEtMS0zOTgzNg_a3a03a79-94e0-419c-b44f-d13ef03589ea"
      unitRef="usd">1801000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS05LTEtMS0zOTgzNg_05041978-e3cf-4959-87e2-37b395b28e7d"
      unitRef="usd">427726000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNS0xMS0xLTEtMzk4MzY_b7e23e83-a87d-4ae4-a2cd-7de5a5e7a23e"
      unitRef="usd">762625000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id00bc4b3a9074f93bce79a9e4c8911e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNi05LTEtMS0zOTgzNg_59d855df-a9bb-418e-b6dc-9e36c37330b7"
      unitRef="usd">47054000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i52837a82692c4071bbd19aa6f8dfc744_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNi0xMS0xLTEtMzk4MzY_3a93a116-b0c6-4943-af41-c34527837827"
      unitRef="usd">23968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1ddb90dcdc5b4e7aa2740103176d7a92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNy05LTEtMS0zOTgzNg_f8c64ca2-3039-4878-be9e-5be855eb8662"
      unitRef="usd">21399000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iedbeaf00736c4ec5b4e73d8f63d31829_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfNy0xMS0xLTEtMzk4MzY_3a66a95d-9df3-4f4c-8f05-d3c567a0b60a"
      unitRef="usd">10940000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfOC05LTEtMS0zOTgzNg_c5b6bf8e-65bf-4a7b-80fe-728ae64610c2"
      unitRef="usd">8798000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfOC0xMS0xLTEtMzk4MzY_55043cb8-9aee-4064-9d0b-80d52e076e11"
      unitRef="usd">1250000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfOS05LTEtMS0zOTgzNg_8d3168fd-2b14-4747-9b49-434a4f191715"
      unitRef="usd">504977000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RhYmxlOjUzZWJkNGU0ZjBiNTQ4MzU5YzQ0Zjg5ZDBlY2ViZjhlL3RhYmxlcmFuZ2U6NTNlYmQ0ZTRmMGI1NDgzNTljNDRmODlkMGVjZWJmOGVfOS0xMS0xLTEtMzk4MzY_ca710523-cb33-4e68-8431-9db22d64ca94"
      unitRef="usd">798783000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTEzNQ_adfbf114-6096-4d2e-90be-076bae8b01b6"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTA5OTUxMTYyOTI1MQ_fa52c2cd-8797-4204-a677-6550681d1b8c"
      unitRef="usd">7500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85MS9mcmFnOmUzN2E0NThiMTEyYTRiMTBiZDVmZjM0NzE3ZTAyYTEwL3RleHRyZWdpb246ZTM3YTQ1OGIxMTJhNGIxMGJkNWZmMzQ3MTdlMDJhMTBfMTI2NA_e6ca08d2-61e9-4115-8074-081b28faf630"
      unitRef="usd">8100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RleHRyZWdpb246YTQ1ZmRkNmViM2Y3NGRmNWE0NDU4MGQzNDFkM2EwMTVfNzc_c0178b3a-923d-4552-beca-4729af16c1bc">Inventory&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RleHRyZWdpb246YTQ1ZmRkNmViM2Y3NGRmNWE0NDU4MGQzNDFkM2EwMTVfNzk_da04819c-db7a-45a3-b186-d72667bd6ecb">Inventory consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfMi0xLTEtMS0zOTgzNg_7a13b9cf-3a28-4f12-99f1-f2be0327e51c"
      unitRef="usd">2575000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfMi0zLTEtMS0zOTgzNg_f520b06b-3d57-44f8-9736-508457b4acd8"
      unitRef="usd">3166000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfMy0xLTEtMS0zOTgzNg_a31bd5a4-d16a-4af0-8c36-0f959fa275f6"
      unitRef="usd">10749000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfMy0zLTEtMS0zOTgzNg_27bfe92f-f258-4822-84a5-204402fe6884"
      unitRef="usd">9342000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfNC0xLTEtMS0zOTgzNg_22a465ad-5f27-4901-ba7c-ba38d1753c96"
      unitRef="usd">5878000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfNC0zLTEtMS0zOTgzNg_6b68b216-cc96-4e8d-8c57-9c7479964f71"
      unitRef="usd">3293000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfNS0xLTEtMS0zOTgzNg_f5bb49a2-a824-41a0-a49f-5b985e972548"
      unitRef="usd">19202000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85NC9mcmFnOmE0NWZkZDZlYjNmNzRkZjVhNDQ1ODBkMzQxZDNhMDE1L3RhYmxlOjZkNWMzYTcyZjA5MjRiYTA4ZDQzNGFiZGVkNGQwY2Q1L3RhYmxlcmFuZ2U6NmQ1YzNhNzJmMDkyNGJhMDhkNDM0YWJkZWQ0ZDBjZDVfNS0zLTEtMS0zOTgzNg_058d6c73-e230-4a4f-8bda-0728d93233e9"
      unitRef="usd">15801000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjc3_e78c0aed-cb21-419c-8c44-b1dbb899f184">Property, Plant and Equipment&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Property, plant and equipment consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Laboratory and manufacturing equipment, including construction-in-process, include assets that support both our manufacturing and research and development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment decreased significantly for the year ended December 31, 2022 as a result of our 2022 Restructuring Plan. As further disclosed in Note 11, we sold our research and development facility in India, we sold or disposed of laboratory equipment and certain computer software, and we recognized impairment charges for leasehold improvements and certain furniture and fixtures for spaces we seek to sublease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Depreciation and amortization expense for property, plant and equipment for the years ended December&#160;31, 2022, 2021, and 2020 was $12.2 million, $13.0 million, and $12.5 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjc1_f85fe4eb-c6ad-47c8-bd02-c662a82f9bbf">Property, plant and equipment consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;We recorded the gains and losses as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net book value of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total (gain) loss on sale or disposal of property, plan and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i7a690bee3fdb41e69aa7a67bfdee3e57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMi0xLTEtMS0zOTgzNg_f6bc1189-2537-4f6b-ad32-d6ad3e23cfb9"
      unitRef="usd">74889000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ib8386997073541c38bb72fe0270ebcf7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMi0zLTEtMS0zOTgzNg_651d674b-7c77-4841-bb08-de0a8655fb76"
      unitRef="usd">97385000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i0b488f3b36c44ef2a771d6736c3a2bbd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMy0xLTEtMS0zOTgzNg_e3a17102-de60-451b-96bb-faf746b8d5c8"
      unitRef="usd">24243000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ie418bae4d52d43e884dd28a74b932d6c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMy0zLTEtMS0zOTgzNg_9bd1a8bc-5dda-4f05-a028-fc11b637bc52"
      unitRef="usd">42704000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i98a44796e8144efd8952281ed5f82527_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNC0xLTEtMS0zOTgzNg_977dc6e2-360c-4a4b-8d12-51573d1fc1be"
      unitRef="usd">26205000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ie3264cdda22e4ccb9b495d63ecf07335_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNC0zLTEtMS0zOTgzNg_76805b3d-e29e-4acf-a05c-873616f35c55"
      unitRef="usd">28829000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ida76ac790e3346c9abae40c1d17bbf09_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNS0xLTEtMS0zOTgzNg_1ce49280-b3b1-49a6-9270-6fb6d3295b43"
      unitRef="usd">25052000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i229a4d508cf44e958dcc2e374b94852b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNS0zLTEtMS0zOTgzNg_369ac31f-195e-4900-a676-2de20bb18965"
      unitRef="usd">22374000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="iea5bf9ea7884421aab5dcf25a470d1db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNi0xLTEtMS0zOTgzNg_837ea8e1-36f7-472b-bd66-a7172a586692"
      unitRef="usd">4263000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i89433d88568a4bbd9019d46526e1fb80_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNi0zLTEtMS0zOTgzNg_a4d2dad4-0f3d-476b-888c-5e1577327589"
      unitRef="usd">10094000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNy0xLTEtMS0zOTgzNg_7e363020-3bd7-4f2f-a43f-b703bb4a1cd2"
      unitRef="usd">154652000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfNy0zLTEtMS0zOTgzNg_93ac6543-fbdb-4070-8f74-ebf6fbe66119"
      unitRef="usd">201386000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfOC0xLTEtMS0zOTgzNg_5e1399b2-4065-42d7-9d1b-e2f2ec908527"
      unitRef="usd">124731000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfOC0zLTEtMS0zOTgzNg_44bf8012-5f59-477c-976f-45f4b9d9c982"
      unitRef="usd">148039000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <nktr:DepreciablePropertyPlantAndEquipmentNet
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfOS0xLTEtMS0zOTgzNg_caf713dd-08da-40f9-9a8f-347b48ea80f7"
      unitRef="usd">29921000</nktr:DepreciablePropertyPlantAndEquipmentNet>
    <nktr:DepreciablePropertyPlantAndEquipmentNet
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfOS0zLTEtMS0zOTgzNg_70bddf00-9587-4433-a4b8-58c0696f0478"
      unitRef="usd">53347000</nktr:DepreciablePropertyPlantAndEquipmentNet>
    <us-gaap:ConstructionInProgressGross
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMTAtMS0xLTEtMzk4MzY_15e80b91-cf50-4bf4-8023-da1244b1fbf2"
      unitRef="usd">2530000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMTAtMy0xLTEtMzk4MzY_32411506-c960-4287-817c-bf6ea33ec279"
      unitRef="usd">7163000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMTEtMS0xLTEtMzk4MzY_976b8224-7401-4b50-837e-ef8375edbf7a"
      unitRef="usd">32451000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RhYmxlOmY3MWExYTUwYjlmNzQxYTFhNjQ2ZWNjZTBkYjFhZmZjL3RhYmxlcmFuZ2U6ZjcxYTFhNTBiOWY3NDFhMWE2NDZlY2NlMGRiMWFmZmNfMTEtMy0xLTEtMzk4MzY_913ed6e3-e7eb-45fc-8096-0c7e596e3cf9"
      unitRef="usd">60510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjQ3_7b6d5c39-6d51-4777-ac0a-08c13da6ab7d"
      unitRef="usd">12200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjUx_336669d9-cd26-46b3-83fe-cd5c2c731e2c"
      unitRef="usd">13000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF85Ny9mcmFnOmI4ODY4OGEzZGFiYzRiNDI4M2I4MWMyYjBkMjc1MDA3L3RleHRyZWdpb246Yjg4Njg4YTNkYWJjNGI0MjgzYjgxYzJiMGQyNzUwMDdfNjU5_c9a33116-317b-47e0-9ae3-0cbead220414"
      unitRef="usd">12500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxMzc_c06c9e1c-80c9-47ec-b211-26893af29038">Operating Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our leases consist of a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. 19, LLC (ARE) for our 155,215 square foot corporate office and R&amp;amp;D facility located at 455 Mission Bay Boulevard South, San Francisco, California (the Mission Bay Facility) and a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) for an additional 135,936 square foot of office space at 360 Third Street, San Francisco, California (the Third Street Facility). The following table presents key information regarding these leases (dollars in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mission Bay Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third Street Facility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease commencement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Renewal terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Two consecutive &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMS0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmZDFjZGUwODRhMjM0MjRiODM0ZTUxNjRlODJmZWYwMl8xOQ_2b0e6231-2800-4ca2-b334-9e61b9740c93"&gt;five&lt;/span&gt;-year terms&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMy0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmNWM1YzY0MzkwN2Q0MjkzODY0ODc2YzY1NzI1Y2VjN183_28da30aa-6692-46e9-9d13-2ccc8f191594"&gt;five&lt;/span&gt;-year term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The monthly base rent for both facilities will escalate over the term of the lease at various intervals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Both leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance costs and taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For the Third Street Lease, our fixed annual base rent on an&#160;industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to our 2022 Restructuring Plan, during the year ended December 31, 2022, we recorded impairment charges of $54.6&#160;million for our right-of-use assets which we are seeking to sublease. See Note 11 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally recognize lease expense for our operating leases on a straight-line basis over the lease term, and we continue to recognize lease expense on a straight-line basis for spaces for which we did not recognize an impairment. For spaces where we did recognize an impairment charge, the aggregate lease expense recognized over the remaining term is reduced by the amount of the impairment charge, but we recognize the remaining lease expense on an accelerated basis. The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the years ended December&#160;31, 2022, 2021 and 2010, we paid $20.1 million, $16.8&#160;million and $16.2&#160;million, respectively, of operating lease payments related to our lease liabilities, which we include in net cash used in operating activities in our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: portion representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2022, the weighted-average remaining lease term is 7.1 years and the weighted-average discount rate used to determine the operating lease liability was 5.8%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into subleases for certain spaces that provide recovery of $10.5&#160;million in aggregate lease payments, as well as the subtenants' share of operating expenses. The reduction to lease expense for the year ended December 31, 2022, was not significant but will increase in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <nktr:AreaOfLeasedSpace
      contextRef="i4700d3b1885a4b0d8c4f82c6feb9dcfe_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzE0NQ_9d602d9b-8db3-4c4b-8807-3025c6ca74ee"
      unitRef="sqft">155215</nktr:AreaOfLeasedSpace>
    <nktr:AreaOfLeasedSpace
      contextRef="i6c4d7fb18f6d46d8988b427878e0c23f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzQwNA_61359db6-c44b-4a37-a6fc-12c7da45e8db"
      unitRef="sqft">135936</nktr:AreaOfLeasedSpace>
    <nktr:LesseeOperatingLeaseTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxMzg_8d212108-2a20-48e9-8879-f8ad13370a02">The following table presents key information regarding these leases (dollars in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mission Bay Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third Street Facility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease commencement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Renewal terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Two consecutive &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMS0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmZDFjZGUwODRhMjM0MjRiODM0ZTUxNjRlODJmZWYwMl8xOQ_2b0e6231-2800-4ca2-b334-9e61b9740c93"&gt;five&lt;/span&gt;-year terms&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMy0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmNWM1YzY0MzkwN2Q0MjkzODY0ODc2YzY1NzI1Y2VjN183_28da30aa-6692-46e9-9d13-2ccc8f191594"&gt;five&lt;/span&gt;-year term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nktr:LesseeOperatingLeaseTableTextBlock>
    <nktr:NumberOfConsecutiveTermsToExtendLease
      contextRef="i7f516ae040844d74a523bf6793681072_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMS0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmZDFjZGUwODRhMjM0MjRiODM0ZTUxNjRlODJmZWYwMl80_9dd7be27-1e6a-4073-8fc1-c4f0e8901896"
      unitRef="term">2</nktr:NumberOfConsecutiveTermsToExtendLease>
    <nktr:NumberOfConsecutiveTermsToExtendLease
      contextRef="i48c8e42537d84cce85b95bb5c5b6d70c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTphYWEyMzBkZGZiYTg0MzhjYmVhNjUwY2RmMjAxMjJjNS90YWJsZXJhbmdlOmFhYTIzMGRkZmJhODQzOGNiZWE2NTBjZGYyMDEyMmM1XzktMy0xLTEtMzk4MzYvdGV4dHJlZ2lvbjpmNWM1YzY0MzkwN2Q0MjkzODY0ODc2YzY1NzI1Y2VjN180_b65851e6-bca7-4da4-9c37-8c61e4e90e7c"
      unitRef="term">1</nktr:NumberOfConsecutiveTermsToExtendLease>
    <us-gaap:AssetImpairmentCharges
      contextRef="i428577ef84824447b2265e91b8e6ca13_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzkzNDU4NDg4NDA2OTQ_eb64d0eb-a267-4f61-afbf-1ee1c7e8a30c"
      unitRef="usd">54600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxNDA_15ac3f26-b480-4c6a-b5ea-5eea9d42818b">The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzItMS0xLTEtMzk4MzY_a291c071-45a6-45c3-8196-e48224618070"
      unitRef="usd">17057000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzItMy0xLTEtMzk4MzY_adf22d26-8cf4-41e1-aa3c-5b5dbef04c13"
      unitRef="usd">19153000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzItNS0xLTEtMzk4MzY_b564f6cd-3a67-45dc-9d1e-51db817a7f0f"
      unitRef="usd">18985000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzMtMS0xLTEtMzk4MzY_4a026638-5ae0-4dd1-9da9-35675cc7fb1e"
      unitRef="usd">10700000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzMtMy0xLTEtMzk4MzY_b10afda5-dcf8-43d2-acec-577887c9075b"
      unitRef="usd">8974000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzMtNS0xLTEtMzk4MzY_b856d014-f985-4625-8973-a0266d1bc7d4"
      unitRef="usd">8179000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzQtMS0xLTEtMzk4MzY_55084149-c3f3-4aa1-8770-7ff3474edf5e"
      unitRef="usd">27757000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzQtMy0xLTEtMzk4MzY_5d360a5c-2976-448b-9ed5-a62d66394019"
      unitRef="usd">28127000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTplMTUwMTIyODNlODQ0OWM4OGY5YWM5Mjg1ZDJmYzhhMS90YWJsZXJhbmdlOmUxNTAxMjI4M2U4NDQ5Yzg4ZjlhYzkyODVkMmZjOGExXzQtNS0xLTEtMzk4MzY_aef9166c-648e-46ca-9b5c-80b64ca8df26"
      unitRef="usd">27164000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzE2OTU_87c6d989-9e3d-45e1-be95-d8bb6dd43fe3"
      unitRef="usd">20100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzE2OTk_0aec7228-88c9-4937-8920-6fd689ab2a82"
      unitRef="usd">16800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzE3MDY_c7ab1d58-35c7-436b-9b60-5fb6ba006ddd"
      unitRef="usd">16200000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxMzU_c2f7eec2-0f76-4c1c-b4da-6a6c5240a75d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: portion representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzEtMS0xLTEtMzk4MzY_79aeeea4-babe-4d26-ad28-7b13982a2478"
      unitRef="usd">19216000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzItMS0xLTEtMzk4MzY_3834bf99-3ebf-4897-94ec-7a2b89acaeab"
      unitRef="usd">21572000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzMtMS0xLTEtMzk4MzY_0ff4d580-35b5-42fc-8911-f9882581b7e5"
      unitRef="usd">22254000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzQtMS0xLTEtMzk4MzY_6b2f5c96-fef6-4809-b07f-0f985d9b4149"
      unitRef="usd">22958000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzUtMS0xLTEtMzk4MzY_a3b7188a-3fb5-4741-acdf-fbc0f5002b72"
      unitRef="usd">23681000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzYtMS0xLTEtMzk4MzY_69acc5b8-a2e0-4319-87a9-81ce2ce2836e"
      unitRef="usd">51732000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzctMS0xLTEtMzk4MzY_121ba350-fbca-48b0-807b-4fae0187abaf"
      unitRef="usd">161413000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzgtMS0xLTEtMzk4MzY_00b48a1f-067a-45c8-8ca3-fe8dcf01184e"
      unitRef="usd">29917000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzEwLTEtMS0xLTM5ODM2_f13c30c1-cc5e-41f3-b1b3-e9c92b5b5d5f"
      unitRef="usd">131496000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzExLTEtMS0xLTM5ODM2_07fee6a8-5960-4368-944a-739c221c0d59"
      unitRef="usd">18667000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90YWJsZTo2OWNiMzQ0ODRlNjI0NGExOTBjNWYxNjg0MTg4MjllZi90YWJsZXJhbmdlOjY5Y2IzNDQ4NGU2MjQ0YTE5MGM1ZjE2ODQxODgyOWVmXzEyLTEtMS0xLTM5ODM2_af178b0f-c831-49b6-924d-7492f95a99a3"
      unitRef="usd">112829000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIwMzk_9e317ea4-593a-4f4a-8bfb-5ff61cafba7a">P7Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzIxMzM_0d2387f5-a020-4aaa-ba42-df4a19ede204"
      unitRef="number">0.058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <nktr:SubleasesIncomeToBeReceived
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDYvZnJhZzoyNWY2YmFmOGM0ODM0M2RlYjVhYjk5YzkwNGM0N2ZlMC90ZXh0cmVnaW9uOjI1ZjZiYWY4YzQ4MzQzZGViNWFiOTljOTA0YzQ3ZmUwXzEwOTk1MTE2MzIyNzg_558e1477-1838-4df8-bf48-359025210559"
      unitRef="usd">10500000</nktr:SubleasesIncomeToBeReceived>
    <nktr:DevelopmentDerivativeLiabilityTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzY0NjY_7b336583-8273-4151-9fd1-744cb5a49fd2">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ has primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we are the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $637.5&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin for the metastatic melanoma, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We presented the SFJ Agreement as a Development derivative liability in our Consolidated Balance Sheets, which we remeasured to fair value at each reporting date. As SFJ conducted the SCCHN Clinical Trial, we recorded non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remitted funding to us to support our internal costs of conducting the trial, we also recorded a corresponding increase to the development derivative liability. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the development derivative liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we valued the derivative using a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and we discount such cash flows to present value using a risk-adjusted rate. The key inputs to the valuation included our estimates of the following: (i) the probability of the  bempegaldesleukin trials meeting their primary endpoints, and if successful, the probability and timing of achieving FDA approval, (ii) the timing and the amount of costs incurred by SFJ for the SCCHN Clinical Trial, including the probability of early termination of the study based on an interim futility analysis, and (iii) each party&#x2019;s cost of borrowing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to zero as of March 31, 2022, and we recognized a corresponding gain in the Change in fair value of development derivative liability. As discussed in Note 1, on April 14, 2022, BMS and we decided to end the development for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and that all other ongoing studies in the bempegaldesleukin program would be discontinued. We also announced that SFJ and we agreed to discontinue the SCCHN Clinical Trial. Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.&lt;/span&gt;&lt;/div&gt;</nktr:DevelopmentDerivativeLiabilityTextBlock>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="iefb7645eeeaf42b793851c3bab72abca_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzMwMg_bcadd77c-59fa-4fa9-ac60-d8056a12ae84"
      unitRef="usd">150000000</nktr:CollaborativeArrangementCommittedFunding>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsAmount
      contextRef="iefb7645eeeaf42b793851c3bab72abca_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzkzNDU4NDg4NDQ0MTE_ef3162ba-22d4-46c6-af89-f7e163c26838"
      unitRef="usd">637500000</nktr:CollaborativeArrangementSuccessBasedPaymentsAmount>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzEwOTk1MTE2NDU4NDE_8274781a-7627-4d00-b9a5-23108becf777">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the development derivative liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibcf73feefa4248f9bc901c6de5114e62_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzItNC0xLTEtNDQxMzY_354b6a91-1bd1-4ba2-b388-65dbcfa98e2c"
      unitRef="usd">27726000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i296d2b099c6744c69a9b940e65fc438f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzItNi0xLTEtNDQxMzQ_a9335c74-15b3-4572-9e05-753ce39fbb14"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="i2cd1c1703c6a49d18229ba501627fd87_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzMtNC0xLTEtNDQxMzY_1e8226b2-4bc3-4511-91ad-695ab8d4d16b"
      unitRef="usd">4951000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="if7b11067296644fba18e31a4fd031969_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzMtNi0xLTEtNDQxMzQ_fce2999a-575b-46b5-bbed-d78eca3499fa"
      unitRef="usd">16703000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i2cd1c1703c6a49d18229ba501627fd87_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzQtNC0xLTEtNDQxMzY_7d8d91c7-391e-42f4-a383-674bb8e78c4f"
      unitRef="usd">750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="if7b11067296644fba18e31a4fd031969_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzQtNi0xLTEtNDQxMzQ_6f4c73ee-de2d-49cc-905a-45993767ef38"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i2cd1c1703c6a49d18229ba501627fd87_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzUtNC0xLTEtNDQxMzY_c4f84286-087c-4b57-8e0c-523b2d8a875a"
      unitRef="usd">-33427000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="if7b11067296644fba18e31a4fd031969_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzUtNi0xLTEtNDQxMzQ_7ee8f9de-c4e4-41c6-938e-73dc4beaaabf"
      unitRef="usd">8023000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i4b7c3411cc864b8fa20d76eb1a6c16ee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzYtNC0xLTEtNDQxMzY_a0f55ae8-2464-4d27-8d84-514adc48a1e1"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibcf73feefa4248f9bc901c6de5114e62_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90YWJsZTozZTY5YTUwZWQzNzk0YzY2YWMxMDEzYWVhMWY2YjQwYi90YWJsZXJhbmdlOjNlNjlhNTBlZDM3OTRjNjZhYzEwMTNhZWExZjZiNDBiXzYtNi0xLTEtNDQxMzQ_fe7b7dc1-3fed-4a72-9fe7-cb2f87614b01"
      unitRef="usd">27726000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie67fe37584df4144b73e3e9eab99c4d3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDMvZnJhZzo3MjJjMmJkYjYwNDk0ZTBiOWE5MTA3ZTgwYmM4MzJjMi90ZXh0cmVnaW9uOjcyMmMyYmRiNjA0OTRlMGI5YTkxMDdlODBiYzgzMmMyXzkzNDU4NDg4NTYxNDI_0b0f8995-3014-4151-a374-0ce57436c1db"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzg4ODU_b3aea71a-6fb5-4ea6-a3b1-8a3d33c12b5c">Liabilities Related to the Sales of Future Royalties&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the 2012 Transaction Royalties.&#160;Although we sold all of our rights to receive royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the effective interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products are remitted directly to RPI. As of December 31, 2022, our prospective effective interest rate used to amortize the liability is 10%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 5, 2020, UCB served notice of a Declaratory Judgment of Patent Invalidity, filed in the United States District Court for the District of Delaware, seeking a declaration of invalidity of certain of our patents that we had licensed to UCB and pursued similar actions in other jurisdictions. On October 14, 2021, RPI and we entered into a Letter Agreement which permitted us to enter into a Settlement Agreement, effective October 13, 2021, with UCB to effect the negotiation between RPI and UCB in which UCB and RPI agreed to a reduction in the royalty term and annual decreases in the royalty rate over the remaining royalty term in exchange for UCB&#x2019;s withdrawal of all of UCB&#x2019;s litigation and challenges. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded that we should account for the decrease in royalty payments to RPI as a result of these agreements as a modification of our liability. Due to the significance of the change in the estimated royalty payments, we concluded that we should treat the modification as an extinguishment of the prior liability and recognize a new liability based on the revised royalty payments and term, discounted to fair value. Accordingly, we estimated the fair value to be approximately $84.7&#160;million, reflecting a discount rate of 16.0%. As a result, we recognized a loss of $23.5&#160;million on the revaluation of the prior liability in the three months ended December 31, 2021, and we wrote off the remaining $0.9&#160;million of unamortized &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transaction costs. We present these charges in Loss on revaluation of liability related to the sale of future royalties line in our Consolidated Statement of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time that certain return thresholds are met as described below, of (a) MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB, as amended, (b) ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH, as amended, (c) REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $208.0&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2020, we received aggregate cash proceeds of $150.0&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $3.8&#160;million in transaction costs, which will be amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these products up to the cap, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, to be received by HCR in the first quarter of 2021. We recorded the $150.0&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. As of December 31, 2022, our prospective effective interest rate used to amortize the liability is 20%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account of each arrangement (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties&#x2014;beginning&lt;br/&gt;balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Pursuant to the 2012 Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $7.0 million and $3.0 million, respectively, as a result of worldwide net sales of MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the 12 month periods ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2013 and 2012 not reaching certain minimum thresholds. The 2012 Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense, as well as the loss on the revaluation described above, over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the appropriate Royalty Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;There are a number of factors that could materially affect the amount and timing of royalty payments from our licensees, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI or HCR are made in U.S. dollars (USD) while significant portions of the underlying sales of the products of our licensees are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from our licensees, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the respective Royalty Obligation. Conversely, for the 2012 Purchase and Sale Agreement, if sales of these products are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the 2012 Royalty Obligation.&lt;/span&gt;&lt;/div&gt;</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i96e50a20c84741bf96617a4a3059d745_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzcxOA_95ee6352-93de-4458-9081-e2a8b71546c4"
      unitRef="usd">124000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i96e50a20c84741bf96617a4a3059d745_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzEwMzQ_0a9c9464-5350-469b-9d22-c94e825e6857"
      unitRef="usd">124000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="i0ee1e09ac15b43f982a08e4065ea0c1c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzkxMjY_110e2f3a-fae5-4b74-afca-165ca07815db"
      unitRef="number">0.10</nktr:RoyaltiesLiabilityMeasurementInput>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ic27548c7b9c047ce81417f7851d5a13b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzI1MTI_ddab91db-bc47-439c-aa7f-89131c502565"
      unitRef="usd">84700000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="i1bb7eac326dd4bd1860d0018b43342d6_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzI1NDY_a04551b2-31cf-4b93-8a61-c7fc7dac0b5b"
      unitRef="number">0.160</nktr:RoyaltiesLiabilityMeasurementInput>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="ia8f403286c134e56995c7fac6aabe42c_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzI3MDg_2c8e67ad-5d32-46d1-b66c-65d8c801c242"
      unitRef="usd">-23500000</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:TransactionCostsRelatedToRevisedRoyaltyPayments
      contextRef="ia8f403286c134e56995c7fac6aabe42c_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzI4MzI_4776f17b-9a4d-4fb1-88f3-cec9ee07971a"
      unitRef="usd">900000</nktr:TransactionCostsRelatedToRevisedRoyaltyPayments>
    <nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved
      contextRef="i6d861344a14b4ed19a94c299e3f1bd9c_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzQ0MDY_715c9b98-ace5-4158-a560-c55ae23e6b28"
      unitRef="usd">210000000</nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved>
    <nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved
      contextRef="i6d861344a14b4ed19a94c299e3f1bd9c_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzQ1MDI_23b1545f-b90b-499c-a146-721055e14df1"
      unitRef="usd">240000000</nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved>
    <nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds
      contextRef="i6d861344a14b4ed19a94c299e3f1bd9c_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzQ3NjY_8e331393-6b26-4476-9e51-2c8a16e65969"
      unitRef="usd">208000000</nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i0a46e523740a48e4bc313c9c8f371a46_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzUxODI_ed553d70-ba26-42f3-96ea-4cfdba5b7211"
      unitRef="usd">150000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties
      contextRef="i0a46e523740a48e4bc313c9c8f371a46_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzUyNjg_d1357dd2-9472-43e6-ac85-70508278b67b"
      unitRef="usd">3800000</nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i0a46e523740a48e4bc313c9c8f371a46_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzU4Njk_19be6b13-3e5b-4bd7-ab00-06d82524327d"
      unitRef="usd">150000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="ib9e6083883184909bf4a11a730aefa63_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzEwOTk1MTE2Mjg2OTE2_02a3a9d0-36fe-465b-bfd6-72ebecd022e1"
      unitRef="number">0.20</nktr:RoyaltiesLiabilityMeasurementInput>
    <nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzg4ODY_3648877e-9fce-4ede-95f0-edce2c3f8909">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account of each arrangement (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties&#x2014;beginning&lt;br/&gt;balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="iee97d6bd60ef4aa78a34aa3a4e187ea1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItMS0xLTEtMzk4MzY_436a7eef-877e-42ad-b3e6-6c76bf32e847"
      unitRef="usd">78282000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ib56808f00dc44ceea4a81c7aadbb5013_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItMy0xLTEtMzk4MzY_700e1402-f777-455b-b771-cc279ab40cc7"
      unitRef="usd">120062000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItNS0xLTEtMzk4MzY_826be46b-d0a7-4821-98dc-0057653894c2"
      unitRef="usd">198344000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i58214773cc764c89b77413cc27cba0d6_I20120224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItNy0xLTEtMzk4MzY_9d9082e3-0f55-41f1-935d-f8651360b9a2"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i50db82185e724189a23e8bcbadd1f46d_I20201216"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItOS0xLTEtMzk4MzY_ae4e9137-8134-42d6-b2b2-cf998e192e6b"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i5e27ff45c6344a70a6715b2e56bebc4a_I20120224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzItMTEtMS0xLTM5ODM2_5e8423ec-5250-408f-b334-a07424463de5"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtMS0xLTEtMzk4MzY_acc70f8c-c8eb-4885-9c4d-25e365b0962e"
      unitRef="usd">0</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtMy0xLTEtMzk4MzY_929a334a-f8b2-46a9-9b8d-12732db2014f"
      unitRef="usd">0</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtNS0xLTEtMzk4MzY_d278cccc-b101-4d0a-b201-3efccf6da02f"
      unitRef="usd">0</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtNy0xLTEtMzk4MzY_a2f18c4b-0a3f-41cb-b7d5-46442fd777bd"
      unitRef="usd">124000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtOS0xLTEtMzk4MzY_684dae20-a784-4e16-9f72-dbc3b4d9430b"
      unitRef="usd">150000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzMtMTEtMS0xLTM5ODM2_f1bcc1d7-7132-4812-8715-86b9df5ff745"
      unitRef="usd">274000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtMS0xLTEtMzk4MzY_65e7ffd2-63d6-4231-a2f4-3667d79cd679"
      unitRef="usd">33865000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtMy0xLTEtMzk4MzY_8f082c5c-a568-48fc-8950-4a6bb38e6b6b"
      unitRef="usd">35929000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtNS0xLTEtMzk4MzY_98bdca44-f6f5-4732-a2ca-64563759c94a"
      unitRef="usd">69794000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtNy0xLTEtMzk4MzY_9aae32da-12d4-489f-ba79-da193e193af9"
      unitRef="usd">316523000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtOS0xLTEtMzk4MzY_38a43833-98be-473c-9112-3163408aed2c"
      unitRef="usd">86722000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzQtMTEtMS0xLTM5ODM2_1f4d2436-3de0-4c7d-a282-e6f55e936662"
      unitRef="usd">403245000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtMS0xLTEtMzk4MzY_e05acdbb-c422-4172-812b-b53465ef8389"
      unitRef="usd">10750000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtMy0xLTEtMzk4MzY_7cfb3655-dd3f-4dee-8634-4dded9f8bebc"
      unitRef="usd">18161000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtNS0xLTEtMzk4MzY_ec95f999-0b06-4703-9d9a-594c2b4c3e28"
      unitRef="usd">28911000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtNy0xLTEtMzk4MzY_f6293760-203b-48d8-8ad1-bdd184b710f9"
      unitRef="usd">234168000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtOS0xLTEtMzk4MzY_c85611ec-a611-4ded-ada6-06a54ed82c4f"
      unitRef="usd">39016000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzUtMTEtMS0xLTM5ODM2_b2722b41-f3d8-48c5-9f49-6d37e3fc3cb8"
      unitRef="usd">273184000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtMS0xLTEtMzk4MzY_12217ec7-04d2-46d1-b92f-5f7070e17a2e"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtMy0xLTEtMzk4MzY_3f18a5df-dc30-4309-8579-587f33ea2317"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtNS0xLTEtMzk4MzY_d3bf0b2a-0739-48d2-9c64-95a081451931"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtNy0xLTEtMzk4MzY_646be4e6-fc31-46ec-b52f-0fabe94bb306"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtOS0xLTEtMzk4MzY_aba03b13-b2a5-4143-a33b-2b70f72ea149"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzYtMTEtMS0xLTM5ODM2_20955ee2-15d3-4c1d-b49d-8700c3597157"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i8aafbe92444d448596c0b17d4de65069_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctMS0xLTEtMzk4MzY_3c21b978-91da-43cb-8e3b-09cda6bc47ae"
      unitRef="usd">0</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="id1c7e6a0d36c4f34ab4242e41cabe841_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctMy0xLTEtMzk4MzY_5ede970a-02f6-4738-a960-b7c480c6ab21"
      unitRef="usd"
      xsi:nil="true"/>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctNS0xLTEtMzk4MzY_6fc602f4-5155-4ec1-a4b6-e5775e32c199"
      unitRef="usd">0</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="id76911a57d904fb5b86b118f1355dee6_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctNy0xLTEtMzk4MzY_0af39998-20e3-4db7-b313-30b03b93ec8e"
      unitRef="usd">-23522000</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i6ff9f2bd994143aaaf54f9f2cc2b4554_D20201217-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctOS0xLTEtMzk4MzY_794a7416-8ed7-4059-8fa5-4070051a6669"
      unitRef="usd">0</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i0211a1334ced40e2833626cd80c87266_D20120225-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzctMTEtMS0xLTM5ODM2_e6d907ce-7921-483b-bd84-3acc038bb04e"
      unitRef="usd">-23522000</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtMS0xLTEtMzk4MzY_f63a77c1-c224-45d1-a1d7-d995517b03f0"
      unitRef="usd">55167000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="icb1ef455fc644610936464822e51b81e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtMy0xLTEtMzk4MzY_b7a3fbd1-35a8-4688-9cf3-c24becbcf33f"
      unitRef="usd">102294000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtNS0xLTEtMzk4MzY_b998cf8f-c352-4104-80a4-d49c0d32da65"
      unitRef="usd">157461000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtNy0xLTEtMzk4MzY_3bd5ac41-505b-45c3-8ff3-f6c341d9ae17"
      unitRef="usd">55167000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="icb1ef455fc644610936464822e51b81e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtOS0xLTEtMzk4MzY_8d5c1a5d-4ee3-4a76-9946-1a1f1a38e0e9"
      unitRef="usd">102294000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzgtMTEtMS0xLTM5ODM2_7973c040-a839-4b09-b572-ed6ed01e496d"
      unitRef="usd">157461000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktMS0xLTEtMzk4MzY_86bb0ea3-1578-49d8-98d7-eaca0adaf0d3"
      unitRef="usd">0</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="icb1ef455fc644610936464822e51b81e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktMy0xLTEtMzk4MzY_7b5e09bb-3d18-4896-912f-9b5cc526bd18"
      unitRef="usd">2083000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktNS0xLTEtMzk4MzY_69849de3-3aba-4bc9-860e-96efd6fb7753"
      unitRef="usd">2083000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktNy0xLTEtMzk4MzY_7fddc1ca-a7c6-412b-9616-b73a50b2650c"
      unitRef="usd">0</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="icb1ef455fc644610936464822e51b81e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktOS0xLTEtMzk4MzY_f5dabcdf-330f-4ac8-819f-2e1dd603ae82"
      unitRef="usd">2083000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzktMTEtMS0xLTM5ODM2_d441204a-0c1c-43ed-9c32-82e8ff6dedab"
      unitRef="usd">2083000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTEtMS0xLTM5ODM2_8ef50d37-99e1-4354-a821-255c2870b086"
      unitRef="usd">55167000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="icb1ef455fc644610936464822e51b81e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTMtMS0xLTM5ODM2_73b91ced-6fbe-431c-9442-73d845d471b9"
      unitRef="usd">100211000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTUtMS0xLTM5ODM2_56da65f3-42b7-4547-93d8-3d24c7013c95"
      unitRef="usd">155378000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ia0f4ba6c9266400796c445c6f33d98d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTctMS0xLTM5ODM2_f75a154e-cdb6-4be7-8be6-c2adfb2354c3"
      unitRef="usd">55167000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="icb1ef455fc644610936464822e51b81e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTktMS0xLTM5ODM2_947e271b-9c9c-40bd-8f46-97be9f699ea1"
      unitRef="usd">100211000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90YWJsZTpiYmI2OTI5OGExNGQ0MTc2YThhMjA3ZGNlZWJhODIwZi90YWJsZXJhbmdlOmJiYjY5Mjk4YTE0ZDQxNzZhOGEyMDdkY2VlYmE4MjBmXzEwLTExLTEtMS0zOTgzNg_04eb3587-22b3-4bf5-aaf8-385f17547fa8"
      unitRef="usd">155378000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:PaymentMadeForMilestoneNotAchievedYearTwo
      contextRef="icfb29fc19c9d46639cf8c5115010c1ec_D20140301-20140331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzYzOTI_faa45281-8a06-428b-a9db-dd5ea45cdcdb"
      unitRef="usd">7000000</nktr:PaymentMadeForMilestoneNotAchievedYearTwo>
    <nktr:PaymentMadeForMilestoneNotAchievedYearOne
      contextRef="i11ff6330b45e466abdfd7de31f51f2d6_D20130301-20130331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMDkvZnJhZzpjY2Q5MjUxYTY1YTc0NWNhYjAwMzJmNDUzMTI2ODkzMS90ZXh0cmVnaW9uOmNjZDkyNTFhNjVhNzQ1Y2FiMDAzMmY0NTMxMjY4OTMxXzYzOTk_7b370a4e-0337-4593-a053-df87cc370a89"
      unitRef="usd">3000000</nktr:PaymentMadeForMilestoneNotAchievedYearOne>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzk5MTM_5e3e5513-9b11-4d63-acf1-a374cd5d0d0c">Commitments and Contingencies&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In the normal course of business, we enter into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&#160;31, 2022, these commitments were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We have recorded no liability for any litigation matters in our Consolidated Balance Sheets at either December&#160;31, 2022 or December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We have operated in a number of foreign countries, but we are in the process of winding down our foreign subsidiaries. As of December 31, 2022, we no longer have any foreign properties and only a few remaining employees in foreign locations. We are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any of these potential indemnification obligations is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Consolidated Balance Sheets at either December&#160;31, 2022 or December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnification of Underwriters and Initial Purchasers of our Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In connection with our sale of equity we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Director and Officer Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification would not be material, other than retention of up to $10.0 million per incident for merger and acquisition related claims, $10.0 million per incident for securities related claims and $10.0 million per incident for non-securities related claims per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i01976cfee21a4bc1ac8121bef4c3c1f7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzYwNjk_119bac4a-49bb-4c55-82b6-06e9cfb6f4f6"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i07893b3959254f9ebfe26a0ff8ffc37b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzYwNjk_aae53d1c-3266-4d1f-a627-625accd24011"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident
      contextRef="id78314c12234445bbd7f0667b5fef4fb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzk0MzM_280f5da4-8b5f-4c46-b29f-c3e5acf8860b"
      unitRef="usd">10000000</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
    <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident
      contextRef="ie58f9f4376a2484a87512c90b4835ff7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzk0OTI_a24e04d9-22f3-4067-9bab-150c99f1aa2c"
      unitRef="usd">10000000</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
    <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident
      contextRef="i9c5fd482c6864667b05d8be19b108140_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTUvZnJhZzo2YzUyMWE1MTNlOTA0NWU1OTY0M2FlZTA5MTdkYjhjMC90ZXh0cmVnaW9uOjZjNTIxYTUxM2U5MDQ1ZTU5NjQzYWVlMDkxN2RiOGMwXzk1NDI_fdaab462-4f4d-4c4e-b601-7fc4942ffc92"
      unitRef="usd">10000000</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzExMTY_f34f05b2-3430-456d-b7f5-802965d750d1">Stockholders&#x2019; Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As discussed in Note 10, on April 3, 2018, we completed the issuance and sale of 8,284,600 shares of our common stock under a Share Purchase Agreement with BMS. These shares are unregistered and subject to certain lock-up and stand-still provisions for a five-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the filing of this Annual Report on Form 10-K, we had an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the SEC. The 2021 Shelf Registration Statement permitted the offering, issuance and sale by us of up to an aggregate offering price of $300.0&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which could be offered, issued and sold in &#x201c;at-the-market&#x201d; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities were sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement. As a result of the recent decline in our market capitalization, we are no longer a well-known seasoned issuer. Accordingly, the 2021 Shelf Registration Statement will no longer be available for us to offer and sell securities pursuant to the 2021 Shelf Registration Statement following the filing of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, shares of common stock reserved for future issuance are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs and PSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future grant under the 2017 Performance Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accumulated other comprehensive loss as of December 31, 2022, includes $1.8&#160;million for net unrealized losses on our available for sale securities and $5.1&#160;million for accumulated net translation losses primarily from our subsidiary in India.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3995f200366f48ddae334a6ff1b42719_D20180403-20180403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzExOQ_e5188534-44bd-439f-bc69-0d956675e348"
      unitRef="shares">8284600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod
      contextRef="i5004dfaad50e4a37b683b94437e9c3fe_D20180403-20180403"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzExMTM_0968f389-c31a-428d-9234-50b0b933eb3e">P5Y</nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod>
    <nktr:SaleOfStockValueAuthorizedInTransaction
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzU5OQ_96516748-4c2e-4124-8f43-478a01bbc093"
      unitRef="usd">300000000</nktr:SaleOfStockValueAuthorizedInTransaction>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzExMTQ_55fc0e92-a195-4ff7-93be-69453874b441">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, shares of common stock reserved for future issuance are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs and PSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future grant under the 2017 Performance Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average volatility factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9dee2bf1b1104b36a37ca5af4f6c6e08_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90YWJsZTo2ODI5NWQwZTMyZjM0YmZiOGQ1M2Q0OTUzN2U0NzMyOC90YWJsZXJhbmdlOjY4Mjk1ZDBlMzJmMzRiZmI4ZDUzZDQ5NTM3ZTQ3MzI4XzAtMS0xLTEtMzk4MzY_dc934727-e520-40b7-a0df-6bb5adb2eca8"
      unitRef="shares">23589000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7a12065b592f45eb91672b4c2ecfc993_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90YWJsZTo2ODI5NWQwZTMyZjM0YmZiOGQ1M2Q0OTUzN2U0NzMyOC90YWJsZXJhbmdlOjY4Mjk1ZDBlMzJmMzRiZmI4ZDUzZDQ5NTM3ZTQ3MzI4XzEtMS0xLTEtMzk4MzY_0edecadb-c46a-4812-a4c0-a824ad4ca92b"
      unitRef="shares">2973000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6a09c769b2cf4b7d96bd94af49863ae2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90YWJsZTo2ODI5NWQwZTMyZjM0YmZiOGQ1M2Q0OTUzN2U0NzMyOC90YWJsZXJhbmdlOjY4Mjk1ZDBlMzJmMzRiZmI4ZDUzZDQ5NTM3ZTQ3MzI4XzItMS0xLTEtMzk4MzY_183ab0d0-bcb0-454e-857a-b16c2a163ab9"
      unitRef="shares">841000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90YWJsZTo2ODI5NWQwZTMyZjM0YmZiOGQ1M2Q0OTUzN2U0NzMyOC90YWJsZXJhbmdlOjY4Mjk1ZDBlMzJmMzRiZmI4ZDUzZDQ5NTM3ZTQ3MzI4XzMtMS0xLTEtMzk4MzY_984134c1-8446-4743-8530-8aa800cf8d16"
      unitRef="shares">27403000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockholdersEquity
      contextRef="ib0a2b75f3c2c497e821c32654dcf273d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzEwOTk1MTE2Mjk3MDI_fb0afa30-6f58-491d-a80d-bede109dab85"
      unitRef="usd">-1800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b2e426dae1d4dcb82e953621113a971_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMTgvZnJhZzoyYTlmODA4YjE0MDI0YmMzOTA0Yjc5ZmJjNzlhMTg3MS90ZXh0cmVnaW9uOjJhOWY4MDhiMTQwMjRiYzM5MDRiNzlmYmM3OWExODcxXzEwOTk1MTE2Mjk3MTY_4b4754d2-3b45-427d-9d74-b811223ef713"
      unitRef="usd">-5100000</us-gaap:StockholdersEquity>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzE2NjA0_eb667dc2-0fec-4cfa-9b48-be229c30ee2e">License and Collaboration Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bristol-Myers Squibb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb (BMS): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bempegaldesleukin (previously referred to as NKTR-214)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and commercialization of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. In 2020, we received non-refundable milestone payments of $50.0&#160;million in aggregate for the first patient, first visit in the registrational trials in muscle-invasive bladder cancer and adjuvant melanoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1, on March 14, 2022, we announced our registrational trial in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the trials in metastatic melanoma and adjuvant melanoma. On April 14, 2022, we announced that our registrational trials in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided that these studies and all other ongoing studies in the program will be discontinued. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. However, without further development of bempegaldesleukin, we will no longer be eligible for the development, regulatory and sales milestones under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;proportionately with the performance of the underlying services. We recognized BMS&#x2019; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#x2019; expenses as research and development expense. As discussed in Note 11, we terminated the development of bempegaldesleukin, and therefore, in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the bempegaldesleukin program in restructuring, impairment and other costs of program. Accordingly, during the year ended December&#160;31, 2022, we recorded $45.7&#160;million for the net reimbursement from BMS, of which we recorded $24.9&#160;million as a reduction of research and development expense for the first quarter of 2022, and $20.8&#160;million as a reduction of restructuring, impairment and other costs of terminated program for the remaining three quarters of 2022. During the years ended December&#160;31, 2021 and 2020, we recorded $101.5&#160;million and $128.2&#160;million, respectively, as a reduction of research and development expense for the net reimbursement from BMS. As of December&#160;31, 2022, we have recorded an unbilled receivable of $4.2 million from BMS in accounts receivable in our Consolidated Balance Sheet, which we received in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eli Lilly and Company (Lilly): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NKTR-358 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop rezpegaldesleukin, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0&#160;million and are eligible for up to $250.0&#160;million in additional development and regulatory milestones. Although we are entitled to significant development milestones under this arrangement if Lilly decides to proceed to Phase 3 development, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently in Phase 1B and Phase 2 development, where we share costs with 75% of the costs borne by Lilly and 25% of the costs borne by us. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to 25% of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the costs of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Phase 3 development on an indication-by-indication basis in order for us to achieve the maximum royalty level under the Lilly Agreement, and further&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if approved, we will have the opportunity to receive a royalty rate up to the low twenties percent based upon our Phase 3 development cost contribution and the level of annual global product sales.  Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur. The Lilly Agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The Lilly Agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study). The primary endpoint of the Phase 2 Lupus Study was not met, and Lilly has notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Baxalta Inc. / Takeda Pharmaceutical Ltd.: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hemophilia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology, resulting in the approval of ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by the FDA in  2015, which is now marketed in the U.S., the European Union, and many other countries. We are entitled to royalties based on worldwide net sales of ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and a sales milestone upon achievement of an annual worldwide net sales target. We are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, we are entitled to single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement. As described in Note 7, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca AB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (naloxegol oxalate)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Through various sublicense arrangements to RedHill Biopharma, Kyowa Hakko Kirin Co. Ltd. and Knight Therapeutics, as of April 2020, AstraZeneca has sub-licensed all of its global commercialization rights. Our rights, including the royalty rate, royalty term and future potential sales milestones, remain unchanged as a result of these sublicenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are generally entitled to escalating double-digit royalty payments and sales milestones for net sales of MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As described in Note 7, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $40.0&#160;million of regulatory milestones, as well as royalties based on net sales, if approved, and sales milestones upon achievement of an annual net sales targets. However, given the current phase of development of the product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzE2NjA2_e894ef4c-cbe6-40d7-98d9-9a9bd8087459">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bristol-Myers Squibb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i41101ca7c6074352b2c8edbbded90a47_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzItNC0xLTEtMzk4MzY_4f557415-dc12-49e6-83d3-ea783ff206ee"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ic6f6ddc21ca64160889eff82cd22dac0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzItNi0xLTEtMzk4MzY_3dacdc2b-c99e-4b16-80eb-6dc20ad8ea23"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ifb79cd1e8a9d4e9b956b054364d945b9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzItOC0xLTEtMzk4MzY_ccadcc4f-7b5d-4afc-a41c-a27f6392131d"
      unitRef="usd">50000000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i3b00cf7a680342eabe29c33d1f30ca48_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzUtNC0xLTEtMzk4MzY_f15efc1f-7f3d-49b2-88c2-1d335e311743"
      unitRef="usd">1913000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="icd4d0375d0754d04bfbcb3001a3a73ab_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzUtNi0xLTEtMzk4MzY_6a68d40a-94cc-4b52-b6eb-b9f4d7de20cd"
      unitRef="usd">436000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i1acc968e13bf49b2af89cb89994d8c21_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzUtOC0xLTEtMzk4MzY_7d247824-166e-4f80-95cf-a4e43c0a3a53"
      unitRef="usd">5849000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzYtNC0xLTEtMzk4MzY_00171857-c266-4700-9878-6e01f88bacc9"
      unitRef="usd">1913000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzYtNi0xLTEtMzk4MzY_838b9083-4db1-4cce-b88f-233032474aee"
      unitRef="usd">436000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90YWJsZTplZTQyMzc0ZmNjNDM0Y2Q5YWY5N2MzNDBlMjdmNTY3MC90YWJsZXJhbmdlOmVlNDIzNzRmY2M0MzRjZDlhZjk3YzM0MGUyN2Y1NjcwXzYtOC0xLTEtMzk4MzY_226b904c-62f7-4439-aad1-299c2c07942b"
      unitRef="usd">55849000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i5a0cc81cd3464c5b93834a7c5444f287_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE5OTYw_b1e79dc8-a071-4edb-ae5c-ccfec546c43e"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i518ea15aaef14db7aa415c20c69633ba_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDA0_70847ab3-79ec-406a-92b0-334c0a57f301"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="if2e2d3e9e2a7461daef194bc19d22bb4_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDE1_d0f97a61-4cbe-41a5-8988-bd1697eee40d"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i93f5d9b4d79b4feca3f3a4d2b14a9583_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDI0_c100ad95-c0a4-4cfd-8e29-1bf2184e5389"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="i034999d286934f979052476fb5f2c14a_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDQy_e9e3c4ff-e0e4-433e-915e-96a6d55a9786"
      unitRef="usd">1000000000</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <us-gaap:SharesIssued
      contextRef="if6238407fbe54f7f8ccc426559162694_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDY2_cd596268-ac24-4ee0-a388-8a1bda14e976"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="i3c808ebe93bd410caafb0853708fc73f_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE5OTgy_5bf2ed09-0ddb-4981-81e7-d362c059b7e7"
      unitRef="usd">850000000</nktr:SaleOfStockConsiderationReceived>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ibcde63790f2b4c09a640ee1fb4bcaf0e_I20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMDkx_24b1665f-0f24-44d4-8ce6-f2e7b48370f5"
      unitRef="usd">50000000</nktr:PotentialDevelopmentMilestones>
    <nktr:ReimbursementOfExpenses
      contextRef="i4cbcedb2872f472f8169616cf817be26_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4NzEy_661c9c3c-9d93-44a8-aa31-c2187a5a1ad1"
      unitRef="usd">45700000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="ia59bf42370df4deeb31e0accd2bdaf1a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE3OTk4_90edaae4-c715-49d7-b89f-d821ac6e07c0"
      unitRef="usd">24900000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i2d8701f92c324d04925cd7cef5dec02f_D20220401-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4MTQy_884c26af-39c8-4eca-b0c1-3df73005e9d9"
      unitRef="usd">20800000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i28f996738350426c90cc53b744993a58_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4MDgy_5fe518d6-6c71-462b-ae58-22d37c2cf502"
      unitRef="usd">101500000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i398cab648ac141a89899e3e28583c043_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4MDk4_6532ad19-609a-4d3d-b992-ccde8664cfae"
      unitRef="usd">128200000</nktr:ReimbursementOfExpenses>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i33ecf05d707f40b5927205653bd6a5c7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzE4MTYy_61dc957f-4fbc-463c-bcac-235eddec9c6c"
      unitRef="usd">4200000</us-gaap:AccountsReceivableNetCurrent>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="if58625a341de4335a5fee3c3a3737dae_D20170723-20170723"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMTIx_60365ed3-fc71-4140-a977-4f30ab614bfe"
      unitRef="usd">150000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="iebb537ce80dc447d8acffa6a5eb73666_I20170723"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMTUy_5b6232d7-fca1-4bba-b953-4210ea03214e"
      unitRef="usd">250000000</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="ib0f6b7f71328485db76064f93dc003eb_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMTcy_8e35b04f-f09e-410e-9b22-fc3968027b8d"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="if58625a341de4335a5fee3c3a3737dae_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzkzNDU4NDg4Nzg1NTU_0412a7e1-200b-4ee3-86cd-23d6d58f72eb"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i45d02ce2e1364896bbbc49fa46ce2648_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzkzNDU4NDg4Nzg1NjQ_14670f9f-473a-4bd6-9f18-cb94f425b8dc"
      unitRef="number">0.25</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
      contextRef="i22df0cf6959c4db1b5ac09a71e43c84c_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMTgx_d1979894-97b1-4eec-b1fc-658774789648"
      unitRef="number">0.50</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
      contextRef="i22df0cf6959c4db1b5ac09a71e43c84c_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzkzNDU4NDg4Nzg1NzM_2f4e4e3b-dabb-4a28-8ee2-1c174adaf5bf"
      unitRef="number">0.75</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur>
    <nktr:PotentialDevelopmentMilestones
      contextRef="if7a7eeedf4d74cc9a9917ed4c99c02c8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjEvZnJhZzo1NjJjYTc0ODVhNWM0Mjk5OTUxMmY2MTE1ZGNmZWU4OS90ZXh0cmVnaW9uOjU2MmNhNzQ4NWE1YzQyOTk5NTEyZjYxMTVkY2ZlZTg5XzEwOTk1MTE2MzIwMjAw_5dfd80de-3c01-4ac6-84b5-09be974367e7"
      unitRef="usd">40000000</nktr:PotentialDevelopmentMilestones>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTU2_5080f635-00fa-428a-b8b1-f81e2ce8e33c">Restructuring, Impairment and Other Costs of Terminated Program&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1, because our registrational trials in bempegaldesleukin did not meet their primary endpoints, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors, and, during April 2022, we announced the 2022 Restructuring Plan to prioritize key Phase 2 development programs, to advance our early stage research pipeline and to reduce our workforce by approximately 70% from approximately 735 to approximately 225 employees. In connection with these events, we reported the following costs in restructuring, impairment and other costs of terminated program for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Severance and related benefit costs pursuant to the 2022 Restructuring Plan;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Impairment of sublease assets, including right-of-use assets and property, plant and equipment resulting from the 2022 Restructuring Plan, reflecting excess office and laboratory leased spaces in San Francisco, CA; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;(Gain) loss on sale or disposal of property, plant and equipment; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Contract termination and other costs associated with the wind down of the bempegaldesleukin program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In prior periods through March 31, 2022, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin program primarily in research and development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Gain) loss on sale or disposal of property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination and other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and other costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The clinical costs associated with winding down the bempegaldesleukin program primarily include clinical trial and other development expenses to transition patients from our sponsor-led trials to standard of care or our post-trial access program, as well as direct employee costs supporting these efforts. We recorded a reduction of expense of $20.8&#160;million for the net reimbursement from BMS primarily for such costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Severance and Benefit Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees affected by the reduction in force under our 2022 Restructuring Plan were entitled to receive severance payments and certain Company funded benefits. We recognized severance and benefit expense in full for employees who were notified of their termination in April 2022 and had no requirements for future service, and we recognized expense for employees who were required to render services to receive their severance ratably over the service period. This service period began in April 2022 with all affected employees terminated on or before December&#160;31, 2022, and therefore we will recognize no further expense. The following table provides details regarding the severance and other termination benefit expense. We present the liability, which we paid in January 2023, in accrued compensation on our Consolidated Balance Sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;No service period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Service period required&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Right-of-Use Assets and Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our 2022 Restructuring Plan, we have consolidated our San Francisco operations in our Mission Bay Facility, and we have vacated our Third St. Facility and certain laboratory and office spaces at our Mission Bay Facility. We are seeking to sublease the vacated spaces, while still maintaining sufficient office and laboratory space to allow our team to develop our proprietary programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of these plans, we reviewed each of our vacated spaces for impairment as of May 31, 2022, when management had determined which spaces we would seek to sublease, and subsequently at each reporting date or as facts and circumstances changed. As part of our impairment evaluation of each vacated space, we separately compared the estimated undiscounted income to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily leasehold improvements (collectively, sublease assets). We estimated sublease income using market participant assumptions, including the length of time to enter into a sublease and sublease payments, which we evaluated using sublease negotiations or agreements when applicable, current real estate trends and market conditions. If such income exceeded the net book value of the related assets, we did not record an impairment charge. Otherwise, we recorded an impairment charge by reducing the net book value of the assets to their estimated fair value, which we determined by discounting the estimated sublease cash flows using the estimated borrowing rate of a market participant subtenant, which we estimated to be 6.4% and 7.9% as of May 31, 2022 and December 31, 2022, respectively. We recorded the substantial majority of our impairment charges as of May 31, 2022, primarily reflecting decreased rental recovery rates for our office lease space on Third St. However, as the office lease market in San Francisco deteriorated after May 31, 2022 in the fourth quarter of 2022, we recorded an additional impairment charge of $12.0&#160;million in the three months ended December 31, 2022, for the Third St. Facility, reflecting an increase in our estimated time to enter into a sublease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded impairment charges as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net book value of impaired sublease assets as of May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Fair value of impaired sublease assets &#x2014; Level 3 of Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Book value in excess of fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total impairment of sublease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may record adjustments to impairment expense in future periods as we enter into sublease agreements or update our estimates as additional information becomes available to us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(Gain) Loss on Sale or Disposal of Property, Plant and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our 2022 Restructuring Plan, we terminated all research and development activities at our owned facility in India, which we sold in December 2022. We also recognized losses including excess equipment, net of sale proceeds, and the disposal of software to support the commercialization of bempegaldesleukin. We recorded the gains and losses as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net book value of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total (gain) loss on sale or disposal of property, plan and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i7395e5dc92e34456b97e26b144017d8e_D20220401-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjI5NDYxOQ_c74c6312-80cd-4523-a887-07effc4bf3ea"
      unitRef="number">0.70</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <dei:EntityNumberOfEmployees
      contextRef="i79208888512146d7bc75e741ef3f64e2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjI5NDYyOA_e5617644-abde-4f8f-ad24-3740d678ac51"
      unitRef="number">735</dei:EntityNumberOfEmployees>
    <dei:EntityNumberOfEmployees
      contextRef="i81256841f310427f8d19dc50d08b735c_I20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjI5NDYzNw_4a3e1da9-e21c-4f95-8e59-ccffd8ce8b93"
      unitRef="number">225</dei:EntityNumberOfEmployees>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTU3_c8eb5cac-bb6d-41ae-ac1b-a657710899fc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Gain) loss on sale or disposal of property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination and other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and other costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The following table provides details regarding the severance and other termination benefit expense. We present the liability, which we paid in January 2023, in accrued compensation on our Consolidated Balance Sheet (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;No service period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Service period required&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded impairment charges as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net book value of impaired sublease assets as of May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Fair value of impaired sublease assets &#x2014; Level 3 of Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Book value in excess of fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total impairment of sublease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:BusinessExitCosts1
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF8xLTItMS0xLTQxODY1_eca30f90-1c5e-4a56-9c15-d18b7f9fb233"
      unitRef="usd">31693000</us-gaap:BusinessExitCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF8yLTItMS0xLTQxODY1_58b81dd8-0f28-4462-bd86-10ee51c1e1d4"
      unitRef="usd">30904000</us-gaap:SeveranceCosts1>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF8zLTItMS0xLTQxODY1_929cf2e3-1b8f-4e7a-8d98-23d91cc56812"
      unitRef="usd">65761000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF80LTItMS0xLTQxODY1_ceb405df-6939-4ba6-866f-22adbc8b8bfb"
      unitRef="usd">3326000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:LossOnContractTermination
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF81LTItMS0xLTQxODY1_4d684817-5ea1-4b4b-a58a-223c8dd8e8b0"
      unitRef="usd">10898000</us-gaap:LossOnContractTermination>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZGQxYjYwY2I5MjE1NDE4NzlmNGYwYzYwNDhlYTQzNjAvdGFibGVyYW5nZTpkZDFiNjBjYjkyMTU0MTg3OWY0ZjBjNjA0OGVhNDM2MF82LTItMS0xLTQxODY1_d9b5131d-df6b-427e-a907-3f36b2e2594d"
      unitRef="usd">135930000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <nktr:ReimbursementOfExpenses
      contextRef="i2d8701f92c324d04925cd7cef5dec02f_D20220401-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjI5MTU2Mg_884c26af-39c8-4eca-b0c1-3df73005e9d9"
      unitRef="usd">20800000</nktr:ReimbursementOfExpenses>
    <us-gaap:RestructuringReserve
      contextRef="idcc20cfb1c4a48679a78206fc2ea8b1d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV80LTItMS0xLTQ0MTc4_4013ac2e-2d7f-4b0b-a93e-59bf6518117a"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2ac9a278cf47443e98c7cfa38fb872b4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV80LTQtMS0xLTQ0MTc4_bbf331e0-5fb2-4c7f-9827-b2eca60bf406"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i79208888512146d7bc75e741ef3f64e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV80LTYtMS0xLTQ0MTc4_64b2b4b0-f6c6-440b-a205-c0dfa16e11f4"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="icb69ada362dc437e9819aaa096864a94_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV81LTItMS0xLTQ0MTc4_c3a827bc-5a4a-4e0a-b828-b733e1f357d9"
      unitRef="usd">22993000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2c9b0c23b6004aa1922ed92ae6e42a1c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV81LTQtMS0xLTQ0MTc4_afa3b51d-54f7-4785-a83a-39ce2d1dffab"
      unitRef="usd">7911000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie391f9f234c444d2ae0b217cc409af4b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV81LTYtMS0xLTQ0MTc4_80ace0c7-d076-4f77-9182-40a810807350"
      unitRef="usd">30904000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="icb69ada362dc437e9819aaa096864a94_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV82LTItMS0xLTQ0MTc4_adcc836a-b8c0-41cd-8231-d93b526d43b2"
      unitRef="usd">22993000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i2c9b0c23b6004aa1922ed92ae6e42a1c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV82LTQtMS0xLTQ0MTc4_c9dc243b-39d2-45f1-b846-d0005c8798a7"
      unitRef="usd">4612000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ie391f9f234c444d2ae0b217cc409af4b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV82LTYtMS0xLTQ0MTc4_4295eccd-d7e4-4a59-8e21-3a07c90d6950"
      unitRef="usd">27605000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i761caeec68a54ac890af6ea722b34752_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV83LTItMS0xLTQ0MTc4_6756fdd3-e1e6-4ae8-aada-ab750e3a7b06"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id3cbdfb27cfb4debb4992b2d68d5cf26_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV83LTQtMS0xLTQ0MTc4_24593e34-4d39-4c6c-b2c7-818954255a3c"
      unitRef="usd">3299000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iab6c152af63d4a498aafc8fa69bf4bca_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6ZThkYTRiY2Q2YWFlNDdlYWExMDI2YWQ4NDU2NmM5YzEvdGFibGVyYW5nZTplOGRhNGJjZDZhYWU0N2VhYTEwMjZhZDg0NTY2YzljMV83LTYtMS0xLTQ0MTc4_cd5caf08-447a-4f8a-be2d-3717b5bd4058"
      unitRef="usd">3299000</us-gaap:RestructuringReserve>
    <nktr:OperatingLeaseMeasurementInput
      contextRef="i36ac95832e534e18a6137ad8de7f1444_D20220531-20220531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTc2_4ce5c355-8571-49b9-a6c2-9650b68ddc20"
      unitRef="number">0.064</nktr:OperatingLeaseMeasurementInput>
    <nktr:OperatingLeaseMeasurementInput
      contextRef="i809049297a1d4491a7387259a291ce70_D20221231-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTgy_c4d2abb8-451c-478f-8d3a-f51a150cb575"
      unitRef="number">0.079</nktr:OperatingLeaseMeasurementInput>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i948d3d10847d41cbaa8d5e99b9e0ca18_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGV4dHJlZ2lvbjpkNDU4NDg5NjFkYjE0NjFjOGRiMGM0Zjk2NmE0ODVkMF8xMDk5NTExNjQxMTg4_8fc851d8-71f4-4cfb-a00c-ea56abcce5a3"
      unitRef="usd">12000000</us-gaap:OperatingLeaseImpairmentLoss>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i678b972618854ccfa5f8b75959d9a207_I20220531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8yLTEtMS0xLTQ0MjIw_49e11a1e-2661-45e4-adc8-48c3cf06b9fc"
      unitRef="usd">72481000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i44bbfe0cc7fd4079a8fc3d2aa0c332c7_I20220531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8yLTMtMS0xLTQ0MjIw_2752b62a-59ab-4bcc-b0d9-deb84defd994"
      unitRef="usd">16348000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i61c9135dab8146c78e84573062004417_I20220531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8yLTUtMS0xLTQ0MjIw_0f0973db-9d42-4ff6-a2c9-6e0c6c2bbb2b"
      unitRef="usd">88829000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i97e18421949d4c96bbefcd9f889dee65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8zLTEtMS0xLTQ0MjIw_d540414d-55d2-4aa0-8db9-2a170ae35e3b"
      unitRef="usd">16174000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i21602aeba0af4306b9db2ff5a747c939_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8zLTMtMS0xLTQ0MjIw_57c827aa-603d-4890-9cf1-02b6fbc8887a"
      unitRef="usd">4780000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i4cf06f89dab34bc49d9056719d6cf796_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl8zLTUtMS0xLTQ0MjIw_912c9cd1-0121-49b7-9aa4-eea2706dfe1c"
      unitRef="usd">20954000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ic43d66fd88c34d01b4ff0cd1a46695cd_D20220601-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl80LTEtMS0xLTQ0MjIw_d60480e3-8f72-4266-83da-b1b75b4aa801"
      unitRef="usd">56307000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="idedb361025fe4dc4be9515a9ddc5cd78_D20220601-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl80LTMtMS0xLTQ0MjIw_3963fa9b-b3c0-465c-b961-cd0e231c0477"
      unitRef="usd">11568000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="iee4cee9d0d7e4f278ad6b604a58efaa1_D20220601-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl80LTUtMS0xLTQ0MjIw_aec45a3e-f812-48fc-a7c7-5a33db2a3e3c"
      unitRef="usd">67875000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="ic43d66fd88c34d01b4ff0cd1a46695cd_D20220601-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl81LTEtMS0xLTQ0MjIw_1fe08e95-29f9-4534-adf4-f38c67733075"
      unitRef="usd">1717000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="idedb361025fe4dc4be9515a9ddc5cd78_D20220601-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl81LTMtMS0xLTQ0MjIw_76fea340-bd15-4cd8-84da-d95b2a56ff3d"
      unitRef="usd">397000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="iee4cee9d0d7e4f278ad6b604a58efaa1_D20220601-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl81LTUtMS0xLTQ0MjIw_f6382c41-79e8-4797-bc0d-64ab329fbd24"
      unitRef="usd">2114000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="i428577ef84824447b2265e91b8e6ca13_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl82LTEtMS0xLTQ0MjIw_946fce7e-92f3-49de-abcd-5fdaa48633ee"
      unitRef="usd">54590000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie0ef1164091d46e7b57ab43df8707987_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl82LTMtMS0xLTQ0MjIw_07fae03f-7ac6-49ad-98d7-aeea732d0c78"
      unitRef="usd">11171000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6MmUyNDAyMThmYzM5NGRhYWIxMzdjYzhjYWRkYzgwMWIvdGFibGVyYW5nZToyZTI0MDIxOGZjMzk0ZGFhYjEzN2NjOGNhZGRjODAxYl82LTUtMS0xLTQ0MjIw_51b1560b-032a-4778-9adc-c6bcdfb502e5"
      unitRef="usd">65761000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="iac8a6dd98aab4d3dbbc732084af7018f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6OGE1OTI5N2YyMmE1NGE0MWFiNTllYzVhMWZiMWVhMzMvdGFibGVyYW5nZTo4YTU5Mjk3ZjIyYTU0YTQxYWI1OWVjNWExZmIxZWEzM18yLTYtMS0xLTQ0MjM2_3f0a66da-5a7a-4fd3-9f5f-2daebdb87d66"
      unitRef="usd">13196000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9e4effa18ad3427aa1e582fbe34e43d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6OGE1OTI5N2YyMmE1NGE0MWFiNTllYzVhMWZiMWVhMzMvdGFibGVyYW5nZTo4YTU5Mjk3ZjIyYTU0YTQxYWI1OWVjNWExZmIxZWEzM18zLTYtMS0xLTQ0MjM2_e2d5c411-ed2f-49ff-984a-63fa95125ecb"
      unitRef="usd">9870000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="iac8a6dd98aab4d3dbbc732084af7018f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xNjY0L2ZyYWc6ZDQ1ODQ4OTYxZGIxNDYxYzhkYjBjNGY5NjZhNDg1ZDAvdGFibGU6OGE1OTI5N2YyMmE1NGE0MWFiNTllYzVhMWZiMWVhMzMvdGFibGVyYW5nZTo4YTU5Mjk3ZjIyYTU0YTQxYWI1OWVjNWExZmIxZWEzM180LTYtMS0xLTQ0MjM2_19b1521d-3e61-4167-a0d8-9983e0965758"
      unitRef="usd">-3326000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwODI_5080252d-25b9-4992-b633-0196498387e9">Stock-Based Compensation&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; 2017 Performance Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our 2017 Performance Incentive Plan (2017 Plan) provides for the issuance of our common stock to members of the Board of Directors, officers or employees, certain consultants and advisors and our subsidiaries. Our 2017 Plan has been amended and restated such that an aggregate 39,200,000 shares have been authorized for issuance as of December&#160;31, 2022, including 5,000,000 shares that were approved on June 8, 2022. Under the 2017 Plan, we may issue stock options, restricted stock, performance stock, stock units, stock appreciation rights and other similar types of awards. When the 2017 Plan was approved on June&#160;14, 2017, any shares of our common stock that were available for issuance under our 2012 Performance Incentive Plan (the 2012 Plan) ceased to be available for future grants. However, options and RSUs granted under the 2012 Plan remained outstanding, and any options or RSUs that were cancelled or forfeited became available for issuance under the 2017 Plan. Shares issued for RSUs, PSUs or any other &#x201c;full-value award&#x201d; are counted against the share limit as 1.5 shares for every one share granted in connection with the award. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted non-qualified stock options, RSUs and PSUs to employees, officers, and non-employee directors. For our employees, the requisite service period is generally four years for stock options, and three years for RSUs and PSUs. For our directors, the requisite service is generally one year for stock options and RSUs. The maximum term of a stock option is eight years from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of our common stock on the NASDAQ Stock Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our Change in Control Plan (the CIC Plan), in the event of a change of control of Nektar and a subsequent termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) within twelve months following a change of control, our employees are entitled to full acceleration of their unvested equity awards. Our Chief Executive Officer, Senior Vice Presidents and Vice Presidents (including Principal Fellows) are also entitled to full acceleration of unvested equity awards if the termination is initiated by the employee for a Good Reason Resignation (as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;defined in the CIC Plan) within twelve months following a change of control. Additionally, non-employee directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Under the terms of our Employee Stock Purchase Plan (ESPP), employees may purchase shares of our common stock based on a percentage of their compensation subject to certain limits. Shares are purchased at 85% of the lower of the closing price on either the first day or last day of each six-month offering period. An aggregate 3,500,000 shares have been authorized for issuance under our ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and other costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Stock-based compensation expense resulting from PSUs and our ESPP was not significant in the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, total unrecognized compensation costs of $83.1 million related to unvested stock-based compensation awards are expected to be recognized as expense over a weighted-average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Black-Scholes Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average volatility factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The average risk-free interest rate is based on the U.S.&#160;treasury yield curve in effect at the time of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of zero. Our estimate of expected volatility is based on the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. We estimated the weighted-average expected life based on the contractual and vesting terms of the stock options, as well as historical cancellation and exercise data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited &amp;amp; canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_______________________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The intrinsic value of options exercised during the year ended December&#160;31, 2022 was not significant and totaled $17.3 million and $15.9 million during the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of RSU Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU award activity is as follows (in thousands except for per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair values of RSUs granted during the years ended December&#160;31, 2022, 2021 and 2020 were $4.14, $14.68 and $19.24, respectively. The fair value of RSU's that vested in the years ended December&#160;31, 2022, 2021 and 2020 totaled $17.5 million, $45.3 million and $33.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;401(k) Retirement Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of 60% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $12,000 per participant for the year ended December 31, 2022, and up to a maximum of $6,000 per participant for the years ended December 31, 2021 and 2020. For the years ended December&#160;31, 2022, 2021, and 2020, we recognized $2.5&#160;million, $3.6&#160;million and $3.5&#160;million, respectively, of compensation expense in connection with our 401(k) retirement plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i7a12065b592f45eb91672b4c2ecfc993_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzM1MQ_37c24788-3fed-47db-9516-fe4eb93e841f"
      unitRef="shares">39200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if6b03bb908cf46a1975c75a41487f342_I20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzQxNQ_828d130d-570b-48b2-ad57-778e430ffe13"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare
      contextRef="i7a12065b592f45eb91672b4c2ecfc993_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzExMjQ_da4c5cf3-9548-4e13-9bb4-b88c23f663a2"
      unitRef="number">1.5</nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i63c718ae96904cc5b999aca6b38e6acc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEzODM_5c3094a5-4246-48f0-a0a7-62b13a51948c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i14542c4fb8594026a9f1f2689a366572_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzE0MDk_57621f1f-d226-467f-b672-68f0cc2f95a5">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i2c9ec41962e341438be60878bcaa9e09_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzE0ODU_08b522b1-8809-4af9-ac96-02370d889027">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6fa5c4f56ceb45109dc0bac18906c879_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzE1ODI_ffcbb713-ab5e-4362-9b14-19e1de83b5e8">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <nktr:ChangeInControlSeverancePaymentPeriodForExecutives
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzIwMTg_cfffe240-2b21-41b8-bfec-ec055407cf2c">P12M</nktr:ChangeInControlSeverancePaymentPeriodForExecutives>
    <nktr:ChangeInControlSeverancePaymentPeriodForExecutives
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzI0MTQ_cfffe240-2b21-41b8-bfec-ec055407cf2c">P12M</nktr:ChangeInControlSeverancePaymentPeriodForExecutives>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i20e80ebc90964b95852b0af70c1a0bed_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzI4NjA_0908f056-1f53-4ab1-9fd8-9f432e84e9e4"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod
      contextRef="i2e36b8afe0164eeca7a3f8aee4dc3069_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU0OTc1NTgyMDk2NQ_3eeb3da2-c770-4439-9de6-5a0048a52df4">P6M</nktr:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ided66bf243294649aa10f28f877a38bd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzI5ODE_ddac291f-b4f0-4faa-a2c7-409ab2f67dd4"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwODQ_96951b49-a585-4725-9f7b-4eccd1f58f95">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and other costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1da4578eb344c37a4ac66d8094312cb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzItMS0xLTEtMzk4MzY_95d43f3a-265b-41f1-9c3f-7fed0e5455fc"
      unitRef="usd">2824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i833b94c48c5d400b9f223dd465244748_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzItMy0xLTEtMzk4MzY_b7ae35c6-ec4c-47ec-9542-df214dbce0b2"
      unitRef="usd">2779000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5cb540e2259a4eb5ba670a48eb66248a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzItNS0xLTEtMzk4MzY_0aab2c14-7c60-4fad-85cc-1811a340c7da"
      unitRef="usd">2825000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie2c7e882eb974894b44df7c39cfa9ea3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzMtMS0xLTEtMzk4MzY_2b8186a8-cc1c-48a3-a001-70e670fa0ddb"
      unitRef="usd">27727000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if13a72164f93445d97d6df5a196ca7b5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzMtMy0xLTEtMzk4MzY_f99250b3-41ac-4116-b2cd-1f0709a412bf"
      unitRef="usd">54821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6627c3421cb942dfafa0a03fa35c32f8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzMtNS0xLTEtMzk4MzY_64f338ee-94c4-4f45-b26a-155675295399"
      unitRef="usd">57116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i25f55b5dda92449f87631aec26801a47_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzQtMS0xLTEtMzk4MzY_3c56876d-7d4e-4af5-ae21-8575e2f9c04e"
      unitRef="usd">24488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic3b60fd0890f4d5ea688cd88f60c0fdc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzQtMy0xLTEtMzk4MzY_d5c2b97e-4d1b-4bd2-b78b-d8c97b87ca4b"
      unitRef="usd">37074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3928dcd65fad4307afa1ad19230facf4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzQtNS0xLTEtMzk4MzY_7741fb08-fb58-420b-86ec-5a8f9d240757"
      unitRef="usd">33295000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76c5c0679b2b4b999749ec226dd1c85a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzUtMS0xLTEtMzk4MzY_5750c5ab-63bb-451b-bb0d-f0d650d89004"
      unitRef="usd">2281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3119b6ee8f3b4dde9cd9450833493c0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzUtMy0xLTEtMzk4MzY_ea7b0077-cdda-41e2-8e64-82290cdd6d1d"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i05810fa0da244bacbdcde63b4b7a095b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzUtNS0xLTEtMzk4MzY_a4de06b3-1e86-402b-82e0-28af41462013"
      unitRef="usd">1025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzYtMS0xLTEtMzk4MzY_a8a5c88f-e6f3-4b25-ad37-e1db6d71b2a9"
      unitRef="usd">57320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzYtMy0xLTEtMzk4MzY_1971ffe7-0751-4307-9b1f-6fc3ca49aaba"
      unitRef="usd">94674000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTo2OThhNmQ0ZWQ0MjI0MTI1YjYxNTYyYTZkMjQ3ODgyNy90YWJsZXJhbmdlOjY5OGE2ZDRlZDQyMjQxMjViNjE1NjJhNmQyNDc4ODI3XzYtNS0xLTEtMzk4MzY_b9e2d3d9-a090-4489-bbf5-37fe0e4b9718"
      unitRef="usd">94261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzM1NjI_fca465e2-8104-4dee-a2b3-b83599c6a3bb"
      unitRef="usd">83100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwNzY_713d6f38-6dc7-4dbf-80f6-e7343d3ad141">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzItMS0xLTEtMzk4MzY_73f86674-c239-45fd-88c5-27d6cd65c3a8"
      unitRef="number">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzItMy0xLTEtMzk4MzY_80c56b98-8cf3-48f2-9927-6649028cbdef"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzItNS0xLTEtMzk4MzY_5c26cdd3-4044-45b8-82db-9b7dbf60a0bd"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzMtMS0xLTEtMzk4MzY_78c02e04-971a-4df9-882c-97a0e3ae1701"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzMtMy0xLTEtMzk4MzY_86534731-c8df-4204-814e-f13044e98003"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzMtNS0xLTEtMzk4MzY_dab75ed8-cc87-405c-a77c-bb6d16fd436c"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzQtMS0xLTEtMzk4MzY_c5289d14-8e73-41fd-b13d-431c172d3384"
      unitRef="number">0.779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzQtMy0xLTEtMzk4MzY_21a1057f-b7bc-446b-b60a-5d5dc049dd51"
      unitRef="number">0.638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzQtNS0xLTEtMzk4MzY_598a8a69-d9df-4973-b1d4-a4e7bbbbc790"
      unitRef="number">0.641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzUtMS0xLTEtMzk4MzY_46697d35-efa9-47cf-be15-b4990f6e9b49">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzUtMy0xLTEtMzk4MzY_b6d236a8-6c03-47d0-ae0d-8622ec4564a8">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzUtNS0xLTEtMzk4MzY_ee8147ba-a084-4fc6-b576-aa53f5724069">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzYtMS0xLTEtMzk4MzY_f36737bd-08e7-4346-b0ed-195cf2efdfb4"
      unitRef="usdPerShare">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzYtMy0xLTEtMzk4MzY_b56aae3c-77ce-47f6-9c53-6a4f185cf177"
      unitRef="usdPerShare">8.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZToyZjRlZWRkNDk0NWM0NjllOWM2NmNiYjRiMGU4NzQ1ZS90YWJsZXJhbmdlOjJmNGVlZGQ0OTQ1YzQ2OWU5YzY2Y2JiNGIwZTg3NDVlXzYtNS0xLTEtMzk4MzY_72114415-9074-4b04-9a90-0117618a6ea3"
      unitRef="usdPerShare">10.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if1708b7bc3884af6be169aa6e4bd9ee9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzQyNDg_e271b62a-ff77-419e-a8f2-05e2676628a3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwODY_67b1a059-ff79-449a-8c11-8daaa47e2852">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited &amp;amp; canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;_______________________________________________________________(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2022.</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzEtMS0xLTEtMzk4MzY_f2bcb004-682b-4bda-94d3-6e32053b1030"
      unitRef="shares">13542000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzEtMy0xLTEtMzk4MzY_9e0877b6-99de-4129-9951-57cf3e84e01a"
      unitRef="usdPerShare">23.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzItMS0xLTEtMzk4MzY_b16c096f-ee04-47e8-b07d-1e578fbb67e4"
      unitRef="shares">6276000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzItMy0xLTEtMzk4MzY_e18763c9-f4bd-47f5-addc-f02174ffba11"
      unitRef="usdPerShare">4.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzMtMS0xLTEtMzk4MzY_a4722488-5722-4205-a91b-2315b657c632"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzMtMy0xLTEtMzk4MzY_eb256807-e001-4280-b546-7b2cff427514"
      unitRef="usdPerShare">12.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzQtMS0xLTEtMzk4MzY_45c70ef6-961d-4651-a545-bd034b52550d"
      unitRef="shares">5715000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzQtMy0xLTEtMzk4MzY_37cb1f61-441d-4831-a750-ed790450c8ca"
      unitRef="usdPerShare">20.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzUtMS0xLTEtMzk4MzY_765656f6-86a7-41ec-aeaa-feeb1ab04fbe"
      unitRef="shares">14088000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzUtMy0xLTEtMzk4MzY_a00ee7f0-b824-413b-af56-08962d9f4f54"
      unitRef="usdPerShare">16.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzUtNS0xLTEtMzk4MzY_20696c2b-803f-4f74-8d6d-edf2f3de2c00">P5Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzUtNy0xLTEtMzk4MzY_2e7f9a7e-75ad-4ca6-ad0f-8d2f9cc99ee6"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzctMS0xLTEtMzk4MzY_53adc36a-2f94-4d51-a06f-f7d73b69d0cd"
      unitRef="shares">6029000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzctMy0xLTEtMzk4MzY_eedeb8ac-7b75-4237-837a-100060c7983d"
      unitRef="usdPerShare">27.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzctNS0xLTEtMzk4MzY_16c6ed4d-ad8e-4c11-aac9-27629649919e">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTpmNmZhNTc5NmMwZTc0MTBjYWQxMWM3ZmEwZmUzYzk3My90YWJsZXJhbmdlOmY2ZmE1Nzk2YzBlNzQxMGNhZDExYzdmYTBmZTNjOTczXzctNy0xLTEtMzk4MzY_43f6aec3-d3cf-4285-8362-c565c6a0078c"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0NTE1_368efa62-66b3-44f1-8122-b2a9ab05bfeb"
      unitRef="usd">17300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0NTIz_af1ddc08-17b2-48db-8632-1049e3589983"
      unitRef="usd">15900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzYwODA_6745fb06-c8f9-4135-8b7b-ed9e0ba40952">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU award activity is as follows (in thousands except for per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia5f2ce65d9b74f5ab00210112601e860_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzEtMS0xLTEtMzk4MzY_4e111c5d-75ba-41dc-a48c-fe4e9d30e025"
      unitRef="shares">9930000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia5f2ce65d9b74f5ab00210112601e860_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzEtMy0xLTEtMzk4MzY_3540a835-b041-4234-97e7-032f7e7be60c"
      unitRef="usdPerShare">16.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzItMS0xLTEtMzk4MzY_f5f63aa3-f083-420d-a9bd-ec37c941d89c"
      unitRef="shares">7708000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzItMy0xLTEtMzk4MzY_a09ac6f5-1a88-4c6a-a1e8-40c098f36ca2"
      unitRef="usdPerShare">4.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzMtMS0xLTEtMzk4MzY_82535a8a-b1e1-4529-a651-e2d6926be361"
      unitRef="shares">2872000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzMtMy0xLTEtMzk4MzY_465f3e6d-9b69-486a-966f-4beda3c31982"
      unitRef="usdPerShare">17.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzQtMS0xLTEtMzk4MzY_193627c3-2712-41b8-8ffd-4968017c039f"
      unitRef="shares">5454000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzQtMy0xLTEtMzk4MzY_d99d25be-7bb6-4f23-81df-0c18f7bad833"
      unitRef="usdPerShare">15.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i61ca801a96804d5caed8be9bb6955df9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzUtMS0xLTEtMzk4MzY_027dba58-1374-4328-9739-416f8e3a3350"
      unitRef="shares">9312000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i61ca801a96804d5caed8be9bb6955df9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90YWJsZTplZjMzMTUzYjE4MDA0YjgzYTY5OTM2ZDVmZTM5NzI0NC90YWJsZXJhbmdlOmVmMzMxNTNiMTgwMDRiODNhNjk5MzZkNWZlMzk3MjQ0XzUtMy0xLTEtMzk4MzY_1d5b7fbe-4023-4855-9e8a-b9e2b9cdf899"
      unitRef="usdPerShare">6.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzUzOTI_2c9d1b3b-090d-4126-817a-5e42a229b9f2"
      unitRef="usdPerShare">4.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iec82e56d740a40949cb39ff40fc8cd9a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzUzOTY_3c4b32ba-2818-48a7-998f-da2dc1696e2a"
      unitRef="usdPerShare">14.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id5277dcb595b47198bdeb0c40ae34d2c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU0MDM_fb39001f-1772-4972-8714-cbec259d54de"
      unitRef="usdPerShare">19.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ief64bc46a28844f3b364287244422030_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU1MDk_58b6110e-9e59-41f1-a81b-c87b55a008bd"
      unitRef="usd">17500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iec82e56d740a40949cb39ff40fc8cd9a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU1MTM_52644e40-9f09-40ef-b51a-efbd50233857"
      unitRef="usd">45300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="id5277dcb595b47198bdeb0c40ae34d2c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU1MjA_027815d0-149f-4ffc-8ae2-01cc79ab8c4b"
      unitRef="usd">33300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU2Njk_4071d0f6-df48-4a54-8aac-91ff918a1f04"
      unitRef="number">0.60</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2MzQ4MzM_e00375cf-7570-4d4f-8bca-e7d3fa2099b5"
      unitRef="usd">12000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU5MDY_68a0ebd7-4f7c-4722-9bf4-09660feb68c0"
      unitRef="usd">6000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzU5MDY_f8a2815a-42b3-4df3-b034-fd59ebc6468b"
      unitRef="usd">6000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0NzUz_1f56d7ad-18da-4ae1-9b68-a8fd67de33f6"
      unitRef="usd">2500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0NzY3_0b132a6f-a5e7-452a-80c1-4cce01fcdd74"
      unitRef="usd">3600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjQvZnJhZzpmNzgxMWUwMzY3ZDc0NzhiYTg1OTYzNGQzNGMwNmQ1ZC90ZXh0cmVnaW9uOmY3ODExZTAzNjdkNzQ3OGJhODU5NjM0ZDM0YzA2ZDVkXzEwOTk1MTE2Mjg0Nzgx_a3edaca8-5929-44dc-ac52-8acca628c917"
      unitRef="usd">3500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MzA_db3de166-2e57-46d4-9b99-9b2f9d4c701c">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Loss before provision for income taxes includes the following components (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(371,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(445,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(523,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provision for Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiration of net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense on liability related to sales of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash royalty revenue related to sales of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(816,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in foreign subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S.&#160;earnings history, other than income resulting from revenue recognized from the BMS Collaboration Agreement, and projected future losses, we have fully reserved our net U.S.&#160;deferred tax assets with a valuation allowance. The valuation allowance increased by $30.5&#160;million and $115.6&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our net deferred tax liability position reflects the provision for the withholding taxes associated with the repatriation of accumulated earnings and profits from India.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Operating Loss and Tax Credit Carryforwards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2022, we had a net operating loss carryforward for federal income tax purposes of approximately $2.4&#160;billion, of which $1.3&#160;billion is subject to expiration beginning in 2023 and a total state net operating loss carryforward of approximately $0.7&#160;billion, portions of which will begin to expire in 2027. We have federal tax credits of approximately $123.8&#160;million, which will begin to expire in 2023 and state research credits of approximately $48.8&#160;million which have no expiration date. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We have the following activity relating to unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;If we are eventually able to recognize our uncertain tax positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Adjustments to the substantial majority of our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carryforwards rather than resulting in a cash outlay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We file income tax returns in the U.S., California, Alabama, certain other states and India. As a result of our net operating loss and research credit carryforwards, substantially all of our domestic tax years remain open and subject to examination. We may be subject to examination in India from time to time, but we do not believe that any liability resulting from such an examination would have a material effect on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. During the years ended December&#160;31, 2022, 2021 and 2020, no significant interest or penalties were recognized relating to unrecognized tax benefits. Although it is reasonably possible that certain unrecognized tax benefits could change in the future, we do not anticipate any significant changes over the next twelve months.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MjY_f26540b4-753e-4767-86a2-fcf208bc9d85">Loss before provision for income taxes includes the following components (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(371,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(445,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(523,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzItMS0xLTEtMzk4MzY_7154afc9-66be-4fac-a116-ad96b95052da"
      unitRef="usd">-371900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzItMy0xLTEtMzk4MzY_c3a34e5c-3c1c-4c32-b5f8-a14dd8aeee45"
      unitRef="usd">-524440000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzItNS0xLTEtMzk4MzY_6b25227c-04b3-46f1-8695-77a8a4bf9eb5"
      unitRef="usd">-445370000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzMtMS0xLTEtMzk4MzY_18731e0d-1b7d-493e-863b-6aee6f236e6c"
      unitRef="usd">6917000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzMtMy0xLTEtMzk4MzY_c5f9ea85-0283-4874-b498-ac1eff8abff7"
      unitRef="usd">1160000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzMtNS0xLTEtMzk4MzY_3d52b9f5-fdfb-41e0-ba08-af7ac395412a"
      unitRef="usd">1423000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzQtMS0xLTEtMzk4MzY_d254c984-7c8a-4ea3-bb80-48e40d37b7c7"
      unitRef="usd">-364983000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzQtMy0xLTEtMzk4MzY_d9284205-0b0f-48e8-ba4f-4faa58cfbd35"
      unitRef="usd">-523280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToxYmQ5MGEwZWIwMDY0OGZjOTk2ZWI0YzIxOTg5ZjYxMC90YWJsZXJhbmdlOjFiZDkwYTBlYjAwNjQ4ZmM5OTZlYjRjMjE5ODlmNjEwXzQtNS0xLTEtMzk4MzY_e4c07542-65d2-45f7-81aa-a798495697e5"
      unitRef="usd">-443947000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MzE_fc5b1633-9ecb-42fc-be83-c4a0e864b894">The provision for income taxes consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzMtMS0xLTEtMzk4MzY_a4995c27-beaf-4115-b9d5-f61e0f3d77db"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzMtMy0xLTEtMzk4MzY_71450a8a-3a5c-4c4a-898a-135040ac294e"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzMtNS0xLTEtMzk4MzY_d6bd38ad-9075-44d6-900a-9c39c19f0e2c"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzQtMS0xLTEtMzk4MzY_0423f71e-40d5-4296-9c71-6bda3a1400c9"
      unitRef="usd">-608000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzQtMy0xLTEtMzk4MzY_a32074d1-d23e-4ad8-97d7-e59f7c57a01c"
      unitRef="usd">50000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzQtNS0xLTEtMzk4MzY_9bd08e43-fc7f-430d-b305-d7d7b9b8f6bf"
      unitRef="usd">165000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzUtMS0xLTEtMzk4MzY_fdb026a9-f669-4aa1-9f00-f0d4bad76d54"
      unitRef="usd">1115000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzUtMy0xLTEtMzk4MzY_922428a6-15fb-4fc7-bd33-cf58abb3b254"
      unitRef="usd">609000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzUtNS0xLTEtMzk4MzY_577401fd-9104-4efc-8ae9-ba4d1f4d4a35"
      unitRef="usd">364000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzYtMS0xLTEtMzk4MzY_7c00ef14-1321-4813-af9a-024548e7549a"
      unitRef="usd">507000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzYtMy0xLTEtMzk4MzY_8ed7c2a2-9bfb-409d-8977-ad910049e25f"
      unitRef="usd">659000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzYtNS0xLTEtMzk4MzY_0d5869be-6ecc-4fef-be2d-d12679b9f886"
      unitRef="usd">529000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzgtMS0xLTEtMzk4MzY_340a7a6f-a341-4896-bb46-467f64a48253"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzgtMy0xLTEtMzk4MzY_278391a4-33c2-4146-8d6a-1d47420fc2ba"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzgtNS0xLTEtMzk4MzY_78b6d51c-86e3-4966-a47d-5abfdaf6d78b"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzktMS0xLTEtMzk4MzY_95e0d70e-3907-4df7-8d39-1a7291bee3fb"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzktMy0xLTEtMzk4MzY_ee98e130-4ac0-4014-b24d-e1d4cb81a884"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzktNS0xLTEtMzk4MzY_7c892447-bc69-4f74-94c1-afa80f04de04"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEwLTEtMS0xLTM5ODM2_1fddc00c-bc88-4755-8352-7429f8d686a0"
      unitRef="usd">2708000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEwLTMtMS0xLTM5ODM2_2f415dc9-6942-4f79-904d-c6bd9ba80098"
      unitRef="usd">-102000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEwLTUtMS0xLTM5ODM2_6e3e64cd-52ac-4237-abee-627f729330c8"
      unitRef="usd">-36000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzExLTEtMS0xLTM5ODM2_579f0f0b-a33c-49a6-8d97-8e6a57706eaf"
      unitRef="usd">2708000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzExLTMtMS0xLTM5ODM2_3ad597de-8c2f-4bd0-9835-f0b0606c0804"
      unitRef="usd">-102000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzExLTUtMS0xLTM5ODM2_fd7ab200-7275-4d50-a848-c3385ca28310"
      unitRef="usd">-36000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEyLTEtMS0xLTM5ODM2_8f79ecb3-c793-48de-8080-11d68f9bcf04"
      unitRef="usd">3215000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEyLTMtMS0xLTM5ODM2_4418d0b4-db1e-46f2-bbc2-0d6eca7757df"
      unitRef="usd">557000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyOTYzN2JlMzc3NWI0MzVmOTY5MjE5YjQwMzUwYzBjMi90YWJsZXJhbmdlOjI5NjM3YmUzNzc1YjQzNWY5NjkyMTliNDAzNTBjMGMyXzEyLTUtMS0xLTM5ODM2_5223660d-1a35-46f4-aada-3ebae2ba54ba"
      unitRef="usd">493000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5Mjc_e668577b-0780-4d2b-b049-812f91f699b2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiration of net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense on liability related to sales of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash royalty revenue related to sales of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzItMS0xLTEtMzk4MzY_39a1950e-b946-4bf9-8e63-02e02dcd24ef"
      unitRef="usd">-76647000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzItMy0xLTEtMzk4MzY_3897d24d-36b5-46b0-92ee-564db3a96074"
      unitRef="usd">-109889000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzItNS0xLTEtMzk4MzY_4160ab57-f059-43c8-a438-6e02f94bcdeb"
      unitRef="usd">-93229000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzMtMS0xLTEtMzk4MzY_83aa14e7-8aa8-47ee-90a8-016c646442f6"
      unitRef="usd">987000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzMtMy0xLTEtMzk4MzY_84d50bcb-75a8-4f53-9847-dc657ec649fb"
      unitRef="usd">4727000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzMtNS0xLTEtMzk4MzY_6314140e-3a28-4418-9cad-2207b103750d"
      unitRef="usd">3081000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzQtMS0xLTEtMzk4MzY_f81649a1-5c9d-40ef-8761-0a9ec07d6ee9"
      unitRef="usd">51108000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzQtMy0xLTEtMzk4MzY_638fd3d5-e0b0-4461-beff-5905db2734b8"
      unitRef="usd">97914000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzQtNS0xLTEtMzk4MzY_7a2815a5-b820-4716-9711-754c72fc090b"
      unitRef="usd">87060000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <nktr:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtMS0xLTEtNDcxNTg_46385de5-1950-40b3-acc7-a47ddb309e5c"
      unitRef="usd">12348000</nktr:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards>
    <nktr:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtMy0xLTEtNDcxNTg_6554162d-3a19-4569-bba2-342ed4d7bb74"
      unitRef="usd">286000</nktr:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards>
    <nktr:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtNS0xLTEtNDcxNTg_9c5db167-8d4d-474f-9af1-e1498f17bab7"
      unitRef="usd">286000</nktr:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtMS0xLTEtNDcxNTg_f505ac67-181b-4632-ba9a-9d46bed79b4c"
      unitRef="usd">15778000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtMy0xLTEtNDcxNTg_57943893-c8a4-4d85-ae63-0821e863a68f"
      unitRef="usd">6627000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtNS0xLTEtNDcxNTg_2e2ff5fa-d86b-472d-a9c6-3562ad82641a"
      unitRef="usd">7929000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtMS0xLTEtMzk4MzY_b5cba60e-6759-4910-91a4-3cc5bd5f1b31"
      unitRef="usd">6071000</nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtMy0xLTEtMzk4MzY_690b7d34-ed69-442a-b471-246204488f23"
      unitRef="usd">9936000</nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzUtNS0xLTEtMzk4MzY_42fcce2f-ff1a-4677-b61c-f73cd9cc15c1"
      unitRef="usd">6356000</nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtMS0xLTEtMzk4MzY_e5d15e61-d50a-48ce-9b4c-6c24e7b662ad"
      unitRef="usd">-7112000</nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtMy0xLTEtMzk4MzY_d25eeb95-7d99-4165-94a3-c7abe4639165"
      unitRef="usd">-7891000</nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzYtNS0xLTEtMzk4MzY_d213db69-08c8-4b72-ac1c-582a643967e8"
      unitRef="usd">-7967000</nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzctMS0xLTEtMzk4MzY_88ce5f6b-9ff2-498e-9319-5f28405860b3"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzctMy0xLTEtMzk4MzY_a87f052f-1942-4a80-b99c-fb30ccc5777c"
      unitRef="usd">4940000</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzctNS0xLTEtMzk4MzY_a148dee1-8fa2-4ebf-bfb1-f6e9c96402db"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzktMS0xLTEtMzk4MzY_675ee62b-94f1-4746-b7d7-24e5cfd1b9df"
      unitRef="usd">2656000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzktMy0xLTEtMzk4MzY_cb90619c-efdf-4e94-9a3f-493412d187dd"
      unitRef="usd">3361000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzktNS0xLTEtMzk4MzY_5d78a2bf-21f6-4d89-8230-bdea2cd6c79e"
      unitRef="usd">3139000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzEwLTEtMS0xLTM5ODM2_fc7f2b22-a691-49e0-8e23-73fc1e899dc8"
      unitRef="usd">3215000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzEwLTMtMS0xLTM5ODM2_442b0cea-c2ae-4bde-b9ed-6841df10c6a5"
      unitRef="usd">557000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTozMjk2N2E1YmJkNGI0ZTMxYTYzNGQ3ZGNhOWRhN2E5MC90YWJsZXJhbmdlOjMyOTY3YTViYmQ0YjRlMzFhNjM0ZDdkY2E5ZGE3YTkwXzEwLTUtMS0xLTM5ODM2_972f737e-b5e5-4763-823c-d3ec69d67302"
      unitRef="usd">493000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MzQ_709c506b-8e96-474d-bf6a-44bf700a37d0">We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(816,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in foreign subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzMtMS0xLTEtMzk4MzY_e81afa93-8aa2-442b-b685-696057896154"
      unitRef="usd">545508000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzMtMy0xLTEtMzk4MzY_7c64b2a8-0f86-4b6d-975e-c44d6718b2eb"
      unitRef="usd">564712000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzQtMS0xLTEtMzk4MzY_2a318e66-9b15-403c-8d77-482112b6d004"
      unitRef="usd">142198000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzQtMy0xLTEtMzk4MzY_754b835a-cb25-4f58-a15b-c487223372d6"
      unitRef="usd">139996000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzUtMS0xLTEtNDgxNTE_e536914b-df4a-439b-96dd-5298d51d8faf"
      unitRef="usd">38445000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzUtMy0xLTEtNDgxNTE_877a525d-d57f-456a-85c4-50a42beafd4c"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <nktr:DeferredTaxAssetsLeaseLiability
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzUtMS0xLTEtMzk4MzY_00d171eb-0462-468e-8182-a37c4d6c0255"
      unitRef="usd">28254000</nktr:DeferredTaxAssetsLeaseLiability>
    <nktr:DeferredTaxAssetsLeaseLiability
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzUtMy0xLTEtMzk4MzY_d529d670-9ba8-4728-a0ed-ff4789a29ef9"
      unitRef="usd">34680000</nktr:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzYtMS0xLTEtMzk4MzY_1b182b78-8a1d-488d-b2d7-616cfc09ca4d"
      unitRef="usd">22110000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzYtMy0xLTEtMzk4MzY_95599523-45d1-443b-9a8d-51eb08eb0171"
      unitRef="usd">33408000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzctMS0xLTEtNDcxNjM_f41348e7-2aab-48b2-802d-97d241e51d17"
      unitRef="usd">24134000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzctMy0xLTEtNDcxNjM_737cf12f-0b44-489a-86a6-c9bc0e923b24"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzctMS0xLTEtMzk4MzY_5e6c35b5-cf90-4dd1-9e57-16bb91288ac7"
      unitRef="usd">13424000</nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties>
    <nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzctMy0xLTEtMzk4MzY_16f52b4a-9d29-4623-befa-a6a6944943eb"
      unitRef="usd">23757000</nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzktMS0xLTEtMzk4MzY_75879d48-e355-41ce-b945-d700e61c8e09"
      unitRef="usd">13935000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzktMy0xLTEtMzk4MzY_5a73c2d0-21d8-4e94-a29e-3f4178927f4b"
      unitRef="usd">17290000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzEwLTEtMS0xLTM5ODM2_ccc25559-836a-4e19-93d9-210862505021"
      unitRef="usd">828008000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzEwLTMtMS0xLTM5ODM2_c5d15fc4-1274-469b-8bb3-c8cb4a3fcf25"
      unitRef="usd">813843000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzExLTEtMS0xLTM5ODM2_119da61c-fe5d-4de2-a84a-5e959d62971b"
      unitRef="usd">816235000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzExLTMtMS0xLTM5ODM2_be0d9c36-a691-4718-a048-fc2c926cbd3e"
      unitRef="usd">785748000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzEyLTEtMS0xLTM5ODM2_c982452b-0e1d-4000-ace2-345dfd165eea"
      unitRef="usd">11773000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzEyLTMtMS0xLTM5ODM2_228f24e8-fa60-4c08-9df9-5b9ba4a9f2b6"
      unitRef="usd">28095000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE0LTEtMS0xLTM5ODM2_397a3463-920d-424f-982e-1b92e52bbc44"
      unitRef="usd">11335000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE0LTMtMS0xLTM5ODM2_0b28db18-fba1-45cf-9425-2a4711aa9cf7"
      unitRef="usd">27204000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE1LTEtMS0xLTQ3MTYz_15c380a4-1e42-4517-81ca-e5f07796deea"
      unitRef="usd">2451000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE1LTMtMS0xLTQ3MTYz_2380fe92-399b-4239-a69c-cbac8d77f136"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE1LTEtMS0xLTM5ODM2_1b369dbf-8ff8-4c73-8088-76d234bce1a9"
      unitRef="usd">392000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE1LTMtMS0xLTM5ODM2_2f2b75a0-698b-443c-9d88-2761c2862851"
      unitRef="usd">564000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE2LTEtMS0xLTM5ODM2_dedf42b7-9ba7-4901-984c-97d6ff1a4da0"
      unitRef="usd">14178000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE2LTMtMS0xLTM5ODM2_7a1cf679-bdfc-4f1a-8fb9-48499e2260dc"
      unitRef="usd">27768000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE3LTEtMS0xLTM5ODM2_2db2d1c0-486b-4a81-939c-3fbdf8fa6430"
      unitRef="usd">2405000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZToyYmQyMjM1OGViOGE0NWFhOWNkZTU3ZGEzYzc5OTFkMC90YWJsZXJhbmdlOjJiZDIyMzU4ZWI4YTQ1YWE5Y2RlNTdkYTNjNzk5MWQwXzE3LTMtMS0xLTM5ODM2_1e3e3a01-9020-40c0-b50f-1cb69c494b52"
      unitRef="usd">327000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MjgxNzU2_1bf83982-fe7f-4134-b0df-a270404e7dcd"
      unitRef="usd">30500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MjgxNzIy_0baceffa-07db-4dc9-a20a-06d5d29260e9"
      unitRef="usd">115600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1aa7a7c1e8844691b326d42966bf4551_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MjgxNzg4_11661ff3-28f6-4532-8a45-62c3fbf089c3"
      unitRef="usd">2400000000</us-gaap:OperatingLossCarryforwards>
    <nktr:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MzIyMzk_5ae7e4a8-ad9d-46f7-9584-80a153323d45"
      unitRef="usd">1300000000</nktr:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia0beac0b0ae64d58915ff881a46e62b6_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzEwOTk1MTE2MjgxODE3_12dbc96e-e298-4f62-a912-f98acb5aa29a"
      unitRef="usd">700000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ie0201532ad324c8c9dbec3f1607c4d7b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzE5MTE_34f74fdb-662a-45f8-9001-7f43272cb159"
      unitRef="usd">123800000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i72308160e9054ecaaaa7ec0beb1ff284_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzE5OTQ_981a2bd4-2d8c-4bc7-940d-6270cb57af06"
      unitRef="usd">48800000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MzY_7ecc4201-877e-442c-879b-46d25d4f7d8a">We have the following activity relating to unrecognized tax benefits (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzItMS0xLTEtMzk4MzY_5df4d4ea-bf50-4729-8ff1-214eba8275f0"
      unitRef="usd">80604000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i448f61765d3a4f728112443592038e8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzItMy0xLTEtMzk4MzY_c4abb8bb-d8c4-4dea-840e-cf085e41bf22"
      unitRef="usd">78665000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8f208c2b206d4f43af4e746f193bb362_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzItNS0xLTEtMzk4MzY_46ba8115-c091-4ccd-9b1e-7816795d4f46"
      unitRef="usd">77410000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzQtMS0xLTEtMzk4MzY_739342f1-4fc4-4bb5-89b5-fc7f598f80e7"
      unitRef="usd">378000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzQtMy0xLTEtMzk4MzY_a54f2282-39ac-4304-a52d-0a825b4af67c"
      unitRef="usd">2371000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzQtNS0xLTEtMzk4MzY_a0c9446d-8d83-4a5d-b37b-9e623203cd38"
      unitRef="usd">2512000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzUtMS0xLTEtMzk4MzY_05753b09-afc2-4ef0-8489-6646c435d452"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzUtMy0xLTEtMzk4MzY_9ed66aaa-4f09-440e-8386-99b60fb6e3cd"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzUtNS0xLTEtMzk4MzY_af0d9d0c-01c0-4db5-9612-fa992768d96d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzctMS0xLTEtMzk4MzY_c9a0cbed-d7b0-4b6c-a2a4-16642f119510"
      unitRef="usd">5272000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzctMy0xLTEtMzk4MzY_5b644482-9270-461e-ae59-2f18a4a42a50"
      unitRef="usd">58000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzctNS0xLTEtMzk4MzY_14110b76-dda3-4d51-88e9-b14072548290"
      unitRef="usd">193000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzgtMS0xLTEtMzk4MzY_b1eeaf97-c29f-4d0f-b224-97f004a1f346"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzgtMy0xLTEtMzk4MzY_8e6b7bc4-2ec7-4a51-b358-a87f881b012e"
      unitRef="usd">490000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzgtNS0xLTEtMzk4MzY_7c605cee-b1cd-49fb-99b3-d4be0a5c3fd1"
      unitRef="usd">1450000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzktMS0xLTEtMzk4MzY_951264a0-4068-465d-a55a-a992f891a358"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzktMy0xLTEtMzk4MzY_34fea6dd-85d6-4c6e-a4b4-5239dbe7e85b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzktNS0xLTEtMzk4MzY_6d508038-3311-4cb4-b45d-7fa545dd16e4"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzEwLTEtMS0xLTM5ODM2_4f812ee1-fc2a-4349-b278-ff619e0f7535"
      unitRef="usd">409000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzEwLTMtMS0xLTM5ODM2_c5b8778b-a2e4-41ca-98e6-b88a58a6dc87"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzEwLTUtMS0xLTM5ODM2_9bea6827-bbab-4abf-8003-87b644dbaf5c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzExLTEtMS0xLTM5ODM2_6fda73f4-249b-4482-9d44-c64f41513583"
      unitRef="usd">85845000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iffeba43c66e94db7b8603276d878e2a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzExLTMtMS0xLTM5ODM2_49b7ce90-fac7-430c-b668-89e6cc0d8821"
      unitRef="usd">80604000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i448f61765d3a4f728112443592038e8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90YWJsZTo1YTdjYTMyYjg4NTk0OGQ1ODNiYTMwOGFkZjEyNzI0OS90YWJsZXJhbmdlOjVhN2NhMzJiODg1OTQ4ZDU4M2JhMzA4YWRmMTI3MjQ5XzExLTUtMS0xLTM5ODM2_b19a74ee-d54c-4a3b-8a99-1db762b27a9d"
      unitRef="usd">78665000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_1a444d3a-4d7f-4388-9f2a-98fb066379bf"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_365e6d47-8eed-4c86-b9a1-f353d05cd908"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_53e9cd54-6452-46c3-b8a1-8961c89662fd"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_658cfc3b-62e7-42c6-81bd-0596bee109e0"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_9e20fcbf-efab-4bfd-a23d-596042aeb4ee"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM2NzA_a5db90be-ab8c-4e93-aa0f-dd9c716d6795"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMjcvZnJhZzo0MTMyYjUzY2FmNzA0YTYxODU3YWVlMjFiMDlmZjJjZi90ZXh0cmVnaW9uOjQxMzJiNTNjYWY3MDRhNjE4NTdhZWUyMWIwOWZmMmNmXzM5MjM_dfee5e05-b89e-4c45-966a-7bac21f7c827">P12M</nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzE0ODY_4aa209d1-67eb-40e8-b433-3283711ed399">Segment Reporting&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We operate in one business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from UCB Pharma, Baxalta / Takeda, AstraZeneca and Pfizer represented 37%, 25%, 14% and 11% of our revenue, respectively, for the year ended December&#160;31, 2022. Revenue from UCB Pharma, Baxalta / Takeda, AstraZeneca and Pfizer represented 36%, 23%, 16% and 13% of our revenue, respectively, for the year ended December&#160;31, 2021. Revenue from BMS, UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 33%, 23%, 14% and 13% of our revenue for the year-ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;At December&#160;31, 2022, all of our property, plant and equipment was located in the United States. At December&#160;31, 2021, $56.1&#160;million, 93%, of the net book value of our property, plant and equipment was located in the United States with the remainder in India.</us-gaap:SegmentReportingDisclosureTextBlock>
    <nktr:NumberOfOperatingBusinessSegment
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzQ4_f68fc394-238d-4660-90c3-47a192ce8ded"
      unitRef="segment">1</nktr:NumberOfOperatingBusinessSegment>
    <nktr:NumberOfOperatingBusinessSegment
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzM5MQ_f68fc394-238d-4660-90c3-47a192ce8ded"
      unitRef="segment">1</nktr:NumberOfOperatingBusinessSegment>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7bf92b2d15d544d6937956567cbd8076_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzkzNDU4NDg4MzgzNzg_2b521e93-343c-4536-9537-74a5ac2c92c7"
      unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifdc6254636f546a2a43ce040c6c6085e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzkzNDU4NDg4MzgzODM_6b0a3509-ac03-42a8-b660-cae1f11094bd"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaa8e4e763a2449e0a04e0609515b8c63_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzkzNDU4NDg4MzgzODg_762d83e7-1c5c-480a-aaf6-df898e7c8c4d"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if00a63dfc4ab4080a7c7be10c52a4120_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzkzNDU4NDg4MzgzOTM_f7b0401a-7bd3-4e09-bd21-bd78837f808f"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5b3e0f8c46714fc9be46c65f8de72fe0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzYyMw_9563c590-2d90-4ed8-82e0-811cc66f6828"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8bd42991fff149128d3dc16bf7316b6f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzYyNw_cbadd349-115d-43cb-bd3a-9a73ed1a224f"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id07a9952dc4c450b824484980ebe8928_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzYzMQ_f2a8f376-d8b3-42d3-aae4-132b039cf046"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7daa5860832a47c08be4e2bbcc929c50_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzYzOA_3d92dbe1-d7a2-4791-83a7-5dc7c0287a36"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i56fc82462fb045c19add828b177099e9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzc3MA_398eb9a2-c58c-4ffb-a86c-e7efbfb5289f"
      unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib462fc56afce4ed7b4b6728742f20fd7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzc3NA_42c9e9d8-5d63-4050-8e80-6fc426618596"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9d4868926af54225af1a855f5d4d34d9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzc3OA_e880002d-c62b-4530-ac15-de4acf9a9b9a"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14494e5a12494d72a7acb39246fa450e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzc4NQ_f29970e8-f748-4945-8cbb-ebea79fb817a"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzE0ODg_6ed9b451-bdf5-4bf7-a196-5f82f980ec7a">The following table sets forth revenue by geographic area (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06754ac5c8fe4627adbc24980fd082b4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzItMS0xLTEtMzk4MzY_dcb093ba-d943-40af-8b06-c579d7c914ff"
      unitRef="usd">9841000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86844cf0f9cb4932bc6509504c7a663f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzItMy0xLTEtMzk4MzY_0e40a269-144d-4fab-916e-f5519e019032"
      unitRef="usd">10114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaecd4f6f9c444958b8f0e06d42b1c2aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzItNS0xLTEtMzk4MzY_3d95dcce-629b-42e9-90df-656b89de0f93"
      unitRef="usd">64966000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71e1f0e358824a6bbe3fb5fb2404dc19_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzMtMS0xLTEtMzk4MzY_11aca244-2193-4fa9-ba1d-0dd90a908efe"
      unitRef="usd">82214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i057ece2c908047309cf984bb11af2ec4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzMtMy0xLTEtMzk4MzY_4affae16-37ca-4e85-8d0d-9e3533cb8304"
      unitRef="usd">91793000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78596537cc1e4bba8d4c10682953227a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzMtNS0xLTEtMzk4MzY_ff2c6ccf-83b3-4da5-bed8-22f456f4d5a2"
      unitRef="usd">87949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzQtMS0xLTEtMzk4MzY_ca08d789-0c8c-4f9a-82f9-8a98e2376566"
      unitRef="usd">92055000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14d92114cae74251becb89962c58cc74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzQtMy0xLTEtMzk4MzY_415c8f47-03b4-4746-a607-e46939aaafe2"
      unitRef="usd">101907000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90YWJsZTpmYjVmZjNhMGZkMGE0ODM3OGY1Yjk3NTUyYWEwNDNmYy90YWJsZXJhbmdlOmZiNWZmM2EwZmQwYTQ4Mzc4ZjViOTc1NTJhYTA0M2ZjXzQtNS0xLTEtMzk4MzY_2addc928-35bb-469f-8a68-1274a0c9da9e"
      unitRef="usd">152915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i836074eda2e7444d9c8ad2e1bd97d05c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzEwOTk1MTE2MzAyMDg_addea9a3-4b4b-4623-b780-d9a4980c57fd"
      unitRef="usd">56100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i54faac177aa94cc8a0cc84d3f8d86a9b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4YmZiY2Y4YTI0MDRhMzZhYTMzN2MzNTExZjZkNTJkL3NlYzo1OGJmYmNmOGEyNDA0YTM2YWEzMzdjMzUxMWY2ZDUyZF8xMzAvZnJhZzpjMjdjZTM1NGExM2U0YTgyODkzMzBiNGE4Njg3MWY0Yi90ZXh0cmVnaW9uOmMyN2NlMzU0YTEzZTRhODI4OTMzMGI0YTg2ODcxZjRiXzEwOTk1MTE2MzAyMjM_9f10be2d-1a2c-48c9-b0b6-6563ea8c044d"
      unitRef="number">0.93</us-gaap:ConcentrationRiskPercentage1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY&"+"G*#A=SO6U+(R]2O9(^HSF0^S.)$OB?A^WW#'W^XPO;E3XFLD@OB(,L
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M)@3/*\/S$\'66:WT@@G!HNS0IP2>:?(&^'S)F-B=R"_8U^</_P502P,$%
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M=G+'_$_.EX]Y45BQ$7,"AH%G9/0ELT-H/>]@-_&T!>](';6U/R-S%JO(]T?
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ME/-^KX3^-M-V:C*]^7)_\^DZ>?_P(0'W#_K/YP]?'N[!S4=P<_OA[OW#M0:
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M.7AL#4@/WYMV1>5 N0""E@Y T4(HM#:A3?4 Z\L'H,I('ZLWNY;$KD4=L?P
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M ?_^)LO*AXOJ(9#=<TCC_P%02P,$%     @ $89<5E92Y3D>"P  13\  !@
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M]LYV^Z$N-LVEY)NBKHMU\[@27#H_!9"_+XNB?OR@7K"[.7_Q?U!+ P04
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MPERLCGPR0BS.3W=!1TW0\).@W1!FTN T7%<99O\#?)-!FT:X3V,4'B5.,.U
MK_L-PB ,X"F9P.G)V1%NK[V>GN/V/N$FQ A-#1+(',9,%S U9:SA]W"I29F2
M^O-1]@VS_S'3MMF57K,4!Y[I(XUJ@U[\]4OW(OAY1'&_5=P_1H\3)M"*S6NJ
M%8*2;TP01PU&;J59TPNIU/3A?VO8/QS;]O,F[G4N(W]S*,@_J+82U<KUE#;,
MNJ*F\-K=MFV'3;7^,V]Z?L;4BE<:!.;&->A\/_= -7W4+$BN7>TN)9E.<-/"
M/#VHK($YSZ6D_<(&:!^S^!U02P,$%     @ $89<5AK+>9*_*   U(4  !D
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M4X=0*UH&"2EB,.(2Y\+J%E(&,NLA:3PV#:X_B!8MR-5L.2"N"V0+"J3UD$:
MS1! 8C;823B7_6-HL+\M3&+144R$4$$9OK3.$(6A0_J'O5GV9%D-64VM6: @
MSQ10@ $%<_EIM71U);5#CXN1R5#=5SGH%05*#!8;JC^YMAE,"G%U"ZZ.4&=:
MQ(<QD69:D66^!59(E43@E_5N2'DR@J_<.JDY]]!:B),8N)G_%Q+B/;P,[S:L
MR#CSIRI9W1U(><(X\4(TKFM/*W\I<TPQU3\=&Y+#:19!M/"NU A9U$>U,N
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MWR#.X:W#ZB1UDX5^3ZKIVBYRV&WSAPR6#1V%^@R[Z<RP_JA0?I]I-]8C$/?
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MZSIQHA-S0_*"W$BP#+HZ+>P8R)Z;1D!Z6^I=O( (ED4C6NA3/;L@<_G06?/
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M$NQH-'U<VSK1GY'4MMA*CGI_3 OHC0;J"_B[AR,9B6Z&K?T5M''[%H=;8?C
MKA,0?M;FEM29B-&IJ)?+M1)6TID9/X H;6PBQ)T;%ZZB-&GMUHVZ,C/X;P>[
M7\&FDYIT6#6]U6= UWSM1^6D5UIU)'U1\$TL'](R2ER(Z'1 %S;;;O_Q;69
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MZQ1H&[2^X\C-;@>)6:O%K&FM8B;EFA?"H<MSI=T7AFM^ "DQ,[P"J <;;HB
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MRUW/7<!7=\9^<U.E"G$_RW+W>F=:%/,7!P<NF:J9=!TS5SG>C(V=R0(_[>3
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MQ;<LS><(BP49M.V!,X6<'_!ZI$UUP1I6%[Y+!.UPWYU:)R1V@/@#"0Z2H\Y
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M.$$P\ZO#'<UO# _3C991A<#<6-I/OH%]TC@OM#A><#UE6E@]].+G9/;B3B*
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M\-7Y8#Z  DO1*G]MNE^PM^>(\7*C7/@+7;R;D<:\==[4O3"M:ZGCK_C:^^%
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M=J]2<M#W[O6\_G$H@AUEZUM[V$%I(5Q/QL%+BH.O3.O(1O?J!$(#!],P=Y?
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MGQ9GXOSLB;A(+L]_$N__J%B/_-9'O!E4W?Y)SHZO/]Q W'T&CY'V[RD1(1R
M1)0Q+E] 9Q_???URLER</Q:?2O&K6IF68G)Q1M5O<<G6&&17B:($9M5:IX?R
MLC@FUP(OAQ8\9CE!:4,)['.+4 /8B0BPEX! (E85^<NMCY>52F4!AFYO%2,L
M05212'+A^9T1-=M*T "O/V##.WC&:[B._*N"C-"1CWG(O-K3)0=JL4*-9FJ!
M5;;[TY^M^%1G^KZ"'RR>GO\L9N+K1G'8(S$A=$A@8DN33DM?"M1W_Q#GFCZO
M_) ' VL0>&7,F)%2E(2VZ-1=QY=1N:MGU98RT$;7C@FD<^&S 14AQ'062B3;
MG'\))TR&\R"])/PX%/A/BL7$A^I,Q).GLXN_DD<X0K R68^T>+:D7_#%1W6'
MPC*E^?[P88FB,C!=T''0'I^).',L.)V-V'@R9.);73D5]DX+Z*?"]@?<D]3A
MG-M%(BVMI<X$\(04956>()1A+;G*55?C4VDWH1C3&8\6LSF@1IZ'[%+[:,O$
M9;*\/$^>($6Q<FRHS:0$+$9Z2>]H^2"<#H8L*[5JR*.S3),D^,C< %A8C9+0
M*?31Y<4<7!6.*W8IRK8A\Q."R<;R[>,.IA03(GW)-1A:DWZ#D6^UL81HX 7D
MG.[Q7EO=Q+Y-T-KSW#@ @A^+UJ:Y.M'EO;1DMU4.T0@ID>L;E\.R?[7WI)X"
MT556A9R)*RLR;=%.61<^'P'SD,,I*C\PJ%B<N\["IY\2$9=2U+9FDA7F!$C)
M4H.0=@?A$%(2G8QV6D,?<!7J=9&NLYKRF,.RS48VG6]N*193G;GL3VPRZ&M=
M3HHDGSCO@+B?@I,>$(O//R0;'\:Y"L8TBET&33,TC"#L3DVUK2EWE3"%RO5:
MPR$2D5<IPSN9W4NG0!/SW1JJH[EF+V1[#12&WS2#R=H'Y9[V9N(5Z:7R^!!+
MT7S;9%*7)*.'D0TZ"^54#_9\,:_*=44Y)OSJ/0^ <6UD@42'E2L5&R1SZ8M.
MX)D$\<%8CWP[WIM5H$=B2<XO74XZH:"F,['PGFD$9/:#M#,3;ZHM$K9). %7
M+6*[-2Q&G,>G$^-6.6'*"O9!,T%97@2;=3$9T4G(+UI8MX+NN4\8MADQTU'[
MP\"X@[^]!1[,I[<PR(/HEX.7EF(?B(+&O7(&]QD2;M1(;$;WD%+'OG99<[^^
MH7ZV#+)6.T[7SE]\$?HS1, $RQR2J7>WONEQ[5_M1@FC#C9:U8-SR!OXZN V
MNK1TX_J0R'WJRG#0-@KAUE5\WT$Q#/#%C(GG._9TWTXQTQ&<[Y'2J+?SQ<=W
M6):@J<02:JA\V?A15^; <SMN&K$S.C2F_R."AW+Y@OV\"\=L[-,'8L-E8P N
MJ UN%7P0NL$/OP%V-Y0I;OLDN@(! G>L?^@TS77)XP/.G8G/+?!FDYTPUO-^
MPY"RJ/-JI\:09Q]SA3SBVM[&M!X/@<$":,-TPXXP)0@-M-L''3$:Q(Y\EXC,
M82DZ:D=-E]IONCKQR"L,_?SH_&+VM*OB@=4267K4_INJ<%U!UQ ,R"S/9S]U
M9/Z$_PPAPYY%:-NCY7QV^? 9?UR%D0<%*P06C*(AMU,ETE=@Q@9NJ#@--&T/
MJ'K!!\?PRBMK,5_,+GI)2+;%\G*V#%\E47$DR_X;^CQL28XPD)IV$&[).HX1
M"FU)2!:?'4ID8$@H\+QGNR/-:-"-*&R\'E]3CNBGL)249,YI[(9&V\G M1P8
MU5%K#/;.9N)UKM'#,_[@ 25-[W;BF+]""\Y=]=G%)<&C_VRQ:ND:U*=3#?6V
M,GFV15;?GT>Z5MH=%+7/G(0?9('*05J=>+- DM_WTA&*-'Z$CQ8M#R$YM62F
M71-@RE@UKJ[RE.J>F,Z204.PKRA)*!R5!I0&3<@ IS,V,B-<T-9$\=%R#]'W
MW<1X_!HAAQXOP*5R0BWKS=2 U&K4H5M("A(QN0F\H6T,.&@DYI3M0!_76T1M
MJASAS]P.G0VA3?!A]=UWTUQ>H[/861WTEJ65+K2 1.&+60<^!TP3J&;XT#@<
M>5_EI'=VB*X^1$SX^GNB[F7>!NRX?QJLS#"\+S8H[[K*G*UL?ZR@L135&,.0
MV)T.\_G4MB%],;Y-M4G; F"\I*%JE0+*N&DF(2""-3QHP4*GN<6UNPKAA^5(
MC50T(_S$^9,E?CKNPP%YT"("+_6!L3RXIH6SN'6:P4!-V"K&J5VFGK3NJFV<
M[[->:'U5-QZK$XPW&BN4=^P]+J:I"@X/J"6#(8G8R6IWTC_1@$>S>BDG&A<X
M[(HPG@89/]?XKHNV\,/[G<B)?H2C1^G$5;: \7GX*VOJ&BC< Z!G/W8RDH>T
M"/)=?.,@N]-H..B%IO5YM17-5CE_]9#7SZE:&HU0,IY2!(/03HTA;3!%%@?Z
M0Y/9PMO7>;6B?!-/WX-A0V<UMBZU9IT=/(&]X4\2\'&O =@F-O()#BT($WH'
M^#9#27.*#O%"Z(X3&&4FX:%T<(4#*:B0.\<T!'+P_V+^UX-T$S?:<WG(X1?*
ME@3.VUS&QP6S=KH**FTTWX0PK-.D'EX((L?D#"7*"0_<@!V12EVWS 1\&$JD
M*+ OJ0&G%*!MP?9)G19=F4CYUL#)Y+N7B:$.9*6@QK$\^>VE#"GDZ[X#._MT
MHPQ4?)W[-7T?NB$ @_H8W+0K3RM4(>F/,.S]0#6YIOZ75>-!6JS&>$(W'H;2
M)(;VV&E6O6DCZ-<E*W>91(56*Y!SWD?K96ZKT::A+_CD&V?<)+KE#+=J8F4H
MR<\&DWX'3.CO:&Q#Y:>F6UF:5\J^5(443;.,G<.!O^_/<676YMW8S;N)W=E&
M%3H5>5LC:RFS:^BUCZ:R>#J^>?_ZL3@.U-_SDALZX[&?Y(X&-,$:$SO$5EH_
MZO'9S6EXX[Y&+54\165THYM^AD(#\=+=C+BITJ1PT^6>[0<A9H"3W^%B4KPM
MTYDX%5_EG<HD;8FO@-\WV>R9>*.*JM[H7,M0&Z4;VS,/I4,.]N M=-(C1O:5
M\3S;7[K*T<5*S-^Q?WI,B-"V*ZLS36J&=J<9#T"3!!#';@TV#S MU'2CZL9A
M^N5\?N%N*QT6[7('= IDX_(6.B5*3=P@RYIJ!:DS4L]5[TQ0""4K*AS]U7%_
MEY[X61TM\GFYRV<TZWGUSX^?_G[U]76X4T  TII?7UW1<H#TBY"R-'G%%GHU
M=ZKI+T,HR[OD\+HU5:U@IV]E5R\*4D[H]%JJ7WX*LG=9'^[6^VN;OA.@GLF-
MPJ98=M=GXQMYKJ<>" 3H+<M0)J=H-]*L5=-Q-ZZ2SGU(C]X5N@QGU&^M-JJ_
M\A]?ZG<W^;.P=P)C<16> *WQ4# Y<#$3!CDN.40IV88\2:=XVX9;()\V^54G
MXC(NSF]+\2EM*N>QTXV:H=>NN(UH5_NM6AQ;B3^JZY#0W9>^1(?PXSX_4.3?
MW;5.'_/1,00WPMP0JN47 %QO9B@U=K>[W69\]GL'ASJVR%H<EK*?^G:OG3PL
MYN1[)Q20.<VOU\BFHPIK8[0W<&L_QG;)($7TFZZR<=L32;\QU-'1+#K4Y+UB
M[*9URJ8 C-&TSAF27J9PLT&2S<;(U8_WNV#$3V]^^;)W\<7O W3W7N23-Y C
M'IM?T>W&?ZE2I<A6U^*9^("8_?CU[;L0M<> 9=5WM:Z0AV -F/$Q>=T@4_XT
MX7?EV,E&)QU'SX\/.5Z\)QHY)%&)"=KN?22X6C^\H@J9TVN.K8/<0/2N6/GP
M37RV=&%KZ3)GK(:AI@ZDA?_+2U?]U#, X7!MXG+3/@-?G3]UKV?%CAZ]8T5R
M?5'9&X*7U[IR+W$EXMVNVDKQ1M[=5>*=1K%%39RY>DA,O"LY?KYR)>.J:7E\
M1HG<7^?2-"Y6 @$3\'#212Q?'=URJCW4G7A7!IKKW#H&?1S(44N6=$\</:[E
MX[>SZHJ,3/AP?/>2^#DDM?_<V6=A#$CUU4>@C2.UKW3]^U=QHD!X2K[*6P-T
M89<Z.9 S)J^"R)B###+E6O^O.<"][!->2PPHX,![B)S _9"3%.HXC@W=MVI]
ME1V0L]T;9</W!D?O4U$7P;'XA]Z]<U.%T-3:/DEW#?&A]PXG(,TXXT?DR)FV
MQ!5Y_\C6L&0W^*/Q<QBER4/J=)FCZVQ=#AM@BE%B',O@1A;2O\3 8^5X%,F-
MSL2\,8FE>$C^T6!E^J[S000WQFTVNJI=0_W^)1XW7*-73JT:7RP.JVX\ZSR@
M5M9\2GUA@^!M=!'=/Z_D"M <44OCLFZ"X-CO7ZP<J(I>+HSNP(;344IZ!R8B
M#PQ*W;".IK5=&$Z]U'P:O;>.^%KSV_G6073W"GOW;?<? *[<>^_]<O>_!SY
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M"=SN\4!]3I6CN"YU-#>7"X,*8E (6,-,<!%FH-PB:]Z09Z@0).+556?>Z3]
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MDL=Q,@(_3K/K*T2 &F@HI]2_$=;2&?LDI\0-# =;T/_+3-J,K$VE90C0:F#
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MXGN5A&(<!2(>Q?$S\L:=K6.6-W[*UHTTRMMZ(1\ K5J<&2.+M>+O_SQ;VMH
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MJ:3NJ/Q@59C:^@7;#ZKK=TQX5'J,I#)4,3RM@S)Q.'8>",6[3&+5JV13@KS
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M()"(Q;-:Q-!B'%%>0XF(P?"H^.^E&]8[L2\!7QFW>"=Z[K#XD P.@(0):>Q
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MY<S+B\#^%BD,:U',AN76H#A_5%H;;.!PE,&8<X"ZV)^N?L&9#LF40H'(B](
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M'%E3RNB_=T;4X]3:%\=T\M(NO!3\;2Q=B$T6FP(#%Z(9'AC"R%%V'"Q$&*-
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M1JM,(F<7^\QA,3^M^AK3)"XG4GQ^M3Q:"M$D&>='>>7$RC >RDHW.<"CY-@
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M.NV8)_!AB6H 1-IZS#CDKCHC?_?(DQTYO=1LL_:BMEYE,7:$&!KE7)_-4&F
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MX@/P^[H&P2,?< *\(8:6]_)_ %!+ P04    "  1AEQ6<0)R1?8#  #<"0
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M#N2XY$UAOLCM;[C+IP68R4*WO[#=Z?H.9(TVLMP9$X)25-V7_]C5X2D&;&?
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M+.E]ALHJT/^5E&8[L1L,+[[%_U!+ P04    "  1AEQ6'/7BE#0#   "!P
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M7)/ST44$INNXW<3I)G2YI7;4,\.PHD<*C3>@_5)KMYOX /VS-_T!4$L#!!0
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M^^M05CJ?V6&?;O NS9H7. UHL@SJ1PQF;]\DP_CJ!**L1Y2=LCZ[IT$N6P)
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M\]#A&KVX2QO4*_]B,. /H>Y:[;G]H^2ZNXN?Q;L7S6>N:?@,U+@DU?AB- A
M=Z^$;F/5VM_,"V7IGO=D10\KU$Z _B\5G<R[C7/0/]5F_P)02P,$%     @
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MVM4PCM<F*;=:XBW'.GW^KLY%Q<@G^L@4F7^BJY*IQ>E20[29L,Q[,9>=&/^
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MK9ES)T5M'?A\HQ3M%S9!WYOCOU!+ P04    "  1AEQ6D1O,@<\+  "4A@
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M;^D2+BZ+5PWF[DDYD[\K0.[R(NM=D:.OS-[-847;6OAK;2_\A1;J06D^E!9
M:2&4%J%HJLX[P]+1&Y9=0K/'B(N>N;=<H8XFE.9!:3Z4%D!I(906H6BJJCM'
MTSG<5JT.U!"%TEPHS8/2?"@M@-)"*"U"T53Q=X:HHU^I^?,C+E#7$TISH30/
M2O-?^%Q,C2<$K4@(I44HVDK.PW+!6.72BIZ?IJR8LRN6)"5I^N&S@1R(6;]*
M"C:3FV.^N[ &PYW7??-=:,K7AQWF_'0I,O9K6LQY5I*$S012;GDS((7<OOC[
M294O17H\$/EX5>5I<[A@=,H*>8'X^RS/J^\GLH#'O+AOJGW^/U!+ P04
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M"G\RH*P#?E](:78;>T#WV\K^ E!+ P04    "  1AEQ6K)Q-XUT$  !W%@
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M-#<N>&ULK9==CYLX%(;_BL56JU;J#-A\SR9([8RJ5FJUHTZ[>U'UPDE.$JN
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MF+60D^U.YDP6?00;B(F'<$V^3X>3J'F2<-^S^[C;??R?W8\-I'\,O,!+(LO
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M#+?+S^J?+;R&F6$)8TZ_DU@M1\ZI@V*8XXRJ.[[^ @50S^A%G$K[C=;YV/[
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MA!F@^^><J^>*>?.4;]SP#U!+ P04    "  1AEQ6</>!8KD$  #1'0  &0
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M2W!,N Y0Y]>,R=<=_0FM_HH[^Q]02P,$%     @ $89<5LR? H+W @  4 H
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M*UV V&:B2SX49H&>7W"NGCJF"JF+R/ O4$L#!!0    ( !&&7%;@"&\.,@,
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MR"K6GI76GNUM&N;,[L;LL;;FX)L1_FY$SY*_^AG8+T7U&T7IC;,NXT;81\=
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MO9?57-U)O4?A>H_\ WODD8]96LX*0M.IFC:,I^[Q_9?&,_?X\Y?&\Q?VWW<
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M:%VUT*@4JC&HQJ&:@&H2I=E5N_6EC4='I>:,K\8:A6:?4"V$:A2J,:C&H9J
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M;:CF0#47JGE0S8=J 4JKYV@]?$-O'[]A)3*4SR3)XRGCY9U6U6]LOM6"#MR
M:F:E#3=O0(S!ZP0A-VE#-0>JN5#-@VH^5 L:=ORHM][QRV!T-Z: QHS?E;.4
M!9FE>2*7LP172U<SH;^6\W]?+7?U$W\YM73-+*=77U)^%ZJK4,1N%:G.WJIW
MRI<SEI=O9)J5$TVGJ91I7+Y<,#IGO%A!?7Z;IO+E3;&!U;SQR?]02P,$%
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MZM,U^4181K[N1*%P$S5U-1(QX;AQ%?1]&73P1M!^0+Z(3.\4^35+(&D"N*A
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MY[(#"8:!P QVQ@T[8Z?)_L&E\JI%)FC$%QG[CUI!47>E13R75B8JV'$)JV.
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M 1P#4PWD\Q6EXGBA.BBWC6;_ 5!+ P04    "  1AEQ6+@X 4^4"  !6"
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M&@-XOQ)"O]Z8$WGS#\S\?U!+ P04    "  1AEQ6HM>%Y#X$  "3%0  &0
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M>ME:X[N-5\C^.L#V=%^%8#/%*Q&;*;[6@+C7#1A)XMYM+ \PL%W :@?RN_-
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M&/%F(?U7U[]3,N20@-DA,)T1;R@FLDC ;)&7"<W!."*5!-Q+$Y39=!]$I)*
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ML6^;55=&YD_[^Y_^-^'3OU!+ P04    "  1AEQ6Q]=S3T<"  #5*P  &@
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M;8?7?#;]H?7F&5!+ 0(4 Q0    ( !&&7%8'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ $89<5H.6
MKXSN    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ $89<5IE<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  1AEQ6I];H/N('  "K
M+P  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ $89<5EK+&,L\ @  OP4  !@              ("!)1
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !&&7%9Y]LT@
MR08  %T<   8              " @9<2  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    "  1AEQ6SH@"8 X#   0"P  &
M@(&6&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ $89<
M5B4XP&Z&!P  82<  !@              ("!VAP  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( !&&7%9'YWU*>0,  %\+   8
M      " @98D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M"  1AEQ6W5Q=A@P'  "3-   &               @(%%*   >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ $89<5E92Y3D>"P  13\  !@
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M970Q,BYX;6Q02P$"% ,4    "  1AEQ67I-4G54$   H"@  &0
M    @(%-;P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M !&&7%;].YG:[P<  $P3   9              " @=ES  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ $89<5K7]U4OC!P  :10  !D
M             ("!_WL  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    "  1AEQ6%-N7.L .  "B+   &0              @($9A   >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !&&7%;?X9SUV@H
M ",>   9              " @1"3  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ $89<5EW%M8!4!0  .@P  !D              ("!
M(9X  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  1AEQ6
MT-1&;0$1   B,0  &0              @(&LHP  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !&&7%8'6?H[/ P  ,,B   9
M      " @>2T  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ $89<5F$5#J76#   +"(  !D              ("!5\$  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  1AEQ6;938/9T*  "^&P
M&0              @(%DS@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( !&&7%8_KVO]4 0  . )   9              " @3C9  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ $89<5G $Q6X2
M+    I8  !D              ("!O]T  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    "  1AEQ6<0)R1?8#  #<"0  &0
M@($("@$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !&&
M7%;:]RJC@P(  &T%   9              " @34. 0!X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ $89<5GTSW)J* P  M0<  !D
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M=#,Q+GAM;%!+ 0(4 Q0    ( !&&7%8$(3KNYP(  &H&   9
M  " @2XD 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M$89<5OPJ<MS5!0  C0X  !D              ("!3"<! 'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    "  1AEQ6)\-,A"\&   )#P  &0
M            @(%8+0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( !&&7%9&7W3J1 <  .<3   9              " @;XS 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ $89<5N$<@?V@ @
MIP4  !D              ("!.3L! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    "  1AEQ6D1O,@<\+  "4A@  &0              @($0
M/@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !&&7%;O
MJT1AO (  'P'   9              " @19* 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ $89<5F%8#"H/!   VA0  !D
M     ("!"4T! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !&&7%:LG$WC700  '<6   9              "
M@=Y@ 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ $89<
M5C.SXTBN @  9@@  !D              ("!<F4! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    "  1AEQ65=?Q+<4"   I"   &0
M        @(%7: $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( !&&7%;*A^&^9P,  .H,   9              " @5-K 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ $89<5EE''8YR @  5@4
M !D              ("!\6X! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    "  1AEQ6'CJ:HI@#  "?"0  &0              @(&:<0$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( !&&7%;D>G4>
MC @  %%F   9              " @6EU 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ $89<5AUXU>)\!P  6#H  !D
M ("!+'X! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  1
MAEQ6GO\,"#,#  #O#@  &0              @('?A0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !&&7%9P]X%BN00  -$=   9
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M970U-RYX;6Q02P$"% ,4    "  1AEQ6&A@OF]D#   *#0  &0
M    @(%NIP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M !&&7%9_R:\)FP,  '<.   9              " @7ZK 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ $89<5L?TZFT3!P  YD(  !D
M             ("!4*\! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    "  1AEQ64>7\WGL#  #_#0  &0              @(&:M@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( !&&7%9G"-"L2@@
M )\_   9              " @4RZ 0!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ $89<5G^<?(HA!   R!4  !D              ("!
MS<(! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  1AEQ6
MZ66W/9 #  #2"@  &0              @($EQP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( !&&7%:C!62B4P0  &T0   9
M      " @>S* 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ $89<5NV4H8?Z P  0A(  !D              ("!=L\! 'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    "  1AEQ6+@X 4^4"  !6"
M&0              @(&GTP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    ( !&&7%95GP%N< ,  + -   9              " @</6 0!X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ $89<5L(S49=7
M!   G0X  !D              ("!:MH! 'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    "  1AEQ6Y?:O8Z$$  "-$0  &0
M@('XW@$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( !&&
M7%:BUX7D/@0  ),5   9              " @=#C 0!X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @ $89<5DQ" \+@ P  SPX  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  1AEQ6EXJ[',     3 @  "P
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52P4&     %( 4@!U%@  R ,"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>232</ContextCount>
  <ElementCount>386</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Liabilities Related to the Sales of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Inventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OperatingLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SegmentReporting</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails</Role>
      <ShortName>Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails</Role>
      <ShortName>Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Inventory - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryScheduleofInventoriesDetails</Role>
      <ShortName>Inventory - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Operating Leases - Schedule of Operating Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails</Role>
      <ShortName>Operating Leases - Schedule of Operating Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Operating Leases - Schedule of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails</Role>
      <ShortName>Operating Leases - Schedule of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails</Role>
      <ShortName>Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CommitmentsandContingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails</Role>
      <ShortName>License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="nktr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail</Role>
      <ShortName>Segment Reporting - Revenue by Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: nktr:LeaseExtensionTerm, nktr:LongTermInvestmentMaturityPeriod, us-gaap:PropertyPlantAndEquipmentUsefulLife -  nktr-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="nktr-20221231.htm">nktr-20221231.htm</File>
    <File>nktr-20221231.xsd</File>
    <File>nktr-20221231_cal.xml</File>
    <File>nktr-20221231_def.xml</File>
    <File>nktr-20221231_lab.xml</File>
    <File>nktr-20221231_pre.xml</File>
    <File>nktr-20221231xexx311.htm</File>
    <File>nktr-20221231xexx312.htm</File>
    <File>nktr-20221231xexx321.htm</File>
    <File>nktr20221231-exx211.htm</File>
    <File>nktr20221231-exx231.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nktr-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="723">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 32,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 723,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 232,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 638,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://www.nektar.com/20221231": 3,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 8
   },
   "keyCustom": 80,
   "keyStandard": 306,
   "memberCustom": 50,
   "memberStandard": 45,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.nektar.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Cash and Investments in Marketable Securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.nektar.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Property, Plant and Equipment",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Operating Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.nektar.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Liabilities Related to the Sales of Future Royalties",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties",
     "shortName": "Liabilities Related to the Sales of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.nektar.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.nektar.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - License and Collaboration Agreements",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.nektar.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.nektar.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.nektar.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Inventory (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.nektar.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Property, Plant and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LesseeOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Operating Leases (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.nektar.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LesseeOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables",
     "shortName": "Liabilities Related to the Sales of Future Royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.nektar.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - License and Collaboration Agreements (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables",
     "shortName": "License and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.nektar.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.nektar.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails",
     "shortName": "Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:InvestmnetsTargetMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:InvestmnetsTargetMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
     "shortName": "Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Inventory - Schedule of Inventories (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails",
     "shortName": "Inventory - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:DepreciablePropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:DepreciablePropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Property, Plant and Equipment - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails",
     "shortName": "Property, Plant and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Operating Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
     "shortName": "Operating Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i7f516ae040844d74a523bf6793681072_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NumberOfConsecutiveTermsToExtendLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "term",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Operating Leases - Schedule of Operating Lease Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails",
     "shortName": "Operating Leases - Schedule of Operating Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i7f516ae040844d74a523bf6793681072_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NumberOfConsecutiveTermsToExtendLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "term",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Operating Leases - Schedule of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails",
     "shortName": "Operating Leases - Schedule of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails",
     "shortName": "Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "iefb7645eeeaf42b793851c3bab72abca_D20210212-20210212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CollaborativeArrangementCommittedFunding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "iefb7645eeeaf42b793851c3bab72abca_D20210212-20210212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CollaborativeArrangementCommittedFunding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "ibcf73feefa4248f9bc901c6de5114e62_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i2cd1c1703c6a49d18229ba501627fd87_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
     "shortName": "Liabilities Related to the Sales of Future Royalties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i96e50a20c84741bf96617a4a3059d745_D20120224-20120224",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "iffeba43c66e94db7b8603276d878e2a5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail",
     "shortName": "Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i5e27ff45c6344a70a6715b2e56bebc4a_I20120224",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i07893b3959254f9ebfe26a0ff8ffc37b_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.nektar.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i07893b3959254f9ebfe26a0ff8ffc37b_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i5004dfaad50e4a37b683b94437e9c3fe_D20180403-20180403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i5004dfaad50e4a37b683b94437e9c3fe_D20180403-20180403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
     "shortName": "License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i14d92114cae74251becb89962c58cc74_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NetExpenseReimbursementsFromCollaborationPartner",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "if6238407fbe54f7f8ccc426559162694_I20180430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i948d3d10847d41cbaa8d5e99b9e0ca18_D20221001-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessExitCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessExitCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i79208888512146d7bc75e741ef3f64e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i79208888512146d7bc75e741ef3f64e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "iee4cee9d0d7e4f278ad6b604a58efaa1_D20220601-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "iee4cee9d0d7e4f278ad6b604a58efaa1_D20220601-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "iac8a6dd98aab4d3dbbc732084af7018f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ChangeInControlSeverancePaymentPeriodForExecutives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ChangeInControlSeverancePaymentPeriodForExecutives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "ia1da4578eb344c37a4ac66d8094312cb_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "iffeba43c66e94db7b8603276d878e2a5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "iffeba43c66e94db7b8603276d878e2a5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "ia5f2ce65d9b74f5ab00210112601e860_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "ief64bc46a28844f3b364287244422030_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails",
     "shortName": "Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i0c9d9fd3ecfa4c9086a8279fc8984311_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "id08cf5e99f4c4729b75cd9f892d3dd95_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i6ba55e78a47f409892a9d1ca1d1e75e3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "iffeba43c66e94db7b8603276d878e2a5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i8f208c2b206d4f43af4e746f193bb362_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NumberOfOperatingBusinessSegment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Segment Reporting - Additional Information (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NumberOfOperatingBusinessSegment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail",
     "shortName": "Segment Reporting - Revenue by Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i06754ac5c8fe4627adbc24980fd082b4_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i3fcd2c816993496185a6cd0f677f3d98_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:SaleOfFutureRoyaltiesTransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20221231.htm",
      "contextRef": "i2b7bbf850d054f41bcf50abd1ccacbaf_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:SaleOfFutureRoyaltiesTransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 97,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Entity number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable and significant customer concentrations.",
        "label": "Accounts Receivable And Significant Customer Concentrations [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Significant Customer Concentrations"
       }
      }
     },
     "localname": "AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions",
        "label": "Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions",
        "negatedLabel": "Amortization of premiums (discounts), net and other non-cash transactions"
       }
      }
     },
     "localname": "AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AreaOfLeasedSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased space.",
        "label": "Area Of Leased Space",
        "terseLabel": "Lease space (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLeasedSpace",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "nktr_AstraZenecaAbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca AB.",
        "label": "Astra Zeneca Ab [Member]",
        "terseLabel": "Astra Zeneca Ab"
       }
      }
     },
     "localname": "AstraZenecaAbMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information [Abstract]",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.nektar.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nktr_BMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS collaboration agreement.",
        "label": "B M S Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BaxaltaIncorporatedOrTakedaPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baxalta Incorporated or takeda PLC.",
        "label": "Baxalta Incorporated Or Takeda P L C [Member]",
        "terseLabel": "Baxalta Incorporated Or Takeda P L C"
       }
      }
     },
     "localname": "BaxaltaIncorporatedOrTakedaPLCMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BempegaldesleukinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bempegaldesleukin",
        "label": "Bempegaldesleukin [Member]",
        "terseLabel": "Bempegaldesleukin"
       }
      }
     },
     "localname": "BempegaldesleukinMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb collaboration agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement [Member]",
        "terseLabel": "Bristol Myers Squibb Collaboration Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol-Myers Squibb",
        "verboseLabel": "BMS"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BuildingAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building and Leasehold Improvements.",
        "label": "Building And Leasehold Improvements [Member]",
        "terseLabel": "Building and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndLeaseholdImprovementsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Line Items]",
        "label": "Cash And Investments In Marketable Securities [Line Items]",
        "terseLabel": "Cash and Investments in Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesLineItems",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Table]",
        "label": "Cash And Investments In Marketable Securities [Table]",
        "terseLabel": "Cash And Investments In Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesTable",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndNonCashRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And NonCash Royalties",
        "label": "Cash And NonCash Royalties [Member]",
        "terseLabel": "Cash And NonCash Royalties"
       }
      }
     },
     "localname": "CashAndNonCashRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ChangeInControlSeverancePaymentPeriodForExecutives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in control severance payment period for executives.",
        "label": "Change In Control Severance Payment Period For Executives",
        "terseLabel": "Change in control severance payment period for executives"
       }
      }
     },
     "localname": "ChangeInControlSeverancePaymentPeriodForExecutives",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_CollaborativeArrangementCommittedFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Funding",
        "label": "Collaborative Arrangement, Committed Funding",
        "terseLabel": "Committed funding"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedFunding",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, Amount",
        "label": "Collaborative Arrangement, Success-Based Payments, Amount",
        "terseLabel": "Collaborative arrangement, success-based payments"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsAmount",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ComputerFurnitureAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture computer and other.",
        "label": "Computer Furniture And Other [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerFurnitureAndOtherMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Liability Related to the Sale of Future Royalties",
        "label": "Deferred Tax Assets, Liability Related to the Sale of Future Royalties",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DepreciablePropertyPlantAndEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "nktr_DepreciablePropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciable Property, plant and equipment, Gross.",
        "label": "Depreciable Property Plant And Equipment Gross",
        "terseLabel": "Depreciable property, plant and equipment at cost"
       }
      }
     },
     "localname": "DepreciablePropertyPlantAndEquipmentGross",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DepreciablePropertyPlantAndEquipmentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciable Property, plant and equipment, Net.",
        "label": "Depreciable Property Plant And Equipment Net",
        "totalLabel": "Depreciable property, plant and equipment, net"
       }
      }
     },
     "localname": "DepreciablePropertyPlantAndEquipmentNet",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DevelopmentDerivativeLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Derivative Liability",
        "label": "Development Derivative Liability [Text Block]",
        "terseLabel": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability"
       }
      }
     },
     "localname": "DevelopmentDerivativeLiabilityTextBlock",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss Carryforwards",
        "label": "Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss Carryforwards",
        "terseLabel": "Expiration of net operating loss carryforwards"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount",
        "terseLabel": "Non-cash royalty revenue related to sales of future royalties"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Non Deductible Expense For Liability Related Sale Of Future Royalties, Amount",
        "terseLabel": "Non-cash interest expense on liability related to sales of future royalties"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly And Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee.",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EmployeeSeveranceWithNoServicePeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance With No Service Period",
        "label": "Employee Severance With No Service Period [Member]",
        "terseLabel": "No service period"
       }
      }
     },
     "localname": "EmployeeSeveranceWithNoServicePeriodMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EmployeeSeveranceWithServicePeriodRequirementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance With Service Period Requirement",
        "label": "Employee Severance With Service Period Requirement [Member]",
        "terseLabel": "Service period required"
       }
      }
     },
     "localname": "EmployeeSeveranceWithServicePeriodRequirementMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_FutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Royalties",
        "label": "Future Royalties [Member]",
        "terseLabel": "Future Royalties"
       }
      }
     },
     "localname": "FutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross",
        "label": "Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross",
        "negatedLabel": "Loss on revaluation of liability related to the sale of future royalties"
       }
      }
     },
     "localname": "GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties",
        "label": "Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties",
        "negatedTerseLabel": "Loss on revaluation of liability related to the sale of future royalties",
        "terseLabel": "Loss on revaluation of liability related to the sale of future royalties"
       }
      }
     },
     "localname": "GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of equipment and other costs for terminated program.",
        "label": "Impairment Of Assets And Other Costs For Terminated Program",
        "terseLabel": "Restructuring, impairment and other costs of terminated program"
       }
      }
     },
     "localname": "ImpairmentOfAssetsAndOtherCostsForTerminatedProgram",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentOfEquipmentFromTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of equipment from terminated program.",
        "label": "Impairment Of Equipment From Terminated Program",
        "terseLabel": "Impairment of advance payments to contract manufacturers and equipment for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfEquipmentFromTerminatedProgram",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncomeTaxesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Line Items]",
        "terseLabel": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureLineItems",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_IncomeTaxesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Table]",
        "terseLabel": "Income Taxes Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureTable",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "negatedTerseLabel": "Operating leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory and significant supplier concentrations.",
        "label": "Inventory And Significant Supplier Concentrations [Policy Text Block]",
        "terseLabel": "Inventory and Significant Supplier Concentrations"
       }
      }
     },
     "localname": "InventoryAndSignificantSupplierConcentrationsPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_InvestmentsWeightedAverageMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments, Weighted Average Maturity Period",
        "label": "Investments, Weighted Average Maturity Period",
        "terseLabel": "Weighted average maturity period"
       }
      }
     },
     "localname": "InvestmentsWeightedAverageMaturityPeriod",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_InvestmnetsTargetMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investmnets, Target Maturity Period",
        "label": "Investmnets, Target Maturity Period",
        "terseLabel": "Target maturity period"
       }
      }
     },
     "localname": "InvestmnetsTargetMaturityPeriod",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LeaseExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease extension term.",
        "label": "Lease Extension Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "LeaseExtensionTerm",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases [Line Items]",
        "label": "Leases [Line Items]",
        "terseLabel": "Leases [Line Items]"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LesseeOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease",
        "label": "Lessee, Operating Lease [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Information"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTableTextBlock",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities on sale of future royalties, unamortized transaction costs.",
        "label": "Liabilities On Sale Of Future Royalties Unamortized Transaction Costs",
        "negatedLabel": "Less: unamortized transaction costs"
       }
      }
     },
     "localname": "LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related to the Sale of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To Sale Of Future Royalties",
        "label": "Liability Related To Sale Of Future Royalties [Roll Forward]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesRollForward",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Abstract]",
        "terseLabel": "Liability Related To Sale Of Potential Future Royalties [Abstract]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract",
     "nsuri": "http://www.nektar.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail": {
       "order": 1.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties noncurrent.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current",
        "periodEndLabel": "Liabilities related to the sales of future royalties \u2013 ending balance",
        "periodStartLabel": "Liabilities related to the sales of future royalties\u2014beginning balance"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liabilities related to the sales of future royalties, net",
        "totalLabel": "Liabilities related to the sales of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Text Block]",
        "terseLabel": "Liabilities Related to the Sales of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties [Roll Forward]",
        "label": "Liability Related To The Sale Of Future Royalties [Roll Forward]",
        "terseLabel": "Liability Related To The Sale Of Future Royalties [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Line Items]",
        "terseLabel": "License And Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsTable",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LicenseCollaborationOtherRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.",
        "label": "License Collaboration Other Revenue",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationOtherRevenue",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LongTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investment maturity period.",
        "label": "Long Term Investment Maturity Period",
        "terseLabel": "Long term investment maturity period"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityPeriod",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_ManufacturingLaboratoryAndOtherEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing laboratory and other equipment.",
        "label": "Manufacturing Laboratory And Other Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingLaboratoryAndOtherEquipmentMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Market Participant Subtenant Borrowing Rate",
        "label": "Measurement Input, Market Participant Subtenant Borrowing Rate [Member]",
        "terseLabel": "Measurement Input, Market Participant Subtenant Borrowing Rate"
       }
      }
     },
     "localname": "MeasurementInputMarketParticipantSubtenantBorrowingRateMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MergerAndAcquisitionRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger and acquisition related claims.",
        "label": "Merger And Acquisition Related Claims [Member]",
        "terseLabel": "Merger and Acquisition Related Claims"
       }
      }
     },
     "localname": "MergerAndAcquisitionRelatedClaimsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Milestone [Axis]",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions",
        "label": "Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds",
        "terseLabel": "Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties"
       }
      }
     },
     "localname": "MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_MissionBayLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mission bay lease.",
        "label": "Mission Bay Lease [Member]",
        "terseLabel": "Mission Bay Facility"
       }
      }
     },
     "localname": "MissionBayLeaseMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NKTR181Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NKTR - 181 [Member]",
        "label": "NKTR - 181 [Member]",
        "terseLabel": "NKTR - 181"
       }
      }
     },
     "localname": "NKTR181Member",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar214Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar 214.",
        "label": "Nektar 214 [Member]",
        "terseLabel": "Nektar 214"
       }
      }
     },
     "localname": "Nektar214Member",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar-358",
        "label": "Nektar-358 [Member]",
        "terseLabel": "Nektar-358"
       }
      }
     },
     "localname": "Nektar358Member",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NetExpenseReimbursementsFromCollaborationPartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net expense reimbursements from collaboration partner.",
        "label": "Net Expense Reimbursements From Collaboration Partner",
        "terseLabel": "Net expense reimbursements from collaboration partner"
       }
      }
     },
     "localname": "NetExpenseReimbursementsFromCollaborationPartner",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liabilities related to the sales of future royalties",
        "terseLabel": "Non-cash interest expense on liabilities related to sales of future royalties",
        "verboseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to the sales of future royalties",
        "negatedTerseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to the sales of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonSecuritiesRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-securities related claims.",
        "label": "Non Securities Related Claims [Member]",
        "terseLabel": "Non-Securities Related Claims"
       }
      }
     },
     "localname": "NonSecuritiesRelatedClaimsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities",
        "label": "Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities",
        "terseLabel": "Accounts receivable recognized in exchange for long-term liabilities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NumberOfConsecutiveTermsToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive five year terms to extend lease.",
        "label": "Number Of Consecutive Terms To Extend Lease",
        "terseLabel": "Number of consecutive terms to extend lease"
       }
      }
     },
     "localname": "NumberOfConsecutiveTermsToExtendLease",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_NumberOfOperatingBusinessSegment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating business segment.",
        "label": "Number Of Operating Business Segment",
        "terseLabel": "Number of operating business segment"
       }
      }
     },
     "localname": "NumberOfOperatingBusinessSegment",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units to evaluate goodwill for impairment",
        "label": "Number Of Reporting Units To Evaluate Goodwill For Impairment",
        "terseLabel": "Number of reporting unit evaluated for goodwill"
       }
      }
     },
     "localname": "NumberOfReportingUnitsToEvaluateGoodwillForImpairment",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations under director and officer indemnifications per incident.",
        "label": "Obligations Under Director And Officer Indemnifications Per Incident",
        "terseLabel": "Obligations under Director and Officer Indemnifications per incident"
       }
      }
     },
     "localname": "ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OperatingLeaseMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Measurement Input",
        "label": "Operating Lease, Measurement Input",
        "terseLabel": "Operating lease, measurement input"
       }
      }
     },
     "localname": "OperatingLeaseMeasurementInput",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Subject To Expiration",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "terseLabel": "Operating loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization [Policy Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PartialRepaymentOfRoyaltySaleProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partial repayment of royalty sale proceeds.",
        "label": "Partial Repayment Of Royalty Sale Proceeds",
        "negatedTerseLabel": "Payments to RPI"
       }
      }
     },
     "localname": "PartialRepaymentOfRoyaltySaleProceeds",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentMadeForMilestoneNotAchievedYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for milestone not achieved year one.",
        "label": "Payment Made For Milestone Not Achieved Year One",
        "terseLabel": "Payment made for milestone not achieved year one"
       }
      }
     },
     "localname": "PaymentMadeForMilestoneNotAchievedYearOne",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentMadeForMilestoneNotAchievedYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for milestone not achieved year two.",
        "label": "Payment Made For Milestone Not Achieved Year Two",
        "terseLabel": "Payment made for milestone not achieved year two"
       }
      }
     },
     "localname": "PaymentMadeForMilestoneNotAchievedYearTwo",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved",
        "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved",
        "terseLabel": "Payment of transaction related to purchase and sale agreement"
       }
      }
     },
     "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved",
        "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved",
        "terseLabel": "Payment of transaction related to purchase and sale agreement if threshold is not achieved"
       }
      }
     },
     "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received, if conditions occur.",
        "label": "Percentage Of Development Milestones Payments To Be Received If Conditions Occur",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced if conditions occur"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received under certain conditions.",
        "label": "Percentage Of Development Milestones Payments To Be Received Under Certain Conditions",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced under certain conditions"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of funding Phase three development costs on an indication by indication basis borne.",
        "label": "Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne",
        "terseLabel": "Percentage of funding phase 3 development costs on an indication by indication basis borne"
       }
      }
     },
     "localname": "PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ProceedsFromSaleOfFutureRoyaltiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale of Future Royalties, Net",
        "label": "Proceeds From Sale of Future Royalties, Net",
        "terseLabel": "Proceeds from sale of future royalties, net of $3.8 million of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfFutureRoyaltiesNet",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties gross.",
        "label": "Proceeds From Sale Of Potential Future Royalties Gross",
        "terseLabel": "Proceeds from sale of royalty rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProgramTerminationAdvancePaymntToContractManyfacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Program Termination, Advance Paymnt To Contract Manyfacturers",
        "label": "Program Termination, Advance Paymnt To Contract Manyfacturers [Member]",
        "terseLabel": "Program Termination, Advance Paymnt To Contract Manyfacturers"
       }
      }
     },
     "localname": "ProgramTerminationAdvancePaymntToContractManyfacturersMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ProgramTerminationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Program Termination",
        "label": "Program Termination [Member]",
        "terseLabel": "Program Termination"
       }
      }
     },
     "localname": "ProgramTerminationMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ProgramTerminationNoncancellableCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Program Termination, Noncancellable Commitments",
        "label": "Program Termination, Noncancellable Commitments [Member]",
        "terseLabel": "Program Termination, Noncancellable Commitments"
       }
      }
     },
     "localname": "ProgramTerminationNoncancellableCommitmentsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure",
        "label": "Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure",
        "negatedTerseLabel": "Property, plant and equipment and Operating lease right-of-use assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PurchaseAndSaleAgreement2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2012",
        "label": "Purchase and Sale Agreement 2012 [Member]",
        "terseLabel": "2012 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2012Member",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2020",
        "label": "Purchase and Sale Agreement 2020 [Member]",
        "terseLabel": "2020 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2020Member",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and sale agreement.",
        "label": "Purchase And Sale Agreement [Member]",
        "terseLabel": "Pursuant to the 2012 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreementMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_RSUsAndPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RSUs and PSUs",
        "label": "RSUs and PSUs [Member]",
        "terseLabel": "RSUs and PSUs"
       }
      }
     },
     "localname": "RSUsAndPSUsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring, Impairment and Other Costs for Terminated Program",
        "label": "Restructuring, Impairment and Other Costs for Terminated Program [Policy Text Block]",
        "terseLabel": "Restructuring, Impairment and Other Costs for Terminated Program"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherCostsForTerminatedProgramPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring, Impairment and Other Costs of Terminated Program",
        "label": "Restructuring, Impairment and Other Costs of Terminated Program [Member]",
        "terseLabel": "Restructuring, impairment and other costs of terminated program"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_RoyaltiesLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Liability, Measurement Input",
        "label": "Royalties Liability, Measurement Input",
        "terseLabel": "Royalties liability, measurement input"
       }
      }
     },
     "localname": "RoyaltiesLiabilityMeasurementInput",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nktr_RoyaltyMonetizationProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties.",
        "label": "Royalty Monetization Proceeds",
        "terseLabel": "Royalty monetization proceeds"
       }
      }
     },
     "localname": "RoyaltyMonetizationProceeds",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SFJPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SFJ Pharmaceuticals",
        "label": "SFJ Pharmaceuticals [Member]",
        "terseLabel": "SFJ Pharmaceuticals"
       }
      }
     },
     "localname": "SFJPharmaceuticalsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SaleOfFutureRoyaltiesTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Future Royalties Transaction Costs",
        "label": "Sale of Future Royalties Transaction Costs",
        "terseLabel": "Sale of future royalties transaction costs"
       }
      }
     },
     "localname": "SaleOfFutureRoyaltiesTransactionCosts",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SaleOfStockValueAuthorizedInTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock Value Authorized In Transaction",
        "label": "Sale Of Stock Value Authorized In Transaction",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockValueAuthorizedInTransaction",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SalesMilestoneRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone revenue.",
        "label": "Sales Milestone Revenue",
        "terseLabel": "Sales milestone revenue"
       }
      }
     },
     "localname": "SalesMilestoneRevenue",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ScheduleOfLeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Leases [Table]",
        "label": "Schedule Of Leases [Table]",
        "terseLabel": "Schedule Of Leases [Table]"
       }
      }
     },
     "localname": "ScheduleOfLeasesTable",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Liability Related To Sale Of Potential Future Royalties",
        "label": "Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]",
        "terseLabel": "Schedule of Liability Related to Potential Future Royalties"
       }
      }
     },
     "localname": "ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_SecuritiesRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities related claims.",
        "label": "Securities Related Claims [Member]",
        "terseLabel": "Securities Related Claims"
       }
      }
     },
     "localname": "SecuritiesRelatedClaimsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation plan's share limit for every one share.",
        "label": "Share Based Compensation Plans Share Limit For Every One Share",
        "terseLabel": "Share-based compensation plan's share limit reduction for every one restricted stock unit granted"
       }
      }
     },
     "localname": "ShareBasedCompensationPlansShareLimitForEveryOneShare",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option, RSUs And PSUs",
        "label": "Share-based Payment Arrangement, Option, RSUs And PSUs [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option, RSUs And PSUs"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionRSUsAndPSUsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period subject to lock-up and stand-still provisions period.",
        "label": "Stock Issued During Period Subject To Lock Up And Stand Still Provisions Period",
        "terseLabel": "Stock issued during period subject to lock-up and stand-still provisions period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_StockOptionsRSUsAndPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, RSUs And PSUs",
        "label": "Stock Options, RSUs And PSUs [Member]",
        "verboseLabel": "Stock Options, RSUs and PSUs"
       }
      }
     },
     "localname": "StockOptionsRSUsAndPSUsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SubleaseOperatingLeaseRightOfUseAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Operating Lease Right of Use Assets",
        "label": "Sublease Operating Lease Right of Use Assets [Member]",
        "terseLabel": "Sublease Operating Lease Right of Use Assets"
       }
      }
     },
     "localname": "SubleaseOperatingLeaseRightOfUseAssetsMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SubleasePropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Property, Plant And Equipment",
        "label": "Sublease Property, Plant And Equipment [Member]",
        "terseLabel": "Sublease Property, Plant And Equipment"
       }
      }
     },
     "localname": "SubleasePropertyPlantAndEquipmentMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SubleasesIncomeToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subleases Income, To Be Received",
        "label": "Subleases Income, To Be Received",
        "terseLabel": "Subleases aggregate lease payments"
       }
      }
     },
     "localname": "SubleasesIncomeToBeReceived",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_TaxPositionsRelatedToCurrentYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Positions Related To Current Year",
        "label": "Tax Positions Related To Current Year [Abstract]",
        "terseLabel": "Tax positions related to current year:"
       }
      }
     },
     "localname": "TaxPositionsRelatedToCurrentYearAbstract",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_TaxPositionsRelatedToPriorYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Positions Related To Prior Years",
        "label": "Tax Positions Related To Prior Years [Abstract]",
        "terseLabel": "Tax positions related to prior years:"
       }
      }
     },
     "localname": "TaxPositionsRelatedToPriorYearsAbstract",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_ThirdStFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third St. Facility",
        "label": "Third St. Facility [Member]",
        "terseLabel": "Third St. Facility"
       }
      }
     },
     "localname": "ThirdStFacilityMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ThirdStreetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third street lease.",
        "label": "Third Street Lease [Member]",
        "terseLabel": "Third Street Facility"
       }
      }
     },
     "localname": "ThirdStreetLeaseMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TransactionCostsRelatedToRevisedRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs Related To Revised Royalty Payments",
        "label": "Transaction Costs Related To Revised Royalty Payments",
        "terseLabel": "Transaction costs related to revised royalty payments"
       }
      }
     },
     "localname": "TransactionCostsRelatedToRevisedRoyaltyPayments",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs related to sale of potential future royalties.",
        "label": "Transaction Costs Related To Sale Of Potential Future Royalties",
        "terseLabel": "Transaction costs related to sale of potential future royalties"
       }
      }
     },
     "localname": "TransactionCostsRelatedToSaleOfPotentialFutureRoyalties",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_TwoThousandSeventeenPerformanceIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen performance incentive plan.",
        "label": "Two Thousand Seventeen Performance Incentive Plan [Member]",
        "terseLabel": "2017 Performance Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenPerformanceIncentivePlanMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UCBPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma.",
        "label": "U C B Pharma [Member]",
        "terseLabel": "UCB"
       }
      }
     },
     "localname": "UCBPharmaMember",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits, period increase (decrease) reasonable period of change",
        "label": "Unrecognized Tax Benefits Period Increase (Decrease) Reasonable Period Of Change",
        "terseLabel": "Unrecognized tax benefits, period may increase or decrease due to tax examination"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20221231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r219",
      "r443",
      "r444",
      "r447",
      "r448",
      "r485",
      "r557",
      "r641",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r219",
      "r443",
      "r444",
      "r447",
      "r448",
      "r485",
      "r557",
      "r641",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r219",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r264",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r318",
      "r319",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r219",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r264",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r318",
      "r319",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r321",
      "r326",
      "r566",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r270",
      "r583",
      "r647",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r360",
      "r516",
      "r532",
      "r559",
      "r560",
      "r580",
      "r587",
      "r597",
      "r646",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r360",
      "r516",
      "r532",
      "r559",
      "r560",
      "r580",
      "r587",
      "r597",
      "r646",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r270",
      "r583",
      "r647",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r266",
      "r519",
      "r581",
      "r595",
      "r638",
      "r639",
      "r647",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r266",
      "r519",
      "r581",
      "r595",
      "r638",
      "r639",
      "r647",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r352",
      "r360",
      "r390",
      "r391",
      "r392",
      "r492",
      "r516",
      "r532",
      "r559",
      "r560",
      "r580",
      "r587",
      "r597",
      "r634",
      "r646",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r352",
      "r360",
      "r390",
      "r391",
      "r392",
      "r492",
      "r516",
      "r532",
      "r559",
      "r560",
      "r580",
      "r587",
      "r597",
      "r634",
      "r646",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r558",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r558",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReportableGeographicalComponentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Geographical Components [Member]",
        "terseLabel": "Reportable Geographical Components"
       }
      }
     },
     "localname": "ReportableGeographicalComponentsMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r217",
      "r218",
      "r321",
      "r326",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r267",
      "r268",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r582",
      "r596",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r542",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r582",
      "r596",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r625",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r594"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r80",
      "r174"
     ],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "nktr_DepreciablePropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r190",
      "r198",
      "r199",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r181",
      "r527",
      "r537",
      "r538"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r24",
      "r27",
      "r133",
      "r484",
      "r533",
      "r534",
      "r612",
      "r613",
      "r614",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r23",
      "r27",
      "r133",
      "r198",
      "r199",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r621",
      "r622",
      "r623",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r48",
      "r76"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedTerseLabel": "Less: Amounts recorded as amortization between May 31 and December 31, 2022 for Third St. facility"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r117",
      "r118",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r48",
      "r77"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of right-of-use assets and property, plant and equipment",
        "totalLabel": "Total impairment of sublease assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r151",
      "r160",
      "r177",
      "r213",
      "r252",
      "r256",
      "r262",
      "r278",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r315",
      "r317",
      "r319",
      "r320",
      "r443",
      "r447",
      "r461",
      "r594",
      "r642",
      "r643",
      "r693"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r170",
      "r184",
      "r213",
      "r278",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r315",
      "r317",
      "r319",
      "r320",
      "r443",
      "r447",
      "r461",
      "r594",
      "r642",
      "r643",
      "r693"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "verboseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r275",
      "r285"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r70",
      "r274",
      "r285",
      "r521"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r69",
      "r285"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r69",
      "r173",
      "r285"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Long-term investments",
        "verboseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Reported Value Measurement"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r540",
      "r541",
      "r594",
      "r610"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r50",
      "r172",
      "r561"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Investments in Marketable Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r45",
      "r50",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r45",
      "r148"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r438",
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Corporate commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r19",
      "r154",
      "r164"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r301",
      "r302",
      "r544",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Total common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r621",
      "r622",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r594"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 188,560 shares and 185,468 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r28",
      "r193",
      "r195",
      "r202",
      "r523",
      "r529"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r59",
      "r60",
      "r146",
      "r147",
      "r270",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r59",
      "r60",
      "r146",
      "r147",
      "r270",
      "r539",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r59",
      "r60",
      "r146",
      "r147",
      "r270",
      "r543",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r59",
      "r60",
      "r146",
      "r147",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage revenue from customers"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r59",
      "r60",
      "r146",
      "r147",
      "r270",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation, Principles of Consolidation and Use of Estimates"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r584",
      "r586",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r35",
      "r519"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r86",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r620",
      "r681",
      "r683"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r620",
      "r681"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r423",
      "r431",
      "r620"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r620",
      "r681",
      "r683"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r57",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer",
        "terseLabel": "Matching 401(k) employer contribution, maximum amount"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r620",
      "r682",
      "r683"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r620",
      "r682"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r48",
      "r131",
      "r424",
      "r430",
      "r431",
      "r620"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense",
        "totalLabel": "Total deferred income tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r2",
      "r3",
      "r152",
      "r159",
      "r417"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r620",
      "r682",
      "r683"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r129",
      "r680"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Net capital loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r129",
      "r680"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r679"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r679"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r129",
      "r680"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r129",
      "r680"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r128",
      "r129",
      "r680"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and other credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r129",
      "r680"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r122",
      "r679"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": {
     "auth_ref": [
      "r129",
      "r680"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.",
        "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates",
        "negatedTerseLabel": "Investment in foreign subsidiary"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r129",
      "r680"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r129",
      "r680"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Compensation expense in connection with 401(k) retirement plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum 401(k) per employee, percentage of annual salary"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r48",
      "r78"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r48",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Development Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Development derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r364",
      "r395",
      "r396",
      "r398",
      "r403",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r107",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options",
        "verboseLabel": "Schedule of Shares of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables",
      "http://www.nektar.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r203",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r233",
      "r235",
      "r237",
      "r238",
      "r239",
      "r241",
      "r452",
      "r453",
      "r524",
      "r530",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r203",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r235",
      "r237",
      "r238",
      "r239",
      "r241",
      "r452",
      "r453",
      "r524",
      "r530",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r676",
      "r677"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Recognized over a weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r98",
      "r168",
      "r197",
      "r198",
      "r199",
      "r220",
      "r221",
      "r222",
      "r224",
      "r230",
      "r232",
      "r242",
      "r279",
      "r340",
      "r399",
      "r400",
      "r401",
      "r426",
      "r427",
      "r451",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r484",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r322",
      "r460",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Closing"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r454",
      "r455",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r135",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r322",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r455",
      "r489",
      "r490",
      "r491",
      "r578",
      "r579",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r135",
      "r141",
      "r322",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r322",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r322",
      "r353",
      "r358",
      "r455",
      "r489",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r322",
      "r353",
      "r358",
      "r455",
      "r490",
      "r578",
      "r579",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r322",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r455",
      "r491",
      "r578",
      "r579",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r137",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Change in the fair value of development derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Cash receipts from SFJ"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value at end of period",
        "periodStartLabel": "Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively",
        "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r322",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r489",
      "r490",
      "r491",
      "r578",
      "r579",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r323",
      "r337",
      "r449",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r576",
      "r626",
      "r627",
      "r628",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Estimated Fair Value at"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Fair value of liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture, fixtures, and other"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r617",
      "r632",
      "r633"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "terseLabel": "Total (gain) loss on sale or disposal of property, plan and equipment, net"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedNetLabel": "(Gain) loss on sale or disposal of property, plant and equipment, net",
        "negatedTerseLabel": "(Gain) loss on sale or disposal of property, plant and equipment, net"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Areas, Revenues from External Customers [Abstract]",
        "terseLabel": "Revenue by geographic area"
       }
      }
     },
     "localname": "GeographicAreasRevenuesFromExternalCustomersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r58",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r175",
      "r290",
      "r520",
      "r577",
      "r594",
      "r630",
      "r631"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r214",
      "r432"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r30",
      "r150",
      "r155",
      "r166",
      "r252",
      "r255",
      "r261",
      "r264",
      "r525",
      "r575"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r214",
      "r432"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r291",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r409",
      "r415",
      "r422",
      "r428",
      "r433",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r216",
      "r231",
      "r232",
      "r251",
      "r407",
      "r429",
      "r434",
      "r531"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails",
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r196",
      "r405",
      "r406",
      "r415",
      "r416",
      "r421",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount",
        "terseLabel": "Loss on revaluation of liability related to the sale of future royalties"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credits",
        "terseLabel": "Income tax research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r518",
      "r616"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "auth_ref": [
      "r90",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.",
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Obligation"
       }
      }
     },
     "localname": "IndemnificationGuaranteeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r149",
      "r157",
      "r200",
      "r249",
      "r470"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r207",
      "r210",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r74",
      "r563"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r182",
      "r562",
      "r594"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r74",
      "r565"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r74",
      "r564"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r481",
      "r593"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: portion representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r213",
      "r278",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r315",
      "r317",
      "r319",
      "r320",
      "r444",
      "r447",
      "r448",
      "r461",
      "r574",
      "r642",
      "r693",
      "r694"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r153",
      "r162",
      "r594",
      "r619",
      "r629",
      "r687"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r171",
      "r213",
      "r278",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r315",
      "r317",
      "r319",
      "r320",
      "r444",
      "r447",
      "r448",
      "r461",
      "r594",
      "r642",
      "r693",
      "r694"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "negatedTerseLabel": "Change in fair value of development derivative liability",
        "terseLabel": "Change in fair value of development derivative liability"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r91",
      "r92",
      "r303",
      "r304",
      "r305",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r303",
      "r304",
      "r305",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r303",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation matters, liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r91",
      "r92",
      "r303",
      "r304",
      "r305",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Contract termination and other restructuring costs"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputInceptionDiscountRateMember": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate at inception of contract to determine present value of future cash flows.",
        "label": "Measurement Input, Inception Discount Rate [Member]",
        "terseLabel": "Measurement Input, Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputInceptionDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r45",
      "r46",
      "r49"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r49",
      "r156",
      "r165",
      "r169",
      "r191",
      "r194",
      "r199",
      "r213",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r236",
      "r252",
      "r255",
      "r261",
      "r264",
      "r278",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r315",
      "r317",
      "r319",
      "r320",
      "r453",
      "r461",
      "r575",
      "r642"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r252",
      "r255",
      "r261",
      "r264",
      "r575"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r475",
      "r593"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Book value in excess of fair value"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion",
        "verboseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r473",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r480",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r479",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r54",
      "r61",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r183",
      "r594"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r186",
      "r187",
      "r189"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r98",
      "r192",
      "r195",
      "r201",
      "r463",
      "r468",
      "r469",
      "r522",
      "r528",
      "r612",
      "r613"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r293",
      "r615"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments during the period"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r41",
      "r68",
      "r204"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r594"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2022 or 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r206",
      "r569"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Financing Activities",
        "terseLabel": "Cash receipts from development derivative liability"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r43",
      "r115"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r68",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r39",
      "r68",
      "r204"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Sales of property, plant and equipment",
        "verboseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r169",
      "r191",
      "r194",
      "r208",
      "r213",
      "r223",
      "r231",
      "r232",
      "r252",
      "r255",
      "r261",
      "r264",
      "r278",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r315",
      "r317",
      "r319",
      "r320",
      "r442",
      "r445",
      "r446",
      "r453",
      "r461",
      "r525",
      "r575",
      "r591",
      "r592",
      "r614",
      "r642"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r81",
      "r163",
      "r526",
      "r594"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentTables",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Repayment of senior notes"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r119",
      "r167",
      "r701"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percent of positions eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r48",
      "r296",
      "r298",
      "r635"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Expense recognized during the period"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs and Asset Impairment Charges",
        "totalLabel": "Restructuring, impairment and other costs of terminated program"
       }
      }
     },
     "localname": "RestructuringCostsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring, Impairment and Other Costs of Terminated Program"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r293",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Liability balance as of December 31, 2022",
        "periodStartLabel": "Liability balance as of March 31, 2022"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r105",
      "r161",
      "r536",
      "r538",
      "r594"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r168",
      "r220",
      "r221",
      "r222",
      "r224",
      "r230",
      "r232",
      "r279",
      "r399",
      "r400",
      "r401",
      "r426",
      "r427",
      "r451",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r247",
      "r248",
      "r254",
      "r259",
      "r260",
      "r266",
      "r267",
      "r270",
      "r349",
      "r350",
      "r519"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r351",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r478",
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets recognized in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r270",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of License, Collaboration and Other Revenue"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Provision Related to Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r113",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income Before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r83",
      "r84",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Restructuring, Impairment and Other Costs of Terminated Program"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r34",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r361",
      "r363",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r108",
      "r109",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity Under Equity Incentive Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r178",
      "r179",
      "r180",
      "r243",
      "r324",
      "r325",
      "r326",
      "r328",
      "r332",
      "r337",
      "r339",
      "r580",
      "r608",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.",
        "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r252",
      "r253",
      "r258",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance and benefit expense"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service period for stock-based compensation award granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited and canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited and canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Units Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Average volatility factor"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of common stock shares available for stock options grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Life (in Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited and canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited and canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r368",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock options term under equity incentive plans"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Weighted-average expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r98",
      "r168",
      "r197",
      "r198",
      "r199",
      "r220",
      "r221",
      "r222",
      "r224",
      "r230",
      "r232",
      "r242",
      "r279",
      "r340",
      "r399",
      "r400",
      "r401",
      "r426",
      "r427",
      "r451",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r484",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r242",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r98",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of stock to Bristol-Myers Squibb (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r98",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r98",
      "r105",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r105",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r67",
      "r594",
      "r619",
      "r629",
      "r687"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "negatedLabel": "Losses recorded in AOCI",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r212",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r340",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r276",
      "r277",
      "r323",
      "r337",
      "r449",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r626",
      "r627",
      "r628",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r292",
      "r293",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r572",
      "r584",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r404",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "auth_ref": [
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense",
        "terseLabel": "Unrecognized tax benefits, penalties recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Unrecognized tax benefits, interest recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapses in statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r476",
      "r593"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r234",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding used in computing diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r233",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding used in computing basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54681-109401",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3505-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r601": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r602": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r603": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r604": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r605": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r606": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r607": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907419&loc=d3e10037-110241",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e13051-110250",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0000906709-23-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-23-000004-xbrl.zip
M4$L#!!0    ( !*&7%9/[X6A&:(# .++(  1    ;FMT<BTR,#(R,3(S,2YH
M=&WL?5E7&\FVYOO]%=F<[MMUUK)PS(.KRKTP@P\^EG"!*%]X\8H1$C1P4A)&
M_/K>D9*8C&VP$5+*\JJRI51D9D1\>XS8>\<?_^^BW<K.0]'+NYT_5_ J6LG^
MW^L__E>M]C]O=M]G&UTW:(=./ULO@ND'GWW.^\?91Q]ZIUDLNNWL8[<XS<]-
MK5;>L]X]&Q;YT7$_(XC0.S\6KYR@6'OF:C(P7&-,A)HA2-4P=H0YBJ(+],71
M*VZT%4% ,Z,9-'.VIG"0-1*\1$$J21EYX5]Q9:-U41G"$#-4&$.I=)1C'(7G
MQ*?7'O=A=##"3N_5A2U:^9\KQ_W^V:N7+S]__KR:KJQVBZ.7!"'Z,N_T^J;C
MPLJX?7[1O[]UWFGEG9"FYV6_,)U>[!9MTX?I@^<05$.DALGD(:X[Z/2+X=6#
MRH?T@EL]ZIZ_'/^8;IO<<.N-GVGY/JRU?GF11C)Y*KS_]!LC23];T[L:2:^X
M'DDT/5NVA(LW7YR&6X..W7KLI*/?&C'F-4"0XLES+K[HW*UAI%^O7_FU06!Z
MXYV3YH->[<B8LR^',O[AUG#2PWQ^>]['$R1>CGZ\>FZ_^.IDZI?PZU5_>UU&
ML/P6#8U:3&[HG-YY="><]DVQZKKMLK.87,^;#_G]5 (_W!Y9+[]O>N']^.7_
MU-_ON>/0-K5;U/RJ93I'?ZZ$3FU_;P68(AC_^H]VZ)LL/:<6_C/(S_]<6>]V
M^L#JM>;P#&YSHV]_KO3#1?]E27TO7__7?_W7'_V\WPJOT]!JDS'\\7)T\8^7
MHT?;KA^^_L/GYUFO/VR%/U=\WCMKF>&K3K<3H /YQ:O4,!2CC[GWH5-^A-\;
M(&^*W(W>?]'?#?'/E9Q&YXE36&A-F198<2.<1U%(&:G7ZM-&Z@K""->NY[5C
MVNG5(7^U!B+,)S&VU3)'*]F(?.&Q%_U7,;\(OA9-*[%+[N&BIW\/[4;W_#W9
M/3^@]8$_V3P_?*M/=D[VV4'[,#\@!^R@N8WJ&[O']<O#XX-F_;)!X/_FYL7A
MR>%IH_GN]#UMM XNNWCG[;OV0;O1WGF[.6QLK"%H2PX^;E[6+_U)_7+_HO[Q
M@!QN[ \/MQ1Z3PZ'!Q^=J&_4\4'347C7Z4[S #4V?-XX.2+P3GQ MH>'S:UV
M_7(W;[S=//=OMW+[=E\<G/P-[]VFY;/>;GYN;&R2P_;6:>/CNY/&QBD[;+]K
M'VZ<?FY<KHWO^1O>Q3N'S;.\\?$O7#_Q9;\/FFNHWCQL'\"U@W8=[32/VZ-^
MK-'ZEAJ^;V[VZWOHXGVSSG<VZN030C;*:&E-11MK+"A>LU;RFG A1H8#<\ZL
MO"ZG]X^7MP">)MX3K;65]YQI'013;,&5WA+@[P%\^07 7B%EHE8U!:JWQ@QR
M-<,,*&_LO-:.663=RNL$PLSP_0#/[_HEP@]"&'V)L#4ZDFAJA!M>8X!!S6H2
M:Y@'*CD'FTJ*E==;!\^([V8'],EP'1 N3&N[X\/%O\-PB>WWL,5?8,MX#-$&
M5'/*BQJ3WM8,C0ILU*"%D0)L9K+R&L$?C81$^C$8PZV*!WBN4)%Q2U3$$A'E
M"(+'4D2_@?'88'OUH>B>A:(__ #V27^MXS?!$#E+C+W?"W'0>I_'&2MEMK.N
MVZZ]U=EI;[4;EZ<7]?;^!2""#D]VCW>:/J]_W+P *AB6Z+6W6O#;Q7NZVPK_
MVAT>?O1GEC!Q\/& [C0W@3(V\>'&;ALH@S?(]L5!$_X]>9?0@_?OPV];L=ZL
M?X;OGZ24S@81:YP&$+;!VIJF.M8LL5%S[#V@M_+Z WT45SH=.)**V^ %\]X8
MI[US+ 2JHO+(EHCA"6+X)F+)W'OUOMLY:H:BO=TY#[U^PJEN^H,"6'4D@F>+
M%:_O3;#:A^=MHD;S.*_#O!\T=^'?-_GAQM_MPY,Z:EQNTL/F&ES?_'P7J\-F
MG1XT_X+W;E_4F^^.&^G?M^^ 4P^!J_^B]:9OU3?>'</S8J.Y?_G)&6 OB4U-
M$YVT(J8UK5SZBR/"@:N4!>GY 3\**!DY%B8@AA1C7C+#";4@/#45"B-)OL%:
M(Z ">'^;%V"_)Z\^039;:"[J&P?GAYUWQX>7W6$#KA\ .^V\!0&V44=ULML"
M 7E\<'+*#RZ!C>!Z@QRVZNL:'7Q\UP,A> S/'=8OWYP>OH4^-H]0_?+XY*#]
M]W'C9/_S =EMUT_6+NHG($SWQO?\S[MCV_8M8%L8P_9E_>WN*0C9XYV-ORYW
MWC;RPX^;I-%\<W+X]F!8WX!GM^OX?RY/Q\(3A.CE*:M?'H P_IOY?[UK'9+6
MN3TY R&]!??L?]Y)\P.D5#_9S=,8#IL@%DYV6SL;(,@_'GRNM]3%SE^?B$5!
M #@UHA"J,6=(S5+*:CH(;+5DR&D*Q,$?11Q,.148X51Z!>8UF-Q6<VNYXU9X
MB=R2.*9%',-O$T?C(U@&EP?P?N@G^0N(X_1R9^, QN$(7,>-RV0A_'W2P(I^
M(LJ#DC2F)H0F-2:"KFD/PH,XYT"3:LPUNY\T7MYVF8L00Q' T^_=X^FGU997
MO7)% (@G*U=?7O7!O_]SI9>WSUII>:"\=EPDVKKEU*]>]#P\XN7M9XS>?_W2
M<1]ZW4%1?BM7V5Z-"79$5S]B#$X>%$I+</(M]^E[S$.1E1T*]ZY6K6__^[9-
M<_?FUY-+MY]^5BJQR;=>WQ3]#=,/I7-3@\XA/+GO^K>K;OKKIIC4*+Y^Q>B7
MR??)2U[>FJA[YPT+RS0H (,ES!L.1F.K-%)($$8B=Y^VRWD3%,W!=(W6F_KC
MR1(UBJX>-/[E83,PZ.2CX0]*ZAM=;(/(&A3A]7AY[=7^WL;D]LE/D^_I_GMG
M$UEBL-.&,5+^I[0*P0$;*2Z%U:&<39KH;[YFDZ8%98)_<C9[QP:8](L)'9-S
M^>.C9Y0*,""YHB1PR@)61F JC5<^R(@98V.^YG3$U^G#M*=V/)YPE(S3T5</
M+[LX:^4N[]=#V\(K?-X>Z;YK1Z0^&G.Z:[MS-NBG)="UBQPFK%29=W^NF^(T
M]#^ $(#'G@$<>P,+^A0^O.D61?=SWCG:!:8?O>^/E_=VXVI^KWK[ T*)WY T
MWQ9*MYH^3BA=$5%GD#K^%2(Z@X^/)B$%6#*PG*7!GH&,,Y(J"6:S 6/:!8E&
M)(0)?3[5\(N1T"UE]3QZ35C#>9#*,!D9TDH3 Z:/ Q+ 0?) 1WIM3LR 6WKM
MU@P\3A+?FH$8@S6,.@%F'_-66B40)5)X)54@AI<S@.=O!O#/S,!-S?XA%'M)
MZ5P-S^?GT*V;34M[U_2[Q5UQ\T CX(O[T\6-T.FV\\Y]CWVH*KSUB)>W>_\]
M<6>-)H0Y[*CUC$=0E11\-S#R2(0_&,_ $GZLN.L5_;1LYP>NOU/LA>(\=V,Q
M=V-1+_TZ?>7W_!9YI%H33@*.1+'(C/'>R.!H!,XE0<G[%M"6^-V+'WXX?OC)
M\%.6,QFD9BY$\*ND14P(98+'"#G!=8D?FN"'EOA]'3_T</S0D^''0Y"8640#
MQ4PA9B67G%E&C",>L[ 0\G.W.S2M_G 1Y2>H.T0L&'Z(<4:YU\(I;)#& H48
MB5\(^?D\^,U$?L:HF7'*&Q? C&%I#]'Q0##WTA(V7GJNNOQ\'OQF(C_!LR91
M)EZSE!GFE8Z"TZ"T"%$:RBHM/TLWN]'MK)O>\1C#W7 >.H.P&UHI=K79W3.M
ML!.W!GTPZD=-\M!;1$$K7<!.DD $)<Q[JH*P3J*(/&.2<5II03NG0,]$(E..
MJ-#46RL)DPK<$AP$#PJ<2>I$])66R',*]$Q$=PQ,**\4)SXPPX4!J(,+TN*T
M111M]47W>_C:Z87U;JME;+<HX\O7.GZG?QR*,>R+**H- 5TL0%;'X!D(:X,5
MHLXY8-KH6<35%]6S!W8VHEDJZ2-23GC)7-0J04LT$SI$;%&U%QOF!-B9B&+,
MO 9&9,X$R0C'-CBKM!;$<>6<9#/@V$HP!+'2VJ@X\HBSR+!UD2-C/7;..&OB
M#!BB$O2&G/8Z>AI<-,QII(111.KH%*A^BG':+<)Z'N7'Q*7>Z\/0TSTIP+<_
M7.^VS[H=^-J[[7G#]7:WL]?ONM.GEQO7VUA8/]E&G@?Q'GG0.C+')-%6<@=8
M*4T\]5[SA8%FS?L\B7?3^F!ROPTF^5G>-ZV*P&0<DMH[ WXP9S00[4)((LA:
M,*F=6B"8G!NT!Z5O5&KAU*X(Q^EIYV&[X[KM*6CDJ4"6A!NQP6OD".,*&P?6
MD[$L1!1!9=B%@6PW]$W>"7[3%)V\<S0%YW4J^*A(0/812Y  +X51$QE80R)B
M3:VE@CP?/K.: :UD2,LL4:FTI\^MBIA[Y2UG@GM1A:67>=+/L[>S' /KBF-/
M $5&*=%<L<B-H<RCR)U9/$"?3:O/'MRT!.Y<$"F5BMF8/'%' J&(:RI<5 L(
M[BQL@=D#K;4"X:NL1H0Q1.$K!9/<.>)UP%0MH%B>O@4Q>U2QYLA@9"*5A&$I
M0$ ;X1T..B@&MGP9,;D(8#Z3#WP7FI^P@RQBAH<@,&A/%I R"@O#G*!@M >'
M]<) ,P,?^ EADL'&8!VBGBBFP/6EG$I*.9<\,BG#XL T6Q_X"2'3PJA !2>&
MIGW[8&3@1DB=%@.IMFIA('M.'_@)\6%,10'*B'MJ6)1$80PV!^6:(# WP=1X
M-GQF-0,.5#)1@E$?)7,,]+-V\-$I3"TW;!9;(576S[/?HZ$**-E[PX7&#/-H
MA([4FN"C0(;*L'B SL8'G@FXDAJO##B[D3)&1+ T@HD6HB:21J+OK?]1<7!G
M[@//!&@OF:)<@=' /:,T6N64T\@IX@5 CA8/Z&?V@6>":HH; 3R5H!$QI[P5
M"DP.$HRRB'N'GB]KL,HZ]JG2&6]+5@;2U =EN,',RV@LQ]9ZK[5D@42S,-#,
MP@=^.IB\),((3I'EC#D,#A6F@4?/D0=;)RP03#/V@9\.,@9V*,(4^<@MHP2\
M*NNL1)0&QADA?F$@>U8?^.GPT92;@+P)+(+#X)2UTCC!,*)!Q*L*#G,=ESQ/
MVFGV\<A.@+O'J6266 "4*0 6%%N*3PY"V;AX@,[& YQ- J:QE,L8!/S%O%&*
M:V* 634"KX JO8#@SMP#G$U6@7#4$R^]$YX9095'AONH@Q528&46#^AG]@!G
M@BH*WBOJE'"!,62]EN .:J*T!3:.UCU?Y9PJZ]BIE/0A43MMJ"#2<P:JTM!4
MMH]C*A682$$N##2S\ "?#B8<L'*<*$>%8MHA(SQA$@7A(DE9"8L#TXP]P"?D
M++!// F2,B:8(PRL%AP=U\!65(!/N#"0/:L'^'3X2*IYX-YI$@ B+JR6@0B+
M04-AZ=6D* L;FQJ(3;]>Z8\"M1MZ_6+@4DWSSM%ZMY=JTL.U4)S?J1&QV3YK
M=8<A[(7S4*1C=J9O;; '6QO0]+KZZL_L!::,(\2]1*E.GP5708*,%)Q:+PQW
M<ZS24M[B>CI<*Q1G,%/#AFG?S%M\4^2]?K=5'X:BMP<L:>WM%,:C(I3L6A$&
M_)&#&.8,L.\>"/%F>+>>IND,HAFSZOL1=MUB.$D_O;KQ.Q@^B)1V3>=H_.[T
MM9YW\O:@O8@.AH_>6N*(%"K5I]26.@N^AK8(8RZ=7)+2$Y.2N5A44I*8.2:B
MP$ ES$5G?-"A#"<1@D>W<%)ITOC-((>G=HX6!-.KJJU%..L6?1C8IW3IBR+0
M)2?=;C-YXL.K01/++#%@32+-!&'6:##]N6&<V)2D40&2^4[%A%3)!@CH5DV;
M!2U!)1#!CDDE@_<,G#>#F56$ GP"2R(7H*[);,"<3>%4!7*;"QJP9$P%K]/.
M>90R'401 =,*)-7,)9BSR7,4PC/PV#D"_+161J6B^]&YZ"45J I5C"?*-JG?
MG;A6%,FL2O?>]/+J>\_EULV>02T)PFE'62"2@;4._*D8<&;P8'HY?E69$[/:
MY,.\8?J].G#_;NYBA7_6"'_P4D_Y4NC/46':Z9"L5/(=GO < @&SAPF$6TU_
MQNO#)%4V9\3(R"0F*7+-,6Q9C)(X2I;$\T3$L^;/TV+A!S-L=_K-[GHW'7#J
M^N" #D<.:"B>1>,\-X&%$$10J5*$]<Q;:H"H%/*1@N()@O E@3T1@8'YXA*%
M);77"FD7-2_/Z5Q(JHJ,(!8HCN5I#(JHZ*VG7GKN<=!CJIIO=_%JMPZ>X//6
MH)^?A[W@TIFJ8'QN7KC6P >_573;:=-HT"]!WHF3':+),2IOAO<_X :ME'OI
M.V?I_M[NWGX/".H#_+.(GJ<$FY8I3Q#H-28(-I$@:@5)XB8XS"MDWRXJ7<RF
M_J BTFHM4M$O9K%4+A66 E=68,&QJ((3N^AT,1M_^ >.Q9XSNIC9+M5L5J-P
M""PHA7E@X/ &$Z62R$E@9H8-K4)ZV\SV@F9S;@AF& >,HHZ2\512*Q E913<
MRAAD!>(6MTQ>_&U: Q"=5Q__!4\TA3L>O@_GH75[%^BJ47G88Z]L09[*.]@"
M:[_C<M/:[B0WX7K=ZSI\LCA+JUYA(]C^M7BO2#P#2%W,G$WQ7I8) S3BM,2(
M.4K3:5UR_E-^EM3R/6IYPM1+\/4<,L9J0YDD1$N$,68&4VNHQ6PI6YZ:6MKM
M4*06'PS 5!&9 N:!Q<2+X(E,LL4Z9DS@' GB CB&2YE272IY.EE"F/,64Q<\
MD^ A!FUB.K/!4BFU-MQ70)9\#YC]O;?=\U!TRE^. K0-O4?)_;DBV'D1+Y99
M&C X)!$A)JBP)$@F Y9>4B.BJH!X61+.+"2.1PA4D:5&(\FB!KT4I#8Z,*<T
MN$RJ A+G"=!ZLGV3[U)QO=L)P[HI3D-_:]#Q57&).%%4&D6$)HXAF6J+8&V2
M9/'12<8J(%^69#)]:8*]MQIYYQVW+$ACP-A%&%$LA9=&DPI(D^\:EJ%([W#@
MKO9VXD8XZ_8FS_L5-,_3B93@;3!@KD@J' LC@J%>14$]3=71*R!2EK3R7&LL
M1FAD0Z#1VW3 **@>N"1M]' M\#G.!'M\-L@D?A\:O0^F%XZ[+;_=/BO ^)U2
M),5T/!)%E=!: G]SAAU-A7E(#(A(%*R+%5A$K0AD3\=ER#*E(DVI#HR%2(R4
MV(LDGZE),7F+Q&77:58/3:^:%\8*#"MK O.<>$:#4LQ[HHQD5E/BA5LDQGIN
ME)ZP+)DRC$DM@L*)E[S2G!"%@^=1$4X62F.-0CU"L34H.GD*(IUD+E:%HR@1
MS'EO" G,.:LMT]R+,OL\G5"P2!PU&ZR><+W*2&&<U"A0RH33)HE"Y+#'Z6Q7
MI!>)KYXH+WA>V(P0;4!KI1-+021JKKQS)*1"?YHI3NPBL=E<0/=T7!<,MU$'
M(\':8 0;8[EWD7##)/+8VP7ANBM7^89PW,HOTJ>JN%U*,TJ]4CP54 ";72.L
M/1.<B("C516HT3W?2#UA86&)D*<6 U: %/+*I1P")V*P&I@KS#]/E;[N)(=H
M8%HI#^2F#,Q[J?T;,RP;SB\#7948Z/TG?EE88 !#23],;GYP-0'PHKV, ' 4
MP('@ 2AE&9%*JH <H14H]?8=@)O'>>'W^D4(_3E'^/9B8N18F( 8 F7F)3.<
M4!N%U%0HC"2I4-K.K#EPMA5!P(UIWU\')/WR:'YERJG "*?2*W #@^)6<VNY
MXU9XB=SBT,7T&7?V25B,*"YEB(HIPAB3EA#!@\8VG<-K<)7*_]S8Z5GK]4)_
MO65ZMU)E!K:58/RJY;2(^(9HI6 \A& B(Q:DM^+846NL),:.#\O&\!^I33[,
M&[[?J1*XM_7NP[$IVL:%03]WIO4,27$)GX?@>*?ISQ2.<%'2&$(TC# 5M77@
MLCCA \>8!4'FWV%YBHU8.H5=X?>YL7DKU7N]EA>39AL T+E)R7?W;&+W)G=6
M)PB?:.&)15H[(1ES0AMM-4,A57IC5,7Y/ZET246S/T^5.(\=EH@Z89CV6!&B
MK>$("R*C5U6J/KDDIXK9,U%:C($,0)()QJ(U6 6*TV&HB&(M= 5R2I>T5]'T
M6&:EHPQCYY1@5D5#D)<B6&R$PR)48"ER27*S7U<+0L9 )5?,1X89$!4---7<
MM6"6,3\^)P'1)14M(A4A^D2!,R)P! +(*289MA'4(9:&&8JX]I*5Q7-P>F,J
MU37Z,*_D]*WBD!\&0%.FE_:M]DPK7-6&3&.:KHH!=@??G3RD5M;=IC]U<E3
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M56=)N7- N>R!\?!ETR<I'!0%H8HA&6W@+,JHG'.,",XU%D1H5F;CSR7!7NU
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MME;Y.P.ZN5C?3,433LD?M,=^2$9B8YWR0*J:!WRS<5I50/<GWPPR <W7L#*
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MNP9=M<R05.2%51R5V$456%P.(>U]91UU%>!IGP90L]WKJ^]U<!MHL[T;0PR
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MD\][TB'8U.-9\K-+<PSW\;UD/-KE'I!C704XNW^FN0,L0SL?C>N6KBH4U7S
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M%?%9=:ME ^S)\+ P7S636;@CYPI]!YU\V$@;@>*@ESP[E6?2#Y/C]JW@1'&
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MH+TI;?S4@<)U^&D-S-'!I$%**L")20X?B4V.#PKH3.\!C6K_HV9&'0V%S)D
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M]O<']Q\>,LW^<G X.#S<%S$",S/@PH6,07>NN,B<5O@D&BPN@??-;9.R6P/
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MQY:RYJ(=KNF!PRR=@"N#%\\81U/Q"#4^+ #-$D7RHR3;..FA.#I%08%D!5
MR,D#Y!)ETJE<U>/AWB575O!I\RBV9M& 5OI(XHQ26RD9>INWV(I+U%FAG85]
M;C!&NVG 0I!@GC234W)WGI8,9&ZN\L'>_GY_Q,*Z-SVLN8PEU(*6".J.Y).%
M2!2&S[<#IZ>G&'.^;$'CT5/]@?:X 4&259A@C+\/_@L")9F2$".VP6A&S+VU
MWOA6U$XF)ZATI=]9L]6<9U"&H1TV"_5@[W!/J*(%YD7R/OT@Z"%O2>RY:42?
M X^I:(#IO<NOM<S<&UP=H$+U5-PDB@JR .9> 0V*J00UD1FYHC*S@M'+\5_]
MA--90IS$0O\J,96.M'S?QN@-(/!19+T-7]C*]Z]5,-L1]5_R2)W4R.RG+;0'
MC$VM/+F5C(WC,=<93:9$FE;,$6.M[-:2%"NV6WL&EYA+6&$D<4;DL-=#]'=)
ML("3CXMI;I5PNH^!B0\.N [D^.W1()Q.X]@HKN8#JI(.:8=0!3^:86XGCF?0
MM&<OM.\BAX5WB)0\;))%.4; 94R60O#P@Q74MC+H87\YX,&S=%0DV\PQVH,'
M/UKW!O17:XI*J-\,3F>$(B &1J]),5  ?Y_6:I\\;S?USH31]6O2/5W4+;S3
M&>W3+HI1>^%4P+)$'C]/BGY(7UHQ5M14Z <7M;M/.E-]_/+B%?C!+U:18Z(H
MF:;UTN;\9L8_(JXFY,&MM.R#W7,&3N2?7T3S+20-ZAL6-T!!2I6.3%Z)IO6$
M@  S9FNF*%["?7!SUG]^1II_O_!.?G/ \!X9&(U8T;39E:$]NO9<X7C$LLW
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M%%[GV)5591"&[,WGC'>7S><-*3:!-:*_1FG.]I.ZF:-RLDHF@NF2-LM2+U>
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M"=RX'VS O#63#:5QU42*?>.%=B8AS=+_T&56BZRC=S&Y4<&%6H.SHT'2=9<
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M.ZM[X:JM$N]-?TS4YJ[U/A:TY!L-DU<>QI[I$VZX835=TSWU#V!LVZPJ^@"
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M4.OP#E->\;FKE]KGML"L8NYY':W0AL#JZ&#_N:DIWXYPI.VI_II'1W9-U+U
M5P'=PQY Q%&O)$Y))/5,*5,Y]*RNI$N5IS+#EZ ]K8&K-*ZR$19&@OO"#/!Y
M*@JOT-=@Y35QI#,8IN=?96-WY[&5P"N8:/!^Z9M92N(?;;!? *6*7@UTF7 C
MX(H;];EW0ZDV1"BG-HB"0;(*#\'MHL5GL.C&AHR%YAIMG%RZ#N.F/(L./@0B
M@?+*@$AJ<;#B=*T,>4'=T8P\J/&RPZ^OB#HE@\:@75APJ#A@TQ[7C0;C=)%-
M0'1L; <-8L@'W;B%>*DZ=>LH-.+A7$I/'I^GZY2W]?.![>YET7J% <"<-#)*
M))WHO,;*<ST2:Y)18KR%VR+H-DSDXAU]"^TOGB1>U>)05UGZ#[=ZWJ3*ZQE]
M1)P46F3+0B&4N*F,TY]M:+6X&;SJSO)-[BU\B(>^)=&H;C@)*AYV>/C@\8[,
MX-;1AYH[.C;>ZCR-\2\VM1VWN"^YR/*<834"EH9B%[G))_KJ-P\TP7OUAJ$!
M&#?-]H4.[J:M\Y2*]K '(N_R?6QM$=">3B4J-TCF9;U4T:T0:=@4NG?KCMUM
MC$<3+S'E&T$J 1<$J)83]$.(J?;882[>51P;!.JK"&_B\E6C)UT ?XA?2.8K
M'I]BT0B^D\+. ;-O/"ZY40Z71BA:[,W-70J'D31=A*K50U)A03R%22_Q]A@,
MS6_-4G"Q(CRQ"/LP_D4/)!60U 0,80!HKY?TS)6T?')'U,AR$SH5DRV&-5(!
M$B,G>URGI").:M):]9VJN<N6+W=&6R7<\B5TJ#&;X@MQNR3T9BDP/G47NW%]
M#QFK,K3T(UO+;8WZ(+ZCJBUE<-H7QBV[V(A;)J!0"1&OT?PPD9*98X/2$AB/
M7JWU*ZR2'G)[X!+)INNV*!(1&:RGK& 917&!W?[+P8.]X9X-+&1%KX!J/<"&
M$1O0#V";%4Z!-=*D*E=I3GXO&PQR<^PJ;*[EA1-#A%Y@S) 9C!+2+%1UGS#.
MVF'K>9@Z(ON7C1I/#;XCKF)K0%J#3R5.8@B1=9H[@8:+\E\'AT*$HB@;1F_A
MPX.[_3_VWKRYC2O+$O\JB)K^]4@12;9$>9'',;\(6EY*7;:EEE3MB/EG(@$D
MR+2 3%1F@A3JT\^[YR[OOEQ 4K8D4L69CFZ+ ')YRWUW.?<<OO?)[.?==M?.
M7G>[Y7Y\183_>?WS#YB=W4(<70QO6%GLP(& #\<67>5_MD*$N0^.T7);ES*(
MN+/\L"YX"1'W7<4G%//:C-P_?#@V3OQ8Q[,78SM$:)NFC*^LU=^+>DO]N?\L
MA'V%_LCKCEF B%!U*7N5V%T:6DD;*MH5],6+(NRI:]6\;I%D]*DM<]H@5#4)
MKC\.(=YO'$#E#;$:JJ4A%QJ.JCBG;1B$-9@"5_E%V(&TM8(%(M..F,61W?(5
MF'VR>)>3;2.XTP5J3#([V[P-@2&QU1@/;'56(V[MF3PE10G#1O"4DT??!MM0
M'04[4*SQA\??\E?EQ LGRX%OIE<GLT;FEFLR*,+0FI:#4BI:>N[63%1&7X9Y
M]-]$$802;QJ'CQW7CE>31J;$57(BA1&VH>2(I.^$\5D4\YHBE;:+C(_9++[8
M8+PZPNV ?/$:SX$D=)C"#LN-YCP<VBV2>%$??$G$ +!$1',U?><>^]]%WI!;
MR@R:N<LGT&W"NC@[XX"+H6(6ZLZ*<%\*G-OHL-"A?OB^^27];Q0'P[7VDJBP
M&2'_AV.U \]/SY62Q.6ZD'2>YV7>ZE+B16//"'M?@N.(X'SM?K/MZ@U2%LRT
MMY')#0%B00:1*?;XVWC\2ES'^-RY, :5DH-U[Y'0@1X8G)&7LNV1K.WAJS$C
M1-ZV1%5DY%T797&IJWQ[OF^%R)BVMIH#R7%,SY-QLMGH88@L=VWO::R$8$P-
MMDBB9$>X(#?#3\)/B?!]RT>#&JK]["Q<M>)<@W$-,C=$8@+S9)FQA5 [."_4
M%')3O88'/8.BUV/VPFH_=1J15\)#<!G5WO,#RYS7-IVVI:!*/,VD2T?(K=5V
M@,66'UJ^?ZW3ZW:'TM^S)^V#5!X9X\K<&#'G!27 PD0@IZ@>7/BW)X#$:3]Z
MN7F!,\D[0CMDG?@0@[_?#MP(N]Y8,($G<'X(4J&1HQR$71RV#3FU_^C4W8WH
M^[=B,,)\9B@CH892H!O%U(QY#E-$]<_ZDQSW^!G"1Z&-+BK:78 O6] 8RX)F
MNLAV%I:S!"%@NS@/CB2Y/2%<#"=>.+3=;5TL=\!"+)2T5%U1?!^G:M&)WR[Q
MF24!_M=[K8^O^^BLHT\X]SB"OOK0((@#CY".S9.38R!$XH*KYTI?Z3>W9ZFV
MK0N88VI3]M_>3]$'GZ*P,1;G";6I'(J1)W@X=PC:P92>3IB$%7=CWFYXCM[2
MF21+US>'#R9SD _UE"#J6/"'BI2K@.8L\08/ $>X.UJ^O591Y'YB_\PM&B<"
M&+\7__W\^Z/'WX09"4.Y"1'@@[80R1.M;4H!C"O'P8NG6O[L\6DXJ#MR?R6>
MN5W(N1>^5&*G>;X$X_$:K*V%^I00W\&_X;8(Y6^Q+3$@29X?0U(@M3@8N4^)
MS9/8\>&TC_HOB?=Y/(WWN370G4]NW>ZBNU%N=#4B/Q^]!G"V.[D+JZ?(KG;^
M1B8Y  I ZL5BA^9+Y,,(,1#W/%-FT@=14B.19>(402R:@)T3?R.*R_9N."]W
M<16TNY;XW*601V(XTM_36Q3L2B)[D"61;>;7"<%U@LF:\DXE92A'R S5/W=J
MY)(WKC3;URK2"DOA?A%\C,ACT>Q*9"/:\'\1:EBB@)([),&U*+<&-+J?F8\T
M,^<Y,NHV&88QBU.B16&UIE0![W8-%\B#L>^.8EZ:<99'N^W]W'VHN8NVLP2>
MI:FW6^959GR<5OVLCA+BO(Y+)1!20?8._Z(RT_T9^!$VV;!?-7Q6 M$#X3Q+
MHT:]P)X+8PIV]]/UP?85P,EMOSSA_(QMO:9Y@A=YMBN7W*\]$-GJI6B^I0F_
MG[6/E3HQ*#+PVM VHNV$\FHSJ\*3Q-.JWEY?J.P6X588HGH0+"<%%!2C!4PR
MJ.&-:YL"T9G45N*E\GE]48P X:Q:K+*G<H?+7JTF4QE 0\!+VF:H=JGZ//U+
M:'48?T8NC(N*O6JA+Q%JX\( =LJ7XA24B6"+Q((&$X*ZN!; _ !6[UD_=\ZK
M-KY%&ZQ,1]W?U=X]/*$GRGI)(0Z.#GYB4=AF5B$\N/19]]07*7S.R1\3D"!C
M]VO60)XWHE7%EX$J,K")TAT!X>ATC B$7_*:<4,=L8_K?6_<QU:7/MA RO7
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MMD=4MV+Q>)3#-9APZ6PB0V# $9?Z$^3R>AU^M6,BE.":=Y9&50BL+L/[R?Z
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M%KYDXEXCRF/Q<\"/^I]<A3YQ):748@$3QX9LN4.3RT#P95I1U(@5QFI%\87
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MM!#LI8740U"U(R9P05[ADA1_Y@41*97=6@D7V+&PY+QL[8QG@OV%@L"1 *@
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MT\"BJQ?U.FY 31>%*)-!GU=:%R[R4J$O+&$J''-3<%/_SKOI@GO_K<2\HVM
M"K;= <UZEG.1?>I$X 0:NDQ1=7!5:)%1,S.B*"O+?'N@(-5XSH/KM6;J(/NJ
MU/G&QG@XK%.AEU@_\*R[<>6B?L&]M3Z\22AY>IE:3\K',*OD,!P<M#%><<0'
M9M<G.)='(&17W8D)!$'0,CUF<@*7S/F@D1H#E9U&7L+),)J2'.><Y>0)[M%G
M8OFDZIZ?WAU[$9F?E!$D4AEO.:^0GQG[&(?ZG!/S[)+JN@[2HC@1(RQ%H=!W
MS7=ZX;/F"%Z+,]O+K2!!I&T^R;#S!@"AMQK+J)[@'<VX=@V\"%MK#:BC+M(+
M6 ]Y'.04.("6*"\^E$!4$9W&8KE2S[XM]DZ809!289_MBJ.B.J=E3Q%DWN7.
MYXNT+^/$IW)C3S+@5T]<*=>@7#K N"2HCA&"I=&G\H_CYDO7I<&#0=M:=NE8
M2;L,YDF!"$=:]N8^%AT\?-68"ND7EW7S%HCC;#PQX0>D",:YWA?01R24 .I<
MFVU>-OT,75,(&^!2T1.S,,4H["?(JM)U>'"SI35411&AB#_U<% !.$F+IL+H
M!B2UGMJ65XA @*4-P)''[X1#/^RS\(<VC!9M-3Z7)#4OVR'E&?'P*+$\15@C
M]8;2Q7*)I"6(WB^V!;D;#E!<#J#-#[\L*1-"[2"\'/L\YY29JR(Q+^ILG\%Y
M\%W!E6'R#XJ.-Q^T!,)WPI:)5=B(X8Z8G+)ECNPVKJ4^#1)3B\MZQ4SCK+%+
M@$TX;;]+-P>GQ2$7<]<.$<*@D0;&R"! 3K&+"7(JHG(.;D0K>/; 59K,D2K
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MP3J^,GH;><PO3F'8UCFSN87E$V:5/UL21QI"#&D?7RJL8!6F(3P)MB8JYPI
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M_-\>/WHTN\S;F4V,(]U)'N=K=:R3>1(3 Y-="8_MU$SAL[Q=YO^8O20(8+Z
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MN$;5UFPH)A<-I=H<[7MZ_M?AV=7)/S<[_AX[_C><OK<P?7]LIN_!%&8\#N+
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MW#"--?ANF7-3\!^#M+C?ZLZ)")$ S2PXQXQ!2,@TB[V(\G%];)5!DQAKK_+
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M$E20&/N&620,6S^*J]U6O=U]%-:H[D%W3;)RUJVSNXW%FIV1IM#YP32%Y7)
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M6$VV]FB>12KR(5@\FVT'!WL=83Q)D[UA/$Q87FC&[O.R&M%^W.JJ(N'74:]
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M]),ZQK5-/4";6A-)%]BOC4T=&IMZ&5"H.U+X?VK?WG*#7VV_7;M=Z[3V'KB
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M(G(DZ1=L4-<VJ-*1D@!5OZ:G,_,%VI==+R/,=?VN$C@94WO1A*QG,FW?P3C
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MY>I%RH6W!9,-6GM.,VIK32,-5VM$:'VKM6V(P1E'&1D]F:90J.1('0C0 \&
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M!0(CAGB=J 0AKZPJU59<%J _7: S@9DT+#BG*%>::DZB%%$G0IB7*12G9<F
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MV-08G7W.3%"#;U.8X)&88-K/\9:R%# *@N4&4]J E4/@5Q>U\#@PJ?3**N?
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MLM<?P;L#C%IP,1VXLH\#VVU]MH-1JY]:H\,XC!G;52ITGL_>2IV>[?D./ E
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M,]_D^W6G*.40Y=&<DS>VT\LBV^GM7@AL)[V]<"7/B6[_,&:N&_XD)),ZWV)
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M\]JW5[^^7=WTAD_%KMY!U(DR=((B5)O6P7K>P'JNCQY/<TEC02E$E *[9D1
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M^NPX9>K@U@:>7B@<HK!['[/T71%0WW H77]YZQ<S^[0N\Y>]BT+X9-5[GRL
M<D\LW=@W.MT%WYJ W.,\XV^@FTK]9BS-LT\M_GU\\O83%Z&(A1*D* (,0FE&
M1)0KDD9"A 4589)'?71)JD((4D0J8IW2 K<DRIE6#*>02Q5EUTU%]IEC]BL3
M:83D^XBI0EL8>RC<8(?*!;O.FM;NIG&;^[$G2T>0AZ,771G&'!7-EPY&'S:<
MV\V@%X/LQT]XQCT^L^/&IM:S,+;#>YOVKOB MC9O?^Z.@VM?N &ZU-1\]BMU
M5QZ<^^8DJ;O!;1@ZZB H'<@99[/9,2H;WFC+#$?[!4.:!HM4NYE=VA#_R/61
MTGO()BWC2U_-0I@#V6]:,P+ET@N:HVY5>?ZOPOJ_8,<%$I5_->10:P_9MO$-
MM>'EK]F>Y>Y@&>;I,-SP72%RXE CKGVPM]E^)&!]AP4$+N8=&K*Z\W-\IE+Q
M3O+:H4;'-C9QSD#O,K6OH'GA=\[[DL8#;3UVBZK13]-I9CBJ;\H.U6N\C]['
MD5K)C-&KO1HY=Q56+V?KXGR9WVNOND[76R=7OJKIESY7[\&UL"?[996.5^4F
MR;<!AJ<1FON1AG/+!&$*UG4!LR50IMIM03TMI)DO'GN7Q'A^L*EE,3%">&'%
M;>YGDG;L@[UP/:;2"4#/:E1;"R)7Z/>:"LW7;CTQG8J8:VO4PJC!LIVW:SJ(
M4;HOMT]&9R!D6!5MN[XNBAO,, Z"74ZF]<295>6)+U$ +4OJ!L(.;Z,L6@QO
M/X"[;Z0F63" N_?C6>X1W'TE6+OO?DN1Y*J@.E8YA0 HSW@JXS2,9%&P1(AM
MX.XKW?;+CI('4@C75FL&9G^S""8S 6IU;D<TV<G8+;X,WP';F7[;.AOFM@*^
MB?RG3DJ:T!^-OK7#-C'V?=BSASQSWUMK7/F8/[DLY"_5*3>TI*U<W //L'W5
MYF$Z;,*19J[Y<QUC^S<B 7@4)F&4%80614YH#)$[#U1 ! ^3+ LDE31\&J"@
MCB",6I+P>-%!QLFP ^=ZP^E;;V?C@FMPPVWF<^B%*NAIGR*U#7AYA9GI[KOR
M-U_ \N3[*:)-YW3#'F[BZED]JG*MC=J-!>-3U_MM$H-U/;/)2F^^?\WB@X'>
MRE"8PS76WZ#]O#X@;JV.<;7760<<_L@P)'2?VWCKN%A\6LUKSB%_C7&;MF#<
MHY? Z[L&[Q:A@=V']85N$<B9[G<<\<)=$=?-:J\:@'LW5,(,RT*7\X;;;MSE
M4^CV\+>X]AI UD9^O,TD5.-1.;_@4TNO[3,*6&\PI$XU\0!FBDUK_+@G*>YS
M]6/4-^RS?F]Z9T][X,-#GUSP9(I&"&JRB)6AIE@@+SF'-W__YA\74\?@VN()
MZ6[YJ'LNUD#UK705-<3:[E2E##% Z\&OZRWLFV5R#1;;S5,MLR8!Y>J5K2I=
MUX!IG%B$>N[*NU6!7)1NU"<+V+X-FKWZI'G V;(!^[%1OJU+/IE]F6/.Z*_Y
MI!E58OC::H-D7&3W?4,2[N=86'()RQ93CW.U <2L?Z>:B+,U0*,]YP!9UUSR
M2WT%U[+:F%@^V9Q':-\'9:BZ7(@V2V*=>_63$%?.^FWETMLJKM9@\MKQQ!%]
MN+"K4IEBI"F6.M-L7J*^=XNB=-,=;6ZER7@7G7/ DZD[0]<DAMSY-]*^<^YJ
MD]5KTN]F:N?M5/6VI4Z#=-_T]0."'SP1[*OZU#">A2<MW@/5A97[L35[9K)!
M8+8+I<?7-.>=F47D MJ>6K>*_LV9[J6F_;W-)+=7>C>M([TG4%Z"S<V:VLQ:
M#G*K@'K/ YT\BQ6P;R2Q*%(MW9.Z3XT[EM#,/ZV?  6W57YRWWA0;ALGIY9L
MU4HI\MMX$1U*T<<GOW]B12Z2(DQ(D E):"(Y@5]E)$@XU4JH())K1 =%H;62
M.@D$4S3,TCP.51*E8:Z#D!5"/XT V)NY#TVUZG'ZE]@0J:8>@:S=R=/Q7WSU
MIBEB5V>>(,L=6@Y/:'WO^F1J.P$8\K8LHQL*LLV5M73J-M S9<<VN8(E']OR
M"-[QGUXX<^:?V<P(PU',#I9K8</K'I '2-6<AAZE554>^F?+K4BW8"LSIDW(
MD*'[3[B^SXU!WF*.GI7C_VI<"SMK>GWA?7QIB.$7TZW+TAPJ)B WQT/ME2 [
MH/U:I^WW.N1_\[+G>,+_64^V6BIE.1S+9J:*X1WP'LW4\N#7@;&A?UR+.)W8
M\)&O(XT0'"EMD@+')1G&7[-=;N1'=V23$4V7#4'(]J(E)JY#=O372IYZ(H6N
M3&R]E^G:1*CKY@5O<_].?!>P75?3C@NK_AD'VK6>J)TN*+V?Y/DVQPUI77LG
ML%'9#OZQA[WYI(<8&D!!Y=GS1%/AQL9=?[5>X@&D!-'SUX/D[K<1?M_FL7Z<
MYK?S"KTA$J 4!NGGN4"VI+4:HUD#^^JA%DV=VUHPY6(M-S9S^T7;9@A_;Z[1
M $9K%6KX;YJL4"<3A!B*A<<*W2@GM*[ERU+!O:Q.=JATK5.+6E'"@S4( V>K
M_</4D^;<$_TP.8!@D:\GBWY$Q;)!*X*U\.(-N,5=U&"N<6Q%)WAV_2B>+!P_
MN'61(8QH5A1'B+B*FC4_EBK7((VKE?C+C.R;.W2^Y\HLW6>QMO5M],/[]T<_
M@G?^UZH]\!2S#Y.ZZ]0C'#H4\(Y@:+)T[$&&GMU W.'H7O"JIF1IPEY[1C:/
M/R] IBI+>UR=67SY03.EIH4,ZX@1&, X&$E^X<+R%F.R:7$PCVY>8VFF6%FQ
MP2>O7.D,0PTTS/B$F&(V)J_F:/>,#F;\H'^NGQTM22-8&_G8[7C%5OI$P1;.
MVKS('2UKUM;6+EM4@'CCA=]\D"AI3AD+SS>[@$F]>@[-9%9/QC(<Q&8HUE,P
MUQ],POK"'WUM/O]W\QDQ0/FR^YE'QB[R#R_9XX:)=GLMJ>/>&44D-H2N,_N-
M<!J?3EV6*6N<O7H\)WC!B&YR!L,T@AR,1N];8SP=6V3KJ<:7U9],Z\'%P@TR
M<+Z0E?$%EF?J[;.OUIOCUJE.V&)/MT8QJB<IV3EPWJL"3\?/AK!Y!;,D&]_/
M<ZB9EA@'W)PX=N#F,#27KS&RE0-_*>-Z;MH'LYNOCM[^Z^CP3E)7R0%+KD7V
MLX:X0@4@\4&(7X<W-@5)!YO"=[ @'G U,OJ )$4O7HY'H[=''UZ]^3"LWW>N
MW]OC_SU\=W+T/W?R%.G![99O[U?O\/4_W\$"GKP9EN\[,N;HMGQX\\O1NW^^
M&];O>]:O:L$V($:9")LS,!BPS"9^=N0G^!)&BY?4NP63RG<Q2#.V'F',2W6.
MAY_UY@T6N3[RK/_:RX8-Z.$;HH?# 3V\'\]RC^CA*]' O8J)C'(5T)3J)&8T
M3(7(F8@XRV0:);R@\3;T\)65EOU+@[6*E1ORP)UHH083NREU_610BXJ_&S,V
M=,FMDJ.+.S!+T=S&S.7 O$*'";$=HOC P<P./3U%2.ZRN:'OHMH4N>(%;C);
MDD6"PJXG*@ERFD94\#P,9,)I$HDX+?05_!_KDT6O*'"^^>9B[T.7&#SAWX8)
MDQN+H7^]@<]^_B2S6,B<)81F6A :"[#9G!<DSK,LCHN0Y9SA,( #ML8 8G.]
M;LSD^$9RD0916-",94I*FL64AU2P* 9)2,,LRL)KSQP=Y&+W<D'?OG[[2;$T
M3Y*T($4*_Z$\U82AF&1Q7F1AD%"1)N )9 ?9Y7)QXW&TC.4Z3M)8@8-+F9(Y
MS\)89UE$(ZU!0HQH!%XT@D$T[E<T3@[!9.01C;.(@!%/"0W"F+!4:Y(PE85I
MG.1<@LG(\H/T"M'PM01#+C92AH)W\_18.RC6R!)N>G=B[+C-I-6J0#8EXQK&
M;>;C>:#Z&9=P+"XGE:]V+LJ)+2E/S)"\X]:HUU9Z'W."34 Q+T>;CO]J9'Q>
M"SK$(KFKV8#@S"0O:^*A#6SB[6D-IG?59/@:X-YEOH:#U+GW'??CK[I:[U;I
M*>3??[OFNSYX)?6&D,-MM57WOJ-_H' _*.;PIQN%^-RU5& 1[%I)?4<-9,$D
M'<"M_[:]X 0'=(*K.RN6#0K6@5*V8&TF/IVP#C<^&+7*'=C<;0 Y70QE+_]0
MWWW2+<SBWTS(92CK+>E\PQWAOE\WIX!^NW&&#6."X3FRF92F$\57$_QM^W&#
M%7=7T0/C"Q$BA QXO7&_EZ/7I=%"!'N0B_1%TOIY?1A2;R%2"%C"K-/5S+=%
MFK1-/<T#*\HSA0 -;N:J;FH'[(4VF^L@UZW8<C>ZE)=7DXX\%</PMCX.WKO=
M?5CC<'@UX8L%WCKP0\.+)1T+0ZG,(;H)=_^UANLUG4H7FTY$C^+:+SSY7</;
M+[TY:I])!7SAY<2/9&WIOC.*:[#"\7I7".]A"7!&*'?-TM8/ [_ERV2^JMK<
MWS678SW=R0V6-OG/EJBL9@Y&CB7>CRA)F[;8XDEP7A3^SAO.E<-M6!F<+#W3
MN!XDH;XY;_!TU7(EL< _F7J4#\Z@;H K+:R=+6_C-CL.6IQ>W6_"L^>\@X*X
M(^K+!![;GG53]86;GIO"'4)=_L@.GM%/XW$*OUIX^[!)1!LR0Y<6LR@9^^G)
MZ:FMGQLN2_"KW97E_-*K#A+3MAT;5+"+BYVX^>97 U\MI8W'<)E9GB[-.#-]
M*&9$ 5X!KEN<D=7"?L/OLI\M/)G5ML7P4;5"P);Y:4*][6ZAZRHQ$>#!Z+!J
M5;9\K<M7N,*@ZWC=+,M1I*FD*I%)D$4TSQEG,<LB711:9G$:9%<DP/K$R!\Q
MNUL[ "[C,60Q-F<QWL+OWGY*=1AR$6F225T0RD+L HD*$F4LCUB>9$$>O7B9
M! ?!%5D,,'2ML-\=GH9(N)O1&+ED1H"'%<<.<I>#V"BCIJBY44Y](^!E%NLR
ML[=A I3A=;/D4%NNY]"B?G*[I7>])$'2!GLWJS,8TH9P9B7<&'HX[(9U:5R2
M;LO)QG/[J41L']J-*J];&O/1M?T_?';'LW5W\@$&8[BMR:9WH/+M":+-B0O'
M<(>3[!P1NPG_,30TI EMHW@^EVK:2O_Z/(*Q7]KRNENTL>FA\N/J*M/%Z0@W
MVDU!GENO/7.B[D1X8)8B+RR',]D2E3>VZ?3Y$A2]?ON))D$<)2(D,E244,H$
M$A3!2BJ:Y0&5,9SG?70"#U6D8I$E,4\HBV1>B#C+:!PF@4I#7CR5?LXM!L:)
MS8,;TMN;S;;I<?1J9=V]+=N3R.P0B09PQDN#,6O&^=:IT(;,PE[1MR#.5TM,
MD]269&Q[7NJ>^-I&HB$YPZD4YONV?M/C][FL.=&C[/OL,69T<<,XU.?A:;?=
M+\\FI:SY-FPKXG96H%\ON:'/SY>6+W;CW<% GY;\W,:!D]D7W]6"K$>8?*[J
M*:Q=#CW'.]$\[(6)R5V;_0U6S/=:VA;.KDRT7GK<VLK^>IA$_"]O/]:G4BD=
M4+_:^-CSQOGMLP]LH8+JL ^8I$:/4="?M9C<7]5)+,_1M/4D>DR#1]S"<E/V
M!,LJ.U2XR^Y<J)F $$LY+?+L7]V,55L(G,#@"/J+K@*X2;((#S4)*DL); _X
M2O4[M%N-:3-U.G>9PS&F2R_LWC<3AN>MH,BUMMFL!/H^*QR<,JOGV]MQ&<Y_
M@C_(.399O>_V"[<[;C']L##5XYG)E,'G&\I>%(BNK^QUWPYJ&?N>6!RBHV8E
M"+O_(+8\U]4?-\&\-QBW7N5EV>7@V#K/T1G?#<- JB7L B9OW(A(E^5?G%FF
M8U<TZ]SPLA&25G NN9]IJ+1VZ<Q-'NE?O8/):R1NFS 9JK?&2/G-:_=Z68/2
M[T!W([1XPP1=$[ZYUW#BWWNDY1PIUIL'\ZUS&U\/G>R%:4<TV]K*JC7#,U3G
M$]:F]4<Q-[?SGVO=RJ7$CF9U&V(W9;N9_07=> ?K=DW>'9>_)V7U6EPY)=JZ
M\$)-4?Y]419>VG;2VP/*#[29&X96,R$:4XE^%2?GKEW1"E(M;,_#MG9-JI?;
M7E/ODS:MWA/<6!+?F.(V.><;661[QTWV%;3FM#%^W74';\IP&1BW;+$JD?:L
MLC68)LE=\Q-MK(W6L E'ZN$]$W=IBTB )]>@QZCIIOE=F\[W[@@CN^+NJ4Q7
M+[B'^%U_!Y>JA#@<E*NTK"$FYC9*JK#^;_J.Q87IT9@X)6R$;N7.$3>N\&*B
MIK).H[8>?>C1N%F/1C3T:.S'L]QCC\:5/1>]+$@D&*=9S+.4,<ISRK,D2"7\
M,D]4&B=;&=ZOS)[LX<'I3=^\YFUP9U7'\7*X2V.%QK[ W35NSA<9N\9M=UT7
M+3OS94(X&_5YA@0SKL^9_Q:78\=,MVSS-J/:\9\ZP:1O[*@M-4+3[!64?9>O
M#A?W%5E$!%:HVIP8W_50S6)L>JXK>E+:!W+K#&Q1FIC$@KV_Y?;LGJ8NNCAM
MZFX-,6Z7O:(SJ7CCD>_\\?9$G8YDU&YO[>$8U%('.OC*DR6V49!M:N&U.[>=
MY:Y/T(=);0"^U 3%E[@8AB%YO,8-8KTIZR_*+R:9WKELG2PWGD#-)&*&8KK;
MV2D)-KV.?ZME;6V^E;F@?3FK,ULW'F46\_C+J:TT\/77?L0.>CU[4FU>]/52
MA26IP_E"PDSADA:5,[..%W['<;)=)TG6Y<KQ.NH\5T_L8I_!VB^_G^TGJB,!
MHV#"TQZU]-JJB]'V2^> 86S8(BO=,B^B!>[JX&)7M<J[%6B /V9T$7[ SW'C
M-@CD" C"DKE_6+R"^W8-^C<C2U$*ZU*YBR-K#]7-5#*:4Y,272?G5ZW?K['<
M[N"I^P/=OOF7K^PKU.=')R-26VSCN_MBOI$D\$C<#YZ !Z>@-?-[FWVSTF'"
M9'R@<XNJN<8;N>0"O$Z+/.Z!BF4&#-.9_=G, 3^<R6,\_5YAZ NAU8D?^"7?
MV_3UP(YZ?'+T20F=R5QPDG#*" VBG(@\S@CG3%+8&$'IVJ2@K! R":7D+*(T
MBB.1!XRG01(50<H3ECZ9:EHC5^/146O,.*B'D:V1$2YCF!OQ&CGY>G2#?0Y=
M0<*:.UM-*[N+,.DN@F\E\(NP;!;!U8@Z35];$%*1.XT\W-]?I>7U"76^4*=\
M*E4U5:O/IGG+7M\4R> 3V\8 CZXWFW@W$Y@?<O>V# &[2E4?;->#JW?]W?^<
M?" A"_UE#T;'L]%_@_^(Z<.0CEUS('[45@)_?7TX.IS!PY^!>UR,7F-X]-Y3
M[1W*+Y,* <VO/,&KK9/CASYRK5PO_ >,D=[R&7?.>/-I.9'U5$X<BBA;T&B;
M604C;U[=/[C!E'*75;/]19/EF2QAQ_W'30,-SJ&QH\6/9K"V+IV_<0G6S];U
M>Y0H[G-]L]Y]$:FTR(N8JBBC(@AY%C*JXTC)0A=%4OA&W) 2_X^K&G%;0O3*
M3EP=,*J;S^*CY/CU'W^_>_WYXMW??P3'OW_229ZEA99$L2 B-&<!845""16:
MA;D0 8-C^25-#J*K^O2;FM5-I$&&D8[SG$8\TS0+(R&D+&@HJ-995,31( UW
MB%C^'+W]ZX]/0<3CF*64Y%D2$YI)3?)(8E\^U87*F ;_^,7+,+^R)1_#BW[\
MV2ZWM"-REZ)HFCL$0O%MFJ*V13?M\5=*I2#'J:1"4BEB#@+$ JGA]3*51LD@
M3'<I3/';OXI/7&DFDHB1*,DEH2I." \B0>(HC6G&0+<#<-2CY""YCC"U1EJ9
M*F]#]XS28]ED0-RF4]=NAB=H+7=;2I"&FA,!"CZ?A7D".ZW;HJJZ'MK=HB\_
M@DRI7S ?",<_QK[FJ#TVC8T06![YH<KH8E;/%8T9O#UY^RF5>92G14'B4,-!
MI7E"6$@5_"O/@C2,M4JS?OS(4O1"@SC$ND41Y(+%C"5!%L1,)9PG3R-^_+B<
M%Y^)$:)16XH>)PK3OHW'=C1OTY\29JOLIE7?$E'A]_R,O;&-+"9F6+G]"QX;
MU>B'#Q__J'X<=]#>G;^_Q[^W1AYB=FYYT4PW'RU0$QU2! G-JU&%.@R/5%4K
M@R[S7WUSOIC.+\"?-Z^$3,*6A!UU>?3#FX_OW_^(,44Y7YV>N32C<E]QV?TV
M 3P:-Z0+-]<R_.?U7 ,7V,"V?E9+VUCSB+/9;7"196(P_4@:(L,1A$"6+*S>
M9]S/\0AWS1AU7%6_(5?/NC>YUVJR[ .!ZHDK.-82C*XT,>?')?Q//?KE>.'Z
MFOL)<) KK29XT%1K3VH^:A_6I,==-ZE#RBZ:RYD/FRR] ;W6'<<]($BG::%N
MA]I2-:MI$_R(FA[.26VYG!NTX%JJN^-;QIZ8H<Y]XW7PF0VVPZ9O.^4ZA7O8
MB;Y;\"&ST^L#8BSFIWDBNU[OS=9?7B#<+D26(<)43^$.;1H0IT=PE%CW8V0!
M8/U1G[:_UXPV,_EZBX3:] #@(PK;-.(D$Z$OYW;LCK4:[?YBH49G(+'*=$I/
MYU_]8(7F52R@UU4B$?;8%%U<CF4C*_[XRKR[W<VKIY=U7T^O9D5[/SEBUPLC
M+-Z>'8RVFO7">M5&R&IZP/J7?IC&;#Y26F,-P8F1?7&\&'[>X+3,@G3D<+OY
M6)76DFX\:&Q)V$ .L>13_71=8]IU$N)^VH[<K=MPA<%E490^(+-OSX&B-H/Y
MIRD_FLWZ9<IA/SX69W/#*+FHNT31DIB.K#K;U[!TN2U>FU/4F)3NQAL.GX6?
MS&1P!\[DV O]L%%D?JS39-NNVSF=_;DM6P!!/)@LIO$:[^EJ@I5KHEVLC":C
M5<!>7HMUG-@Q-7Y<4CO_(N#S:)>F$PB'3&5QW$B\:[S],D>,FAW(M;$]S2C!
MV$$83 W1#4["FR,&U'LW;<>K&28C%.CMQ, E!^VY*^TYV72XX(EBR4^,\!EO
MHSU<PH#.#0[<? '$4!HV,YS78JJX8 NY*TC7@\K@A<U,B6:TZCM>2?[OWBAW
M.UJG%JASQ2OP@UI([_:@'HB\%JKG'7@<Y/8G-!?OT"FT;,A;#,]'KW@YQ6&^
MEN8!B_U&JRXQ$ANUWJKKI9<$G9N7B[D;+-8:7M8&[[95K77TV'K" #^]&?PT
M'N"G^_$L]P@_O0:<]":GRE[53:].4?526D42LE3+0!<)Y4HR!5]A81+$&56I
M#%Z\[)H;"V4T)[2NV0NWV71COL>ULP.[;FV)]>W-J/7&C_!-G-W+.8BE^XS+
M3)CKHB.P9LX>OVNP95NOVJ;^MN92:LFS3 0AY305+ 2I"))$ZU0EBK5<D&UK
MN"].R98%N?(%3;]/QZF&]_GP\0^#W?RW8:UU+(W3>=5P/=6]1BT'?"WPWU3-
MOL\T_]$,P78G_-N !3L^^>,3USI(:%Z03*B,T(#') ^*A,@XUBKG0D8L?AJY
M>;OQ(]CYQSIS]<]Z9K0)OR?VA9;X0JWPUL.R+^JAPW^XO]7=D^/N5&RIM#+T
M"7 I2_Q4K0&\Z]! 3K2VHRN1#W;Y53ET:],?V/3_FM,+KMG\1OB&X,VW&?LX
M13IF&#7C)L0U5ZE!K%/^M9GNC8DPVTPH#-S7):<\I:#_,^876H]NP+S(90FQ
MQ0>%B.WZ<-VT'!/?J(WQDTD!.Y2OXN4,'K0:MUM.72O"RJ9,W0SQLD5V6;<N
M(,1XU*1A#:[9Y'SY*7RL6FY\&//L.$85[PE6NN!E:1AUK;DVTU;]_?U 0X,M
MGDX^8Z+3Y# Q*V'7K#2O;^#>?LTJ;,Z=5&<6B^YOM?%!6^-";>_(VO.._?C3
M+Y/*<\)W9->@WVN"LA:DN4\"WX4B&^#V9V4#/"_-FY!]CZGDLD)_$;L'1LNO
M<S!Q:F$19]B(XF#I3;N+4Y9&KLRJ^U"R;MQ%[DYSI8F1'9?V=]1QK2^8G7%W
M,#^+9F"R(6RV/JQ]-:/$-5S?=X&B?XGC:WUCP^02X:M+'?[VO@NB6E7X,F@$
M3+$%)6D%=JM$HZ:^<;_-[41;EUG6"R6F-9 ,P+!K+_T ]+J?:XROQ&<7=J$J
MA76&]DKY]?4+Y2F^739A:C+CRY:JNP^,VW.F^T27S<#S"\]UV5%2LT!)\'_]
M@IG+VE>T>FI7Q1<NX+&7R^G-2$/V9>SLKY=,AQAM'0QAZ6J\_6@9E@:28O>_
MAIZ\4Y^7O!P=@6QR3-I6$_A'>=&!:OH(;0NHN$.48]/<7R<>P8F_1S+&R>FL
MN7QGO%V#M.T90IM#7W"D1_#2BUTL1EPPM^O.%Y_R-3Q&IHW>O$T;ZQSO&NN\
MYP[='0<*;]S*OU>E@08-\<+QZ]\_%1 ZLD!CLXABA*8R)BQ7(<DX#8-(,2:C
ML!]1TQ@672<RD*FF/)0,8T^:Y;'0!80>83^^>*>6H]]PA#LL_<BL_7HV=I_]
M]\UA]Y6KL-4M,"R-TVF-B'!4B,UPBVMA(ZR'BK.LL16XVVK7#MEMCK]:B_7K
M,J^_A'%B"SXMC*DR9UG17!_):$S-H%NAM@NG).$(]3MM%TW\0SC(R&II2*7-
MM("5'XF]O@:;\@G7/%?Z!XM] U.0GV *7FYZ&^[\@0J,A>?P0OOO/ZH:(+^K
M'9Z[\T)]LT"IQ1Q/D(GIZS,W,@3:JH"77-IIX69ZD6%"-X>'.7V6D_JS3?E]
M_?ELY?V;&W[B00[-T(WV'HS\'K37N@?>ZD!E/#;"5(3@^UOQP/:^/4BPIE%
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M;'_O$]SWPX_:WL=&/?W]'A#CV\%I[?(3J^V%5FWG8P.NE\&U+^N?#FW(7$;
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M^ND_3;@3J[__?%K_!M?;^<IK[S]=UG?>G=3HV_/:WC]9_=(?>DR4=LPB0UE
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M%>;1,WJNX_?RI5HE\/VBP.<TT^#H*ZR8X,0S[9RB6<14X>A\II;B=2V![SF
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M+F*T7=_(_Q'B]]CJ#+.>X1;?F_UF[&TN;/DS-;G%4C;; 7[_BCU?UX>;FP
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M><@XX> -LLBBB=89XWD8-F+ ; T,D3GN'WZA-LA*"!GW]G_4=SX<8H<S;8Q
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M"+FTI0*[03*!AH,UFB:TQ#7#$>Y'%JX9"MN*P6N*P2634#E%2^X%H2'#MMP
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M8TM@NRB!0Y%IEDE/K#,YD<87I#0^)Y9K%PP7F;2B#4*T K@5P&T0HA7 =R&
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MOW"2?H]KTX,I/G ZBF\TJE24 ^(X@X]-#^Q1.",]JK\]B2X*DE2_#ULSU9$
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M3)PUB%5%,JM%FG&S1_X$[H4%3_,$T"D8S^B&5L^(YS'!BS%.Y4=H3,>B'HQ
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M(C&2RC[&(%XMQ"!F.F@FV*^QE:M(3M9Z'\*OE^P&&@O?9B^N*2*N'Q6XDWC
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MRK9<&M [AI*0VYQ(B78;IQFQU 7-<L]8D$]+MOTHA=,I!UJEZQH9O&K$0)Q
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MW'"7ERZS@>=W)S5;8_IK1>>27\QEIH078$<[!)RUN26&VX*4K%29Y%FFA47
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M!XN"$6"G")D2"RMKS%3*^DJ5=>YN1[7Q/I,F3_@<23)-/2=(F:@15T8AYW%
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M5;:[RRJ_=&UYWM_87[JD]SOI7!#^34SRQ4GU_[I/;KNS0D2E+5>)8Z,-N(8
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M-,QN@A-)DE%R2:4)/$AP@8T68%[!QJ(Y-W&R"4Y4Q,HH,%:99M<+HP1G4B:
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MJ;UE5@>WLE90-EXW?<__X!,]<<0JX\42S)R-VY_N@N<S-^4K<7C8\+T7+SJ
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MQSK8]N8_K>VCKWC[X%N[<?X9/+H&WOD8#K?AFITOG^#SP]/_G*]/L\<92XS
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M00[Q"8]L%ZTFXK27%43N-;1V*WTI3%-8-FH1NQ;J\HEC!39:>)9+!6?PGR\
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M70V([R;6J_>!U?(6U"J\7TV@K3DV<<OI6@UU&NIFH([2(/%LWW-CA]'$)P'
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M81+9ML>DHM2%O6%RX='C ZJO7-M:YQX:W?0[^D*D]V7F^M;=%FS;6?,H0ZH
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M8N%'$VZRP%-0>)HD*1>J)TAK+EXJ3V?:2]#OGVFWR(?&.98_'H[R6\Y8464
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M?XY#_HT--0)ZLDG\G.>Y3%<3XV406M$.)"0Y\+$0F"(R<*:+]LX)R5N;$+=
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MF4C6.M/2#C3PNY&-27.W9,_5#6P .353M*?8/JQPE9_-TQOZC5L1:LF#2ZY
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M9&5F+GAM;.R]6W=;.9(F^CZ_(D_.ZT$E[I=>73W+=CJK?<:9\K&=IV>>N )
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M,&<M+:V&<^:]\BR -&0&A4!;9"_.M$#SK)BT=_4,L#=UKM)&&8U$X<Y+HYD
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MN'$F@Q;)>B0S %P12A@.3H]V&GF'L,ZKX[ZZ&/?H[G$O#UZT5$A+56*<U_K
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M)MT2 _/H';/2QI*<R:GO-=-MC]__14$KX4^;2JYU?,#GK^-9_K28(2ZN0M)
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MB&NM<LB6672%Z2H2B%*PY)-#GT7QX=Y;GNV&?.'4V%;HMQQ1[MC/J9] EH%
MN12!2B,3W-/ZAJHF9)#G@-H4)865V?=K#K#-J/MI)+0W7@PF\,>2=/*9/G=4
MKE1][&(R#"\Y.EKU5*P7[+538H0$3*I$#.?>&]4Z6O16( =I/32<SJ>M93]
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MZ"(R7ITNODYG-<7KW>1*K-I(AN*C=(Z9[(CJ00&+RG(FLG<^%J\X[U> H^>
M3Y\8 PAV@)K[-[?P4;W/\ )HHJE6=8#(66U"P<!F"$6*:J8-L<=<0_&4]=](
MM@.4_5U543N?YNNS;M++HY%0(/JD LO*6*8Q) 9:U-,O3/1-,*9Y3>@[X.PK
M:F4 K3>2\6.)6J&-:]$]<4GA-].3;]-)%]M</7J=I%>V( LJ!::UCRQ8G9B
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MM'R_=# V/ZI_CY\)]%YD.L58H0-,A1C &Y>!_%27BY/)\-:&^+@S_+DRCH=
M=Y>+/Y@M=+TTU\77;_5?+7[]ZQLF$LHOD^^3C-/\(2SQC'&AM0GU_(N<)L@L
MN!(<>'2R&"^T*:VK3 T^J1>W*(Z+)O>$9O9.2GCR#-]M)T4>^&2!B[>;B\S5
MGO!VNB2_9S%)*QF<(1IO+1V&)G+RSJTFQR>C %ET$"YC9,W; 8\QKY_+X=!D
MN6=%'"Y:61-*EC_>3NLKL%6RZBIU[].7,-U,?^487<[]'UBK)])16B]T/^/J
ME[_0EG"Y=9RE)&-*OH#.WI$A63Q$BXRV"AXQ"^LQ-6\I?2R3_[FV3H)V]RS
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M[QL.W/RX?HEA@?_SO_U_4$L#!!0    ( !*&7%8*[%G1;8 # *:U!  4
M;FMT<BTR,#(R,3(S,5]G,2YJ<&?LO'=44]_^-GAH(D60KK2@U*\TI:J4J$@7
M(R@=B8I($P&5#@E%J0(* @)*0$6:$.F=T(M(K](34#HDH"&0]AZ_,_/.>N^]
M\[[W-[/6S!]SS\I>BY7L?<XNS^?Y/,_.#O0I^B)PW,3 V !@ "\3!A, H,\
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MFZ2J!5[@WN-A=D$I-:PTX<_0_A[9OS>PB/];(_OO _L_QS4-<#(Q@(O'Q -
M >K-]W%RP'_*?\I_RG_*?\I_M;02TI-"U/$[QIXW.W4E1B@7\I6>^!;-&WJ*
M&Y[G7&8,+6 *BL-/81[!POC<C_0CE )N73NWIY$3+W2>#J1%+^]L;*QZ3%*T
M<)Z0SNE;=I^>%TUMV#U<6-]1VWA=^YR6^"R2) R,_OVH+XUWEP:/A>B,V-\B
MP&+4,%QN?1,[EHV)T\J?5B1<IAOS:2+IBZPSB#XZP/&DK?F1YB-RT %R?V%N
ML-J5:7;U,_1HP$8[\KA:ZAA%&;V&D!RU#_?/<S1\(ABJ>4I2O>X2BT J#B;H
MFGUL%%D9<OGSVJ$@JM&06&*RIHB;#5+:E[B_2,@>_XILOQ*B0 ?>IR_2 0K$
MC@X0O@*_V,]DO_IL$Q!I5C/VM&'#TQ16!U/A:+A@99,'WY$O/!5=JZ[3_TW#
M;W?6P>3E9=Z34FD&[ 4Y]\MDPX"=2[S#CD@Z<(P-7T&+@T?2 7RH!QWHEO^(
M1R<V:BX5!Z[@%V*>HH^W,C%GFITARJ<FQ/1PFB=R:0D#L^_KH+PA]GC-R"J-
MT2HZ<)(4K#<FH)=E9FH9,7\C/W=JFXN[5%Z9)LR'=:'R8UCIP.+A)!U(O,&:
M8^X@C>Y&1_E/<K#4=,#99J]]GQ&U^U%\KJ6WA7M5OC;J?FVL=.R$T3L]^=R>
M.X',XK@PB+[ S5OCGRMU-%9NC*$5?Y$Y[JL,^OJ>Z>0WNEBA>IR?V\*5<4Z@
M=8820G(*].$_'F* ?SWZM54R4>?Q>,;46P!(28:Y[_Q!S.*VKF[(N8K:-#::
M9(#)2=R]9$.9.O?/+[B.2O2VLE8!_J^M473@GZ<Y<W)IL%UK;4+$*R:;KS:C
MWE"PYN$W;Q5OIB%67WU#3L+<E>3VTWU\"7VGSSK?73^Z87&#0=];!3$$X<A]
M]2$%9_C,?"S5V=-O[+CA#<.,V\N/I88_ORJO/\OY.5\B<BCR$M?[,HKYDAA3
MRZ'].D)RXM<6DUG2SKQ[NL_,%8SU8]8-1WWEK7$RM#T@K9_@U?;3H.NDEYZL
M;JFN.2D3V+>3S\)#.]!L(==&,^E FZ[L, 5VOY9;-RE48.24SIL/8OE3>[>E
M 7YSVWD)@DP*5D?)$V8_KE#IJ<&3X:7.\2R"GPX$SH9!^2X)JUE'S2%FD8"G
MLF0U,CY;P$UT4<TNPNB=3U_I+81,DVP+4D#[),&D$ZT-P36)= KV[B^/>.'J
MOF_.G-C2[>9G&!O6OS5>%2S&:E8WYJLU$ZH%J]:3VK=^_-G\ZH=BU3(&PSHU
MAD=QN$I4P@)7U9;)S/51[5!LJ.&-.A]1P>K,_LKRK]WOB^23NZ?8MUR!]X4;
MP@,H[);*DOFX5TEEO^Z<?[]_H$HGO^GZ0 >@TUOZI)T.G&ADP?5;B2GK$3#1
MZN^NW^F2UX%:U62[3'-HC!E*+3)>9P6$@8W5]W& W)]2"L&Q=BM'H]CO)T)/
M!BRTTTYDPNJX"@LZF=';/&_.B2]:"WR@S< 9?&?*/-W J<[V02IP))B<9SJW
M%GGJ!N)]F$YU'/IN@=UZM?>\K4-[H)M*=!QN_A*A/ONYC;=A;3$_8.ZP$M<L
M%6#:4F'?B8/SKS:+IV%-]<2+"_0>CLB=E[[Z0N6((<RNC0Y$/2/9T@%]Y58Z
M0-(%(VCI-<,J_[]&7\U'RB.2+]K=:MHO8VF'8_WB\[Z8Q:K*"<^\-"L= 7.'
M--V6&ZP>^OP@Z"3/6DJ]9>B5*<=@%8;HP*IJ/AAYMY!+EX3'K& 4Z4P(]<A3
M\+[L213W'XG%SD7R65I]P5_>GHNP#*U;>RLNQSC.;^45$V+V,<#0-.7FI*^]
MF)#9BZ*FG[G>+Z_D)?(+/09Z);B"AXZD"K3;A/B1/(H6[+_;AES!E_SXT1'/
MJ4$\G*OHE2]K*RH(238&&'K[_=4 <WWOR06Q9N$U_TE!:\QQBKQ;H)>DGGKC
MX5RY,5_AJ5>OF_48CTKL'LWA^AGW<YF4@3T:HBP4>Y]@%0N)ED8JZ=RM.J'_
MH1K7<'6FFJ^6Y\5O9BL(14VV;?#P+P0W'6C]C:8#HCG<E]XWTH%_HAOS?V8W
M.:8AN<\H3E+#%<*GM[[<W!YVB(8[4N=$2E36M6(BP]AN]QCU,/MDXZH*@/<5
MVOI@<FB[Z)"9W5 TM5K_T-ER1UWD=80 B*SM2\S9K.J#KG1 1%>,%'FS9K02
M+4YRLAA3$KFOD1;4V5C^=3XN;CEEDP7P>VUN/NN@[^*EL/<5Y.#T9.,39]Z'
M)QMK ZQ!0'+<'H@ 5]ASU"\+"H0.1&[ :1<,_^4(:TM4E_S;2]S7/"OI "3
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MDIY%8]3(8*>=]-S8-UXYB;&[_GXZC 4/4S;E/^8PQLF!1?X=P;H#R18@:!I
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M8^PDA-EH'\F)5#X; B1VC62=!TL1['-Z+YV2LD\@[;: 6P!"B35<W-[2$\4
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M[1<2NM3%@/5+@!WQJ/&'UU;W,EI\+YQ:NGTZ:NVQ9!&_%V8*-X7"_X:R&8,
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MX7YPV!/U.\6^D^<V_>F@4D_0_.F5:"&)+DLN+9H][33S"U*:D8,4_#7'3:;
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MVKOF2&1HWVE5.0U.*^'X)7#+1?V)B3K09>A1YA28?(D/0KU+D47CU;GA]X+
MB(NCUR359.?#;6[L@I;IGZ*;F_\XI7NF6KE6K0NP$MM,!NX:ZCW_)]+!7\ F
MLITJ-M\@HQU5.S!+2EYJ\ <QCA=A(8P4%G452OJ0%(BP=39X>7L6G)?H%MLS
M6/)-=&,-44L;DB7+R%^L%$J.YN8@O%]#M9K@8& !9 ^.#Z%'M./[N>->&_)F
M><$N4^V25;5];Z9MNX?*ETN'[.Z;@*]<AN:]A[S/(>6]]1V?KD>O+I7-_MHZ
MI?99XVS /:;G[<*G3[@W[ATP//3GX@R3IYRB3C!N]O"CC.#-2PD!VI2V2D:)
MCFAE:L50]YU2[T]R1RP;E_)'V7;<S.ZC#S&/ I'$AMC?:%&XHWV"X]<0R_/4
MB4OY!XRNQ?RX?O':$WSL@2,";C(@8<?%+9($*\6]0N%BA0)OAZPH2[$_K!L(
M^X25'*T,'H ZI%_P$3JE&'RN2L!)^+GP*8BF[:CCS_=9;Z=A3=?R2\N^*<S&
M?5>Y&W17HJ]7ZK77S=6S7)0"WF![Q>=JQ'"OD%3Y*Y_7[@@?LE)ZAQF$)H')
M5RNA':C#962QU04\)_"R\IQE@+OO8O88%?VB^Z#9]049P_%@U]\<ARVY?@:(
M;%>_1HZA&R#MD9P4_B0DQ\^FG(2)K9'V5S,M69VR%^\<:7KZ]="/A=L@[JT=
M&/4<H[&%G^;V<TNEI%LI@>YV(S^ -<WK"OPG[G[GUU8"<7OT@MZ!8DV\)%RC
MHZ3^<O_PP6Y,VAP?(X\I.PMO[VJ*J1TIOGE0E%Q%2^KM4;@9=T9'#_3G"(A;
M'F2+T"EASN+JH:2#P_X0#N9^IU:"=T"ZO_[BTAE"4\6&;1#WKQZV:O3'N6B(
M]6O,P*P.D^<R)0QOEZPY*T7-!LX9:I0N'WPCVE#8>:PH^!MPQD8:X!!U^GZ0
MB_PB!EHD*T51S%G@8[>;T+0!M&SE+NWU%%-S-;QOOL=+E\X6\!W_G_,@#Z,&
MJ0E?PD/:=!%6Y*TV"#D7-OBFW7<Z:$KI0\?)3-$L3WF=_<(^90,FLBMF\*W'
M$-\D_CA4K?%+B@]1YNEX=GFQT[R_?LC+6HGB#XU.">D9'SC VB9H/7'FL5.V
MP;A]V./ME'8".-XP+*@,^S2H:II19:"G(&AH?3WZX"?019 2.PY9QS;W7Q4*
M4'E4ZSG<[2 A9#=3DAQ:2J@4LQHO':]:4UNTO6I3+ZIIOC]4?R-,MOZ/0Q)B
M)S_E9OBQMT:=+?=J,";7SQY!!K.%_G7-\=ZS+?<)]5[G<8LC+0*.PU_K2BII
M)\R*#JT='2T29%1.W8PUD5*OE7C:I'X3ZO+U_XR8^;_/WY[K^<H4131^%\2W
M/$VMU*T?_MUL%52U%)C1+BD62A>QJM0'8$R>7Y1&N@XCKY@<]?"'%D9J-NGP
MZSO$+\=J7$_MH(^?,7CL'&UH1^4"[)1(J-?(8;"(H1>;"TJZ=#!!3:9K8=_
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M$4&1Q?&X+KN#<ZZF712Z]_5)<^H7/;%?@3Q1\@6'^CN@]3FD8C+Z?%:7NP'
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M/FX?&3-Z^8B^)Z3HGP.H,E(1RZ;_)LFI>R %BL9AB(7MWI_@?[1;>-)%:K'
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M:K4?8\3^\]DLFY7ZJV\XL7>L(3_Y<++J^I?)?2$+F7W/(I8^1G? 4UT^R7
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M_#U\CJ2,929H\.IDW<>8SO1ZD$DFRK(I=^7=$+!1'JTX_9O"^G4P8PP]XI=
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M.BN>G':MS;9?QLJW?\ZWZ]SIKB\7=,F77!]XK< [-,3[]=A(U:.-W;0AW]
M9>A3*BG\7+Y0X%V_.-6?0Q*]*&:I;^DRTE4NIJ#A'/!*(3<Q!-WS42T,_F.!
M@>M#8L%)@I:HB4%)FA+,7JG\T"[NXBXM$$_AO7Q'L<W6T+QMYI[:9 ]H+EUT
M,*5:F_O^/X!+9+?.?'@(L#%;I]R,XFW"U1">52$\-V:1R3>@C 2$FFG8&P@_
MLN68M6'D2UY\L3"S&*YI0(P@R&''^D',< F8+K8@[N\([Q-L<X'8Z^,1LPW+
ME0G+X5%9A\9</R%ND>3G^UT&K>SV^==P'F0<2ETD"$^I&V(.<66MO_P1W&ZM
M"8D"S;+9'4JQR\%&_ W!G<\L^5DR?ITF4"Z5F(Y">U:0KSNNZ_#926*:WJQ:
M%%UZK)BHR=OX*"1<Y$DX&6T0N%W\U^4:].' (@4&U#G&/+:ZQ"$ZF5O FGAG
M7ZOY&9O>B%!EODF:;8XN?:[>[9:9+>-]F3-]<G#5%G39,O3F;&2'K;Z;/IC1
M=6K,<,CX?=-@T4UF0!,\UF9>B5=;68K2Y)_[5AJE?JL(ZCRMD_5*?W*U06_@
M0:4[18T"L59=;O60#T9'IM;+R0QNB^)8FJ_G -;OH^7JOKJ?!N35_>S6NX;N
M5?IP;@PYNO :T(9B8E85F_L.HT@<V*J\]ZUAU<A2G;(^#S4::*8N(WOL<FK^
MKYD9?LS+E3T$'?P:'M3E:Q-6Z\]T VVDK#+P?OQ>V5@2.E9,X._L3]J- @+'
M_>X3W:F.2] =#=750X.? 8:U80KW[Q?=1H%9KXT;7G;J#UEM2T:IX3YA]/=-
MR9J'A!^JAEYOI/#X5%)5,FR5T1+]-&7>NF7Y-N7-V=&0\M.9^=/_DN15)HJM
M-+_VYQ?8!4^JRWS<1IF.,_DZN)7JL%V[ZL?PL<R,H N  @G7Y$@/7JZ0)6G'
M.6#B+.??#%DGGP-$C7'V%\WKSP&DY$F/XU>&$WL-AER5#;MJH0PJ=<+-C7$.
MB?)@%5/ %3 HT>P_)"W2VC+ Z,: 2>:O-];?UNONVXM1OY6^,A%88WQW6PLH
MC>AZ< YPMG7 I> I7_5<U=B,;U<,(I8Z.7 -V5TW2==&[F=<SYKJY\37J1_B
M0LFGKQ*FE+RR'QV'C?_S&*.?[&\1%5W"/YKU4GY^Y.IE1TKQN=1WR=G\YAY>
M_#<]#G=^JYMB@CHU5=NMQUCQPCWYU]O,KM3OM!I]&XZ(OJFC>BTUXA\] &_8
MA6@L[1M#2^%J)F0TZ1?<[3CP<A\4'&Q^>1V?!7*FQC!)W+"8%TECU.>1F*>Q
M64M!%F7HW/OI/\:XG;+=JIGG5N+VDU'7S8&RA\VAFIT- *(PWP+4##/C1;T)
M><K[PN< 2 U9:\VPGR(L0\RC_&UI=C9VC<;W%'9SB[(W&IL,\I^D^?5IR0R*
M%5@!:M:2+[DNL1" E5!(K]+C'=4;5>ZXK, )?^C\LV6<<)EPBI9P*F1L8)\%
M\Z2OH%Y_@($Y"O5K?V0S1F'!8B>'<<*7OY=3CC5[*M"9 UL4T>EJ(%!Z*ER9
MY]&MRAF[$>EIK3OY%URX*B'GZ9!=M F2>.;[G5_\/^U3-_L/\>:@^@0!QKJ"
MH6EUST 9^@K[J+>BCGDQO]K?C96E5BPAGU_T><,4(IP+J*%ZKM0\E8':)T^Y
M>L+J$(L_2F?LO:6!]]AW3@=>^\NQV-S5K/BX??H>X\N6E5D[//ZGX.T7D9?;
M5E,4=J3^I:>U7^O:HF0]91U<G:/O9J1R7?VA[W-7""F.M-<P6<.!B-\Z! F7
M?VVX-LB$N+PR<HO[5YS O5<\N"9OW5;^-_!NOM3?S-J#=F#AD@?+SHSJC5S?
MS_VF::?6!BA_J1,#/V7&P LI586O*")HD^?L0IH6$,'7K!Q>&5E-?KTHEP.6
M,]'H5GD]\:^*JH5V,%5$;,B96OZ]GR'%X30$8RD7?L(#1'M)MUM[A-"JNDT^
M=P.O7;<P^I+LUU-Z%^(_Q&K$.R DG=HB^;WG>L3.Y>,:]59B+IP5XDY)VESQ
MCCR0>YLFZX3Y6V0@#P;=2M8 $T8 \!>VNR3Q__"X*0&:*?]D>@@^:/DD4I8Q
MW5UY1W[',0F<\=Y)??O>8\$XPWTJ7Q'G;P[_4ZD24L>?J#D#KHT>[4?QJJFP
MB9CAL+%KB?I:GVD .'9S&\QBZJH'='E:H4W&[/+%XP&O__%XX-K8-P <2K@H
MP^R#<6.2>PX97<WSN;'S62%V61Y.M[OL'1U<DD3U)(UF19P>RE,,N&]HWD1T
M/6K7/=.%(DSP86>:,&6L[FA;I=;TA'O6U0H;5/>:1YT.1<IUP=2-AG Q&Y?4
MTSOG /J"SG/ \8W_U'_X(+#L;<5;(4$Q^Y>JLTI1VTV=OW7<Z'NS_Z(*Z0'_
MR/+CSYD8:"\7\WA?L8<.F]DFN<,SV;^2QB@KU'Q%Q9XG<Y#/*ZA+F*;#D)C^
M[L+JPL2;'V;W/JRB.Y^9T;_).UM5L3&+OUEH!%1?!?]L^#]O2>4^<S=*+FHM
M0\%3J <,CI672:S3YDMZO4^E,KBKQ9/Q;YL\QV2\C%Q<!S,T=#4P@U>V:GEW
MG'WJYV^5^KP,G=\OW[[333:^-0*/^N6I8]3PJ[*DOJ,Q&C=AWV08&MN;VG(L
MJ7?Y]"?ML":#)RV)_OH9XZSU;KVDC<?I<S3$1KOP6V:Y5R>W:>ASUYZH@P0:
MGU]'M)U U,L!!,;(NB+Y-8BO7;A\":JDEI6K-^,?L2GM_KO^LN6/XB_U3KAU
M6P;-I^F-"--C6RI#S$)VXX0_VDAVZFM*CQ-E=U0LH.D7P"5BK)%GX]4G:.Z#
MW(?3"KM&UL;OGEL;;G&XO@\AXSQ)*!PDB/ X1)\98VE[PQA6@5W -W"IR48/
M:Y5*1TQ[#CCY8:J9OM_18;I'[:(>HW<GEU/?<](H7+.!6(3TJF#F)XTO"M5A
MDFI*=+U??MSBR6C(#)R\7Q308.#TST%79I-I/YL_6ME+\71AY1P0 6*"B7UF
M,KR'#UVQY7W,&OSQC_&X3&$NXJ3Y(U4!; :$_8.SP+N<&;H]MH+^Z?'9,5?:
M,IEY$I' F5GXY^A^B\J8FK6D\2-7JFGV5V5.U]\F1*KR6)5\W,+9\8_O^5<I
M+<@H['()-S8U)]@_CV.3%!2(T )&V1;^IX5DR5(=)+Y#!!1-ND60!>>NRKV*
MS&JN5VGYVIPX/-XNC"^)&[II5\T7D<;^4*R;&2^M'.[5P'5\#GC#<Z-V^9!K
M+H()TUCGMN^4XC-<42 O;[#._7!^[65 S<_6WS!;#*(3<566!\&&%^OI$,E^
M*Y%N/N%Y\*ZLG\919X#JJ)!YI #E0:*_5$&::54<Z"J8V^VVPI4KQW+NH?(K
M%%O /%/OP3R"8D.)$13K*64,+0YY/?MR<RZXAY-P"OCP-J;_U/7PX*^!+-"N
MO8E7M_>$KL[HZUYYDZ*(GS!UQ'OS>CRD2Y,?8U2!A@9I31PS!/9O^;>I[*>L
MJ7S7I?I*&/'\2?M[9F\,6W'1E>(YX1XVJ%LN0=6NA#,B0$/W+S]O;V;F"ZS:
M)8OA'[2R:7HIZT\S$[.H^7N39G"]Y#^(P;NL-?<,+;T&4>P'>//C<_NVB7FB
MOZIS%<#L;2P;'T7*JO=V,\1<3<V<%SIKQL>NXB&ZV(#DV8 %H1ZKNE'X2)FU
M"':3:W2&VE_L3R62!B:#@?1$O84:=JLR1_46O7BE.WF]8?'V>Z",N;!(07DA
M<YXF!X'Z*S$7L9R??QUC5SS>\148U1BZ\/B#YR NNVH]4"OT]26'[[OU&KMC
MB.4$T)$[SQ(QL;G@U- - IVW[@OVEK[6F]XE^3;M#IM\:VKD9?6K^NZE'_$(
M<HP466WS>.9GN8\ZWIS32OGP'"#3J,7=R7=&#R"@_M?:\U,/RQ!DU+'W52-/
MI?)BBYTG5FD_P<$OTAKNI8"U._=_7\F/;"23=7,2W;7_D)[\"](30TJ>JGAU
M >#N)&',.6#_ P;R%!-5F;4H63=9Y>7?9E$DKS C@9#2Y[I[TGR3RANVBGQZ
MC&#<(@$S=VSEP+633JW/9IA=7J1RQPY>^A'1DC@R,W4ZLW&R3PXA"6EB-FBW
M*>L<4*I?R&S^ZN):0@D$:*HJ U=90*O%8W.[C3[]\#);IFJ]I31^19G12_K*
M9=&[W_G$"-=>K9@GP&_ W+$G^QIK^Y)&UPF/1&.TZ_,,;DCP&]XO7/[GQN?;
MFZ _R@#4AF_^ZF#"4]EA*3U0!1'MRF6[L>BL)VT3,NM?GZ3XB3I*7]'2"#6W
MGXSH+&0>&D-1&6/-]YC/?.Q@89/'4H<LL)M8F.>5UFE?+P\'"6-5H066]MFB
M;(9GRA+YG[XEK](2V-'+\)CEX$9FNL4=.VFL0BJ+VX?J7(U:UGPV0Y'XJ[*^
M>5&CJI0>^VU#*HH,EI[5A4D;*"<)D=N"_@$:=VDC-2J2_W=N3<(UM<C;8 4?
M)=W":&:O);\!LDAO3+8_61N*4##+>OSO2?&E14M1?^'?%[<QJ2G"M/B*6/S+
MLR#H$LX&CUU#Q"PU<GSX#-G^\U#D)\'P2O;5.'N3+AM];Y[#^'OB?A'9_/<S
M!M40AE*\O20F\D8G5IH-]5IQY-;,57A;AYE,J+WK"8GRT0O;HCK:)=$SGUD2
M;A KVQD^PM3Q3TH68'K8]8T2!HL=#I3Z.-BY,&V;.X-#3ZX[@Z&9^[G?QU8D
M^FR%5($I)=&E8\:Z>7YW>SKHM4^\./C1$F!IA@K[7JGZN> M4)?]E'F9K)MH
M\%X3S:_;N<E'A$&AB%7I3<E=9YL0H RG8EOEEJI+[%[?IZI2*_?,#Z]BY00M
MTWU&KTQ3NZ23LSW,]$P/:OX8FT5@M>OON5^7^Z@CN2M?H-U"4'NL#E@[) 6X
MH^8 YMV2ND:B&SDS)<^]&7-15T.Q*/,0R#:'AV^@<!*%C[VE)?LL!@0=TDP>
M^3QU8-JZ??*KL5(IL-;:NH>/8UPP2<7A45D\#66X"N#*+1M<% ;9U<'Y:_V7
MOS>=:XA>N>RA_.F 433=4M#BT.?H.X-CZC]IUS?WEK N%XAE!S/#QG2/O;%R
M+M84\# ?"2W"YTR/YRL[45#_H%TR3[C';R[#*\@EF&Y7==$4XW&[QJK<Y5)R
M!+I8?WO2M\2B.,B*FC@= V=?>B<F;7)GC4FDF.DS)3OOFVM'X0@M];LK><"^
MG.#:&85<?N?O[W,]M>?$$MZSY%5?WC+>M" QXXV6$3'I8.4H&"]Y=1F'A#*"
M%<)D&?2<Q$2N\3 F_/E;R,@\-P3&QQ01>##S(/;&#]7X4X,'J.)=-I;*AWN6
M]I1L3]78/F<"UE_QI>B&F%[TIH$0.&E)]X!1!;AKW\X!XX]GR(+YDO,Y()T?
M,T.,]A\CWLCIV)U1ERN"YJL43?N_X;>\+EIDO>OX[KJ& >,5$'VZ&0:743-;
ME5G^R7+'S+TK<_%@033A/\^U'2D1JH 5D#/DG])2%! GX08ZU6>'29V15_*'
MG28-8E9^X!R@OV2^'555J:0T;HWNX?_6+BZ<Q/564NB_-XI*H/\0L!+&<V;Q
MRNSKA+27HK4/!^^V9VII F,*^_?Y6^D_3Q0H,,T$=N%EN3>*;NJTV*&5O^D[
M F)XA%_]@K4.2YJ.-U^%^NU+?%_B=9__N(.6T&";GHFY:-JW1'G8P:]?M=/,
MTY2UZM2\(!=]S3C3+:&3K_AEU-4,$9_AW2[JB.] WQG6)2H2'R@N)A9-7O(H
M=._UX2(S59EFU$EZ2W-N/?SEZ,OI<) <TKZ !YJ[JDQ@V^RSD\0&)BO'_*WR
MT/LZ!:H[8*M 6QNRMZ$^?*=>G>\9!.2W</>%-!/8U%80B7!FTL]%&F(9C+9X
MK*;O0['/;M/-?IL>/ONWW]%WA>Y<3UUS'AAL$"# 8P96\H3XO6R=%"K8?JW;
MIKDSO(A<F0$\&TSL?48Q4\C^\0>W@; @YFXA\YM]Q'(UJ'YXD8%G&#5=XUT1
M+*2'.<0]V ]"<M^*H_Q'O9F0#5BM1SZ#Q%^4_;HF\T';5HT3JP\40*^;H^]>
MZ TWRG])HVT\=QYHFR>I=%TZN10$2]A_IOFI8!G8PUMEXUY/QKNWK87;83=B
MW"?_TAZ^.PF@0MK;HLITZ0LE(\)I[VH!LX"-B%X9#QR)6.J?/#>SLO]G8%F#
M9FL>GV79]*\H*'8_1SM$7K= AE8O@ZCT!47\!G+<1K@L@+H@_'":V>J(SS!0
M_.+,H\;Z!_\R4P&I\RI\W[4W[H '_6'-]+VD-ZYPYI^PV])U6Z<W<DL,;S((
MSZ+TZ7SN #*H0(EN\VB=8&^9;[U@==8/20;%CW[LZ-&G0 63IBB.."Y>L[^!
M\4H^DX!ZKSVUDIFN9R*5<,25N4X_^3AB#WN>!A9^OJ!U=,2,E2H*JBDF727H
M->&_89#=BXKU]5G&C3/'6P%<52[/QEB_?XBLY6.]C6I'XLKP]I]W(!3D^#6.
M.@<P'S,9VF#I2*-H^2ZW2Y'#R;Q+?#7#XU)\#AO_ZFXGEDYV7(%I)*_(=2-H
M\;)2R4VR$<5HMT^;7']RQ#.XL6A?ZK7%<#6>_])&[/^,_PRI#2D@6L@(@5MI
MP5\JA8;9-TV\<&R=:GQ3[G<TB(-NW(OBC'HD:E//"OX.<! ;0RY_6FJD[96;
MJ^Y9*>Z@_/5L8LFZHS7R>,R%?>!=['5)VG>EWDM>^0T4N+]LC__SJN%_!OLZ
MHE$_6;& O+7U-;U #FC(BHSB-Z!!SL%HL) EN\CC+LG.5\="'2KD!.&-Z-)M
M/$Q:E)_J ,*>3'G>P,K,*EMQ?&!O#QSR84>$OC %V"Y3";UWC!#4X!0$%OD_
MAC"Y(1OE>@V3\9)*%1@[(ZMY@F9SDZ7P)*F/\QW7]BV;<T 5&DGTN#:#+@&$
M#>FR8R 75OH=^&1,T:K8JPX^&%\^$&]8?;S[S=O$K"%^O6.$SVLKOOHR4Q-#
MC' U^ZWI<,WCCQTPXFMRK']%NHW-36ICS4H53/"9*+#"B.N]^#>XLB]!^WQ,
MV :_9P":(]K[IS1@#O&YA4BAA/I;G513/ZG*:H;/ =?@: @0Y,$<;[7Y&N&T
M(#1IC!F-)]F.Q1^N1@V'IU&7?&+B<UVW?D[MQL4T[\<A [GP[X^! 2<.8 :+
M$N.P4 _73QZ)0HMJ'MG\;(XIT9??8PLRE>9#J?H \)QQR&U2#Z@I.N_,'DK[
MJ"WW8;(.%AXGXK-SZOC02NZ]<I;"O3^UN):N]?LIX)7D,4C3P+X1=JD+T40;
MW<%*$)M1.&.I=FMR1J%.^Q=U/;(=L\'R!J_#M>6^D#\\:1SRWGP:B'D\9/'K
MXQ1,!@KN,N!\2!U*V/I8!Q/[C^W&X)DFP6!2'7CV"$HIPVN,]"RO<<.\<)U*
M82SL/V3J=4MMN:<C#NJ%FU"<NNB:309(V3H\;$36MB0=_-@1S6>(M9 WY 7\
MV+DPIJ5=K(.%K1DIKR C_IX#V'=9@U7-WM@K??#KJ<EBY7RF :8"!(G0 Y8^
M(B7. 4YR>/'2OG, *PR.8<_J4WNCBV%.3NSK2%VWZ*$?D,A;B7D1_R'WFO[O
ME('BB&1WHD4A9?P?!(IA[3 *Y(R,#HE);(?XB@1R['WI\O"B,@Y6<W&\)2$L
M[6,L!I!BU:+IH,0@!VK0$-SP[5TR&WNA4!.M2>W&(V7=5F:/5MT$[I8FZ;]-
MBEI)-%</8*,X?:,+=X#VK'+NH\]$9I%Q[9 ;K[ .7=/W[?Y5R:RE>J[19CG'
MBXL]3@K*<'JDZ:52TPAR0J#2NQ&-,3T!6/WH]B&UBB .U*=4O[LY_6NN:F!@
M\.5U&Y\>=4IN+=JZ\?^8#:8A&9'NS&A.7"R^8.WP"DP9>^.5")RW/<-.[8Q!
M)5!GL]TW?(1['G[_F-_ZPDXD$0\6F^(9ZR&)-#?H2*&M=$OO9&L-TH<7)^B?
MF*=!N0N9)W+68;Z8TB[0M8_Q("ZHCC;61/MRK(?5"V6XA4;@O_A $ON?F#W>
M,W_E?4N/:JAWGZJ")C<^>>7O4EAI)__SEC?P_DP%/SOY)&W56VJ&<F*!G(BU
M_J]GVA;PB27&%R3^;7+8X)^HD259]V/?WZCFS$_;KY<48H:Y8FA_$^X4,GMC
MY+J]J6%R\:X$_F4B;7?Y34K(GJT2K[$RO_*[*:_M)<5?XQ<&^I!;,!=BG0B9
MU)L1%/'"G_!A7C6P!_9?O_TZ*.D-Q!W\$3=(#7:CB^IP%I359\H':.9]C!<'
M_%^CXSKQW3G G3D6PGH.\%I*(-._OT0SAIK+4'>IC4E/X?IXY=B^4$9P-KN.
M$LNLG['-#'KJ_]Z*TH[[S!MF@N7L@LR]'-!4P.3-!VH*3JPV>EC'V8,S&!9Z
M>)WXV$%27WX'50!K$;U+5V&.Q'?M=&MR; OZH34[39/@(%\^*=8VF=ZRF_&4
MR1GFA?M: C/_SQ;3HN< ZFWBYPYATL\E5I+L%DGYU_Y?*>8K0_3;XSU.;#0W
M)Q_&B+)QK"KN;D,"?U)86#6'$V[7[&;R3)>O+(B93$O3YQII'_1+>,G@FM:/
M?CM)O_/2N]RUT>Q*/O]2FQ#TR1HP'DY)&K83PF:]\G:8_'NFEJNRTI*S(&9J
M*<L"_.WS=-T"5\C\L:Q&BIA!"*XD/"+FP8'0^EYENJ"J79Y[RD'I ZS]-<)7
M#$P!S(7L.V__ZRZ>$%72$I*+\ 3#B7N.Y4QHYPT5**B9FY\;8.J=WE;]/.@3
M>PX0CBR5'&@,7*I#DE-%/+"^IN>0 QJ](OOWFX-!],$1=-7BUV_[0?I"BF/*
M< V3>*D-.?1MW/=T'.27)M"5)RAFQG)&W0GFZ7D@ZX3V=.,QI#?8*]H())ZN
MW*6*!*]14VVCI/I GLQQ'8)XY;-;T,-^.X[6I"'(1-6'M(E5 S-3/8_8E'4N
M\@8J/UZL(/6"V-IUL14X&XQRHKIE$/])K*)!=<[.JK@)NU_62[V6>Q3Z/^)5
M^,NHYK<^_O=.&N(?ZPEW@V0+"G?,'^75ZWB*Q/:Z,%Y-'9AZ1!/%_H_][ YI
M M*TM&]4LFM.HL;*Q53+',<516XM6<QIZ:AF_C?RWC.HR:@+%WT1I&.D22<H
M32G2B[0H2!,Q*DH5(KV#*"4H$$#I34! 40@("$J3CH"$CE*E2 D(";V3 ,9(
M"C=^]]PYY]P[=\XY/^[,G3D_=GZ]F7>_>Z^UGN?99:T']'PZEZKMD6;_?-:
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M%J6T<0*PMXMZ9JI5$]8:V)^8RC[2KU.]NW;WA?JWY2Y&NG>KUNB?**\3 &U
MD,!/Q;B3KE\K)I(ZM(:Z?NE "_73=3C>U=BG&[')K";[\\LQ#9 %CT%4EO22
MS6/8CC%N?G,;?'R/IAJX+D2ZO%ZX)5RS9W3*A7!5V]**S&MG7M-.B0\+4%OZ
MF#NR?"M_[,TUV4M?8Y1US_2_=/^1"]"8_VGP3WFUT1GI):FBTOG^4,=0]])Y
MN_FNS@SKA>/9K,G4@FAFO=^E-+C ICM1XB/X6C]?MQ.*'NH'0 VCWZO?D5T_
MVF\A<89LH=6,4O:,7:?7(:UI]V(U3P!\K^T1<K9EZ[B?RJ)U6;6V^VY<I]9*
M=LG3!&/T .=^*P_=6@MRMQP_2F@A?JT@2A.<ZL:/%#@\4BWW^VR'S&1:\@9J
M&X^"4D2R&L52?D7O:0IE.>+_](/0),+YS%MXC5YO)(AL3PR1&/0/#2KIR3Z8
M.Z=YVUXL(3UA8R@UKE LW3Z'S!EG-K&+<,U[?#SKK#'M</&+W4?]E!- \FOS
M=>F/@$A'\,+"A_8L2FW@G(@% 4K\ROC^T]0@UM?(\:L!G43POL1U^GFM0E',
M;28K[&B**!?>N',.D4#(+?;&; 8V3@D>WV)0E.'+A MT2TVQ?TU,1[?3XV"[
M()(5]9>#Y%20?W334^.NZEBT[Z!M;YG7%/[&'W;UQNF06*?QW?.)?9\2^2\Y
M/8(BR0K3#=7$QXL]D@WS'Z8M,D:D+#M)LHNV;U"G)%]S;IB'_RN_.U974T>)
MIPI0HNY)3/VY.S  R"NU(8>D)V,9PGF>WF;J1]:[[Y:3[D<,/&7&N:=AQU!8
MF;9FLTKQON/[]7?1#N@"61TC]>1+#X<%1GI<]XJ5<X^="3W$8;P_=G_G"58A
MT0&8<JR;DM\](E6&#$U@\URCEW@YQ*PLZBM&P;\ZNIM*'M& *D6ORW\VIVNZ
M[A.'_F+O;6-?J1]VWNA? F=%.W;NAH]Y;Z'8B'SFQ#R2W$8$YQ1WQ)LJN/X<
MM'E9\JZ9FGXWI?#=\YE(#WHS0A"QP1\_@0F))H?X6037?>A7ZS+^X_P%E@'O
M)]56)!&MAI'UTKL:>$;_N6=89 <J5JNR'<GS+2=?NME;LTK T<DU<"@QF+<I
MX35G\IM73ZW>T63$):HD%-=O2$3A_/MR9)V?X4Z V\V3;TJD?8*W;+7?HW8D
MTIE&$1!51*=2O?=B*EBP725B7&OEC,14$(MJGMA-9:?DK Q#\.\1R89DSAG-
M45N  G[_KTSR-)691+.9(D+4"5 U=0(<6P19;"&:_O3S0[P4$I$L89=*[. 3
M#IG62!-<-E*^7K';23Q]*//FLK>F20[Q]9D**+\BHA.,6*F/^ 'YC5X\ 6[X
M?5K<@7TP"*6YGS6E8*_$?MS6L%S580@=4YOYEPLB"+CW[G-'+"S60>.DB&E+
M"GQ$[UZJ2+U+SIWQ(])%J=0IY1G*4I*'"S,+4'_+A($++A$^1U(BAWZF%+4S
M$KV7."I82O/T&?FRG_UALXN?*?[>O+S*7AS]]*/%PD?JS$#MOV35_ 87'4\
MYOP/CXQ"SXV?16C]Y28(M+>.T\)>%N)LM2HA$-4TT6:JUFKTJ,NP\7$Q^$'4
M59[?4/3^\OIN.CX)A@O9&5;/P?HSP<,)]D241>(5!DSV_?1<DQ7F#%Y_>2[E
ME4M.5[_!Q"E?='Q)IF$*1*'R,$WBBFJ:T$;^A>9&7_&^%ID*,YX?0[4-;9]J
MC%@NOHB\ V6(#1,.YZ;9N_W$3@$EFVP0<JIO.D=4]HO=FU,IR[Z553W2S71-
M='.AOZO_G4VH\" (ENX8+]LE]2:/ELYO3EOZ7EBIZ#O@3X#I.V=?ZW?3K;LJ
M,KUC4VZS :F!=G- [[0D#D+K<$-6&AH6GZVQ"6?K6KE_ "S2/ZP&%D0H-+WK
M63WWI"__?!J&P5:A^P2(>WJ_LP'&Y9V]+9&17Q0 7Z4L7Q8:3(6\5([UNZ9K
ME:#&-JQ 99YCG[HXJ@)7'F=D#3U8R=5<A5Q-7L=5LU(2:.-%ND;)"]-#,8>=
MQPP;=_Q1L8?ZAGXT/_LE%ZH[92&FP7R-/<;H7MBGKT]?@BPG45X*:&V"%+XI
M;A?ED5Y$)&'7FK30"HGU_);2]6$KE&_O!V5<:3 PS[/[I*%\VQ_]>'W)L@2G
M]<>!*%[5"4KT=;*_,:+DS3%O6]+>-<SJ;RGTQL1%_",0Z),6#_$ Q2*:^&BH
MO88X#>_N<&"C?L]>DBV4C%GAA JGORN7%<JFC[ZV7"1(&B58X=(2],#4$12H
M36EIVZ4.?R:IV*#4_IKPH'+I*W6Q,\7/#V2.5.F63X#/_KOE[B2C,+[)ZC;'
M<,\/\-$NC^X>(_//1HYT;_S5<9RLY8PBO.G-0&7H],XTZ4Z8':4&XCEZ=A%N
M<!MZADR/VUG2\%3=R TW .*7N;3.6;U*4XKLSQ%E8K\&X41TWI C7\&1"!_P
M#=5=PY8'D]N"3DC^F4V7RGJ+[S)M-2J75A_$B_Q(9O)QE_A$K8OHI4W;,#?!
M#:>#8)<@&<=\J+7IG4P\M_3L.?7K>J?FVR'V"F7]7;3>?1ZZO7_KZ;RX]5U[
MDCO98((*\40 5 :/1L'JM/44R<D@>=.07N<O.C^B3%G5>Q,$YL28@$M^R(#I
M'G!]_^YW+.(%1&BB$W9&CU^AYP1(KA6+]50E!5DU7BYX;7LOI22]4:;N8M>G
M9?F#EX F32YST,PU,DP+M_LGV8E8@H7Q)#$+KFU?&]^1'^2?D.N2S!BFQ[@7
M,6D"?IK5[Q$/]]$M,/0<IA6>9%'3.*%C5K*@GO?)SF;OK&K4_7'K;B[]VL]_
M335ENG5E.]5 \8M-I?^DXS5:S.M$L@<&1\U6-_#92-U#F[D*>K[5!!_V!)$_
M0S#QB ,S/<D38,:-%H2N"P)]DR> _WZJ8L0DC%>/BVAQHQ'_X:M4C5XZ5E[/
MSL,QML=8_(W4F[ZI1^D*>$41ZWQ%JZ4_"2A__]G2[LPP8SQ?$EEMZ00X@U8V
M*]M\&OZ*V]A;P"<";UBOS, 0:2LM<8I%APM,XMM\N8#HM(1X:'^T"LQ.]QKF
MJU,O]"FF7D_K:U^@U&2Y4#*IBK&WNZF<NC<QR0?RQ6+40+HG!&?BH2/).(R#
MIAJ%K+FA6B_8%>3^[)UKXJPQS0SH'Q P9?A]M_1KF,VGB&D$&.*3EFQ[ CQ'
MN7G6H]C@VMW[M?N]Q^_N?)-FJ*U('C<6N_ZR/-0C/>>\&1>C_CPEUK_J"$64
MA/7(#NOF*>P>[7.9^XV]4TSW??>1:5K,RN!_)OX4@/)0?E"AB'$8&Y5Q:_&,
MWA4.&M9*QU?)OS7!5R66<_6JJLA5^LM4W(F^<5Z,QZ+S/)()7$ASEVKR&YI$
MA9+X=D^ K-!I,J^S\>>?$">(X+R#G%NXWOJMECI//DDWC9<]-XZYA6O/:"OM
MYA[!9JRH-&&'E:8D$4Z @4C=*900+5"7YH+ZS"!H;NQ.OC3^7-2SDD5O*_=.
M3IN^Z[EA"(_&CA;*P,I*YX_O?^SPE)?50]5$V1QR=MIL*;4K!'9LX7A5-(ED
MM $1T('\RVM#[&?J&^7T$)7$R[8I> 9A9P:N9K>'E]U[Z)BTOB !"<09Z\9%
M1?0A.!&>R"08$*:& 44%MTA'JX)9>@/\R^"#/3<D[%K?^$F^,V16'&#\F7[M
ME(88IN[B0]G=-.(E$/F-0J_"\0%-((\WRVI06:*<3Z?M:.-FNOF-WOBOI4>N
MOEZ<?QP.!\*! E"^#HAD&_%CL8X6K;"P&&3]S6-8HBJ$&\K1D!,OYYBH^]Z8
M4Z+FN^!U@7/Z]!4U<<#>T2_"_NXE_ F@3WG3?M;;07LZ9Y=S-B9QI%."17)W
M B\L [WY+N-1\*>ZA[O5-#&,J7KYGFQ+>;UV_Y3EE,*]YJVKR%MB$0*0/-KD
MGVY'M<'HPF0GEBT(;"EW"9Y(S3LRAH)](*P$*KV  Q3G($YI.0&\(!P&RR@0
M/*<+QDI6"Z>FEU@[V)SW+DN;?R2Z@"5PDF]9A;#S?&1L79QM(@P14PK)H1 Z
MA$>X:+\9OG[#95SGFF.C=KC)V1N7[ASD86'.5?-9,[?5O7/'R(:T/M"-![Z5
M%0(!9-W$OBF&Z 7-]3BOOD^\5T\ L\U(V<%VR8A1<".XWS]Y\8Q.T#*, >XP
M1>K2(!P:Z*67S77=]'R4Z7BHO>YYUPC2]O0'T]:J"[&.:FCO3FW[< *,^=K^
MS%P:_<L;A#P^H$DLPP8@P@;1*=*N2%/\:=%Z$IW+8"'BDZXGO[;4T_Q%OY3;
MS:H.U)CP%V1-?F9(3M^&%5I0:42(OA(;:K<,CDQ\GWT!PC6K';#Q7M^4< HE
M2QO>-XB:M&Y_]-NN_"LH_*_&DH" 8H>Y:UX^_K8 [W*P3^255<.G<;O/:7;W
M]D<8"T8()40^KY5%Z4M$>J%P?:5*S7S9FT.Q?+>KA '3FZN1VB8/Z8$G$,ZV
M\ _4>23. A1KA63;K5((A+$./O17Z^1,-CN=-S<_^$AEH'1TM? ABQ.D[73X
MOPN!#T^ 3$D\@A*QN7ALQ?M_WEER(MK@%;"\O6G1;9+OB:#>W-!KU1MHK[-N
M?@F/JU:^2_A^$YI-%/ZH*U"-Z+2&K'P/@YT L)80:E;O59$F,G<_]683UHKR
MG.:!QH,P@P?_+Y>$_JY366CX*&6'*Z=VTE1'T6KU^S+Z@S0"I XVBZ*R9N+!
M6(=46P4.;],08?4; <(W+MAMAYU9TQSL Q4A;?_5$:S>SDWKA:+%,6D=;^WB
M&FM^2C>VOBL25IT.,1K7<)Q0JGB<OB'I-4*45232M._IUWAD8B#R*$^[>]'W
ML-3B2\#IQ,WB:,W.]%A=0VTJZYWS1#/2LS!F8E%942_VVS14@P_P.P'2S*\5
M-]//&^JXBQ[1'3_#[#-OZM'A/J1COS(.Z&H;C5<ZU]4W) <(>Q3>>_;NC.G*
MN\QAGXGS;RY?,'4*RI"^/;#QF%_T&E-S=315!=&I'&:/MULJ3=2!N9*N;3L(
M-4SY%[>EF3Z_F7N]WA*R]3-FZQ13V9VC E $$4H2(/)AIOLA_TX'[?95,GY9
M>J[8,H$./,<I5Y7QC4OR:FBZADM-GPD_[[X:\00@*<-5>B&G()B/MK"NKV9+
MC-7+VKI2 H._[$WE[LR'MF@_2.X8_\8X<1$,I\SC?T1TW&9$Q*NF5WMH9;^>
M4&M9F#/U<4O;ESJ2;7Z6O(8"GP#_B_LKO[O[%W1^4/F(&I9X6$+UK;R"S=M"
M;P<;HDW;RCJ!QF\_W_W>X0@EQ 7AGA$FB<[>59<S2^"DKB?FJNH'6RV>\VE"
MKQXGR;"(7Q%Y5,KP] <CHAL\%X)Q[]V\$->-X JT^II#)Q<D(-B%?4LJ%^DP
M>D+=@&29X=P)!L1PG/B2<5); %:S@5\-P:,S&BX\;;<;F>&O[1,00Z??J/^[
M0^*) Q/>@J94<,9]C7^XX#8-:<"6'$M"A5_NP:32WM@MF_A17$4"T2H+\;^X
MX2(FA*P/V5W%6V%&=VNJ: QF#0E.JI_UD?>MAW#(5SP<+GMPC3.YK8"%E2G8
MB9X=PU[V-Y:/9HUG(Q81IW6$GN'-[/'^L9?KS=BA".RP^CC:V9,1<^:W.J;V
ME)&-E#M]QB,6MDI/W!889_=+XE;4E!"G\L?-+X$VK,@.#.5J=1/$Q]4&XD)C
M6.=?*9X +Z 6FN(Z29[,D#P@+ D+GJ,GQ%(:C[RU(9&V4ND8R0G?\[2'TGIM
MJ;-B9@0![V>N+CF7HEJE-'PX\]KX*FG#64DIT#M-_:DG3)0EZ0^7$A/G>CY<
M#-SU&V=^&9OY6!_?9LJ?+GC_8$:+B>D=/O8HC2B^FZR.JEGAZGGKL.[0GFU!
M61.U=:?^-03'A*:1>52HT'W"'<AO@0G4T38'$+Z('UQF3,&!L!H)8>'53)GF
M8[YAR^SN()WDS@L)4*<#93'IJ%;I1"(,FY:*\DV;8^NJ7H:Q$..Z("QDH3)3
ML8FB_!^F.OB/EUXIL \98:X]J9/@*N*O;F[7#3/%675!8VS7$R/$F"5QP\F.
M'QKS3[^;_YZ^VI/>=&9GAA4DL/*23GP)Q!0Q#ZN7[OTEJ(*C)_C5-. "K\]M
M-CUM_1M<PK/;Y;B[Q']%Z$Z\17KF\ZL\.M(DFX@Q6.WBK@A6(195KSN2OE0-
M(K[WJ-P-(K'!)QZ&<,K5Z-SI_W)_UJ X/:Z3P5D\)(@6:_)I<?7V&&3'MXX&
MZ'8M?]D(?2= # G2YQ_-AQ19P9'Y0@2S RL5KK%1XZ/79LS6E)_G]0_V[X.%
MH+]&(0XTHNJ.6IE4A9*$?$Z H^R]2-UJRQ/@%7SA!)B50U!4<VE83A3W)^?J
MKE.2IU'',@M?G_\/'HC442 \FUBBE$(P%6#.-N@2_]1!?^?CA<'2CO7 A^B;
MV9:EHK,JSS1'IW\_1<F< (Y38.9_) HE%,;[R6G*_N$6\J&1YB%D/&-/&/3L
M\2C1:JL$"$W;Y29I$Z&$?&* 0C39J<GS0\.D1OJ#S0.)$$4S@6\>LV.1 ]D&
M!\BLN<).OC8E[#X;=1A\VGGB?6M+$R[N^=$75PV^0X'5Q"E)3_XZ9VFOYY%,
M5X%R%'_[9?@3#*P[S[F/*M><,7UM?$KE$:Y_S<3L6\W[3^MKDGE&LJ!N%+A=
M.,R(" ["*R]:)2+BW*:6[-[N&HV8.!^\E\MD3+W.WL'KVL&@Q"]0 $IH%Z+^
M0#8@=U&A5=Z+S*6XZ:[1N,8<7T_O,N]SVSH'69VRV8F^!Z==Y5_<$P"XKJF-
M$M<)&91RVD! !(EN_LG'C4EX:2RU/(#@_,S97_!E0316PL0QW8TUA.Y";2/_
MJ4<FFSKRI CR36+^<2J2I!PQ$O"+Z#"%'0N2/3I'&%8)&[(75[J>_)B_.M?N
MI>E:^[_,&7$+$1/'TUU(CBVD<*6. O8$ 'VOE)GUT)+JS[O<EF 2'.09<?OM
MM*CG2BKH-MV??C*/&2$.#^M(FVVZA4=U#]\5DC<ZM*J/UO[H>S?H6:A3%M&&
M)S7XXXB*@R1&(0'6< +L(@M*D]J%O-&@+L2IZ^6^S@'EMOV2(S5R8:8:BN8Q
MA[Q1<S7&OT3=^'_26.@HN6BT _*;5(38%&X@(':6BSV/03LDW%2WF?4T-*[[
M*?Q%7Z'!<Y^X"%WKC)X_$KG 7P7"$THM]2*1CQ +C434AU=&XG4W[KPGYG:I
M)FI/^2Y8/XRZDV%?+"YSGEU=>24/%6ZU!B+S]BD5DX,I[QKR9%?QS%_?R98.
MG  M+75P/3]4^$I_J=IQ^%4P+Z+3 ;$RW  F<5@C-GSO(US <P:8N"B$&R2V
M'3Q-E=AH<:@K]?AL]VMV5)PI]NH5RZ[?O-Y4UD,:J? MH\DXK^X3P,!K!>4*
M(DJG[9#P"@1_8L@2D@M.3S)V^%D/]ZNFP7MC$'/;K/7C.2[L_8A$H( =-3='
MF"?:X>TPMVIP==B1]XM<.LY+_4UU]35C%:MY%V1U[OI+>\S3WL%I$? K.?)T
MN :)E2PTU7Z*.AC!@D/$Q^54S?6J_5QMQW0MF*Z'ME5$&]TVX5E.Z5AJ1U *
M(9@L"(LS\5FY-Y+](8H8OO1+$&VN/["V:/&E.=;T@CX6/)+^1ME(H^A4*1,3
MORX?F:N(D('7Z!^-UFK/6V;[VY 2TM54,YMR%[.7NX8V^6.XUH3_5N)RMS^;
MSO3[=[&S__*N([P@\>#Z^^N]O7A"M7^9 79NSJ3BIF6 '7/Z\!2EE\=O26+E
MJ#=TJI3D17Y"J6I7\-9CH;RN./K*UFTKGM6*SZ[C&J@J?5Q1^57$V=C5-UX\
MY&%K*N,J[-*_O.KV,&LR!Z6NZC\KUJ899G>_7G\_=_>B<?N.U0\8SDA$ =I
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MI8@_,4CNT G,'#_6)E8),>-<<2K%]'$(VZGT>\S))Z7*L&PH"5N;!>M].;+
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MRPWH*$_"#:JW5;>$_,H7E[PE;>WM@[.D[PT"WQV:O!+ZHAA6Y-08#H($?]&
M%211/B21>HPZU2U#C,#V %OY(8D/'"^;G3>[?[K_\Y[ATGKDXU<?S'Y&\]@^
MOP6L^T76X5#8Q#CJV=!;2P.%7/,[708O/D>.5IW68/'?V+KW;J7C-=>E:%T)
MLW^"Q^'_980E[M)CK+3I )*P2P-*S]F4SS]&3-. _2M=1C3 'W5H)0B$1_[=
MH_QOA\U@#^YZSU+. *3!*0]#D>H+Y]((IP%))_.-#R(-1&H4!8]4'(G*4'%H
MN6=\!) ^'Z +MB/V#!>*$"/*RIYCBWB]=$1?AS&;!%5##;SX+VX\?WF'0^=)
M'9C2TGT2;D:$D72V\M?[)/C,0@9E0YU1?C!"A:+BTJ5O4HEL8VY]J7>B>P*8
M3PO^BL>M$^0H)4C_"7Z]%6AR_OCS%YZM8)5M)]E;WZ\9/;6[S=VFWWN,=R@P
MTPSQ 7X1IYW1#P%" _LT75OY-Q>%GL'*ED:#26NAV+3KII+K1S0!;4" @8C'
MM5(Y^O$D0@.>D3B*)72^"G5ZO\TUWRWKT?91YMJZ;_! +-\!8&P%.W9#_@!*
M@%&>DN5(2F2UV%[$4?OR!I+^LJ,CRE@RHC/1^M:C=PQZBTG%IP!FB7V+BO_8
M?$ORDJXB!HLX:8"WV<6)E!_7O; L&6X]23\^Z$?RL+WG7.$KIJY&1XT,@=3W
MY78>T?W- 7&>I$B=S>UH*<+N:L(2MK]R7_[*\86G'/8Z+L74ZJE)>S2;M-*T
MOF3:H9L!$):1 O&JBR_D(!;<Q?UTP@_EE(8.'0AB9I3<SB!\?6W@OFD%4MZ7
M6'W3BK^^T>QFHW33 '2^#\G(9Q[%"^>H,"HC'AI+F8YI_JKWJ?AES,N.J#>M
MMU:Y'W<RMC47<A$Q5-1B,X1<6%^!)'8SDZVF#ASM+3IGCT^?:)A=<7FUF6#(
M.S3Y#CG7F\W#<?>UVS&&& 82Y__<IO5_.4YW2:8T8(0/#Z9T(C>O66\>? 4W
M]9"SE'EIP%(K]:]!7<FBOWN,_VT0Q"";6G<+<*.$V],/B8VV)/,WTA&[\$ME
MN[F'R,M6QPT32=]NW@O(&00B2N%!)$]DKW&7%$E^RT:2;T9M'>\Q(!CMYJ<-
M?=]<S].9^=ED/N#&,<,2&6/I6CT=;=+QWP6YNNE755&S@!VSY)$9/ZK$"-=8
MB$3U?:T.!U.Q8U^S5S-%GO25G8\*N<<@4E>-D*(.(%F[%<FVL5CEAUH2K(W8
M"RO&:]_+<G;F[0';14^]I1/6#(@[>@ C#RL .4]EV$(UE^^VXOO[ER$/!S1;
MHC%^JM?3;\UBW!NG=IWI,LU2EUV8R^:,T;BY;C!3/B5UMLD18F<?\,K6#O4P
M[%:HP0=YN4?'-[;;Q,^.](K/SIT_O^CV5"@W&&]GIQMSH3B:4=J3E;$R'6!Z
M7;'QORW$*ZT\.R*'*F 5IG=]E$K\JS.7M<ZX)YO?%WSWCDWNN.1!< I _EW>
MZ2^X/X4N@3QZ4B0E\(DQ,-=FHB/,[ZCL\IA<B\^+51.);S;WN,ZS7&1B6SOQ
MW>DC2139>T6+GW33;FDC9-DFCGJB&MDUI23S(22.JW&QG;02<\UC_7I1%^O6
M8?FM:=^@795M\]GJW0-NG:WS"=CI+9GLTR5W$VQN,9^5BN&&GZY ]DK#!<NI
MDSH2Q%CTA" TU$A_IOF"^NVNBURL#B8",;HM/R7O>&8^$C^Z=O]>.,#PLUD0
MTW.LQ\\B#LG0+>6YS(ZO2S;/J?6^+KU"$36*6=1POQGVDLF;U0U6+.*KK+Z;
M&Y)[F/94.#AG.,A'RT?!J@\S?>7N([>[O<Q']20"=?FO&P@ _S=C\X]R*CSR
M'S67)5OYU#_!2/_9L5''<V(MXJG\1+OM <39>=\N[1=V&<M.T*N\@;'QUS]^
M6HFWM"6PUFTB9&>Z3,H<ECU%T]*;LM0R]QH[3%SXE6T7,C/9+S 'B6Q"TT43
M=PI(UM3/12)[Z\12>K88US2FLXF->./'%2QT[AL-L'%A?&I^;FKRD2_CM.MJ
M%"*9.H9LG>]77BS LO9@P.Q*]:PEI4O-JS>\@Q\*A+1L;:4IV+H?9WWPRT'^
M;O0PE_!;K=MTF9'62'Q",@XM&>Y6(\:'589";6=+9WL:%=$+X4M+]UJ]%I)L
M)^\R6(]8 [Y;.OF47!K@ DDL:O!_J*8CT)C_W?%-LO.L.D6O]8LC$-CDLI:F
M.C[(5/S9-G6^<Y+M-&X"8Q.'X";>0O4CCN H>8D//"_:^UP@[/D"CI_(TQ??
MCM8K1.1O;?SGWKS7,:!T]*"+#H5WO<K*>DH=Y1*I4EZ$98.RY\=EE_?597(Y
MHUAU1\]+.]D$O+L;I2-%2:4!GA.IR/J]X6?":(T!;F'+-Y/-BE<E-+4E-T1D
M7WN]_)0G=)\K(:[^\TV^.%;YY@:+G>:;!28-;;.*>VN-K;F'7V[?[0C]:Y2O
M=?G(IW=LW9J3+!WRWT,(/RA-5$WJ>V23>^JA?X&'7-]"S=T(GXB'9Z>\_3)0
M)9_]OHA7Z@.5GXY<3VD)@-Y!?.AI-HJF*\0ZIMHW&/DO>:]9'$T-VN\H_?C%
M3JI],XO>S837Q$[& &SU?[>A_W%'_]18!YG=&M6?\6^6N+J/LIC9=?&J5:HM
MM7V1H"[B$>+,^(I).B<:FE_47$X6)%W#T56JEBK.\-A!C;'[:2V;"-[SF:WZ
M!,_'[C<N_OK,_ [C(#[)ME$W !;W0G*1.;$@H6V8=+AAHLOYYP\FRW[N8R_O
M"$8\Y6&K0:C#W2FMB(O492<%9&+1D1_:1H:XW:]6)&'#^_ZUSN.<RPXX/ITP
MAVJ7"\Z?12G'*0EP,[P-=GAGG;"7WN%Z8RO_T0"^5X)0)-&5U^$S%&V'_7Q*
MKZVI1.RFBI]T8,X.BIMZE"B'IA8$W$47'=G4$6IJSQDKU%;Z>.)[T3&N5:YZ
MINC"OQB^EY/Y&PE*'VF *X399P]KYJ]M.E H$Q'FOU/]N,!4)AGJ?/K"\J]'
M/W4 C.YF>W?'_\%]!&L(6;(RKF<(PK(E*8!/R(#5>MJ,MMC[Q&\8?7EP][UF
MH?YI9LF$;BXB/2]D[L<7[:R3[+UT-'!UZ35BF+6"#Q/B8R>WK'0W;'8:AOA'
M [)[=# _-5AN<4)+FBS95&D IT8?V[!<K\N@Z$5\:.RNG![I =)O'_^,:K[[
M:5A;,W"ZPYM,%VXQ68@!^KNN#_A9$6*)+A&OG,[E:^M;-3>$""\ZU+^H6RR^
M$Z*&/.[,=NY Y-H.88\H%T(6T$-ZL<1B?J9?]T-(V2VI94*O/+_S<275K<"3
ME,/P726Z*>IV0$PQT[>MO_M1[?\N\D,0SXG%)<SPSFCQYPGLQ-$%_3KUIZVB
MB!B)Q:\''\T'ED0O&=:^57X\VA2XX9-*>82$322@F@@YI8M&%0NA'L.MIB<*
M^FPTE/:?V]QY<;KPU-Q]2[8^1EUIWOT<7;#9=4LHU-XK-_#+LH.!EQ>CB$QA
M"'M6L8C"AU" YVMWZ$<(^D518VY&3<NC +S5U8C2^_&[Q>V%7*D>/_$#4RN%
MG:\]F3:VY,%].F<GR9&8;>V(_O WA>TE3K*DB&V.7,^7DA_*1238M]A[J_>2
M4 )P&5QB/ZR..#&@B4SX$1\@O-C,$><]'GXRO7J8>=?2G$$[#0A2LWE(EJ<T
M4#GAOGC&#2=N8FR9]^)H'N\GS5$_M27$S]S&D\)H_OWU* MSGT5ZJM E/XQJ
M57Z;D:!S*J^_6XKXZ.7"]MD/?NO-T6[M^]),C[*>&]F^VPCAC>U=3SDH8B&B
M=(EIF$[(4;J8:)QO,AW\PG(0-ZI@$1O#($'7U&'TKV+N][^G_L]6AO\HU19"
MH2O]A0PS+K-:%EANY?Y<OJNO9>9J(B2JS:0B9[FE %N"R$@Q=\>O84(AY4VW
M$&(4N2'ZK42V$YO;"^79Z)3IT$6FW+!5T*>LM*V?,#,BA7^!N\.BZL!OW\FU
MX[G7=BR7S<HZ'KZK?@(-7,HV^F _RI+WU=K9\%P[XBSE$0U 9VF6)RN?P"<.
M=RY@^'L6D1CAYG;EH'L?[IM]>2OG;VYR4R8]+.BB  .AL!Z&J2.>:MT)[3>9
M;;;@W%A6BCWW^=CL9[LQEG$1:=TEU^L*TKQMK$YZ(LSW(0UU9'Y]3-'.?!!K
M>V21)'%<""547[ETQL!;#[VT],TMK0.^,_[VQ]WI[G)<3WQ3!C,QQ&+R ??Y
M)>.I)N(M3GLQXSX#+I<7K\"KA3ZW_DL6@[^.+<OI$AJVP(81[H>FS-, 7K(Z
MNE-;:K U!?.M.-M"24H6/I3"M^S@%MU[JB1U1>0B0?,4$Q8*T(!>:X0$L6#E
M:R-N:<!.?2]&<;=N=<:W>=<NB-<L0#Q!):=LBN#[&IU[EX)]1!@/?+=JTXML
M72?S0\V)OR1^9NB(]\)>P@VM5;Y\6C7PJ[D3V/8C'6FT,9PX%$+7M$09\  H
M]:>F18J.)/GJ9%!;DS*7D7BX4WG-H@E7R_BQJMNP>US1-EPEV5$NEZX"#(?_
MG>_8L:%=[#:0$A!?4%IKD="!3<S^W/R L&9D\]B[)--([]K<W(*&"P86CXR6
M]ZW#1M@6D1Y[1-FG-$!"AYT,)CY'(T7JHK5T\8YF%0XC HWM[0F';JV%XA<^
M]5[7$V%:O7%Q/+*'>N1WF)Z=UI$:P_8\I'+/O<!]:^?^Z["LL?3+E0D?Q-05
MQ]*TO,<OW?2S$FY)@__ZIHC7>%NT^) 034GODD<_0RBW0.'R<Q^FO3IN5?;Y
MZ>SRN=^>%A;Q">%CNW"C7"[@%ELF:#J#>!K2#TF#"E'9/"6/$#U*3;"LG>W?
MX2:*S[Z\R<P]5<+BLJ!6>5M2O\<Y5^J]92!JA,KWNU%BMX092>MVSP!XUT\#
MJ_ZM<-XF/P;%8G;&F9-]P/N:;WTJZV?[ "X]2T.(;K=$Z(H%L0 -Y@GM-$%1
MGM1NSAT^>IUY=^ZBBXUE?R/P26I6E$R7X#&IR-[+<GB9CS][P;&-)A6?H1=G
M@FI<S%EMVCPNB0[-^YL*R?FT;6=7?9YD$Z;/C#DQNDX/[S-$Y;C]-:]?PT[>
M!^1O[I*P=1&=[, TV7#U[4KMX'APZGU42WIS)6(>C+ONIXKQ\18^2K^$/]9T
M7?3-RC3H>)86H5)G1NH:M[@NRC3=O4H?A@]U* 32L-=O/^8Q>-:PZ*C65=X]
MEUL@ J?;UTM^_6D+,D_3.18O?N(@"F-B1H7)@H<XASL0LH*B0SKJ=/8Z;,,
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MHR(U#8')18$@+G<_3_M)6PJ3:4IB&QJC()G!PP2;Y,O.I:]FX(WGN6:!/T<
M/^P,81J?1!#L(BV>I)S2*YB-KJQ"RKR<!HD/O?8??5CVI?%4=LC'+\M\F<.,
M361+0D!G(6.K%&M,*PA[: ERYX'UROF=^0ESAGU65I JW+HD&S[H__S?AQ37
M<QXVO/B9.:699J;2U''CDG1!5Z$-7(/@DD84[#P8CMX]A-;_:FZKR++.PLZP
MH]?OACV2C(R<$!MA&=/Z4O:U,S/FRKDO4E/Y4$Z*-OD%#OI=L?? M6LX/CB_
MMX$0<"=W<X&+N+LH:P[I+EW4, 2>5#T!A,&2I\43FGA0F(I@6/C+8K*5C9*.
M,WYKR(UQL_Y!F:DF8[KY1;:EYIA+Q6F/8@RYTHTZ,U\F1AQ?/XZ,:Y>!72=J
MX(>7DFYC%;ONW_(2Q5KE*LZTNA-9QFE02%OI]P:C>4U7,6Y$4[CB=P<&PH4D
MPD!GL&*TCN[CQW_,)2;E\9+N(I?3BCJ87Z5;-A5Q_J,O/.B8D3Y0TRE\AS9D
M\*$@>NH(>#A9>3?WVG1E:NC[KLO:"+A*>+-*MW,-T+T#)3TF0/#@0W;:9(YQ
MN (%4N9)XYVNT_1"6GU=N/>G?,[J265@.D/<PZ2+Z/JQXB=+7O"OH_K,_/LO
MZ-Y5G-Q_: P?@DC4^H@'.MNT)F #8YAJ(S2C<IX6,IDSX[@JEGDKOFO;/'[P
M]>FN[*;OH5^@'*F.<& WUQK,FESIM/@A\!GN!I2QHG[SZ4K/G_ULS0>:\@Q_
MVDY:^:?A%.30G,'-#J6N']62NFWOLVM'O9P;:OQQ,M=T]J^BOT:&@-L_0IKX
M?RB5_)_WS"[T/'P&0;@!9:;U/TT2W!S&I4C,Z\LVC. 7!Y*9'D>GX^S%XY^8
MW& 7>P[$(*,AKDD!I%)J(\H-#*(80+D]<@2C_H1>N^32WA!0.Z;@>$_E3"MW
MY(L?V6<-%DPD33H>C+".0PFWAV>[<:6==BAV,@C[/C/HD1\NQ,49)^=I5."2
MVF3@Z1FFG\OX5%.>Z44#:PYA:\:.QJ:!@X ]/I%7EW[N_LRSYJ56MFJOOE9C
MGY+UWVAZH6?CO<[FFY$>@[)S*SI>6?FFIB%^84$ZYGBJL=C3#W<-&0% "SAO
M^V^M.,=L;R]:U.6L_P[$>Q7?VC97B;IZLU^^+XSU(S*3]M<> 0LX T5*94XQ
MWJ[7MN+JQVI"[>5-5UI+^J?=/ZF%'L!!<SPEA)Q/MZ]<<M(2^^+F<(S#\?%6
M+1D]^]M0GPFD/>EL/,_)(^#S75H=&A1U!#3(X@-V-CX'?IXS:OHY;=\L<N;%
M[='VKSIM2P4GT/,W6#<*4XX =W T@AV&)D+1$,Y? 3R)N6;YUQ1KX=PQ%Q#,
MR/Q6.@MG?D8M@"FJ5G]?;]Z*3X1YC]9FWW4>TM=@D:<&^_8:J^W(AB$P<5J[
MPQF*27"9M=D H-^SV'W[/M_FF<R2OFG' ^M1/;8C($*'PD08,_(+QT$$S3H1
M>''++XD'8?4;PG16V6K9!@2YQD,PC7I"=?X2XN1[Y>ONA9EUYE9R*KNGI'(7
MVX+:J^DM:2/6=AP!CR@J(_)#+'HSH;I]EU9_QQU:_]*(1C@JSAQVEI58DLVP
M'^L3&<ML$6[@(4S_<%NP2P:AL&-!3+06Q4(.,6//R#6_</QI <J/&8 K4J[1
M6U8#NT9NP%"A705G":S=E7;=LWDNYRI^/S]<V??-?-!%X/?3/#7-Q'V\!X8Z
M MCG^LIK)&3:N7(8")^_25/7UUQN*\Y<+0QQ,75HFMEV]>$_Y"?*X:Q?0+PM
M13V@QVD\Z[?=4"=4F_0&EB!Q C#V:HIM:.1SK^Z8IYVLAZ]XB;?A@X6<&"I*
M7H]/,;IB.!S4)>4QZZRX< 18^JYD'RYX;Q5^&\(OJOOJ@Q5AI^C-K0TLQ0Q'
M/$>PN8'98:*.16N?CI?45Q_>.9-+?NOB;I_E,L [(UU@'B(8B\ T#AU[WT)X
M87,$G#SP;TNQ2&L%W]ZCLK8%KT:J>:9\3^F=@K#K*75ZX5(B<R8670G9*7YF
M-C_5.2>?4PWB,0#KU]4P%N,OQV/7?;CA Q 6G0?OS6]C72-]<BQS\:Q7ZWG%
MEI=-/HCF94RW ; 2+(2L(-OYXUZ6KD^W@_R(M.Y#N\ +CF)[<F=]*+Y3;2V=
M*,+-X9GQWD$Q_T*^YW@]%TWE#27+!R</6[]\)/_N>4ANH;%%'FH&5M]#81EH
MO8V0[463">\'?:,ZW6":MH/P$I1\&MJ=?^V2:%>['E$F4@7TTN-))T*D\$$Y
MN_/ZS%X1: 3*0>XV(%85*+;J5JXU[Z;U7G@^T/C;>;7T6U3\=V0OB _1>0JN
M U.;$+U+ ,7_"?5V\UWN+UT<> ^%BX89TEVN@B<'+(C:"'DX)8<+I-SV>VMW
M!%3X\'ZG4YE[J=JBG8U+U!GCDPR' 89P*Y@<?3;F8])%$2\@7/7G^EY_(#NL
M:N[VU/;1G[:>11Q'^5B&(T1:XYXK@M>F;//F.17M9+I6 _9.FD6G'@'3ZG2C
M/A9O^.#K\4NLJ88*?S\5_U?$A9S1'6R=J"J*Y[,?K_0+/7T@$['>NWU*7L4H
MN/P<)IX<B=VB\)9V'P%L* ]S$,XUJM4YZ'T@]%JCYR^8UDC-4#J_W')"_KY2
M?I_VR_K1VJQYF] E0P!6>&B'Z-1O!\.'#P(28>><*T,;<'59!9PQ">)Y8V>;
M7EOW+TI:*O[DE7]G=NR.\T> #-KLP]"UF-:!$J=P%I'G[A8< ?2O"M5^[RWV
M>S:7U8>.-]LW;/F]<S6DN44O^$Q0*=[]4&41/@>N*^SQ3(D*#GVI0E:Y7E\_
MY2/[\FUP>\7;C^%"E'+)%]<?YG'2L9"R:,-=Q,Q2%TH4Y>X3<03PZ+&0CX#+
M4TN%G5,)98&WT5J#K:GS[L%UM?&GJW?R.#M'YQG3;VH\6'H @#^I6L?2>E%@
M"/8-[=@O!^E6"<L77AKNMM3R"WV1-V+9SSZBB2_*AX>P 7@'[#\ ]?D7PD]$
MX%_37>LY G03&UI.EC5*WD*#N06&#.F=9R.%7@A(419^O2T<\S,T7C0\IM=S
M\ APAI+/[\72)!5C=7B(=^;7VB^VIE6BL-+*Z)S0B>%SVYF9P+;%U-6AL2;[
M+.$BT&C\6606ZO'6W$;7$5"-[PU_/[\&P@USKQ>O>)V?VGT08N>',3MU_CO'
MXOE$W[HAN"UPD!7_DR80B-63A2D38A.=:KWT%+E_D8*;9W4*',,LCUWCKF?!
MM1#S.);>!>[A_0Z]R,8D;2A["N^:2%6=1ASG\ QV#/9FM$+/:B7T=R/3UR+G
MD8,;K*.JUJO6%+UQK"OU^%^;\MJ]$.3=T'<$Z)+W"V()9BB!>'[H7*TY^ZWZ
MK"WO#U]2?,2>:6F;7.$'@A[[YCF%Z7+%D]EQK!0!*!8<K7/WZ=M?<# 1E"!?
M^5[9M-RV0JGS DCA>,#\QB\;F9"GD=!;= !<QQIV!'CXL/3CP$S0 <F&I_RD
MU[ (N0'!2^<_%[F(A9D\DB]E994,8]A0_<^X&GC[_I2:B\N)LHOWD@&)NI\.
M3-2R=EZ*!3GI YFOJUUK;'?XY'<I4[7,8G^KNX<+]BVP)O\]GAJ>Q9,,HS!;
M\B &%0[G:20J)NL8N!>YWWPH-Z_^,)]8>.%LKZTQY,<-2RR4#P:F>^C*^[!G
MU ^U$" 0BIT?#]2VRJ]T;L]RIA:%'>M=&WV6(!)F)F/*2 =6W?:+>.TC@&F.
MW'9H 9\4*8SS0XJY$V%Z^:DS]@/2Z<.E<U[ 7(]G6$NX?4:CG/>\!<ZJ?82:
M=_17->!8R.>M6$1-*_^;BH =(]X]NU9TPW3CZE[Z T??T9/G4Z[OZ(M-]VQ]
ME\/L]2DF6!5R4Z#%]SU$)F[VB?<T.^CX-[Q1COOVY9)7$<-V)A,@I(0,&?T3
M @*M^3>[9#_R>;\VE5:A3LI*D[]Y.>S!^=-A)QF^GVCZMU94$V@CD'K6+M1,
M0<]<;[M,C*ZU"_FY*(>]!]_3M#B#?8;-,7XHJ7SG-NX(H/#;+0GV5?K0>!0C
M%D2:">B J!X0"<9Z8\K;8.EG5V:"U&'\O1!= /Z.XD0MT1.%,8S#9Y86!=?:
MP?.YN-HLRXOKCAMBQSF2+RJGON7:W<<2YVCLYJICYN\H8 *<73RADISJ[>2;
MV.<I"C><)WWUKU+!]%%XC7$IO9QWR*5+EO$RA+$%C7P=7DMJ287]:FORMUL7
MC2ZY^(M%O$$9MC/2T$< *\I5$Y/;!>>MS["-X]B8K;JPU4\CI,5(#3\5,L#K
M@[.F$#4H?,+A\_M7$$NB^0[#W3M*::[$.ZOFGRR-D@=/\HW'F'P*''C&&7J7
MX$L[CB*L=I]C7D1;\GH4J+4S*CH['P&\A_)[MVM?VXEKL%X_"(:_&-47$^P&
MA:&XVMEGJ(4=-([15M43^* *+W[75$0#_=<TIMZ6V?\.[9N.@#B)X^/M9P*E
M[ E55=.F[S8$GMVSK\OL-E!*FO@XN_Z,"S3R1S+"X-?9(BX[;&$WA!,F03#*
MQH*/KSWY=2"0*YC-W"J%] _PKMA\=B]%.MW\+B)R@3L#-X'@LS,93EH:0U4+
MWCF\/G]O/\92[NOB3^JV!;ZEC7@__R3#(,R([(L=3G!@G]21Q0V>%W<UF'BC
M;&\[I*G;?4ZL_%RGE9!DF,&74M@E@L!K0D-'L&#4<ZOF4#FCVN2O,\@JD:!X
MR8YY?#\D51R@TQ>M?RYSR-C3K@#O+62FJ4L/XI"QL[H]?XI6;WV.W0QXO:MR
M^6XN:YZRU%P&E)?R@&YA,N[9ET-0,1(Z!5T6U]SALG%FPGH1N#,<16";[TLH
M,5KQJ#XX%OJ]L#YV4SBK[@B(BJ3QF%GX>AC5E 0Y?SRW$W=R2?BT^M(:]#*,
M@_ZZ2?> %4X(;CIRT>PEULZ6,/4H4@_I)>5S0SLS0"\!^D%M!]6'^"Z(0>*9
M20F5 5U/UD0V9V3M1Y1=_6UV76?5KX4N6Q6!3,GFQ!WL8I^Y(I[&2(1GXTPR
M _HY*[XW1B'&3>QXZ9S[V,W[5+@ZS('^25.8'5F[[ CH,B>$H/&X=[6^"LVS
M0\]_."R.%,_S?!'^>=^&9/'T+IS.KSIOMVO AYNG*:<+A6 :3W&O\,=-BZ<>
M>&G;A <_^ZE$>4@CLCT.)>J#:VJMPVC#D ;%+O#L+4T%BC+N:C61*7*%0*I)
M\,0\3><QE;N@Z^S2![-&_>VYP/^+."@</H#!4DA/Z?$.+'"9J?E/O"J5:]I[
MI7%"YFM7,2+!YR+_[^JZ$/- 8[S9H?2OQ;JK#KRT2:)U7*O"4VQNOV*%MP[D
M29I&WISZEX!SW<6))Q]UVC=4 N!J:,<EB&MA6+/ZBX\K/@(>CV>'X[S?>HV9
M(_1$] <I=BS?=Q9=0G+V@NG(BR:^7X48'88]H4]*F26AY/_V=Q$':%]5<6Z:
M%@H7H7A33G\F,KG^V4DX CIR$"8;^ -R+MUQ$*YK6XI?<?;!%:84"E#,7%V?
M9Z?:K3?_:K)Y;Q^=QA37:7^L0TE86(W4ZOFSM[RQ?C1I<.(P!_#[NT'9/\LM
M%:9;WRY_$);^<Y*!S.:)@X HBE2DGD9A0K#O_<7Y'IRVG'9"@L\EK]U+E.&:
M>7[)_%)I.8;M_0_S#&DD\&;N(3M%@EJ.>%08M7"**-:0YCFK6[F;_VOD C:Z
M=)"R)?(#CB]\AOSQTV+ZM_K2-.3Q$3#3AS'&ZV(+A<A5B_;CC\@OL&TL&S<T
MX**3DB$O;ATW._WCJH:/_N4J'".@SZ')O^_[/I 5%[O931C'%N(9L8J\ZJ\=
M<?=*(Q:6+/WO*:S&W[O1^23J<9JXHS^PK,1Q7&B9D>1)&B&NH@NCP(!D!O9,
M]%#+TJ4MK^>YT#\R$Q?\+WYRO\P0\_23^+<3VZ;\Y,%#6_@PA(_&(QNMXTCT
MO>NY)43^B;RP6M>8-V\_5Z%G(O'\M5SCBR<\S[@EA6G\U#6R(%&X71$F3+!,
M>MA@9KJ+EYB^D;.@DQEO*F7U_%:0I/(#4!%RL)!\P9H2#>>DDS!Q.L&[7$.G
MCL@9;9JY*V:1^B)'@Y;:#<TJ)-BD"-F22TCEA-+HWS[P_O=NS6JM ;>Y[;X$
MK0:DD3Y(XQ2E,<<LM"3D=A5)%D= QCVRQA'@Y))T!+Q5FDZ&N=,=RQ/8*?(/
MXA?*52*\$CE8X:%R>4]+:>)T\ACQ5+0S#S//?EG+397JSHV1O#!0 468:$=C
M6Z.'Y9/=1<C(YWBQ@?.=7"45[KX&[J=TV3*"OC<M/0_7WPH?#-ZCG/2]/08'
MX)T!"\($M0HM@:1R^[E?_D]L^'[V,0WM?"M[!K<V^<DZ<6D7*4)O1Q&\!W4"
M+@P?3@U<ZI00KB-D(=^N"Y"JZIFC IY\]>?WD_X9/MO93-U<U0F$IK2Z5U'H
M'8HP)AO4G?M]8:ZK7<=<V24[W>O6U%/>U>;261[6]QW:=$B]2+B&F G!KB8>
M 2X*4#1<B>"?A NALR>/ /5V_X^N8EO\%1[5<4LN3+T!^TF9DLL?A[\V[B_1
MV%K*%V!\]"]$>RR"))M2UZ;'UQ<D&HT>QZJW/ZYNZA,-K^^ X!LJ0[O_JK;9
M'+]$4AXM2>IN%:FC/#M+$]@)>$#C*"4B(U&/0A!D$PBFDF_8I=?N*6Z+Y_Y^
M=1Y(_LP&XY]+C,0BT/R_NF^PJK!W%A*O!JU&=&G@V$/9!Q9)*7K]WCKS^+G$
MPFPAGZK0\C[XI4#?OBPPNU_3+E+(UB/'*4C"ZZVMT^4QE\ N;.<2AP%%61]L
M^+>OI/YO$4,_/\ZDBFD-%6,?KQ.JZ8-RS%=O7+SW @.PF*HR*/#OVQU:(3JA
MLLW-383LC@3U]'MB<V#^!;LM5Z<G]&$SELYS7&;5S2A&VOUUU2Y%BKR'O0>[
MNP1):%ZHDWB-.WX7KRH>C%]M#AJ(\6PP=GJ@;318RC'7!)Q?9OR)F'4FQ5"+
M45Z@) DI\B5,$J/5:*V<Z-KC]P1JO%IK^M7DVX,3+M+,5Z;='<'GE= L$$=X
M%Y1@WJ9-LIL\343%JT436=&"=8&\VDI6?1;W "XI:9;,+U^WO$HX]!U6\1W%
MII* S?+AV+^Q1\<7PJ-WAFR'58RNHI@NB0</=#>?^? M.WLLRIYT5_S^\*,;
M-G^ Z156O *=)4=/4HS]-&+TF']MSU0,DYX39=YY2[>\?M%QJ-9PRE27(_?%
M\/QM??";17&(NT\LI"8Y0@TB$9@U;>I^LJZ^H'2PM;G/K1CZ.B;P1UA)$_^^
M#W& =B*%Z$N*(P($:*<"WRU"6_[.JP>TP;CYC8"2F52P;#(B8(<#O.#TFJ!(
M8PLG!I#2IU.2:&H;S=G1FSZOS%4\DKW56D9I2QG+B4]?ZSF&'WZ6VY7%6&X.
M$I9(/B.(&AU6;$NHPK)^@U9B85M;2U^0B\_KF*!9I:(_-_7!N8B:10K/84^[
MU@0?>E$,9J">P#] ?>,ET8NQ7[?FL# MP/PVZ=]*44ZV/._Y9QJSUP&)/0*
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M^W2WUO-X;U&(WWOOJVRT\6=&_N4/IG\.%2/AHRC"'60<R]<QC<@N_YI(4N#
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M>"XO:$>[[#C%O+1;-E,UZ^+/XF<7^4>PJ6E#0B< _-]?>N>_ZAO]!P2ECO(
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MTW36-/W" H]4O/B-X"/!XUE@(_D&J+?P ^L,WL8;G+<[I\U39)CNC]WOLF$
M%0"R!\\'JF:V?D'=\2*['"=V?OHS^=LZ&1%!/O5U R4LO GEHWV!N?=+/9=P
M[T+QG>][6/;^^Z2?DGCW23O8[ZZ@ED08+KVENCC>.!?&XQ4F]B+FC,=^$^WQ
MB&JW+20<6XN(243A8J&"C;\EVUL$:_/42\UWDZ JT_L'!FM@^3#>$99]VW=K
M=L%]!;ZAQ3-&H6X/(\T?^!0)F!W-3RPOBN0K*=-<@GQ<;KV!NH>*A$+ $-Y:
MOWF^C3:5'I1NT.W%#+M4LEEZ%>NY]D5*F@7&GJD6U$K:>QBN<*X&LK%',404
MF,IP#=UODG-_,N#I7;X:R)U9A\,_$ EXH2VZOOU2G=/4^%Y!%.JO5)>P\RW/
M;'X,A_8EE661UF.+DJH90.@ ^QI!F(CY*_FJN0-(HRK-$%\AA(OU@C?AG&)L
M*+> 'C\#8!'>#..A-<+<&8#T'U=+$(/_.GGIH-75Q=4^BQ6MZ=B^T"I#F2T3
M=X\PA2&D];V3.Z%7>^UJ#)2J/ED4PHC'%.R2_O,#-?\GV_]1@:UV9O%-SJ]!
MT?,-8TUFY3=6'$W>;^90KGPRETL,:3QR$,E.HM"YCN&LV68LWU)/#_PB+6WX
MUNY:UGGKL43U?<=DJY^'KJF?Y^($]@O)G;17<K0<.@"BN]:^30X:W7XS]:$G
MAVYC)U</1E*'^&=<O:B[1 9 R"/&D*_1LMQ MV('3-><%)C,E5 @8B7U:?AM
M4\.ERQ]G;F5'EM[X?<3MUM.MJ]YOZQI'F(PA_]S'CTT)-D1(>),X_E<&\8+=
M_?7ZB[:<RP?,1VU.L?/4BKE=RI89)++3#XL2,_%6(XZ9B0^4P+SR"Y1"YXLL
M/L65?.P;[W\T[<=)CS  ?QMV8:8=\*<5;C:YX:3A>*W/)T(Q'5<2:/Q%C]SR
MNRUN7LR2?Q%]]9743M;)0]]V^=B8SIM2&!MHC9V,B<.4:\($.S0[;CJN-'0-
MA$A>JO)IO&+[EE7G@-WMB*]*.1B*/^(D*C*XN ,SJ=0FX6@<0"0C=@C>5A\2
M3>L=A2JJ%CAU.MVF/+I%?ZA1#S2W$_OC-+;$$(&6XS4A1<U# 7HWMM1.NE(^
M=AR-,97I,M=@<;48NN\OK35E/:Q:L;/.=9>_S=M3H$O(7/?$FW A/L,3,_^=
M;RHWFD^3WD41]SH"9V5))S'NKU?JCO^Z"8=?.AI_>M/Z$0)X9 '<S?E33ZYC
M.M)Q2%U:IL^F?]8[:U&0>* 43X/Z)3S!'EJ[DLK! -P/]IGU1GT*\_',EZ$5
M,D&\&:8]GEZ+>>JCA)T\QN?[QM.UH?-EMEL;X7.?Z2_;12!$E&#+-!%W2)!.
MJZMP5B3+QR_5]8WI&PGS_/=_E+I42[_VD6L[[5Y]Y.XY,?Y4.]3=.5"A&;/
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MY?!6X5$1F9.7B[V/Y<W4H$L)&>)"A:6TO?-%\3L%/V&XO4YX> M 0/*39!B
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M!15$G!GO0#^:=6X:-@VPNFC<Q^WWC#_2C/@\O=B14D@_S  JD/[C=-Y9%V1
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MJD3T/#"4A=RRUR9)SD-BZ(*@_ U28'P VU -CR($NDD8J>OZ:G,@W/+TG?>
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M["UNEA>W;#^<X66!%$%EB.1LO %OA\G@?;6=+XKMPO6UU;6)9D*G2]K?E^
ME3SB7-L6!\)L'A)/?5RT"KE+LHZWFPE(8  U?Z'HB.+7EB=]5[0PD*.5(;_"
M8>S0$T@VL(/"2T74#=>$T$S[[5,G=GA"+K@G>GU81):\RNO?L\7I)9N+W?KF
MM-$_$4/G$A=*<T($+F1DDRU&8EOP)X9\^K[O*/Z:"+JV-LC* &YB'6F<X Q1
MO6VN1CO"G5B<Y-]?O]JWKG'VPJQS5U'OGENTT3>=Q;L!;)$<"O;)?[/)7BYX
MVE)CFOG+NK@77R!LPMDE&J?1K?98<;0]-V4Q(3]*=?F[#F4^'!I+]$VJX8MU
MD:X>;SI=/N$]J3FY&4FQSKL71S-=,C [SR=+]'[0PJOO0-0F9S$-OA>8L]PY
M*SSR *-_K$ECLCFYPN_=M.R*NEHNU $KF75+\&FZ_O@$ZN,65;BC%2X,Q;Y&
M7HJ&Q#0K(DW5)WJ&'L!'S(.BH&D"A?1@P2X@](^)B7< SVZYO=:PF9_OF</R
M.8K<R45W3\E'<FR></S/=[O^PUK.!K]#LOF5]!H!E!S3#+(U^55X,X J=8(G
M*6RX4X+5*VY>A<?U4K1GW#6U_->?7S<^FS"_ W7^N:EP*>IE: $#8*.0V#?6
M2<4X]0YU -'-QPFFSZO''&V.E(9TVEW<QN0&JB[=%CS9\S%7[.E,HE3$C\ "
MH18/V 26/$2$=,*X;G3YS,_Q(P([)/*K7+6*BWI]U*I-Q'O;%-ZGJ1S:[KF2
MF/PJW)#:"Z93M":0^K2T9E[JPT'-WD\!UORSTQ.S$Q9'HZ,1Q9^V[]6?8%7F
M\OWMKG#Z*D>?,BO9F#P..I $YZU;=:CBQ.@M"NN-3RUU]4%JOJCJ^<A.E3BA
MC[=B21^$#"VD;B6.+P82VBBBDW1LF"3HZJWU:9\!Q-6"NX=KG;+&W=YKF$XK
M/"R5K$.?WO[1ZZ[C$D5N(7N0PBI(K.0@T'O>RK]Z71<34^Y[<NDA2X99!)=%
M!&T[$-5:]KN,SO6" <C!HU"[6#L&,%"^PKJC\B]KKBYVC:3^HR)UL[[C5U$[
M(K@X%?2(NG:UX[@$_RH]L1#B2'.GI;<LCOTM_?HSNQ"URJWYYWA1:PO/WSP%
M0TDVH=GN8(3?T2T]U,+NS&O]?=IKO@6F6L.89O 3\<?;_C9,3+.<QSB!'$SY
M::8(]3WI'1@HOO.CP?XYTA8L+9EA &WBS=)=QSJCG2UM$SJJ!944)4-RBY/"
M(GR.BNW(O%B?(SKY/)J<P_F&:P0^5#])-1WW>Q=TNL/GQ#EL53ZLKTEOOKBC
M=QT%REMWJ,34WQISD9.89@#')>_DS).5?U+X_425T%E,CC0*(YK-<=U8A7T4
M&SGZC*>OMF+6VG_)%'[OIZW%Y@'L,*UP'2Y []!FQ<.I0O2M#@E7,8W/FJ$A
MAAZ#=:61IQ\.5NHE$2_X;:ALJH,*O/7>[\.P3S)2=#QK9A[L3P;TG]BX>F7G
MCYLCZ$U6CX,>_5OUNGA< [^\6D!,\=['9K6<.O+1.<@GM9O+4JS_"Q V-VKE
M1#>R;]GM8@ [@G9K[S ,0#9W;A_' /8/O^+#]H-*RQN6$((:4>\F*?GSO,&U
M"V,:N9B-%K8UD;,?M= :9T)+-\]'LD;GW'>53;2(/&PG8T"YC+Q'XB-P-*M\
M!-_.ARJ Z?CHG :M3)^W7Y%)#Q@ Y;+R XR\#F=G^YEOIU/>?WMUB'4,YEXP
MR8: T ^O![Q#.'7JOHCI1%"MM9X5K4Q>FC]7N:G^U(>['.BQM<WUI&_[;*KT
MAD$1O/UT(6LR7P<HV24C!'K<2>^<U<G"3"B.;A8E'Z_8$#MYUWGS;58:9W=,
M>,E-UD$H/[CF*^(E(TM[48..IT.(>VTH@E[2192(LXOJ-8MWIY,*+M6F7>6/
M2YU2A9(5;EUT<_I"2]%7Q_N&PXA7^@4\1&3.#@>H'Y@ O=8IK-?3K\:;VXUY
MOLZ[)1 ]Z2"]=*W/PDY''-./BB\XB+Q-=.\.=!$C749KYA=S'UWE]G)12;CS
M-F->D?578OCES9]R'XQ84X;+QVV:D@\U1/8'M6;@/AB&?F6'7,-6 "BK^@+Q
M9L@J,;NR*0!?YE&-/N/C,B,*S5:_CL*_AHJ@!BV)*#I?!0I<"N/RA'_PQ:H+
M(,*D SOH7-9"'ND,H'1$'U9^8XW?HD_G5%^GC.GU<+.'*HDDT8TN$JK]=NX-
MT&E!&JJYW)=[_C,_>86BE5_X!4 9%Q '"KA@*V]!YJIA'VNA/D*#'M;/"G:N
M4B$,(&H=3C\'#X<?1+GVQ\,@]ZDV= 'BCYFNOBBVQ_JB'FK/.C0B+EDHO+7_
MSJI>DV\KV3PP)5%/%?Q-CAVTJ<6V)STQ% W<ETU>W,6:YWTFO^*;A?]SYV94
M#:7V_OWC87Q,K=UEZJ$4IK6L?R)L&5\7P5M,RF  =J"3&JVG?LA_*HFG<G/+
M5DC\U^ELU^T%--+X,>3EUR=1554+CKL5SY+K43YOY^I*WW7HO:W]W7K+.[;C
MR$>QGF/:W-)%+]W%7_&M>M,E!/'N-*&6O^5]]L>9-/@* ^ Y3*RFQ\.CF(YD
M*-,&8%7^% YNF):6_9PX:Y[@I_\P(QYVNOL7J]PC;9G@N^XC]C_AM>Q4P8_]
MY#N@)3M:O5EY"I'_;=TFX5)MC-F0]F%%Q*Q1@[%?[76%RX_[B8F/#2'5\/]W
M"?_XE5L,ZMI YRK7,["LL'N#MW/S:0^&FBO_GJC/#V8G^.)_.-D1X5W%M3Z*
M_I'DCAO$B>AY 5S6SZ<- 2?:G-A.4XIU7O%-_%O$VZ4N'H:%':)#P*GKQ(PO
ME"L>&;KTS+-.LTYHSKF+*=^:SHC;U(1$X,(GV(X$L=F;X;9 I;GV+8A71LZ#
M9Q0[A.+>E<;GQK[WQDR/OTM9X(C]77I/(1R0RC\(A'6A.LXC51G FTPFDE A
MC@R ] WVS[KK,8UJ.U(;8N[B23_EF=(9I::0H_*^9%>AOTM7'92C5VMX*J!$
M:R;D'XH[^YO)1:P8_=ZW85]U_Q<O4O@O9M/^%X:JLWR3.7Y],?-:LC4=9O;/
M%PPA;_\-\Y'30ES(>TR/GV6:^LAS,) &^:??0-B+?\N[>C& CN2 _GV58!2=
M8Y$!+.R@_NDWR[[MO]1!9080_11T8  FZFT, (36,N]\\:>, ?">&X>M5*PR
MK\DS%SQZ\%]<&6!?M?\/E%3)+'T$=JAFXJD]2H3*Y7U<,M)JWE+A?C"N=SB>
MNL  8J36"W;L=I@"X>]AOL?:+IIZ9&C3/*X)_,$ML(F_1>QY[CJN2 A:[U9F
MW8'0);"X&)J(=0SSZ:_?8 IPLC"$<I=Z>/@7?R\IJDVU\\%W74)3V9_"U (O
M4(\NY<H ;*L9@)HUG5!6Q_3M0W5U8IO K@#]QD\>^KI5W,&WINL-@GX H9^9
M(JT@"M+C]_Z*U$<4'%69FVHDA_ZC8^^.OQUKAWG1/3CZ:Y%^?V4XP !6*M8@
MH#R:*</1*:8>,H"GA4\36N)U1[:7HV,N16MBWW'5PY* 4#=FWW\H^@Q@\ :1
M =!H*+IBM0)3*]!A/TCF7^>$=H:NISR9=#ZU,!#[ <7YIY N%8-#,V=#E@&T
MBL&Z:^:9]QZCJM\8L%CH%]7/DLP.^_8J?Y%/&1>F&&[0; V>@&Q@A1*32)H6
M5XVF7GO=U]DY.L5.+,^&X<KFJN\^.H,6AYL+I4C[6W[7_O3]%CU@V0_5)D0_
M7.ZA0(*C\R_Q?*\G7SR\:4B1:Z5:>9LPF:HWR"/E48%:."YN>'#J>HS:IA\@
MOL\)3*33.0D4?3-YY5'-U0-IK)5H1<GINU%_QJX7$!WXPKWEE>M(C\,?BOM_
M^A#:?>^'!Y,JL$71\@N3A,N1)O+*0*,7(6-/Q^;LCG"9*%7@,=DW6<..F/_V
M[U^\ QU\'\>PPHP,95!_B]N5@2I"CQ)\.<'->5N\]HV)-]H&C\EO#*DJ!RAT
MKL?$[7-"#E0]DL8J.JO?H.D"Y)9XM0O)[>]12%KV_1Q1",^%(5/V'UKU)<T+
MR>7O%CRI5<X'T53!?K+_\,+=!/SEQ+9DZ_S?%U$'M@6461?UML"3IIE2=R>H
MD*9/Z8%<L-BK<NB;"?>6IX3[Y_[FP-GU5'CL1HSLF]&BOEGHY#O.+FTALIY*
MZ H+_TGO;CF@L:K=142U79YZ0F< QO59KBLKIHCUL08U&#D O%94;NE*Q+;5
M61Z>$:L?4)/G>/PRT:RM7]^&?:GY;V+A&O#9?V/O/:.:ZKJVT2 @("7T#E&*
M*$6D20L$19H(*!::% 6D"9$F("$!D=X$%!2D*=@H$>D(A%[D1D!Z)P&D!A*%
ML"&%$Y\QWN_'^YUSQAEONY_O&>?'_)7LM?9::ZXYKVONN>8*!F?#":OMQ-)C
M,@ZO*D[?MM9Q43T"V0,=G9!JN?B=FM*$759?J$11 7<'+LF*RTM^X/WD!H\"
M4X[PBL?4?JX\UTCK3,PUV'V,%SAI7!],U,.T89Y(@H=JTI(;=^\6]'U^:N\I
MV!D8%GIID5M,/B6_\%E J=P*IELY2C4TNB?-"TMUW&M6G>@B.;&W$&-(=GOE
MC]9,]VT8OJ!"Q(RYS\@M3\Z^$G[&#@&AO*W2,!SEP3X+<?.B$38WB++]L]Z2
M4A''?*^0K5]6!?RNQ4_*8$WZ7V>HFNE_P=1DXP]PS"8C03#A8N\ND;(6R-N/
MT(==Y6+"%)T)5[(2PH@8LM6UZ("./Y3(ZRY:I"K?\ 7CLCOPK7<\IY]>E:;]
MJ+KTD/&#]=KYK]'HV5LJ$4N?4&T&&(\4(<.J,3^D_)HO//C8K,SM<MF!]H_7
M'A(ZRZ5@T+=G7$*[/1E_!S?1K2$S%U&T\24T@MN8R[_DXOV P*$#K_0MK77\
ME04VS&+1_!G54RW$+7W/WUS06\RIVBP@:LF%(U"CRD)JS2&6,+&D&=VB$LH,
M]5IL]H(:82=X?1MJ8@W(;\EK]]QY%=*V7S M^_>B^^D4J(#@ !::]];,:F$
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M"8;RZ:=O/?]X)Y8I6!A=]J>L?AN_OL3:_,T6-6)W,RXLF[EHY%Z2551:$<M
M@'[RNY8#((Q [C@"G4 (%(>:MT\'/;:,*NY8MK?K_JM-2";#+D'13#:)UTPF
MLZ\0_+,#N]IZ!(IW%JRXK,])N/T5=^.KJ]E[6S/%Z_D%T$C?B_E;!NCJ%@9Z
MI^)(*6#QSAS%8A0'A+A)W_#U87GQP?$;W:GR%N?R& S>5LHX/E]#AAF!D'Y3
MJ#8>),1$11/%@[" VF+OUM6E5&UFE/=@'4@0@I'5$T+Q_9TNI$[C"P>EE?FI
M[F2U$8B[#!+U ADU;  !3]*[DT1YD"_]O$4TVMY^$F%GO/"N=V*O(LF*;LRO
MT09J[_-I1J-W2!SGZ\=W6%[UW)Z2HKU$HS\4@E\^0"V^.@)561:(R3BSX^^H
M]/W>,S^P^OD[0Z&DDDKW3AX#^E:JRD];1!_-U/%-'W3\"C".V)SW+ 2?_8%R
MH[>> \EZT,(#2(E(?Y]"826KO8X'%KSN=FC8<?3+)J#;[ 4'MQ98UG20K;>0
M_>\N"@X]CJHQ5OB(5@9>D:\A9 %=]7&:"A!3N)8]E-SWOC_TBR-:Y AT+;=X
MS82P7PB^&LN*OVM:E'(OX?A8"K_\AUU0T$>%Q<%XN@M0?I(O]/LNX7L!3EET
MEF,K:W[(;D9S[*?4Q2,0<@#1LP0'%+.[%B064/<14()^&O;@'-?DS>+&\NUP
M7W*\%;5*G8$,N3-;P-MT"IRX2&C*EQ^6)BJ2D^W5O,\G]5U(KIT,@6M)/-1"
M=X\#[N1'M#&/1U5RR8J[I:EN%D[X( 6]]T476KOJ(Z3]:K9152P47I9."!@I
M&^K0/:]''(C,OC1Z<DSZ1Y.>>(:(>T)G>ND=4S[O[>M?60-4&40&0,BBB33D
M..TD\(K.X_3E1FD\7@O32.U8+5K?B9FDA%L<B;*A;[1Y33_8?GH68&),?C])
MG_%..@1QP\R8DTK3[Q/SOG_U>G<U\ @DD%4VGC6\2GL]FF75SN.T2NBAL2:]
M[UBQ(H)Q>EUT!):5)2E:;1MY>,?B*VQ_S69#CY_A-[P# L@Y;U$)Z&]9/5A\
M;%T$!/: R.-K-)F&FSJK\O$(%,P<(7#W_?3Z[8?3=@Z&'EXG\*GLH>W&26N?
MM!C7;__]:<;_'7+<G-="K$=*,;U>OK?C5-0&ZRXZ]@CDK0S(@CO2DA<>3$!9
M78%@7)_:*7/;JG>.,/)#\-[EUXAA%XZ,ZRD1@_2=+.J)XH%Y[0"G80E%PWNE
M9MM0R5_I$C$'/LV"! ^9F:NP,6T1+>ORWG-Q)<AGR'X4X3HZ!E.-F5+/I.,0
M5GB*>_L1R,7[UX??"S^F_03A^TB;S5\N]UM>$I5CU=-$/$-RSC673&W:&^&$
M*Q3ABW9%+ZSN&S/Q.-/M=XT<A6?"<BQGLQ/&5,,\O!.6WJ3TZ6KWU. =A^\!
MPP5&F0_[R&MT"C;2J$!TP+)0^,%+=5NNN*<$H6Y.L#61*]TC?L9J(B'M>FU:
MH4]X9L$%*)<FW!ITXIO"GC()02UM$46./(;,-(%QK!5P5X-]>XWY4YCJ0<IN
M_.LE*-RZU\I8G6%S].].V?IO$J0E<AI"N+H@ )AW.RD 5024;6W5L!/[P(WK
M/T17ROT4GW<.!'S6.G!+&.W_Q5O/6<6A\!WCAJ'STD[GZ:HV?08B2PK%E02.
M'I?R?^>5/M=4IW^M/O.[Z:F>;*X#08L?*G-#>)?C,$\-3OT)FY'M!_#RHN;*
MQH3"_&F<BDQ =VNI]$=A]Y//+BY&WZ2H81V%VG0D*I*P<U(=%X?+#=DC=*_6
MFON$&JK<9Q,%E6;=EV/,,-LQ$%2/D.KO.#1*S7XW8^+QWK8U:WQ\F$/FNE3,
MY>N3S"!P"<*<CE@4J<E0%-G>&:&7V\;G23P=+7'H> 3R<83*O$IIL,AU?7 $
M^O1@%^\<>-U '-:*.;Y T0:D"?OMCS_&U%BP=$PCLQ^-;]FKJ0L.=Y+90"]F
MXU@84\=^*>./0'1\O#$*\T3SVR-,@>!/,VLT_;K$,W[E?LN>=YMM![=7[&[R
MB?>>;^AFO;5R99FZ0I]E(R\8P0(S;4**(_Y,@O44B%0C(3^.0$%^YX*O?W \
MT&;.F!,Z4P: OCX+[>.,!*]CDEM80ZVZ,<QHI*#C9$1!NY"H]3K/]$S>NWE^
M@TKAON^BJA^^689=?ST106]=7Y/"]YY4!O!] J(O 19+%S6?UL3]6FD8V2O8
M(N4HND"'5<3$CUU4R=):\W>^@VK3HV]%%."6![M)!">@\<$HB \WNYU]+Q_\
M[@-AE5A-%_8L=^/[)\'I!N+N+?UO(D^4?CH;H8J_*>C*'LERXU=.C1$(I?S8
MK\2#(P<1R2F[.W/;O(C_A\QADLC"0V/63?'\FU\97/A9$U92P0L%8AA?Y4B:
M%C4J&!8# >^F&+;I?"E/G 8>;PPU5IF$<'S!3//)+\<\.K=BEQJ@ZN]<+N0,
MABI$^,MV#<8&A2<LZ^;;/9"Z[[IA=B?3R89\!:%&0*".!Q]DMN>(6D"FOIDV
M!IW*UN1AC*Y+9>-G.!@@^])FG5F0L%"6]A9N0G=ZH#_.5QN?@DZM$5ZN2C*6
M=GE>:!168LT?:Q$9Y"+R_,3!#$F)FKVK/(U:RJHCD*\3.<;'GWD)A3QZ/)[.
M<^:7D>*5C >O!)(?B.>5\31 @HC.S9L$3-N'(IMV>]Y/R2#U20,(@/?RI/$-
M4705,];M+Q2\,SLYO>/AG2XH\?!*5+H!)$E?A9H,\SH"37HXUQ.M.E)N7!L/
MBO^^/P:5&3CE)M+:^,7%G*'O9%F\;DVXR=8^774+Y,>G8=UPCA<NEWUQ$+ )
MX)<SEH:[ZKMK.7;XWED?.53P.:UM9]K([QS%!%L\ C6\8$61T3D]XS"W,!_
M8&=%#;I-Z@(]#FG'I.@?!^8*4SQ:6\Z,-)G?C6HN*_GK6>:P>S)V"4YRO$BJ
M&,<(M<BCVE20NL@!42(1U;; [13ZCAW:9*/#5.Y>VM[<]E1SQ^1B_%12X/-C
MC591*((M6 *A,QH72[L W'?F-O&F73U,*3[6?ZM.&IW+Z)MZ24]%9-NL$/P#
M-LU.L@/\R5;K.KYIG9P\>]+OH&FNP?! V292MP$CWDWZ)/Y.Z3'5PJ7$ ^?.
M!8(1)MK^W8$ZBA?HN/RBJD9T8QXGL$E18H5;+>&!B7%G)I176BRFVC*3M,,
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M7SII]@<36#B%EQ&KW($2\\P_W4 'U13#P&)'PW#FO-$AHP>_C=N>]_(J=86
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M65-"2X>0@.6--1>7&'7B]60=Q*<T.E& >8-JAN5:_R:M:0T(B/6U7'Q]6:B
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M4+51F(3S^&8]7Y1+=22QRUK+H;Q(=U9,JD!UG_J,$O;ZQK.5I9OAV0PYIM!
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M@GM2WL_:"0^-98V&?B>I>A]NT$P(@9Q&"+"'H,),I7ST**+D1TH@*5!R_?R
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M;VHT0J5K^6G'KX(6;6G\419'*6D7<X4[@F-??3BN(->XS[K-WHAK'H\S96E
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MVP'448?0"Z,E?VRJ0K).K.'Y3Y34J,2<"8T><3DN@<T/^V:T7VP15L7=C15
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M,*![T\7[^_N'UQM#/DG*_[DN^_".\[W>]J/_+ BM&AW\$+N[0>UA5!AHTN1
M\5G+D9(I&XI:H>-Y>>-8HX3'O0>6%;R?7JJWK^$]_HSS[3-(S@ELQXF_?2^F
MH-2(4;7U)HZ#)0R,0+QM?RM3VBY:E:Q9G>^:%TI(E-S].J]@M=B&!D_ANMC
M.'/6@7O^R!O=&!757T+NXK;IF0U/L:[Z:6UR*AP_)B5^MTAGG,N&X*64^5N:
M=0=1"J"^*04>A;QU<U#;XV%C57U2;E>[O'RA? [WJPO<R795_V^]&Z"'M1-<
MVG&\!L@BT$<AM4-'3_;/6&:R\:*^?7YCE9'IBZ8-_DW"XL<3G-@/S?O^Z^;>
M *+*M',C9D9A&'7&#?_N?91';E:<3C-Y:?B?GT&44LY=L[JU1[N^&_@O4=0A
M1@/]#.W(\E/Q\>#KL]%--L5&6V[XATJ]4>ZO/II]E"/9OX^53-3CZ /"SID\
MQG#0V=AA3BAX;N#TJ7U_32YV*3WX78=.=G2*68Z-Y UABP$[3@5,\/K2_WCK
MF/\V:_Y[VS82U<,T8'PV@,R]DVX]HEP^@*Y$'L^DP4==,J7M1OUNQ/<)GU.5
MM&I1?O%;5YX3QL4"VM,,=5G P#"9!;#3A^XL/<H(6JUE3:REG[LUCV8(PB L
M@.P4QB:H?NC_]%DT"_AQ"[T>SP+6GS0785N1H#\+Z(2!"!RY$%?[M[LPKQ)=
M'D9.8Q23,A!.-'5\\[?*@,G:W<;=KKY&=)R!=?;_?@S:F]BU#1:@-$FS9P$_
M<UG QWH/ @1\4L".A#TI%/N/"5TT%O!JM9_^MRD #BR83XJ#"J&.3'@P(5&V
M9'5J /6?'8D,<Z3NU#TWXN9=.W'/4Z^FTAX'>\L,<&]<%P-+6,#!V^ L"S"&
MM[, ^N%9]*8LE/P+SB;8VUIT&#MM)>RP@*,#W*3_CH?#V#^Y-A@IH6B:(@CO
MS+1.-+ N6"U?R=#9G'##7^_8LIWD&>U(_'AW(#(U>-^^>2%U)0,@S!_1[T*Z
M24@P)2)(?^;[>9>/6%-+:XF+PR2#W_A(MX<\S[/*?IJ>+]X3P;;A1-"]]D=9
M0,4;-Q:0[S/ ;<Y^8SVC0!WF@DNHG>4+?;"YW RE'*=4NB(U,),-%1A5<\Z=
M@+1#M77Q;_=KY[ AEITM4E/(2$;L#1:P[#SJ#R-;STYJ-YTA7C'4#7PP_"BK
MZ$IZ\]%$L9;P#8X']?/9KX#/Z.:B( WKKMFJ6I)L(6K(=&[]4RFO N5(Q%S=
M]OFKZQ:H<84 D8;^/ZX+20&T^TD73W#NS,[5QFCU<Z-^-(N.^V=]W6;(7R=7
MO_LU/=+-*V#F&K\6]HQK_#<\!D;XP)8Z 20SBM)-\L;:[MRN7X+&B<F<R+%>
M_N)9!9F@X;[39SH;Y8 SX48"W:G;.Z3B(H=E--D\Z/V@Q2,R\P52.8F0\*O*
M"I;XE 6T%!/@$]Q$#(F#C+M$B<=P-4NZH<Z&[Q&G_<V_K9XL2!$W0:N==JJ+
MXSRXR"4%[$ B<&1+; *NDNW.JV@NYE"#>?]]S>R&1HQ%[-A>KZZ":@?JXN=;
M'0=]J\V.6HPI>,&<T*U7U>5&8/>A,;I60WG48?R$N6CYV^)BA-VAEATN*?H&
MH\B FV:+&L]L?OX);">X+P<TJ A/&:M%."DHWIU.J_GJ7)=Z].J[NB[=6OOQ
M<5R58@;Q/#^35\@PC;AZ<GM#R(TI.^192O)&CW4-.DY=SJDW(-WI P(1=&$8
ML2"RF8\N 2[.JXNOG/SH&FR_YU=Y]6?ENPP.)Q.FTJ.C=TPM36"$#5(U#8Z:
MF(5N:*E'6J<?$29GP1>_;[G=<##-G5AT#7KHKVAV]Z"$O&_*@5$N["(ZG*X[
MCX"ZZ?V(F,M2-;<>]I1+18QX?FYU_9 XHS/M>V)Y4[Z,:VOKU3E/Z,@&>(P%
M=,$%5J"04#/R@!LUV"7.CY8^>KWCJKB#Y>A7A_7@RDL=2MG6UR!-KIQI;&AK
M#8PCCKUQ^0#:GMVH5G^Y:%:&L1Q3&'82ZBF*BXO8+;C-(9OVP-!V#N7-K4V$
MD:^S #:)E(CRWSBXA(9H)5S<FO-B ?$JW='KI&V_^LCC ;7F[[;^430P$GTK
M]+PO;)KMT4%LC]890:]IWV<!.=4^,/(E*I3<Q]2T3VCO3$G19P'=[[#@C0,P
MTC+[83E*1CLL#D'^9'AP\H)NC"K^A/J?DRK,\3,-_RB;(KTD3O5%W3!7=LYR
M!3XIM=*#:*:H6=@^O[--]^>#_/FAD*;!SRF(I0:G%LEG?!4\'Z8/&1S\E+KN
ML8R9$F'RF<YA(A"BN62E%P8<+A2E[@:OMI;Q +?7:TA=P5<=8E)FSER;ATH/
M/^,]Q_F;!>"_=2%JK#O5)[<Z]A8[9@66F[E!!&32N7GX06TXKXNJ/U_;AW-'
MS-.4E2];7!7@?+N=#1E0G]"GEF51ZT!-]>CJ\SJ"2AW!#JMN#>^^?$(>7>!)
MK.@ZG%+4RP+\4BY82<H?:.:FC-/%H,39-@P^JSM3YU.AG8<A+QN"H_T3# 4E
MM6B!,W?G4@))N6[A2$"OL[["@L/@/02+;F7S^87T4#:VE/7AF-':%'?PT7@7
M@GS[O/'EYN?>G[V;51SXHV6<'T:[E_[("Q;C@CH906U17]%5IJ00BC4UC5R"
M32".;"=QK/*?9W0$)T4,#7U;2\[QO' RQCZE2XO[N]/6)_T(5-Y-$T!L]P)[
M5=AC?H5MQ>W-%Z.7K/SW<(A_H&1[["X?79H%E.K5,B-<C* (-@!KL ?6;7@8
M/2Z]P5"O+T:3+:&[&HA8Q)]?2#8>/KX#!Q41]->+[9"]>78^R]_11C+YC%F
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MM -?S(F7R]S\6.[O]0D//P'5;Q69TC+"F+A][*;]KI_%^W9(-;(C40&US\3
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M>\051IZAC0\);4Z*ZBIP)P*%'4;*E3:C1A:Q"H;^UV_<P'".."=],DE-3QU
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MOPE*5]+)WHXWEJ6>>/8JN5@U$2/6=JVZZ9[-N]9DDYL.KX F0<9.O),4J7C
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M>;^LW-S&J+M*+.9V,T?#H S^3)E#2V;WL5C%>Q:T/%:2D:<&T1XQ)_+K:U)
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MW@(K'E3E<\/C0>)4.S-,];LTZ=";GZ17"K.DQ]V2G(\,2;)]&+BX5"OIE2]
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MI=.4IW<O;OB_L)#/'P920Z$'*G:B70<J=FVT?4"ZRE>D\('\<I<R76S:T#>
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M7I_./&ZI+Y(T)$V+_A("VN#T]_2G22.4GXG.<8VG2GB".^P"7NP#</?65W@
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MEO:?[Y/F,+ZT3^M';Y1[IG[DJ3@0H!>E<M*"J9-XSP2F$APU &63\+KSD"_
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MO E(D:6:F[**=@/HA$=+,M; 9]@MGCZB;S:N;_GEHUG0X4?(2V^2\T_214C
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M8VT?\]T<]X;USY8_N:$E?MN<,QOVENJH-C/F4LA)Q63K TNR69TC8$A415P
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M?3X^K"&$;Z^'>"Z=OVM$2W.7'02Z3P-[?GI@<!H#Y438SNH)D,).BA\U+\#
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M+HG$!YT@L<]"KJ$BW7K;8M;$DM9L.]E-<[];"]_,DS8KO&EN)5E.M2G)[ G
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MU-4-05!1*@A'@1LRW%@=G*[OE4IAW(OO6[&DO_6)3TBB([6O8;YO^76(B'.
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M!H?!K\U#U+RCY,:_!N_XB?T1&^#S)0>;%.AUC/Y!X\8Y@/XW-ESP)8K?JTJ
M#S5Y^^F2K0/?1C>PXQA[3R0C(%M8 BP5Q3R)Q(D=[2,^0]C1 O/)A,BPL J"
M*2;DS*=*].^X\*+>P4]ZJ G3D\.,M-J7PUHF<RH[, JH6F@ -@9G\@'WIR_[
M93ERX.W!EI]S8T%H+MT=7J:P0_F^:,:08/6<LG)^0[<@QB6))1LZRJA(14:
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M#Y70O+%*T,4%;2;C_FY-G0"V#TH\4+'?>K^3'LF]3TGE!VP_X00X=E)BVW6
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MJW3V,S=$J'5?<TVL\UM7V+WHYT.5].\:8CU7_;"^;!%GU0]N\DT]0<2U#*J
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M#K1K=O6:UURK^L>VMVV=B<)^$U?-7O=BHJ[38E0.R+[A%70:V&"?C3<(7=Z
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MY9DL7!)RFF;9:AD^VC'4X'W;C;CE M^>^RS'0CRL>\:29KZ.C9?U"E&6G3M
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M4./O79;L@H60AI2!AY*=>$%C[53U7_EU(@E>+@?O:'/\>5)A>*"DYG@7;]C
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M1VHAOW<:KX2*6)-'NW)=4RUIIYS;!7[,[5"6![@M0%N="VZ!(!ZE/X\D XN
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M@W*Z--EAY.LI(.X:Q;3&-\V _5"JS.FAZ(]2*AQJ#@;F@]!IFBNJ^S/R&J.
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M7'\_S+EOGO9&ZT7]N'KAZGDI9/.6=TI\Y_6/O5Z.^![,7!XU!Q!?[C B[*;
M?$8%$.N]$CJRMO73.R[N52>)J>?ZQP>EM(N,SM'G$WXM2TT[T8XQAS$"X=7I
MKKLD24J_4=2I?M=\#KPE>;7BE\0MM4+X)[;CH?R'RUK2/ZTR/<]"[CBM._7B
M_M@H=J-I(KY[H''I2SCS0,*F#%V<TEC**JP#$$(1F>Z)>(^0M?TLW]CZ9<IR
MEO!T#EYD8? IXH+8=_J_FGV5_*>-Z@$\HDSTPX]"Y9SICN2G,M*LJ'A'L"<G
MU%7,9@%UM]S:4S;XCXCLYZ@?H+\6_\TKQOO\_P)X9#,)SX4+P,Q;]KO:QJ!4
M$+YF9-%N=PT7FL?+R)+A6%9&,G1P#CIV*M/)Z+:P2=1(9CGGMY'X5&R.9Y"W
M/[>;JYM%30^O)X^$$MO5(YV@0\[__6.F_Q/^0*CCC$*F,M#6O\0%5)/A+FDP
M2833[N5OHM,*DNZ70:M38)62U8+S;4HJZ[RE%JCF5]$P&-*;8DI= !H(>;A#
MK(!ZZ"X<Y![PI*, _TAABI@15'S=84GM_+PU)RCFN-234['0;$8ZVJ<--GME
M.>'%<E*(TY5)X^\:OXUV;!Z=68@Q%>9\4OXVZ=3@8:Z?R=2/2O_5L\#[[+//
M/OOLL\\^^^RSSS[[[+///OOLL\\^^^RSSS[[[+///OOLL\\^^^RSSS[[_&^
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MN$+EB86LNQV5CES!..0EY_?[$=1ML=0L]WE9EK. *D5%2B&A(8$H(MJ2H:&
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M;2-Q_8MJ]9UQE<@4(P:SA!*(@HQ#$J0A#-(T0C&/%>7(T>G#58:IT<Q[6CX
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M4 LDZP*P=_+OZ[Q>VYN<(9)QG/&,PIB(&"*11)!1G,*,\%!%#"5I:)\:K(<
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M^H9P=_"V"H&/>X/W?G_P6JU,EH=ZWW(%:LT\QOOY!-I72* 7F<:-&O0)XZO
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M,QY#HJ<^1-2XS*0X@#SFB#$DF JLV,"]ZZE1Q%9XXR)1UN*;M;U2 $1 ;!4
MW&C@<+SE-B@6YXB#03TPR^R@?*- ([DY2*Q1UL*#'>GK<K:#X>QPC#@8WB,=
M([I_W;Y<+'LAUWF(Z-;B>(>(O33=.T3LUX+7.K'::BW,]?9^_<$FF4==K48_
M?;LL\[J"* NB)!,A@4&,$HAX&D.,C#F99BI4L0I#Z;2A]R/6U!:7-H6[GY*O
MKF-D9Z".C_S :TU'8==6J<.ZKFV^H5JOZJ6-9H-7<NV)]+#%6UV%FD*]UIY
M6I9H[=NZ/__(\IO\OGHW-[5)%%<H3!(.,>891($0D-&80Q+2"(D$D13Q2QTA
MM]U-C58/G/$<V?4,M':LZ0^P@=GPA .CN3/6TH)*7(][?3M<!O1'W.GLS1T/
M7RMNXV%XY*U^'&*.%7[1GT9U6A5$(0]8)&"0$ GU#C^&3$4*$A0*@4DH>>1T
M,[S;^-3XH3K%,L*Y$<,>7G8TT!>%H;?;+0#>S_*.*>QI-N\U/>K</:;4X4P]
M^DS/J+=GFL^-/\C/R^(KW?42^2#9:ONO6480HCCE,!(*0Y1&)MPA$S 5,<6<
M9AF.G5*GVG8\M?F\3:3@&&%F"[3=9!\"OH&)P BVXRAV!38Z0+4LH-'"8^R7
M(SZ^PKMLNQTW@LL1C%=!6J[O]TPTM'YZFE>^(W1N?-E^GB__.)8N%$6$AHIB
MJ&T&!A'2?$1XIJ#B(L&<!!PE3N<]EOU.C8EVQ08B+_E\:7QOS.$J-QZ;2JL!
M\JT>?W%,_6,Y&G9\-0#& ]/5'KR5"ZR1>;!<KCV!\I7CQK+7<1/4N$'Q*KN,
MX^L#94<K3R6QJ:N:E9I3E<Q7>N:6GQ;UV<U!*IN/WV7!<U/V-^=R)O36B28T
M@AD550Y[!AEG!*H 87,2$P74R7EB; 6F1J.-%D#5:IBL! NA&51_HG/]#Y-2
M0)C<$\5.H@''[ *C?R.6G#SAD1^:W"TRJI5G4JK=M#G4=F"HKC,K((ZD5FO!
M !4:(V96&V@<Q\JOYEO\:659&VAPG'.M#25'#_^AG0B6@RZ^4..EM'JI^Y\E
M(@Y9I&+(9$@ARO0F *N(PAB%7**$1"FQ3[AFV^O4%K!7V70>&W'->J7E=?!=
ML0:^>X$9#,Z!5X4=D8_0=RMV0_!#P.K@#30$O",Y OF!V<T%R!6N3N\?Z\;&
M<_QQU6_/Y\?YY;[WR-3D<5M4VZXUG7^3Q6.3"B'D:9"@C,$0RQ0BD@00!RB#
M2J1",I2%2,5N=\BGNIH:>U>2@AU1@9&U9];Y#H1MKY)]X#;X-7(_R'I<()]#
MP]OE\<F.1KXX/J?PZTOCLV]X<R OEF+-J_B5VG66ARK!@8*A0A%$$8L@88DI
MW"Y"$<M0(I5=Z#>^W^/4J..X0^W31FA/+N('L%N8?K[!'/J&^J1#^!9*/U[@
MAU_PI<[?_2%]:Y_OPZ]T6%?OXSCU\/ ^:.BM';N/ZV7ASWWBQ<M\>QI+ R>!
M8"A1,$BXWI0CH2 ),(.1C) 45$8B47V\>Z9IOUWHW^-DG?5'8F@&W?KX>#?"
MCBOMV<_G+8RMXXJ=\O6YW*AJLP7FLKQ9F&O\&_7SVISGW2U?Z-S\^%<]QLMB
M53D;%W11TIVU2C',&282<A2%$$F>Z5E-"-0S6RG& RY9,EO(>ZHWCQ;VUD7"
M6'WYI/[R=T4:<DM2EG\!ZZW(8+65V=D.NVRD+ RTX=$?JRS"1@]PLP!&$V/"
MU;J C3)@1QNPHXZS57?9P#C53QAI@$:KJ; =*(U[:09*&X2J'JBB5>JJ>PKY
M*[G@ =TS91@NZ6',T@P>D#@HU^"CQ9Z^&*;0M_F:;U3K\%%NO<80E9G^']2K
M%8+(9*REG"40BT2D(LDH"YS2UG9U-C4C=2.KF70;7Z;2N9"W%="6S@>>X!O:
M4: _<N[W^!:0^+IS[^IJW/MQ"Z5?W67;O-/#0G[WY>M^F9G[0E;]M/6]DE@P
M(CC46UQ-(8FBD,4,0TP#'(59B%ED%>EFT]G4*$2+>UA]JA78P8 ZA["%[>H1
MMX&YXQWX DZ"UJ=4USGT' Q,CRB.9$*:#_"@)%<KLR^[T!*43LOO7!OCV7:6
MVNQ9;[;ON)&KD/GLXV*5KUZNA=#?1%D1^$UQ6RR?<Y/B+XRY3&5@F)0(X]$?
M0BR-,P]-<(J2E(DXL"'6<QU-C51K64$C[!6HQ-60@E9@.W(XBV\WK?I$;6!*
M[0^8-1/8HG'$$BLE__/]\ODGW41MA.F_;&VOLPV/0@VVZK6T8/U\+S^_)CVA
M+#]LXE>:^@(B3(C^/Q34U/^F*(,TBR04+,T(Q0P1.T8XT\_4"&&;[E.68"MK
MCVSV'=A:&%E^$!N8#$8!R\DESP=HHSGA5>"M*O"VT6.^3*GS6)SQL#OY^I@^
M=>=T./"B._MXOV.M3;7K*J5V^=DDX0H;DU^F%/$@RDSV:E-O5"'(DBR&),E0
M%H>,!<CILK6CKZEQ924;"-U.KKJPM#NX\H30P-RX#5._JM/F:V.I 6R C/D6
MF'@ZN.KJ:=1S*PN5#X^M;%[I8455E9!O:;%:R*+YDL,HS20)0DABIK3U%,<0
MXU# D$<HC9C96UFQPHGVI\8$E80.R_T1Q"QLHLMP&'B^UV7@&^GZG"T=P<3!
M]+D,FY%,GDI(7P;.:8T[#9LCKXUGT)R6><^0Z7BL9QW)QZ?Y\D7*KZLE_[WY
MN+( ITFJ*,PRQ"%*30ZH3*4P#3&*,Y-0CE"G*I*O^Y@:3;4B@DI&<*O;K3+?
M&A<?QWJ21P"ULUXNA&GHXYU]A/P;*AWJ^ZHC>:2'<:M(GE;Q50W)CD<OR(;
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M5'^5@MGRM1[^N[7C3Q5_4T4&-Q=._VE.;W>28\YB254@.8$)$B9:#F60,!+
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M]4Z9SO*;2>7X37Y?O=.8_#Z+,*<*(:19+S5''$1"ADD*.9,HI8F*2.94&F]
M6:?&D:VJ9K_T.>?FY/+JX%C?S.V;U8,L3%H.N5A;1A*/,?!V3#N1X1R8E_=T
MVW,(,@.X^^]Z,%</= 'V7_JM4@X8[4"EGD\7H>$'P9?OT("2CNM4-#SDK[R-
M1NBRW_IS)\M5L>:KM:D7WY9YO2Y+N?KT^*27/-/Y>VV[W\MR%@:*(DDRJ-+
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M&2F'>_^/PVZ'.>TA'WCINSA'_!5H8+C:S2=RI&C/P5<TQ(W(VXWD6R>B[Z_
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M0IV[\'(P?3WA-I+!NRNM+Y/6 H%.0[;K_?',5PLM]HQ6F^=[E<QH<H#=U2G
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M- :%_'@NCF&[[.G0N%KRWQ^6<_U&^?'OZWSULG$2#D@6QD$4PR0A4MN2>M7
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MIA %*H,D"?1_2!"%"BM.J5-5I0MDF1K/[9X3W^Y%7.SZY_=-V^\^5'8<-](
M#,Q\N]AO]3#_VF+?%N,#/S3:_#CHT:P'8+TG_W>7Y(V* ?2&['1Q@/Y-CIUV
MN3[1U;WJA>!6?^:_Z __P_*1YHM93*C)(TEA$(L$(DDSB)DV+;5!&=.,*QP+
MIQ230P@Y-5YNG?N-P&.E2>X80DM:?N.!&9BOZYLQ(R7XK1;.)_,.B-V;IQKN
M$/$?)*'P>9#]I0VVZ.NR-"E?9?&<<WE<PE^6U?96UF*4WTS8[^[O3?3U+\O5
M?\C5G>3+^T7^GUKZ*JWQS\NB^9%Y+IS)F.-,< $#1D*(E$*0$<0A3XA$,N.)
M4+Q/SI5QQ)_:BK 5%RR?S>D;^*-)(PUIDR#]J=*C7U:7D;X)NX5DNB,]]);@
MF$/&EC*J..E:Z3:'OM%2_W0%7N0*;!6]:M+H5UNY'67]YZH9=XP\)[X92?@W
MR:(S[L"<2LDSLA07;'M8QUK=+-6L.\._V8D=Y/:_DV;=SA?W)A;=W)&NZ?R;
M+![#61JDL1"<0I+H_Z (Q9":^\TPYB2*.$X%<3N4&E^'J2V1K=RPK1BRD1SL
MB X^YTIN:HX8?7MLL$;^6!SV7]/]!$9<.T]Y/3H6I#%('"E$<_RS,GAXW@^^
MS5CZW"Z.K,'XN\FW&:*CF\TW$J7?DKM7]M3L<IN3)BQ$@"E/8!Q$QKLGC2 F
M2.H]9! FF"59DF*79?%$/U-;NO;+^AHYSY\Q.>%JMX)X0&M@EN\#E#/YGH'!
M$T&>ZF54$CNCZB'1G'O<C0R$S&<?%ZNJNN1];IP(%RMSVC5+8Q+$C'.(E$A-
M:2IM)B/$8"I)H!+&>)I9I40ZU<'4IG\M(]@*"8R4=C/_)(C=4]X'- //=4=4
MK*?Y.=6/S.]2\C_?+Y]_TJ_64UO_93NC3S8XRE0^ITX[A\\^=T%F,Q,D*,6'
MFA:J'7H=8?B+_*/Z53F+4LY%AO4&5]$0(BD"2(, PP@)E:D081XCYRQG9[N=
MVD3_VA2=**O8N=42O"OT2"SG\,N+[AU\_?LZ9ZPJEUJ52"U=:Z3:C87E=M([
MPD/O "M0:XG!A\9":*J)UE)? 2UW_83'^DMN0/G,D7:^T_'SI5D#<31WFOW;
M WDXG+J5,T&P50SL3JRL\<3@>J_T(3=5HA;BCJ[D+,A2%$3:; DRFD&$(@:Q
M2O4_J?YYDJ5AG#E=>PTN\=0XLI4-O.1R[MO[X>+A]>0*,>:@3?_@;2?"?$?O
M*]!J#C;?A-%]1*\+7\,TE@O&Q?).RQ_#%_S.SAG>.NX1"K=U_ZO2W9>5A]\L
M3!A6L0CU.J*-:,13!EF:I##E*6812?0LM:HX<;J+J:T#&_]84U"J$K/Q?74)
MVCH.9C>)^X%H:-8=#AV'0+:+41HI?*T'6FZQ:YU =$:L'7]SO#BU3LGWHM.Z
MG_1P#]"D'[I;SN<_+PO#M[,L8S()>0AQ8F@OI 22@"&82(UB@A(5$:N\#9;]
M38T#]X^[&WG!;T9BT(A\R07!$<![7!1<!N.H%P:."%YV<W :ER%N$([T]G8W
M":=5[[Q1Z'BM'[W4A0G;NTMS<9DOZF4M5F$4"D(@9L;_)LL"R$*40APC'&4\
MD2ER.H\\V=/4**45$:RV,FYCN4&Q-U_XLEPYAG^=AMR.6KP .3"IM+6&-UCN
MB.F/3,XBX8E&3O<S*H&<5?>0.LZ_T(\TKKFV2==UFA.](RSG]>Y0_)]U'?;=
MY'N(4<09BX7>AU$$M2F201*) "HAHR",F$@2IQJ =MU.C4YVI#;KJ<SO%TUA
M3/X"ML*?J%/B1BV6 V/',_[A'IAT+D/Z?,839WYR0] 365EV.BISN0%Q2&..
M;_<Y4:)FTW90<[GJ2_-FXV==SK)0952)3)M 2F^U8H$AI@3#D*9*Q2A3(7$X
M8;+I<FI<UM[.JCKS;='*#59;P5U,(@?P;4ZD?$,Z] E5@^9AH7>P(W,5O^(?
M39<3+-^HCG6B=3FZCB=<+D!UGWA9M33B"9B+9OLG8DYO]K-&-U<.7R0U*5?-
MM_6W?/7PZV+)S&[9+/.?%D_K56DB8A8\G^?5IW=GDA&93=P[6N9E6\?DY:\T
M7QC#^=."S]="BD^+*L&4N0<IY(-<E/ES4QYQAE-%,$MC*+/(Y-R6)F4*"B#F
MF B,0RR54\[M-]-D:NO,^P=SSV221VF!@3*7G\]M>FTAG^5\66?YTQ])_JPA
M>)9@WFKM9C&_W<=C9X3_0WP2 Z^3V\OO*[ # _A#XP!V@0 U$F ?BBNP 0-4
M:%QM*DB]7 &#2%N4MT7%?'AU%L0]8-JT,_73_K8);S[&GG8>;Z?'J)N9-Q^N
MP_W1VPO4^VI+ZI=,:K0/6U+?<3+8G%PM;V6AEL6CWM57LI3O7JK\#Z9L91)S
MSK,P@HJP$"(<(\APG$"!A4S^?_;>M,EM7$L;_"N(F(EYJR*$VUQ $NC^E-YJ
MW%%E.VQ7=W34!P76M/HJI7Q)*:NR?_T 7"0JM0$4P&2],7VC7>DT"9SS@'@
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MA+DS;*X&YW%28"&2 DJ]QD&41%*O>8B9 %G!"IFC),7S)UFRM76RGI%$=Z&
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M0H.=U,"(K5D#M()WN38&D*\#O@Y,' ;GD6C9&F]/+.T.UD7*=FAN//YVU_&
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M0Y]36PTZJ6M[T;*3&RQZ@CN0DB7N%JSO'\W ?+\#TH3;[T0&?9F'Q&]9(NI
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M06_[/@);24<;]>F;41LH0 \+T%0GW6@T0 O'##2 U+OM&I(9V&<PG8"MU<N
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MTE0(SKA[X9O;@!VO:LT;>;]8&?=QP.C2A)/=CF>4"AF+'$:$,/V)HDQ_K(F
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M-T#6H@,S97:ESHV08"_S#.ST@6I=0O.8/PX:BIXG=G+N?E3>&@K.2T8;W,Y
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M<800E$Q%BD8YBS.W;54@0:?&1XVXAHUX8^EJ2HU6S1:!=N(#M2[;?UHWZ;W
MO5&GJA,R-D^/E87QVJ=@N8.;P "/>&8?F"EQ_WFTF\:[@R^BUG@".0\MQ^2U
MLQA>$_/OD9?0$FQOF09M^QN0S?^K7#RPK699T]EGU6[%JKD)U5$,ZS4$%<CX
MY4M(XAS!0A DBXS%)*/6Z?G/=#*UE>! 3#/CVQM9RR/W13PO4[(OE +3Z2%
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MQR:%E1M;7!\%(47$--'"(D-FHR8B2..H@#S.)$U15$3"RBDIR!B,4L#PM4?
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ML6-:L"!?AMVN\;7'.S!EO^90#Z]N'F L?-="]RGBZU1.#P#RV3KK(?H:6-M
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M./ Z]TJCZWQ."34$GDXGWL4;]4P2"MR7)Y%@_0Q;6KZ4K0&NCHUJ*C_>[<(
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MJ',SY5M:X^M:M-@AGB0!CI) 041E E&0)I"@&$&2\I0@'F"E(KM#W-$PG^:
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M^'5 6P#'V;(S.B//P=B1K!K^6OZ;IF[_YG06>9=IA"K]<IBR;R5S0R'IN8/
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M*AT&R# W&VW$OP'FOZ"CQ4WUX>\4Z7ABCN3\ V;)S@:/C/W(UM89]I'(7ZY
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M-*U0,4,10S2&0L,"D<12.WT)ACR-XD02F7&2V-,7>)-K;N:P/5(Y("PH:N7
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M&2 L6;O/W>UFBX3,%^]7&[TE^_QL,O#NU/O'I^7Z16H7)TYC1-(P@R(QAB?
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MP/VHC+CEH;3S\V;T)>[)7&UJ6V:.G=A>S[0'@^4M#]]VW(FS[QWA.,ZY=WW
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MB@?M(S6$I+DLW^4E7Z[+Y\(UV?R*$6;T1N^TZ&Y'JB!)HPC8:0)VJHRR"_$
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M[1RM=,?NL_[IKW_:_D;_P6@E__JG_P=02P,$%     @ $H9<5B6 0*KRNP
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M8;$8!>6HH<D0=*!S*5<QQ&7TJJPVD!CU(=@:EL6=1??#0<,1R&,9V00.7E_
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MKGS_H0QF/,]X:701AM44A;N_LO&..LI61",C$)V3)5))4\HWR@ T9B,$'?&
M[>?M5*6KM;X456$YM!S;>?Q^@ G%8+ZU=;JMCZ* S*V*1.6$)S1F1X)-GM!
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M .<&%OAOZ&Y?7%ZL"1<T1OR?)EP)*)V#-0G>RY((GI56A@:^5Q;]$R*_L^C
M0C]$9+,:_!M:\/[[!N%X)2+>A2>.,42]TY1X[BA1^+-H0D0-N%?6\%."WUQT
MF&>T:H(_F'\5B\E[**EY<?4)/Z)3A8;S**COQ@66/N*!%T/*DZ@T=TQK@%"[
MJ^4>9 T#FR&LB+YDU<"CP>ZJ(?R 5[,+/YZ.$DO4:DJ),'B<I*$E$X)Z8D.,
M@5(3/3M9X_);LAIMX7TH%/:NYCI,+D./#O_-3R^S7]? O5O5E<_F5]=#IF^V
M=WT90#(25"(FA5":+1EB-3(Q):J,"<G3L%_/KN>MVRBF#I7Y[#0":$"-O;A$
MSN+&UM0KR)HR:XF6J31(D(J@]4<)Y]YX!MD;6COL?I>"83.3^@)2!6X/;&PC
M9])E7)[/UV5<G9[.!NU$Y3)1ABDBT=@DWJ9$0H[*"Q=5='O=;T_8W ^M/4Q2
MT%"1F*.YWP9ZNIEWJQTLUJ>)@9%XF$I#/EE2110EEN-]#Q)"$E($!37\]9T$
M#.>['R_3^P YDL%#VSKK67>_SZ;EJYM&CFMMB=XMBRSBN5&N5&.@SG5!>\)#
MF7;LJ#?,[67:/+K,X( X5H:S7A@Z-#1^_X]/'YAE:\IIII9#L$1U?8^5!1(
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M@.TJ@C^8?T-G:NU[_=T^51L+5*:0B:)*$:FC)"Z&2)))04-60IK]T@R?O?2
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MK"++Q66Z<R(Y+;EH<"4F+;5E!5L71CU.T;2O6?W@L:'>.D!AS>Z>Z4(\FR0
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M(_>I9OR7VFT8#;CD,@I3L B<$GQ$X[2],:<"WZ'*>4;@>U5HS6LF>6'<<5?
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MMT2_*[>8O.9O7XK!F_*)0+3^LCS+;]:O2$GX#?-,N:)L[>^'FEPSI;R &'0
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M/%ORKM_0_R\NYM^PLK@[$9VT(7)+YD,=..0Y!^<% O.&B9BU-V%83/[PM?O
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M[5DT1K4NXVA!]S"PO]0D@R?7?!]H?VB#U^#DK6A_1"LQ9P,I<+JC#$_@2*S
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MFI37=MF>;"4O+/3-YJY,.J0T&>^O#YJD9-UH\=*'IZFI<LD21?'@\J$;0#<
ML(X'&VKYI.NF7G 7ALZZLFG,9&D[F/2R>QU2J_+D<O(AU]Y+]/JJ[SJ)Y@HO
M:A&+F,@2),^% 2H90#G:Y3%9!]SZZ'/VVHE!SB).R^9YYTL;@KQ5==2)$->+
M4;;9X^_-(]3"<:RNAO$6065E(<C@H43A-#*6./8VR7(K,^>=_!S8P$9'SS,P
MHXU#7-NF;>X:!!=%,%4 AI2A3)" 1BO@CD56LHTV]7:Z]X")LR[+'=/O.PX.
MS\L>GCB49&@C%@A1)0IOE2:Q) 9"!"RA7@,-O6TR.[)VUM6WG=A.,^CT8E%'
M^++;Q;+-E^63K)F(GI%7(%EM1!,S^&0<!(PI\2RU&:;>ZK1L[F1I@PW8&]O2
M.H;4\[*ZNPXNGS!:?XHKFC0G//G=6@!*;4%F53B30H72L7'=XV8G&QILZ-_S
ML*%C '*>;2%6/<^GM>7,ZIV_S:9KV5QW01BP%<2NCSY!^X>#I-!'RP=7A%*.
M/"?&"]:HA-?S4P&6(*IDCE:+9];RX:91^N%GU>OFZ 6%=-;K6G!I0 5GP&&T
M0)8=A"C,Z2!:+_^MB#_KQ@[[8';[6,!3JK\#/VA-.;UY-4LLN(PZ.JRC+6IR
M3K*:,DR0$WJF;(RH6[LN=PCH9=S?24%POZ_\P1KI $Z'"^X'V[-4&R*]Q:]Y
M,WH%?2E&!0U:U+I?1DZ3#U:#=ZKD(GUF[.1]<P[@8UQP'P&K9I>Y&NFX YP_
MXMHM/WS\;3.TIZCHL_0&8LP:E X4=PC+B;=H1/)")VQ]_?&G!'5^C#PX7A[.
MF6NDO Z0>'!6]<W-%!096#%.1DB&49CL183@:+=2=6I]UHKGW'HV^/%4]S)7
M:4Q7X<2Z/V>T7[=<K+/85EI9#5_[] 5GFWS-V_GL=UH7<KI=I8ZB)%&[2OML
M"ZC(+3@;$X44C$)TY5PRW=S7.XC#SG>&QOAM93[#@^G/86J;(W GE##>UD*W
MVM8-50!ON &K8]$F%ZO"R4NY6C%WI@9V H2?WA@/@-OYU#L?+)Z[%:D3*;7'
M6&]EZ5I7H#4'9.B !ZF40L&*Z.;BQ9Z\G>EEO^=DBT> K8MIWL-)YK]6&KR1
M3.$V,8IH(4=R;E36&8*,C@3E'=->68>#3/$X 6]G6MC\G,SP"+"==Z.X)R6S
M*32])1SFDPL^<S"NKE&V9'#&TW<JBNBY$\*=SX;X@+TS+6-^3L9X'.2>N3W>
M=]Z-#C8')D!GGT$9H<%CDL R4UD8X5@R9V.-A\2*_=4P/R=;/ 9NYU[!O+MP
MGIQ\=%O1R:>@;&1@K$OD7.1$X;92],4D9E-$^G=^%KN/",XT[CR;).M@</QS
M9&&?GF.69.&AQ#JXC#%0M0D98D%@0@;)C;44Q3]#$W[VN=OA#*?#16 O%/_I
M\KY/BX]GQTO,Y 5Q+4A\Z,#':(";[#$;C:J?Z66MF3_3'?Q/M1(,B>=G[0C<
M308^+;B0$X4]VH*5)#-E2@#/@X:0F!+:UJ&GYW-<NR?SSSYW_0P6@B'Q_*P7
M@EM-%I^6FE!69ND%:,7JT9UC@-IZX#$93O*42IR/.[ /Y\\^8_X,EH#!D/RL
M[7^/6$J'P+/0I.=L$)0/$3 P!0QC45K:(ONY,GSJC, Y9^B?@>T/A.*FV?VF
MQ=B_SNC;_ G_R,L?M<?K%]_,E\N7N<P7^?UB_OMT2<^A'V[]P1&%V"T>VZ (
MNSGWC0JP;Q[SHZKUIE(5"V9E+*^%5YI"3TN&(\B$HA/1\%("9[;QZOD3<H[=
MD'X(^Q=:LFICD.GL:CK[_(Z0OU+G1@FW!4_?+"^G<9*)65&-3S*D)<0J!)<#
M0K;2DH D2M[ZFM,1Y(Z;$&Z%J/M+\:GTUX'O= "KM-G1/C*K5Q5CS"12:Z6J
MPS0%!,XSN"C0&\&T5!T@=4/MN/G*CH!ZB/;.$Z>O_R !DV:G,UQ\7QW;DB,4
M:Y<F\MC6;3@SX>!RXDLL6FI&HD@UW!$,G!>U;U-2RHGL'+:N:1J0G7$3<ATA
M?1#]'VX*\TN\.*G#>R('=R2'MC,'-H;L40D#GE'TI%C,$*))D*52+"/A6[3N
M83N@ _OJ:E&-_>8)K_^H 6E^F6>Y3"\?L[X;0>10HJ/(%RK/H&I!>C!<@I&*
M>\V=5KIU%O1P:OMU7_?!T_VU\D3:Z\ KV'#Z2R9%X<4#5B=$MBNY)'#)9=IV
MO .G4@19F!&>:\/40&#<1M*XB#L5,AX'9!,U]8.ZCZ2WVH?C#?W!(TPESP2+
M44.T&$ %:<%+7T<D<"E$X,(TG\>Q$V'C1D+C(K"AROK!X2:B>\A.[3!K.<L@
M>4CUDJJ"D!-%?"IK%HJ.K'E/XR=(&C<V&7GU:Z&F?E"W18H3FX)5%A.)IK9R
M9368<IF#<#9*K6,JS<_!?D[1N*?3XV*NA9*:1;Q'M&[=//80*3(>W*J6QBIC
M0*'V@$(A?6>S53(Z$5J/*C^"W'[3E,<$)*?27P>KXS6K&U]WFP$Z[30M[@H2
M<DW2]#7EI"24DHP-)0EN6Z<<=Z-LY'ZWIP+*%H VU%H7S1FN^;KC]V[C+FME
M72''@QP25OT0<GQU+L 86J5+),>XM;NX#WWC+HUC([.Y!GM:*]>>\3:N2F3"
M<1X@%ZS.2A2 UBK(O)B0F=#(6K<;V(VRD6>]CKU6MM-:1UC<ZC&3GY-2$)!C
MD*!*X(#&(P1+/KG(/)?4^HK_$R2-/'%N9/2UT%,'D<TV-KQ(SEDT1+=VH()1
M@!DE9*MM85'+R <[3NIID1LJ(FDA]S,Z"KYY\>;4=#-!XG+^F*4.<P=R[\</
M>Q?R.&F<X$B9EC(3D%G(20=0FG%P5B(([5BT)O)H6OOC@]^)I(_^D.-\%J<7
MTY5TMQCBB^O#HNKW7M$G?__Q]Z2I29+9JQ0=%+>:Y$N[!_I,D5CRRB;: J)M
M[1,V9:#?@^=]4+=U53VYCCOP(+<P3R^\(F)J0WU2,E'X9>)3,MKG.NBLN%IL
M6ROKL@"&15MCI#=:G@:\#XGK-P$Y #"/U$T7C<:VL/;J2RT;^75V[2_3&UXL
ME_ER6>L\UOJ\N)C_'\YBGI@8F9*E ).UF4VT'KSD#C!(+;6+2;C!G,V#J>[7
M+QT J$-I<\1EL[J.D]>EY#KZ+]]9^>_R3IO&=.V)O2MO\^7&+YM]KG=!7^%B
M\;VLBZ^6DR1*D=)0V.<T T5:@% L@X N:Y>5?) H>NB_MB=KW#B]-5!'5EL'
M^_PNS#]>R_?ZCYB72_J#:P?HZ_QJ1FJPK,A"9BH0D?AW%KRN;0"CUCPS4TSS
M=JJM>1BW"G2HQ7A439_#TOQV3CM2NJ*WA8N\<>Y_F2_>3#'06RZ_;\+JCUC'
M OUR5:O//\R_X\7E-"\W(@E1&A$B@ZP]B80%#>B0MJQ8O% 1'<^NV9I]/+WC
M#E ?;3$_L:+/!/NO</EES28)X/<\N\H;.7R:5TDLMXDBB^1$[2M>2FVAFG@$
M-)*!H]B#N6 5TZHEY@^D<]Q!YV-B_12*[<"3V1)LD,"_S9?3M>NV#C,FM0-Q
MJ3=CN:Q=3C7G$*)*P%FV*CE7I&@]OW%WZG8"JCL7H ZLG7YQMVI;\2+]_6IY
MN6IC,;$^>8(%A:ZV)'*7R&?R@;8,B5HS4;@/HO75O1U)VPEQ_ID@[BB]] 2W
M>V=]T9"H<C$0L;+!8P17E #O-$9M"EK7NH?O49?NV-GBZ0C!G]$AZ\?IY]FT
M3"/.+FLL.)]58YF7!SD[G*5KQWG:OASW."J&.G)M*)L3G+PF B*//(/(]1 @
M:UKJ>*(O0C*3E+2Z>3_/(8MY;P3^[J' 7]P1^(]2?8L8A<IU!GHMB8_5B14&
M2.Y2(1JR_.95'/N3V>\IZCX(>E"[,;"^.MB2'[#UD_0PURGHJ#3$(FIK8M3@
MA,Z0K4@H:Z>2YMTY]B!OY'K>H:&RY?9=:[WU",F;P^$[;-T<%).?8DQ,C+S>
MK&HS$PG(M(1,'C KI8[):5U:OB>)(Q?ZC@W-AOKK$9ZO\-NT>K@/["[2MB-<
M/3_+:,CN9*I%  9DX=D+67>@UK=+=B9NY/K?L2'91&=C)\<?</4F(WWN]5'
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M9[H'D#G.@>_00!Q:7SU#<L/8^SQ;E\9=\Z=MT9BB &MK\VY4-=C*&HI#I#T
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M<EVBY5243O  EAM9W?-Z99>^Q)BL9!&3:MX2]0 RQSW4;8*=!S60 RNK@]3
M*]H]B/9U1<*'Z?(?+[_3,AV_?,7%/U9E[%HQXX-$<A%0@<) :[6(Y-#H8*S@
M64C7VO:>HFEDI T-B@?=>1MJJ$O$77.SJ5HF'[20A3) R8@?PR20_"QH5%:*
M@EJ*UO?4GJ)I[ Z\+1'P)+R.4$<'\*I#:B@R^CW/KO+;?+FI5D>2$ 4X'I3@
MI5Z?H0B(BPB9&^58*M(U3UX^2DAO0#I&U_<WRZ,%WP%ZWB_F%#=<?G]_@;/+
M%[/T^G^OIJO)6]==#YS6K [9-+J.VT0I(9B4H2064&B6;?.)&T^0-';'Y0$1
MU5(9(V)KN;B<_!7_/E^\NEI>SK_2YZT6;4MQM2W%09&^3FY-"EQ,K@;!+#&%
M#/-.;;WIXV_!B'[Z :''GSPN8D[E/C60^LB8>8M?24IW>-@85;0L9JMI%<VU
MHT'FM0-O)#NP@?CCMHC=XN$GH+.5@'%VL18:G;<6[^A58*]>OO^"9#:;-3$4
M&8N-2)HL#%0*MM8IT?(;?? YF!+CO1D]V^JY[G[P>"IOI*=Y(Z&-K?"7^ =>
M7&(MIEC0PED3[>\6G_ ?.>'[-Z\V#&F.2#P%R%(D4(4%8DA(B@\4S\ES42S;
M"06[/&V<_60@:#07[]AX>5'S8/^39SGBBW!-OY",*>-!1Y7)*1,"D!@D$4D3
MK"N.R]T:7CWRX>,<1@^$AF.%-[;RWY?I/_-B0SAWB$$%1GK,2/&8\."U,\!R
M(#^\"*7];G46MS]UG-.O@=1]L+C&UO/+Q90D</'7[_1Q'RE*"J$V],?9=0-(
MD60H&CW8&B2I4@>;YU5=NY;:6TLRVDWU3SQHG)X60VT%#85Z,$!^SXLP'R[7
M_XG^=.5%*^Z8L 1T\H ([89<Z4 Q%S GE"O:"HJSAT_S7Y,S[G7K#C+\!^FE
M@_S9 U8J(QM#S*)X8:."4EBU%QO!U2*;&(D7853PIG7N["?D]):)/5#E3T'I
M0/GW *7-,OZ I>NFQC*1'QXU<+NZ6L49>(>!0!"2,4(%IUIW 7Z"I,X@=:CJ
M[T.JH1XZ@-5_Y/GG!7[[4GMD/\Y02&@]<PRB2;77BM" *AN(R(H2N<Z>;[T5
M/DE49UG^1M!JJXN1T[6KAMG5(?C!%5ZL%G046NO:^E\%7'F@$C 9A,*2S:GP
MDMQ.&]\3Z=JM!(Q[0_&4"?\V.A@;2&M)W&;A.I310F67.-3&[J"DS>"<#L"\
M1<U=Y)[M5%'V%)"V$3!>$KB18N>MI3PB5.)ZQ,/DMX\3+9$60T0@22A0+$GP
MH@3@(1<4):GB?W9!<)GCOWZ>__YOFT]<0V/SPP]D_'C>B#!HH[3Y41+LP(GY
MR4KZYJ9E7<F!R9 "E%@KOY4TX)G($+3SA7ZIF&[=KV(7NL8=='GJV+ZYIL9.
M-;Z]JH[9NW+3ZOKEU9(862XWG$X8$UX)D<"45 </AP"(DKQ"C($A"JG#;B>0
M3SVIKPO'QRMV/I24.UBP'OCW[_.BOH"?,Y]DYH2/%#UXG6--># (GE9@2[P%
MZ2FN4*T'W/^,GI'OQPR%J^:JZ !66V^(U;FOT@C.F.4@0TF@!#)P&3F47(0A
M:K1H/G_W9_2,G-,>&E;-5-%G^]K[\MM<= W??_BB+Q89U^51=UDYK-KKYP\8
MH-QK#XZ&KO="VMB<%@&R5;5FA[Y#*VL#I>R-(U<_A_.K]WH]NYQ>?O_;-.6-
MI%]^OWN;[>7WFZ=OJ%FN_4\?A4YDEY!LW>NC3H#96K L*Z6-H\A7M1;'\63W
MY9X=A*WM]6"G4>;8B:BM21=OLC->&) ^UU9B*H$+.D+*D?FHF=5EIXK$03.:
M)Z@ .Q$,=LIP[J.3L8&U-8VCR>? (@N0QT$>B V:' 470)./8"6J>ACP9\MP
M[J78G3*<^TBYCPRG=3:[9#1@;5.DG+#@DZL]D!G/+'K&BO@)+IY#AG,OI3W,
M<.XCP0XBN[?SV6_+S2&@8X8B#RE >.YHRW:US@=K>&JY#(81 ZV[U=QZ_'C7
MF]MBX5C)CKQGO)K/EO.+:5I)?A6NKB_+,(VILIYTO7W N*GUA0X"<69-T)("
MK 8;QN-/[Z62ZO1N2 -M=(>GZY,D7VC'C1%XM(;"@L0H0*BM;TH@J8AHT+1P
M0;8]?[RMIX5.?PJ1 P0\,DC65E,MY?8B7*\!SV?5B*Z+G-%6:7!@OI:@F:S
M:YTA.6(I:LUV[/3Z!&1VHZ8G !VB\?F@XN_ M7FP6M]9JW]D8Y5'I'U8U4E?
MM"735@P8F8)8O"A,N,A=Z_SUCJ3U<CW[M/O>D/KK )9WT[[7G1R6M;?@ZS_H
M,3.RO)O"VYML&IDN%SJ 8:Y.DV4%,$D'QGFNC==!\-:IR4/H'#=?- A@MEZE
M'$A['2!TP]1JWL%\MF*A]GB]YNM'C\/E,M._VG)PDH-T6H4"WM63)^4%.#0,
M,N/:.8^"-Y\%? "9X^)S>.P\F-@VK"*'/T+<_*)^";C,__XO_P]02P,$%
M  @ $H9<5H;B!S:[!P  .!\  !@   !N:W1R+3(P,C(Q,C,Q>&5X>#,Q,2YH
M=&W566MOVS@6_;Z_@N-@.PG@E_S(PTD#I$F*!CO3%IDL@OVTH,0KBX@L:DC*
MCN?7[R$I.T[L=)R=1^$"=23Q\O(^S[TDSWZX^G)Y]Y^OURRSDYQ]_?>'GVXN
M6:/5Z=SW+SN=J[LK]NGNYY_8H-V-V)WFA9%6JH+GG<[UYP9K9-:6HTYG-INU
M9_VVTN/.W6W'L1IT<J4,M845C?,S]P6_Q,7Y/\Y^:+78E4JJ"166)9JX)<$J
M(XLQNQ=D'EBK55-=JG*NY3BSK-?M]=F]T@]RRL.XE3:G\P6?LTYX/^OX1<YB
M)>;G9T).F13O&W)P/(@$G1SRPR0:)"(YB7O'1^EP&!T-^&$T&/XW@I =D(<Y
MQLYS>M^8R**5D5M_-.BUCX:E/9U)8;-1U.W^L_&<E.LQJ*TJ,5A:#*:JL)!#
M@V]X#.S7%WD^\]32HVWQ7(Z+D5>]9K4@3U2N]&BOZ_^=NI%6RB<RGX]^O),3
M,NPSS=BMFO#BQZ:!NUJ&M$P#H9&_45C$O\Z":D?@D\N"%JI&/:?<]6,F8VE9
M/VI'SS5X1?;CY[(G< KI[R3\Y?7MW<W'F\N+NYLOGW_92OQ>^==;>K!1V)LF
M^Z1F7 MVWP:_6!9-EI"V,ITSFW'[;F]X?+J-#H<+#\A"P/JCP?"[Z12UV0W+
M^)28IJFD&1+<9M*PBZ*H>,YNJ53:,E6PCTI/6-1M_8NI%(L_6*[974::EU19
MF1B6*HVIQ.:$$8)B@EU10I.8]+N]Z+![VH^:#AUZ,-/)KIFIUV8?N(%*L,1D
MSAX*-<M)C*D9K*6#F83"BH4"5H(AEP7CQ9Q5A=4506"@IP=2V(^S"=ZTA(53
MGN"39FJ"'+8JT*T1%+"D,5S/'<F$/Y W]9*GP3<!8;!D[E$8:SB"1&J@+L@*
M3(<D@C2;93+)F*G<S]/\&6FJF3@%)M+D@&>']#-I,RAH2DJ\@(YO"=&4@)I3
M3!,LGJ^:81?]V_^&?XFELH %G3-6+,8+4&-4KPS+ ED SZ'PXCG)*Y<%<,J*
M=9IPJ-3YG)6PJ0L'%R9Y_N3OVM3FQ<H(*>$K>M-15#D(X&0%3_CE@CP)-QE+
M<S4SBPC0-);&HAVPC+N/34\'*9LKCC0+8=:DW45?#MH.F%8T?[=WW(N.3DWM
MKAJR76RK-)5XW3<'WBPWC&OR#H!!99R3!S6"T^-<FLS-<&03I+9+;_<NI$ER
M92K,<TFO51X\46J5D,!GP_9A>$'P9+#N]6.2\6),[ +Y=%OEH(CZO!4-]RE(
M$0U%> NOTI7G(D2 X\]<TJT$1G"4D^5;"^G5A=)G"Z58: '>J^$""E<8=K&J
M\0/4'H/N!I;P2/?[;FHZ$$YX9;:?XM P)IB\7BG@*^##5,BKJ30^6T%$A6?C
M>H2G/%_%"DTY]RZL\?7)#<T:1]R@1,Y#%*-R*7PK;JK82"&YEDY^&:J !Z_"
M<:J,0V8?],;#N,]M]/H0"$VXGU1RQ$Y2Y=Q!$K3R0CPA/&:$>K%:YO 4DR,$
M:F ^B5U$B?AEB&R=9VN1LGV&;@P85>FUB$&03:5P@< --G$.BKA!$+E"[J(#
M3>C"4X@=R6.92SMWH+]I61>VWJG>7R'DGI&NE#6/>(^U0F6E2\2+\44J2906
M7@#?$HRI0.W)$388H=+%HR-!NQ-" W$K2X#.+@9'<L"NISRO?)8YRU&:HB;+
M*70V&VKKLL)L 1KA=7.Y];& B<AX$XIZK"K[N@3;P!I?4I/K6-+?;^!8O&B%
M?'A3L 3D\:YT"^R8.P5R/5AJW>*N1:_KI!_9Z-8W9+C#>)4DE79V70'4#5PG
MRJ PD]N @Y=)P.C7"G@,UONO3$D1(,B]%]2UX.C^R.\NW,;#;]^"7 =!JHR;
M9?5Q6>L#BH2',V^/&FKFV$,\4%YO-5[0-_^PB=H[%CS#/]!.^HVU6(1>\RFQ
M7)ZONO\IQYP#WU"*UAJ&I70<38-5VBS1WW\ RPEVFI;H&R@6*W?(@7$A(9]G
MLH\@ 6@8!TKXZUJ71633KY6$^#Z*JR+QNY&#'>T:+[ 3<\59PI&N"7;M="()
M9J^1>]F^S8@_."@.Q=&#L2_K?B^_V)6]R9EUIQ6V(!MRD0M,-+1,Q5<=7S<#
MF +OH68W0STP* :FFL#VL(E7IH; C?O77<5Z]'47@/14(]R;,"GY)(53_+%&
M[;UF0$193%4^)0>+!1_7IS.ZSFN:E+F:$T9GF0J9S)_%!GSYI]2,70/$*QC1
MIS?[2+%&"9J'\[W>L3_?Z[_A%-?ZSK8>CA&JI%M0(^>EH='BX10 6N9\/I*%
M%\9/.JV9Q<I:-1FY$_^I V*4Q?I<VULK#->7 8.3]O&P[^X#K,9_L5BXOBIH
M^ZN"CA7K8R?'[9/NZ\/==K0<ZWC>@3\T,"4OWC?ZC<6$D@O7N8]ZY2.+GA_$
MYY2N*1'D#S<8?[NWO<;O]@:(9O_+/BU<^Z<*<KR5'%_N+VZO_I+UMS2$/_3_
MG@;X<//YQ0W5%O%6)Y7/N1(BN[,#MI#UC<$()G]/)*[=%7D#O+A[>;LM_B]U
MOX>FEYFDE%T_4E*Y'1_[$OK*)ON*'9UT^._+]U7=G2TML;1!QV/DEA5E_0IS
MPVWH"H\7%ZVE"C?-HW"(-:57KUYKK.X^3>$Q K*RKT]YXVUM_1ONE/WM]OG_
M %!+ P04    "  2AEQ6=X<])=$'   ['P  &    &YK='(M,C R,C$R,S%X
M97AX,S$R+FAT;=59;6_;.!+^?K^"Z^"Z"> W^:5)G#1 FJ38[';3(LU><9\.
ME#BRB4BBEJ3L^'[]/21EQXF3KH-M+W"!.I(X',[K,T/R^*?S3V<W__Y\P28V
MS]CG/]Y_O#QCC5:G\[5_UNF<WYRS7VY^_\@&[6[$;C0OC+12%3SK="ZN&JPQ
ML;8<=3JSV:P]Z[>5'G=NKCN.U:"3*66H+:QHG!R[+_@E+D[^<?Q3J\7.55+E
M5%B6:.*6!*N,+,;LJR!SRUJMFNI,E7,MQQ/+>MU>GWU5^E9.>1BWTF9TLN!S
MW GOQQV_R'&LQ/SD6,@ID^)=0PY%,MSOBC@94'>P_W;_<#",:3_N)]';X>$@
M2O\30<@.R,,<8^<9O6ODLFA-R*T_&O3:^\/2'LVDL)-1U.W^L_&0E.LQJ*TJ
M,5A:#*:JL)!#@V]X#.S7%WDX\\C2G6WQ3(Z+D5>]9K4@3U2F]&BGZ_\=N9%6
MRG.9S4<_W\B<#+NB&;M6.2]^;AJXJV5(RS00&OE?"HOXUUE0;1]\,EG00M6H
MYY2[N)O(6%K6C]J]AQH\(_O!0]D3.(7T*PE_=G%]<_GA\NSTYO+3U9<U\7^T
M4(/'0D4]"'799+_*+).\8._;[&:B<D-%DR6DK4SGS$ZX?;,S/#C:Q-IO%\:6
MA8"A1X-A^>,#94TM;^NHS2[9A$^):9I*FB&7[40:=EH4%<_8-95*6Z8*]D'I
MG$7=UF],I5C\UG(-*Y#F)556)H:E2F,JL3EAA*"88.>44!Z3?K,3O>T>]:.F
M X(>S'2X;6;JM=E[;J 2+)'/V6VA9AF),36#M70PDU!8L5" 13#DLF"\F+.J
ML+HB" R@])@)^W&6XTU+6#CE"3YIIG*DJU6!;HV@@"6-X7KN2')^2][42YX&
MWP2$P9*9!URLX0@2J0&P("LP'9((TFPVD<F$F<K]W,^?D:::B5,@ER8#$CM0
MGTD[@8*FI,0+Z/B6$$T)J#G%-,'B^:H9MM&__6_XEU@J"UC0.6/%8KP -4;U
MRK LD 7P'&HLGI.L<ED IZQ8IPF'2IW-60F;NG!P89)E]_ZN36T>K8R0$KYX
M-QU%E8$ 3E;PA%\NR)-P,V%IIF9F$0&:QM)85'[+N/O8]'20LKGB2+,09DW:
M;?3EP,'SJN9O=@YZT?Z1J=U50[:+;96F$J^[9L^;Y9)Q3=X!,*B,,_*@1G!Z
MG$DS<3,<68[4=NGMWH4T2:9,A7DNZ;7*@B=*K1(2^&S8+@PO")X,UKVX2R:\
M&!,[13Y=5QDHHCYO1<-="E)$0Q'>PJMTE;@($>#X,Y=T*X$1'.5D^=9">G6A
M],%"*19:@/=JN(#"%89MK&I\#[7'H)&!)3S2_;6;F@Z$$UZ9S:<X-(P))J]7
M"O@*^# 5\FHJC<]6$%'AV;@>X3[/5[%"4\:]"VM\O7=#L\81-RB1\Q#%J$P*
MWW6;*C922*ZEDU^&*N#!JW"<*N.0V0>]\3#N<QMM/01"O^TGE1RQDU09=Y $
MK;P0]PB/&:%>K)8Y/,7D"($:F$]B&U$B?APB&^?96J1LGJ%/!HRJ]%K$(,BF
M4KA X ;[-0=%W""(7"%WT<&U6'@*L2-Y+#-IYP[TGUK6A:UWJO=7"+D'I"ME
MS2/>7:U06>D2\6)\D4H2I847P+<$8RI0>S*$#4:H=/'H2-#NA-! W,H2H+.-
MP9'LL8LISRJ?9<YRE*:HR7(*G<T3M759838 C?#Z=+GUL8")R'@3BGJL*ON\
M!)O &E]2D^M8TK]NX%B\:(5\>%.P!.3QKG0+;)D[!7(]6&K=XJY%K^ND'WG2
MK2_(<(?Q*DDJ[>RZ JA/<,V506$FM]<&+Y. T9\5\!BL=Y^9DB) D'N/J&O!
MT?V1WUVXC8??O@6Y]H)4$VZ6U<=EK0\H$A[.O#UJJ)EC#W%+6;W5>$3?_-LF
M:F]9\ S_1COI-]9B$7K-^\1R>;[J_OL<<PY\02E::QB6TG$T#59ILT1__P$L
M<^PT+=$W4"Q6J"]N7$C(YYGL(D@ &L:!$OZZUF41V?1G)2&^C^*J2/QN9&]+
MN\93[,1<<99PI&N"73N=2(+9:^1>MF\SXK<.BD-Q]&#LR[K?RR]V92]R9MUI
MA2W($[G(!28:6J;BLXZOFP%,@?=0LYNA'A@4 U/EL#ULXI6I(?#)_>NV8CWZ
MNE- >JH1[DV8E'R2PBG^6*/V7C,@HBRF*IN2@\6"C^O3&5WG->5EIN:$T=E$
MA4SF#V(#OOPN-6,C0(QZKV;1<QC-IS/[0+%&R9F'\[S>@3_/Z[] ?.L[V7HX
M1FB2;D&-C)>&1HN'(P!FF?'Y2!9>&#_IJ&86*VM5/G*'^5,'O"B#]9&UC[\P
M7)_S#P[;!\.^.^JW&O_%8N'Z%J#M;P$Z5JR/'1ZT#[O/#W?;T7*LXWD'_M#
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M(=DT5LAS/!_="7G/'G A5TPE]+BR<V07OX]LX^0H$&1Q?$38 V+D78/U0B?
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M0T1D$$Z;^EC_0F2;3T>[PBS>AED8X&"MHE[$S!JO=7S)QK;[I),?DL;?27<
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M7S.ACY[-#6M]USO\#U!+ 0(4 Q0    ( !*&7%9/[X6A&:(# .++(  1
M          "  0    !N:W1R+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( !*&
M7%:#&0YI]1D  "(O 0 1              "  4BB P!N:W1R+3(P,C(Q,C,Q
M+GAS9%!+ 0(4 Q0    ( !*&7%9H'DK#_RD  !ZF 0 5              "
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M>#,R,2YH=&U02P$"% ,4    "  2AEQ64Z0;L]@!  #/!   %P
M    @ %IY@D ;FMT<C(P,C(Q,C,Q+65X>#(Q,2YH=&U02P$"% ,4    "  2
MAEQ6$Z=\&2 $  !&%@  %P              @ %VZ D ;FMT<C(P,C(Q,C,Q
A+65X>#(S,2YH=&U02P4&      P #  H P  R^P)

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
